<SEC-DOCUMENT>0001390478-17-000020.txt : 20170315
<SEC-HEADER>0001390478-17-000020.hdr.sgml : 20170315
<ACCEPTANCE-DATETIME>20170315162858
ACCESSION NUMBER:		0001390478-17-000020
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170315
DATE AS OF CHANGE:		20170315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		17691634

	BUSINESS ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gale-20161231x10xk.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD5A20989B8BDF36702DA6F9E6798D93E"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#254;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">For the year ended December&#160;31, 2016 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Commission File Number: 001-33958</font></div><div style="line-height:120%;text-align:center;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;font-weight:bold;">___________________________________________________</font></div><div style="line-height:120%;text-align:center;"><img src="logo-verticala14.jpg" alt="logo-verticala14.jpg" style="font-family:Helvetica,sans-serif;font-size:6pt;font-weight:bold;height:106px;width:133px;"></div><div style="line-height:120%;text-align:center;font-size:22pt;"><font style="font-family:Helvetica,sans-serif;font-size:22pt;font-weight:bold;">Galena Biopharma, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;font-weight:bold;">_______________________________________________________</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">20-8099512</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">(State of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">(855)&#160;855-4253</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant's principal executive offices)</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:38%;"></td><td style="width:24%;"></td><td style="width:38%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Exchange Act:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Name of Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Common Stock, $0.0001 Par Value per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">The NASDAQ Capital Market</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Exchange Act:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#254;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;No</font></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Exchange  Act.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#254;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160; No</font></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#254;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160; Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;No</font></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#254;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;No</font></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically and posted on it corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12 months (or for any such shorter time that the registrant was required to submit and post such files).&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#254;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;No</font></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act (Check one):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:40%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#254;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font></div><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Helvetica,sans-serif;font-size:10.5pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font></div><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Helvetica,sans-serif;font-size:10.5pt;"><br></font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10.5pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#254;</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;No </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Based on the closing price of the Registrant's common stock as reported on the NASDAQ Capital Market, the aggregate market value of the Registrant's common stock held by non-affiliates on June 30, 2016 (the last business day of the Registrant's most recently completed second fiscal quarter) was approximately </font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$85,410,521</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">February&#160;28, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">, Galena Biopharma, Inc. had outstanding </font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">35,921,324</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#32;shares of common stock, $0.0001 par value per share, exclusive of treasury shares.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sA27AC893D520AD0036986F9E67CA02F8"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ANNUAL REPORT ON FORM 10-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">FOR THE YEAR ENDED DECEMBER 31, 2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:69%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Part No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Item No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Page&#160;No.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Business</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sDB307E9D2D96F4F83BE46F9E686CE27F">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Risk Factors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sD5090CB2CE184A4F875B6F9E688FD6B2">19</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1B</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Unresolved Staff Comments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s46489A445327DC1D4BF06F9E68C18531">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Properties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sBD8F222EE39560EB34626F9E68E627BA">39</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Legal Proceedings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s6EFACC6B1F50DBDACB176F9E6914FD75">40</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Mine Safety Disclosures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s9247B3586745C03A37CE6F9E693A17C5">42</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sAF57E3D79C09B3BB48776F9E63FC8832">43</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Selected Financial Data</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sC1310E2C3C6169AD088A6F9E69BD7DA4">46</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s414DDE9B30558CC482B46F9E69E19A35">47</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Quantitative and Qualitative Disclosures About Market Risk</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sBCF333E64178EF3BF4D06F9E6B7FF0AF">61</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Financial Statements and Supplementary Data</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s7773FB1E73ABB0863AC26F9E6B867F51">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sD3739FDC656D68A71AFF6F9E71E2E27C">100</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Controls and Procedures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sE87933002158B7A90F436F9E71FE3EDD">100</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Other Information</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s17BFB4DBB9A607FBBC346F9E7232E78C">101</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">III</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Directors, Executive Officers and Corporate Governance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s135EBF9279BAF440B7336F9E7288B149">102</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Executive Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s3187379469F673D72E306F9E72A922DA">102</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sA411B05F392907FFEDE46F9E72DBE785">102</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Certain Relationships and Related Transactions, and Director Independence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#s45F5477FE7071AD9504F6F9E72FCC05E">102</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;">Principal Accountant Fees and Services</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sD2397F90385FF93855D06F9E732C9398">102</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;" href="#sAA65A9421028E494B7896F9EB5FDDC50"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:none;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s89E49B7F82703021BCB86F9E734F3CED">103</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Index to Exhibits</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">EX-3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">EX-3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">EX-4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">EX-21.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">EX-23.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">EX-31.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">EX-31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">EX-32.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;"><img src="logo-verticala15.jpg" alt="logo-verticala15.jpg" style="font-weight:bold;height:186px;width:233px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s3EF496048141F62C3C296F9E681B8B97"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">"SAFE HARBOR" STATEMENT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Some of the information contained in this annual report may include forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. We make these statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include the words &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;will&#8221; and similar statements of a future or forward-looking nature identify forward-looking statements for purposes of the federal securities laws and otherwise.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  There are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These factors include, but are not limited to, those factors set forth in the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; &#8220;Legal Proceedings,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221; and &#8220;Controls and Procedures&#8221; in this annual report, all of which you should review carefully. Please consider our forward-looking statements in light of those risks as you read this annual report. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If one or more of these or other risks or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by this &#8220;Safe Harbor&#8221; Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s41E1914C5D4EF5D5BC8D6F9E683EDCDD"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART I</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sDB307E9D2D96F4F83BE46F9E686CE27F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1. BUSINESS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Overview</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax&#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and the asset is ready to advance into a pivotal trial in patients with essential thrombocythemia (ET). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are seeking to build value for shareholders through pursuit of the following objectives: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:114px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Develop hematology and oncology assets through clinical development with a focus in areas of unmet medical need. Our hematology asset is targeting the treatment of patients with ET to reduce elevated platelet counts. Our immunotherapy programs are currently targeting two key areas: secondary prevention intended to significantly decrease the risk of disease recurrence in breast, gastric, and ovarian cancers; and primary prevention intended to prevent ductal carcinoma </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">in situ</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(DCIS) from becoming invasive breast cancer. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:114px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Evaluating strategic alternatives that may include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:114px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Leverage partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The chart below summarizes the current status of our clinical development pipeline: </font></div><div style="line-height:120%;text-align:center;"><img src="pipeline21027.jpg" alt="pipeline21027.jpg" style="height:374px;width:638px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Hematology </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-401 (anagrelide controlled release (CR)) </font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-401 contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (&#8220;MPNs&#8221;) to lower abnormally elevated platelet levels. The currently available immediate release (&#8220;IR&#8221;) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent, and may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration (&#8220;C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">max</sub></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8221;) and increasing the half-life of the drug is hypothesized to reduce the side effects, while preserving the efficacy, potentially allowing a broader use of the drug. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Multiple Phase 1 studies in 98 healthy subjects have shown GALE-401 reduces the C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">max</sub></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of anagrelide and increases the half-life following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet levels effectively. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of the Phase 2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of concept trial enrolled 18 patients in the United States for the treatment of thrombocytosis, or elevated platelet counts, in patients with MPNs. Final safety and efficacy data from this Phase 2 trial were presented in December 2015 and demonstrated a prolonged clinical benefit with a potentially improved safety profile. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have analyzed our data and the treatment landscape for MPNs, with a current focus on Essential Thrombocythemia (&#8220;ET&#8221;). Subject to completion of the manufacturing of the new formulation and other internal work, GALE-401 is ready to advance into a Phase 3 clinical trial in ET patients who are intolerant or resistant to hydroxyurea. The trial is designed to compare GALE-401 (drug arm) versus best available therapy (BAT) to include a sizable population of patients treated with anagrelide IR. A productive meeting with the U.S. Food and Drug Administration (FDA) in December 2016 confirmed that the GALE-401 development program is appropriate for a New Drug Application (NDA) filing using the 505(b)(2) regulatory pathway. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Essential Thrombocythemia is a myeloproliferative blood disorder, and is characterized by the overproduction of platelets in the bone marrow. Elevated platelets alter the normal process of blood coagulation and can lead to thromboembolic events. About a third of patients are asymptomatic at the time of diagnosis. However, many patients develop symptoms during the course of the disease that affect the quality of life. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Novel Cancer Immunotherapies </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow; and, primary prevention intended to prevent ductal carcinoma </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">in situ</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(DCIS) from becoming invasive breast cancer. Once a patient&#8217;s tumor becomes metastatic, the outcome is often fatal, making the prevention of recurrence a potentially critical component of overall patient care. Our secondary recurrence programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have residual disease. Minimal residual disease, or micrometastasis, that are undetectable by current radiographic scanning technologies, can result in disease recurrence. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&#8217;s own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to induce immunologic memory and provide long-lasting protection with a convenient, intradermal mode of delivery. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">NeuVax&#8482; (nelipepimut-S) </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S) is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict reduced Disease Free Survival (DFS) and Overall Survival (OS) suggesting a presence of isolated micrometastases, not detectable clinically, but, over time, can lead to recurrence of cancer, most often in distant sites. After binding to the specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocytes, or CTLs, causing significant clonal expansion. These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Breast Cancer</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">: According to the National Cancer Institute (NCI), over 230,000 women in the U.S. are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the U.S., metastatic breast cancer remains incurable. Approximately 75% to 80% of breast cancer patients have tissue test positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patients-those with HER2 immunohistochemistry (IHC) 3+ disease, or IHC 2+ and fluorescence in situ hybridization (FISH) amplified-have a HER2 directed, approved treatment option available after their initial standard of care. This leaves the majority of breast cancer patients with low-to-intermediate HER2 expression (IHC 1+, 2+) ineligible for therapy and without an effective targeted treatment option to prevent cancer recurrence. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently have two investigator-sponsored trials (IST) ongoing with NeuVax in combination with trastuzumab (Herceptin</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">; Genentech/Roche). The combination of trastuzumab and NeuVax has been shown pre-clinically and in a pilot study to be synergistic. Our Phase 2b clinical trial is a randomized, multicenter, investigator-sponsored, 300 patient study enrolling HER2 1+ and 2+, HLA A2+, A3+, A24 and/or A26, node positive, and high-risk node negative patients. Eligible patients are randomized to receive NeuVax + GM-CSF + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is disease-free survival. Genentech/Roche is providing the trastuzumab and partial funding for this trial. Data presented in October 2016 demonstrated that this novel combination of trastuzumab and NeuVax with HER2 low-expressing patients is well tolerated and the cardiac effects of trastuzumab are not impacted by the addition of NeuVax. In February 2017, the Data Safety Monitoring Board (DSMB) reported that there were no safety concerns with the trial and the trial is not futile. The recommendation from the DSMB was to continue the trial with one revision to the statistical analysis plan regarding the timing of the pre-specified interim analysis. Given the lengthy duration of enrollment for the trial, the DSMB determined that the pre-specified interim efficacy analysis be moved up from 12 months to 6 months after the last patient is enrolled. Completion of enrollment is expected in the second quarter of 2017; therefore, the DSMB expects to perform the interim efficacy analysis near the end of 2017. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our second combination IST is a Phase 2 in HER2 3+ breast cancer patients who have completed neoadjuvant therapy with an approved regimen that includes trastuzumab and fail to achieve a pathological complete response, meaning they have microscopic evidence of residual disease and are therefore at an increased risk of disease recurrence. This multi-center, prospective, randomized, single-blinded Phase 2 trial is enrolling approximately 100 patients with a diagnosis of HER2 3+ breast cancer who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence. High-risk is defined as having received neoadjuvant therapy with an approved regimen that includes trastuzumab but not obtaining a pathological complete response at surgery, or those who undergo surgery as a first intervention and are found to be pathologically node-positive. These high-risk patients are known to have higher recurrence rates than other HER2 3+ breast cancer patients. Eligible patients will be randomized to receive NeuVax + GM-CSF + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is disease-free survival. Funding for this trial was awarded through the Congressionally Directed Medical Research Program (CDMRP), funded through the Department of Defense (DoD), via a Breast Cancer Research Program (BCRP) Breakthrough Award. In February 2017, the Data Safety Monitoring Board (DSMB) reported that there were no safety concerns with the trial and the trial is not futile. The pre-specified interim safety analysis was also completed on n=50 patients and demonstrated that the agent is well tolerated with no&#160;increased cardiotoxicity associated with giving NeuVax in combination with trastuzumab. The recommendation from the DSMB was to continue the HER2 3+ trial unmodified. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A Phase 2 trial clinical with NeuVax as a single agent in patients with ductal carcinoma </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">in situ</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, or DCIS, is open for enrollment. The trial is being run in collaboration with the NCI, potentially positioning NeuVax as a treatment for earlier stage disease. The trial has an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T-cell) response in vaccinated patients. DCIS is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct and have not spread outside the duct to other tissues in the breast. DCIS is the most common type of breast cancer. In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions could become invasive. Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen. According to the American Cancer Society, in 2015 there were over 60,000 diagnoses of DCIS. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node- Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) study enrolled 758 HER2&#160;1+/2+ patients who are node-positive and HLA A2 or A3 positive. On June&#160;27, 2016, the Independent Data Monitoring Committee, or IDMC, recommended that the Phase 3 PRESENT clinical trial be stopped for futility. The PRESENT trial was stopped, and we initiated an investigation into the causes of the recommendation. Our analysis of the data showed that there was a separation of the curves, albeit not statistically significant, with the control arm performing better than expected and the NeuVax arm performing consistent with our protocol assumptions for the control group. Because the study was deemed futile, we closed the PRESENT trial, and we expect to present the data at a future medical conference. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Gastric Cancer:</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;According to the NCI, gastric (stomach) cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of gastric cancer are gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas. Infection with bacteria called Helicobacter pylori (H. pylori) is thought to be the cause of gastric cancer and age, diet, and stomach disease can affect the risk of developing gastric cancer. Gastric cancer is often diagnosed at an advanced stage because there are no early signs or symptoms, and is the second-most common cancer among males and third-most common among females in Asia and worldwide with over 63,000 new cases a year in India, where an initial clinical trial of NeuVax is planned. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas, predominantly those of the intestinal type. Overall, without regard to the stage of cancer, only approximately 28% of patients with stomach cancer live at least five years following diagnosis and new adjuvant treatments are needed to prevent disease recurrence. We currently have an agreement with Dr.&#160;Reddy&#8217;s Laboratories to conduct a Phase 2 investigational study in gastric cancer in India. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-301 and GALE-302 </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our second immunotherapy franchise targets folate binding protein (FBP) receptor-alpha. FBP is a well-validated therapeutic target that is highly over-express in ovarian, endometrial and breast cancers, and is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes (CTLs) to recognize and destroy FBP-expressing cancer cells. Current treatments after surgery for these diseases are principally with platinum based chemotherapeutic agents. These patients suffer a high recurrence rate and most relapse with an extremely poor prognosis. GALE-301 and GALE-302 are immunogenic peptides that consist of a peptide derived from FBP combined with GM-CSF for the prevention of cancer recurrence in the adjuvant setting. GALE-301 is the E39 peptide, while GALE-302 is an attenuated version of this peptide, known as E39&#8217;. Two early stage clinical trials have been completed with our FBP peptides in ovarian, endometrial, and breast cancers. In June 2016, the U.S. Food and Drug Administration (FDA) granted two orphan-drug designations for the treatment (including prevention of recurrence) of ovarian cancer: one for GALE-301 (E39), and one for GALE-301 (E39) and GALE-302 (E39&#8217;). </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Ovarian Cancer</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">: According to the NCI Surveillance, Epidemiology, and End Results (SEER) Program, new cases of ovarian cancer occur at an annual rate of 11.9&#160;per 100,000 women in the U.S., with an estimated 22,280 new cases and 14,240 deaths in 2016. Only 46.2% of ovarian cancer patients are expected to survive five years after diagnosis. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2011 - 2013 data). The prevalence data from 2013 showed an estimated 195,767 women living with ovarian cancer in the United States. Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 80% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy is approximately 70%. Unfortunately, for these women, once the disease recurs, treatment options are limited and the disease is most likely incurable. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Alliance Partners in Therapeutic Areas </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We leverage our technology platforms by working with pharmaceutical and biotechnology partners in a number of therapeutic areas in oncology. </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="partnerchart020717.jpg" alt="partnerchart020717.jpg" style="height:325px;width:642px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Intellectual Property </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Patents and other intellectual property rights are crucial to our success. It is our policy to protect our intellectual property rights through available means, including filing and prosecuting patent applications in the U.S. and other countries, protecting trade secrets, and utilizing regulatory protections such as data exclusivity. We also include restrictions regarding use and disclosure of our proprietary information in our contracts with third parties, and utilize customary confidentiality agreements with our employees, consultants, clinical investigators and scientific advisors to protect our confidential information and know-how. Together with our licensors, we also rely on trade secrets to protect our combined technology especially where we do not believe patent protection is appropriate or obtainable. It is our policy to operate without infringing on, or misappropriating, the proprietary rights of others. The following chart summarizes our intellectual property rights: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:40%;"></td><td style="width:22%;"></td><td style="width:27%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Drug Candidate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Scope </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exclusivity</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Period </font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-401 (Anagrelide Controlled Release)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Platelet Lowering</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2029</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Breast cancer recurrence</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2028</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gastric</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2028</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">DCIS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2028</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; in combination with trastuzumab</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Breast cancer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2026</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; in combination with other compounds</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Breast cancer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2037</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 &amp; GALE-302</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Breast, ovarian and endometrial cancer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2036</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Out-License Agreements </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:36px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Teva Pharmaceuticals </font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:36px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective December&#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&#8220;ABIC&#8221;). Under the agreement, we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase all supplies of NeuVax from us at a price determined according to a specified formula. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:36px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Dr.&#160;Reddy&#8217;s Laboratories Ltd. </font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective January&#160;14, 2014, we entered into a strategic development and commercialization partnership with Dr.&#160;Reddy&#8217;s Laboratories Ltd. (&#8220;Dr. Reddy&#8217;s&#8221;), under which we licensed commercial rights in India to Dr.&#160;Reddy&#8217;s for NeuVax in breast and gastric cancers. We currently have an agreement with Dr. Reddy's to conduct a Phase 2 investigational study in gastric cancer in India. To date, Dr. Reddy's has not initiated the Phase 2 study with NeuVax.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:36px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Kwang Dong Pharmaceutical Co., Ltd. </font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective April&#160;30, 2009, we entered into a license agreement with Kwang Dong Pharmaceutical Co, Ltd (Kwang Dong). Under the agreement, we granted Kwang Dong exclusive rights to seek marketing approval in The Republic of Korea (South Korea) for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in South Korea assuming such approval is obtained. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Recent Developments (in reverse chronological order</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">) </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Evaluation of Strategic Alternatives and Resignation of President and Chief Executive Officer.&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January&#160;31, 2017, the Board of Directors announced that it is in the process of engaging an outside advisor to evaluate strategic alternatives for the company focused on maximizing stockholder value. On March 9, 2017, it was announced that Canaccord Genuity, Inc. was engaged as the Company's financial advisor to assist in the review process. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in a transaction.  On January 31, 2017, the Company also announced the resignation of Mark W. Schwartz, Ph.D., from his position as President and Chief Executive Officer and as a member of the board of directors of each of Galena Biopharma, Inc. and our Apthera, Inc. and Mills Pharmaceutical, LLC and subsidiaries. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Appointment of Interim Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 21, 2017, our Board of Directors appointed Mr. Stephen Ghiglieri to be our Interim Chief Executive Officer (CEO).  Mr. Ghiglieri previously held the position of Executive Vice President and Chief Financial Officer (CFO).  He will continue to serve as the Company&#8217;s CFO, a position to which he was appointed in November 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Closed a Public Offering of Common Stock and Warrants</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, we closed the previously announced underwritten public offering of common stock and warrants. The net proceeds to us were approximately $15.5 million.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Positive Outcome from the Data Safety Monitoring Board on the Two NeuVax Clinical Trials in Combination with Trastuzumab&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February&#160;6, 2017, we reported the results from a meeting of the Data Safety Monitoring Board (DSMB) for the two investigator-sponsored (IST) combination clinical trials with NeuVax plus trastuzumab.&#160;The&#160;DSMB reported that there are no safety concerns with either trial and neither was found to be futile. For the Phase 2b trial in patients with low-to-intermediate HER2 expression (HER2 1+/2+), n=242 patients were evaluated, and the recommendation from the DSMB is to continue the trial with one revision to the statistical analysis plan regarding the timing of the pre-specified interim analysis. Given the lengthy duration of enrollment for the trial, the DSMB determined that the pre-specified interim efficacy analysis be moved up from 12 months to 6 months after the last patient is enrolled. Completion of enrollment is expected in the second quarter of 2017; therefore, the DSMB expects to perform the interim efficacy analysis near the end of 2017. For the Phase&#160;2 trial in high-risk, HER2 3+ patients, and per the trial protocol, the pre-specified interim safety analysis was also completed on n=50 patients and demonstrated that the agent is well tolerated with no&#160;increased cardiotoxicity associated with giving NeuVax in combination with trastuzumab.&#160;These findings were similar to the findings presented in October 2016 from the HER2 1+/2+ trial. The recommendation from the DSMB is to continue the HER2 3+ trial unmodified.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">FDA Confirms 505(b)(2) regulatory pathway for GALE-401 Phase 3 Trial&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;28, 2017, we announced that after a productive meeting with the U.S. Food and Drug Administration (FDA), the Agency confirmed that the GALE-401 development program is appropriate for a New Drug Application (NDA) filing using the 505(b)(2) regulatory pathway in patients with ET who are intolerant to or failed to achieve an optimal response with hydroxyurea.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Settlement with the Securities and Exchange Commission</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;22, 2016, Galena and its former CEO reached an agreement in principle to a proposed settlement that would resolve an investigation by the staff of the Securities and Exchange Commission (SEC) involving conduct in the period 2012-2014 regarding the commissioning of internet publications by outside promotional firms. The proposed settlement is subject to approval by the Commission and would acknowledge our cooperation in the investigation and confirm our voluntary undertaking to continue that cooperation. If the Commission does not approve the settlement, we may need to enter into further discussions with the SEC staff to resolve the investigated matters on different terms and conditions. As a result, there can be no assurance as to the final terms of any resolution including its financial impact or any future adjustment to the financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Announced the Phase 2 Clinical Trial of NeuVax in DCIS is Open for Enrollment and Screening Patients</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;14, 2016, the Company announced the NeuVax Phase 2 clinical trial entitled VADIS: Phase 2 trial of the Nelipepimut-S Peptide </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">VA</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ccine in Women with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">D</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">IS</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Breast is now open for enrollment and screening patients. The trial is being run in collaboration with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center Phase I and II Chemoprevention Consortium.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Presented Two Posters at the San Antonio Breast Cancer Symposium</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;12, 2016, we announced that two posters were presented at the San Antonio Breast Cancer Symposium (SABCS). The poster, entitled, &#8220; VADIS trial: Phase 2 trial of the nelipepimut-S peptide </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">va</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ccine in women with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">D</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">IS</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the breast,&#8221; presented the trial design for the planned, Phase 2 investigator-sponsored clinical trial with NeuVax in patients with DCIS. The poster, entitled, &#8220; Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39&#8217;) to maximize the immunologic response in breast cancer patients,&#8221; was presented on the breast cancer patients in the Company&#8217;s GALE-301 (E39) and GALE-302 (E39&#8217;) Phase 1b clinical trial targeting Folate Binding Protein. In the trial, both the E39 and E39&#8217; peptide vaccines were noted to be well tolerated and immunogenic with no clinicopathologic differences between groups. Local reaction increased in all groups with administration of the vaccine as measured and assessed using orthogonal means. The greatest increase was seen in the treatment arm that administered GALE-301 followed by GALE-302, which approached statistical significance, and this arm was also the only arm with a statistically significant increase in DTH.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Presented GALE-301/GALE-302 Phase 1b Data</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November&#160;14, 2016, data from our GALE-301/GALE-302 clinical program was presented at the Society for Immunotherapy of Cancer Conference 2016 in National Harbor, Maryland. The presentation, entitled, &#8220;Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Booster Vaccines (E39 and E39&#8217;) in Breast and Ovarian Cancer Patients,&#8221; reported the peptide-specific immune response to E39 and E39&#8217; after different combinations of vaccination and boosting. The data showed that both E39 and E39&#8217; are well tolerated with all related adverse events at grade 1 or grade 2. Though numbers were small, patients boosted with the attenuated peptide showed increased CTL response to boosting regardless of significant residual immunity (SRI) resulting from the primary vaccination series (PVS). While this data needs to be confirmed with a larger sample size, this is consistent with the theoretical advantage of boosting with an attenuated peptide, which is expected to induce less antigen-induced cell death of CTLs.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Announced a Reverse Stock Split</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October&#160;31, 2016, we announced a reverse stock split of our shares of common stock at a ratio of 1-for-20 as approved by the Board of Directors on October&#160;26, 2016. The reverse stock split was authorized by the Company&#8217;s stockholders at the Special Meeting of Stockholders held on October&#160;21, 2016. The reverse stock split became effective on November&#160;11, 2016 and the Company&#8217;s common stock commenced trading on a split-adjusted basis on Wednesday, November&#160;14, 2016 under the symbol &#8220;GALE&#8221; but under the new CUSIP number 363256504. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Presented GALE-301/GALE-302 Phase 1b Data</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October&#160;20, 2016, Dr.&#160;Doreen Jackson delivered a podium presentation on our GALE-301 and GALE-302 clinical program at the American College of Surgeons Clinical Congress 2016. The Phase 1b is a single-center, randomized, single-blinded, three-arm study in patients with breast or ovarian cancer diagnosis who were treated with standard of care and were without evidence of disease. The presentation was entitled, &#8220;A Phase Ib Trial Comparing Different Doses/Schedules of a Folate Binding Protein (FBP)-derived Peptide Vaccine, E39, and its Attenuated Version, E39&#8217;, to Induce Long-term FBP- specific Immunity in Disease-free Cancer Patients.&#8221; In this trial, which enrolled mostly breast cancer patients who have lower FBP exposure than ovarian patients, the 500mcg dose appears to provide a more optimal immunological response. This differs from the results in ovarian cancer patients, who have much higher FBP expression, with potential secondary immune tolerance, where 1000mcg was the optimal dose. E39&#8217; (GALE-302) given after E39 (GALE-301) was able to induce long-term immunity in both dosing cohorts, underscoring the potential importance of attenuated peptides in relatively antigen-na&#239;ve patients.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Presented NeuVax plus Trastuzumab Interim Safety Data</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October&#160;10, 2016, we presented interim safety data from the NeuVax Phase 2b combination study with trastuzumab at the European Society for Medical Oncology (ESMO) 2016. The clinical trial is a randomized, multicenter, investigator-sponsored, 300 patient Phase 2b study enrolling HER2 1+ and 2+ node positive, and high-risk node negative patients. The poster, entitled &#8220;Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression,&#8221; demonstrated that this novel combination of trastuzumab and NeuVax in HER2 low-expressing patients is well-tolerated and the cardiac effects of trastuzumab are not impacted by the addition of NeuVax.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Competition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The biotechnology industry, including cancer immunotherapy vaccines and hematology therapies, is intensely competitive and involves a high degree of risk. Potential competitors in the U.S. and worldwide are numerous and include pharmaceutical and biotechnology companies, educational institutions and research foundations. We compete with many of these companies who have far greater experience, capital resources, research and technical resources, marketing experience, research and development staffs and facilities than us. Some of our competitors may develop and commercialize products that compete directly with those incorporating our technology, and they may introduce products to market earlier than our products or on a more cost effective basis. We may be unable to effectively develop our technology or any other applications on a cost effective basis or otherwise. In addition, our technology may be subject to competition from other technology or methods developed using techniques other than those developed by traditional biotechnology methods. Our competitors compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our technology. We, and our collaborators, may face competition with respect to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price, and patent position including potentially dominant patent positions of others. </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For patients with myeloproliferative neoplasms (MPNs), current treatment options include Agrylin</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(anagrelide hydrochloride) and its generic equivalents, hydorxyurea and interferon alpha. Agents currently being studied in patients with MPNs include investigational JAK2 inhibitors (e.g., LY2784544 (Eli Lily), momelotinib (Gilead Sciences) and pegylated interferon alfa-2a (Pegasys, Genentech/Roche)).</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For patients with early stage breast cancer, adjuvant therapy is often given to prevent recurrence and increase the chance of long-term disease free survival. Adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, radiation therapy, or combinations thereof. In addition, the HER2 targeted drug trastuzumab (Herceptin</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) may be given to patients with tumors with high expression of HER2 (IHC 3+), as well as other novel targets such as MUC1 which may be useful in treating breast cancer.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There are a number of cancer vaccines in development for breast cancer, including but not limited to Lapuleucel-T (Dendreon), AE-37 (Antigen Express), and Stimuvax (Merck KgA). While these development candidates are aimed at a number of different targets, and AE-37 has published data in the HER2 breast cancer patient population, there is no guarantee that any of the these compounds will not in the future be indicated for treatment of low-to-intermediate HER2 breast cancer patients and become directly competitive with NeuVax.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A number of chemotherapeutic agents have demonstrated activity in gynecological carcinomas (ovarian and endometrial), particularly platinum based regimens. New chemotherapy agents are being evaluated including trabectedin (Yondelis) and belotecan as well as targeted agents such as bevacizumab (Avastin) and pazopanib (Avotrient). Monoclonal antibodies are also being developed including farletuzumab and catumaxomab. The Company is not aware of any of these agents being evaluated in the adjuvant setting where GALE-301 is being considered for further development. TPIV200 (TapImmune) is in development targeting FBP in ovarian cancer.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The U.S. and other developed countries extensively regulate the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of drugs and biologic products. The FDA regulates pharmaceutical and biologic products under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">To obtain approval of our future product candidates from the FDA, we must, among other requirements, submit data supporting safety and efficacy for the intended indication as well as detailed information on the manufacture and composition of the product candidate. In most cases, this will require extensive laboratory tests and preclinical and clinical trials. The collection of these data, as well as the preparation of applications for review by the FDA involve significant time and expense. The FDA may require post-marketing testing to monitor the safety and efficacy of approved products or place conditions on any product approvals that could restrict the therapeutic claims and commercial applications of these products. Regulatory authorities may withdraw product approvals if we fail to comply with regulatory standards and or the conditions of the regulatory approval at any time following initial marketing of our products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The amount of time taken by the FDA for approval of an NDA or Biologics License Application (BLA) will depend upon a number of factors, including whether the product candidate has received priority review or fast track designation, the quality of the submission and studies presented, and the workload at the FDA.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We anticipate that our products will be manufactured by our strategic partners, licensees or other third parties. Before approving an NDA or BLA, the FDA will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facilities are in compliance with the FDA&#8217;s current good manufacturing practice (&#8220;cGMP&#8221;), which are regulations that govern the manufacture, holding and distribution of a product. Manufacturers of biologics also must comply with the FDA&#8217;s general biological product standards. Our manufacturers also will be subject to regulation under the Occupational Safety and Health Act, the Nuclear Energy and Radiation Control Act, the Toxic Substance Control Act and the Resource Conservation and Recovery Act and other applicable environmental statutes. Following approval, the FDA periodically inspects drug and biologic manufacturing facilities to ensure continued compliance with the good manufacturing practices regulations. Our manufacturers will have to continue to comply with those requirements. Failure to comply with these requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing or recall or seizure of product. Adverse patient experiences with the product must be reported to the FDA and could result in the imposition of marketing restrictions through labeling changes or market removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The labeling, advertising, promotion, marketing and distribution of a drug or biologic product also must be in compliance with FDA and Federal Trade Commission requirements which include, among others, standards and regulations for off-label promotion, industry sponsored scientific and educational activities, promotional activities involving the internet, and direct-to-consumer advertising. In addition, we will be subject to various laws and regulations governing laboratory practices and the experimental use of animals. In each of these areas, as above, the FDA has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of product approvals, seize or recall products, and deny or withdraw approvals.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We will also be subject to a variety of regulations governing clinical trials and sales of our products outside the U.S. Whether or not FDA approval has been obtained, approval of a product candidate by the comparable regulatory authorities of foreign countries and regions must be obtained prior to the commencement of marketing the product in those countries. The approval process varies from one regulatory authority to another and the time may be longer or shorter than that required for FDA approval. In the European Union, Canada and Australia, regulatory requirements and approval processes are similar, in principle, to those in the U.S.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Financial Condition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We had cash and cash equivalents of approximately $29.1 million as of February 28, 2017. We believe that our existing cash and cash equivalents, funding available under our Lincoln Park Capital, LLC (LPC) purchase agreement and At The Market Issuance Sales Agreements (ATM), should be sufficient to fund our operations for at least one year. This projection is based on our current limited operations and estimates of legal expenses associated with the ongoing government investigation and legal matters pending against the company, and is subject to changes in our operating plans, resolutions of such government investigation and legal matters, uncertainties inherent in our business, strategic alternatives outcomes, and the need to seek to replenish our existing cash and cash equivalents sooner than we project and in greater amounts that we had projected. There is no guarantee that any debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate, our operations or to seek to merge with or to be acquired by another company.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, the Company closed an underwritten public offering of 17,000,000 shares of common stock and warrants to purchase 17,000,000 shares of common stock priced at $1.00 per share and accompanying warrant. The warrants are immediately exercisable with a strike price of $1.10 and will expire on the fifth anniversary of the date of issuance.  The net proceeds of the February 2017 Offering were $15.5 million, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the proceeds from the February 2017 Offering, in January and February 2017 the holder of the Debenture redeemed $3.95 million of outstanding principal that was satisfied by the Company with 3,518,663 shares of our common stock. The Company was able to transfer the $3.95 million out of restricted cash and cash equivalents and into unrestricted cash and cash equivalents to be used to fund the Company's ongoing operations. The outstanding principal balance as of March 15, 2017 is $13,617,702. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 31, 2017, the Company announced that it is in the process of evaluating strategic alternatives focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in a transaction. While the Company evaluates its strategic alternatives, Galena&#8217;s investigator-sponsored immunotherapy trials will remain ongoing.&#160;With the confirmation from the FDA that the GALE-401 development program is appropriate for a New Drug Application (NDA) filing using the 505(b)(2) regulatory pathway in patients with ET who are intolerant or resistant to hydroxyurea, we have developed a clear path forward for GALE-401 in the treatment of ET. Subject to completing the manufacturing of the new formulation and the internal work to prepare the Phase 3 trial for initiation, the Company is evaluating the appropriate time to commence enrollment of the GALE-401 trial and anticipates making a definitive determination in the second half of 2017. The Company has focused on reducing expenditures in order to preserve liquidity while pursuing a strategic alternative.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the funds raised through underwritten public offerings and the debenture, we maintain a purchase agreement with LPC and ATM with future availability of $2.0 million and $19.1 million, respectively subject to certain terms and conditions. On February 6, 2017, the Company and LPC amended the Purchase Agreement, as amended, to decrease the value of Common Stock that the Company may sell to LPC from $42.2 million to $2.0 million, a reduction of $39.4 million of availability. We may also continue to use the ATM, or other instruments, in order to fund our operations going forward.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect to continue to incur operating losses as we advance our product candidates through the drug development and the regulatory process. In the absence of revenue, our potential sources of operational funding are proceeds from the sale of equity, funded research and development payments, debt financing arrangements, and payments received under partnership and collaborative agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Environmental Compliance</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our development programs involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. We are also subject to numerous environmental, health and workplace safety laws and regulations. The cost of compliance with these laws and regulations could be significant and may adversely affect capital expenditures to the extent we are required to procure expensive capital equipment to meet regulatory requirements.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Human Resources</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of March&#160;15, 2017, the Company had 14 full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement, nor have we experienced any work stoppages.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Corporate Information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our principal executive offices are located at 2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583, and our phone number is (855)&#160;855-4253. Our website address is www.galenabiopharma.com. We do not incorporate the information on our website into this annual report, and you should not consider such information part of this annual report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><a name="sD5090CB2CE184A4F875B6F9E688FD6B2"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1A. RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Our business is subject to numerous risks. We caution you that the following important factors, among others, could cause our actual results to differ materially from those expressed in statements made by us or on our behalf in filings with the SEC, press releases or communications with investors and others. Any or all of our statements in this annual report and in any other public statements we make may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. The factors mentioned in the discussion below will be important in determining future results. Consequently, actual future results may vary materially from those anticipated in this annual report or our other public statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Risks Relating to Our Former Commercial Operations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to U.S. federal and state health care fraud and abuse and false claims laws and regulations, and we recently have been subpoenaed in connection with marketing and promotional practices related to Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;(fentanyl) sublingual tablets. Prosecutions under such laws have increased in recent years and we may become subject to such prosecutions or related litigation under these laws. If we have not fully complied with such laws, we could face substantial penalties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our former commercial operations and development programs are subject to various U.S. federal and state fraud and abuse laws, including, without limitation, the federal False Claims Act, federal Anti-Kickback Statute, and the federal Sunshine Act. A federal investigation led by the U.S. Attorney&#8217;s Office for the Southern District of Alabama (SDAL) of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. On April&#160;28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. The criminal trial</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;which began on January 4, 2017, concluded with a jury verdict on February 23, 2017 finding these physicians guilty on 19 of 20 counts; sentencing is scheduled for May 2017. At the end of the SDAL case</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;SDAL dismissed count 18 of the indictment charging that the physicians conspired, through the C&amp;R Pharmacy, to receive illegal kickbacks in exchange for prescribing Abstral. Though certain former employees received trial subpoenas to appear at the trial and provide oral testimony, only one former employee testified at the trial. We agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we were not a target or subject of that investigation. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There have also been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December&#160;16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office for the District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and are cooperating in the production of the requested documents. We have come to understand that the investigation being undertaken by the U.S. Attorney&#8217;s Office for the District of New Jersey and Department of Justice is a criminal investigation in addition to a civil investigation that could ultimately involve the company as well as one or more former employees. Pursuant to the Company&#8217;s charter, we are currently reimbursing any former employees&#8217; attorney&#8217;s fees with respect to the investigation. We are cooperating with the civil and criminal investigation and through our outside counsel we have recently begun preliminary discussions with the government aimed at the ultimate resolution of the investigation regarding the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may be subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Many of the regulatory provisions that we are subject to include criminal provisions. If we are unable to comply with these provisions in the operation of our business we may become subject to civil and criminal investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government. Qui tam suits filed under the False Claims Act can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;relators&#8221; or &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of health care companies to have to defend such qui tam actions and pay substantial sums to settle such actions. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program such as the Medicare and Medicaid programs. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, the statute has been violated. The Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal health care programs. An alleged violation of the Anti- Kickback Statute may be used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only Medicare and Medicaid programs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The federal Patient Protection and Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims acts to be at least as effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws including qui tam provisions. The federal Patient Protection and Affordable Care Act includes provisions known as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data beginning in 2013 to the Centers for Medicare and Medicaid Services for subsequent public disclosures. Manufacturers must also disclose investment interests held by physicians and their family members. Failure to submit the required information may result in civil monetary penalties of up to $1 million per year for knowing violations and may result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the U.S., and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states such as Massachusetts and Vermont imposed an outright ban on certain gifts to physicians. These laws could affect our product promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our system. Both the disclosure laws and gift bans also will impose administrative, cost and compliance burdens on us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We face product liability exposure and, if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The commercial sale of our products after they are approved as well as the use of our products in clinical trials exposes us to possible product liability claims. This risk exists even if a product is approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the FDA, if our products were sold to third parties, or if our products are provided in clinical trials. Our products are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with our products could result in injury to a patient or even death. For example, because the placebo may have performed better than NeuVax in the PRESENT Trial, the use of NeuVax may have worsened the patient&#8217;s condition.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Product liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products or generic versions of our products. If we cannot successfully defend ourselves against product liability claims we could incur substantial liabilities. Because we have sold Abstral and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) oral soluble film and provided NeuVax as a study drug in the PRESENT Trial and other clinical trials, regardless of merit or eventual outcome, product liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">impairment of our business reputation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">costs of related litigation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">distraction of management&#8217;s attention from our primary business; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">substantial monetary awards to patients or other claimants. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have obtained product liability insurance coverage for commercial product sales with a $10 million per occurrence and a $10 million annual aggregate coverage limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost, in sufficient amounts or upon adequate terms to protect us against losses due to product liability. If we determine that it is prudent to increase our product liability coverage based on sales of our products, we may be unable to obtain this increased product liability insurance on commercially reasonable terms or at all. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects, including side effects that may be less severe than those of our products. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and have a material adverse effect on our business, results of operations, financial condition and prospects.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our third-party manufacturers and suppliers activities involve the controlled storage, use and disposal of hazardous materials. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials even after we sell or otherwise dispose of the products. In some cases, these hazardous materials and various wastes resulting from their use will be stored at our contractors or manufacturers&#8217; facilities pending use and disposal. We cannot completely eliminate the risk of contamination, which could cause injury to our employees and others, environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we expect that the safety procedures utilized by our third-party contractors and manufacturers for handling and disposing of these materials will generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this will be the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources. We do not currently carry biological or hazardous waste insurance coverage and our property and casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We will continue to be responsible for certain liabilities and obligations related to Abstral and Zuplenz, and if unknown liabilities were to arise it could have a material adverse effect on us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under our respective asset purchase agreements with Sentynl Therapeutics, Inc. and Midatech Pharma PLC, our future obligations under our former agreements with Orexo AB and MonoSol Rx have been assumed by Sentynl and Midatech, respectively, except that we will continue to be responsible for chargebacks, rebates, patient assistance and certain other product distribution channel liabilities related to Abstral and Zuplenz for a specified period of time post-closing. We also will be responsible for any pre-closing liabilities and obligations related to Abstral and Zuplenz, including unknown liabilities, and have agreed in the respective asset purchase agreements to indemnify Sentynl and Midatech for any breach of our representations, warranties and covenants in the respective asset purchase agreements up to a certain agreed to amount. We cannot quantify these responsibilities to Sentanyl and Midatech, but if substantial unknown liabilities were to arise, it could have a material adverse effect on our financial condition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Risks Relating to Our Development Programs</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our drug candidates may not receive regulatory approval or be successfully commercialized.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Before they can be marketed, our products in development must be approved by the FDA or similar foreign governmental agencies. The process for obtaining FDA approval is both time-consuming and costly, with no certainty of a successful outcome. Before obtaining regulatory approval for the sale of any drug candidate, we must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. Although our drug candidates have exhibited no serious adverse events (&#8220;SAEs&#8221;) in the Phase 1 and 1/2 clinical trial, SAEs or other unexpected side effects may arising during further testing and development, and A failure of any preclinical study or clinical trial can occur at any stage of testing. The results of preclinical and initial clinical testing of these products may not necessarily indicate the results that will be obtained from later or more extensive testing. It also is possible to suffer significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our Phase 3 PRESENT clinical trial has been stopped due to futility and though we have conducted an investigation of the causes for the failure of the clinical trial, we are not certain that the investigation has identified the reason(s) for the failure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June&#160;27, 2016, the Independent Data Monitoring Committee conducting the pre-planned interim analysis of the PRESENT Trial recommended that we stop the clinical trial because of futility. We have conducted an investigation of the causes of the failure of the trial. As a result, our observations are that a phenomenon known as pseudoprogression likely had a meaningful impact on the events assessed as NeuVax recurrences in the trial. The purpose of the NeuVax vaccine is to generate a HER2 directed T cell-based immune response targeting those undetected micrometastases and eradicate them before they grow into a clinically detectable tumor. Pseudoprogression is a phenomenon that occurs when radiographic scans in patients responding to treatment with immunotherapy give the appearance of progression due to increased tumor size or swelling from tumor-infiltrating lymphocytes, or TILs, and other immune cells. In simple terms, the cancer looks like it has progressed on radiographic images, but in reality, the immunotherapy has done its job to create an immune response via inflammation around a micrometastasis. Therefore, a growing tumor or a new tumor detected via imaging isn&#8217;t always progressing cancer and may simply represent an immune system response to an undetectable micrometastasis that would not otherwise be seen on the scan. In the trial, we believe that the low rate of recurrences in the control arm resulted from an overall improvement in the standard of care. In addition, proactive imaging led to the discovery of lesions, some of which may not have had any clinical significance at the time of identification. Finally, the inflammation caused by TILs within the micrometastases and more specifically the NeuVax-induced cytotoxic T-cells, made them visible on scans in the NeuVax group and not in the control group. We now believe that causing this inflammation may have identified lesions via proactive scanning that may have never progressed to a clinical tumor. Because patients were discontinued from this study at the time they were identified as having DFS event, we do not know if some of these patients who were diagnosed with a recurrence on the CT scan would have progressed to have metastatic cancer. In summary, though we are applying the knowledge and observations to our other immunotherapy programs, we may not have identified the reason(s) for the failure of the clinical trial.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our products, GALE-301 and GALE-302 have the same mechanism of action as NeuVax and may not be a viable product to prevent the recurrence of ovarian cancer or other types of cancers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 and GALE-302, which have a similar mechanism of action as NeuVax, may no longer be a viable product to prevent the recurrence of ovarian cancer or other types of cancer, depending upon the reasons for the causes of the failure of NeuVax.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">A number of different factors could prevent us from obtaining regulatory approval or commercializing our product candidates on a timely basis, or at all.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We, the FDA or other applicable regulatory authorities, an Independent Data Safety Monitoring Board or &#8220;IDSMB&#8221; governing our clinical trials, or an institutional review board, or &#8220;IRB,&#8221; which is an independent committee registered with and overseen by the U.S. Department of Health and Human Services, or &#8220;HHS,&#8221; that functions to approve, monitor and review biomedical and behavioral research involving humans, may suspend clinical trials of a drug candidate at any time for various reasons, including if we or it believe the subjects or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a drug candidate on subjects or patients in a clinical trial could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing to approve a particular drug candidate for any or all indications of use.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trials of a new drug candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the drug candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, and delays in patient enrollment can result in increased costs and longer development times than we expect at present. Patients who are enrolled at the outset of this standard of care also may eventually choose for personal reasons not to participate in the study. We also compete for eligible patients with other clinical trials underway from time to time, and we may experience delays in patient enrollment due to the dependency of other large trials underway in the same patient population.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trials also require the review and oversight of IRBs, which approve and continually review clinical investigations to protect the rights and welfare of human subjects. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or information derived from a clinical investigation not subject to initial and continuing IRB review and approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, cancer vaccines are a relatively new form of therapeutic treatment and a very limited number of such products have received regulatory approval. Therefore, the FDA or other regulatory authority may apply standards for approval of a new cancer vaccine that is different from past experience.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Numerous factors could affect the timing, cost or outcome of our drug development efforts, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">difficulties or delays in enrolling patients in our planned clinical trials in conformity with required protocols or projected timelines; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">difficulties or delays in arranging for third parties to conduct clinical trials of our product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">problems in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our drug candidates having very different chemical and pharmacological properties in humans than in laboratory testing and interacting with human biological systems in unforeseen, ineffective or harmful ways, and the possibility that our previous Phase 1 or Phase 2 trials will not be indicative of our drug candidates&#8217; performance in larger patient populations; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the need to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">insufficient or inadequate supply or quality of our drug candidates or other necessary materials necessary to conduct our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">disruption at our clinical trial sites resulting from local social or political unrest or other geopolitical factors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">effects of our drug candidates not having the desired effects or including undesirable side effects or the drug candidates having other unexpected characteristics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to our own or inability to generate statistically significant data confirming the efficacy of the product being tested; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">adverse results obtained by other companies developing similar drugs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">modification of the drug during testing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our capital resources; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reallocation of our financial and other resources to other clinical programs. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">It is possible that none of the product candidates that we develop will obtain the appropriate regulatory approvals necessary for us to begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the complexity of the drug candidate. Any analysis we perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenue from the particular drug candidate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, the length of time to develop the product candidates as well as any regulatory delays in the development and regulatory approval process could cause the patent exclusivity to be unavailable or greatly reduced for each product candidate. The lack of patent exclusivity could have a material adverse effect on our ability to generate revenue from the particular drug candidate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are also subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the U.S.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent upon contract manufacturers for clinical supplies of our product candidates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We do not have the facilities or expertise to manufacture supplies of any of our product candidates for clinical trials. Accordingly, we are dependent upon contract manufacturers for these supplies. There can be no assurance that we will be able to secure needed supply arrangements on reasonable terms, or at all. Our failure to secure these arrangements as needed could have a materially adverse effect on our ability to complete the development of our product candidates or, if we obtain regulatory approval for our product candidates, to commercialize them.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our current plans call for the manufacture of our compounds by contract manufacturers offering research grade, Good Laboratory Practices grade and Good Manufacturing Practices grade materials for preclinical studies (e.g., toxicology studies) and for clinical use. Certain of our product candidates are complex molecules requiring many synthesis steps, which may lead to challenges with purification and scale-up. These challenges could result in increased costs and delays in manufacturing. For GALE-401, we will change contract manufacturers for the supply of the clinical study drug and the commercial product, which may lead to delays in the initiation and completion of the Phase 3 trial and filing for regulatory approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">In the clinical trials using NeuVax, Leukine is also administered and its availability is dependent upon a third-party manufacturer, which may or may not reliably provide Leukine, thus jeopardizing the completion of the trials.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax is administered in combination with Leukine, a &#8220;GM-CSF&#8221; available in both liquid and lyopholyzed forms exclusively from Genzyme Corporation, or &#8220;Genzyme,&#8221; a subsidiary of Sanofi-Aventis. We will continue to be dependent on Genzyme for our supply of Leukine in connection with the ongoing NeuVax and GALE-301/GALE-302 trials and the potential commercial manufacture of these programs. Any temporary interruptions or discontinuation of the availability of Leukine, or any determination by us to change the GM-CSF used with NeuVax or GALE-301/GALE-302, may have a material adverse effect on our clinical trials and any commercialization of the assets.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to establish or maintain the third-party relationships that are necessary to develop or potentially commercialize some or all of our product candidates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect to depend on collaborators, partners, licensees, clinical research organizations and other third parties to support our discovery efforts, to formulate product candidates, to manufacture our product candidates, and to conduct clinical trials for some or all of our product candidates. We cannot guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully negotiate such agreements will depend on, among other things, potential partners&#8217; evaluation of the superiority of our technology over competing technologies and the quality of the preclinical and clinical data that we have generated, and the perceived risks specific to developing our product candidates. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates. Under certain license agreements that we have already entered into, we have minimum dollar amounts per year that we are obligated to spend on the development of the technology we have licensed from our contract partners and other obligations to maintain certain licenses. If we fail to meet this requirement under any of our licenses that contain such requirements or any other obligations under these licenses, we may be in breach of our obligations under such agreement, which may result in the loss of the technology licensed. We cannot necessarily control the amount or timing of resources that our contract partners will devote to our research and development programs, product candidates or potential product candidates, and we cannot guarantee that these parties will fulfill its obligations to us under these arrangements in a timely fashion. We may not be able to readily terminate any such agreements with contract partners even if such contract partners do not fulfill its obligations to us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, we may receive notices from third parties from time to time alleging that our technology or product candidates infringe upon the intellectual property rights of those third parties. Any assertion by third parties that our activities or product candidates infringe upon its intellectual property rights may adversely affect our ability to secure strategic partners or licensees for our technology or product candidates or our ability to secure or maintain manufacturers for our compounds.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to competition and may not be able to compete successfully.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The biotechnology industry, including the cancer immunotherapy market, is intensely competitive and involves a high degree of risk. We compete with other companies that have far greater experience and financial, research and technical resources than us. Potential competitors in the U.S. and worldwide are numerous and include pharmaceutical and biotechnology companies, educational institutions and research foundations, many of which have substantially greater capital resources, marketing experience, research and development staffs and facilities than us. Some of our competitors may develop and commercialize products that compete directly with those incorporating our technology, introduce products to market earlier than our products or on a more cost effective basis. In addition, our technology may be subject to competition from other technology or methods developed using techniques other than those developed by traditional biotechnology methods. Our competitors compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our technology. We and our collaborators may face competition with respect to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent position, including the potentially dominant patent positions of others. An inability to successfully complete our product development could lead to us having limited prospects for establishing market share or generating revenue from our technology.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">GALE-401 must successfully complete a Phase 3 clinical trial and obtain regulatory approval before we can market the product and our competitors may obtain a successful clinical trial result and regulatory approval before we do.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-401 contains the active ingredient, anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. These adverse events may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration (Cmax) is hypothesized to reduce the side effects, while preserving efficacy, potentially allowing a broader use of the drug. We have analyzed our data and the treatment landscape for MPNs, with a current focus on Essential Thrombocythemia (ET) where we see an unmet medical need in patients who are intolerant to the current standard of care. We may be advancing GALE-401 into a pivotal trial. The risks include but are not limited to regulatory (agreement with regulatory agency on the development plan), operational (rate of enrollment), and statistical confirmation of the safety and efficacy endpoints. In addition, there are other potential competitors whose clinical trials may be successful and obtain regulatory approval prior to our regulatory approval, if our pivotal trial is successful.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on technologies we license, and if we lose the right to license such technologies or we fail to license new technologies in the future, our ability to develop new products would be harmed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently are dependent on licenses from third parties for technologies relating to our product candidates. Our current licenses impose, and any future licenses we enter into are likely to impose, various development, funding, royalty, diligence, sublicensing, insurance and other obligations on us. If our license with respect to any of these technologies is terminated for any reason, the development of the products contemplated by the licenses would be delayed, or suspended altogether, while we seek to license similar technology or develop new non-infringing technology. The costs of obtaining new licenses are high.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Risks associated with operating in foreign countries could materially adversely affect our product development.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may conduct future studies in countries outside of the United States. Consequently, we may be subject to risks related to operating in foreign countries. Risks associated with conducting operations in foreign countries include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">differing regulatory requirements for drug approvals and regulation of approved drugs in foreign countries; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign taxes, including withholding of payroll taxes; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the U.S.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">business interruptions resulting from geopolitical actions, including war and terrorism. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Risks Relating to Our Financial Position and Capital Requirements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are conducting a review of strategic alternatives for the Company, including evaluating potential paths forward for NeuVax, GALE 301/302 and GALE 401 that could significantly impact our future operations and financial position.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2017, we announced that our board of directors had initiated a review of strategic alternatives that could result in changes to our business strategy and future operations. As part of this process, our board of directors is reviewing alternatives with the goal of maximizing stockholder value. Potential strategic alternatives that we may explore and evaluate during the ongoing review process include, among others, a sale of the company, a reverse merger, a business combination or a sale, license or other disposition of corporate assets of the company. Pending any decision to change strategic direction, we have limited our research and development activities to manage our cash position. We cannot provide any commitment as to the timing of our determination or the strategy we may adopt. If we determine to change our business strategy or to seek to engage in a strategic transaction, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or projected by our management. If we determine to further develop NeuVax, GALE 301/302 and GALE 401, or all of the products, we will need to obtain substantial additional funding. Because of the significant uncertainty regarding our future plans, we are not able to accurately predict the impact of a potential change in our business strategy and future funding requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain sufficient financing, and may not be able to develop our product candidates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We had cash and cash equivalents of approximately $29.1 million as of February 28, 2017. We had no revenue during the year ended December 31, 2016, and our cash burn from operations for the quarter ending December 31, 2016 was approximately $8.0 million. We believe that our existing cash and cash equivalents should be sufficient to fund our operations for at least one year from the date of issuance of the Company's consolidated financial statements. This projection is based on our current limited planned operations, anticipated payments for defense costs for the governmental investigation, and estimates of potential resolution of the SEC investigation, and is also subject to changes in our operating plans, resolution of and unanticipated developments in the ongoing government investigation and other legal matters and uncertainties inherent in our business. We may need to seek to replenish our existing cash and cash equivalents prior over the next year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, we have approximately $13.7 million of restricted cash as of February 28, 2017. We negotiated an amendment with the holder of the debt that reduces the restricted cash amount to the lesser of $18.5 million or the outstanding balance of the amended debenture under certain conditions. We also have limited funding available under our amended purchase agreement with Lincoln Park Capital Fund, LLC and sales agreements with FBR &amp; Co. and Maxim Group LLC. There is no guarantee that such funding will be available to us on favorable terms or will be sufficient to meet all of our future funding needs.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At our annual meeting of stockholders adjourned on July&#160;15, 2016, our stockholders approved an increase in our authorized common stock from 275,000,000 to 350,000,000. In addition, our shareholders authorized the Board of Directors to approve a reverse stock split within twelve months of October&#160;21, 2016 at a ratio between 1:2 and 1:20. There was no reduction in the amount of authorized shares. The Board of Directors approved a reverse stock split at a ratio of 1:20, effective on November&#160;11, 2016.  We are not able to predict whether volume of shares post reverse stock split will be sufficient based upon the reverse stock split price to meet the Company&#8217;s ongoing financing requirements to maintain the Company&#8217;s operations.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we fail to obtain additional future funding when needed, we could be forced to scale back or terminate our operations, or to seek to merge with or to be acquired by another company. We may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We expect to continue to incur significant operating and non-operating expenses, which may make it difficult for us to secure sufficient financing, and may lead to uncertainty about our ability to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Substantial funds were expended to develop our technologies and product candidates, and additional substantial funds will be required for further preclinical testing and clinical trials of our product candidates, and to manufacture and market any products that are approved for commercial sale. Because the successful development of our products is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to generate enough revenue, even if we are able to commercialize any of our product candidates, to become profitable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the event that we are unable to obtain additional financing if needed or if we incur significant expense related to the resolution of the ongoing government investigation, we may not be able to meet our obligations as they come due, that in turn may raise substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will secure additional financing if we need such financing. Our financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Changes in our operating plans, our existing and anticipated working capital needs, defense costs related to the recent securities lawsuits, resolution of the ongoing government investigation, the acceleration or modification of our expansion plans, increased expenses, potential acquisitions or other events may affect our ability to continue as a going concern. Future financing may be obtained through, and future development efforts may be paid for by, the issuance of debt or equity, which may have an adverse effect on our security holders or may otherwise adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we raise funds through the issuance of debt or equity, any debt securities or preferred stock issued will have rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the holders of common stock. In addition, if we raise funds through the issuance of additional equity, whether through private placements or additional public offerings, such an issuance would dilute your ownership in us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The terms of debt securities may also impose restrictions on our operations, which may include limiting our ability to incur additional indebtedness, to pay dividends on or repurchase our capital stock, or to make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of our control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">You may have difficulty evaluating our business, and our historical financial information may not be representative of our future results.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have closed our PRESENT trial due to futility, are evaluating the appropriate time to commence the GALE-401 trial and anticipate making a definitive determination in the second half of 2017, and plan to continue to support the investigator-sponsored immunotherapy trials. As a result, we will have no recurring revenues unless and until we are able to obtain marketing approval of one or more of our other product candidates and our historical financial information may not be representative of our future results</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to comply with our reporting and other requirements under federal securities laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As a publicly traded company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the &#8220;Exchange Act,&#8221; and the Sarbanes-Oxley Act of 2002, or the &#8220;Sarbanes-Oxley Act.&#8221; In addition, the Exchange Act requires that we file annual, quarterly and current reports. Our failure to prepare and disclose this information in a timely manner could subject us to penalties under federal securities laws, expose us to lawsuits and restrict our ability to access financing. The Sarbanes-Oxley Act requires that we, among other things, establish and maintain effective internal controls and procedures for financial reporting. From time to time we evaluate our existing internal controls in light of the standards adopted by the Public Company Accounting Oversight Board. It is possible that we, or our independent registered public accounting firm, may identify significant deficiencies or material weaknesses in our internal control over financial reporting in the future. Any failure or difficulties in implementing and maintaining these controls could cause us to fail to meet the periodic reporting obligations or result in material misstatements in our financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Section&#160;404 of the Sarbanes-Oxley Act requires annual management and independent auditor assessments of the effectiveness of our internal control over financial reporting. Our failure to satisfy the requirements of Section&#160;404 on a timely basis could result in the loss of investor confidence in the reliability of our financial statements, which in turn could have a material adverse effect on our business and our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain and enforce patent rights or other intellectual property rights that cover our product candidates and that are of sufficient breadth to prevent third parties from competing against us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our success with respect to our product candidates will depend in part on our ability to obtain and maintain patent protection in the U.S. and abroad, to preserve our trade secrets, and to prevent third parties from infringing upon our proprietary rights. Our patents and patent applications, however, may not be sufficient to provide protection for NeuVax or our other products and product candidates against commercial competition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The active peptide found in NeuVax, the E75 peptide, has been known and studied for many years. We have one issued U.S. patent, US 6,514,942, covering the composition of matter of the E75 peptide, which expired in mid-2015, prior to any potential commercialization of NeuVax. We do not have and will not be able to obtain any composition of matter patent protection for E75, the active peptide in NeuVax. We also have a license from The Henry M. Jackson Foundation to issued U.S., European, Japanese, Korean, Mexican and Australian method of use patents, which expire in 2028, that are directed to a method of inducing immunity against breast cancer recurrence by administering a composition comprising the E75 peptide to patients who have both an immunohistochemistry (IHC) rating of 1+ or 2+ for HER2/neu protein expression, as well as a fluorescence in situ hybridization (FISH) rating of less than about 2.0 for HER2/neu gene expression. The license further includes an issued U.S. method of use patent directed to a method of inducing immunity against recurrence of any HER2/neu expressing tumors by administering the E75 peptide to patients with tumors having a FISH rating of less than about 2.0 for HER2/neu gene expression; an allowed U.S application which includes claims to the use of E75 to reduce the risk of cancer recurrence, including bone only recurrence; and pending applications with similar claims in a number of foreign jurisdiction, all of which expire in 2028. Also included in the license is a method of use patent, which expires in 2026, that is directed to the use of NeuVax in combination with Herceptin</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(trastuzumab) to treat any HER2/neu expressing cancer. Thus, our method of use patents may not prevent competitors from seeking to develop and market NeuVax for use in cancer patients who do not meet these criteria. If any such alternative uses were approved, this could lead to off-label use and price erosion for our NeuVax product. We may seek FDA approval for use of NeuVax to treat cancer patients who fall outside the claimed IHC and FISH ranges and for other cancers as well. Although we are pursuing additional patent protection for NeuVax through pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant commercial advantage.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Anagrelide hydrochloride, the sole active pharmaceutical ingredient, or &#8220;API,&#8221; in GALE-401, has been approved for many years and, thus, it is not possible to obtain composition of matter patents that cover anagrelide hydrochloride. As a result, competitors who obtain the requisite regulatory approval can offer products with the same 43 API as GALE-401, so long as the competitors do not infringe any formulation patents that we may have or may obtain or license, if any. The only patent protection that we have or are likely to obtain covering GALE-401 are patents relating to specific formulations, methods using these formulations, and methods of manufacturing and packaging. We have an issued U.S. Patent, which expires in 2020, covering methods of using anagrelide to reduce platelet count in patients subject to veno-occlusive events. We have granted patents in the U.S., United Kingdom and Japan, which expire in 2029, covering controlled release formulations of anagrelide and methods of use. We also are prosecuting pending patent applications in other territories including, but not limited to, the U.S., Europe, India, and Japan, which may not issue prior to any potential commercialization of GALE-401. We may seek FDA approval for use of GALE-401 to treat patients with myeloproliferative neoplasms that include several hematological disorders, including essential thrombocythemia. Although we are pursuing additional patent protection for GALE-401 through pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant commercial advantage.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The active peptides found in GALE-301 and GALE-302 are derived from Folate Binding Protein. One of the active peptides, E39, has been known and studied for many years. The other active peptide, GALE-302, is a derivative of E39. We have a license from The Henry M. Jackson Foundation to issued and granted patents in the U.S., Europe, Canada, and Japan, covering composition of matter for the E39 derivative peptides, including GALE-302, alone and in combination with E39, as well as the use of these compositions for the treatment of cancer. These patents are expected to expire in 2022, prior to any potential commercialization of GALE-301. We do not have and will not be able to obtain any composition of matter patent protection for the E39 peptide in any territory. The license we have from The Henry M. Jackson Foundation grants us the right to develop and market GALE-301 for any use, including methods of treating cancer. Our patents may not prevent competitors from seeking to develop and market the E39 peptide alone. If any such alternative uses of compositions containing the E39 peptide were approved, this could lead to off label use and price erosion for GALE-301. We may seek FDA approval for use of GALE-301, alone or in combination with GALE-302, to treat cancer patients with ovarian and endometrial cancers and for other cancers, as well. Although we are pursuing additional patent protection for GALE-301 and the combination of GALE-301 and GALE-302 through pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant commercial advantage.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under any patents we have or may obtain or license may not provide us with sufficient protection for our commercial product and product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. Nor can we guarantee that the claims of these patents will be held valid or enforceable by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Changes in either the patent laws or in the interpretations of patent laws in the U.S. or abroad may diminish the value of our intellectual property. In addition, on September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act, in particular the first-to-file provision and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement of or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">While we intend to take actions reasonably necessary to enforce our patent rights, we may not be able to detect infringement of our own or in-licensed patents, which may be especially difficult for methods of manufacturing or formulation products, and we depend, in part, on our licensors and collaborators to protect a substantial portion of our proprietary rights. In addition, third parties may challenge our in-licensed patents and any of our own patents that we may obtain, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. Litigation or other proceedings to enforce or defend intellectual property rights is very complex, expensive, and may divert our management&#8217;s attention from our core business and may result in unfavorable results that could adversely affect our ability to prevent third parties from competing with us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If another party has reason to assert a substantial new question of patentability against any of our claims in our own and in-licensed patents, the third party can request that the patent claims be reexamined, which may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential infringement suits and, interference and reexamination proceedings, we may become a party to patent opposition proceedings where either the patentability of the inventions subject of our patents are challenged, or we are challenging the patents of others. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful. As the medical device, biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our commercial product and/or product candidates infringe their patent rights. If a third-party&#8217;s patents were found to cover our commercial product and product candidates, proprietary technologies or its uses, we or our collaborators could be enjoined by a court and required to pay damages and could be unable to continue to commercialize our products or use our proprietary technologies unless we or it obtained a license to the patent. A license may not be available to us or our collaborators on acceptable terms, if at all. In addition, during litigation, the patent holder could obtain a preliminary injunction or other equitable relief, which could prohibit us from making, using or selling our commercial product and product candidates pending a trial on the merits, which could be years away.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how, by entering into confidentiality agreements with third parties, and proprietary information and invention agreements with certain employees, consultants and advisors, third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our licensors, collaborators and suppliers. There can be no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time consuming, and the outcome is unpredictable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their other clients or former employers. As is common in the biotechnology and pharmaceutical industry, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our commercial product and product candidates, many of whom were previously employed at or may have previously been or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Litigation may be necessary to defend against these types of claims. Even if we are successful in defending against any such claims, any such litigation would likely be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates may face competition sooner than expected after the expiration of our composition of matter patent protection for such products.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our composition of matter patents for many of our product candidates have expired or will expire prior to any product approval. We intend to seek data exclusivity or market exclusivity for our NeuVax as well as our GALE-301 and GALE-302 product candidates provided under the Federal Food, Drug and Cosmetic Act, or FDCA, and similar laws in other countries. We believe that these product candidates will qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which was enacted as part of the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, the Affordable Care Act or ACA) enacted in March 2010. Under the BPCIA, an application for a biosimilar product or BLA cannot be submitted to the FDA until four years, or if approved by the FDA, until 12 years, after the original brand product identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. The new law is complex and is only beginning to be interpreted and implemented by the FDA. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological product candidates. There is also a risk that the U.S. Congress could amend the BPCIA to shorten this exclusivity period, potentially creating the opportunity for biosimilar competition sooner than anticipated after the expiration of our patent protection. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If our product candidates are not considered biologics that would qualify for exclusivity under the BPCIA, they may be eligible for market exclusivity as drugs under the FDCA. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA, submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by FDA to be essential to the approval of the application, for example, for new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Even if, as we expect, NeuVax, GALE-301 and GALE-302 are considered to be reference products eligible for 12 years of exclusivity under the BPCIA or five years of exclusivity under the FDCA, another company could market competing products if the FDA approves a full BLA or full NDA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the products.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In some countries outside of the U.S., peptide vaccines, such as NeuVax, GALE-301 and GALE-302, are regulated as chemical drugs rather than as biologics and may or may not be eligible for non-patent exclusivity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Although we have received orphan drug designation for both GALE-301, as well as GALE-301 and GALE-302, there is no guarantee that the drugs will be successfully approved by the FDA, that they will be commercially successful in the marketplace, or that another drug will not be approved for the same indication ahead of our drugs.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Significant disruptions of information technology systems or breaches of information security could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We rely to a large extent upon sophisticated information technology systems to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual property). We also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. The size and complexity of our information technology and information security systems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from malicious attacks by third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage and market manipulation) and expertise. While we have invested significantly in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow third parties to gain material, inside information that they use to trade in our securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Risks Relating to Ownership of Our Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our common stock trades at prices less than $1.00 which is the minimum bid price requirement under NASDAQ&#8217;s continued listing standards, as such our common stock may be subject to delisting from the NASDAQ Capital Market.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The continued listing requirements of the NASDAQ Capital Market require that the closing bid price of our common stock not be less than $1.00 for 30 consecutive trading days. On March&#160;14, 2017 the last reported sale price of our common stock on the NASDAQ Capital Market was $0.55 per share and has been below the $1.00 closing bid price since February 8, 2017. If our trading price falls below $1.00 for 30 consecutive trading days or more, we may receive a notice from NASDAQ informing us that we may be delisted unless our trading price is above $1.00 for more than 10 consecutive trading days. In accordance with NASDAQ Listing Rule 5810(c)(3)(A), we would have 180 calendar days to regain compliance with the $1.00 minimum bid price requirement. We can regain compliance with the $1.00 minimum bid listing requirement if the closing bid price is at least $1.00 per share for a minimum of ten consecutive trading days during this initial 180-day compliance period. If compliance is not achieved within the 180-day period, NASDAQ would provide written notification to us that our common stock is subject to delisting. In the event that we fail to regain compliance with NASDAQ continued listing standards by the expiration of the applicable cure period or any extension period, NASDAQ will commence suspension and delisting procedures with respect to our common stock, which could impair the value of your investment. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January&#160;18, 2017, we received an inquiry from NASDAQ Listing Qualifications Department seeking information in connection with the subpoenas issued to the Company by the US Attorney&#8217;s Office for the District of New Jersey and the U.S. Attorney&#8217;s Office for the Southern District of Alabama. We responded to the inquiry on February&#160;1, 2017. If we are not in compliance with the listing requirements under NASDAQ Listing Rule 5502(a)(2), we could be delisted by NASDAQ.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If our common stock is delisted from NASDAQ Capital Market in the future, such securities may be traded over-the-counter on the &#8220;pink sheets.&#8221; Such alternative market, however, is generally considered to be less efficient than, and not as broad as, NASDAQ. Accordingly, delisting of our common stock from NASDAQ could have a significant negative effect on the trading volume, liquidity and market price of our common stock. In addition, the delisting of our common stock could adversely affect our ability to raise capital on terms acceptable to us or at all and could reduce the number of investors willing to hold or acquire our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The market price and trading volume of our common stock may be volatile.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The market price of our common stock has exhibited substantial volatility recently. Between January 1, 2016 and February&#160;28, 2017, the sale price of our common stock as reported on The NASDAQ Capital Market ranged from a low of $0.62 to a high of $49.80 as adjusted for the reverse stock split effected in November 2016. The market price of our common stock could continue to fluctuate significantly for many reasons, including the following factors:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reports of the results of our clinical trials regarding the safety or efficacy of our product candidates and surrogate markers; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">announcements of regulatory developments or technological innovations by us or our competitors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">announcements of business or strategic transactions or our success in finalizing such a transaction; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">announcements of legal or regulatory actions against us or any adverse outcome of any such actions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">changes in our relationship with our licensors, licensees and other strategic partners; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our quarterly operating results; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">developments in patent or other technology ownership rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">additional funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stockholders; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">government regulation of drug pricing; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">general changes in the economy, the financial markets or the pharmaceutical or biotechnology industries. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Factors beyond our control may also have an impact on the price of our stock. For example, to the extent that other companies within our industry experience declines in their stock prices, our stock price may decline as well.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are, and in the future may be, subject to legal or administrative actions that could adversely affect our financial condition and our business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;22, 2016, Galena Biopharma, Inc. and its former CEO reached an agreement in principle to a proposed settlement that would resolve an investigation by the staff of the SEC involving conduct in the period 2012-2014 regarding the commissioning of internet publications by outside promotional firms. Under the terms of the proposed settlement framework, Galena and the former CEO would consent to the entry of an administrative order requiring that we and the former CEO cease and desist from any future violations of Sections 5(a), 5(b), 5(c), 17(a), and 17(b) of the Securities Act of 1933, as amended, and Section&#160;10(b), 13(a), and 13(b)(2)(A) of the Securities Exchange Act of 1934, as amended, and various rules thereunder, without admitting or denying the findings in the order. Based upon the proposed settlement framework, the Company will make a $200,000 penalty payment. In addition to other remedies, the proposed settlement framework would require the former CEO to make a disgorgement and prejudgment interest payment as well as a penalty payment to the Commission. To address the issues raised by the SEC staff&#8217;s investigation, in addition to previous governance enhancements we have implemented, we have voluntarily undertaken to implement a number of remedial actions relating to securities offerings and our interactions with investor relations and public relations firms. The proposed settlement is subject to approval by the Commission and would acknowledge our cooperation in the investigation and confirm our voluntary undertaking to continue that cooperation. If the Commission does not approve the settlement, we may need to enter into further discussions with the SEC staff to resolve the investigated matters on different terms and conditions. As a result, there can be no assurance as to the final terms of any resolution including its financial impact or any future adjustment to the financial statements. A special committee of the Board of Directors has determined in response to an indemnification claim by the former CEO that we are required under Delaware law to indemnify our former CEO for the disgorgement and prejudgment interest payment of approximately $750,000 that he would be required to pay if and when the settlement is approved by the Commission. Any penalty payment that the former CEO will be required to make in connection with this matter ($600,000 under the proposed settlement framework) will be the responsibility of the former CEO. In the event the Commission does approve the proposed settlement, the Company may not have available certain exemptions and safe harbor protections under the securities laws.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Miller v. Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. On February 15, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Kattuah v Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Within the time allowed under the federal rules and statutes, the Company and the other defendants, former and current officers, will respond to the complaints through an appropriate pleading or motion.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation of two of the high-prescribing physicians for Abstral (former commercial product) has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial began in January 2017 and is ongoing. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&#8217;s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April&#160;28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. The criminal trial</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;which began on January 4, 2017, concluded with a jury verdict on February 23, 2017 finding these physicians guilty on 19 of 20 counts; sentencing is scheduled for May 2017. At the end of the SDAL case</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;SDAL dismissed count 18 of the indictment charging that the physicians conspired, through the C&amp;R Pharmacy, to receive illegal kickbacks in exchange for prescribing Abstral. Though certain former employees received trial subpoenas to appear at the trial and provide oral testimony, only one former employee testified at the trial. We agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we were not a target or subject of that investigation. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December&#160;16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office for the District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and are cooperating in the production of the requested documents. We have come to understand that the investigation being undertaken by the U.S. Attorney&#8217;s Office for the District of New Jersey and Department of Justice is a criminal investigation in addition to a civil investigation that could ultimately involve the company as well as one or more former employees. Pursuant to the Company&#8217;s charter, we are currently reimbursing any former employees&#8217; attorney&#8217;s fees with respect to the investigation. We are cooperating with the civil and criminal investigation and through our outside counsel we have recently begun preliminary discussions with the government aimed at the ultimate resolution of the investigation regarding the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may be subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Litigation is inherently uncertain. We have incurred and may continue to incur substantial unreimbursed legal fees and other expenses in connection with these or other legal and regulatory proceedings that may not qualify for coverage under, or may exceed the limits of, our applicable directors and officers liability insurance policies and could have a material adverse effect on our financial condition, liquidity, and results of operations. These matters also may distract the time and attention of our officers and directors or divert our other resources away from our ongoing development programs. An unfavorable outcome in any of these matters could damage our business and reputation or result in additional claims or proceedings against us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Future sales in the public market of shares of our common stock, including shares referred to in the foregoing risk factors or shares issued upon exercise of our outstanding stock options, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2016, we had reserved for issuance 560,925 shares of our common stock issuable upon the exercise of outstanding stock options at a weighted-average exercise price of $41.50 per share and 2,569,751 shares of our common stock issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $29.12 per share. Upon exercise of these options and warrants, the underlying shares may be resold into the public market. In the case of outstanding options and warrants that have exercise prices that are below the market price of our common stock from time to time, our stockholders would experience dilution upon the exercise of these options.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our outstanding warrants may result in dilution to our stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our outstanding April 2011 warrants to purchase a total of 12,900 shares of common stock as of December 31, 2016 at a current exercise price of $1.00 per share contain so-called full-ratchet anti-dilution provisions. Our outstanding December 2012 warrants to purchase 151,565 shares of common stock as of December 2016 with a current exercise price of $10.32 per share contain so-called weighted-average anti-dilution provisions. These anti-dilution provisions may be triggered by the issuance of the shares being offered hereby or upon any future issuance by us of shares of our common stock or common stock equivalents at a price per share below the then-exercise price of the warrants, subject to some exceptions. The share and per share amounts described above are presented on a post-split basis that was effected November&#160;11, 2016.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">To the extent that these anti-dilution provisions are triggered in the future, we would be required to reduce the exercise price of all of the warrants on either a full-ratchet or weighted-average basis, which would have a dilutive effect on our stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may issue preferred stock in the future, and the terms of the preferred stock may reduce the value of our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are authorized to issue up to 5&#160;million shares of preferred stock in one or more series. Our Board of Directors may determine the terms of future preferred stock offerings without further action by our stockholders. If we issue preferred stock, it could affect stockholder rights or reduce the market value of our outstanding common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws and provisions of Delaware law could delay or prevent a change of control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger or other change of control that stockholders may consider favorable or may impede the ability of the holders of our common stock to change our management and may be constrained by other contractual agreements with third parties. These provisions of our amended and restated certificate of incorporation and amended and restated bylaws, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">divide our board of directors into three classes, with members of each class to be elected for staggered three-year terms; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">limit the right of security holders to remove directors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">prohibit stockholders from acting by written consent; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">regulate how stockholders may present proposals or nominate directors for election at annual meetings of stockholders; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">authorize our board of directors to issue preferred stock in one or more series, without stockholder approval. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, Section&#160;203 of the Delaware General Corporation Law provides that, subject to limited exceptions, persons that acquire, or are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation such as our company shall not engage in any business combination with that corporation, including by merger, consolidation or acquisitions of additional shares for a three-year period following the date on which that person or its affiliate crosses the 15% stock ownership threshold. Section&#160;203 could operate to delay or prevent a change of control of our company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have never declared or paid cash dividends on our capital stock and we do not anticipate paying cash dividends in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our business requires significant funding. We currently plan to invest all available funds and future earnings in the development and growth of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future, and are prohibited by the terms of our outstanding indebtedness from paying dividends on any common stock, except with the prior consent of our lenders. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of potential gain for the foreseeable future.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The terms of our outstanding indebtedness may inhibit potential acquirers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are prohibited by the terms of our outstanding indebtedness from disposing of any of our business or property, except with the consent of our lenders or if we were to prepay the outstanding indebtedness and related fees in accordance with the loan security agreement. Our outstanding indebtedness may inhibit potential acquirers or other interested parties from seeking to acquire all or a part of our business or assets, and there is no assurance that our lenders would consent to any proposed future transaction that might be beneficial to our stockholders</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><a name="s46489A445327DC1D4BF06F9E68C18531"></a></div><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 1B. UNRESOLVED STAFF COMMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have received no unresolved written comments from the staff of the SEC regarding our periodic or current reports.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sBD8F222EE39560EB34626F9E68E627BA"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 2. PROPERTIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 10, 2015, we entered into a lease with Legacy III SR Crow Canyon, LLC for our facility located at 2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583. The facility is approximately 8,100 square feet and is used for our general and administrative offices. The monthly rent is approximately $20,000.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="s6EFACC6B1F50DBDACB176F9E6914FD75"></a></div><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;3. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval to the settlement awarding attorney&#8217;s fees of $4.5 million plus costs, which was paid by our insurance carriers. The settlement included a payment of $15 million in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of 1,200,000 outstanding director stock options. The settlement also required that we adopt and implement certain corporate governance measures. The settlement did not include any admission of wrongdoing or liability on the part of us or the individual defendants and included a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval of the settlement awarding attorney&#8217;s fees of $4.5 million plus costs, which was paid out of the settlement funds. The settlement agreement provided for a payment of $20 million to the class and the dismissal of all claims against us and our current and former officers and directors in connection with the consolidated federal securities class actions. Of the $20 million settlement payment to the class, $16.7 million was paid by our insurance carriers and $2.3 million in cash was paid by us on July 1, 2016, along with $1 million in shares of our common stock (24,002 shares) issued by us on July 6, 2016. We are responsible for defense costs and any settlements or judgments incurred for any related opt-out lawsuits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In July 2016, we resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for $150,000 plus $150,000 in shares (14,563 shares) of our common stock, and in another case for $1.5 million in shares of our common stock (168,337 shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements did not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and included a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 13, 2016, we filed a complaint in the Circuit Court for the County of Multnomah for the State of Oregon against Aon Risk Insurance Services West, Inc. where we are seeking attorney's fees, costs and expenses incurred by us related to our coverage dispute with a certain insurer and for amounts we were required to contribute to the settlements of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as a direct result of certain insurer's failure to pay its full policy limits of liability and other relief. We are currently engaged in written discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;22, 2016, Galena and its former CEO during the period March 2011 to August 2014 reached an agreement in principle to a proposed settlement that would resolve an investigation by the staff of the Securities and Exchange Commission (SEC) involving conduct in the period 2012-2014 regarding the commissioning of internet publications by outside promotional firms. Under the terms of the proposed settlement framework, Galena and the former CEO would consent to the entry of an administrative order requiring that we and the former CEO cease and desist from any future violations of Sections 5(a), 5(b), 5(c), 17(a), and 17(b) of the Securities Act of 1933, as amended, and Section&#160;10(b), 13(a), and 13(b)(2)(A) of the Securities Exchange Act of 1934, as amended, and various rules thereunder, without admitting or denying the findings in the order. Based upon the proposed settlement framework, the Company will make a $200,000 penalty payment. In addition to other remedies, the proposed settlement framework would require the former CEO to make a disgorgement and prejudgment interest payment as well as a penalty payment to the Commission. To address the issues raised by the SEC staff&#8217;s investigation, in addition to previous governance enhancements we have implemented, we have voluntarily undertaken to implement a number of remedial actions relating to securities offerings and our interactions with investor relations and public relations firms. The proposed settlement is subject to approval by the Commission and would acknowledge our cooperation in the investigation and confirm our voluntary undertaking to continue that cooperation. If the Commission does not approve the settlement, we may need to enter into further discussions with the SEC staff to resolve the investigated matters on different terms and conditions. As a result, there can be no assurance as to the final terms of any resolution including its financial impact or any future adjustment to the financial statements. A special committee of the Board of Directors has determined in response to an indemnification claim by the former CEO that we are required under Delaware law to indemnify our former CEO for the disgorgement and prejudgment interest payment of approximately $750,000 that he would be required to pay if and when the settlement is approved by the Commission. Any penalty payment that the former CEO will be required to make in connection with this matter ($600,000 under the proposed settlement framework) will be the responsibility of the former CEO.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Miller v. Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. On February 15, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Kattuah v Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Within the time allowed under the federal rules and statutes, the Company and the other defendants, former and current officers, will respond to the complaints through an appropriate pleading or motion.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation of two of the high-prescribing physicians for Abstral (former commercial product) has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. We received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&#8217;s Office for the Southern District of Alabama (SDAL), which is handling the criminal trial, and are cooperating in the production of documents. On April&#160;28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. The criminal trial</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;which began on January 4, 2017, concluded with a jury verdict on February 23, 2017 finding these physicians guilty on 19 of 20 counts; sentencing is scheduled for May 2017. At the end of the SDAL case</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;SDAL dismissed count 18 of the indictment charging that the physicians conspired, through the C&amp;R Pharmacy, to receive illegal kickbacks in exchange for prescribing Abstral. Though certain former employees received trial subpoenas to appear at the trial and provide oral testimony, only one former employee testified at the trial. We agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we were not a target or subject of that investigation. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office for the District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral, the commercial product we sold in the fourth quarter of 2015. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and Department of Justice, and we have come understand that the investigation being undertaken by the U.S. Attorney&#8217;s Office for the District of New Jersey and Department of Justice is a criminal investigation in addition to a civil investigation that could ultimately involve the Company as well as one or more former employees. Pursuant to the Company&#8217;s charter, we are currently reimbursing certain former employees&#8217; attorney&#8217;s fees with respect to the investigation. We are cooperating with the civil and criminal investigation, and through our outside counsel we have recently begun preliminary&#160;discussions with the government aimed at the ultimate resolution of the investigation regarding the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s9247B3586745C03A37CE6F9E693A17C5"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;4. Mine Safety Disclosures</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><a name="s75E4B2C0683502C365EE6F9E696823E7"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART II</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAF57E3D79C09B3BB48776F9E63FC8832"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our common stock is listed on The NASDAQ Capital Market under the symbol &#8220;GALE &#8221; The following table shows the high and low per-share sale prices of our common stock for the periods indicated:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">42.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Second Quarter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">47.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">25.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Third Quarter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">38.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fourth Quarter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Second Quarter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">49.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Third Quarter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fourth Quarter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Holders</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of February 28, 2017, there were approximately 189 holders of record of our common stock. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of individual stockholders represented by these holders of record.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Dividends</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have never paid any cash dividends and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We expect to retain future earnings, if any, for use in our development activities and the operation of our business. The payment of any future dividends will be subject to the discretion of our Board of Directors and will depend, among other things, upon our results of operations, financial condition, cash requirements, prospects and other factors that our board of directors may deem relevant. Additionally, our ability to pay future dividends may be restricted by the terms of any debt financing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Equity Compensation Plan</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth certain information as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, regarding securities authorized for issuance under our equity compensation plans:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:50%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Available for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Under Equity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Plans</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Excluding</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Reflected in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Column (a))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Plan Category</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Securities&#160;to&#160;be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issued Upon</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Options,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">of&#160;Outstanding</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Options,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants&#160;and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equity compensation plans approved by our security holders:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated&#160;2016 Incentive Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">560,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">500,692</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equity compensation plans not approved by our security holders:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NA</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NA</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,930</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding warrants </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">124,109</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">685,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">521,622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The warrants shown were issued in discrete transactions from time to time as compensation for services rendered by consultants, advisers or other third parties, and do not include warrants sold in private placement or public offering transactions. The material terms of such warrants were determined based upon arm&#8217;s-length negotiations with the services providers. The warrant exercise prices approximated the market price of our common stock at or about the date of grant, and the warrant terms range from three to ten years from the grant date.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following graph shows the value of an investment of $100 on December 31, 2011 in each of Galena Biopharma, Inc. common stock, the NASDAQ Composite Index, the NASDAQ Biotechnology Index, and Standard &amp; Poor's Index (S&amp;P 500). All values assume reinvestment of pretax value of dividends and are calculated as of December 31 of each year. The historical stock price performance of our common stock shown in the performance graph is not necessarily indicative of future stock performance.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">COMPARISON OF FIVE YEAR CUMULATIVE RETURNS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="performancechartv2.jpg" alt="performancechartv2.jpg" style="height:464px;width:590px;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">325.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,055.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">321.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">312.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S&amp;P 500</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115.88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">153.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">173.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">176.07</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">196.78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NASDAQ Composite</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">117.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">164.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">188.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">202.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">220.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NASDAQ Biotechnology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">132.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">220.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">202.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">330.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">260.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;The cumulative return depicted above for Galena Biopharma, Inc. does not include the value of our former subsidiary, RXi Pharmaceuticals Corporation ("RXi"), which we spun off to our stockholders in April 2012. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the period covered by this annual report, there were no sales by us of unregistered securities that were not previously reported by us in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><a name="sC1310E2C3C6169AD088A6F9E69BD7DA4"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 6. SELECTED FINANCIAL DATA </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following selected consolidated financial data is not necessarily indicative of results of future operations and should be read in conjunction with Item&#160;7,&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#160;and Item&#160;8,&#160;Financial Statements and Supplementary Data. On November 11, 2016, the Company effected a reverse stock-split and the following amounts related to earnings per share and shares outstanding have been adjusted for the reverse stock split for all periods reported. See Note 1 of Item&#160;8,&#160;Financial Statements and Supplementary Data&#160;for further detail on the Stock Split.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(amounts in thousands, except share and per share data)</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,424</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,614</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General, and administrative </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,065</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (loss) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,009</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,616</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(41,786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13,178</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from continuing operations </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(38,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(28,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(71,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(33,325</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from continuing operations per share, basic and diluted</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5.02</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10.60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65,811</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">82,144</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80,488</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">87,976</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">54,986</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total debt</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other long-term obligations</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,756</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,560</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,704</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,874</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,311</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stockholders' equity</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;See Note 3 of the notes to the consolidated financial statements for discussion of our spin-off of RXi activities being classified as discontinued operations in the consolidated statements of expenses for 2012. The net assets of RXi were removed from the consolidated balances sheet as of the date of the spin-off and were recorded as an equity distribution. The selected financial data referenced for the year ended December 31, 2012 is exclusive of RXi activities.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:14pt;"><font style="font-family:Helvetica,sans-serif;font-size:14pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><a name="s414DDE9B30558CC482B46F9E69E19A35"></a></div><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">You should read the following discussion in conjunction with the consolidated financial statements and the notes to consolidated financial statements included elsewhere in this annual report. This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For a discussion of indicators of forward-looking statements and specific important factors that could cause actual results to differ materially from those contained in forward-looking statements, see &#8220;Risk Factors&#8221; under Part I &#8212; Item&#160;1A of this annual report. This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section should be read and interpreted in light of such factors. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those discussed below and elsewhere in this annual report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">You may have difficulty evaluating our business, because we completed a partial spin off of RXi on April&#160;26, 2012. Since the partial spin-off, our financial statements no longer reflected the consolidated financial condition and results of operations of RXi, and we have accounted for our partial ownership of RXi based on the cost method of accounting. In addition, during the quarter ended September 30, 2015 the Company completed a strategic review of the Company's commercial business including the ongoing sale, distribution and marketing of our two commercial products, Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;(fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;(ondansetron) Oral Soluble Film (our &#8220;commercial business&#8221; asset group). As a result of the review, we made a determination to sell or otherwise dispose of our commercial business, which was completed during the quarter ended December 31, 2015. These actions caused the Company to meet the relevant criteria for reporting the Company's commercial business as held for sale and in discontinued operations. For these reasons, the historical consolidated financial information included in this annual report does not necessarily reflect the financial condition, results of operations or cash flows that we will achieve in the future.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><a name="s6F8291FC976246CC91A06F9E6A0E1BE0"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Overview</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax&#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and the asset is ready to advance into a pivotal trial in patients with essential thrombocythemia (ET). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are seeking to build value for shareholders through pursuit of the following objectives: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:114px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Develop hematology and oncology assets through clinical development with a focus in areas of unmet medical need. Our hematology asset is targeting the treatment of patients with ET to reduce elevated platelet counts. Our immunotherapy programs are currently targeting two key areas: secondary prevention intended to significantly decrease the risk of disease recurrence in breast, gastric, and ovarian cancers; and primary prevention intended to prevent ductal carcinoma </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">in situ</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(DCIS) from becoming invasive breast cancer. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:114px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Evaluating strategic alternatives that may include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:114px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Leverage partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><a name="s5E650248D41F97951CAD6F9E6A305880"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The preparation of our financial statements requires management to make estimates, allocations and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to impairment of goodwill and long-lived assets, accrued liabilities, net revenue, and certain expenses. Our estimates about the carrying values of assets and liabilities that are not readily apparent from other sources are based on historical experience and on other assumptions believed to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. Additionally, the financial information included here may not necessarily reflect the financial position, operating results, changes in our invested equity and cash flows in the future.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our significant accounting policies are summarized in the notes to our consolidated financial statements. We believe the following critical accounting policies involve significant judgments and estimates used in the preparation of our financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations ("CROs"), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We follow the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, &#8220;Compensation &#8212; Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options granted as consideration for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220;Equity Based Payments to Non-Employees.&#8221; Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of our common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of each option grant is estimated using the Black-Scholes option-pricing model, with the following weighted average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the volatility of a basket of companies that we consider comparable to us. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC 718-10, which averages the contractual term of the options of ten years with the average vesting term of four years for an average of six years. The expected life assumptions for non-employees were based upon the contractual terms of the options. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has an estimated annualized forfeiture rate of 15.0% for options granted to employees, and 8.0% for options granted to senior management and no forfeiture rate for directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Derivative Financial Instruments</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the normal course of business, from time to time, we issue warrants and options to vendors as consideration to perform services. We may also issue warrants as part of a debt or equity financing. We do not enter into any derivative contracts for speculative purposes.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We recognize all derivatives as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. During the years ended December&#160;31, 2016 and 2015, we issued warrants to purchase approximately 1,382,159 and 700,320 shares of common stock, respectively, in connection with equity transactions. In accordance with ASC Topic 815-40, &#8220;Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Stock&#8221; (&#8220;ASC&#160;815-40&#8221;), the fair value of these warrants is required to be recorded as a liability, as the holders have an option to put the warrants back to us in certain events, as defined, and the warrants are determined not to be indexed to the Company&#8217;s own stock.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The derivative liabilities are remeasured each period end to the estimated fair value. The fair value of our derivative liabilities is estimated using the appropriate pricing model, with the following assumptions used for the initial measurement of warrants granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.77%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.41%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">119.08%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73.41%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the volatility of a basket of companies that we consider comparable to us. The expected life assumptions for the warrants are estimated to coincide with the contractual terms of the warrants.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Business Combinations and Asset Purchases</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We allocate the purchase price of our acquisitions to the assets and liabilities acquired, including identifiable intangible assets, based on their respective fair values at the date of acquisition. Some of the items, including property and equipment, other intangible assets, certain accrued liabilities and other reserves require a degree of management judgment. Certain estimates may change as additional information becomes available. Management finalizes the purchase price allocation within 12 months of the acquisition date as certain initial accounting estimates are resolved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Goodwill, Other Intangible Assets and Impairment of Long-Lived Assets</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">significant negative industry or economic trends;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">significant decline in stock price for a sustained period; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">significant decline in market capitalization relative to net book value.</font></div></td></tr></table><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit (the &#8220;First Step&#8221;). If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment (the &#8220;Second Step&#8221;). Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible product rights when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, and has determined that there has been no impairment to these assets as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;The Company met the relevant criteria for reporting the commercial operations as held for sale as of September 30, 2015, and as a result, assessed the commercial asset group for impairment pursuant to ASC Topic 360, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Property, Plant, and Equipment.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;The net carrying value of the commercial asset group was compared to its fair value as of September 30, 2015. The Company determined that the fair value using a risk adjusted net present value of deal consideration received from bids from potential acquirers. The Company determined that the carrying value exceeded its fair value and as a result recorded an $8.1 million impairment charge on assets classified as held for sale in the quarterly period ended September 30, 2015.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Refer to Note 12 of the notes to the consolidated financial statements for further information regarding the acquisition of Abstral U.S. rights and Note 15 as to our reporting the commercial operations as held for sale and in discontinued operations.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Valuation of Contingent Purchase Price Consideration</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Acquisitions may include contingent consideration payments based on the achievement of certain future financial performance measures of the acquired company (earnout). Contingent consideration is required to be recognized at fair value as of the acquisition date. We estimate the fair value of these liabilities based on financial projections of the acquired companies and estimated probabilities of achievement. We believe our estimates and assumptions are reasonable; however, there is significant judgment involved. We evaluate, on a routine, periodic basis, the estimated fair value of the contingent consideration and changes in estimated fair value, subsequent to the initial fair value estimate at the time of the acquisition, are reflected in income or expense in the consolidated statements of comprehensive loss. Changes in the fair value of contingent consideration obligations may result from changes in discount periods and rates, changes in the timing of development milestones achieved and changes in probability assumptions with respect to the likelihood of achieving the various earnout criteria. Any changes in the estimated fair value of contingent consideration may have a material impact on our operating results.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Legal Fees and Insurance Recoveries</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Discontinued Operations</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We met the relevant criteria for reporting our commercial business as held for sale and in discontinued operations in the accompanying financial statements as of December 31, 2016 and 2015 and for the three years ended December 31, 2016, pursuant to FASB ASC Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB ASC Topic 360, Property, Plant, and Equipment.</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><a name="sDD6A8E4EF3CF91A21C496F9E6A62088F"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Results of Operations for the Years Ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">, 2015 and 2014</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;For the year ended December&#160;31, 2016, our net loss was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with net losses of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$63.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$36.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the years ended December&#160;31, 2015 and 2014, respectively.  The </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;decrease in net loss from 2015 to 2016 was primarily driven by a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in non-operating income and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;decrease in loss from discontinued operations. The loss from discontinued operations for the year ended December 31, 2015 includes an $8.1 million impairment charge recognized in the third quarter of 2015 and $4.5 million in the loss on the sale of the commercial assets. The </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$27.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in net loss from 2014 to 2015 was primarily driven by a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$16.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in loss from discontinued operations, which includes the one time impairment charge and loss on the sale of commercial assets in 2015. In addition, 2015 had an increase of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in non-operating expense and a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;decrease in operating loss compared to 2014.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016 vs. 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015 vs. 2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(31,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(43,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,009</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,616</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,946</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,322</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,549</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(63,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(36,606</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4.74</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Further analysis of the changes and trends in our operating results are discussed below.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sD513C4923F8B5ADA433F6F9E64460E1E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Research and Development Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expense consists primarily of clinical trial expenses and compensation-related costs for our employees dedicated to research and development activities, compensation paid to our Scientific Advisory Board (&#8220;SAB&#8221;) members, and licensing fees and patent prosecution costs. Research and development expense for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and 2014 were as follows (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,860</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The majority of our research and development expenses to date relate to our Phase 3 PRESENT clinical trial using NeuVax as a HER2 directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment. The trial costs were more significant during the recruitment and enrollment phase. We established more than 140 sites in 13 counties and screened over 3,300 patients in order to enroll qualifying patients who currently have no available treatment options to maintain their disease-free status after their standard of care. Once the patient was enrolled, they received vaccination and were to be monitored for a minimum of three years for recurrence of breast cancer, development of other cancers, or death. On April 14, 2015 we announced the completion of over-enrollment in the PRESENT trial of 758 patients, which was 7.7% higher than called for under our FDA-approved Special Protocol Assessment.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The decrease in research and development expense of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended December 31, 2016 compared to the year ended December 31, 2015 was primarily due to the decrease in enrollment efforts surrounding the Phase 3 PRESENT clinical trial, and ultimately the closing of that trial in the third quarter of 2016 as a result of the recommendation from the IDMC that the trial was futile. The decrease was partially offset by additional consulting expenses incurred in connection with the investigation of the PRESENT trial data to attempt to determine the cause of the futility conclusion.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The completion of over-enrollment in April 2015 reduced expenses related to the trial as we entered the monitoring phase and continued toward our interim safety and futility analysis on June 24, 2016, which resulted in the stopping and eventual closing of the Phase 3 PRESENT trial in the third quarter of 2016. The decrease in recruitment and enrollment expenses related to the Phase 3 PRESENT clinical trial were partially offset by recruitment, enrollment, and monitoring expenses in our other ongoing or planned clinical trials. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 31, 2017, we announced that we are evaluating strategic alternatives for the Company focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in a transaction. While the Company evaluates its strategic alternatives, we anticipate our research and development expenses to be driven by our two ongoing Phase 2 clinical trials of NeuVax in combination with trastuzumab for the prevention of recurrence of breast cancer and our Phase 2 clinical trial of NeuVax in patients with Ductal Carcinoma </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">in</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Situ. We are evaluating the appropriate time to commence the GALE-401 Phase 3 trial and anticipate making a definitive determination in the second half of 2017. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sCD7969CDC5DB9CF0805D6F9E632853D6"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">General and Administrative Expense</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expense includes compensation-related costs for our employees dedicated to general and administrative activities, legal fees, audit and tax fees, consultants and professional services, and general corporate expenses. General and administrative expense for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were as follows (dollars in thousands):</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The year-over-year increase was primarily related to $0.8 million of additional legal expenses related to reaching an agreement in principle for a proposed settlement that would resolve an investigation by the staff of the SEC, $0.4 million increase in non-cash stock-based compensation, and $0.4 million increase in outside services. These increases were partially offset by a $0.3 million decrease in insurance related expenses. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general and administrative expense for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was as follows (dollars in thousands):</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The year-over-year decrease was significantly impacted by the reduction in legal expenses related to the ongoing litigation and proceedings described in Part I, Item 3 of this report, which were approximately $7 million in 2014. We exceeded the retention (deductible) under our insurance policy during the third quarter of 2014, and therefore realized insurance recoveries of $2 million that partially offset these fees. In 2015, excluding legal expenses associated with the litigation settlement, the majority of the legal expenses incurred were paid by our insurance carriers. In addition to a reduction in legal expenses, non-cash stock-based compensation decreased $3.3 million from 2014 to 2015. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Non-Operating Income (Expense)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense) for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was as follows (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$ Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Litigation settlement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,750</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,532</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,508</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(760</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,748</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total non-operating income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,009</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">25,380</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The increase to our non-operating income in 2016 was primarily due to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in the non-cash gain on our fair value of warrants accounted for as liabilities. The decrease in the estimated fair value of our warrant liabilities was primarily due to the decrease in our common stock price, which declined 93% in 2016. In addition to the decrease in the fair value of warrants, our contingent purchase price consideration related to the approval of NeuVax also decreased by $4.5 million from 2015 to 2016. The interim analysis of the Phase 3 PRESENT clinical trial and subsequent close down of the trial triggered an intangible asset and goodwill impairment analysis of the carrying amount and the fair value was determined to exceed the carrying amount based on the other ongoing and planned trials with NeuVax. The contingent purchase price consideration is fair valued at each reporting period and the lower probability and extended time line for approval were updated to align with the valuation performed of NeuVax and significantly decreased the fair value which are the two largest variables impacting the liability.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The gains recognized from the changes in the fair values of our warrant liability and contingent purchase price liability were partially offset by $2.8 million in litigation settlements and $3.5 million of interest expense. The litigation settlements in 2016 are comprised of $1.8 million of opt-out cases from our class action settlement that was settled in 2015 and $1.0 million related to the proposed settlement framework with the SEC. The increase of $2.7 million of interest expense was driven by the interest on our debenture, including amortization of discounts and debt issuance costs.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense) for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was as follows (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$ Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Litigation settlement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(760</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total non-operating income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,616</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(19,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The increase to our non-operating expense in 2015 was primarily due to a $15.4 million decrease in the non-cash gain of the fair value of our warrants accounted for as liabilities. The $1.2 million non-cash gain on the fair value of our warrant liabilities in 2015 was primarily due to a 3% decrease in our common stock price, which is one of the most impactful inputs into the pricing model we use to estimate the fair value of our warrant liabilities. The $16.6 million non-cash gain on the fair value of our warrant liabilities was in 2014 was primarily due to a 70% decrease in our common stock price.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the change in our warrant liability, on December 4, 2015 we announced the settlement of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The majority of the $20.0 million settlement payment for settlement of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was covered by the Company's insurance carriers and $3.3 million was paid by the Company through a combination of $2.3 million in cash and $1.0 million in shares of the Company's common stock. In addition, to obtain the agreement of the insurance carriers to fund most of the settlement, we also agreed to pay all outstanding defense attorney fees going forward with respect to this litigation and opt out securities litigation amounting to about $2.0 million.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the years ended December 31, 2016 and 2015, we recognized income tax expenses of $0.2 million and $0.4 million, respectively. There was no income tax expense or benefit during the year ended December 31, 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Loss from Discontinued Operations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;During the quarter ended September 30, 2015, we completed a strategic review of our commercial business and operations, and as a result of that review we sold the assets of our commercial business during the fourth quarter of 2015. Our loss from discontinued operations for the year ended December 31, 2016 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with losses from discontinued operations of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the years ended December 31, 2015 and 2014, respectively. </font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial business in 2016, 2015 and 2014 that are presented in the consolidated statements of comprehensive loss as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,886</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(921</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(440</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,562</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,118</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on sale of commercial business assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,549</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance and exit costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,349</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,448</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The 2016, 2015 and 2014 discontinued operations are comprised of the net revenue, cost of revenue, and expenses attributable to our commercial operations, which we sold in the fourth quarter of 2015.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Net Revenue </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations comprises revenue from the sale of Abstral, which was provided by our commercial operations. </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Additional Channel Obligations</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;included in discontinued operations in the first quarter of 2016 is comprised of larger than anticipated rebates of Abstral sales that we were responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement. The additional channel obligations for the year ended December 31, 2016 relate to adjusted Medicaid billings from previous quarters since the first quarter of 2014 and additional returns received.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cost of revenue </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of direct product costs and related overhead, Abstral royalties based on net revenue, inventory obsolescence, and other direct costs. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and development expense</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;included in discontinued operations consists of expenses related to our Abstral RELIEF trial and other product stability costs.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Selling, general and administrative expense </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of all other expenses of our commercial operations that were required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, consulting, and other outside services necessary to support the commercial operations. During 2016 we incurred $9.2 million related to legal expenses from external counsel associated with an internal and government investigation, and from cooperating, and document production for the subpoenas related to the sales and marketing practices of Abstral. These legal proceedings are further disclosed in Part I, Item 3. </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-indent:36px;"><font style="padding-bottom:12px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Impairment charge from classification as held for sale</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;included in discontinued operations consists of impairment recognized from determining that the carrying value exceeds the fair value of the assets.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-indent:36px;"><font style="padding-bottom:12px;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Loss on sale of commercial business assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;included in discontinued operations consists of the calculation of the gain or loss recognized upon the sale of the company's commercial products, Abstral and Zuplenz, and their related assets.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-indent:36px;"><font style="padding-bottom:12px;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Severance and exit costs </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of one-time termination benefits provided to employees that were part of the commercial business and did not accept employment opportunities at the companies who purchased Abstral and Zuplenz. In addition to severance costs there are costs included to terminate contracts prior to their contractual term with no economic benefit to the Company.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><a name="sC6BF6837A2284BB5D9E56F9E64BD7AAC"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We had cash and cash equivalents of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$29.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of December&#160;31, 2015. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The decrease of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash and cash equivalents from December&#160;31, 2015 to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was attributable to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$44.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;net cash used in operating activities and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;principal payments on long-term debt. The decrease was partially offset by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$33.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;net proceeds received from the sale of common stock.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, the Company closed an underwritten public offering of 17,000,000 units at a price to the public of $1.00 per unit for gross proceeds of $17.0 million ("February 2017 Offering"). Each unit consists of one share of common stock, and a warrant to purchase one share of common stock at an exercise price of $1.10 per share. The net proceeds of the February 2017 Offering were $15.5 million, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the proceeds from the February 2017 Offering, in January and February 2017 the holder of the Debenture redeemed $3.95 million of outstanding principal that was satisfied by the Company with 3,518,663 shares of our common stock. As a result of the redemptions, the Company was able to transfer $3.95 million out of restricted cash and cash equivalents and into unrestricted cash and cash equivalents to be used to fund the Company's ongoing operations. The outstanding principal balance on the Debenture as of March 15, 2017 is $13,617,702 and is maintained by the Company as restricted cash.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the funds raised through underwritten public offerings and the debenture, we maintain a purchase agreement with Lincoln Park Capital LLC (LPC) and At Market Issuance Sales Agreements (ATM) with future availability of $2.0 million and $19.1 million, respectively subject to certain terms and conditions. We may also continue to use the ATM, or other instruments, in order to fund our operations going forward.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 31, 2017, the Company announced that it is in the process of evaluating strategic alternatives focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in a transaction. While the Company evaluates its strategic alternatives, Galena&#8217;s investigator-sponsored immunotherapy trials will remain ongoing.&#160;With the confirmation from the FDA that the GALE-401 development program is appropriate for a New Drug Application (NDA) filing using the 505(b)(2) regulatory pathway in patients with ET who are intolerant or resistant to hydroxyurea, we have developed a clear path forward for GALE-401 in the treatment of ET. Subject to completing the manufacturing of the new formulation and the internal work to prepare the Phase 3 trial for initiation, the Company is evaluating the appropriate time to commence enrollment of the GALE-401 trial and anticipates making a definitive determination in the second half of 2017. The Company has focused on reducing expenditures in order to preserve liquidity while pursuing a strategic alternative.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect to continue to incur operating losses as we continue to advance our product candidates through the drug development and the regulatory process. In the absence of revenue, our potential sources of operational funding are proceeds from the sale of equity, funded research and development payments, debt financing arrangements, and payments received under partnership and collaborative agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We believe that our existing cash and cash equivalents, funding available under an amended LPC purchase agreement, ATM and other instruments, should be sufficient to fund our operations for at least one year from the date of issuance of the Company's consolidated financial statements. This projection is based on our current limited operations and estimates of legal expenses associated with the ongoing government investigation and legal matters pending against the company, and is subject to changes in our operating plans, resolutions of such government investigation and legal matters, uncertainties inherent in our business, strategic alternatives outcomes, and the need to seek to replenish our existing cash and cash equivalents sooner than we project and in greater amounts that we had projected. There is no guarantee that any debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate, our operations or to seek to merge with or to be acquired by another company.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes our cash flows from operating, investing, and financing activities for the year ended December&#160;31, 2016 and 2015 ($ in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows from continuing operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in continuing operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(33,230</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(38,802</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in continuing investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows provided by continuing financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34,324</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows provided by continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows from discontinued operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in discontinued operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,685</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows provided by (used in) discontinued investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,749</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows provided by (used in) discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,735</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(44,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(48,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,056</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total increase (decrease) in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,647</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,080</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Operating Activities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in operating activities was approximately $</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">44.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The decrease of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;resulted primarily from a decrease in cash used in our continuing operations of $5.6 million associated with reduced research and development spend from the discontinuation of the Phase 3 PRESENT trial. The increase was partially offset by a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in cash used in discontinued operations primarily driven by legal expenses from external counsel associated with an internal and government investigation, and cooperating and document production for the subpoenas related to the sales and marketing practices of Abstral.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Investing Activities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used by investing activities was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with net cash provided by investing activities of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The sale of our commercial business assets in the fourth quarter of 2015 resulted in the receipt of $11.3 million partially offset by purchases of property and equipment. The sale of the commercial business assets in 2015 resulted in $1.1 million of payments for selling costs paid in the first quarter of 2016 that were incurred from the sale of commercial assets.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Financing Activities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$34.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$43.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In 2016, we received proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$33.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the issuance of common stock and $0.3 million from the exercise of common stock options and warrants, and $5.8 million unrestricted net proceeds from our debenture, partially offset by $5.6 million in principal payments on long-term debt. In 2015, we received proceeds of $47.4 million from the issuance of common stock, partially offset by $3.9 million in principal payments on long-term debt.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth our contractual obligations as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Payment Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Less than 1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1 to 3 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3 to 5 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Long-term debt </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancelable license agreements </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,791</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-cancelable employment agreements </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-cancelable operating leases </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">974</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,936</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Long-term debt payments presented are comprised of principal and interest payments. See Note 5 of the notes to the consolidated financial statements for additional information on our long-term debt.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;See Note 6 of the notes to the consolidated financial statements for additional information on the referenced contractual obligations. </font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s99AAD5992EA038AB78956F9E6B72BF2A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not entered into any off-balance sheet financing arrangements other than operating leases.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><a name="sBCF333E64178EF3BF4D06F9E6B7FF0AF"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The primary objective of our investment activities is to preserve capital. We do not utilize hedging contracts or similar instruments.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are exposed to certain market risks relating primarily to (1) interest rate risk on our cash and cash equivalents and (2) risks relating to the financial viability of the institutions which hold our capital and through which we have invested our funds. We manage such risks by investing primarily in money market mutual funds.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, we are exposed to foreign currency exchange rate fluctuations relating to payments we make to certain vendors and suppliers and license partners using foreign currencies. We do not hedge against foreign currency risks. Consequently, changes in exchange rates could adversely affect our operating results and stock price. Such losses have not been significant to date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><a name="s7773FB1E73ABB0863AC26F9E6B867F51"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">FORM 10-K &#8212; FISCAL YEAR ENDED DECEMBER 31, 2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;text-decoration:underline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Page&#160;No.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sE614BB319E3DD55C1CA16F9E6BB25298"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sE614BB319E3DD55C1CA16F9E6BB25298">63</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s591EF5004A820AB93E336F9E57861C7A"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consolidated Balance Sheets as of December 31, 2016 and 2015</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s591EF5004A820AB93E336F9E57861C7A">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s9B1B97FC89C420C2B96C6F9E5806D2C4"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consolidated Statements of Operations for the years ended December 31, 2016, 2015, and 2014</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s9B1B97FC89C420C2B96C6F9E5806D2C4">65</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sAC60492664112D9577026F9E58A28A8E"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31 2016, 2015, and 2014</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sAC60492664112D9577026F9E58A28A8E">66</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sFDC7109A2FB948A528BD6F9E591F24AB"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2016, 2015, and 2014</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sFDC7109A2FB948A528BD6F9E591F24AB">67</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s8FA2482952E0A9E9E6846F9E6DABDB54"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s8FA2482952E0A9E9E6846F9E6DABDB54">68</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><a name="sE614BB319E3DD55C1CA16F9E6BB25298"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Helvetica,sans-serif;font-size:11pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Board of Directors and Stockholders</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Galena Biopharma, Inc. (the Company), as of December&#160;31, 2016 and 2015, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December&#160;31, 2016. We also have audited the Company's internal control over financial reporting as of December&#160;31, 2016, based on criteria established in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express an opinion on these consolidated financial statements and an opinion on the Company's internal control over financial reporting based on our audits.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the consolidated financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Galena Biopharma, Inc., as of December&#160;31, 2016 and 2015, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, Galena Biopharma, Inc. maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2016, based on criteria established in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">/s/ Moss Adams LLP</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">San Francisco, California</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="s591EF5004A820AB93E336F9E57861C7A"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Table of Contents</font></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;color:#00497f;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">18,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">29,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">18,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Litigation settlement insurance recovery</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">21,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current assets of discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">813</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">392</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">53,621</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Equipment and furnishings, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">335</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">GALE-401 rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">12,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">12,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deposits and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">65,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">82,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;color:#00497f;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">840</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Litigation settlement payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">950</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants potentially settleable in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,860</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,397</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current liabilities of discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">6,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">30,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">57,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">6,142</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">37,154</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">68,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; no shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Common stock, $0.0001&#160;par value; 350,000,000&#160;shares authorized, 15,224,223 shares issued and 15,190,473 shares outstanding at December 31, 2016; 275,000,000&#160;shares authorized, 8,129,087 shares issued and 8,095,337 shares outstanding at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">335,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">296,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(302,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(279,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Less treasury shares at cost, 33,750 shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">28,657</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">13,513</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">65,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">82,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ee accompanying notes to consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><a name="s9B1B97FC89C420C2B96C6F9E5806D2C4"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">19,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">23,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">27,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">12,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">31,867</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">34,220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">43,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(31,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(34,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(43,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Non-operating income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Litigation settlement</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(2,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(5,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">22,220</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,556</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(3,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of the contingent purchase price liability</font></div><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">170</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total non-operating income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">21,009</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(4,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">15,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Loss from continuing operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(10,858</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(38,591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(28,284</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Loss from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(11,101</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(38,956</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(28,284</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(12,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(24,946</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(8,322</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(23,549</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(63,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(36,606</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Basic and diluted per share, continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(5.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(4.74</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Basic and diluted loss per share, discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(3.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(2.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(8.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(6.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Weighted-average common shares outstanding: basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,958,802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">7,763,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,969,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><a name="sAC60492664112D9577026F9E58A28A8E"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:41%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;font-weight:bold;">Additional Paid-In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;font-weight:bold;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;font-weight:bold;">Shares Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,505,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">188,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(178,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">331,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,704</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,705</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock under milestone achievement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">219,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">9,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">9,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock upon exercise of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">273,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">37,741</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">37,742</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with employee stock purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock based compensation for directors and employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock based compensation for services</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">172,488</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(36,606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(36,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,507,317</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">12</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">256,377</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(215,481</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">37,059</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,607,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Common stock warrants issued in connection with March 2015 common stock offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(10,296</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(10,296</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with employee stock purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">11,566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock based compensation for directors and employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,896</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,896</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(63,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(63,902</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,129,087</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">296,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(279,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,872,803</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">33,534</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">33,534</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Common stock warrants issued in connection with common stock offerings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(9,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(9,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock to satisfy principal and interest on long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,981,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,079</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,079</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Common stock warrants issued in connection with debt financing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with settlement of litigation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">206,903</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">557</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">557</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock upon exercise of warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">20,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with employee stock purchase plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock based compensation for directors and employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(23,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(23,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15,224,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">335,423</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(302,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">28,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="sFDC7109A2FB948A528BD6F9E591F24AB"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from continuing operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(11,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(38,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(28,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Adjustment to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-cash accretion of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,054</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">248</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">276</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Deferred taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-cash stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,931</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Litigation settlement payable in common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(22,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,161</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(16,556</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Litigation settlement insurance recovery</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">21,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(21,700</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Litigation settlement payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">24,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(757</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(289</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in continuing operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(33,230</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(38,802</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(37,037</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from discontinued operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(12,448</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(24,946</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(8,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Loss on sale of commercial assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Impairment charge from classification of assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,071</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Changes in operating assets and liabilities attributable to discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in discontinued operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(11,685</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(9,358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,832</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(44,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(48,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(42,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid for acquisition of GALE-401</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(2,415</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid for purchase of equipment and furnishings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash provided by (used in) continuing investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(354</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(2,472</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds received from sale of commercial assets (selling costs paid)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">11,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid for commercial assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(534</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,056</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash provided by (used in) discontinued investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,056</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,395</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds from issuance of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">33,534</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,416</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,704</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Proceeds from exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Proceeds from common stock issued in connection with ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds from issuance of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">23,401</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Minimum cash covenant on long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(17,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Principal payments on long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,579</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,911</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,766</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">34,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">43,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">24,260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(11,647</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,080</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(24,137</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash and cash equivalents at the beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">29,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">23,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">18,083</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">29,730</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">23,650</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash received during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">117</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Supplemental disclosure of non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of warrants issued in connection with common stock recorded as cost of equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">9,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of warrants issued in connection with long-term debt recorded as debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,139</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Principal and interest repaid through issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Reclassification of warrant liabilities upon exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">27,026</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in settlement of GALE-401 milestone</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of shares issued to acquire Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,500</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Future obligations for Zuplenz rights included in accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,716</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><a name="s8FA2482952E0A9E9E6846F9E6DABDB54"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="sA724776F05F6E50FDA576F9E5A48E90A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">1. Business and Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax&#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and the asset is ready to advance into a pivotal trial in patients with essential thrombocythemia (ET). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers. </font></div><div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the generally accepted accounting principles (GAAP). Unless the context otherwise indicates, references in these notes to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer (i)&#160;to Galena, our wholly owned subsidiary, Apthera, Inc., or &#8220;Apthera,&#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, Inc. or "Mills."</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Management's Plans</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;-  We had cash and cash equivalents of approximately $18.1 million as of December&#160;31, 2016, compared with $29.7 million as of December&#160;31, 2015. We expect to continue to incur operating losses as we continue to advance our product candidates through the drug development and the regulatory process. In the absence of revenue, our potential sources of operational funding are proceeds from the sale of equity, funded research and development payments, debt financing arrangements, and payments received under partnership and collaborative agreements.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, the Company closed an underwritten public offering of 17,000,000 units at a price to the public of $1.00 per unit for gross proceeds of $17.0 million ("February 2017 Offering"). Each unit consists of one share of common stock, and a warrant to purchase one share of common stock at an exercise price of $1.10 per share. The net proceeds of the February 2017 Offering were $15.5 million, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the proceeds from the February 2017 Offering, in January and February 2017 the holder of the Debenture redeemed $3.95 million of outstanding principal that was satisfied by the Company with 3,518,663 shares of our common stock. As a result of the redemptions, the Company was able to transfer $3.95 million out of restricted cash and cash equivalents and into unrestricted cash and cash equivalents to be used to fund the Company's ongoing operations. The outstanding principal balance on the Debenture as of March 15, 2017 is $13,617,702 and is maintained by the Company as restricted cash.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the funds raised through underwritten public offerings and the debenture, we maintain a purchase agreement with Lincoln Park Capital LLC (LPC) and At Market Issuance Sales Agreements (ATM) with future availability of $2.0 million and $19.1 million, respectively subject to certain terms and conditions. We may also continue to use the ATM, or other instruments, in order to fund our operations going forward.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 31, 2017, the Company announced that it is in the process of evaluating strategic alternatives focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in a transaction. While the Company evaluates its strategic alternatives, Galena&#8217;s investigator-sponsored immunotherapy trials will remain ongoing.&#160;With the confirmation from the FDA that the GALE-401 development program is appropriate for a New Drug Application (NDA) filing using the 505(b)(2) regulatory pathway in patients with ET who are intolerant or resistant to hydroxyurea, we have developed a clear path forward for GALE-401 in the treatment of ET. Subject to completing the manufacturing of the new formulation and the internal work to prepare the Phase 3 trial for initiation, the Company is evaluating the appropriate time to commence enrollment of the GALE-401 trial and anticipates making a definitive determination in the second half of 2017. The Company has focused on reducing expenditures in order to preserve liquidity while pursuing a strategic alternative.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We believe that our existing cash and cash equivalents, funding available under an amended LPC purchase agreement, ATM and other instruments, should be sufficient to fund our operations for at least one year from the date of issuance of the Company's consolidated financial statements. This projection is based on our current limited operations and estimates of legal expenses associated with the ongoing government investigation and legal matters pending against the company, and is subject to changes in our operating plans, resolutions of such government investigation and legal matters, uncertainties inherent in our business, strategic alternatives outcomes, and the need to seek to replenish our existing cash and cash equivalents sooner than we project and in greater amounts that we had projected. There is no guarantee that any debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate, our operations or to seek to merge with or to be acquired by another company.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reverse Stock-Split</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;- On November 11, 2016 the Company effected a 1:20 reverse stock split of the Company's outstanding shares of common stock, outstanding stock options to purchase shares of our common stock and warrants to purchase shares of common stock. In addition, the number of shares of common stock and number of shares of common stock subject to stock options or similar rights authorized under the Company&#8217;s equity incentive plan and employee stock purchase plan were proportionately adjusted for the reverse stock-split. Further, the per share exercise price under such plans were proportionately adjusted for the reverse stock-split. These consolidated financial statements give retroactive effect to such reverse stock-split and all share and per share amounts have been adjusted accordingly.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 15, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. The Company generally considers assets to be held for sale when (i) the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) the assets are available for immediate sale in their present condition, (iii) the company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to the current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment for sale, the Company discontinues depreciating the asset and writes down the asset to the lower of the carrying value or fair market value, if needed. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Restricted cash consists of the minimum cash covenant as required by the debenture certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The carrying amounts reported in the balance sheet for cash equivalents, marketable securities, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years for equipment and furniture) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div></td></tr></table><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit (the &#8220;First Step&#8221;). If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment (the &#8220;Second Step&#8221;). Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible product rights when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets.</font></div><div style="line-height:120%;text-indent:60px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, and has determined that there has been no impairment to these assets as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Contingent consideration is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Fees and Insurance Recoveries </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations ("CROs"), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015, we recognized income tax of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$243,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$365,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively. There was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;income tax expense or benefit for the year ended December 31, 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The Company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$17,583,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in interest-bearing accounts above federally insured limits.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><a name="s71ACA086DE4D1E0ED3646F9E5A6A0670"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">2. Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company has adopted this ASU.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-03,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Further, ASU 2015-03 requires the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 must be applied retrospectively. The Company adopted this ASU on January 1, 2016. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or ASU 2015-17.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ASU 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. Previous guidance required deferred tax liabilities and assets to be separated into current and noncurrent amounts on the balance sheet. The guidance will become effective for us beginning in the first quarter of 2017 and may be applied either prospectively or retrospectively. Early adoption is permitted. At the time of adoption, we will reclassify current deferred tax amounts on our Consolidated Balance Sheets as noncurrent. The Company adopted this ASU on January 1, 2017. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2016, the FASB issued ASU No.&#160;2016-01,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#32;Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016-01 will be effective for the Company beginning in its first quarter of 2019 and early adoption is not permitted. The Company does not believe the adoption of the new financial instruments standard will have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of our pending adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2016, the FASB issued Accounting Standards Update 2016-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation-Stock Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU 2016-09 includes several areas of simplification to stock compensation including simplifications to the accounting for income taxes, classification of excess tax benefits on the Statement of Cash Flows and forfeitures. ASU 2016-09 is effective for annual reporting periods beginning after December&#160;15, 2016. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this ASU on January 1, 2017. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.. </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2016, the Financial Accounting Standards Board issued ASU No. 2016-15 "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force." The objective of ASU No. 2016-15 is to provide specific guidance on eight cash flow classification issues and how to reduce diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years.  We are still evaluating the effect of this update.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. We are evaluating the effect of this update.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sFB15BFFFFBD6F6F5FD5B6F9E5A7C4632"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">3. Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company categorized its cash equivalents and marketable securities as Level&#160;1 inputs. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 3</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 3</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company has not transferred any financial instruments into or out of Level 3 classification during the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or 2015. A reconciliation of the beginning and ending Level 3 liabilities for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The decrease in the estimated fair value of the contingent purchase price consideration during 2016 reflects a lowering of the probability and lengthening of the timeline for the potential approval of NeuVax, as these assumptions are now based principally on our Phase 2 combination trial with trastuzumab whereas previously, the valuation was based on our Phase 3 PRESENT trial, which was deemed futile by the Independent Data Monitoring Committee ("IDMC") in June 2016 and subsequently closed.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s4AF6DE5A22867D5730026F9E5ABB1B50"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">4. Accrued Expenses and Other Current Liabilities </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><a name="s5C9C2176861D2F75A5866F9E5ACAD2BC"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">5. Long-term Debt</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 8, 2013, we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;("Loan"). The Loan payment terms include </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months of interest-only payments at the fixed coupon rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.45%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, followed by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash facility fee and a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash final payment and granted to the lender </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,109</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$49.4</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. On May 10, 2016, the Company prepaid the outstanding principal amount and cash final payment.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, the Company entered into a&#160;Securities Purchase Agreement ("Purchase Agreement"), with certain purchasers pursuant to which the Company sold, at a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.375%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;original issue discount, a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25,530,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Senior Secured Debenture&#160;(&#8220;Debenture&#8221;) and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company's common stock. Net proceeds to the Company from sale of the&#160;Debenture, after payment of commissions and legal fees, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;The&#160;Debenture&#160;matures November 10, 2018, accrues interest at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per year, and does not contain any conversion features into shares of our common stock. On August 22, 2016, the Company, the purchasers and certain other parties entered into an amendment agreement, which provides for the amendment and restatement of the Debenture, an amendment to the terms of the Series A Common Stock Purchase Warrant issued by the Company to the purchasers pursuant to the terms of the Purchase Agreement, and certain other terms and conditions, as summarized below.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 14, 2016, the Company and the holder entered into a waiver (the &#8220;Waiver&#8221;) that amended the Securities Purchase Agreement dated May 10, 2016 between the Company and the holder, as amended on August 22, 2016 (the &#8220;SPA&#8221;). The Waiver provides that solely with respect to the calendar months of December 2016, January 2017, February 2017 and March 2017 (collectively, the &#8220;Specified Months&#8221;), the holder waives, subject to certain delineated exceptions, the requirement of paragraph (i) of the definition of &#8220;Equity Conditions&#8221; set forth in Section 1 of the Debenture, thereby continuing to allow the Company to deliver shares of its Common Stock in respect to a portion of its amortization obligation under the Debenture. Furthermore, the waiver sets out a Monthly Allowance for each Specified Month equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and required the Company to withdraw all cash and/or cash equivalents in excess of eighteen million five hundred thousand dollars (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) from certain accounts and deposit such funds into an account in a form acceptable to the holder, such that the Company requires the prior written consent of the holder for certain withdrawals. The Waiver also grants the holder special redemption rights depending upon the price of our common stock, including the right to redeem the debenture.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Debenture carries an interest only period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months, following which interest is due monthly and payable in cash or stock at the election of the Company. Interest deferred during the interest only period is added to and considered principal. Following the interest only period, the Company has the right under the Debenture, commencing November 10, 2016, to pay the monthly redemption amount of the outstanding balance in cash, shares of the Company's common stock or a combination thereof, if certain conditions are met. The maximum monthly redemption amount was increased from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;under the amended Debenture; provided, that if the trading price of the Company&#8217;s common stock is at least </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share (as adjusted for stock splits, combinations or similar events) during such calendar month, then such maximum monthly redemption amount may be increased to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2,200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;at the holder's election and if the Company has already elected to satisfy such monthly redemptions in shares of common stock. In addition, notwithstanding the foregoing limitations on the monthly redemption amount, the holder may elect up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;times in any 12-month period to increase the maximum monthly redemption to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If the Company elects to pay the redemption amount in shares of its common stock, then the shares will be delivered at the lesser of A) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;discount to the average of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;lowest volume weighted average prices over the prior </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;trading days or B) a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;discount to the prior trading day&#8217;s volume weighted average price. The Company may only opt for payment in shares of common stock if certain equity conditions are met. The Company, at its option, may also force the holder to redeem up to double the monthly redemption principal amount of the Debenture but not less than the monthly payment.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The holder received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;warrants upon the closing on the sale of the Debenture at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30.20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5 years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from issuance, and in accordance with the terms of the amendment agreement, the exercise price of the warrant was reduced to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. Additionally, the holder received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The amendment agreement provides that, following November 10, 2016, the holder may elect to convert any portion of the outstanding balance into shares of common stock at a fixed price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share (as adjusted for stock splits, combinations or similar events). </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the&#160;Debenture&#160;can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company&#8217;s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the&#160;Debenture in cash. The Company&#8217;s obligations under the&#160;Debenture&#160;are secured under a security agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries.  Under the subsidiary guarantee agreement, each subsidiary guarantees the performance of the Company of the Purchase Agreement, Debenture and related agreements. The Company must also maintain as a compensating cash balance, the lesser of a minimum of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash or the outstanding principal and accrued and unpaid interest, which such amount is included in restricted cash as of December 31, 2016. The holder of the Debenture has the right, at any time and from time to time, to require the Company to prepay the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus accrued and unpaid interest or the outstanding principal and accrued and unpaid interest. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2016 the outstanding principal balance of the Debenture was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$17,621,702</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The current portion of long-term debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$16,397,030</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;is net of unamortized discounts and debt issuance costs of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,224,672</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In January and February 2017, the holder of the Debenture redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3,950,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of principal, which the Company satisfied with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,541,077</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock. The outstanding principal balance as of March 15, 2017 is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$13,671,702</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Armentum Partners, LLC (&#8220;Placement Agent&#8221;) acted as the&#160;placement agent&#160;in the offering of the&#160;Debenture and the Company paid the Placement Agent a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the funds received from the sale of the&#160;Debenture. The Company paid half of the placement fee upon funding and paid the other half during the third quarter of 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><a name="s750FBEC328CA58B7AD466F9E5ADCD56D"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">6. Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval to the settlement awarding attorney&#8217;s fees of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus costs, which was paid by our insurance carriers. The settlement included a payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">60,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;outstanding director stock options. The settlement also required that we adopt and implement certain corporate governance measures. The settlement did not include any admission of wrongdoing or liability on the part of us or the individual defendants and included a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval of the settlement awarding attorney&#8217;s fees of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus costs, which was paid out of the settlement funds. The settlement agreement provided for a payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to the class and the dismissal of all claims against us and the other defendants in connection with the consolidated federal securities class actions. Of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;settlement payment to the class, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$16.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was paid by our insurance carriers and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was paid by us through a combination of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares of our common stock (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,002</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares) issued by us on July 6, 2016. In addition to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;settlement payment, the company paid </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in December 2015 in attorney fees outstanding as a condition of the settlement. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In July 2016, we resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,563</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares) of our common stock, and in another case for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares of our common stock (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">168,337</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements did not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and included a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 13, 2016, we filed a complaint in the Circuit Court for the County of Multnomah for the State of Oregon against Aon Risk Insurance Services West, Inc. where we are seeking attorney's fees, costs and expenses incurred by us related to our coverage dispute with a certain insurer and for amounts we were required to contribute to the settlements of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as a direct result of certain insurer's failure to pay its full policy limits of liability and other relief. We are currently engaged in written discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Miller v. Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. On February 15, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Kattuah v Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Within the time allowed under the federal rules and statutes, the Company and the other defendants, former and current officers, will respond to the complaints through an appropriate pleading or motion.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">two</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the high-prescribing physicians for Abstral (former commercial product) has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial began in January 2017 and is ongoing. We received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&#8217;s Office for the Southern District of Alabama (SDAL), which is handling the criminal trial, and are cooperating in the production of documents. On April&#160;28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. The criminal trial</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;which began on January 4, 2017, concluded with a jury verdict on February 23, 2017 finding these physicians guilty on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;counts; sentencing is scheduled for May 2017. At the end of the SDAL case</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;SDAL dismissed count </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the indictment charging that the physicians conspired, through the C&amp;R Pharmacy, to receive illegal kickbacks in exchange for prescribing Abstral. Though certain former employees received trial subpoenas to appear at the trial and provide oral testimony, only </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">one</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;former employee testified at the trial. We agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we were not a target or subject of that investigation. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There are also federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office for the District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral, the commercial product we sold in the fourth quarter of 2015. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and the Department of Justice, and we have come to understand that the investigation being undertaken is a criminal investigation in addition to a civil investigation that could ultimately involve the Company as well as one or more former employees. Pursuant to the Company&#8217;s charter, we are currently reimbursing certain former employees&#8217; attorney&#8217;s fees with respect to the investigation. We are cooperating with the civil and criminal investigation, and through our outside counsel we have begun preliminary&#160;discussions with the government aimed at the ultimate resolution of the investigation regarding the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;22, 2016, the Company and its former CEO reached an agreement in principle to a proposed settlement that would resolve an investigation by the staff of the Securities and Exchange Commission (SEC) involving conduct in the period 2012-2014 regarding the commissioning of internet publications by outside promotional firms. Under the terms of the proposed settlement framework, the Company and the former CEO would consent to the entry of an administrative order requiring that we and the former CEO cease and desist from any future violations of Sections 5(a), 5(b), 5(c), 17(a), and 17(b) of the Securities Act of 1933, as amended, and Section&#160;10(b), 13(a), and 13(b)(2)(A) of the Securities Exchange Act of 1934, as amended, and various rules thereunder, without admitting or denying the findings in the order. Based upon the proposed settlement framework, the Company will make a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;penalty payment. In addition to other remedies, the proposed settlement framework would require the former CEO to make a disgorgement and prejudgment interest payment as well as a penalty payment to the Commission. To address the issues raised by the SEC staff&#8217;s investigation, in addition to previous governance enhancements we have implemented, we have voluntarily undertaken to implement a number of remedial actions relating to securities offerings and our interactions with investor relations and public relations firms. The proposed settlement is subject to approval by the Commission and would acknowledge our cooperation in the investigation and confirm our voluntary undertaking to continue that cooperation. If the Commission does not approve the settlement, we may need to enter into further discussions with the SEC staff to resolve the investigated matters on different terms and conditions. As a result, there can be no assurance as to the final terms of any resolution including its financial impact or any future adjustment to the financial statements. In response to an indemnification claim by the former CEO, a special committee of our Board of Directors has determined that we are required under Delaware law to indemnify our former CEO for the disgorgement and prejudgment interest payment of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$750,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;that he would be required to pay if and when the settlement is approved by the Commission. Any penalty payment that the former CEO will be required to make in connection with this matter (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$600,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;under the proposed settlement framework) will be the responsibility of the former CEO.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The litigation settlements are summarized as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" style="padding-left:0px;padding-right:0px;padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Class action settlement in 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Derivative settlement in 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shareholders securities litigation settlements in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SEC settlement in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the Company in cash as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the insurance carriers in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the Company in cash in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the Company in common stock in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Commitments </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&#8217;s contractual obligations that may require future cash payments as of December&#160;31, 2016 are as follows (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Operating</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Leases</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-Cancelable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Employment</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Agreements</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cancelable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">License</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Agreements</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,350</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,586</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2021 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">974</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,256</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December&#160;31, 2016, 2015, and 2014 were approximately </font><font style="font-family:Helvetica;font-size:10pt;">$291,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica;font-size:10pt;">$116,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica;font-size:10pt;">$72,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License agreements generally relate to the company&#8217;s obligations with The Board of Regents, University of Texas M.D. Anderson Cancer Center and the Henry M. Jackson Foundation for our oncology therapies and the obligations with Biovascular Inc. and Mills Pharma for our GALE-401 asset. The company continually assesses the progress of its licensed technology and the progress of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, </font><font style="font-family:Helvetica;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;amounts will be due.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the disclosure provisions FASB ASC Topic 460 (&#8220;ASC 460&#8221;), &#8220; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Guarantor&#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others,"</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to its agreements that contain guarantee or indemnification clauses. The Company provides (i)&#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&#160;460. In 2016, the Company has incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$750,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as a result of these obligations as a result of its obligation to its former CEO as noted above. Accordingly, the Company has accrued this liability in its financial statements related to these indemnifications.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><a name="s80DA2A2DEF21E47D69DD6F9E5B0AD92C"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">7. Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Issuances of common stock are as follows:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">November 2014 Purchase Agreement with Lincoln Park Capital, LLC - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 18, 2014, the Company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the Company has the right to sell to LPC up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares of the Company's common stock, subject to certain limitations and conditions over the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">125,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company's common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31,561</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the Company received initial net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting commissions and other offering expenses. In addition to the LPC&#8217;s initial purchase of our common stock under the purchase agreement, during 2014, we received net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from LPC&#8217;s subsequent purchases of a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">230,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock, excluding the commitment fee shares.  During the years ended December 31, 2016 and 2015 we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;by issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">135,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock, respectively.  On February 6, 2017, Purchase Agreement was amended to the total value of common stock that the Company may sell to LPC from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$55,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15,600,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">At-The-Market Issuance Sales Agreements </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- On May 24, 2013 the Company entered into At-The-Market Issuance Sales Agreements (ATM) with FBR &amp; Co. (formerly MLV &amp; Co. LLC) and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the gross proceeds from the sale of shares, up to a total limit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in gross proceeds. The ATM is available to the Company until it is terminated by the Agents, or the Company. During the years ended December 31, 2016 and 2015 we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;by issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">334,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock. During the year ended December 31, 2014, we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in net proceeds from the sale of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">70,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock through the ATM. On December 4, 2015 we replenished the ATM limit up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in gross proceeds available for future sales of our common stock.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;- On March 18, 2015 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,217,948</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;units at a price to the public of $</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$41.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,692</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">91,346</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">91,346</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,692</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock for additional net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the Company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">January 2016 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;- On January 12, 2016 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">988,636</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$22.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;("January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$28.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,295</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">88,977</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">88,977</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. The underwriters did not exercise their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,295</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">July 2016 Registered Direct Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;- On July 13, 2016, we closed the sale to certain institutional investors of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,400,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at a purchase price per share of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;in a registered direct offering, and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock with an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$13.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share in a concurrent private placement. The warrants are initially exercisable </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">one</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;day following issuance and have a term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses were approximately&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">February 2017 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;- On February 13, 2017, the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and warrants to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock priced at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and accompanying warrant ("February 2017 Offering"). The warrants are immediately exercisable with a strike price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and will expire on the fifth anniversary of the date of issuance. The shares of common stock and the warrants will be issued separately and will be separately transferable immediately upon issuance</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The net proceeds of the February 2017 Offering were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><a name="sED5076633DA97070E4666F9E5B486811"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">8. Warrants</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015 (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:17%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">January 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">November 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:17%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">November 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in July 2016, January 2016, March 2015, September 2013, December 2012,&#160;April 2011,&#160;March 2011,&#160;March 2010 and August 2009. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:26%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">July 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">117.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">January 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">120.38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">131.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">164.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">204.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">103.79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65.60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">47.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">40.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">71.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected volatility is based on a combination of implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the company has no present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015 were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">January 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,590</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">529</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,852</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(278</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(259</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,886</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(22,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:31%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,560</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(627</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,358</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,109</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$49.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, which equaled the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-day average market price of our common stock prior to the date of the grant. The warrants were valued using the Black Scholes model. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.34%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, risk free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In 2016, we issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to the holder of the Debenture. The holder received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;warrants upon the closing on the sale of the Debenture at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30.20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from issuance, and in accordance with the terms of the amendment agreement, the exercise price of the warrant was reduced to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">77.13%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, risk free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.26%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Additionally, the holder received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">106.63%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, risk free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.35%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition to the warrants issued to the holder of the debenture we have </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;outstanding warrants issued to service providers with a weighted average exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$79.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of December 31, 2016 and 2015. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><a name="s52356B3668B7ACEF4E826F9E5C16127B"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">9. Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company follows the provisions ASC&#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is being re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the Consolidated Statements of Comprehensive Loss for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, 2015, and 2014 (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,966</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,591</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,903</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:56%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">102.62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average fair value of options granted during the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.09</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, respectively.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the Company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the Company has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for options granted to its employees, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for options granted to senior management and zero for non-employee directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2,295,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,325,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock were reserved for issuance under the Company&#8217;s 2016 Incentive Plan, including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">561,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares subject to outstanding common stock options granted under the plan and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">501,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares available for future grants.  On July 14, 2016, shareholders approved the 2016 Incentive Plan. The 2016 Incentive Plan replaced the 2007 Incentive Plan that expired on February&#160;23, 2017. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The options generally will expire, unless previously exercised, no later than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the grant date. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:69%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted average remaining contractual life of options outstanding as of December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.63</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.35</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, respectively. The weighted average remaining contractual life of options exercisable as of December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.52</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.51</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, respectively.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic value of outstanding options as of December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$539,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$610,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic value of exercisable options as of December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">,  </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$518,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$509,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company's common stock and the exercise price of the underlying options.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic value of options exercised during the years ended December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$56,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$37,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$13,429,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;respectively. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212;&#160;The Company also has an employee stock purchase plan (&#8220;ESPP&#8221;) which allows employees to contribute up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of their cash earnings, subject to certain maximums, to be used to purchase shares of our common stock on each semi-annual purchase date. The purchase price is equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the market value per share on either the first or last day of the semi-annual period, whichever is lower. Our ESPP is non-compensatory pursuant to the provisions of generally accepted accounting principles for share-based compensation expense. The ESPP contains an &#8220;evergreen provision&#8221; with annual increases in the number of shares available for issuance on the first day of each year through January&#160;1, 2015 equal to the lesser of: (a)&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,500</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares increased on each anniversary of the adoption of the Plan by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;of the total shares of stock then outstanding and (b)&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares.&#160;As of December&#160;31, 2016, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,930</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock were authorized and available for future issuance under the ESPP. The Company has issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,070</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares under the ESPP through December&#160;31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Stock Units</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; In addition to options to purchase shares of common stock, the Company may grant restricted stock units (&#8220;RSU&#8221;) as part of its compensation package. If granted, each RSU would be granted at the fair market value of the Company's common stock on the date of grant. Vesting is determined on a grant-by-grant basis. There were no RSUs outstanding as of December 21, 2016 and 2015.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><a name="s85E57545ECABED4993F26F9E5C6AB7E3"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">10. Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">561</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><a name="sC390BDFC4692880B96466F9E5C7108C0"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">11. Income Taxes </font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of federal and state income tax expense are as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total deferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax assets are as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">97,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,866</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Licensing deduction deferral</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,910</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">117,329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">95,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(117,329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(95,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In-process research and development not subject to future amortization for tax purposes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected federal income tax benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,447</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State income taxes after credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,375</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,283</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Changes in warrant value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,728</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(456</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effect of change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,852</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,029</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,275</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has incurred net operating losses from inception. At December&#160;31, 2016, the Company had domestic federal and state net operating loss carryforwards of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$251.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, available to reduce future taxable income, which expire at various dates beginning in 2016 through </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2036</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company also had federal and state research and development tax credit carryforwards of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, available to reduce future tax liabilities and which expire at various dates beginning in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2023</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;through </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2035</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The income tax expense for the year ended December 31, 2016 relates to indefinite lived deferred tax liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At December 31, 2016, approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Company's net operating loss carryforwards were generated as a result of deductions related to the exercises of stock options. If utilized, this portion of the Company's carryforwards, as tax effected, will be accounted for as a direct increase to contributed capital rather than as a reduction of that year's provision for income taxes. Net operating loss carryforwards created by excess tax benefits from the exercise of stock options are not recorded as deferred tax assets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership may result in a limitation on the amount of net operating loss carryforwards and research and development credit carryforwards which could be utilized annually to offset future taxable income and taxes payable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Based on an assessment of all available evidence including, but not limited to the Company&#8217;s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;deferred income tax valuation allowance has been recorded against these assets. The valuation allowance increased by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the years ended December 31, 2015 and 2014, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company files income tax returns in the U.S.&#160;federal, Massachusetts, Colorado, California, Connecticut, Georgia, Oregon, and Texas jurisdictions. The Company is subject to tax examinations for the 2012 tax year and beyond. The Company does not believe there will be any material changes in its unrecognized tax positions over the next </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12&#160;months</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company has not incurred any interest or penalties. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial statements as general and administrative expense.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><a name="s461F10BCFC3337B110956F9E5CA8F1E2"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">12. License Agreements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed asset through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In conjunction with the acquisition of NeuVax, the Company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, clinical milestone payments including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;upon commencement of the Phase 3 PRESENT trial of NeuVax and royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective December&#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&#8220;ABIC&#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 19, 2015, Galena Biopharma, Inc. (the &#8220;Company&#8221;) and Sentynl Therapeutics Inc., a Delaware corporation (&#8220;Sentynl&#8221;), entered into and closed upon an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell to Sentynl and Sentynl agreed to purchase from the Company, certain assets of the Company related to and including its Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl) sublingual tablets product (&#8220;Abstral&#8221;). The assets sold and assigned to Sentynl pursuant to the Purchase Agreement included all of the Company&#8217;s rights and interests in the Asset Purchase Agreement by and between the Company and Orexo AB (&#8220;Orexo&#8221;) dated March 15, 2013, and the License Agreement by and between the Company and Orexo dated March 18, 2013 (collectively, the &#8220;Orexo Agreements&#8221;).  The Company&#8217;s future obligations under the Orexo Agreements were assumed by Sentynl pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Abstral, as well for certain channel liabilities related to Abstral for a period of time post-closing. In connection with the transactions contemplated by the Purchase Agreement, the Company assigned to Sentynl all of its rights to and interests in the Orexo Agreements. In connection with such assignment, Orexo released the Company from any future liabilities and obligations under the Orexo Agreements.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The total potential consideration payable to the Company under the Purchase Agreement is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, comprised of an </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;upfront payment and up to an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, consisting of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">two</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;one-time payments based on Sentynl's achievement of "net sales" of Abstral in amounts ranging from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$35 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills"), and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of myleoproliferative neoplasms (MPNs). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. We are responsible for patent prosecution and maintenance.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 17, 2015, Galena Biopharma, Inc. (the &#8220;Company&#8221;) and Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (&#8220;Midatech&#8221;), entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell to Midatech and Midatech agreed to purchase from the Company, certain assets of the Company related to and including its Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film (&#8220;Zuplenz&#8221;). The assets to be sold and assigned to Midatech pursuant to the Purchase Agreement include all of the Company&#8217;s rights and interests in the License and Supply Agreement by and between the Company and MonoSol Rx, LLC (&#8220;MonoSol&#8221;) dated July 17, 2014 (the &#8220;MonoSol License&#8221;).  The Company&#8217;s future obligations under the MonoSol agreement will be assumed by Midatech pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Zuplenz, as well for certain channel liabilities related to Zuplenz for a period of time post-closing. The transaction was completed on December 24, 2015.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The total potential consideration payable to the Company under the Purchase Agreement is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$29.75 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, comprised of a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.75 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;upfront payment upon the closing and up to an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$26 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, consisting of four one-time payments based on Midatech's achievement of "net sales" of Zuplenz in amounts ranging from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$70 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Through a separate agreement with MonoSol entered into on December 16, 2015 (the &#8220;MonoSol License Amendment&#8221;), (i) the Company and MonSol agreed to amend the MonoSol License in order to reduce the number of field representatives that the Company is required to maintain with respect to Zuplenz, and (ii) the Company agreed to pay MonoSol </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$900,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the upfront fee payable to the Company under the Purchase Agreement and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of any future milestone payments received by the Company under the Purchase Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 24, 2015, the Company and Midatech closed upon the Purchase Agreement. In connection with the closing of the transactions contemplated by the Purchase Agreement, the Company assigned to Midatech all of its rights to and interests in the Company&#8217;s License and Supply Agreement, dated July 17, 2014 (the &#8220;MonoSol License&#8221;).  As a result of such assignment, Midatech assumed all of the Company&#8217;s obligations under the MonoSol License.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sD4B4B0E330D7A3C1A5BE6F9E5CD350D5"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">13. Related Party Transactions</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">From 2011 to 2016, the Company retained TroyGould PC as outside corporate counsel. Sanford J. Hillsberg, the Chairman of Galena, is a senior lawyer with TroyGould PC. The Company incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$209,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$577,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$533,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for services provided by TroyGould PC during the years ended December 31, 2016, 2015, and 2014, respectively. At December 31, 2015, Galena owed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to TroyGould PC. There was no payable to TroyGould PC as of December 31, 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><a name="sBD51CFDA2630049B00386F9E5CEC16DD"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">14. Employee Benefit Plan</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company sponsors a 401(k) retirement savings plan (the &#8220;Plan&#8221;). Participation in the Plan is available to full-time employees who meet eligibility requirements. Eligible employees may defer a portion of their salary as defined by Internal Revenue Service regulations. The Company may make matching contributions on behalf of all participants in the 401(k) Plan in an amount determined by the Company&#8217;s Board of Directors. The Company may also make additional discretionary profit sharing contributions in amounts as determined by the Board of Directors, subject to statutory limitations. Matching and profit-sharing contributions, if any, are subject to a vesting schedule; all other contributions are at all times fully vested. The Company intends the 401(k) Plan, and the accompanying trust, to qualify under Sections&#160;401(k) and 501 of the Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that the Company will be able to deduct its contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, invests the assets of the 401(k) Plan in any of a number of investment options. The Company made matching contributions totaling </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$108,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended December 31, 2016. For the years ended December 31, 2015 and 2014, the Company made matching contributions totaling </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$115,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$70,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively </font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><a name="s3187D0B4F4BB4536C3D26F9E5CFB0A34"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">15. Discontinued Operations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of the Company's strategic objective to focus its resources on its development pipeline, our management and Board of Directors decided and committed to pursue a plan to sell or otherwise divest the Company&#8217;s commercial business during the third quarter of 2015. The Company&#8217;s commercial business was comprised of two products: Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film. As described in Note 14, both products were sold in the fourth quarter of 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company met the relevant criteria for reporting the commercial business as held for sale and in discontinued operations in the accompanying financial statements pursuant to FASB Topic 205-20,&#160;Presentation of Financial Statements--Discontinued Operations, and FASB Topic 360,&#160;Property, Plant, and Equipment. The Company assessed the commercial business net asset group for impairment pursuant to FASB Topic 360, as discussed in Note 1, determining that the carrying value exceeded the fair value of the assets, therefore the Company recorded a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;impairment charge as of September 30, 2015. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company entered into an agreement with a third party firm to assist the Company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, in the event the Company successfully completed a divestiture through the sale of its commercial operations to a third-party, the Company paid a success fee to the third party firm in an amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, reimbursement for reasonable out-of-pocket expenses and agreed to pay </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of realized future revenue and payment streams. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management. Under the terms of these arrangements, if the Company met certain sales and margin numbers in the fourth quarter of 2015 and successfully completed a divestiture through sale of its commercial operations to a third-party, the Company paid a retention fee to the three employees in a combined total amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$352,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of cash consideration received as upfront payment in the transactions. These employees will also receive severance payments equal to one month&#8217;s salary for between four and seven months. In addition to these compensatory agreements loss from discontinued operations includes one-time termination benefits provided to employees that were part of the commercial business and did not accept employment opportunities at the companies who purchased Abstral and Zuplenz. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Abstral and related assets on November 19, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Zuplenz and related assets on December 24, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net proceeds from sales</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Less selling costs*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proceeds from sale, net of selling costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*Note selling costs related to the sale of Zuplenz and related assets are included in accrued liabilities and were paid in the first quarter of 2016.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the upfront proceeds received from the sale of Abstral and Zuplenz and their related assets, the Company is eligible to receive up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in future milestone payments based on future net revenue of the products. The additional consideration will be recognized in the period that the net revenue milestones are achieved.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,491</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,059</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,925</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial business in 2016, 2015, and 2014 that are presented in the consolidated statements of comprehensive loss as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,734</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,886</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(355</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge form classification as held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on sale of commercial business assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance and exit costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,349</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,448</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations included in discontinued operations in 2016 is comprised of larger than anticipated rebates of Abstral sales for which we were responsible through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control and was partially offset by lower than expected patient assistance program reimbursement.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general and administrative expense</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of all other expenses of our commercial operations that were required in order to market and sell our marketed products prior to our sales of the rights to these commercial products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the year ended December 31, 2016 we incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. See Note 6 for further disclosures related to these legal proceedings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><a name="s320804245F29CA0383CE6F9E5D5C8B80"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF184096030FC664448596F9E73ADB854"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">16. Selected Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following amounts are in thousands, except per share amounts:</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,493</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,389</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,516</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss) per share, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,382</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross profit on net revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,537</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,660</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18,026</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(19,678</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD18DC1F32B18460962DC6F9E5D74431D"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">17. Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated all events or transactions that occurred after December&#160;31, 2016 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the Company did not have any material recognizable or unrecognizable subsequent events.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><a name="sD3739FDC656D68A71AFF6F9E71E2E27C"></a></div><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sE87933002158B7A90F436F9E71FE3EDD"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;9A. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Rule 13a-15(e) under the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), defines the term &#8220;disclosure controls and procedures&#8221; as those controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and that such information is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our Interim Chief Executive Officer and Chief Financial Officer has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, our Interim Chief Executive Officer and Chief Financial Officer has concluded that our disclosure controls and procedures are effective.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Evaluation of Disclosure Controls and Procedure Management&#8217;s report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Interim Chief Executive Officer and Principal Accounting Officer, we conducted evaluations of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). Based on our evaluations under the framework in Internal Control-Integrated Framework (2013) issued by the COSO, our Interim Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of December&#160;31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">This annual report includes an attestation report of the company&#8217;s registered public accounting firm regarding internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There have been no changes in our internal controls over financial reporting during the fourth quarter and the year ended December&#160;31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></div><hr style="page-break-after:always"><div><a name="s17BFB4DBB9A607FBBC346F9E7232E78C"></a></div><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;9B. OTHER INFORMATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">None.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></div><hr style="page-break-after:always"><div><a name="s3D26520D96DC70A8EE576F9E7254F3A4"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART III</font></div><div><a name="s135EBF9279BAF440B7336F9E7288B149"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We will file with the SEC a definitive Proxy Statement, which we refer to herein as the &#8220;Proxy Statement,&#8221; not later than 120 days after the fiscal year ended December&#160;31, 2016. The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s3187379469F673D72E306F9E72A922DA"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;11. EXECUTIVE COMPENSATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sA411B05F392907FFEDE46F9E72DBE785"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s45F5477FE7071AD9504F6F9E72FCC05E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sD2397F90385FF93855D06F9E732C9398"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></div><hr style="page-break-after:always"><div><a name="s89E49B7F82703021BCB86F9E734F3CED"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALENA BIOPHARMA, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Stephen F. Ghiglieiri</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Stephen F. Ghiglieri</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Interim Chief Executive Officer and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: March 15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dated: March 15, 2017</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Stephen F. Ghiglieri</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interim Chief Executive Officer and Chief Financial Officer (Principal Executive and Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stephen F. Ghiglieri</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Sanford J. Hillsberg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director, Chairman of the Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March&#160;15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sanford J. Hillsberg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ William L. Ashton</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">William L. Ashton</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Richard Chin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Richard Chin, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Irving M. Einhorn</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Irving M. Einhorn</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Stephen S. Galliker</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stephen S. Galliker</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Mary Ann Gray</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Mary Ann Gray</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Rudolph Nisi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Rudolph Nisi, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></div><hr style="page-break-after:always"><div><a name="s73CE882372A710C4F07E6F9E7380BDB2"></a></div><div></div><div><br></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 15. EXHIBITS</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:10%;"></td><td style="width:62%;"></td><td style="width:9%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit  Number</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Form</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Filing Date/Period End Date</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Underwriting Agreement dated as of March 13, 2015 by and between Galena Biopharma, Inc. and Raymond James &amp; Associates,</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16-Mar-15</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Inc.</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Underwriting&#160;Agreement&#160;dated&#160;as&#160;of&#160;January&#160;7,&#160;2016&#160;by&#160;and&#160;between&#160;</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7-Jan-16</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena&#160;Biopharma,&#160;Inc.&#160;and&#160;Raymond&#160;James&#160;Financial,&#160;Inc.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unit Purchase Agreement, dated as of January 12, 2014, between Galena Biopharma, Inc. and Mills Pharmaceuticals, LLC.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17-Mar-14</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated Certificate of Incorporation of</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation),</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">amended as of February 10, 2017**</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certificate of Ownership and Merger</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26-Sep-11</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated By-Laws of Galena Biopharma, Inc.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Common Stock Certificate**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant Agreement by and Galena Biopharma, Inc., Computershare Inc. and Computershare Trust Company, N.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13-Sep-13</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant Agreement by and Galena Biopharma, Inc., Computershare Inc. and Computershare Trust Company, N.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16-Mar-15</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form&#160;of&#160;Warrant&#160;agreement&#160;by&#160;and&#160;among&#160;Galena&#160;Biopharma,&#160;Inc.,&#160;</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7-Jan-16</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Computershare&#160;Inc.&#160;and&#160;Computershare&#160;Trust&#160;Company,&#160;N.A</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant, to be issued by Galena Biopharma, Inc. to the Investors on July 13, 2016.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-Jul-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9% Original Issues Discount Senior Secured Debenture of Galena Biopharma, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-May-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Securities Purchase Agreement dated May 10, 2016 between Galena Biopharma, Inc. and Purchasers</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated 9% Original Issue Discount Senior Secured Debenture Due November 10, 2018, issued to JGB (Cayman) Newton Ltd. as of August 22, 2016</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Series A Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Series B Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Subsidiary Guarantee dated May 10, 2016 between Galena Biopharma, Inc. and JGB Collateral LLC.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Registration Rights Agreement dated May 10, 2016 between Galena Biopharma, Inc. and Purchasers.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Security Agreement dated May 10, 2016 between Galena Biopharma, Inc. and JGB Collateral LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment Agreement between Galena Biopharma, Inc. and JGB (Cayman) Newton Ltd. dated August 22, 2016.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Securities Purchase Agreement, dated as of July 7, 2016, by and among Galena Biopharma, Inc. and the Investors</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-Jul-16</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">First Amendment to Securities Purchase Agreement, dated as of July 12, 2016, by and between Galena Biopharma, Inc. and each purchaser identified on the signature pages therein, amending the Securities Purchase Agreement, dated as of July 7, 2016, by and among the Company and the purchasers named therein</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18-Jul-16</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:10%;"></td><td style="width:62%;"></td><td style="width:9%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Common Stock Purchase Warrant issued in April 2011</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Apr-11</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of December 2012 Warrant.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19-Dec-12</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of warrants granted on May 8, 2013 under the Loan and Security</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.7</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-May-13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Agreement</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Agreement, dated as of March 18, 2015, by and among Galena Biopharma, Inc., Computershare, Inc. and Computershare Trust Company,</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6-Aug-15</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">N.A.</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Agreement, dated as of January 12, 2016, by and among Galena Biopharma, Inc., Computershare Inc. and Computershare Trust Company,</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.9</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Mar-16</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">N.A.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Registration Rights Agreement, dated January 12, 2014, between Galena Biopharma, Inc. and each former owner of membership units of Mills Pharmaceuticals, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17-Mar-14</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Contingent Value Rights Agreement among Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company,</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14-Apr-11</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">N.A., Computershare Inc., and Robert E Kennedy, dated April 13, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">First Amendment to Contingent Value Rights Agreement among Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated February 15, 2012</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28-Mar-12</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation)</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Schedule 14A</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Annex A</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23-Apr-10</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated 2007 Incentive Plan*</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment to Galena Biopharma, Inc. (formerly RXi Pharmaceuticals</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Schedule 14A</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Annex A</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31-May-11</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Corporation) Amended and Restated 2007 Incentive Plan*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. 2016 Incentive Plan*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Incentive Stock Option*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-Aug-15</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Nonstatutory Stock Option*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-Aug-15</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Patent and Technology License Agreement, dated September 11, 2006, by and among the Board of Regents of the University of</font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Aug-11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;Texas System, the University of Texas M.D. Anderson Cancer Center, </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></div></td></tr><tr><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 1 to Patent and Technology License Agreement, dated</font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td rowspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Aug-11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December 21, 2007, by and among the Board of Regents of the </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">University of Texas System, the University of Texas M.D. Anderson </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancer Center, the Henry M. Jackson Foundation for the Advancement </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></div></td></tr><tr><td rowspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 2 to Patent and Technology License Agreement, dated</font></div></td><td rowspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td rowspan="5" style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Aug-11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September 3, 2008, by and among the Board of Regents of the</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">University of Texas System, the University of Texas M.D. Anderson </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancer Center, the Henry M. Jackson Foundation for the Advancement </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:10%;"></td><td style="width:62%;"></td><td style="width:9%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 3 to Patent and Technology License Agreement, dated</font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td rowspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Aug-11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 8, 2009, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></div></td></tr><tr><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 4 to Patent and Technology License Agreement, dated</font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.5</font></div></td><td rowspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Aug-11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">February 11, 2010, by and among the Board of Regents of the </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">University of Texas System, the University of Texas M.D. Anderson </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancer Center, the Henry M. Jackson Foundation for the Advancement </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></div></td></tr><tr><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 5 to Patent and Technology License Agreement, dated</font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.6</font></div></td><td rowspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Aug-11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 10, 2011, by and among the Board of Regents of the </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">University of Texas System, the University of Texas M.D. Anderson </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancer Center, the Henry M. Jackson Foundation for the Advancement </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Scientific Advisory Agreement between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and </font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.19</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12-Mar-13</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">George E. Peoples, Ph.D., dated May 1, 2011 as amended through</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;November 1, 2017</font></div></td></tr><tr><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exclusive License Agreement, dated as of July 11, 2011, by and among</font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td rowspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21-Sep-11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Galena Biopharma, Inc. (formerly RXi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pharmaceuticals Corporation) and its wholly-owned subsidiary, Apthera, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employee Stock Purchase Plan*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License Agreement, effective as of April 30, 2009, between Kwangdong Pharmaceutical Co., Ltd. and Apthera, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28-Mar-12</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 1 to License Agreement, dated as of January 13, 2012, by and among Apthera, Inc., Kwangdong Pharmaceutical Co.,</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.46</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28-Mar-12</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;Ltd., and Galena Biopharma, Inc.</font></div></td></tr><tr><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Amendment to Stock Options Granted under Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) 2007 </font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td rowspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Aug-11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Incentive Plan, entered into in April 2011 by Galena Biopharma, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">with all directors of Galena Biopharma, Inc., as of April 1, 2011,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;and Mark J. Ahn, Ph.D.</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License and Supply Agreement, effective December 3, 2012, between</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.43</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12-Mar-13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. and ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loan and Security Agreement dated May 8, 2013 among Galena Biopharma, Inc., Apthera, Inc., Oxford Finance LLC and the Lenders</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.6</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-May-13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At Market Issuance Sales Agreement dated May 24, 2013 between Galena Biopharma, Inc. and Maxim Group LLC.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31-May-13</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At Market Issuance Sales agreements dated May 24, 2013 between Galena Biopharma, Inc. and MLV &amp; Co. LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31-May-13</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of warrants granted on May 8, 2013 under the Loan and Security</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.7</font></div></td><td rowspan="2" style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-May-13</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Agreement</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:10%;"></td><td style="width:62%;"></td><td style="width:9%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License and Development Agreement, dated January 13, 2014, between Galena Biopharma, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.36</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17-Mar-14</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exclusive License Agreement, dated as of December 20, 2013, between Mills Pharmaceuticals, LLC and BioVascular, Inc.</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.37</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17-Mar-14</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License and Supply Agreement dated as of July 17, 2014 between Galena Biopharma, Inc. and MonoSol Rx, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11-Aug-14</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Purchase Agreement, dated as of November 18, 2014, by and between</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20-Nov-14</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. and Lincoln Park Capital Fund, LLC</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment dated August 8, 2016 to the Purchase Agreement, dated as of November 18, 2014, by and between Galena Biopharma, Inc. and Lincoln Park Capital Fund, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9-Nov-16</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Separation and Consulting Agreement, dated as of June 24, 2015, by and between Galena Biopharma, Inc. and Margaret Kivinski, </font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6-Aug-15</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">and General Release, dated as of June 24, 2015, by Margaret Kivinski</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.29</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment Offer Letter effective June 25, 2015, between Galena</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.5</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6-Aug-15</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Biopharma, Inc. and Thomas J. Knapp</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment Agreement, dated as of October 30, 2015, between Galena Biopharma, Inc. and Bijan Nejadnik, M.D.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Mar-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Asset Purchase Agreement, dated November 19, 2015, between Galena Biopharma, Inc. and Sentynl Therapeutics Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Mar-16</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment, dated as of December 16, 2015, to License and Supply</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.35</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Mar-16</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Agreement dated as of July 17, 2014 between Galena Biopharma, Inc. and MonoSol Rx, LLC</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Asset Purchase Agreement, dated December 17, 2015, between Galena Biopharma, Inc. and Midatech Pharma PLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.36</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Mar-16</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Separation Agreement and Releases, dated December 31, 2015, between Galena Biopharma, Inc. and Ryan Dunlap</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.37</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Mar-16</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment, dated December 31, 2015, to Employment Offer Letter</font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.38</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Mar-16</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">effective June 25, 2015, between Galena Biopharma, Inc. and Thomas J. Knapp</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Undertaking re Advancement of Expenses between Galena</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.39</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Mar-16</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Biopharma, Inc. and certain of its Existing or Former Directors and Executive officers</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Placement Agency Agreement, dated as of July 7, 2016, by and between Galena Biopharma, Inc. and Raymond James &amp; Associates, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-Jul-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance Agreement, dated as of August 22, 2016, between Galena Biopharma, Inc. and John T. Burns</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Second Amendment to Employment Agreement, dated as of August 22, 2016, between Galena Biopharma, Inc. and Bijan Nejadnik</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22-Aug-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Second Amendment to Offer Letter between Galena Biopharma, Inc. and Thomas J. Knapp</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6-Oct-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment Agreement between Galena Biopharma, Inc. and Stephen Ghiglieri dated November 1, 2016</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">99.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3-Nov-16</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Code of Ethics and Conduct, as amended January 2012</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15-Apr-08</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Subsidiaries of the Registrant.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consent of Moss Adams LLP, Independent Registered Public Accounting Firm.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sarbanes-Oxley Act Section 302 Certification of Stephen F. Ghiglieri.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sarbanes-Oxley Act Section 906 Certification of Stephen F. Ghiglieri.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Instance Document.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:10%;"></td><td style="width:62%;"></td><td style="width:9%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Schema.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Calculation.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Definition.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Label.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation.**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:174%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:0px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Indicates a management contract or compensatory plan or arrangement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:0px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Filed herewith.</font></div></td></tr></table><div style="line-height:174%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>gale-20161231xex31.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s87f309de09fb4eb59203332aa1b7d1cc"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 3.1</font></div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:48pt;"><font style="font-family:inherit;font-size:48pt;">Delaware</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;">The First State</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:582px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page 1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:232%;padding-top:5px;text-align:left;padding-left:30px;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS FILED FROM AND INCLUDING THE RESTATED CERTIFICATE OR A MERGER WITH A RESTATED CERTIFICATE ATTACHED OF &#8220;GALENA BIOPHARMA, INC.&#8221; AS RECEIVED AND FILED IN THIS OFFICE.</font></div><div style="line-height:120%;text-align:left;padding-left:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">RESTATED CERTIFICATE, FILED THE SIXTH DAY OF FEBRUARY, A.D.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">2008, AT 4:40 O`CLOCK P.M.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:232%;text-align:left;padding-left:30px;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATE OF AMENDMENT, FILED THE TWENTY-SIXTH DAY OF JULY, A.D. 2011, AT 4:08 O`CLOCK P.M.</font></div><div style="line-height:232%;text-align:left;padding-left:30px;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATE OF OWNERSHIP, CHANGING ITS NAME FROM "RXI PHARMACEUTICALS CORPORATION" TO "GALENA BIOPHARMA, INC.", FILED THE TWENTY-SIXTH DAY OF SEPTEMBER, A.D. 2011, AT 10:28 O`CLOCK A.M.</font></div><div style="line-height:232%;text-align:left;padding-left:30px;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATE OF AMENDMENT, FILED THE TWENTY-EIGHTH DAY OF JUNE, A.D. 2013, AT 4:56 O`CLOCK P.M.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="coiimage.jpg" alt="coiimage.jpg" style="height:145px;width:576px;"></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:48pt;"><font style="font-family:inherit;font-size:48pt;">Delaware</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;">The First State</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:582px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page 2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:232%;padding-top:5px;text-align:left;padding-left:30px;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATE OF CHANGE OF REGISTERED AGENT, FILED THE TWENTY- SECOND DAY OF JULY, A.D. 2013, AT 9:13 O`CLOCK A.M.</font></div><div style="line-height:120%;text-align:left;padding-left:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATE OF AMENDMENT, FILED THE NINETEENTH DAY OF JUNE,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">A.D. 2015, AT 2:23 O`CLOCK P.M.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:232%;text-align:left;padding-left:30px;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATE OF AMENDMENT, FILED THE SEVENTEENTH DAY OF OCTOBER, A.D. 2016, AT 10 O`CLOCK A.M.</font></div><div style="line-height:120%;text-align:left;padding-left:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATE OF AMENDMENT, FILED THE SECOND DAY OF NOVEMBER,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">A.D. 2016, AT 10 O`CLOCK A.M.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="coiimage.jpg" alt="coiimage.jpg" style="height:145px;width:576px;"></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#111111;">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</font></div><div style="line-height:120%;text-align:center;padding-left:177px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#111111;">RXI PHARMACEUTICALS  CORPORATION</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:177px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">a Delaware Corporation</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">RXi Pharmaceuticals </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">a </font><font style="font-family:inherit;font-size:11pt;color:#262626;">corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">organized and existing under the laws of the State of Delaware (the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">"Corporation </font><font style="font-family:inherit;font-size:11pt;color:#505050;">"</font><font style="font-family:inherit;font-size:11pt;color:#111111;">), does hereby </font><font style="font-family:inherit;font-size:11pt;color:#262626;">submit </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this Amended </font><font style="font-family:inherit;font-size:11pt;color:#262626;">and </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Restated Certificate of Incorporation</font><font style="font-family:inherit;font-size:11pt;color:#505050;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">duly </font><font style="font-family:inherit;font-size:11pt;color:#262626;">adopted </font><font style="font-family:inherit;font-size:11pt;color:#111111;">pursuant to Sections 242 and </font><font style="font-family:inherit;font-size:11pt;color:#262626;">245 </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of the General Corporation Law of the State of Delaware, for the purpose </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">amending </font><font style="font-family:inherit;font-size:11pt;color:#262626;">and </font><font style="font-family:inherit;font-size:11pt;color:#111111;">restating the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Certificate </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of Incorporation of the Corporation, as originally filed with the Secretary </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">State </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">State </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of Delaware on April 3, 2006 and </font><font style="font-family:inherit;font-size:11pt;color:#262626;">as subsequently amended on November 28, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">2006, January 8, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">2007 </font><font style="font-family:inherit;font-size:11pt;color:#111111;">and June 19, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">2007. </font><font style="font-family:inherit;font-size:11pt;color:#111111;">The text of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Certificate </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of Incorporation is hereby </font><font style="font-family:inherit;font-size:11pt;color:#262626;">restated and </font><font style="font-family:inherit;font-size:11pt;color:#111111;">amended to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">read </font><font style="font-family:inherit;font-size:11pt;color:#111111;">in its entirety as </font><font style="font-family:inherit;font-size:11pt;color:#262626;">follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:177px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#111111;">ARTICLE I</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:26px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">The name </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this corporation is RXi Pharmaceuticals </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:177px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#111111;">ARTICLE II</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">The nature of the business and the purposes to be conducted and promoted by the Corporation </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">conduct </font><font style="font-family:inherit;font-size:11pt;color:#111111;">any lawful business, to promote any lawful purpose, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">and </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to engage in any lawful act or </font><font style="font-family:inherit;font-size:11pt;color:#262626;">activity </font><font style="font-family:inherit;font-size:11pt;color:#111111;">for </font><font style="font-family:inherit;font-size:11pt;color:#262626;">which corporations </font><font style="font-family:inherit;font-size:11pt;color:#111111;">may be organized under the General Corporation Law of the State of Delaware  </font><font style="font-family:inherit;font-size:11pt;color:#262626;">(the "DGCL").</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:177px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#111111;">ARTICLE III</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:18px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:22px;">A.</font><font style="font-family:inherit;font-size:11pt;color:#111111;">Classes of Stock. This </font><font style="font-family:inherit;font-size:11pt;color:#262626;">corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">i</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">s </font><font style="font-family:inherit;font-size:11pt;color:#111111;">authorized to issue 55,000,000 </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shares. </font><font style="font-family:inherit;font-size:11pt;color:#111111;">50,000,000 </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shares shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be Common </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Stock </font><font style="font-family:inherit;font-size:11pt;color:#111111;">with </font><font style="font-family:inherit;font-size:11pt;color:#262626;">a </font><font style="font-family:inherit;font-size:11pt;color:#111111;">par </font><font style="font-family:inherit;font-size:11pt;color:#262626;">value of $0.0001 </font><font style="font-family:inherit;font-size:11pt;color:#111111;">per </font><font style="font-family:inherit;font-size:11pt;color:#262626;">share </font><font style="font-family:inherit;font-size:11pt;color:#111111;">("Common Stock") and </font><font style="font-family:inherit;font-size:11pt;color:#262626;">5,000,000 </font><font style="font-family:inherit;font-size:11pt;color:#111111;">shares </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be Preferred </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Stock </font><font style="font-family:inherit;font-size:11pt;color:#111111;">with </font><font style="font-family:inherit;font-size:11pt;color:#262626;">a </font><font style="font-family:inherit;font-size:11pt;color:#111111;">par </font><font style="font-family:inherit;font-size:11pt;color:#262626;">value of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">$0.0001 per </font><font style="font-family:inherit;font-size:11pt;color:#262626;">share </font><font style="font-family:inherit;font-size:11pt;color:#111111;">("Preferred </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Stock").</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:20px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#111111;">8.  </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Rights, Preferences, Privileges and Restrictions of Preferred Stock. Preferred Stock may be issued from </font><font style="font-family:inherit;font-size:11pt;color:#262626;">time </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to time in </font><font style="font-family:inherit;font-size:11pt;color:#262626;">one </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or more </font><font style="font-family:inherit;font-size:11pt;color:#262626;">series, each of such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">series to have </font><font style="font-family:inherit;font-size:11pt;color:#262626;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">tem1s as </font><font style="font-family:inherit;font-size:11pt;color:#262626;">stated or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">expre</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">ss</font><font style="font-family:inherit;font-size:11pt;color:#111111;">ed herein </font><font style="font-family:inherit;font-size:11pt;color:#262626;">and </font><font style="font-family:inherit;font-size:11pt;color:#111111;">in the re</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">s</font><font style="font-family:inherit;font-size:11pt;color:#111111;">olution or resolutions providing for the issue </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of such series </font><font style="font-family:inherit;font-size:11pt;color:#111111;">adopted by the Board </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Directors of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">(the "Board of Director </font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">s"</font><font style="font-family:inherit;font-size:11pt;color:#111111;">) as hereinafter provided. Any </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shares </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of Preferred </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Stock that </font><font style="font-family:inherit;font-size:11pt;color:#111111;">may be redeemed, purcha</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">se</font><font style="font-family:inherit;font-size:11pt;color:#111111;">d or acquired by the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">may be reissued except as </font><font style="font-family:inherit;font-size:11pt;color:#262626;">otherwise </font><font style="font-family:inherit;font-size:11pt;color:#111111;">provided by law or </font><font style="font-family:inherit;font-size:11pt;color:#262626;">this </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Certificate of Incorporation</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">. </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Different </font><font style="font-family:inherit;font-size:11pt;color:#262626;">series </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of Preferred Stock shall not be construed to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">constitute </font><font style="font-family:inherit;font-size:11pt;color:#111111;">different classes of shares for the purposes </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#262626;">voting </font><font style="font-family:inherit;font-size:11pt;color:#111111;">by cla</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">ss</font><font style="font-family:inherit;font-size:11pt;color:#111111;">es unless </font><font style="font-family:inherit;font-size:11pt;color:#262626;">expressly </font><font style="font-family:inherit;font-size:11pt;color:#111111;">provided in the resolution or resolutions providing for the issue of such </font><font style="font-family:inherit;font-size:11pt;color:#262626;">series </font><font style="font-family:inherit;font-size:11pt;color:#111111;">adopted by the Board of Directors as hereinafter provided.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:20px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#262626;">Authority </font><font style="font-family:inherit;font-size:11pt;color:#111111;">is hereby expressly granted to the Board of Directors </font><font style="font-family:inherit;font-size:11pt;color:#262626;">from </font><font style="font-family:inherit;font-size:11pt;color:#111111;">time to time to issue the Preferred Stock in </font><font style="font-family:inherit;font-size:11pt;color:#262626;">one </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or </font><font style="font-family:inherit;font-size:11pt;color:#262626;">more </font><font style="font-family:inherit;font-size:11pt;color:#111111;">series, and in connection </font><font style="font-family:inherit;font-size:11pt;color:#262626;">with </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the creation of any </font><font style="font-family:inherit;font-size:11pt;color:#262626;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">series, by resolution or resolutions providing </font><font style="font-family:inherit;font-size:11pt;color:#262626;">for </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the issue </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shares </font><font style="font-family:inherit;font-size:11pt;color:#111111;">thereof</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to determine and fix </font><font style="font-family:inherit;font-size:11pt;color:#262626;">such voting </font><font style="font-family:inherit;font-size:11pt;color:#111111;">powers, full or limited, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">no voting power</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">s, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">and </font><font style="font-family:inherit;font-size:11pt;color:#262626;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">de</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">s</font><font style="font-family:inherit;font-size:11pt;color:#111111;">ignations</font><font style="font-family:inherit;font-size:11pt;color:#505050;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">preferences and relative participating</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">optional or other </font><font style="font-family:inherit;font-size:11pt;color:#262626;">special </font><font style="font-family:inherit;font-size:11pt;color:#111111;">rights, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">and qualifications, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">limitations or restrictions thereof,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">including without limitation thereof, dividend rights, conversion rights, redemption privileges </font><font style="font-family:inherit;font-size:11pt;color:#262626;">and </font><font style="font-family:inherit;font-size:11pt;color:#111111;">liquidation preferences, as </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be stated and expressed in </font><font style="font-family:inherit;font-size:11pt;color:#262626;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">resolutions, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">all </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to the full extent now </font><font style="font-family:inherit;font-size:11pt;color:#262626;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">hereafter permitted by the DGCL. Without limiting the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">generality of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">foregoing, the </font><font style="font-family:inherit;font-size:11pt;color:#111111;">resolutions providing </font><font style="font-family:inherit;font-size:11pt;color:#262626;">for </font><font style="font-family:inherit;font-size:11pt;color:#111111;">issuance of any series of Preferred Stock may provide </font><font style="font-family:inherit;font-size:11pt;color:#262626;">that such series shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be </font><font style="font-family:inherit;font-size:11pt;color:#262626;">superior or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">rank equally or be junior to the Preferred Stock of any </font><font style="font-family:inherit;font-size:11pt;color:#262626;">other </font><font style="font-family:inherit;font-size:11pt;color:#111111;">series to the extent permitted by law </font><font style="font-family:inherit;font-size:11pt;color:#262626;">and </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this Certificate </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Incorporation. </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Except </font><font style="font-family:inherit;font-size:11pt;color:#111111;">as </font><font style="font-family:inherit;font-size:11pt;color:#262626;">otherwise </font><font style="font-family:inherit;font-size:11pt;color:#111111;">provided </font><font style="font-family:inherit;font-size:11pt;color:#262626;">in </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Certificate of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Incorporation, no </font><font style="font-family:inherit;font-size:11pt;color:#262626;">vote of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the holders </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Preferred </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Stock </font><font style="font-family:inherit;font-size:11pt;color:#262626;">or Common </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Stock </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be a prerequisite to the</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">designation or issuance of any </font><font style="font-family:inherit;font-size:11pt;color:#262626;">shares of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">any series of the Preferred Stock authorized by and complying with the conditions </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this Certificate </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of lncorporation, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the right to have </font><font style="font-family:inherit;font-size:11pt;color:#262626;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">vote being expressly waived by all present and future holders of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">capital stock </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">A.</font><font style="font-family:inherit;font-size:12pt;color:#111111;font-weight:bold;">Common Stock. </font><font style="font-family:inherit;font-size:11pt;color:#111111;">The </font><font style="font-family:inherit;font-size:11pt;color:#262626;">voting, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">dividend and liquidation rights of the holders of the Common </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Stock </font><font style="font-family:inherit;font-size:11pt;color:#111111;">are </font><font style="font-family:inherit;font-size:11pt;color:#383838;">s</font><font style="font-family:inherit;font-size:11pt;color:#111111;">ubject to and qualified by the rights </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the holders of </font><font style="font-family:inherit;font-size:11pt;color:#262626;">the </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Preferred Stock of </font><font style="font-family:inherit;font-size:11pt;color:#262626;">any </font><font style="font-family:inherit;font-size:11pt;color:#111111;">serie</font><font style="font-family:inherit;font-size:11pt;color:#383838;">s </font><font style="font-family:inherit;font-size:11pt;color:#262626;">as </font><font style="font-family:inherit;font-size:11pt;color:#111111;">may be designated  by the Board of Directors upon issuance of any </font><font style="font-family:inherit;font-size:11pt;color:#383838;">s</font><font style="font-family:inherit;font-size:11pt;color:#111111;">uch Preferred Stock. The holders </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the Common Stock shall have no preemptive rights to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">subscribe for </font><font style="font-family:inherit;font-size:11pt;color:#111111;">any shares of any class </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">s</font><font style="font-family:inherit;font-size:11pt;color:#383838;">t</font><font style="font-family:inherit;font-size:11pt;color:#111111;">ock </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation whether </font><font style="font-family:inherit;font-size:11pt;color:#111111;">now or hereafter authorized.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:57px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;text-decoration:underline;">Dividend Rights</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. Dividends may be declared and paid </font><font style="font-family:inherit;font-size:11pt;color:#262626;">on </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Common </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Stock from  funds lawfully available therefor as and when determined by the Board of Directors and </font><font style="font-family:inherit;font-size:11pt;color:#262626;">subject </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to any preferential dividend rights </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">any then </font><font style="font-family:inherit;font-size:11pt;color:#262626;">outstanding </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Preferred Stock.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;text-decoration:underline;">Liquidation Rights</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. Upon the dissolution or liquidation of the Corporation, whether </font><font style="font-family:inherit;font-size:11pt;color:#262626;">voluntary </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or involuntary</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">holders </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Common Stock </font><font style="font-family:inherit;font-size:11pt;color:#262626;">will </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be </font><font style="font-family:inherit;font-size:11pt;color:#262626;">entitled </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">receive </font><font style="font-family:inherit;font-size:11pt;color:#111111;">all assets of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">available for distribution to its </font><font style="font-family:inherit;font-size:11pt;color:#262626;">stockholders, subject </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to any preferential rights of any then outstanding Preferred Stock.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;text-decoration:underline;">Redemption</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. The Common Stock is not redeemable</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;text-decoration:underline;">Voting Rights</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Each </font><font style="font-family:inherit;font-size:11pt;color:#111111;">share of Common Stock shall be entitled to one </font><font style="font-family:inherit;font-size:11pt;color:#262626;">vote. </font><font style="font-family:inherit;font-size:11pt;color:#111111;">There </font><font style="font-family:inherit;font-size:11pt;color:#383838;">s</font><font style="font-family:inherit;font-size:11pt;color:#111111;">hall be no cumulative </font><font style="font-family:inherit;font-size:11pt;color:#262626;">voting.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;text-decoration:underline;">Number</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. The number </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">authorized shares of Common </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Stock </font><font style="font-family:inherit;font-size:11pt;color:#111111;">may be </font><font style="font-family:inherit;font-size:11pt;color:#262626;">increased or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">decreased (but not below the number of shares thereof then outstanding) by the affirmative </font><font style="font-family:inherit;font-size:11pt;color:#262626;">vote </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of the holders </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of a </font><font style="font-family:inherit;font-size:11pt;color:#111111;">majority of the </font><font style="font-family:inherit;font-size:11pt;color:#383838;">s</font><font style="font-family:inherit;font-size:11pt;color:#111111;">tock of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:285px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">ARTICLE </font><font style="font-family:Arial;font-size:10pt;color:#111111;">IV</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#262626;">The </font><font style="font-family:inherit;font-size:11pt;color:#111111;">corporation is to have perpetual existence.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:285px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">ARTICLE V</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">Except to the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">extent </font><font style="font-family:inherit;font-size:11pt;color:#111111;">that the DGCL prohibits the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">elimination or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">limitation of liability </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">directors for breaches of fiduciary duty, no director of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be personally liable to the Corporation </font><font style="font-family:inherit;font-size:11pt;color:#262626;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">its stockholders for monetary damages for any breach of fiduciary duty as </font><font style="font-family:inherit;font-size:11pt;color:#262626;">a</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">director, notwithstanding any provision </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of law </font><font style="font-family:inherit;font-size:11pt;color:#111111;">imposing such liability. No </font><font style="font-family:inherit;font-size:11pt;color:#262626;">amendment </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to or repeal of</font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:6px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">this provision shall </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">apply </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">have any </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">effect on </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the liability </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or alleged </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">liability </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of any </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">director </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">or with respect to any acts </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">omissions of </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">such </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">director occurring prior to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">such amendment or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">repeal.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:285px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;font-weight:bold;">ARTICLE VI</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">The corporation shall, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">the </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">fullest </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">extent </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">p</font><font style="font-family:inherit;font-size:11pt;color:#383838;">e</font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">rmitted by the provisions </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of Section </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">145 </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">General Corporation </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Law </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the State </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Delaware, as </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">the same </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">may be amended and </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">supplemented, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">indemnify </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">any </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">and </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">all </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">persons whom it </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">have </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">power to </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">indemnify </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">under said </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Section </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">from </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">and </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">against any and all of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the expenses</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">liabilities, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or other </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">matters referred </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">to </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">in </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or covered </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">by </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">said section</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">and the indemnification provided </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">for </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">herein </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">not be deemed </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">exclusive of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">any other rights to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">which those indemnified </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">may be entitled under any Bylaw, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">agreement, vote </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">of </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">stockholders or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">disinterested </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">directors or otherwise</font><font style="font-family:inherit;font-size:11pt;color:#505050;">, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">both </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">as </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to action in his </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">official capacity </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">and </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">as </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">action in </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">another capacity </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">while </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">holding </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">such office</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">and shall </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">continue </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">as </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">a </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">person </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">who </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">has </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">ceased </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to be </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">a </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">director, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">officer</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">employee</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">agent </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">and </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">shall inure to the benefit </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the heirs, executors, </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">and administrators of such </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">person.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:285px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;font-weight:bold;">ARTICLE VII</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">A.</font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;font-weight:bold;">Indemnification. </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">The </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">Corporation shall, to </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the maximum </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">extent </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">permitted under the DGCL </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">and </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">except </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">as set forth </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">below, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">indemnify </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">and upon request </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">advance expenses to each </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">person </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">who </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">was  </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">is a party or is threatened to be made </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">a </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">party to any threatened, pending </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or completed </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">action, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">suit or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">proceeding, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">whether civil, criminal, administrative or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">investigative, by reason </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">fact that he is or was</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">or ha</font><font style="font-family:inherit;font-size:11pt;color:#383838;">s </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">agreed to become, a </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">director </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">officer </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">Corporation, or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">is </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or was serving, or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">has </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">agreed </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">serve, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">at the request </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">Corporation, as </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">a director, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">officer, employee </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">or </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">trustee </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">of, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">in a </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">similar capacity with, another corporation, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">partnership, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">joint venture</font><font style="font-family:inherit;font-size:11pt;color:#505050;">, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">trust </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or other </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">enterprise,  </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">including any </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">employee benefit plan </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">(all such </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">per </font><font style="font-family:inherit;font-size:11pt;color:#383838;">s</font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">ons </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">being referred to hereafter as </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">an </font><font style="font-family:inherit;font-size:11pt;color:#505050;">"</font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">lndemnitee"), </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">by reason of any </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">action alleged </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to have been taken or </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">omitted </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">in </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">such </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">capacity</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">against all expenses (including attorneys' </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">fees)</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">judgments </font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">fines </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">and </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">amounts paid </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">in settlement </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">actually and </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">reasonably incurred </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">by </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">him </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or on </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">his behalf in </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">connection with such action</font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">suit or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">proc</font><font style="font-family:inherit;font-size:11pt;color:#383838;">e</font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">eding </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">and </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">any appeal </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">therefrom </font><font style="font-family:inherit;font-size:11pt;color:#383838;">, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">if he acted in </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">good faith </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">and </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">in </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">a manner he reasonably believed to be in, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">not </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">opposed </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to, the best interests </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the Corporation, and, with respect to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">any </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">criminal action </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">proceeding, had no reasonable </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">cause </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to believe his conduct </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">was </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">unlawful. </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">Notwithstanding </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">anything to the </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">contrary in this </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Article, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">the Corporation shall </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">not indemnify </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">an </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Indemnitee </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">seeking indemnification </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">in </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">connection with any </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">action, </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">suit, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">proceeding, claim or counterclaim, or part thereof, initiated by the Indemnitee unless </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">the </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">initiation thereof </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">was approved </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">by the Board </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Directors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:18px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:22px;">B.</font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;font-weight:bold;">Determination of Entitlement to Indemnification </font><font style="font-family:inherit;font-size:11pt;color:#383838;font-weight:bold;">. </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Any indemnification under Paragraph </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">A of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">this Article (unles</font><font style="font-family:inherit;font-size:11pt;color:#383838;">s </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">ordered </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">by a court) </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">be made by </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">the </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">only </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">as authorized </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">in </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#383838;">s</font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">pecific case </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">upon </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">a </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">determination </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">that indemnification is proper in </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the circumstances </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">because such </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">person has either met the </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">applicable standard of conduct set forth </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">in this Article </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">and </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">that the amount </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">requested </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">has been actually </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">and </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">reasonably incurred. Such determination </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">be made:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:56px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">by </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">a </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">majority </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">vote of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">directors who are </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">not partie</font><font style="font-family:inherit;font-size:11pt;color:#383838;">s </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">to </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">such action, suit or </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">proceeding, even though less than </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">a </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">quorum; </font><font style="font-family:inherit;font-size:11pt;color:#1f1f1f;">or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:56px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">by a committee of such directors designated by a majority vote of such directors, even though less than a quorum; or</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:56px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">ifthere are no such directors, or if such directors </font><font style="font-family:inherit;font-size:11pt;color:#282828;">so direct, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">by independent legal </font><font style="font-family:inherit;font-size:11pt;color:#282828;">counsel </font><font style="font-family:inherit;font-size:11pt;color:#111111;">in a written opinion; or</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:56px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">by the holders </font><font style="font-family:inherit;font-size:11pt;color:#282828;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Common </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Stock</font><font style="font-family:inherit;font-size:11pt;color:#626262;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">Advance of Expenses</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. Notwithstanding </font><font style="font-family:inherit;font-size:11pt;color:#282828;">any </font><font style="font-family:inherit;font-size:11pt;color:#111111;">other provisions of this </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Certificate </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of Incorporation, the By-Laws of the Corporation, or any agreement, </font><font style="font-family:inherit;font-size:11pt;color:#282828;">vote </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of stockholders or disinterested directors</font><font style="font-family:inherit;font-size:11pt;color:#414141;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or </font><font style="font-family:inherit;font-size:11pt;color:#282828;">arrangement </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to the contrary, the Corporation may advance payment of </font><font style="font-family:inherit;font-size:11pt;color:#282828;">expenses </font><font style="font-family:inherit;font-size:11pt;color:#111111;">incurred by an Indemnitee in </font><font style="font-family:inherit;font-size:11pt;color:#282828;">advance </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of the final disposition of any matter </font><font style="font-family:inherit;font-size:11pt;color:#282828;">only </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to the extent </font><font style="font-family:inherit;font-size:11pt;color:#282828;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">advance is not prohibited by </font><font style="font-family:inherit;font-size:11pt;color:#282828;">applicable law, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">and then only upon receipt of an undertaking by or </font><font style="font-family:inherit;font-size:11pt;color:#282828;">on </font><font style="font-family:inherit;font-size:11pt;color:#111111;">behalf of the lndemnitee to repay all amounts </font><font style="font-family:inherit;font-size:11pt;color:#282828;">so </font><font style="font-family:inherit;font-size:11pt;color:#111111;">advanced in the event that it </font><font style="font-family:inherit;font-size:11pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">ultimately be determined that the Indemnitee is not entitled to be </font><font style="font-family:inherit;font-size:11pt;color:#282828;">indemnified </font><font style="font-family:inherit;font-size:11pt;color:#111111;">by the Corporation as authorized in this Article. Such undertaking may be accepted without reference to the financial ability of the Indemnitee to make such repayment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:18px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">B.</font><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">Subsequent Amendment</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. No amendment, termination or repeal of this Article or of the relevant provisions of the DGCL or </font><font style="font-family:inherit;font-size:11pt;color:#282828;">any </font><font style="font-family:inherit;font-size:11pt;color:#111111;">other applicable laws shall </font><font style="font-family:inherit;font-size:11pt;color:#282828;">affect </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or diminish in any way the rights </font><font style="font-family:inherit;font-size:11pt;color:#282828;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">any lndemnitee to indemnification under the provisions hereof with respect to any action, </font><font style="font-family:inherit;font-size:11pt;color:#282828;">suit, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">proceeding or investigation </font><font style="font-family:inherit;font-size:11pt;color:#282828;">arising </font><font style="font-family:inherit;font-size:11pt;color:#111111;">out of or relating to any actions, transactions or facts occurring</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">prior to the final adoption of </font><font style="font-family:inherit;font-size:11pt;color:#282828;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">amendment, termination </font><font style="font-family:inherit;font-size:11pt;color:#282828;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">repeal.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:20px;">C.</font><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">Other Rights</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. This corporation may, to the extent </font><font style="font-family:inherit;font-size:11pt;color:#282828;">authorized </font><font style="font-family:inherit;font-size:11pt;color:#111111;">from time </font><font style="font-family:inherit;font-size:11pt;color:#282828;">to </font><font style="font-family:inherit;font-size:11pt;color:#111111;">time by its Board of Directors, grant indemnification rights to other </font><font style="font-family:inherit;font-size:11pt;color:#282828;">employees or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">agents </font><font style="font-family:inherit;font-size:11pt;color:#282828;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the Corporation or other</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">persons </font><font style="font-family:inherit;font-size:11pt;color:#282828;">serving </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">and </font><font style="font-family:inherit;font-size:11pt;color:#282828;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">rights may be equivalent to, or greater or less than, those set forth in this Article.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">D.</font><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">Merger or Consolidation</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. </font><font style="font-family:Arial;font-size:11pt;color:#111111;">If </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the Corporation is merged into </font><font style="font-family:inherit;font-size:11pt;color:#282828;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">consolidated </font><font style="font-family:inherit;font-size:11pt;color:#282828;">with </font><font style="font-family:inherit;font-size:11pt;color:#111111;">another </font><font style="font-family:inherit;font-size:11pt;color:#282828;">corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">and the </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">is not the surviving corporation, the </font><font style="font-family:inherit;font-size:11pt;color:#282828;">surviving </font><font style="font-family:inherit;font-size:11pt;color:#111111;">corporation shall </font><font style="font-family:inherit;font-size:11pt;color:#282828;">assume </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the obligations of the Corporation under this Article with respect to any action, </font><font style="font-family:inherit;font-size:11pt;color:#282828;">suit, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">proceeding </font><font style="font-family:inherit;font-size:11pt;color:#282828;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">investigation </font><font style="font-family:inherit;font-size:11pt;color:#282828;">arising </font><font style="font-family:inherit;font-size:11pt;color:#111111;">out </font><font style="font-family:inherit;font-size:11pt;color:#282828;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or relating to any actions</font><font style="font-family:inherit;font-size:11pt;color:#414141;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">transactions or facts </font><font style="font-family:inherit;font-size:11pt;color:#282828;">occurring </font><font style="font-family:inherit;font-size:11pt;color:#111111;">prior to the date </font><font style="font-family:inherit;font-size:11pt;color:#282828;">of such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">merger or consolidation</font><font style="font-family:inherit;font-size:11pt;color:#414141;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">E.</font><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">Savings Clause</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. </font><font style="font-family:Arial;font-size:11pt;color:#111111;">If </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this Article </font><font style="font-family:inherit;font-size:11pt;color:#282828;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">any portion hereof shall be invalidated on any ground by any court of </font><font style="font-family:inherit;font-size:11pt;color:#282828;">competent </font><font style="font-family:inherit;font-size:11pt;color:#111111;">jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses, including attorneys' fees</font><font style="font-family:inherit;font-size:11pt;color:#414141;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">judgments, fines and amounts paid in settlement in connection with any action, </font><font style="font-family:inherit;font-size:11pt;color:#282828;">suit, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">proceeding or investigation, whether civil, </font><font style="font-family:inherit;font-size:11pt;color:#282828;">criminal </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or </font><font style="font-family:inherit;font-size:11pt;color:#282828;">administrative, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">including an action by or in the right </font><font style="font-family:inherit;font-size:11pt;color:#282828;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the Corporation</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to the fullest extent </font><font style="font-family:inherit;font-size:11pt;color:#282828;">permitted </font><font style="font-family:inherit;font-size:11pt;color:#111111;">by any applicable portion of this Article that </font><font style="font-family:inherit;font-size:11pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:11pt;color:#111111;">not have been invalidated and to the fullest </font><font style="font-family:inherit;font-size:11pt;color:#282828;">extent </font><font style="font-family:inherit;font-size:11pt;color:#111111;">permitted by applicable law</font><font style="font-family:inherit;font-size:11pt;color:#414141;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">F.</font><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">Scope of Article</font><font style="font-family:inherit;font-size:11pt;color:#111111;">. Indemnification and </font><font style="font-family:inherit;font-size:11pt;color:#282828;">advancement </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of expenses</font><font style="font-family:inherit;font-size:11pt;color:#414141;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">as </font><font style="font-family:inherit;font-size:11pt;color:#282828;">authorized </font><font style="font-family:inherit;font-size:11pt;color:#111111;">by the preceding provisions </font><font style="font-family:inherit;font-size:11pt;color:#282828;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this Article, shall not be deemed exclusive of any other rights to which those </font><font style="font-family:inherit;font-size:11pt;color:#282828;">seeking </font><font style="font-family:inherit;font-size:11pt;color:#111111;">indemnification or advancement of expenses may be entitled under any agreement, vote </font><font style="font-family:inherit;font-size:11pt;color:#282828;">of stockholders </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or disinterested directors </font><font style="font-family:inherit;font-size:11pt;color:#282828;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">otherwise</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">both </font><font style="font-family:inherit;font-size:11pt;color:#282828;">as </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to action in an </font><font style="font-family:inherit;font-size:11pt;color:#282828;">official </font><font style="font-family:inherit;font-size:11pt;color:#111111;">capacity and </font><font style="font-family:inherit;font-size:11pt;color:#282828;">as </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to</font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">action in another capacity </font><font style="font-family:inherit;font-size:11pt;color:#212121;">while </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">holding </font><font style="font-family:inherit;font-size:11pt;color:#212121;">such </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">office. The indemnification </font><font style="font-family:inherit;font-size:11pt;color:#212121;">and </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">advancement of expenses provided by or granted pursuant to this Article </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">unless otherwise provided </font><font style="font-family:inherit;font-size:11pt;color:#212121;">when </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">authorized </font><font style="font-family:inherit;font-size:11pt;color:#212121;">or </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">ratified, continue as to </font><font style="font-family:inherit;font-size:11pt;color:#212121;">a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">person who has ceased to be an authorized </font><font style="font-family:inherit;font-size:11pt;color:#212121;">representative and shall </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">inure to the benefit of the heirs, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">executors </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">and </font><font style="font-family:inherit;font-size:11pt;color:#212121;">administrators of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">such </font><font style="font-family:inherit;font-size:11pt;color:#212121;">a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">person.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:20px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#0f0f0f;font-weight:bold;">I.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;font-weight:bold;">Insurance</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">. The Corporation may purchase </font><font style="font-family:inherit;font-size:11pt;color:#212121;">and </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">maintain insurance on behalf of any person who is </font><font style="font-family:inherit;font-size:11pt;color:#212121;">or was a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">director, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">officer, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">trustee, employee or </font><font style="font-family:inherit;font-size:11pt;color:#212121;">agent of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the Corporation</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">or </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">is or </font><font style="font-family:inherit;font-size:11pt;color:#212121;">was serving </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">at the request of the Corporation </font><font style="font-family:inherit;font-size:11pt;color:#212121;">as </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">a director, officer, trustee, employee </font><font style="font-family:inherit;font-size:11pt;color:#212121;">or </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">agent of another corporation, partnership, joint </font><font style="font-family:inherit;font-size:11pt;color:#212121;">venture, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">trust or </font><font style="font-family:inherit;font-size:11pt;color:#212121;">other </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">enterprise </font><font style="font-family:inherit;font-size:11pt;color:#212121;">against any </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">liability asserted against the person </font><font style="font-family:inherit;font-size:11pt;color:#212121;">and </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">incurred by the person in any </font><font style="font-family:inherit;font-size:11pt;color:#212121;">such capacity, or </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">arising out of his </font><font style="font-family:inherit;font-size:11pt;color:#212121;">or </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">her </font><font style="font-family:inherit;font-size:11pt;color:#212121;">status </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">as </font><font style="font-family:inherit;font-size:11pt;color:#212121;">such</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">whether </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">or not the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">would have the power or </font><font style="font-family:inherit;font-size:11pt;color:#212121;">the </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">obligation to indemnify such person </font><font style="font-family:inherit;font-size:11pt;color:#212121;">against </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">such liability under the provisions </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">thi</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">s </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">Article</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:282px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;font-weight:bold;">ARTICLE VIII</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">Incorporation </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">in the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">manner </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">now </font><font style="font-family:inherit;font-size:11pt;color:#212121;">or </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">hereafter prescribed by </font><font style="font-family:inherit;font-size:11pt;color:#212121;">statute </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">and this </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Certificate </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">of Incorporation, and </font><font style="font-family:inherit;font-size:11pt;color:#212121;">all </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">rights </font><font style="font-family:inherit;font-size:11pt;color:#212121;">conferred </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">upon </font><font style="font-family:inherit;font-size:11pt;color:#212121;">stockholders </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">herein </font><font style="font-family:inherit;font-size:11pt;color:#212121;">are granted </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">subject to this reservation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:282px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;font-weight:bold;">ARTICLE IX</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:20px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">This Article is inserted </font><font style="font-family:inherit;font-size:11pt;color:#212121;">for </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">management of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the business </font><font style="font-family:inherit;font-size:11pt;color:#212121;">and </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">for the conduct </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">affairs of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Corporation</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:20px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:21px;">A.</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;font-weight:bold;">Number of Directors</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">. The Board </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">Directors </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">consist </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of one </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">or more members</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">each of whom shall </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">be </font><font style="font-family:inherit;font-size:11pt;color:#212121;">a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">natural person. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">The exact </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">number </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">directors </font><font style="font-family:inherit;font-size:11pt;color:#212121;">within </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the limitations </font><font style="font-family:inherit;font-size:11pt;color:#212121;">specified </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">in the preceding sentence </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">be fixed </font><font style="font-family:inherit;font-size:11pt;color:#212121;">from </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">time to time by, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">or in </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the manner </font><font style="font-family:inherit;font-size:11pt;color:#212121;">provided in</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the By-Laws </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Corporation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:18px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:22px;">B.</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;font-weight:bold;">Classes of Directors</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">. The Board </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">Directors </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">be and is divided into three classes: </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Class </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">I, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Cla</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">s</font><font style="font-family:inherit;font-size:11pt;color:#212121;">s </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">II </font><font style="font-family:inherit;font-size:11pt;color:#212121;">and Class </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">III. </font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">N</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">o </font><font style="font-family:inherit;font-size:11pt;color:#212121;">one cla</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">ss </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">have more than </font><font style="font-family:inherit;font-size:11pt;color:#212121;">one </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">director more than </font><font style="font-family:inherit;font-size:11pt;color:#212121;">any other </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">class. </font><font style="font-family:Arial;font-size:12pt;color:#0f0f0f;">If</font><font style="font-family:inherit;font-size:11pt;color:#212121;">a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">fraction is </font><font style="font-family:inherit;font-size:11pt;color:#212121;">contained </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">in the quotient arrived </font><font style="font-family:inherit;font-size:11pt;color:#212121;">at </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">by </font><font style="font-family:inherit;font-size:11pt;color:#212121;">dividing the </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">designated </font><font style="font-family:inherit;font-size:11pt;color:#212121;">number of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">directors by three, then</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">if such fraction </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">is one-third, the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">extra </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">director </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">b</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">e </font><font style="font-family:inherit;font-size:11pt;color:#212121;">a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">member </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of Class </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">III, and if </font><font style="font-family:inherit;font-size:11pt;color:#212121;">such fraction is </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">two-thirds</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">one of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the extra directors shall be </font><font style="font-family:inherit;font-size:11pt;color:#212121;">a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">member </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of Class </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">III and </font><font style="font-family:inherit;font-size:11pt;color:#212121;">one of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the extra directors </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall be </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">a </font><font style="font-family:inherit;font-size:11pt;color:#212121;">member of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">Class II</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">unless otherwise provided </font><font style="font-family:inherit;font-size:11pt;color:#212121;">from </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">time to time by resolution </font><font style="font-family:inherit;font-size:11pt;color:#212121;">adopted </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">by the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Board of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">Director</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">s.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:18px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:22px;">C.</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;font-weight:bold;">Election of Directors</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">. Elections of </font><font style="font-family:inherit;font-size:11pt;color:#212121;">directors </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">need not be by written ballot except </font><font style="font-family:inherit;font-size:11pt;color:#212121;">as </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">and to the extent provided in the By-Laws </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Corporation</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:18px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">D.</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;font-weight:bold;">Terms of Office</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Except as </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">pro</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">v</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">ided in Paragraph </font><font style="font-family:inherit;font-size:11pt;color:#212121;">G of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">this Article</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">each director </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall serve </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">for </font><font style="font-family:inherit;font-size:11pt;color:#212121;">a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">term </font><font style="font-family:inherit;font-size:11pt;color:#212121;">ending on </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the d</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">a</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">te </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">third annual </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">meeting </font><font style="font-family:inherit;font-size:11pt;color:#212121;">following </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">annual</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">meeting at </font><font style="font-family:inherit;font-size:11pt;color:#212121;">which such </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">director was </font><font style="font-family:inherit;font-size:11pt;color:#212121;">elected</font><font style="font-family:inherit;font-size:11pt;color:#3b3b3b;">; </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">, that each </font><font style="font-family:inherit;font-size:11pt;color:#212121;">initial director in Class </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">I  </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shal1 serve for a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">term </font><font style="font-family:inherit;font-size:11pt;color:#212121;">ending on </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the date </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the annual meeting in </font><font style="font-family:inherit;font-size:11pt;color:#212121;">2008; each </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">initial director in </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Class </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">II </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall serve for a </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">term ending </font><font style="font-family:inherit;font-size:11pt;color:#212121;">on </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the date </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">annual </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">meeting in 2009; and each </font><font style="font-family:inherit;font-size:11pt;color:#212121;">initial </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">director in Class Ill </font><font style="font-family:inherit;font-size:11pt;color:#212121;">shall serve for </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">a term ending on the date </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">the </font><font style="font-family:inherit;font-size:11pt;color:#212121;">annual </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">meeting in </font><font style="font-family:inherit;font-size:11pt;color:#212121;">20 </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">I O; </font><font style="font-family:inherit;font-size:11pt;color:#212121;">and </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">, </font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;text-decoration:underline;">further</font><font style="font-family:inherit;font-size:11pt;color:#0f0f0f;">,</font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">that the term </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of each director shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">be </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">subject </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">election and qualification of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">his </font><font style="font-family:inherit;font-size:11pt;color:#313131;">suc</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ce</font><font style="font-family:inherit;font-size:11pt;color:#313131;">sso</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">r </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">and </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to his earlier death, resignation or </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">removal.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">E.</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">Allocation of Directors Among Classes in the Event of Increases or Decreases </font><font style="font-family:inherit;font-size:12pt;color:#1c1c1c;font-weight:bold;">in </font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">the Number of Director</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">s</font><font style="font-family:inherit;font-size:12pt;color:#444444;">. </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">In </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">the event of any </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">increase </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">or </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">decrease in the authorized number </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">directors, (i) </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">each </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">director then </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">serving </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">as </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">such </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">shall nevertheless continue </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">as </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">a director </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">class of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">which he is </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">a </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">member </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">and </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">(ii) </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">the </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">newly </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">created or eliminated </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">directorships </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">resulting </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">from such increase </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">or </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">decrease </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">be apportioned by the Board of Directors among the three classes </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">directors </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">so as </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">ensure </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">that no </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">one </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">class has more than </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">one </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">director more than any </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">other class. To </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">extent </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">possible, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">consistent with </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">foregoing </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">rule</font><font style="font-family:inherit;font-size:11pt;color:#313131;">, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">any newly </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">created </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">directorships </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">shall be </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">added to those </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">classes whose terms of office </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">are to expire at the latest dates </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">following </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">such allocation</font><font style="font-family:inherit;font-size:11pt;color:#444444;">, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">and </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">any </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">newly </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">eliminated </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">directorships </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">be </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">subtracted </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">from tho</font><font style="font-family:inherit;font-size:11pt;color:#313131;">se </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">classes </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">whose </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">terms </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of offices </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">are </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">to expire at </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the earliest dates following </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">such allocation, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">unless </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">otherwise </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">provided from time to time by resolution </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">adopted </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">by the Board </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Directors</font><font style="font-family:inherit;font-size:11pt;color:#313131;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:20px;">F.</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">Removal</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">. </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">The directors </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">may be </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">removed only </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">for </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">cause </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">by the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">affirmative vote </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of the holders </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">at least seventy five percent </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">(75%) of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">outstanding </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">shares </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">capital </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">stock of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">entitled to </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">vote generally </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">in the election </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">directors</font><font style="font-family:inherit;font-size:11pt;color:#313131;">, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">voting </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">together </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">as </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">a </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">single class, cast </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">at </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">a meeting </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of the stockholders </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">called </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">for that </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">purpose.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:20px;">G.</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">Vacancies</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">. </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">Any vacancy in </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the Board </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Directors, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">however occurring</font><font style="font-family:inherit;font-size:11pt;color:#444444;">, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">and any </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">newly </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">created directorship resulting </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">from </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">an enlargement of the Board</font><font style="font-family:inherit;font-size:11pt;color:#444444;">, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">be </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">filled only by </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">vot</font><font style="font-family:inherit;font-size:11pt;color:#313131;">e </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">a majority </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of the directors </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">then </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">in office</font><font style="font-family:inherit;font-size:11pt;color:#444444;">, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">although </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">les</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">than a quorum</font><font style="font-family:inherit;font-size:11pt;color:#444444;">, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">or </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">by </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">a sole </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">remaining director. A </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">director elected </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to fill </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">a </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">vacancy </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">be </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">elected for the </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">unexpired </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">term of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">his </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">predecessor in office, and a director chosen to fill a </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">position r</font><font style="font-family:inherit;font-size:11pt;color:#313131;">es</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ulting </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">from </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">an increase in the number </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">director</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">hold </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">office </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">until the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">next election of the </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">class </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">for which such director shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">h</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ave </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">been </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">chosen, subject to </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">election </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">and </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">qualification of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">hi</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s successo</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">r and </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">to </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">hi</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">earlier death, resignation or </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">removal.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:20px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:21px;">H.</font><font style="font-family:inherit;font-size:12pt;color:#1c1c1c;font-weight:bold;">Stockholder </font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">Nominations and Introduction of Business, Etc</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">. </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">Advance </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">notice </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of stockholder nominations for election of directors and other </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">business to </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">be </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">brought by </font><font style="font-family:inherit;font-size:11pt;color:#313131;">s</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">tockholders before either </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">an annual or special </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">me</font><font style="font-family:inherit;font-size:11pt;color:#313131;">e</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ting </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of stockholders shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">be </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">given </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">in </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">the manner provided </font><font style="font-family:Arial;font-size:11pt;color:#0c0c0c;">by </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">the </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">By-Laws </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#313131;">Corpo</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ration.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">I.</font><font style="font-family:inherit;font-size:12pt;color:#1c1c1c;font-weight:bold;">Amendment </font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">to Article</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">. </font><font style="font-family:inherit;font-size:11pt;color:#313131;">No</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">twithstanding </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">any other </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">provi</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ions </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of law, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">this </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">Certificate of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Incorporation </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">or </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">By-Laws, each as amended, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">and notwithstanding </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">the fact that a </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">lesser percentage </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">may </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">be </font><font style="font-family:inherit;font-size:11pt;color:#313131;">spec</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ified </font><font style="font-family:Arial;font-size:11pt;color:#0c0c0c;">by </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Jaw</font><font style="font-family:inherit;font-size:11pt;color:#444444;">, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">this </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">Certificate of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Incorporation </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">or </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">By-Laws </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of the Corporation, the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">affirmative </font><font style="font-family:inherit;font-size:11pt;color:#313131;">vote </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#313131;">at </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">lea</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">t </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">seventy </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">five percent </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">(75%) of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">outstanding shares of capital </font><font style="font-family:inherit;font-size:11pt;color:#444444;">s</font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">tock of the Corporation entitled </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">vote generally </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">in the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">election of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">directors</font><font style="font-family:inherit;font-size:11pt;color:#444444;">, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">voting </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">together </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">as a single </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">class, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">shall </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">be </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">required to amend or </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">repeal, </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">or to adopt any </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">provisions </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">inconsistent with the </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">purpose </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">or intent of</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">this </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Article </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">IX.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:284px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">ARTICLE X</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:20px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">Except as </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">otherwise provided </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">in </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">By-Laws, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">stockholders </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">Corporation and </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the Board </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Director</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">may hold </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">their meetings </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">and have </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">an office or offices outside of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">State of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Delaware </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">and, subject </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">provisions of the </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">laws of </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">said State, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">may keep the books </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">corporation outside of</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">said State at </font><font style="font-family:inherit;font-size:11pt;color:#262626;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">places as may, from time to time</font><font style="font-family:inherit;font-size:11pt;color:#464646;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">be designated by the Board of Directors or by the By-Laws of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:282px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">ARTICLE XI</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">At any time during which a class of capital stock of the Corporation is registered under Section 12 of the Securities Exchange Act of 1934 or any similar successor </font><font style="font-family:inherit;font-size:11pt;color:#262626;">statute, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">stockholders of the Corporation may not take any action by written consent in lieu of </font><font style="font-family:inherit;font-size:11pt;color:#262626;">a </font><font style="font-family:inherit;font-size:11pt;color:#111111;">meeting</font><font style="font-family:inherit;font-size:11pt;color:#343434;">. </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Notwithstanding </font><font style="font-family:inherit;font-size:11pt;color:#111111;">any other provisions of law</font><font style="font-family:inherit;font-size:11pt;color:#464646;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">thi</font><font style="font-family:inherit;font-size:11pt;color:#343434;">s </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Certificate of lncorporation or the By-Laws, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">each </font><font style="font-family:inherit;font-size:11pt;color:#111111;">as amended</font><font style="font-family:inherit;font-size:11pt;color:#343434;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">and notwithstanding the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">fact </font><font style="font-family:inherit;font-size:11pt;color:#111111;">that a lesser percentage may be </font><font style="font-family:inherit;font-size:11pt;color:#262626;">specified </font><font style="font-family:inherit;font-size:11pt;color:#111111;">by law</font><font style="font-family:inherit;font-size:11pt;color:#343434;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this Certificate of Incorporation or the By-Laws of the Corporation, the affirmative vote of at least </font><font style="font-family:inherit;font-size:11pt;color:#262626;">seventy </font><font style="font-family:inherit;font-size:11pt;color:#111111;">five percent (75%) of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">outstanding </font><font style="font-family:inherit;font-size:11pt;color:#111111;">shares of </font><font style="font-family:inherit;font-size:11pt;color:#262626;">capital stock </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of the Corporation entitled to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">vote </font><font style="font-family:inherit;font-size:11pt;color:#111111;">generally in the election of directors, voting together as a </font><font style="font-family:inherit;font-size:11pt;color:#262626;">single </font><font style="font-family:inherit;font-size:11pt;color:#111111;">class, shall be required to amend or repeal or to adopt any provisions inconsistent with the purpo</font><font style="font-family:inherit;font-size:11pt;color:#343434;">se </font><font style="font-family:inherit;font-size:11pt;color:#111111;">or intent of this Article XI.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:282px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">ARTICLE XII</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:20px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">Special meetings of stockholders may be called at any time only by the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Chairman </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of the Board of Directors, the Chief Executive Officer (or if there is no Chief Executive Officer, the President) or the Board of Directors </font><font style="font-family:inherit;font-size:11pt;color:#343434;">. </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Any business transacted at any </font><font style="font-family:inherit;font-size:11pt;color:#262626;">special </font><font style="font-family:inherit;font-size:11pt;color:#111111;">meeting of stockholders shall be limited to matters relating to the purpose or purposes </font><font style="font-family:inherit;font-size:11pt;color:#262626;">stated in </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the notice of meeting</font><font style="font-family:inherit;font-size:11pt;color:#343434;">. </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Notwithstanding any other provisions </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">law</font><font style="font-family:inherit;font-size:11pt;color:#343434;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this Certificate of Incorporation or the By-Laws</font><font style="font-family:inherit;font-size:11pt;color:#343434;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">each as amended, and notwithstanding the fact </font><font style="font-family:inherit;font-size:11pt;color:#262626;">that </font><font style="font-family:inherit;font-size:11pt;color:#111111;">a les</font><font style="font-family:inherit;font-size:11pt;color:#343434;">se</font><font style="font-family:inherit;font-size:11pt;color:#111111;">r percentage may be </font><font style="font-family:inherit;font-size:11pt;color:#262626;">specified </font><font style="font-family:inherit;font-size:11pt;color:#111111;">by law</font><font style="font-family:inherit;font-size:11pt;color:#343434;">, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">this Certificate </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Incorporation </font><font style="font-family:inherit;font-size:11pt;color:#262626;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">the By-Laws of the Corporation, the affirmative </font><font style="font-family:inherit;font-size:11pt;color:#262626;">vote </font><font style="font-family:inherit;font-size:11pt;color:#111111;">of at least </font><font style="font-family:inherit;font-size:11pt;color:#262626;">seventy </font><font style="font-family:inherit;font-size:11pt;color:#111111;">five percent (75</font><font style="font-family:inherit;font-size:11pt;color:#343434;">%</font><font style="font-family:inherit;font-size:11pt;color:#111111;">) of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">outstanding shares of capital </font><font style="font-family:inherit;font-size:11pt;color:#111111;">stock of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">entitled to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">vote </font><font style="font-family:inherit;font-size:11pt;color:#111111;">generally in the election of director</font><font style="font-family:inherit;font-size:11pt;color:#343434;">s, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">voting </font><font style="font-family:inherit;font-size:11pt;color:#111111;">together as a </font><font style="font-family:inherit;font-size:11pt;color:#262626;">single </font><font style="font-family:inherit;font-size:11pt;color:#111111;">cla</font><font style="font-family:inherit;font-size:11pt;color:#343434;">ss, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">shall be required to amend </font><font style="font-family:inherit;font-size:11pt;color:#262626;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">repeal </font><font style="font-family:inherit;font-size:11pt;color:#262626;">or </font><font style="font-family:inherit;font-size:11pt;color:#111111;">to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">adopt </font><font style="font-family:inherit;font-size:11pt;color:#111111;">any provi</font><font style="font-family:inherit;font-size:11pt;color:#343434;">s</font><font style="font-family:inherit;font-size:11pt;color:#111111;">ions inconsistent with the purpose or intent of this Article XII.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:282px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;font-weight:bold;">ARTICLE XIII</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">The regi</font><font style="font-family:inherit;font-size:11pt;color:#343434;">s</font><font style="font-family:inherit;font-size:11pt;color:#111111;">tered office of the corporation in the State of Delaware is </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Trust </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Center, </font><font style="font-family:inherit;font-size:11pt;color:#111111;">1209 Orange Street, City </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">Wilmington, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">County of </font><font style="font-family:inherit;font-size:11pt;color:#111111;">New Castle. </font><font style="font-family:inherit;font-size:11pt;color:#262626;">The </font><font style="font-family:inherit;font-size:11pt;color:#111111;">name of </font><font style="font-family:inherit;font-size:11pt;color:#262626;">its </font><font style="font-family:inherit;font-size:11pt;color:#111111;">registered agent at </font><font style="font-family:inherit;font-size:11pt;color:#262626;">such </font><font style="font-family:inherit;font-size:11pt;color:#111111;">offi</font><font style="font-family:inherit;font-size:11pt;color:#343434;">ce </font><font style="font-family:inherit;font-size:11pt;color:#111111;">is The </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation Trust Company</font><font style="font-family:inherit;font-size:11pt;color:#464646;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:6px;text-indent:20px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010101;">IN WITNESS WHEREOF, the Corporation has caused this Certificate of lncorporation to be signed by its President and Chief Executive Officer on this 5th day of February, 2008.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:321px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010101;">RXI PHARMACEUTICALS CORPORATION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:352px;text-indent:-32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010101;">By:  </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;text-decoration:underline;">/</font><font style="font-family:inherit;font-size:11pt;color:#010101;text-decoration:underline;">s/ Tod Woolf</font><font style="font-family:inherit;font-size:11pt;color:#010101;">&#32;Tod Woolf</font></div><div style="line-height:120%;text-align:left;padding-left:352px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010101;">President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:21px;text-indent:6px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#0e0e0e;">State </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">of Delaware </font><font style="font-family:inherit;font-size:9pt;color:#0e0e0e;">Secretary   </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">of </font><font style="font-family:inherit;font-size:9pt;color:#0e0e0e;">State </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">Division of Corporations</font></div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">Delivered 04:08 PM 07/26/2011 FILED 04</font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;font-style:italic;">:</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">08 PM 07</font><font style="font-family:inherit;font-size:10pt;color:#282828;font-style:italic;">/</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">26</font><font style="font-family:inherit;font-size:10pt;color:#282828;font-style:italic;">/</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">2011</font></div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">SRV 110859225 </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">- </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-style:italic;">4136433 FILE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:7px;text-align:center;padding-left:269px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;font-weight:bold;">CERTIFICATE OF AMENDMENT TO</font></div><div style="line-height:120%;text-align:center;padding-left:201px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;font-weight:bold;">RESTATED CERTIFICATE OF INCORPORATION OF RXi PHARMACEUTICALS  CORPORATION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:101px;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">RXi Pharmaceutical </font><font style="font-family:inherit;font-size:10pt;color:#282828;">s </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">Corporation, a Delaware corporation (the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">"</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">Company"), hereby certifies that:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:101px;text-align:left;text-indent:42px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">The following resolution has been unanimously adopted by the Company's Board of Directors and has been approved by the holder</font><font style="font-family:inherit;font-size:10pt;color:#282828;">s </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">of a majority of the Company's outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Company </font><font style="font-family:inherit;font-size:10pt;color:#282828;">'</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">s Restated Certificate of lncorporation </font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:101px;text-indent:85px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">RESOLVED, that the Restated Certificate of lncorporation of the Company be amended </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">by </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">deleting in its entirety Article III, Section A, and by replacing it with the foll</font><font style="font-family:inherit;font-size:10pt;color:#282828;">o</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">wing:</font></div><div style="line-height:120%;padding-top:7px;text-align:left;padding-left:144px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">"</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-weight:bold;">A</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-weight:bold;">Classes of Stock</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">. This Corporation is authorized to is</font><font style="font-family:inherit;font-size:10pt;color:#282828;">s</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">ue 130,000</font><font style="font-family:inherit;font-size:10pt;color:#282828;">,</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">000 shares</font><font style="font-family:inherit;font-size:10pt;color:#282828;">, </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">of which 125,000,000 shares shall be Common Stock with a par value of $0.000 I per share ("</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">") and 5,000</font><font style="font-family:inherit;font-size:10pt;color:#282828;">,</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">000 shares will be Preferred Stock with a part value of $0</font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">.</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">0001 per share ("</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;text-decoration:underline;">Preferred Stock</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">")."</font></div><div style="line-height:120%;padding-left:101px;text-align:left;text-indent:41px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:49px;">2.</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">The above </font><font style="font-family:inherit;font-size:10pt;color:#282828;">a</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">mendment was duly adopted by the Company in accordance with the provisions of Section 242 of the Delaware General Corporation Law.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:101px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">IN WITNESS WHEREOF </font><font style="font-family:inherit;font-size:10pt;color:#282828;">, </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">RXi Pharm</font><font style="font-family:inherit;font-size:10pt;color:#282828;">a</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">ceuticals Corporation has caused this Certificate of Amendment to be signed by a duly authorized officer this </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">18th </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">day of July </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">2011.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:389px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">RXi Pharmaceuticals Corporation</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:393px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:  </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Mark J. Ahn</font></div><div style="line-height:120%;text-align:left;padding-left:393px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Mark J. Ahn</font></div><div style="line-height:120%;text-align:left;padding-left:393px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:469px;text-indent:4px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;font-style:italic;">State </font><font style="font-family:Arial;font-size:8pt;color:#1d1d1d;font-style:italic;">of </font><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;font-style:italic;">Delaware Secretary  </font><font style="font-family:Arial;font-size:8pt;color:#0c0c0c;font-style:italic;">of   </font><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;font-style:italic;">State </font><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;font-style:italic;">Division of Corporations</font></div><div style="line-height:120%;text-align:center;padding-left:456px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;font-style:italic;">Delivered   10:28  AM   09/26/2011 FILED  10:28 </font><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;font-style:italic;">AM </font><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;font-style:italic;">09/26/2011</font></div><div style="line-height:120%;text-align:left;padding-left:145px;text-indent:309px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;font-style:italic;">SRV 111039489 </font><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;">- </font><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;font-style:italic;">4136433 FILE</font></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:145px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">CERTIFICATE OF </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">OWNERSHIP </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">AND MERGER MERGING</font></div><div style="line-height:120%;text-align:center;padding-left:145px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;padding-left:145px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">(a </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Delaware corpor</font><font style="font-family:inherit;font-size:11pt;color:#313131;">a</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">tion)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:145px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">WITH AND INTO</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:145px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">RXI </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">PHARMACEUTICALS  CORPORATION</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:145px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">(a Delaware corporation)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#313131;">(</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Pursuant </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">to Section </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">253 </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">of the Delaware General Corporation Law)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">RXi Pharmaceuticals </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Corporation, </font><font style="font-family:inherit;font-size:12pt;color:#1d1d1d;">a </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Delaware </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">corporation </font><font style="font-family:inherit;font-size:11pt;color:#313131;">(t</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">he </font><font style="font-family:inherit;font-size:11pt;color:#313131;">"</font><font style="font-family:inherit;font-size:11pt;color:#313131;text-decoration:underline;">Co</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;text-decoration:underline;">mpan</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">y"</font><font style="font-family:inherit;font-size:11pt;color:#313131;">), </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">does </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">her</font><font style="font-family:inherit;font-size:11pt;color:#313131;">eby </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">c</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ert</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ify to the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">following </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">facts </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">relating </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to the merger </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">(the </font><font style="font-family:inherit;font-size:11pt;color:#313131;">"</font><font style="font-family:inherit;font-size:11pt;color:#313131;text-decoration:underline;">M</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;text-decoration:underline;">erger</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">") </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">of Galena </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Biopharma, Inc</font><font style="font-family:inherit;font-size:11pt;color:#484848;">., </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">a Delaware corporation (the </font><font style="font-family:inherit;font-size:11pt;color:#313131;">"</font><font style="font-family:inherit;font-size:11pt;color:#313131;text-decoration:underline;">Su</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;text-decoration:underline;">bsidiary</font><font style="font-family:inherit;font-size:11pt;color:#313131;">"), </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">with and into </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Company, with the Company </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">r</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ema</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ining </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">as the </font><font style="font-family:inherit;font-size:11pt;color:#313131;">surv</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">i</font><font style="font-family:inherit;font-size:11pt;color:#313131;">v</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ing </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">corporation </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">under </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the name </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of </font><font style="font-family:inherit;font-size:11pt;color:#313131;">"Gal</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ena </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Biopharma, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">In</font><font style="font-family:inherit;font-size:11pt;color:#484848;">c.</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">"</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:46px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:42px;">1.</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">The </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Subsidi</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ary </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">is </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">a corporation </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">incorporated </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">on September 8, 2011 </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">under </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the Delaware General Corporation </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Law (the </font><font style="font-family:inherit;font-size:11pt;color:#313131;">"</font><font style="font-family:inherit;font-size:11pt;color:#313131;text-decoration:underline;">DGC</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;text-decoration:underline;">L</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">").</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:97px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:52px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">The Company </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">i</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">a corporation </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">incorporat</font><font style="font-family:inherit;font-size:11pt;color:#313131;">e</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">d </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">on April 3, </font><font style="font-family:inherit;font-size:11pt;color:#313131;">2006 </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">under </font><font style="font-family:inherit;font-size:11pt;color:#313131;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">DGCL.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:44px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:45px;">3.</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">The Company is </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the owner </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">of all </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">outstanding </font><font style="font-family:inherit;font-size:11pt;color:#313131;">s</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">hares </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">of the cap</font><font style="font-family:inherit;font-size:11pt;color:#484848;">it</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">al stock </font><font style="font-family:inherit;font-size:11pt;color:#313131;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Subsidiary.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:44px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:45px;">4.</font><font style="font-family:inherit;font-size:11pt;color:#313131;">The </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Board </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">o</font><font style="font-family:inherit;font-size:11pt;color:#484848;">f </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Directors </font><font style="font-family:inherit;font-size:11pt;color:#313131;">of </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the Company, by resolutions duly adopted </font><font style="font-family:inherit;font-size:11pt;color:#484848;">a</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">t </font><font style="font-family:inherit;font-size:11pt;color:#313131;">a </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">me</font><font style="font-family:inherit;font-size:11pt;color:#484848;">et</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">i</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ng </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the Board </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">of Directors of the Company </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">held </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">on August </font><font style="font-family:inherit;font-size:11pt;color:#313131;">23</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">, </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">2011</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">determined </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">t</font><font style="font-family:inherit;font-size:11pt;color:#313131;">o </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">merge into </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">itself the Subsidiary, </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">and </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to effect a </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">change of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Company's </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">name t</font><font style="font-family:inherit;font-size:11pt;color:#313131;">o "Galena </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Bioph</font><font style="font-family:inherit;font-size:11pt;color:#313131;">arma, </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">In</font><font style="font-family:inherit;font-size:11pt;color:#484848;">c.</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">" </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">in </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">connection with such </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">merger, pursuant to </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Section 253 of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">DGCL. </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Such r</font><font style="font-family:inherit;font-size:11pt;color:#313131;">eso</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">lutions </font><font style="font-family:inherit;font-size:11pt;color:#313131;">are as </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">WHEREAS, in view of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Company</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5b;">'</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">s </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">proposed transfer </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">and contributi</font><font style="font-family:inherit;font-size:11pt;color:#484848;">o</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">n </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">a </font><font style="font-family:inherit;font-size:11pt;color:#313131;">wholly</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">&#173; owed </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">subsidiary of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Company </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">certain </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">RNAi </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">assets and </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">rel</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ate</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">d </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">obligations of RXi Pharmaceuticals Corporation (the "</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">") (the "</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;text-decoration:underline;">Spin-Off''</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">), the Company has proposed to change </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">its </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">corporate </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">name </font><font style="font-family:inherit;font-size:11pt;color:#313131;">so </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">as not to include </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">name "RXi" or "RNAi"; and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">WHEREAS, after thorough </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">con</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ideration</font><font style="font-family:inherit;font-size:11pt;color:#313131;">, </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the Board of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Dire</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ctors </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">belie</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ves </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">it </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">i</font><font style="font-family:inherit;font-size:11pt;color:#313131;">s </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">ad</font><font style="font-family:inherit;font-size:11pt;color:#484848;">v</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">isable and </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">in the best </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">interests of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Company </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">and its </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">stockholders </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">change the </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">name </font><font style="font-family:inherit;font-size:11pt;color:#313131;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Company to Galena Biopharma, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Inc. </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">from RXi Pharmaceuticals Corporation </font><font style="font-family:inherit;font-size:11pt;color:#313131;">(the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">"</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;text-decoration:underline;">Name Change</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">"), and to </font><font style="font-family:inherit;font-size:11pt;color:#313131;">effect </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">such </font><font style="font-family:inherit;font-size:11pt;color:#313131;">Name </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Change pursuant </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">to </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the provisions </font><font style="font-family:inherit;font-size:11pt;color:#313131;">of </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Section </font><font style="font-family:inherit;font-size:11pt;color:#313131;">253 </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">of the Delaware </font><font style="font-family:inherit;font-size:11pt;color:#313131;">Genera</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">l </font><font style="font-family:inherit;font-size:11pt;color:#313131;">Corporat</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">i</font><font style="font-family:inherit;font-size:11pt;color:#313131;">o</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">n </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Law (the "</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;text-decoration:underline;">DGCL</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">"); and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">WHEREAS, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">in </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">order to effect the Name Change, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">Company </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">desir</font><font style="font-family:inherit;font-size:11pt;color:#313131;">es </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">to form a </font><font style="font-family:inherit;font-size:11pt;color:#313131;">new </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">corporation named Galena Biopharma, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Inc., </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">a </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Delaware </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">corporation </font><font style="font-family:inherit;font-size:11pt;color:#313131;">(th</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">e </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">"</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;text-decoration:underline;">Subsidiary</font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">"), </font><font style="font-family:inherit;font-size:11pt;color:#313131;">and </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">to acquire shares </font><font style="font-family:inherit;font-size:11pt;color:#313131;">of </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">common </font><font style="font-family:inherit;font-size:11pt;color:#313131;">stock, </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">par </font><font style="font-family:inherit;font-size:11pt;color:#313131;">va</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">lue </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">$0.0001 </font><font style="font-family:inherit;font-size:11pt;color:#313131;">pe</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">r </font><font style="font-family:inherit;font-size:11pt;color:#313131;">share, </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">of the </font><font style="font-family:inherit;font-size:11pt;color:#313131;">Subs</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">idi</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ary (co</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">llectiv</font><font style="font-family:inherit;font-size:11pt;color:#313131;">ely, </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the </font><font style="font-family:inherit;font-size:11pt;color:#313131;">&#32;"</font><font style="font-family:inherit;font-size:11pt;color:#313131;text-decoration:underline;">I</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;text-decoration:underline;">ncorpora</font><font style="font-family:inherit;font-size:11pt;color:#313131;text-decoration:underline;">tion</font><font style="font-family:inherit;font-size:11pt;color:#313131;">"); </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">WHEREAS</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">followin</font><font style="font-family:inherit;font-size:11pt;color:#313131;">g </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">the effecti</font><font style="font-family:inherit;font-size:11pt;color:#313131;">veness </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the Incorporation, the Company will own </font><font style="font-family:inherit;font-size:11pt;color:#313131;">all of </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the outstanding </font><font style="font-family:inherit;font-size:11pt;color:#313131;">s</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">har</font><font style="font-family:inherit;font-size:11pt;color:#313131;">es </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">o</font><font style="font-family:inherit;font-size:11pt;color:#484848;">f </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">the capital stock of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">th</font><font style="font-family:inherit;font-size:11pt;color:#313131;">e </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Sub</font><font style="font-family:inherit;font-size:11pt;color:#313131;">sidiary; </font><font style="font-family:inherit;font-size:11pt;color:#1d1d1d;">and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:9px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#111111;">WHEREAS, in </font><font style="font-family:inherit;font-size:10pt;color:#232323;">order </font><font style="font-family:inherit;font-size:10pt;color:#111111;">to consummate the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Name Change, </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the Board of Directors of the Company believes it is advisable and in the best interests of the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Company </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">its </font><font style="font-family:inherit;font-size:10pt;color:#111111;">stockholders that, following the effectiveness </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the Incorporation, the Subsidiary </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#111111;">be merged with and into the Company (the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">"</font><font style="font-family:inherit;font-size:10pt;color:#232323;text-decoration:underline;">Merger</font><font style="font-family:inherit;font-size:10pt;color:#232323;">") </font><font style="font-family:inherit;font-size:10pt;color:#111111;">pursuant to Section </font><font style="font-family:inherit;font-size:10pt;color:#232323;">253 of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the DGCL</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:10pt;color:#232323;">so </font><font style="font-family:inherit;font-size:10pt;color:#111111;">that the Company will be the surviving corporation following the Merger and that the Name Change be effected as part of the Merger as permitted under the DGCL;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:44px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#111111;">NOW, THEREFORE, BE IT RESOLVED, that the Incorporation is hereby authorized and approved in all respects</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">; </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and it is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#111111;">RESOLVED FURTHER, that the officers of the Company be </font><font style="font-family:inherit;font-size:11pt;color:#111111;">and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">each </font><font style="font-family:inherit;font-size:10pt;color:#111111;">hereby is authorized, empowered and directed, by and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">on </font><font style="font-family:inherit;font-size:10pt;color:#111111;">behalf </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Company </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and in its name</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:10pt;color:#111111;">to prepare </font><font style="font-family:inherit;font-size:10pt;color:#232323;">or </font><font style="font-family:inherit;font-size:10pt;color:#111111;">cause to be prepared, </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and </font><font style="font-family:inherit;font-size:10pt;color:#111111;">to </font><font style="font-family:inherit;font-size:10pt;color:#232323;">execute </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and file </font><font style="font-family:inherit;font-size:10pt;color:#232323;">with </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the Delaware Secretary </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">State a Certificate of Incorporation to form the Subsidiary, and to take all such other actions as </font><font style="font-family:inherit;font-size:10pt;color:#232323;">they </font><font style="font-family:inherit;font-size:10pt;color:#111111;">or </font><font style="font-family:inherit;font-size:10pt;color:#232323;">any </font><font style="font-family:inherit;font-size:10pt;color:#111111;">one of them shall deem necessary or </font><font style="font-family:inherit;font-size:10pt;color:#232323;">appropriate </font><font style="font-family:inherit;font-size:10pt;color:#111111;">to consummate the Incorporation; </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and it </font><font style="font-family:inherit;font-size:10pt;color:#111111;">is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:44px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#111111;">RESOLVED FURTHER, that the Merger and the Name </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Change </font><font style="font-family:inherit;font-size:10pt;color:#111111;">are hereby authorized </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and </font><font style="font-family:inherit;font-size:10pt;color:#111111;">approved; and it is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:44px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#111111;">RESOLVED FURTHER, that following </font><font style="font-family:inherit;font-size:10pt;color:#232323;">the </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Incorporation, the officers </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the Company be </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and </font><font style="font-family:inherit;font-size:10pt;color:#111111;">each hereby is authorized</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:10pt;color:#232323;">empowered </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and directed, by and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">on </font><font style="font-family:inherit;font-size:10pt;color:#111111;">behalf of the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Company </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and in its name, to effect the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Name </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Change by merging the Subsidiary with and into the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Company pursuant to </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Section 253 </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the DGCL, so that the Company will be the surviving </font><font style="font-family:inherit;font-size:10pt;color:#232323;">corporation </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and possess </font><font style="font-family:inherit;font-size:10pt;color:#232323;">all </font><font style="font-family:inherit;font-size:10pt;color:#111111;">of the Subsidiary's </font><font style="font-family:inherit;font-size:10pt;color:#232323;">property, </font><font style="font-family:inherit;font-size:10pt;color:#111111;">rights, privilege</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">s </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">powers, and assume all of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">th</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">e </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Subsidiary's liabilities </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and </font><font style="font-family:inherit;font-size:10pt;color:#111111;">obligations; and it is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:44px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#111111;">RESOLVED FURTHER</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:10pt;color:#111111;">that by virtue of </font><font style="font-family:inherit;font-size:10pt;color:#232323;">the </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Merger and without any action on the part </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the holder thereof, each then </font><font style="font-family:inherit;font-size:10pt;color:#232323;">outstanding share of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">common </font><font style="font-family:inherit;font-size:10pt;color:#232323;">stock, </font><font style="font-family:inherit;font-size:10pt;color:#111111;">par </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">va</font><font style="font-family:inherit;font-size:10pt;color:#111111;">lue $0.0001 </font><font style="font-family:inherit;font-size:10pt;color:#232323;">per </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">s</font><font style="font-family:inherit;font-size:10pt;color:#111111;">hare</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Company </font><font style="font-family:inherit;font-size:10pt;color:#111111;">(the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">"</font><font style="font-family:inherit;font-size:10pt;color:#232323;text-decoration:underline;">Common</font><font style="font-family:inherit;font-size:10pt;color:#232323;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#111111;text-decoration:underline;">Stock</font><font style="font-family:inherit;font-size:10pt;color:#111111;">") shall remain unchanged and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">continue </font><font style="font-family:inherit;font-size:10pt;color:#111111;">to remain </font><font style="font-family:inherit;font-size:10pt;color:#232323;">outstanding </font><font style="font-family:inherit;font-size:11pt;color:#232323;">as </font><font style="font-family:inherit;font-size:10pt;color:#111111;">one </font><font style="font-family:inherit;font-size:10pt;color:#232323;">share of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Common Stock, held by the person who </font><font style="font-family:inherit;font-size:10pt;color:#232323;">was </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the holder of such </font><font style="font-family:inherit;font-size:10pt;color:#232323;">share </font><font style="font-family:inherit;font-size:11pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Common </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Stock immediately prior to the Merger; and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">it </font><font style="font-family:inherit;font-size:10pt;color:#111111;">is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:44px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#232323;">RESOLVED </font><font style="font-family:inherit;font-size:10pt;color:#111111;">FURTHER</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:10pt;color:#111111;">that by </font><font style="font-family:inherit;font-size:10pt;color:#232323;">virtue </font><font style="font-family:inherit;font-size:10pt;color:#111111;">of the Merger and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">without </font><font style="font-family:inherit;font-size:10pt;color:#111111;">any </font><font style="font-family:inherit;font-size:10pt;color:#232323;">action </font><font style="font-family:inherit;font-size:10pt;color:#111111;">on </font><font style="font-family:inherit;font-size:10pt;color:#232323;">the </font><font style="font-family:inherit;font-size:10pt;color:#111111;">part of the holder thereof, each then outstanding share </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">common </font><font style="font-family:inherit;font-size:10pt;color:#232323;">stock, </font><font style="font-family:inherit;font-size:10pt;color:#111111;">par </font><font style="font-family:inherit;font-size:10pt;color:#232323;">value $0.0001 per share, of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the Subsidiary </font><font style="font-family:inherit;font-size:10pt;color:#232323;">shall </font><font style="font-family:inherit;font-size:10pt;color:#111111;">be cancelled and no </font><font style="font-family:inherit;font-size:10pt;color:#232323;">consideration </font><font style="font-family:inherit;font-size:10pt;color:#111111;">shall be issued in respect thereof; </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and </font><font style="font-family:inherit;font-size:10pt;color:#111111;">it is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#232323;">RESOLVED </font><font style="font-family:inherit;font-size:10pt;color:#111111;">FURTHER, that </font><font style="font-family:inherit;font-size:10pt;color:#232323;">the </font><font style="font-family:inherit;font-size:10pt;color:#111111;">directors and </font><font style="font-family:inherit;font-size:10pt;color:#232323;">officers of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Company </font><font style="font-family:inherit;font-size:10pt;color:#111111;">immediately prior to the Merger </font><font style="font-family:inherit;font-size:10pt;color:#232323;">shall continue </font><font style="font-family:inherit;font-size:10pt;color:#111111;">to remain the directors </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and </font><font style="font-family:inherit;font-size:10pt;color:#111111;">officers of the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Company </font><font style="font-family:inherit;font-size:10pt;color:#111111;">until the earlier </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of their </font><font style="font-family:inherit;font-size:10pt;color:#111111;">death, resignation </font><font style="font-family:inherit;font-size:10pt;color:#232323;">or </font><font style="font-family:inherit;font-size:10pt;color:#111111;">removal or until their respective successors </font><font style="font-family:inherit;font-size:10pt;color:#232323;">are </font><font style="font-family:inherit;font-size:10pt;color:#111111;">duly </font><font style="font-family:inherit;font-size:10pt;color:#232323;">elected </font><font style="font-family:inherit;font-size:10pt;color:#111111;">and qualified, as the case may be; </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and </font><font style="font-family:Arial;font-size:11pt;color:#111111;">it </font><font style="font-family:inherit;font-size:10pt;color:#111111;">i</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">s</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#232323;">RESOLVED </font><font style="font-family:inherit;font-size:10pt;color:#111111;">FURTHER, that, </font><font style="font-family:inherit;font-size:10pt;color:#232323;">pursuant to Section 253(b) </font><font style="font-family:inherit;font-size:10pt;color:#111111;">of the DGCL, </font><font style="font-family:inherit;font-size:10pt;color:#232323;">upon </font><font style="font-family:inherit;font-size:10pt;color:#111111;">th</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">e </font><font style="font-family:inherit;font-size:10pt;color:#232323;">effective </font><font style="font-family:inherit;font-size:10pt;color:#111111;">date of the Merger, the corporate name of the Company </font><font style="font-family:inherit;font-size:10pt;color:#232323;">shall be </font><font style="font-family:inherit;font-size:10pt;color:#111111;">changed to </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Galena </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Biopharma</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:10pt;color:#111111;">Inc. </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">; </font><font style="font-family:inherit;font-size:10pt;color:#232323;">and </font><font style="font-family:inherit;font-size:10pt;color:#111111;">it </font><font style="font-family:inherit;font-size:10pt;color:#232323;">is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#232323;">RESOLVED </font><font style="font-family:inherit;font-size:10pt;color:#111111;">FURTHER, that </font><font style="font-family:inherit;font-size:10pt;color:#232323;">the Certificate </font><font style="font-family:inherit;font-size:10pt;color:#111111;">of Incorporation </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the </font><font style="font-family:inherit;font-size:10pt;color:#232323;">Company as </font><font style="font-family:inherit;font-size:10pt;color:#111111;">in </font><font style="font-family:inherit;font-size:10pt;color:#232323;">effect  immediately  </font><font style="font-family:inherit;font-size:10pt;color:#111111;">prior  to  the  </font><font style="font-family:inherit;font-size:10pt;color:#232323;">effective  </font><font style="font-family:inherit;font-size:10pt;color:#111111;">time  </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of  </font><font style="font-family:inherit;font-size:10pt;color:#111111;">the  Merger  shall  be  the  certificate  </font><font style="font-family:inherit;font-size:10pt;color:#232323;">of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">incorporation of the surviving </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">corporation, except </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">that Art icle </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">1 </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">thereof </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">shall </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">be amended </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">in </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">its </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">entire</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ty </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">to </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">read as fo</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">llo</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">ws:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:102px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#424242;">"A</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">RTICLE </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">I</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:92px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">The name of this </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">corporatio</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">n is </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Galena Biopharma, Inc</font><font style="font-family:inherit;font-size:10pt;color:#424242;">.</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">"</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:18px;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">RESOLVED FURTH</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">ER, </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">that </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the Bylaws of the Company as in effect immediately prior </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">to </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the effective </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">time </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of the Merger shall be amended and restated to reflect the Name Change; and it is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:17px;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">RESOLVED FURTHER</font><font style="font-family:inherit;font-size:10pt;color:#424242;">, </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">that </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">t</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">he </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">office</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">rs </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of th</font><font style="font-family:inherit;font-size:10pt;color:#424242;">e </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Company be and each hereby is </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">auth</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">oriz</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ed</font><font style="font-family:inherit;font-size:10pt;color:#424242;">, </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">empowered </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">directed, in </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">the </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">name </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">on behalf </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the Company, </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">to </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">prepare or cause to be prepared, and to execute and </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">file </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">wit</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">h </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the Delaware Secretary of State a Certificat</font><font style="font-family:inherit;font-size:10pt;color:#424242;">e </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Own</font><font style="font-family:inherit;font-size:10pt;color:#424242;">e</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">rship and Merger that sets forth </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">therein </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">a copy of these </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">r</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">esolut</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ion</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">s </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">and </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">the </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">date th</font><font style="font-family:inherit;font-size:10pt;color:#424242;">a</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">t </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">such </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">re</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">solu</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">tion</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">s </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">were </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">adop</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ted </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">by </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">the </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Board of </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">Di</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">rec</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">tors; </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">a</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">nd it </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">is</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:17px;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">R</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">ESOLVED </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">FURTHER, </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">t</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">hat </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the officers of the Company be, and each </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">them </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">her</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">eby </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">is, authorized, empowered and directed, </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">in </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the name and on </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">behalf </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">the </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Company, to (i) </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">notify </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">Company's </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">transfer </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">agent and </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">reg</font><font style="font-family:inherit;font-size:10pt;color:#424242;">i</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">strar </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">for </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the Company </font><font style="font-family:inherit;font-size:10pt;color:#424242;">'s </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">common stock </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of the Name </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">Change, </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">(ii) obtain a </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">new </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">CUSIP </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">number, </font><font style="font-family:inherit;font-size:9pt;color:#1c1c1c;">(iii) </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">prepare </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">and </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">file with </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">the </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">SEC </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">a </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">cur</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">rent </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">report </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">on Form </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">8-K to </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">dis</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">close </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the transactions contemplated by the foregoing resolutions, and {iv) </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">exe</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">cute </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">su</font><font style="font-family:inherit;font-size:10pt;color:#424242;">c</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">h </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">document</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">s, </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">di</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">sburse </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">such funds, engage </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">s</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">uch </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">persons, and take all </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">such </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">other actions that </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">such </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">officer may </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">deem </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">n</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">ecessa</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ry </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">or advisable in </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">connection </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">with the Name Change </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the Merger </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">to </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">carry </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">out the intent and purpose </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:Arial;font-size:9pt;color:#1c1c1c;">t</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">he</font><font style="font-family:Arial;font-size:9pt;color:#1c1c1c;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">foregoing </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">re</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">so</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">luti</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">ons.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:17px;text-align:left;text-indent:41px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:37px;">1.</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">T</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">h</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">e Compa</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ny </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">shall be the </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">su</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">r</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">viving </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">corporation of the Merger.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:17px;text-align:justify;text-indent:41px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">2.</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">The </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Certificate of Incorporation of the Company as in effect immediately prior to th</font><font style="font-family:inherit;font-size:10pt;color:#424242;">e </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">effective time </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the Merger shall be </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">the </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">certificate of </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">in</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">co</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">rp</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">orat</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ion </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">surviving </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">corporation</font><font style="font-family:inherit;font-size:10pt;color:#424242;">, </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">except that Article </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">I </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">thereof shall be amended </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">in </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">its entirety </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">to read </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:100px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">"ARTICLE   I</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:89px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">The name of </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">this </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">corporation is </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">Ga</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">lena </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">B</font><font style="font-family:inherit;font-size:10pt;color:#424242;">i</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">opharma</font><font style="font-family:inherit;font-size:10pt;color:#424242;">, </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">I</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">n</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">c."</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:100px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:57px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">The Merger shall be effective </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">as </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">September </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;text-decoration:underline;">_26</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">, </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">2011</font><font style="font-family:inherit;font-size:10pt;color:#424242;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:16px;text-indent:41px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">IN WITNESS W HEREOF, </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">RXi </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Pharmaceuticals </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">Corporation </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">ha</font><font style="font-family:inherit;font-size:10pt;color:#424242;">s </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">caused this </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">Cert</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ifi</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">cate </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">Ownership </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">and Merger </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">to </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">be </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">s</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">igned </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">b</font><font style="font-family:inherit;font-size:10pt;color:#424242;">y </font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">it</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">s </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">duly </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">autho</font><font style="font-family:inherit;font-size:10pt;color:#0a0a0a;">ri</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">zed </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">officer, this </font><font style="font-family:inherit;font-size:10pt;color:#757575;">&#183;&#183;</font><font style="font-family:inherit;font-size:10pt;color:#757575;text-decoration:underline;">26</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">day </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of September </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">201 1.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:290px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1c1c1c;">RXI PHARMACEUTICALS </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">CORPORATION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:290px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">By; </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;text-decoration:underline;">/S/ Mark J. Ahn</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:290px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Name</font><font style="font-family:inherit;font-size:10pt;color:#424242;">: </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Mark J. Ahn, Ph.D.</font></div><div style="line-height:120%;text-align:left;padding-left:290px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Title:   President and  Chief Exe</font><font style="font-family:inherit;font-size:10pt;color:#424242;">c</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">utive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:21px;text-indent:6px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">State of Delaware </font><font style="font-family:inherit;font-size:10pt;color:#080808;">Secretary </font><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">of State Division </font><font style="font-family:inherit;font-size:9pt;color:#080808;font-style:italic;">0&#163; </font><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">Corporations</font></div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">Delivered  04 </font><font style="font-family:Arial;font-size:8pt;color:#2b2b2b;font-style:italic;">:</font><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">59 PM 06/28/2</font><font style="font-family:inherit;font-size:8pt;color:#080808;font-style:italic;">0</font><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">13</font></div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">FILED  04 </font><font style="font-family:Arial;font-size:8pt;color:#2b2b2b;font-style:italic;">:</font><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">56 PM 06/28/2</font><font style="font-family:inherit;font-size:8pt;color:#080808;font-style:italic;">0</font><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">13</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">SRV 130832067 </font><font style="font-family:inherit;font-size:8pt;color:#080808;">-</font><font style="font-family:Arial;font-size:8pt;color:#080808;">&#32;</font><font style="font-family:Arial;font-size:8pt;color:#080808;font-style:italic;">4136433 FILE</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:138px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;font-weight:bold;">&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;font-weight:bold;">CERTIFICATE OF</font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;font-weight:bold;">AMENDMENT</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:138px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;color:#1a1a1a;font-weight:bold;">TO</font></div><div style="line-height:120%;text-align:center;padding-left:138px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#080808;font-weight:bold;">AMENDED AND </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">RESTATED </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;font-weight:bold;">CERTIFICATE </font><font style="font-family:inherit;font-size:11pt;color:#080808;font-weight:bold;">OF INCORPORATION OF</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:138px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#080808;font-weight:bold;">GALENA </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;font-weight:bold;">BIOPHARMA, </font><font style="font-family:inherit;font-size:11pt;color:#080808;font-weight:bold;">INC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">that:</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Gal</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">en</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">a Biopharma ,</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Inc</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">., </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">a </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Delaw</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">a</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">re </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">co</font><font style="font-family:inherit;font-size:11pt;color:#080808;">rp</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">oration </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">(</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">"</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">Corpora</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">tion&#8221;), </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">hereby certifie</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">s</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:89px;text-align:left;text-indent:46px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:56px;">1.</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">The </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">following </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">resolution </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">ha</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">s </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">been </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">unanimously adopted </font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">by </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">th</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">e </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Corporation</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">'</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">s </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Board of </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Direc</font><font style="font-family:inherit;font-size:11pt;color:#080808;">t</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">ors and </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">ha</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">s </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">been approved by </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">the holder</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">s </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">of </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">a </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">m</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">ajo</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">r</font><font style="font-family:inherit;font-size:11pt;color:#080808;">it</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">y of </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">Corpora</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">tion'</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">outs</font><font style="font-family:inherit;font-size:11pt;color:#080808;">t</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">anding common stock </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">in </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">accordance </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">with </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Delaware </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">General </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">Co</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">rporation </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Law for </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">t</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">he purpose of </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">amendi</font><font style="font-family:inherit;font-size:11pt;color:#080808;">ng </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">the </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Corporat</font><font style="font-family:inherit;font-size:11pt;color:#080808;">ion</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">'s </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Amended and Re</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">tated </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Certificate of </font><font style="font-family:inherit;font-size:11pt;color:#080808;">Inc</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">orporation:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:182px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">RESOLV</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">E</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">D. that </font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">AR</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">T</font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">ICL</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">E </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">III, Sec</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">tion </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">A </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">of </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">the Amended and </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">Re</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">tated</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:182px;text-indent:-94px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">C</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">ertificate of Incorporati</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">o</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">n </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">o</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">f the </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Corp</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">o</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">r</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">a</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">tion </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">hall </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">be amended </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">read </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">in i</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">ts </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">enti</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">rct</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">y </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:136px;text-indent:45px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">"</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Classes </font><font style="font-family:inherit;font-size:11pt;color:#080808;">of </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Stock.  </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">This </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Corporation is auth</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">or</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">i</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">ze</font><font style="font-family:inherit;font-size:11pt;color:#080808;">d t</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">o </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">iss</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">ue 205</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">,00</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">0</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">,</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">000 share</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s, </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">of which 200,000,000 </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">hares </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">sha</font><font style="font-family:inherit;font-size:11pt;color:#080808;">ll </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">be </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Common </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Stock </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">with </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">a par </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">va</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">lue </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">$0.0001 per </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">share </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">(&#8220;</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">") </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">and </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">5</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">,</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">000.000 shar</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">es </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">hall </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">be </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Preferred </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">Sto</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">ck </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">with a par value of </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">$0.0001 </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">per </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s</font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">hare </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">("</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Preferred Stock</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">).'</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">'</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:90px;text-align:left;text-indent:45px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:56px;">2.</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">The above </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">amend</font><font style="font-family:inherit;font-size:11pt;color:#080808;">ment </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">was </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">duly adopted </font><font style="font-family:Arial;font-size:9pt;color:#1a1a1a;">by </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">the </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#080808;">i</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">n </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">acccmi&lt;rnce </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">with </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">pro</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">v</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">i</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">ion</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">of Section </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">2</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">42 </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">the D</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">e</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">laware G</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">enera</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">l </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">Law.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:136px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#080808;">l</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">N  </font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">WlT</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">NES</font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">S </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">WHEREOF. Galena </font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">Biopharm</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">a, </font><font style="font-family:inherit;font-size:10pt;color:#b6b6b6;">.</font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">I n</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">c. </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">has </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">caused  t</font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">hi</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">s </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Cer</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">tifi</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">ca</font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">t</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">e </font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">of</font></div><div style="line-height:120%;text-align:left;padding-left:90px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">Amendment </font><font style="font-family:inherit;font-size:11pt;color:#080808;">t</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">o </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">be s</font><font style="font-family:inherit;font-size:11pt;color:#080808;">ign</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">ed </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">b</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">y </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">duly </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">authorized officer </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">t</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">hi</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">s </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">28</font><font style="font-family:Arial;font-size:5pt;color:#2b2b2b;">th  </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">da</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">y </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">o</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">f June </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">20 </font><font style="font-family:inherit;font-size:11pt;color:#080808;">1</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">3</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:394px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">Galena </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">Biopha</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">rma. </font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">I</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">nc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:290px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">By; </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;text-decoration:underline;">/S/ Mark J. Ahn</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:290px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Name</font><font style="font-family:inherit;font-size:10pt;color:#424242;">: </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Mark J. Ahn, Ph.D.</font></div><div style="line-height:120%;text-align:left;padding-left:290px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Title:   President and  Chief Exe</font><font style="font-family:inherit;font-size:10pt;color:#424242;">c</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">utive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:42px;text-indent:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#0e0e0e;font-style:italic;">State of Delaware Secretary of State</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;text-indent:14px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#0e0e0e;font-style:italic;">Division  of  Corporations Delivered 11:17 AM </font><font style="font-family:inherit;font-size:8pt;color:#0e0e0e;font-style:italic;">0</font><font style="font-family:Arial;font-size:8pt;color:#0e0e0e;font-style:italic;">7</font><font style="font-family:Arial;font-size:8pt;color:#262626;font-style:italic;">/22/20 13</font></div><div style="line-height:120%;text-align:left;padding-left:21px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#0e0e0e;font-style:italic;">FILED 09: 13 AM </font><font style="font-family:inherit;font-size:8pt;color:#0e0e0e;font-style:italic;">0</font><font style="font-family:Arial;font-size:8pt;color:#0e0e0e;font-style:italic;">7</font><font style="font-family:Arial;font-size:8pt;color:#262626;font-style:italic;">/22/20 13</font></div><div style="line-height:120%;text-align:center;padding-left:5px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#0e0e0e;font-style:italic;">SRV 130900861 </font><font style="font-family:inherit;font-size:8pt;color:#0e0e0e;">-</font><font style="font-family:Arial;font-size:8pt;color:#0e0e0e;">&#32;</font><font style="font-family:Arial;font-size:8pt;color:#0e0e0e;font-style:italic;">4136433 FILE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:182px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">C</font><font style="font-family:inherit;font-size:11pt;color:#262626;">ERTIFICATE </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">OF </font><font style="font-family:inherit;font-size:11pt;color:#262626;">CHANGE OF </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">LOCATION </font><font style="font-family:inherit;font-size:11pt;color:#262626;">OF REGISTERED OFFICE AND </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">OF </font><font style="font-family:inherit;font-size:11pt;color:#262626;">REGISTERED </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">AGENT</font></div><div style="line-height:120%;padding-top:1px;text-align:center;padding-left:269px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#262626;">OF</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:269px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;color:#0e0e0e;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:114px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#262626;">It </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">i</font><font style="font-family:inherit;font-size:11pt;color:#595959;">s </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">hereb</font><font style="font-family:inherit;font-size:11pt;color:#414141;">y ce</font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">rtified </font><font style="font-family:inherit;font-size:11pt;color:#262626;">tha</font><font style="font-family:inherit;font-size:11pt;color:#414141;">t:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:224px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:206px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">The </font><font style="font-family:inherit;font-size:11pt;color:#262626;">name </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">of </font><font style="font-family:inherit;font-size:11pt;color:#262626;">the </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">corporation (hereinafter </font><font style="font-family:inherit;font-size:11pt;color:#262626;">called </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">"corporation </font><font style="font-family:inherit;font-size:11pt;color:#414141;">"</font><font style="font-family:inherit;font-size:11pt;color:#262626;">) i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">s</font><font style="font-family:inherit;font-size:11pt;color:#262626;">:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:269px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;color:#0e0e0e;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:113px;text-indent:92px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#262626;">2</font><font style="font-family:inherit;font-size:10pt;color:#414141;">. </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Th</font><font style="font-family:inherit;font-size:11pt;color:#414141;">e </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">register</font><font style="font-family:inherit;font-size:11pt;color:#414141;">e</font><font style="font-family:inherit;font-size:11pt;color:#262626;">d office of </font><font style="font-family:inherit;font-size:10pt;color:#262626;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">corporation within </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Stat</font><font style="font-family:inherit;font-size:11pt;color:#414141;">e </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">D</font><font style="font-family:inherit;font-size:11pt;color:#414141;">e</font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">l</font><font style="font-family:inherit;font-size:11pt;color:#414141;">a</font><font style="font-family:inherit;font-size:11pt;color:#262626;">ware </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">s </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">hereby changed to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">2711 Centerville </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Road</font><font style="font-family:inherit;font-size:11pt;color:#414141;">, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Suite </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">400</font><font style="font-family:inherit;font-size:11pt;color:#414141;">, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">City of Wilmington 19808, C</font><font style="font-family:inherit;font-size:11pt;color:#414141;">o</font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">unty </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of N</font><font style="font-family:inherit;font-size:11pt;color:#414141;">e</font><font style="font-family:inherit;font-size:11pt;color:#262626;">w </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Castle</font><font style="font-family:inherit;font-size:11pt;color:#414141;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:113px;text-indent:92px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#262626;">3. </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">The registered </font><font style="font-family:inherit;font-size:11pt;color:#262626;">agent of the corporation within the Stat</font><font style="font-family:inherit;font-size:11pt;color:#414141;">e </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of Delaware i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">s </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">hereby changed to </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Corporation Service Company, the </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">busines</font><font style="font-family:inherit;font-size:11pt;color:#414141;">s </font><font style="font-family:inherit;font-size:11pt;color:#262626;">office o</font><font style="font-family:inherit;font-size:11pt;color:#414141;">f </font><font style="font-family:inherit;font-size:11pt;color:#262626;">which </font><font style="font-family:inherit;font-size:11pt;color:#414141;">i</font><font style="font-family:inherit;font-size:11pt;color:#262626;">s </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">identical </font><font style="font-family:inherit;font-size:11pt;color:#262626;">with the registered office </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">of the </font><font style="font-family:inherit;font-size:11pt;color:#262626;">corporation as </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">hereby </font><font style="font-family:inherit;font-size:11pt;color:#262626;">changed.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:114px;text-indent:90px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">4. </font><font style="font-family:inherit;font-size:11pt;color:#262626;">The corporation </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">has </font><font style="font-family:inherit;font-size:11pt;color:#262626;">authorized </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">the change</font><font style="font-family:inherit;font-size:11pt;color:#414141;">s </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">hereinbefore </font><font style="font-family:inherit;font-size:11pt;color:#262626;">set forth </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">by </font><font style="font-family:inherit;font-size:11pt;color:#262626;">r</font><font style="font-family:inherit;font-size:11pt;color:#414141;">es</font><font style="font-family:inherit;font-size:11pt;color:#262626;">olution of its </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Board </font><font style="font-family:inherit;font-size:11pt;color:#262626;">of </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Directors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:269px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Signed:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:388px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Galena </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Biopharma, </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:388px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;text-decoration:underline;">By: /s/ Mark W. Schwartz             </font></div><div style="line-height:120%;text-align:left;padding-left:388px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Name</font><font style="font-family:inherit;font-size:11pt;color:#414141;">. Mark W. </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Schwartz</font><font style="font-family:inherit;font-size:11pt;color:#414141;">, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Ph.D.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:388px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Title</font><font style="font-family:inherit;font-size:11pt;color:#414141;">: </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Executi</font><font style="font-family:inherit;font-size:11pt;color:#414141;">ve Vice </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Pr</font><font style="font-family:inherit;font-size:11pt;color:#414141;">es</font><font style="font-family:inherit;font-size:11pt;color:#262626;">ident </font><font style="font-family:Arial;font-size:10pt;color:#262626;">&amp; </font><font style="font-family:inherit;font-size:11pt;color:#262626;">COO</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:21px;text-indent:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;font-style:italic;">State </font><font style="font-family:Arial;font-size:8pt;color:#0c0c0c;font-style:italic;">of </font><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;font-style:italic;">Delaware Secretary </font><font style="font-family:Arial;font-size:8pt;color:#0c0c0c;font-style:italic;">of </font><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;font-style:italic;">State </font><font style="font-family:inherit;font-size:9pt;color:#0c0c0c;font-style:italic;">Division   of   Corporations</font></div><div style="line-height:120%;padding-top:1px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;font-style:italic;">Delivered 02:36 PM 06/19/2015 FILED 02:23 PM 06/19/2015</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;font-style:italic;">SRV 150947213 </font><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;">- </font><font style="font-family:inherit;font-size:10pt;color:#0c0c0c;font-style:italic;">4136433 FILE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:116px;text-indent:-110px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">CERTIFICATE OF AMENDMENT TO</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:286px;text-indent:-148px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">that:</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Galena Biopharma, Inc</font><font style="font-family:inherit;font-size:11pt;color:#313131;">., </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">a Delaware corporation </font><font style="font-family:inherit;font-size:11pt;color:#212121;">(the "Corporation"), </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">hereby certifies</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:89px;text-indent:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">The following resolution has been unanimously adopted by the Corporation </font><font style="font-family:inherit;font-size:11pt;color:#313131;">'s </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Board of Directors and has been </font><font style="font-family:inherit;font-size:11pt;color:#212121;">approved </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">by the holders of a majority </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of the </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Corporation's outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Corporation's Amended </font><font style="font-family:inherit;font-size:11pt;color:#212121;">and </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Restated Certificate of Incorporation:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:89px;text-indent:90px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">RESOLVED, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">that </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">ARTICLE III, Section A of the Amended and Restated Certificate of lncorporation of the Corporation shall be amended to read in its entirety as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:136px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#313131;">"</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">A</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;font-weight:bold;">Classes of Stock</font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">. </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">This Corporation is authorized to issue 280,000,000 shares, of </font><font style="font-family:inherit;font-size:11pt;color:#212121;">which 275,000,000 shares </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">shall be Common Stock with </font><font style="font-family:inherit;font-size:11pt;color:#212121;">a </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">par </font><font style="font-family:inherit;font-size:11pt;color:#212121;">value </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of $0</font><font style="font-family:inherit;font-size:11pt;color:#484848;">.</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">0001 per share </font><font style="font-family:inherit;font-size:11pt;color:#212121;">("Common </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Stock") and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share ("Preferred Stock"</font><font style="font-family:inherit;font-size:11pt;color:#313131;">).</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">"</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:89px;text-indent:45px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#0c0c0c;">2</font><font style="font-family:inherit;font-size:11pt;color:#313131;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">The above amendment was duly adopted by the Corporation in accordance with the provisions of Section 242 of the Delaware General Corporation Law</font><font style="font-family:inherit;font-size:11pt;color:#313131;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:89px;text-indent:45px;font-size:12pt;"><font style="font-family:Arial;font-size:11pt;color:#0c0c0c;">IN</font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">WITNESS WHEREOF, Galena Biopharma, Inc</font><font style="font-family:inherit;font-size:11pt;color:#313131;">. </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">has caused this </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Certificate </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">of Amendment to be signed by a duly authorized officer this </font><font style="font-family:inherit;font-size:12pt;color:#0c0c0c;">I 9</font><font style="font-family:inherit;font-size:7pt;color:#0c0c0c;">1 </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">day </font><font style="font-family:inherit;font-size:11pt;color:#212121;">of </font><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">June </font><font style="font-family:inherit;font-size:11pt;color:#212121;">2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:11px;text-align:left;padding-left:396px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">Galena Biopharma, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:388px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;text-decoration:underline;">By: /s/ Mark W. Schwartz             </font></div><div style="line-height:120%;text-align:left;padding-left:388px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">Name</font><font style="font-family:inherit;font-size:11pt;color:#414141;">. Mark W. </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Schwartz</font><font style="font-family:inherit;font-size:11pt;color:#414141;">, </font><font style="font-family:inherit;font-size:11pt;color:#262626;">Ph.D.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:425px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0c0c0c;">President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:3px;text-align:center;padding-left:476px;text-indent:-2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#38383d;">Stat</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">e o</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">f </font><font style="font-family:inherit;font-size:9pt;color:#282828;">Delaware </font><font style="font-family:inherit;font-size:9pt;color:#38383d;">S</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">ec</font><font style="font-family:inherit;font-size:9pt;color:#151515;">r</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">e</font><font style="font-family:inherit;font-size:9pt;color:#151515;">tar</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">y </font><font style="font-family:inherit;font-size:9pt;color:#38383d;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">Stat</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">e </font><font style="font-family:inherit;font-size:9pt;color:#151515;">D</font><font style="font-family:inherit;font-size:9pt;color:#0a0f2f;">i</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">v</font><font style="font-family:inherit;font-size:9pt;color:#151515;">i</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">sion </font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">o</font><font style="font-family:inherit;font-size:9pt;color:#1d3444;">f </font><font style="font-family:inherit;font-size:9pt;color:#282828;">Corporations</font></div><div style="line-height:120%;text-align:center;padding-left:465px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#151515;">D</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">eli</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">v</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">ered 10:00 </font><font style="font-family:inherit;font-size:9pt;color:#282828;">AM 10</font><font style="font-family:inherit;font-size:9pt;color:#a8a8af;">/</font><font style="font-family:inherit;font-size:9pt;color:#151515;">1</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">712</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">016 </font><font style="font-family:inherit;font-size:9pt;color:#282828;">FILED </font><font style="font-family:inherit;font-size:9pt;color:#151515;">1</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">0</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">:</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">00 </font><font style="font-family:inherit;font-size:9pt;color:#282828;">AM1</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">0</font><font style="font-family:inherit;font-size:9pt;color:#919193;">/</font><font style="font-family:inherit;font-size:9pt;color:#282828;">1</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">7n0</font><font style="font-family:inherit;font-size:9pt;color:#151515;">1</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">6</font></div><div style="line-height:120%;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#38383d;">SR </font><font style="font-family:inherit;font-size:9pt;color:#282828;">2</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">0</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">16625</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">0</font><font style="font-family:inherit;font-size:9pt;color:#6b6b6e;">7</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">4</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">0 </font><font style="font-family:inherit;font-size:9pt;color:#38383d;">- </font><font style="font-family:inherit;font-size:9pt;color:#282828;">File </font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">N</font><font style="font-family:inherit;font-size:9pt;color:#282828;">umb</font><font style="font-family:inherit;font-size:9pt;color:#4f5059;">e</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">r  </font><font style="font-family:inherit;font-size:9pt;color:#151515;">41</font><font style="font-family:inherit;font-size:9pt;color:#38383d;">36433</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:146px;text-indent:49px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#151515;font-weight:bold;">STATE OF DELAWARE CERTIFICATE OF AMENDMENT</font></div><div style="line-height:120%;text-align:center;padding-left:112px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#151515;font-weight:bold;">OF CERTIFICATE OF INCORPORATION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:232%;text-align:justify;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;">Galena Biopharma</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">, </font><font style="font-family:inherit;font-size:10pt;color:#151515;">Inc</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">., </font><font style="font-family:inherit;font-size:10pt;color:#151515;">organized and existing under and </font><font style="font-family:inherit;font-size:10pt;color:#282828;">by </font><font style="font-family:inherit;font-size:10pt;color:#151515;">virtue of th</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e </font><font style="font-family:inherit;font-size:10pt;color:#151515;">General Corporation Law of the State of Delaware, does hereby certify:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:36px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;font-weight:bold;">FIRST</font><font style="font-family:inherit;font-size:10pt;color:#38383d;font-weight:bold;">: </font><font style="font-family:inherit;font-size:10pt;color:#151515;">That at a meeting of the Board of Directors of Galena Biopharma, Inc. resolutions were duly adopted </font><font style="font-family:inherit;font-size:10pt;color:#282828;">setting </font><font style="font-family:inherit;font-size:10pt;color:#151515;">forth a propo</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">se</font><font style="font-family:inherit;font-size:10pt;color:#151515;">d amendment of the</font></div><div style="line-height:120%;text-align:justify;padding-left:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;">Certificat</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e </font><font style="font-family:inherit;font-size:10pt;color:#151515;">of Incorporation of said </font><font style="font-family:inherit;font-size:10pt;color:#282828;">corporation, </font><font style="font-family:inherit;font-size:10pt;color:#151515;">declaring said </font><font style="font-family:inherit;font-size:10pt;color:#282828;">amendment </font><font style="font-family:inherit;font-size:10pt;color:#151515;">to be advisable and calling </font><font style="font-family:inherit;font-size:10pt;color:#282828;">a </font><font style="font-family:inherit;font-size:10pt;color:#151515;">meeting of the stockholders of said </font><font style="font-family:inherit;font-size:10pt;color:#282828;">corporation </font><font style="font-family:inherit;font-size:10pt;color:#151515;">for </font><font style="font-family:inherit;font-size:10pt;color:#282828;">consideration </font><font style="font-family:inherit;font-size:10pt;color:#151515;">thereof. The resolution  </font><font style="font-family:inherit;font-size:10pt;color:#282828;">setting </font><font style="font-family:inherit;font-size:10pt;color:#151515;">forth the proposed amendment i</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">s </font><font style="font-family:inherit;font-size:10pt;color:#282828;">as </font><font style="font-family:inherit;font-size:10pt;color:#151515;">follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;font-weight:bold;">RESOLVED, </font><font style="font-family:inherit;font-size:10pt;color:#151515;">that the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">Certificate </font><font style="font-family:inherit;font-size:10pt;color:#151515;">of Incorporation </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">this </font><font style="font-family:inherit;font-size:10pt;color:#282828;">corporation be amended </font><font style="font-family:inherit;font-size:12pt;color:#151515;">by </font><font style="font-family:inherit;font-size:10pt;color:#151515;">changing th</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e </font><font style="font-family:inherit;font-size:10pt;color:#151515;">Article thereof numbered " Section </font><font style="font-family:inherit;font-size:10pt;color:#282828;">(A) </font><font style="font-family:inherit;font-size:10pt;color:#151515;">of Articl</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e </font><font style="font-family:inherit;font-size:10pt;color:#151515;">III " </font><font style="font-family:inherit;font-size:10pt;color:#282828;">so that, </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">as </font><font style="font-family:inherit;font-size:10pt;color:#282828;">amended</font><font style="font-family:inherit;font-size:10pt;color:#4f5059;">, </font><font style="font-family:inherit;font-size:10pt;color:#151515;">said Article </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">s</font><font style="font-family:inherit;font-size:10pt;color:#151515;">hall be and read as follows:</font></div><div style="line-height:120%;padding-top:5px;text-align:justify;padding-left:36px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;font-weight:bold;">A. Classes of Stock. </font><font style="font-family:inherit;font-size:10pt;color:#282828;">This Corporation </font><font style="font-family:inherit;font-size:10pt;color:#151515;">is </font><font style="font-family:inherit;font-size:10pt;color:#282828;">authorized </font><font style="font-family:inherit;font-size:10pt;color:#151515;">to issue </font><font style="font-family:inherit;font-size:10pt;color:#282828;">355,000,000 shares</font><font style="font-family:inherit;font-size:10pt;color:#4f5059;">, </font><font style="font-family:inherit;font-size:10pt;color:#151515;">of </font><font style="font-family:inherit;font-size:10pt;color:#282828;">which </font><font style="font-family:inherit;font-size:10pt;color:#151515;">350</font><font style="font-family:inherit;font-size:10pt;color:#4f5059;">,</font><font style="font-family:inherit;font-size:10pt;color:#151515;">000</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">,</font><font style="font-family:inherit;font-size:10pt;color:#151515;">000 shares </font><font style="font-family:inherit;font-size:10pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:10pt;color:#151515;">be </font><font style="font-family:inherit;font-size:10pt;color:#282828;">Common </font><font style="font-family:inherit;font-size:10pt;color:#151515;">Stock with a par </font><font style="font-family:inherit;font-size:10pt;color:#282828;">value of $0.0001 </font><font style="font-family:inherit;font-size:10pt;color:#151515;">per </font><font style="font-family:inherit;font-size:10pt;color:#282828;">share ("Common Stock") and </font><font style="font-family:inherit;font-size:10pt;color:#151515;">5,000,000 </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">s</font><font style="font-family:inherit;font-size:10pt;color:#151515;">hares shall be Preferred Stock </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">w</font><font style="font-family:inherit;font-size:10pt;color:#151515;">ith </font><font style="font-family:inherit;font-size:10pt;color:#282828;">a </font><font style="font-family:inherit;font-size:10pt;color:#151515;">par </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">va</font><font style="font-family:inherit;font-size:10pt;color:#151515;">lue </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of</font></div><div style="line-height:120%;text-align:justify;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;">$0.0001 per share </font><font style="font-family:inherit;font-size:10pt;color:#282828;">("Preferred </font><font style="font-family:inherit;font-size:10pt;color:#151515;">Stock")</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:7px;text-align:justify;padding-left:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;font-weight:bold;">SECOND</font><font style="font-family:inherit;font-size:10pt;color:#38383d;font-weight:bold;">: </font><font style="font-family:inherit;font-size:10pt;color:#151515;">That thereafter, pursuant to resolution </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">its Bo</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">ar</font><font style="font-family:inherit;font-size:10pt;color:#151515;">d </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">Director</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">s, </font><font style="font-family:inherit;font-size:10pt;color:#282828;">at </font><font style="font-family:inherit;font-size:10pt;color:#151515;">the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">annual </font><font style="font-family:inherit;font-size:10pt;color:#151515;">meeting of the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">stockholders of </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">sa</font><font style="font-family:inherit;font-size:10pt;color:#151515;">id </font><font style="font-family:inherit;font-size:10pt;color:#282828;">corporation </font><font style="font-family:inherit;font-size:10pt;color:#151515;">duly </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">ca</font><font style="font-family:inherit;font-size:10pt;color:#151515;">ll</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e</font><font style="font-family:inherit;font-size:10pt;color:#151515;">d </font><font style="font-family:inherit;font-size:10pt;color:#282828;">and </font><font style="font-family:inherit;font-size:10pt;color:#151515;">held upon notice in accordanc</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e </font><font style="font-family:inherit;font-size:10pt;color:#282828;">with </font><font style="font-family:inherit;font-size:10pt;color:#151515;">Se</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">c</font><font style="font-family:inherit;font-size:10pt;color:#151515;">tion </font><font style="font-family:Arial;font-size:10pt;color:#151515;">222 </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">th</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e </font><font style="font-family:inherit;font-size:10pt;color:#282828;">General Corporation Law </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">the St</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">a</font><font style="font-family:inherit;font-size:10pt;color:#151515;">te </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">Delaw</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">are </font><font style="font-family:inherit;font-size:10pt;color:#282828;">at </font><font style="font-family:inherit;font-size:10pt;color:#151515;">which meeting the necessary number </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">shares </font><font style="font-family:inherit;font-size:10pt;color:#282828;">as </font><font style="font-family:inherit;font-size:10pt;color:#151515;">required b</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">y s</font><font style="font-family:inherit;font-size:10pt;color:#151515;">tatute </font><font style="font-family:inherit;font-size:10pt;color:#282828;">were </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">vo</font><font style="font-family:inherit;font-size:10pt;color:#151515;">t</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">ed </font><font style="font-family:inherit;font-size:10pt;color:#151515;">in </font><font style="font-family:inherit;font-size:10pt;color:#282828;">favor of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">amendment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;font-weight:bold;">THIRD</font><font style="font-family:inherit;font-size:10pt;color:#38383d;font-weight:bold;">: </font><font style="font-family:inherit;font-size:10pt;color:#151515;">That </font><font style="font-family:inherit;font-size:10pt;color:#282828;">said amendment was </font><font style="font-family:inherit;font-size:10pt;color:#151515;">duly </font><font style="font-family:inherit;font-size:10pt;color:#282828;">adopted </font><font style="font-family:inherit;font-size:10pt;color:#151515;">in </font><font style="font-family:inherit;font-size:10pt;color:#282828;">accordance </font><font style="font-family:inherit;font-size:10pt;color:#38383d;">w</font><font style="font-family:inherit;font-size:10pt;color:#151515;">ith the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">provisions of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">S</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">ec</font><font style="font-family:inherit;font-size:10pt;color:#151515;">t</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">io</font><font style="font-family:inherit;font-size:10pt;color:#151515;">n </font><font style="font-family:Arial;font-size:9pt;color:#282828;">242 </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">the Gene</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">ra</font><font style="font-family:inherit;font-size:10pt;color:#151515;">l </font><font style="font-family:inherit;font-size:10pt;color:#282828;">Corporation </font><font style="font-family:inherit;font-size:10pt;color:#151515;">L</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">a</font><font style="font-family:inherit;font-size:10pt;color:#151515;">w </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of </font><font style="font-family:inherit;font-size:10pt;color:#151515;">the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">State </font><font style="font-family:inherit;font-size:10pt;color:#151515;">of D</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">elaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;font-weight:bold;">IN WITNESS  WHEREOF</font><font style="font-family:inherit;font-size:10pt;color:#38383d;font-weight:bold;">, </font><font style="font-family:inherit;font-size:10pt;color:#151515;">said </font><font style="font-family:inherit;font-size:10pt;color:#282828;">corporation </font><font style="font-family:inherit;font-size:10pt;color:#151515;">ha</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">s </font><font style="font-family:inherit;font-size:10pt;color:#282828;">caused </font><font style="font-family:inherit;font-size:10pt;color:#151515;">thi</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">s c</font><font style="font-family:inherit;font-size:10pt;color:#4f5059;">e</font><font style="font-family:inherit;font-size:10pt;color:#151515;">rt</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">i</font><font style="font-family:inherit;font-size:10pt;color:#151515;">ficate </font><font style="font-family:inherit;font-size:10pt;color:#282828;">to </font><font style="font-family:inherit;font-size:10pt;color:#151515;">b</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e </font><font style="font-family:inherit;font-size:10pt;color:#282828;">signed </font><font style="font-family:inherit;font-size:10pt;color:#151515;">this</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:36px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#151515;">14th </font><font style="font-family:inherit;font-size:10pt;color:#151515;">day </font><font style="font-family:inherit;font-size:10pt;color:#282828;">of September </font><font style="font-family:Arial;font-size:10pt;color:#282828;">2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;padding-left:344px;text-indent:-70px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;">By</font><font style="font-family:inherit;font-size:10pt;color:#151515;text-decoration:underline;">:/S/ Thomas J. Knapp</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#38383d;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;color:#151515;">Authorized </font><font style="font-family:inherit;font-size:10pt;color:#282828;">Officer</font></div><div style="line-height:120%;text-align:left;padding-left:257px;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;">Titl</font><font style="font-family:inherit;font-size:10pt;color:#38383d;">e: </font><font style="font-family:inherit;font-size:10pt;color:#282828;text-decoration:underline;">Corporate</font><font style="font-family:inherit;font-size:10pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#151515;text-decoration:underline;">S</font><font style="font-family:inherit;font-size:10pt;color:#38383d;text-decoration:underline;">ec</font><font style="font-family:inherit;font-size:10pt;color:#151515;text-decoration:underline;">retary</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#151515;">Name: </font><font style="font-family:inherit;font-size:10pt;color:#38383d;text-decoration:underline;">T</font><font style="font-family:inherit;font-size:10pt;color:#151515;text-decoration:underline;">hom</font><font style="font-family:inherit;font-size:10pt;color:#151515;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#38383d;text-decoration:underline;">as</font><font style="font-family:inherit;font-size:10pt;color:#38383d;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#282828;text-decoration:underline;">J.</font><font style="font-family:inherit;font-size:10pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#151515;text-decoration:underline;">Knapp</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;padding-left:481px;text-indent:-2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#494b52;">S</font><font style="font-family:inherit;font-size:9pt;color:#363638;">tate of </font><font style="font-family:inherit;font-size:9pt;color:#242426;">D</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">e</font><font style="font-family:inherit;font-size:9pt;color:#242426;">lawar</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">e </font><font style="font-family:inherit;font-size:9pt;color:#363638;">Secretar</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">y o</font><font style="font-family:inherit;font-size:9pt;color:#363638;">f </font><font style="font-family:inherit;font-size:9pt;color:#494b52;">S</font><font style="font-family:inherit;font-size:9pt;color:#242426;">tate Divis</font><font style="font-family:inherit;font-size:9pt;color:#343d5e;">io</font><font style="font-family:inherit;font-size:9pt;color:#131313;">n </font><font style="font-family:inherit;font-size:9pt;color:#494b52;">o</font><font style="font-family:inherit;font-size:9pt;color:#242426;">f </font><font style="font-family:inherit;font-size:9pt;color:#494b52;">Co</font><font style="font-family:inherit;font-size:9pt;color:#242426;">rporati</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">o</font><font style="font-family:inherit;font-size:9pt;color:#242426;">n</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">s</font></div><div style="line-height:120%;text-align:center;padding-left:470px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#242426;">Deliver</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">e</font><font style="font-family:inherit;font-size:9pt;color:#363638;">d  </font><font style="font-family:inherit;font-size:9pt;color:#131a3d;">1</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">0:00 </font><font style="font-family:inherit;font-size:9pt;color:#363638;">AM 11/02</font><font style="font-family:inherit;font-size:9pt;color:#939aa1;">/</font><font style="font-family:inherit;font-size:9pt;color:#363638;">2</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">0</font><font style="font-family:inherit;font-size:9pt;color:#363638;">1</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">6 </font><font style="font-family:inherit;font-size:9pt;color:#363638;">FIL</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">E</font><font style="font-family:inherit;font-size:9pt;color:#242426;">D </font><font style="font-family:inherit;font-size:9pt;color:#363638;">10</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">:00 </font><font style="font-family:inherit;font-size:9pt;color:#363638;">A</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">M 11/0</font><font style="font-family:inherit;font-size:9pt;color:#242426;">2</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">/20</font><font style="font-family:inherit;font-size:9pt;color:#363638;">16</font></div><div style="line-height:120%;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#363638;">SR 2</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">0</font><font style="font-family:inherit;font-size:9pt;color:#131313;">1</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">66</font><font style="font-family:inherit;font-size:9pt;color:#242426;">4</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">6</font><font style="font-family:inherit;font-size:9pt;color:#363638;">8</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">00</font><font style="font-family:inherit;font-size:9pt;color:#242426;">4 </font><font style="font-family:inherit;font-size:9pt;color:#363638;">- Fil</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">e N</font><font style="font-family:inherit;font-size:9pt;color:#242426;">umb</font><font style="font-family:inherit;font-size:9pt;color:#494b52;">e</font><font style="font-family:inherit;font-size:9pt;color:#363638;">r 4136433</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;padding-left:138px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#131313;font-weight:bold;">STATE OF DELAWARE CERTIFICATE OF AMENDMENT</font></div><div style="line-height:120%;padding-top:1px;text-align:center;padding-left:104px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#131313;font-weight:bold;">OF CERTIFICATE OF INCORPORATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-top:16px;text-align:justify;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#242426;">Galena </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Biopharma</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">, </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Inc</font><font style="font-family:inherit;font-size:11pt;color:#363638;">., o</font><font style="font-family:inherit;font-size:11pt;color:#131313;">rganized </font><font style="font-family:inherit;font-size:11pt;color:#242426;">and </font><font style="font-family:inherit;font-size:11pt;color:#363638;">exis</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ting </font><font style="font-family:inherit;font-size:11pt;color:#242426;">under </font><font style="font-family:inherit;font-size:11pt;color:#131313;">and by </font><font style="font-family:inherit;font-size:11pt;color:#242426;">virtue of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">t</font><font style="font-family:inherit;font-size:11pt;color:#363638;">he </font><font style="font-family:inherit;font-size:11pt;color:#242426;">General </font><font style="font-family:inherit;font-size:11pt;color:#363638;">Co</font><font style="font-family:inherit;font-size:11pt;color:#131313;">rporation </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Law of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the State of Delaware</font><font style="font-family:inherit;font-size:11pt;color:#606060;">, </font><font style="font-family:inherit;font-size:11pt;color:#131313;">does hereby </font><font style="font-family:inherit;font-size:11pt;color:#242426;">certify:</font></div><div style="line-height:120%;padding-top:7px;text-align:justify;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#242426;font-weight:bold;">FIRST</font><font style="font-family:inherit;font-size:11pt;color:#242426;">: That at a </font><font style="font-family:inherit;font-size:11pt;color:#131313;">meetin</font><font style="font-family:inherit;font-size:11pt;color:#363638;">g </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Board </font><font style="font-family:inherit;font-size:11pt;color:#363638;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Directors </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Galena Bi</font><font style="font-family:inherit;font-size:11pt;color:#363638;">op</font><font style="font-family:inherit;font-size:11pt;color:#131313;">harm</font><font style="font-family:inherit;font-size:11pt;color:#363638;">a, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Inc.</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">,</font><font style="font-family:inherit;font-size:11pt;color:#242426;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#131313;">r</font><font style="font-family:inherit;font-size:11pt;color:#363638;">esol</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ution</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">s </font><font style="font-family:inherit;font-size:11pt;color:#242426;">were duly </font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">dopted </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ettin</font><font style="font-family:inherit;font-size:11pt;color:#363638;">g </font><font style="font-family:inherit;font-size:11pt;color:#242426;">forth an amendment </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">the Certificate </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of Incorp</font><font style="font-family:inherit;font-size:11pt;color:#363638;">orat</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ion of </font><font style="font-family:inherit;font-size:11pt;color:#363638;">sa</font><font style="font-family:inherit;font-size:11pt;color:#131313;">id corporation</font><font style="font-family:inherit;font-size:11pt;color:#363638;">, </font><font style="font-family:inherit;font-size:11pt;color:#131313;">de</font><font style="font-family:inherit;font-size:11pt;color:#363638;">cl</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ar</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ing sa</font><font style="font-family:inherit;font-size:11pt;color:#131313;">id </font><font style="font-family:inherit;font-size:11pt;color:#242426;">amendment </font><font style="font-family:inherit;font-size:11pt;color:#131313;">to be </font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ffective based </font><font style="font-family:inherit;font-size:11pt;color:#242426;">on </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#242426;">vote </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tockholder </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s </font><font style="font-family:inherit;font-size:11pt;color:#242426;">at </font><font style="font-family:inherit;font-size:11pt;color:#363638;">a s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">pe</font><font style="font-family:inherit;font-size:11pt;color:#363638;">cial </font><font style="font-family:inherit;font-size:11pt;color:#131313;">meeting </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tockholders </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#494b52;">s</font><font style="font-family:inherit;font-size:11pt;color:#242426;">aid corporation. </font><font style="font-family:inherit;font-size:11pt;color:#131313;">The re</font><font style="font-family:inherit;font-size:11pt;color:#363638;">sol</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ut</font><font style="font-family:inherit;font-size:11pt;color:#363638;">i</font><font style="font-family:inherit;font-size:11pt;color:#131313;">on </font><font style="font-family:inherit;font-size:11pt;color:#363638;">se</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tting </font><font style="font-family:inherit;font-size:11pt;color:#242426;">forth </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#363638;">amen</font><font style="font-family:inherit;font-size:11pt;color:#131313;">dm</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ent is </font><font style="font-family:inherit;font-size:11pt;color:#242426;">as </font><font style="font-family:inherit;font-size:11pt;color:#363638;">follows</font><font style="font-family:inherit;font-size:11pt;color:#131313;">:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#131313;font-weight:bold;">RESOLVED</font><font style="font-family:inherit;font-size:10pt;color:#363638;font-weight:bold;">, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">that </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#363638;">Ce</font><font style="font-family:inherit;font-size:11pt;color:#131313;">rtific</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ate </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of Incorporation of thi</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s </font><font style="font-family:inherit;font-size:11pt;color:#131313;">corporation </font><font style="font-family:inherit;font-size:11pt;color:#242426;">be </font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">mended b</font><font style="font-family:inherit;font-size:11pt;color:#363638;">y c</font><font style="font-family:inherit;font-size:11pt;color:#131313;">h</font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">nging the Articl</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#131313;">thereof numbered </font><font style="font-family:inherit;font-size:11pt;color:#242426;">" </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Sect</font><font style="font-family:inherit;font-size:11pt;color:#363638;">io</font><font style="font-family:inherit;font-size:11pt;color:#131313;">n (A) </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Articl</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#131313;">ITI " </font><font style="font-family:inherit;font-size:11pt;color:#363638;">so </font><font style="font-family:inherit;font-size:11pt;color:#131313;">that</font><font style="font-family:inherit;font-size:11pt;color:#363638;">, as ame</font><font style="font-family:inherit;font-size:11pt;color:#131313;">nd</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ed a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">nd </font><font style="font-family:inherit;font-size:11pt;color:#242426;">re</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">s</font><font style="font-family:inherit;font-size:11pt;color:#242426;">tated, </font><font style="font-family:inherit;font-size:11pt;color:#363638;">sa</font><font style="font-family:inherit;font-size:11pt;color:#131313;">id </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Article </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">hall be </font><font style="font-family:inherit;font-size:11pt;color:#242426;">and </font><font style="font-family:inherit;font-size:11pt;color:#131313;">re</font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">d </font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">s follows:</font></div><div style="line-height:120%;padding-top:7px;text-align:justify;padding-left:9px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363638;">"</font><font style="font-family:inherit;font-size:11pt;color:#131313;">A. </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Classes of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Stock. This </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#131313;">is </font><font style="font-family:inherit;font-size:11pt;color:#363638;">au</font><font style="font-family:inherit;font-size:11pt;color:#131313;">thoriz</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ed </font><font style="font-family:inherit;font-size:11pt;color:#131313;">to </font><font style="font-family:inherit;font-size:11pt;color:#242426;">issue </font><font style="font-family:inherit;font-size:11pt;color:#131313;">355</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">,</font><font style="font-family:inherit;font-size:11pt;color:#242426;">000,000 </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">h</font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">res</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">which 3</font><font style="font-family:inherit;font-size:11pt;color:#363638;">5</font><font style="font-family:inherit;font-size:11pt;color:#131313;">0,000</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">,</font><font style="font-family:inherit;font-size:11pt;color:#131313;">000 </font><font style="font-family:inherit;font-size:11pt;color:#242426;">shall </font><font style="font-family:inherit;font-size:11pt;color:#131313;">be </font><font style="font-family:inherit;font-size:11pt;color:#363638;">Co</font><font style="font-family:inherit;font-size:11pt;color:#131313;">mmon </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Stock with a </font><font style="font-family:inherit;font-size:11pt;color:#131313;">pa</font><font style="font-family:inherit;font-size:11pt;color:#363638;">r va</font><font style="font-family:inherit;font-size:11pt;color:#131313;">lue </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#363638;">$</font><font style="font-family:inherit;font-size:11pt;color:#131313;">0</font><font style="font-family:inherit;font-size:11pt;color:#363638;">.</font><font style="font-family:inherit;font-size:11pt;color:#131313;">0001 </font><font style="font-family:inherit;font-size:11pt;color:#242426;">per </font><font style="font-family:inherit;font-size:11pt;color:#363638;">sha</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">r</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#242426;">(the </font><font style="font-family:inherit;font-size:11pt;color:#494b52;">"</font><font style="font-family:inherit;font-size:11pt;color:#242426;">Common Stock</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">"</font><font style="font-family:inherit;font-size:11pt;color:#363638;">) </font><font style="font-family:inherit;font-size:11pt;color:#242426;">and </font><font style="font-family:inherit;font-size:11pt;color:#131313;">5,000,000 </font><font style="font-family:inherit;font-size:11pt;color:#242426;">shares </font><font style="font-family:inherit;font-size:11pt;color:#131313;">sh</font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ll be Pr</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ferred Stock wi</font><font style="font-family:inherit;font-size:11pt;color:#363638;">th </font><font style="font-family:inherit;font-size:11pt;color:#242426;">a </font><font style="font-family:inherit;font-size:11pt;color:#131313;">par </font><font style="font-family:inherit;font-size:11pt;color:#242426;">value of </font><font style="font-family:inherit;font-size:11pt;color:#363638;">$0.0</font><font style="font-family:inherit;font-size:11pt;color:#131313;">001 </font><font style="font-family:inherit;font-size:11pt;color:#242426;">per </font><font style="font-family:inherit;font-size:11pt;color:#363638;">sha</font><font style="font-family:inherit;font-size:11pt;color:#131313;">r</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e.</font></div><div style="line-height:120%;padding-top:7px;text-align:justify;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#131313;text-decoration:underline;">Rever</font><font style="font-family:inherit;font-size:11pt;color:#363638;text-decoration:underline;">se</font><font style="font-family:inherit;font-size:11pt;color:#363638;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#131313;text-decoration:underline;">Stock S</font><font style="font-family:inherit;font-size:11pt;color:#363638;text-decoration:underline;">p</font><font style="font-family:inherit;font-size:11pt;color:#131313;text-decoration:underline;">lit</font><font style="font-family:inherit;font-size:11pt;color:#131313;">. </font><font style="font-family:inherit;font-size:11pt;color:#363638;">Effec</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tive </font><font style="font-family:inherit;font-size:11pt;color:#242426;">at </font><font style="font-family:inherit;font-size:11pt;color:#131313;">12:0I </font><font style="font-family:inherit;font-size:11pt;color:#363638;">a.</font><font style="font-family:inherit;font-size:11pt;color:#131313;">m</font><font style="font-family:inherit;font-size:11pt;color:#363638;">., Eas</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tern Standard Time </font><font style="font-family:inherit;font-size:11pt;color:#242426;">on </font><font style="font-family:inherit;font-size:11pt;color:#363638;">November </font><font style="font-family:inherit;font-size:11pt;color:#131313;">11, </font><font style="font-family:inherit;font-size:11pt;color:#363638;">20</font><font style="font-family:inherit;font-size:11pt;color:#131313;">16 </font><font style="font-family:inherit;font-size:11pt;color:#363638;">(</font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#363638;">"E</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ffective Time</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">"</font><font style="font-family:inherit;font-size:11pt;color:#242426;">), </font><font style="font-family:inherit;font-size:11pt;color:#131313;">each 20 </font><font style="font-family:inherit;font-size:11pt;color:#242426;">shares </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">common </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tock is</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ued </font><font style="font-family:inherit;font-size:11pt;color:#363638;">an</font><font style="font-family:inherit;font-size:11pt;color:#131313;">d </font><font style="font-family:inherit;font-size:11pt;color:#242426;">out</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tandin</font><font style="font-family:inherit;font-size:11pt;color:#363638;">g </font><font style="font-family:inherit;font-size:11pt;color:#242426;">or </font><font style="font-family:inherit;font-size:11pt;color:#131313;">held </font><font style="font-family:inherit;font-size:11pt;color:#242426;">by </font><font style="font-family:inherit;font-size:11pt;color:#363638;">t</font><font style="font-family:inherit;font-size:11pt;color:#131313;">he </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Corporation </font><font style="font-family:inherit;font-size:11pt;color:#131313;">in treasury </font><font style="font-family:inherit;font-size:11pt;color:#363638;">i</font><font style="font-family:inherit;font-size:11pt;color:#131313;">mmedi</font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tely </font><font style="font-family:inherit;font-size:11pt;color:#242426;">prior </font><font style="font-family:inherit;font-size:11pt;color:#131313;">to th</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">e </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Effective Time </font><font style="font-family:inherit;font-size:11pt;color:#363638;">(</font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#363638;">"O</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ld Common </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Stock") </font><font style="font-family:inherit;font-size:11pt;color:#131313;">shall </font><font style="font-family:inherit;font-size:11pt;color:#242426;">automatically without </font><font style="font-family:inherit;font-size:11pt;color:#363638;">fu</font><font style="font-family:inherit;font-size:11pt;color:#131313;">rther </font><font style="font-family:inherit;font-size:11pt;color:#363638;">actio</font><font style="font-family:inherit;font-size:11pt;color:#131313;">n on t</font><font style="font-family:inherit;font-size:11pt;color:#363638;">he </font><font style="font-family:inherit;font-size:11pt;color:#242426;">part </font><font style="font-family:inherit;font-size:11pt;color:#363638;">of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">the </font><font style="font-family:inherit;font-size:11pt;color:#363638;">Co</font><font style="font-family:inherit;font-size:11pt;color:#131313;">rporati</font><font style="font-family:inherit;font-size:11pt;color:#363638;">o</font><font style="font-family:inherit;font-size:11pt;color:#131313;">n or </font><font style="font-family:inherit;font-size:11pt;color:#363638;">any h</font><font style="font-family:inherit;font-size:11pt;color:#131313;">old</font><font style="font-family:inherit;font-size:11pt;color:#363638;">er of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Old </font><font style="font-family:inherit;font-size:11pt;color:#363638;">Co</font><font style="font-family:inherit;font-size:11pt;color:#131313;">mmon Stock</font><font style="font-family:inherit;font-size:11pt;color:#363638;">, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">be </font><font style="font-family:inherit;font-size:11pt;color:#131313;">recl</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ass</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ified</font><font style="font-family:inherit;font-size:11pt;color:#363638;">, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">combined </font><font style="font-family:inherit;font-size:11pt;color:#131313;">and </font><font style="font-family:inherit;font-size:11pt;color:#363638;">c</font><font style="font-family:inherit;font-size:11pt;color:#131313;">hanged into one </font><font style="font-family:inherit;font-size:10pt;color:#242426;">fully </font><font style="font-family:inherit;font-size:11pt;color:#131313;">paid </font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">nd n</font><font style="font-family:inherit;font-size:11pt;color:#363638;">o</font><font style="font-family:inherit;font-size:11pt;color:#131313;">na</font><font style="font-family:inherit;font-size:11pt;color:#363638;">sses</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">s</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ab</font><font style="font-family:inherit;font-size:11pt;color:#131313;">l</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#242426;">share </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of new </font><font style="font-family:inherit;font-size:11pt;color:#242426;">common stock (the </font><font style="font-family:inherit;font-size:11pt;color:#131313;">"N</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ew </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Common Stock"). Th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">er</font><font style="font-family:inherit;font-size:11pt;color:#131313;">e shall be no </font><font style="font-family:inherit;font-size:11pt;color:#242426;">fractional </font><font style="font-family:inherit;font-size:11pt;color:#494b52;">s</font><font style="font-family:inherit;font-size:11pt;color:#242426;">hares </font><font style="font-family:inherit;font-size:11pt;color:#131313;">i</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ssue</font><font style="font-family:inherit;font-size:11pt;color:#131313;">d </font><font style="font-family:inherit;font-size:11pt;color:#242426;">with respect </font><font style="font-family:inherit;font-size:11pt;color:#131313;">to th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#242426;">New Common Stock</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">. </font><font style="font-family:inherit;font-size:11pt;color:#131313;">I</font><font style="font-family:inherit;font-size:11pt;color:#363638;">n </font><font style="font-family:inherit;font-size:11pt;color:#131313;">li</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">u </font><font style="font-family:inherit;font-size:11pt;color:#242426;">thereof, </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#242426;">aggregate of </font><font style="font-family:inherit;font-size:11pt;color:#363638;">all frac</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tion</font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">l </font><font style="font-family:inherit;font-size:11pt;color:#363638;">shares o</font><font style="font-family:inherit;font-size:11pt;color:#131313;">th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">erw</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">i</font><font style="font-family:inherit;font-size:11pt;color:#363638;">se </font><font style="font-family:inherit;font-size:11pt;color:#131313;">i</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ssua</font><font style="font-family:inherit;font-size:11pt;color:#131313;">b</font><font style="font-family:inherit;font-size:11pt;color:#363638;">le </font><font style="font-family:inherit;font-size:11pt;color:#131313;">to the holder</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">reco</font><font style="font-family:inherit;font-size:11pt;color:#363638;">rd </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Old </font><font style="font-family:inherit;font-size:11pt;color:#363638;">C</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ommon Stock </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">hall b</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#242426;">issued </font><font style="font-family:inherit;font-size:11pt;color:#131313;">to </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Computershare (the </font><font style="font-family:inherit;font-size:11pt;color:#494b52;">"</font><font style="font-family:inherit;font-size:11pt;color:#131313;">Trans</font><font style="font-family:inherit;font-size:11pt;color:#363638;">fer </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Agent")</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">as </font><font style="font-family:inherit;font-size:11pt;color:#131313;">ag</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">nt</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">, </font><font style="font-family:inherit;font-size:11pt;color:#131313;">for th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#242426;">accounts </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">all </font><font style="font-family:inherit;font-size:11pt;color:#131313;">holder</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">record of Old </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Common </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Stoc</font><font style="font-family:inherit;font-size:11pt;color:#363638;">k ot</font><font style="font-family:inherit;font-size:11pt;color:#131313;">herwis</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ntitled t</font><font style="font-family:inherit;font-size:11pt;color:#363638;">o </font><font style="font-family:inherit;font-size:11pt;color:#131313;">have </font><font style="font-family:inherit;font-size:11pt;color:#363638;">a </font><font style="font-family:inherit;font-size:11pt;color:#131313;">fra</font><font style="font-family:inherit;font-size:11pt;color:#363638;">c</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tion of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">a </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">har</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#131313;">i</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ss</font><font style="font-family:inherit;font-size:11pt;color:#131313;">u</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">d to th</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">m</font><font style="font-family:inherit;font-size:11pt;color:#363638;">. </font><font style="font-family:inherit;font-size:11pt;color:#242426;">The </font><font style="font-family:inherit;font-size:11pt;color:#363638;">sa</font><font style="font-family:inherit;font-size:11pt;color:#131313;">le </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">all </font><font style="font-family:inherit;font-size:11pt;color:#242426;">fractional interests </font><font style="font-family:inherit;font-size:11pt;color:#363638;">will </font><font style="font-family:inherit;font-size:11pt;color:#242426;">be effected </font><font style="font-family:inherit;font-size:11pt;color:#363638;">by </font><font style="font-family:inherit;font-size:11pt;color:#242426;">the </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Transfe</font><font style="font-family:inherit;font-size:11pt;color:#363638;">r </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Agent </font><font style="font-family:inherit;font-size:11pt;color:#363638;">as </font><font style="font-family:inherit;font-size:11pt;color:#131313;">soon </font><font style="font-family:inherit;font-size:11pt;color:#242426;">as </font><font style="font-family:inherit;font-size:11pt;color:#131313;">practicable</font><font style="font-family:inherit;font-size:11pt;color:#363638;">&#32;af</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ter the </font><font style="font-family:inherit;font-size:11pt;color:#363638;">E</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ffecti</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ve </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Tim</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e on </font><font style="font-family:inherit;font-size:11pt;color:#131313;">t</font><font style="font-family:inherit;font-size:11pt;color:#363638;">he </font><font style="font-family:inherit;font-size:11pt;color:#131313;">ba</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">is </font><font style="font-family:inherit;font-size:11pt;color:#363638;">of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">prevai </font><font style="font-family:inherit;font-size:11pt;color:#494b52;">l</font><font style="font-family:inherit;font-size:11pt;color:#131313;">in</font><font style="font-family:inherit;font-size:11pt;color:#363638;">g </font><font style="font-family:inherit;font-size:11pt;color:#131313;">mark</font><font style="font-family:inherit;font-size:11pt;color:#363638;">et </font><font style="font-family:inherit;font-size:11pt;color:#131313;">prices </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of the </font><font style="font-family:inherit;font-size:11pt;color:#131313;">New Common St</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ock </font><font style="font-family:inherit;font-size:11pt;color:#242426;">at </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#242426;">time </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">sale</font><font style="font-family:inherit;font-size:11pt;color:#010101;">. </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Aft</font><font style="font-family:inherit;font-size:11pt;color:#363638;">er </font><font style="font-family:inherit;font-size:11pt;color:#131313;">su</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ch sale </font><font style="font-family:inherit;font-size:11pt;color:#242426;">and upon </font><font style="font-family:inherit;font-size:11pt;color:#363638;">the su</font><font style="font-family:inherit;font-size:11pt;color:#131313;">rrender of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">the </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">tockhold</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">rs' </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">to</font><font style="font-family:inherit;font-size:11pt;color:#363638;">c</font><font style="font-family:inherit;font-size:11pt;color:#131313;">k </font><font style="font-family:inherit;font-size:11pt;color:#242426;">certificates</font><font style="font-family:inherit;font-size:11pt;color:#606060;">, </font><font style="font-family:inherit;font-size:11pt;color:#131313;">th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Tran</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">f</font><font style="font-family:inherit;font-size:11pt;color:#363638;">er </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Ag</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">nt </font><font style="font-family:inherit;font-size:11pt;color:#363638;">w</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ill p</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ay </font><font style="font-family:inherit;font-size:11pt;color:#242426;">to </font><font style="font-family:inherit;font-size:11pt;color:#363638;">such </font><font style="font-family:inherit;font-size:11pt;color:#131313;">ho</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">l</font><font style="font-family:inherit;font-size:11pt;color:#131313;">d</font><font style="font-family:inherit;font-size:11pt;color:#363638;">er</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">s </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of record </font><font style="font-family:inherit;font-size:11pt;color:#131313;">th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ir </font><font style="font-family:inherit;font-size:11pt;color:#242426;">pro </font><font style="font-family:inherit;font-size:11pt;color:#131313;">rata </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">hare </font><font style="font-family:inherit;font-size:11pt;color:#242426;">of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#242426;">net </font><font style="font-family:inherit;font-size:11pt;color:#131313;">proceeds deriv</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">d from the </font><font style="font-family:inherit;font-size:11pt;color:#242426;">sale </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#131313;">fract</font><font style="font-family:inherit;font-size:11pt;color:#363638;">io</font><font style="font-family:inherit;font-size:11pt;color:#131313;">n</font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">l intere</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">t</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">. Fro</font><font style="font-family:inherit;font-size:11pt;color:#363638;">m </font><font style="font-family:inherit;font-size:11pt;color:#131313;">and af</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">t</font><font style="font-family:inherit;font-size:11pt;color:#131313;">e</font><font style="font-family:inherit;font-size:11pt;color:#363638;">r </font><font style="font-family:inherit;font-size:11pt;color:#131313;">th</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e E</font><font style="font-family:inherit;font-size:11pt;color:#131313;">ffectiv</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Tim</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">certificates </font><font style="font-family:inherit;font-size:11pt;color:#131313;">repr</font><font style="font-family:inherit;font-size:11pt;color:#363638;">ese</font><font style="font-family:inherit;font-size:11pt;color:#131313;">nting the </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Old </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Common Sto</font><font style="font-family:inherit;font-size:11pt;color:#363638;">c</font><font style="font-family:inherit;font-size:11pt;color:#131313;">k </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">hall </font><font style="font-family:inherit;font-size:11pt;color:#242426;">represent </font><font style="font-family:inherit;font-size:11pt;color:#131313;">the </font><font style="font-family:inherit;font-size:11pt;color:#242426;">number of whole </font><font style="font-family:inherit;font-size:11pt;color:#494b52;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">hare</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">New </font><font style="font-family:inherit;font-size:11pt;color:#363638;">C</font><font style="font-family:inherit;font-size:11pt;color:#131313;">omm</font><font style="font-family:inherit;font-size:11pt;color:#363638;">o</font><font style="font-family:inherit;font-size:11pt;color:#131313;">n Sto</font><font style="font-family:inherit;font-size:11pt;color:#363638;">c</font><font style="font-family:inherit;font-size:11pt;color:#131313;">k </font><font style="font-family:inherit;font-size:11pt;color:#242426;">into </font><font style="font-family:inherit;font-size:11pt;color:#363638;">w</font><font style="font-family:inherit;font-size:11pt;color:#131313;">hich </font><font style="font-family:inherit;font-size:11pt;color:#242426;">such </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Old </font><font style="font-family:inherit;font-size:11pt;color:#363638;">Co</font><font style="font-family:inherit;font-size:11pt;color:#131313;">mmon </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Stoc</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">k </font><font style="font-family:inherit;font-size:11pt;color:#363638;">sh</font><font style="font-family:inherit;font-size:11pt;color:#131313;">all </font><font style="font-family:inherit;font-size:11pt;color:#363638;">have </font><font style="font-family:inherit;font-size:11pt;color:#242426;">been </font><font style="font-family:inherit;font-size:11pt;color:#131313;">reclassified, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">combined </font><font style="font-family:inherit;font-size:11pt;color:#363638;">a</font><font style="font-family:inherit;font-size:11pt;color:#131313;">nd changed pur</font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">uant to this </font><font style="font-family:inherit;font-size:11pt;color:#242426;">Certificate of </font><font style="font-family:inherit;font-size:11pt;color:#131313;">Am</font><font style="font-family:inherit;font-size:11pt;color:#363638;">en</font><font style="font-family:inherit;font-size:11pt;color:#131313;">dm</font><font style="font-family:inherit;font-size:11pt;color:#363638;">en</font><font style="font-family:inherit;font-size:11pt;color:#131313;">t</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">, </font><font style="font-family:inherit;font-size:11pt;color:#242426;">subject </font><font style="font-family:inherit;font-size:11pt;color:#131313;">to t</font><font style="font-family:inherit;font-size:11pt;color:#363638;">he </font><font style="font-family:inherit;font-size:11pt;color:#242426;">elimination </font><font style="font-family:inherit;font-size:11pt;color:#131313;">of </font><font style="font-family:inherit;font-size:11pt;color:#242426;">fractional </font><font style="font-family:inherit;font-size:11pt;color:#363638;">s</font><font style="font-family:inherit;font-size:11pt;color:#131313;">hare </font><font style="font-family:inherit;font-size:11pt;color:#242426;">interests as </font><font style="font-family:inherit;font-size:11pt;color:#131313;">describ</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#131313;">d abov</font><font style="font-family:inherit;font-size:11pt;color:#363638;">e</font><font style="font-family:inherit;font-size:11pt;color:#494b52;">.</font><font style="font-family:inherit;font-size:11pt;color:#242426;">"</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-weight:bold;">SECOND: </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">T</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">h</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">t pursu</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">nt to resolution of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">its </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">Board </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">Director</font><font style="font-family:inherit;font-size:10pt;color:#424242;">s, </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">at </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">s</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">pecial meeting of the </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">stockholders </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">of </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">sa</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">id corp</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">ora</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">tion </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">duly called </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">nd held </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">upon </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">notic</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">in accordance with Section 222 </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">th</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">e Gener</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">al </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">Co</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">rpo</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">r</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">ation </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Law </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">of </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">State of Delaware at </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">w</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">hi</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">ch mee</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">tin</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">g the </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">n</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">ec</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">es</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">sary </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">number </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">shares as </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">requi</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">re</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">d by </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">statute were voted </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">in </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">favor of </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">th</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">e ame</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">ndm</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">ent.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-weight:bold;">THIRD: </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">Th</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">t </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">sai</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">d </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">amendment wa</font><font style="font-family:inherit;font-size:10pt;color:#424242;">s </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">duly adopted </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">in </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">accor</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">dance </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">wit</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">h the </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">provisions </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">of Sec</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">tion </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">242 </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">Ge</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">ne</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">ra</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">l </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">Co</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">rp</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">orat</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">i</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">on </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Law of the State </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-weight:bold;">IN WIT</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;font-weight:bold;">N</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;font-weight:bold;">ESS WHEREOF</font><font style="font-family:inherit;font-size:10pt;color:#424242;font-weight:bold;">, </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">sa</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">id </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">co</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">rporation h</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">as </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">cau</font><font style="font-family:inherit;font-size:10pt;color:#424242;">se</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">d thi</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">s </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">c</font><font style="font-family:inherit;font-size:10pt;color:#424242;">e</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">rt</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">ificate </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">to b</font><font style="font-family:inherit;font-size:10pt;color:#424242;">e </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">s</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">i</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">gned </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">t</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">h</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">i</font><font style="font-family:inherit;font-size:10pt;color:#424242;">s </font><font style="font-family:inherit;font-size:11pt;color:#0e0e0e;">1st</font><font style="font-family:inherit;font-size:11pt;color:#424242;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">d</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">ay of </font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">Nov</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">em</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">ber </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;padding-left:317px;text-indent:-70px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">B</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">y: </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;text-decoration:underline;">/S/ Thomas J. Knapp</font></div><div style="line-height:174%;text-align:left;padding-left:317px;text-indent:-70px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">Authorized </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">Officer</font></div><div style="line-height:120%;padding-top:3px;text-align:center;padding-left:241px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">Title: </font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Co</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;text-decoration:underline;">rporat</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;text-decoration:underline;">e Secre</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;text-decoration:underline;">t</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;text-decoration:underline;">ary</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#0e0e0e;">Nam</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;">e: </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;text-decoration:underline;">Thomas</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;text-decoration:underline;">J.</font><font style="font-family:inherit;font-size:10pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;text-decoration:underline;">Knapp</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>gale-20161231xex34.htm
<DESCRIPTION>EXHIBIT 3.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s916E0CDB0C18F21498DDB9E3361CCE65"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:right;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;font-weight:bold;">Exhibit 3</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;font-weight:bold;">.3</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">AMENDED AND RESTATED BY-LAWS, AS AMENDED</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#161616;">OF</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#161616;">(a Delaware Corporation)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12.5pt;"><font style="font-family:inherit;font-size:12.5pt;"><br></font></div><div style="line-height:265%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">REFLECTING AMENDMENTS THROUGH MAY 10, 2016</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">w</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s391D9668C601DE125E94B9E336737B07"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:265%;padding-top:2px;text-align:center;padding-left:6px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:265%;padding-top:2px;text-align:center;padding-left:6px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:131%;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">AMENDED AND RESTATED BY-LAWS</font></div><div style="line-height:111%;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:111%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#161616;">OF</font></div><div style="line-height:265%;padding-top:2px;text-align:center;padding-left:6px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">GALENA BIOPHARMA, INC. (FORMERLY RXI PHARMACEUTICALS CORPORATION) </font></div><div style="line-height:265%;padding-top:2px;text-align:center;padding-left:6px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:265%;padding-top:2px;text-align:center;padding-left:6px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;font-weight:bold;">ARTICLE   I  &#8211; OFFICES</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s087D3A4DC57115D30565B9E336926BCE"></a></div><div style="line-height:132%;padding-top:1px;text-align:left;padding-left:62px;text-indent:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#161616;">1.1 </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Registered Offices</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. The registered office of [amended August 6, </font><font style="font-family:Arial;font-size:9.5pt;color:#161616;">2013) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Galena Biopharma, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Inc. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(formerly RXi </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Pharmaceuticals </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation) (the "Corporation") </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in the State of Delaware </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be located </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">at Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Trust Center</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">1209 Orange </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Street, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Wilmington </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">County, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">New </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Castle</font><font style="font-family:inherit;font-size:9.5pt;color:#575757;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Delaware 1980I. The name of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Corporation's registered </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">agent at </font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">uch address </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be The </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Trust Company. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">registered </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">office and/or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">registered </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">agent </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">changed from time to time by action </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the Board of Directors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:62px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">1.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Other Offices</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Corporation may </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">also </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">have </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">offices </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">other places both </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">within and without </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">State </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of Delaware as the Board of Directors may </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">time to time determine </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the business of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may require.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:127%;text-align:left;padding-left:61px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Books</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">books of the Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">may </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be kept within or without of the State of Delaware as the Board of Directors may from time to time determine or the business </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of the Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may require.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:292px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;font-weight:bold;">ARTICLE 2 &#8211;STOCKHOLDERS</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Place of</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Meetings</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">. All </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of stockholders shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be held </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">at such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">place </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">within or without </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">State </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of Delaware as may be designated from time to time by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Board of Directors or the Chief </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Officer (or</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">if there is no </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Officer, the President) or, if not so designated, at the registered office of the Corporation</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Annual</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders for </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">election </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of directors and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">for </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the transaction of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">other business </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may properly be brought before the meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be held at such other date </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">time as </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be fixed by the Board of Directors, pursuant to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">resolution adopted by the affirmative </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of a majority of the total number of directors then in office, or the Chief Executive Officer </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(or</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">if there is no </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Officer, the President) and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stated </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in the notice of the meeting. If no annual meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">is </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">held in accordance </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the foregoing provisions, the Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">cause the meeting to be held </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">soon </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">thereafter </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">convenient. If no annual meeting is held in accordance </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the foregoing provisions, a </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">special </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting may be held in lieu of the annual meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">action taken at that </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">special </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting shall have the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">same </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">effect as if it had been taken </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting, and in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">case al l </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">references </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in these By-Laws to the annual meeting of stockholders shall be deemed to refer to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">special meeting.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:131%;text-align:left;padding-left:60px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Special Meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. Special meetings of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may be called at any time by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">only the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Chairman of the Board of Di rectors, if there is one, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Officer </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(or</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">if there is no </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Officer</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the President) or by the Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">pursuant to a resolution adopted by the affirmative vote of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">majority of the total</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">number </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">directors then </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">in office. </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Any business transacted at any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">special </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be limited to matters relating to the purpose or purposes </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stated </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in the notice of meeting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Notice of Meetings</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Except </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">as otherwise provided by law</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">written notice of each </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">whether annual </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or special, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">shall be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">given </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">not less than ten (10) nor more than </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">sixty (</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">60) days before the date of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to each </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder entitled </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting. The </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">notices of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">all meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall state the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">place</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">date and hour of the meeting. The notice </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of a special </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting shall </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">state</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in addition, the purpose or purposes for </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">which </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the meeting is called. If mailed</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice is </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">given when </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">deposited in the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">United </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">States mail, postage prepaid, directed to the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">his </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">her address </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">it appears on the records of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation. </font><font style="font-family:Arial;font-size:9.5pt;color:#161616;">If </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice is </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">given </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by electronic transmission</font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">, s</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">uch notice will be deemed </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">given at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the time </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">specified </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in Section </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">232 </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the General </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Law of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12.5pt;"><font style="font-family:inherit;font-size:12.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:58px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s571B72C70F050AB74031B9E336C2D974"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:132%;padding-top:5px;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Voting</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;text-decoration:underline;">List</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The officer who </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">has </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">charge </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the stock </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">ledger </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation shall </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">prepare</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">least ten (10) days </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">before every </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of stockholders, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">complete </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">list of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders entitled </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote at </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the meeting, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">arranged </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">in alphabetical order</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and showing </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the address of each </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder and </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the number of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shares </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">registered </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the name of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">each stockholder. Such </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">list </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">be open to the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">examination of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">for any purpose </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">germane to </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the meeting, during ordinary business hours, for a period of at least </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ten </font><font style="font-family:Arial;font-size:9pt;color:#151515;">(I</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">0) days prior to the meeting, at a place </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">within </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">city where </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the meeting is </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to be </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">held. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">list </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">also </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">produced and kept at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">time and place of the meeting during the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">whole time of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the meeting, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">may </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">inspected by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any stockholder who is </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">present.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;text-decoration:underline;">Quorum</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Except as </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">otherwise provided by law, the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Certificate of Incorporation </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">these </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">By-Laws, the holders </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">a majority </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shares </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">capital stock </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">issued and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">outstanding and entitled </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote at </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the meeting, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">present </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">in person or represented by proxy</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">shall constitute </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">quorum </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">for </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the transaction of business</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">.  </font><font style="font-family:Arial;font-size:9pt;color:#151515;">A </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">quorum, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">once established at a meeting, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall not </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">be broken by the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">withdrawal of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">enough </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">votes </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to leave less than a quorum.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9pt;color:#151515;">2.7 </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;text-decoration:underline;">Adjournments</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Any meeting of stockholders may </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">adjourned </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">other time </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any other </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">place </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">which a meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">may be held under these By-Laws by a majority </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">present or represented </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the meeting and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">entitled </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote, although </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">less than a quorum, or, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">if </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">no </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">is present, by any officer </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">entitled </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to preside at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">act as Secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of such meeting. </font><font style="font-family:Arial;font-size:9.5pt;color:#151515;">It </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">not be necessary to notify any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any adjournment </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of less than thirty</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(30) </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">days if the time </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">place </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the adjourned meeting are </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">announced </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">at the meeting at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">which adjournment </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">is taken, unless after the adjournment a new record date is fixed for the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">adjourned meeting. At </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the adjourned meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">may transact </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">business, which</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">might have been transacted </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the original meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:133%;text-align:left;padding-left:60px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#151515;">2.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Voting and</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;text-decoration:underline;">Proxies</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Except </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">as otherwise provided by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the General Corporation Law of the </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">State </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of Delaware, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Certificate of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">Incorporation or these By-Laws, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">each stockholder shall </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">have one </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote for each share of capital stock </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">entitled to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">and held of record by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such stockholder</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">To </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the extent permitted by Jaw, each </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of record entitled to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote at a </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">may </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote in </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">person </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(including </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">by means </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">remote communications, if any</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">which stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">may be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">deemed </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">present in person </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and vote </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">meeting in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">accordance with </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">General Corporation Law </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of Delaware) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or may authorize </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">another person or persons to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote or act for him or her by </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">which </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy may be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">authorized in writing, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">by telephone or by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">electronic </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">means by the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder or </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">his or her </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">authorized agent. No such </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall be voted </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">or acted upon </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">after three years from </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the date </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">its </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">execution, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">unless the proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">expressly </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">provides for a longer period.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#151515;">2.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;text-decoration:underline;">Proxy Representation</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Every stockholder may </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">authorize </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">another </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">person or persons to act for him or her by proxy in all matters in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">which a stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">is </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">entitled </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to participate, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">whether </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">by waiving notice </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">any meeting, objecting to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">voting or participating at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">meeting, or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">expressing consent </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">or dissent without a meeting. The </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">delivery </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">of a proxy on behalf of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a stockholder consistent </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">with telephonic </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">electronically transmitted instructions </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">obtained pursuant </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">to procedures of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">reasonably designed to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">verify that such </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">instructions have been authorized by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such stockholder shall constitute execution and </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">delivery of the proxy by or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">on </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">behalf </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder. No </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">voted </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">or acted upon </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">after </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">three</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">years </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">its </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">date unless </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy provides </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">for </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">a longer period. A duly </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">executed </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shal</font><font style="font-family:Arial;font-size:9.5pt;color:#151515;">1</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">be irrevocable if it </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">states </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">that it </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">is </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">irrevocable and, if, and only as long </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">as, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">it is coupled </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">with an interest sufficient </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">in law to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">support </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">an irrevocable power.</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">A proxy may be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">made </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">irrevocable regardless of whether the interest with </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">which </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">it is </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">coupled </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">is an interest in the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stock </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">itself </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or an </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">interest </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation generally. </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">The authorization of a proxy may, but need not, be limited to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">specified </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">action, provided, however, that if </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy limits its authorization to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">meeting or meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of stockholders, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">unless otherwise </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">specifically </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">provided </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall entitle </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the holder thereof to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote at any adjourned session </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">but </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">not be valid after </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">final adjournment thereof </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">A </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">proxy purporting to be authorized by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">on behalf of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a stockholder, </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">if </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">accepted </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">by the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">in its discretion, shall be deemed </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">valid </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">unless challenged at or prior to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">its exercise, and </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the burden of proving invalidity </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">rest </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">on </font><font style="font-family:inherit;font-size:9.5pt;color:#151515;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">challenger.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:289px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#262626;">2</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:58px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sE87D426819DA11C33F13B9E336E90290"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:131%;padding-top:5px;text-align:justify;padding-left:62px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#151515;">2.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Action at Meetin</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">g. When a quorum is present at any meeting, a plurality of the votes properly cast for election to any office </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">elect to such office and a majority of the votes properly cast upon any question other than an election to an office shall decide the question</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">except </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">when a larger vote is required by law, by the Certificate of Incorporation or by these</font></div><div style="line-height:131%;text-align:left;padding-left:62px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">By-laws. </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">No </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">ballot </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be required for any election unless requested by </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">a stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">present or represented at the meeting and entitled to vote in the election.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:133%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#151515;">2.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Nomination of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. Except for any directors </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">elected </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">in accordance with Section 3</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">.6 </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to fill a vacancy or newly&#173; </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">created </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">directorships, only persons who are nominated in accordance with the following procedures </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be eligible for election as directors. The nomination for election to the Board of Directors of the Corporation at a meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">may be made by the Board of Directors or by any stockholder of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">entitled </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">vote </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">for the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">election </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of directors </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">at such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">who </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">complies with the notice procedures </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">set </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">forth in this Section 2.11. Such nominations, other than those made by or on behalf of the Board of Directors, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be made by notice in </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">writing </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">delivered or mailed by first class United </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">States </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">mail, postage prepaid</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Secretary</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and received at the principal executive offices </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the Corporation not less than </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">sixty </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">(60) days nor more than ninety (90) days prior to the anniversary date of the immediately preceding annual meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholders; </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">provided,</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">however, that if the annual meeting is not held within thirty (30) days before or after </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">anniversary </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">date</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">then </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">nomination </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">have been delivered to or mailed and received by the Secretary not later than the close of business on the 10th day following the date on which the notice of the meeting was mailed or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">public disclosure </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">was </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">made</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">whichever </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">occurs first. Such notice </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall set </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">forth</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">(a) as to each proposed nominee </font><font style="font-family:Arial;font-size:9pt;color:#181818;">(i) </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the name, age, business </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">address </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and, if known, residence address of each </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">nominee,</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">(ii) </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">principal </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">occupation or employment of each such nominee, (iii) the number of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shares </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stock </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Corporation which </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">are beneficially owned by each </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">nominee, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">(iv) any other information </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">concerning </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the nominee that must be </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">disclosed </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as to nominees in proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">solicitations </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">pursuant to Regulation 14A under the Securities Exchange Act of 1934</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as amended, including </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">person's written consent to be named as </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">nominee and to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">serve </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as a director if elected; </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">(b) </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">giving the notice (i) the name and address, as they appear on the Corporation's books</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">(ii) </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the class and number of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shares </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Corporation which are beneficially owned by </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">(iii) a </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">description </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">arrangements or understandings between </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and each proposed nominee and any other person or persons (including their names) pursuant to which the nomination(s) </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">are </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to be made by </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such stockholder, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">(iv) a representation that </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">tockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">intends </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to appear in person or by proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">at the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">meeting to nominate the person(s) named in its notice and (v) a representation whether the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">intends or is part of a group which </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">intends (a) </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to deliver a proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">statement </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and/or form of proxy to holders of at least the percentage of the corporation's outstanding capital stock required to elect the nominee and/or (b) otherwise to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">solicit </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">proxies from stockholders in support of such nomination; and</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">(c) </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as to the beneficial owner</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">if </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">any</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">on whose behalf the nomination is being made (i) such beneficial owner 's name and address</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">(ii) </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the class and number of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shares </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stock </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the corporation which </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">are </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">beneficially owned by such beneficial owner, (iii) a description of all arrangements or understandings between </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">beneficial owner and </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">each </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">proposed nominee and any other person or persons (including their names) pursuant to which the nomination(s) are to be made and (iv) a representation </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">whether </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the beneficial owner intends or is part of a group which intends (a) to deliver a proxy statement</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">/</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">or form of proxy to holders of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">least the percentage of the corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#595959;">'</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">outstanding capital </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stock </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">requirement to elect </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">nominee and/or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">(b) </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">otherwise to solicit proxies from </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">in support of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">nomination. </font><font style="font-family:Arial;font-size:9pt;color:#181818;">In </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">addition, to be </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">effective, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholder's </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">notice must be accompanied by the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">written consent </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the proposed nominee to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">serve </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as a director if elected. The Corporation may require any proposed nominee to furnish such other information as may reasonably be required by the Corporation to determine the eligibility of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">proposed nominee to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">serve </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as a director of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:1px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">The chairman of the meeting may, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the foregoing procedure</font><font style="font-family:inherit;font-size:9.5pt;color:#494949;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and if he or she </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">should so </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">determine, he or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">she shall so </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">declare to the meeting and the defective nomination </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be disregarded.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:289px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#181818;">3</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:60px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="s809BDC913FACED04515FB9E33719D5EF"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:132%;padding-top:5px;text-align:left;padding-left:64px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#151515;">2.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Notice of</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Business</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">at</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Annual</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Meetings</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">At </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">an </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">annual meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">only </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">conducted as shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">have been properly brought before </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">To be </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">properly brought before </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">an annual meeting, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business must be (a) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">specified </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in the notice </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting (or any supplement thereto) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">given </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by or at the direction of the Board of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Directors, (b) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">otherwise properly brought before the meeting by or at the direction of the Board of Directors, or</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(c) otherwise </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">properly brought before </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">an </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">annual meeting by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a stockholder. For </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business to be properly brought before an annual meeting by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a stockholder, if </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">such business relates to the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">election of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">directors of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the procedures in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Section 2.11 </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">must be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">complied with. </font><font style="font-family:Arial;font-size:9.5pt;color:#161616;">If </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business relates to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">other matter, the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">must have given </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">timely notice</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">thereof </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">writing </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Secretary. </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">To be timely, a </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder's </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice must be delivered to or mailed and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">received at</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">&#32;the principal </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">executive </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">offices of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">not less than </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">sixty (60) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">days nor more than ninety (90) days prior to the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">anniversary </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">date of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">immediately preceding annual meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders; </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">provided,</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">however, that </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">if the annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting is not held </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">within </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">thirty (30) days before </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or after such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">anniversary date, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">then for </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the notice </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">by the stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">timely it </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">must be so </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">received not later than the close of business on the 10th day </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">following </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the date </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">on which </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">notice of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">was </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">mailed or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">public disclosure </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">was </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">made, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">whichever </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">occurs first. A </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder 's </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice to the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Secretary shall set </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">forth as </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">each matter the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">proposes to bring before </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">annual meeting (a) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">brief </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">description </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the business desired to be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">brought </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">before the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the reasons </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">for conducting such business at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the annual meeting, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(b) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the name </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and address, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">as they appear on the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation's </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">books, of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">proposing </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(c) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the class and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">number </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shares of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation which </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">are beneficially owned by the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">(d) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">description </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">arrangements</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or understandings  between </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">beneficial </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">owner</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">if </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">other person or persons </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(including </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">their names) in connection </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the proposal of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business by such stockholder and any material interest of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">beneficial owner, if </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">(e) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">representation that </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">intends </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to appear </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in person or by proxy at the annual meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">bring </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business before the meeting, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(f) a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">representation </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">whether </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the stockholder or the beneficial owner, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">if </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">any</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">intends </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or is </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">part </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of a group which intends (i) to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">deliver a </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">proxy statement </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and/or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">form of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">proxy to holders of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">at least </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the percentage of the corporation's outstanding capital </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stock </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">required to approve or adopt the proposal </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and/or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">(ii) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">otherwise </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">solicit </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">proxies from stockholders in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">support </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">proposal, and (g) </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">material interest of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Notwithstanding anything </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in these By-Laws </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the contrary</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">no business </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be conducted at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any annual meeting except </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">accordance with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the procedures </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">set forth </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">this Section 2.12, except </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">that </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">proposal which </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">complies with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Rule 14a-8 of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">rules</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">successor </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">provision, promulgated under </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Securities Exchange Act </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of 1934, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">as amended, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and is to be included in the Corporation's proxy </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">statement for an annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of stockholders shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be deemed </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">comply with the requirements of this </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Section 2</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">.</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">12.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">The chairman of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">if the facts </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">warrant</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">determine and declare to the meeting that business </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">was not </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">properly brought before the meeting in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">accordance </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">with the provisions </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">this Section </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2.12</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(including </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">whether the stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">beneficial owner, if </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">on </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">whose </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">behalf the proposal is made </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">solicited (or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">is part of a </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">group which solicited) or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">did not </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">so solicit, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">as the case may be, proxies in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">support </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">stockholder's proposal in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">compliance with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">representation </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">respect thereto required by this Section </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2.12), </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and if he or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">she should so </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">determine, the chairman shall </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">so </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">declare to the meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and any such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">not </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">properly brought before the meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">not be transacted.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:131%;text-align:left;padding-left:60px;text-indent:16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Notwithstanding </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the foregoing provisions of this Section 2.12, if the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">(or a qualified representative </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">does not </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">appear </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to present business, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">business </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">not be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">transacted, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notwithstanding that proxies in respect </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">vote may have been received by the corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:77px;"><font style="font-family:inherit;font-size:9.5pt;color:#151515;">2.13</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:9.5pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Action without Meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. Stockholders may not take </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">action </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">by written consent </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in lieu of a meeting.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#151515;">2.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Organization</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. The </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Chairman </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the Board, if there is one, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in his or her absence the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">President shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">call meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">order, and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">act as chairman of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting; </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">however, that the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Directors may appoint any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to act </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">chairman </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting in the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">absence </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Chairman of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the Board. The </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">shall act as </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at all meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of the stockholders; </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">, however</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">that </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in the absence of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at any meeting of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">acting chairman </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may appoint </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">person </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">act </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">as secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the meeting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:289px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#161616;">4</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:58px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="sE149504CD07AEEE401F2B9E337372709"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:131%;padding-top:5px;text-align:left;padding-left:62px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#151515;">2.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Conduct</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">of</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Meetings</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Board </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Directors of the corporation may </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">adopt </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by resolution </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">rules, regulations </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">procedures for the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">conduct </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of any meeting of stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the corporation as it </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">deem appropriate including</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">without</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">limitation</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such guidelines </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and procedures as it may deem appropriate regarding the participation by means </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">remote </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">communication </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and proxyholders not physically present at a meeting. Except to the extent inconsistent </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">with such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">rules, regulations and procedures as adopted by the Board of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the chairman </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">have the right </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and authority </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to prescribe </font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">uch rules, regulations and procedures </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">do </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">all such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">acts as, in the judgment </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">chairman</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">are appropriate </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">for the proper conduct </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">rules</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">regulations or procedures, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">whether </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">adopted by the Board of Directors or prescribed b</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">chairman </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the meeting, may </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">include</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">without </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">limitation, the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">following</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">: </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">(i) the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">establi</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">hment of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">an agenda </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or order of business </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">for </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">; </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">(ii) rules and procedures for maintaining </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">order at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">safety </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of those present</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">; </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(iii) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">limitations on </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">attendance at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or participation in the meeting to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of record of the corporation, their duly authorized and constituted proxie</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">other persons as </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be determined; </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">(iv) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">restrictions on </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">entry to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">after </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the tim</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">fixed for the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">commencement </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">thereof; </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and (v) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">limitations </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">on </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the time </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">allotted </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to questions or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">comments </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by participants. Unless and to the extent determined by the Board of Directors or the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">chairman of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the meeting, meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of stockholders shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">not be required to be held in accordance </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the rules of parliamentary procedure.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;font-weight:bold;">ARTICLE </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">3 </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#161616;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;font-weight:bold;">DIRECTORS</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">General Powers</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">The business and affairs of the Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be managed by or under the direction </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Board of Directors, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">who </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may exercise all of the powers </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation except </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">as otherwise provided by law, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Certificate of Incorporation or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">these </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">By-Laws. In the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">event of a vacancy </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Director</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the remaining directors</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">except </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">as otherwise provided by law</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">exercise the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">powers of the full Board of Directors until the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vacancy </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">is filled.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Number;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Election and</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Qualification</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. The number of directors which </font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">hall constitute the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">whole </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Board </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">determined </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by resolution </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Directors, but in no event shall </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">less than three</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">directors shall be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">elected at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such stockholders as </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">have </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">right to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">vote </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">on </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such election. The </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">directors need not </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">be stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#161616;">3.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Classes</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. The Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">is divided into three classes: </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Class </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">I, Class II </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Class III. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">No </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">one </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">class shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">have more than </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">one </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">director more than any other class. </font><font style="font-family:Arial;font-size:9.5pt;color:#161616;">If </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">a fraction is </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">contained </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in the quotient arrived at by dividing the designated number of directors by three, then, if </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">fraction is one-third, the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">extra </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">director </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be a member of Class </font><font style="font-family:Arial;font-size:9.5pt;color:#161616;">III, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and if </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such fraction </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">is two-thirds, one of the extra directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be a member of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Class </font><font style="font-family:Arial;font-size:9.5pt;color:#161616;">III </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">one of the extra directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">member of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Class </font><font style="font-family:Arial;font-size:9pt;color:#161616;">II, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">unless </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">otherwise </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">provided from time to time by resolution adopted by the</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Board of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:131%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#161616;">3.4 </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Terms</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">of</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Office</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Except </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">as otherwise provided in the Certificate </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Incorporation or these By-Laws, each director </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall serve </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">for a term ending on the date of the third </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">annual meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">following the annual meeting at which </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">director </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">was </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">elected; </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">however, that </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">each </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">initial director in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Class </font><font style="font-family:Arial;font-size:9.5pt;color:#161616;">I </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall serve </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">for a term </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ending on </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the date of the annual meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">2008; </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">each initial director in Class II </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall serve </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">for a term </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ending </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">on the date </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the annual meeting of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in 2009; and each initial director in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Class </font><font style="font-family:Arial;font-size:9pt;color:#161616;">III </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall serve for </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">a term ending on the date of the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting of stockholders in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">201</font><font style="font-family:inherit;font-size:10pt;color:#161616;">O; </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">provided,</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">further, that the term </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of each </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">director </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">subject </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to the election </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">qualification </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">his or her </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">successor </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and to his or her earlier death, resignation or removal.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12.5pt;"><font style="font-family:inherit;font-size:12.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#161616;">5</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:90px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="s5B3208AD6C9959D939B2B9E3376FB877"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:132%;padding-top:5px;text-align:left;padding-left:61px;text-indent:8px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Allocation of Directors Among Clas</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;text-decoration:underline;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">es</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">in</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">the</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">Event of Increases</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">or Decreases in the</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">Number</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. In the event of any </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">increase </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or decrease </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">authorized </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">number of directors, (i) </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">each </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">director then </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">serving as such shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">nevertheles</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">continue </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">a director of the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">class of which </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">he or </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">she </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">is a member and (ii) the newly created or eliminated directorships resulting </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">from such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">increase or decrease </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be apportioned by the Board of Directors among the three </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">classes </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of directors </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">so </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">as to </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">ensure </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">that no </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">on</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">class has more </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">than </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">one director more than </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">other class. </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">To </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">extent </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">possible, consistent </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the foregoing rule, any newly created directorships </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">added </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to those classes </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">whose </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">terms of </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">office </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">are to </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">expire </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at the latest dates following such </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">allocation</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and any newly </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">eliminated </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">directorships </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">subtracted </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">from those </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">classes whose terms of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">offices are to </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">expire </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">earliest </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">dates following </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">allocation, unless otherwise provided </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">time to time by resolution adopted </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">by </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the Board of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Vacancies</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. Any </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">vacancy </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">in the Board of Directors, however occurring, including a </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">vacancy </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">resulting </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">from an enlargement </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the Board of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be filled </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">only </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">vote of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">a majority </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the directors then in </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">office, although less </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">than a quorum, or by a </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">sole </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">remaining director and </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">not be filled by </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">stockholders. A director elected to fill </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">vacancy shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">elected for </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the unexpired term of his or her predecessor in office</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">and a director </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">chosen to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">fill </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">position resulting from an increase in the number of directors </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">hold office until the next </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">election </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the class </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">for </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">which </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">director </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">have been </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">chosen, subject </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to the election and qualification of his or her successor and to his or her </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">earlier </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">death</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">resignation </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">removal.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Resignation</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Any director may </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">resign </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by delivering his </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">her </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">written </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">resignation to the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at its principal office or to the President or Secretary. Such resignation </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be effective upon receipt unless it </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">is specified </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to be effective </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">ome other </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">time or upon </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">happening </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">of some </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">other </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">event.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Regular Meetings</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. The regular meetings of the Board of Directors may be held without notice at </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">time and place</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">either within or </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">without </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the State </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Delaware, as </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be determined from time to time by the Board of Directors; provided, that any director </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">who </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">is absent </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">when such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">a determination is made </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">given </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice of the determination. </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">A </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">regular meeting of the Board of Director</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">may be held </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">without </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice immediately </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">after and </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">at the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">same </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">place as the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">annual </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">of stockholders</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:13px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">Special</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Meetings</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. Special meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the Board of Directors may be held at any time and place, </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">within </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">without </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the State of Delaware</font><font style="font-family:inherit;font-size:9.5pt;color:#545454;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">designated in a call by the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">Chairman </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the Board of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">if there </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">is </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">one, the </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Officer </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">(or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">if there </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">is </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">no </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Officer</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the President), two or more directors </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by one director in the event </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">that </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">there is only a </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">single </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">director </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">office.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:60px;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">Notice</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">of</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">Special</font><font style="font-family:inherit;font-size:9.5pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Meetings</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">Notice </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of any </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">special </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting of the Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">given to </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">each director by the Secretary or by the officer or one of the directors calling the meeting. The notice shall be duly given to each director</font></div><div style="line-height:106%;padding-left:58px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:9.5pt;color:#161616;padding-right:16px;">(i)</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">giving </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice to </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">director in person or by telephone </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">least </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">twenty </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">four (24) hours </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">in advance </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the meeting,</font></div><div style="line-height:133%;padding-left:58px;padding-top:1px;text-align:left;text-indent:0px;"><font style="padding-top:1px;text-align:left;font-family:inherit;font-size:9.5pt;color:#161616;padding-right:16px;">(ii)</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">sending </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">a telegram, telecopy</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">facsimile or electronic </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">email, or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">delivering </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">written </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice by hand</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">to his or her last known business, home or </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">electronic </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">mail </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">address at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">least twenty four </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">(24) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">hours in advance of the meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#424242;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">or (iii) by mailing </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">written </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">notice to his or her last known business or home address </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">least </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">seventy </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">two </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">(72) </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">hours in </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">advance </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the meeting. A notice </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">waiver of notice of a </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">special </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting of the Board of Directors need not </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">specify </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the purposes </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">the meeting.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:58px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;text-decoration:underline;">Meetings by Telephone Conference Calls</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">. The Board of Directors or any members of any </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">committee </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">of the Board of </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">designated by the directors may participate in a meeting of the Board of Directors or </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">such committee </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by means of conference telephone or </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">similar </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">communications </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">equipment </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">by means of which all persons participating in the meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">can </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">hear </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">each other. </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">Participation by </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">means </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">constitute presence in person at </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">meeting.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#161616;">6</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:57px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="sBB7F7E97140E2440C469B9E337998C66"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:131%;padding-top:5px;text-align:left;padding-left:62px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Quorum</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. A majority of the total number of the whole Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">constitute a quorum at al l meetings of the Board of Directors. </font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">In the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">event </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">one or more of the directors </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be disqualified to vote at any meeting, then the</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">required quorum shall be reduced by one for each </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">director so disqualified; </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">however, that in no case shall less than one-third (1</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">/</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">3) of the number of directors so fixed constitute a quorum. In</font><font style="font-family:Arial;font-size:9.5pt;color:#181818;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the absence of a quorum at any </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">meeting, a majority of the directors present may adjourn the meeting from time to time without further notice</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">other than announcement at the meeting, until a quorum shall be present.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:131%;text-align:left;padding-left:62px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Action at Meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. At any meeting of the Board of Directors at which a quorum is present, the vote of a majority of tho</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">se </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">present </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be sufficient to take any action, unless a different vote is specified by law</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the Certificate of Incorporation or these By-Laws.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:62px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Action by Consent</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee of the Board of Directors may be taken without a meeting, if all members of the Board or committee, as the case may be</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">consent </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to the action in </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">writing </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">or by electronic transmission</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">written </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">consents or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">electronic </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">transmis</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">ions are filed </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the minutes of proceedings of the Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">committee of the Board of Directors, a</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Removal</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">directors of the Corporation may not be removed without </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">cause </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and may be remo</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">ve</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">d for cause only b</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the affirmative vote </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the holders of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">seventy-five </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">percent (75%) of the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shares </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the capital </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stock </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the Corporation issued and outstanding and entitled to</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">vote generally in the election of directors cast at a meeting of the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholders </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">called for that purpose</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Committees</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Board of Directors may</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">by resolution passed by a majority of the whol</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Board, designate one or more committees</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">each committee to consist of one or more of the directors of the Corporation</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">The Board of Directors may designate one or more directors as alternate members of any </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">committee, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">who may replace </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">absent or disqualified member </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">at any </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">meeting of the committee. In the absence or disqualification of a member of a committee</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the member or members of the committee present at </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">and not </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">di</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">qualified from </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">voting, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">whether or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">not </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">he</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">he </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">they </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">constitute a </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">quorum, may unanimou</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">ly appoint another member </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Directors to act at the meeting in the place of any </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">absent or disqualified member. Any </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such committee, to </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the extent provided in the resolution of the Board of Directors and </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">subject </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to the provisions of the General Corporation Law of the State of Delaware, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">authorize </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">seal </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the Corporation to be affixed to all papers which may require it. Each </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">committee </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">keep minutes and make </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">reports as the Board of Directors may from time to time request. </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Except </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as the Board of Directors may otherwise</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the directors or in such rules, its business </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be conducted as nearly as possible in the same manner as is provided in these By-Law </font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">for the Board of Directors.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#282828;">3.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;text-decoration:underline;">Compensation</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">of Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">The directors may be paid </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">compensation for their </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">services and such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">reimbursement for expense</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of attendance at </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as the Board of Directors may from time to time determine </font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">.</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">No such payment </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">preclude any director from </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">serving </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the Corporation or any of its parent or </font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">ubsidiary corporations in any other capacity and receiving </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">compensation </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">for </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such service.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;font-weight:bold;">ARTICLE 4 &#8211;OFFICERS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:131%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Enumeration</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">The officers of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">consist of a </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Chief </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Executive Officer</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">a President</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">a Treasurer. </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">The Board of Directors may appoint other officers with </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">titles and powers, as it may deem appropriate, including, without limitation, a Chief Financial Officer, one or more Vice Presidents and one </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">more Controllers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Election</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. The Chief </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Officer, President, Secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Treasurer </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">elected </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">annually by the Board of Directors at its first meeting following the annual meeting of stockholders. Other officers may be appointed by the Board of Directors at </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">meeting or at any other meeting</font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#181818;">7</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:60px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="s8C8E7AAEDEF6E94E9EBAB9E337EBCA40"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:134%;padding-top:5px;text-align:left;padding-left:62px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">Qualification</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">No officer </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">need be </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">a stockholder of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Corporation. Any two or more offices may be </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">held </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">by the same </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">person</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">Tenure</font><font style="font-family:inherit;font-size:9.5pt;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Except as </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">otherwise provided by law</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">by the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Certificate of Incorporation or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">b</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">these By-Laws, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">each officer </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">hold </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">office </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">until his </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">her </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">successor </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">is </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">elected </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">and qualified</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">unless a different term </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">is specified in </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">vote choosing or appointing </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">him or </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">her, or until his or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">her earlier death, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">resignation or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">removal.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">Resignation</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">and</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">Removal</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Any officer may resign </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">by delivering his </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">her </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">written </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">resignation to the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Corporation at its </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">principal </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">office or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">to the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chief Executive Officer </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Secretary. Such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">resignation </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">effective </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">upon receipt unless it is </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">specified </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">to be </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">effective at </font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">so</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">me </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">other time or upon </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">happening of some other event. Any officer may </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">removed at any </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">time</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">with or without cause, by vote of a </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">majority </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">entire </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">number of directors </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">then in office</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:133%;text-align:left;padding-left:61px;text-indent:16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Except as the Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">may otherwise determine, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">no officer who </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">resigns </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or is removed shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">have </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">right to </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">any compensation as an officer for any period following </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">his </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">her </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">resignation or removal, or any right </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">damages </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">on account </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">removal</font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">whether </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">his of her compensation be by the month </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">by the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">year or otherwise, unless such compensation </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">is </font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">ex</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">pressl</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">provided in a </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">duly </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">authorized written agreement with </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Corporation.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:133%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">Vacancies</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">. The </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Board </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Directors may fill </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">any vacancy occurring in any office for </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">any reason </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">and may, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">its discretion, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">leave unfilled </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">for such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">period </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">as it may </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">determine any </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">offices other </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">than those of </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chief Executive Officer, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">President, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Treasurer. Each such successor shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">hold office </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">for </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">unexpired term of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">hi</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">her predecessor </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">until his </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">her </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">successor is elected and </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">qualified</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">until </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">his or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">her </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">earlier </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">death</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">resignation or removal.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">Chairman</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">of the</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">. The Board </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">of Directors may appoint </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">a Chairman </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Board. </font><font style="font-family:Arial;font-size:9.5pt;color:#111111;">If </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Board of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">appoints </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chairman of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Board, he or she shall perform such duties and </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">possess </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">powers </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">as are </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">ssigne</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">d </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">him </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">her </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">by the Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">and as </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">are consistent with </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">customary duties of the chairman of a corporation organized under laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:133%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">Chief Executive</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">Officer</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">. The </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chief Executive Officer shall, subject </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">to the direction </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Directors, have </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">general charge and supervision </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">business of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Corporation. Unless </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">otherwise </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">provided </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">by the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">he or she shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">preside </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">at all </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">meetings </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">stockholders and, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">if he </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or she </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">is a director, </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">at all meetings of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Directors. The </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chief Executive Officer shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">perform </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">such other duties </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">and pos</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">sess </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">such other powers </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">the Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">may from time </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">time </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">prescribe.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">President</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">The President shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">perform </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">duties </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">possess </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">powers as the Board of Directors or the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Officer may </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">from time to time prescribe. </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">In the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">event </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">absence, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">inability or refusal to act of </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Chief </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Officer, the President </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">perform the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">duties of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Officer and </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">when </font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">so </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">performing </font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">hall have </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the powers </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of and </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">subject </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the restrictions upon </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">the office of Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Officer.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:133%;text-align:left;padding-left:60px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;text-decoration:underline;">Chief Financial Officer</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chief Financial Officer shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">perform </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">duties </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">possess </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">powers as the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Board of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Director </font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Officer </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">may </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">from time to time prescribe. </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">The Chief Financial Officer shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">have the custody </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">corporate funds and securities; shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">keep </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">full </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">and accurate all books </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">and accounts of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">shall be </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">neces</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">ary </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">desirable in </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">accordance with applicable </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">law </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">generall</font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">accepted </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">accounting principle </font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">s; </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">deposit </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">monies </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">and other valuable effects </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">the name and to </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">credit </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">the Corporation as </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">may </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">be ordered </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">by the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Chairman of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Board </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">or the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Board of Directors; </font><font style="font-family:inherit;font-size:9.5pt;color:#3a3a3a;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">hall </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">cause </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">funds </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">the Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">to be disbursed </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">when such </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">disbursements have</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">been duly </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">authorized, taking proper vouchers </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">for such disbursements; </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">and shall render to the </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Board </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">of Directors, at its regular meeting or when the </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">Board of </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Directors so requires, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">an </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">account </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#111111;">8</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:58px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="s06B31FE14837CF6B9934B9E338649C83"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;padding-top:5px;text-align:left;padding-left:64px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Vice Pre</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">si</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">dent</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">An</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Vice Pre</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">si</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">en</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">sha</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ll perform </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">duti</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">es and </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">possess </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">u</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">c</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">powers as </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">he </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Bo</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ard of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">D</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ire</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">c</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">tors, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">C</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hief Executiv</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Officer </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">o</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Presid</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">nt ma</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">time </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tim</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">pr</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">esc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rib</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">The Board </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">m</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ay ass</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">gn </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">o a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">n</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Vi</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ce </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">President </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">title of </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Exec</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">utive Vice President, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Senior </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Vice President </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">or any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">other </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ti</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">tle.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:64px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">Controllers</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Any </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Controller </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">sh</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">perform such </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">duti</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">es </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">p</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ossess s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uch </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">powers </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Board of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Di</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">rectors, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Chief Execu</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ti</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ve </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Offi</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">cer </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">or any Vice </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Pre</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">side</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">nt </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">may </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">from time </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ti</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">m</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">pre</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">sc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rib</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:133%;text-align:left;padding-left:64px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">3 </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">Secretary</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e Secre</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ta</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ry </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">perform </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uch dutie</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and po</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ssess s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uch power</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s as the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Bo</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rd </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Director</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e C</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hie</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">f </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Officer ma</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">time to </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">time prescribe. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">In addition</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e S</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ecr</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tary </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">p</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rform </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">su</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">c</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">h </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">duties and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ave such </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">p</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">owers </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">as are </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">incident to th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">office </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of the Secretary</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">including without limitation </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">duty </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and power to </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">give </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">notices of </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">meetings of </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">stoc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">kholders and </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">p</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ec</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">l meetings of the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Directors, to </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">attend all </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">meetings of </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ockhol</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ers </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Bo</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rd </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of</font></div><div style="line-height:132%;text-align:left;padding-left:64px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">and ke</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ep a </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">record of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the proc</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ee</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">din</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">gs, t</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">o maintain </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ock </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">led</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ger </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">prepar</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e lists of stockhol</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">de</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">rs </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and their addresses as </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">requ</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ed, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">to be </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">custo</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">dian </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">corpora</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">records and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e cor</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">p</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">orate seal </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and to </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">affix and attes</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">to the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">same </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">on </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ocume</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">nts</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:62px;text-indent:17px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">In th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">event of the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">abse</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">n</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ce, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">inability </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">or refusa</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">l </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">act of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Secretary at any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">mee</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ting </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">stockholde</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s o</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r di</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">recto</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s, the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">person </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">presiding </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">m</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">eet</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ing </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">designat</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e a </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">temporary </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">se</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">cret</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ary </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to keep </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">record </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the meeting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;text-align:left;padding-left:62px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Treasur</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">The Treasurer shall perform </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">u</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">c</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h duties and </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">possess </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uch power</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">as the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Board </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of Director</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">C</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hi</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ef </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Offic</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">er may </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tim</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to time </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">prescribe. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">In </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">addition, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Treasurer </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hall </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">perform </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">such dut</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">es a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">nd </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">have </font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">uch</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">powers </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">are incident to the office </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Treasurer</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">including without limitation the duty </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">and power to keep and be </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">respons</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">ble </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">fo</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">funds </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">sec</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uriti</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">es </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of the Corporation, to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">po</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">it fund</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Co</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rporati</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">on </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">in depo</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">si</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">torie</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">s se</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">lected in </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">accordance with</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">&#32;th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ese </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">B</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">-Law</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">o </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">di</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">sb</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ur</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">se s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uch fund</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s as </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">ordered </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Dir</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ectors, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">m</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ake p</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">o</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">p</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">er ac</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">coun</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ts </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">suc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">funds</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">o </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rend</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r as </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">required </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Board of Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">sta</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tements of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">suc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h tr</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ansa</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ction</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">financia</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">l </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">condition </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the Corporat</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">ion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:62px;text-indent:17px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#262626;">In </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the event of the absence, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">inability </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">efusa</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">l to </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">act </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">of the Tr</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">easurer, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of Dir</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">ec</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">tors </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hall </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ppoint </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">te</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">mporary treasurer, </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">w</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ho </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">all </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">p</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">form </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">duties and </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">exe</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rci</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">se </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the power</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Treasure</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:62px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Other</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">Officers</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;text-decoration:underline;">,</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">Assistant</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">Offi</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">cers an</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">d</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">Agents</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Offi</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">cers, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">assistant </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">officers and age</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">n</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">ts, </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">f </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">any</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">other than those </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">whose </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">duties are provided for </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ese </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">B</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">-la</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ws, s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hall h</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ave suc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h authori</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ty a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">nd p</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rform </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">u</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">c</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h du</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ties as </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">ma</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tim</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e to t</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ime b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">prescribed </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">by re</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">solu</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tion </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Board of Dir</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ec</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tor</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:62px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">4.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">Sa</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">lari</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">es</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">. Officers of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">enti</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">tl</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">ed </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uch </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">sa</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">laries</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">compensation </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">o</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">reimbursement </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">as s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ll </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">be fixed </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">o</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r allo</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">we</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tim</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e to </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">time </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">by th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">B</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">oard of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Directors.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#262626;font-weight:bold;">ARTICLE 5 - CAPITAL STOCK</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#363636;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;text-decoration:underline;">I</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">ss</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">uanc</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">of</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">Stoc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;text-decoration:underline;">k</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Un</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">l</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">ess o</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">erwise </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">vote</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tockhold</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ers a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">nd </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">su</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">bj</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ect </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">to the pr</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ov</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ons of t</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Certificate of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">In</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">co</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rporation, th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">whole </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">or any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">part of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uni</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ss</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">u</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d balance of </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uthorized </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">capital </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">stoc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">k </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">he </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">the who</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">l</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">e or any </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">part </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">any uni</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ss</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">u</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d balance of the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">authorized </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">capital </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">stock of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Corporation h</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">el</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d i</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">n </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">i</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">ts </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">easury </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">may b</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">is</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">sued</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">so</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ld</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">transferred </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">otherwise </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">di</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">posed of by </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">vote </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Board of Dir</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ec</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">tor</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">uch mann</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">er, for </font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">uch consideration </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">and on such te</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rms </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">as </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Directors </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ma</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">de</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">te</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rmin</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#363636;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">Certificates of</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;text-decoration:underline;">Stock</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">. Every </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">holder </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">toc</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">k </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hall b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">nti</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">tled </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">o </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ave </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">certifica</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">suc</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">form as </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">m</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">ay </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">prescribed b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">la</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">w </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Board </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Directors</font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">certifyin</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">g </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">number </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">c</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">l</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">ass </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of sha</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">es </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">owned </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">him </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">her </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">in th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Corporation. Each </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">u</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">c</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">certificate </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hall </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">be </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ign</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">d b</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">y, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">th</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">e name </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Co</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">rp</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">oration </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">by</font><font style="font-family:inherit;font-size:9.5pt;color:#6e6e6e;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">h</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e C</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">hairman </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Boa</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">r</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">d of </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Directors, </font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Chief Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Officer or th</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">Pre</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">id</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">e</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">nt, </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">the Tre</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">as</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">urer or the Sec</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">retary of </font><font style="font-family:inherit;font-size:9.5pt;color:#5d5d5d;">t</font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">he </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">Co</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">rporation. </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">Any or </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">a</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ll </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">ignatures on the </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">cert</font><font style="font-family:inherit;font-size:9.5pt;color:#111111;">ificate </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">may be </font><font style="font-family:inherit;font-size:9.5pt;color:#363636;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">fac</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">s</font><font style="font-family:inherit;font-size:9.5pt;color:#262626;">imile.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">9</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:61px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="s7AC96C59247F89E35183B9E338F6DF04"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:139%;padding-top:5px;text-align:left;padding-left:61px;text-indent:18px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#232323;">Each certificate </font><font style="font-family:inherit;font-size:9pt;color:#131313;">for </font><font style="font-family:inherit;font-size:9pt;color:#232323;">shares </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stock </font><font style="font-family:inherit;font-size:9pt;color:#131313;">that are </font><font style="font-family:inherit;font-size:9pt;color:#232323;">subject </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to </font><font style="font-family:inherit;font-size:9pt;color:#232323;">any </font><font style="font-family:inherit;font-size:9pt;color:#131313;">restriction on transfer pursuant </font><font style="font-family:inherit;font-size:9pt;color:#232323;">to </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Certificate of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">Incorporation, the By</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">-Laws, </font><font style="font-family:inherit;font-size:9pt;color:#232323;">applicable securities </font><font style="font-family:inherit;font-size:9pt;color:#131313;">Jaws </font><font style="font-family:inherit;font-size:9pt;color:#232323;">or any agreement </font><font style="font-family:inherit;font-size:9pt;color:#131313;">among any number of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stockholders </font><font style="font-family:inherit;font-size:9pt;color:#131313;">or </font><font style="font-family:inherit;font-size:9pt;color:#232323;">among such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">holders </font><font style="font-family:inherit;font-size:9pt;color:#232323;">and the Corporation shall </font><font style="font-family:inherit;font-size:9pt;color:#131313;">have </font><font style="font-family:inherit;font-size:9pt;color:#232323;">conspicuously </font><font style="font-family:inherit;font-size:9pt;color:#131313;">noted </font><font style="font-family:inherit;font-size:9pt;color:#232323;">on </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the face </font><font style="font-family:inherit;font-size:9pt;color:#232323;">or </font><font style="font-family:inherit;font-size:9pt;color:#131313;">back of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">the </font><font style="font-family:inherit;font-size:9pt;color:#131313;">certificate </font><font style="font-family:inherit;font-size:9pt;color:#232323;">either </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the full text of the restriction </font><font style="font-family:inherit;font-size:9pt;color:#232323;">or </font><font style="font-family:inherit;font-size:9pt;color:#131313;">a </font><font style="font-family:inherit;font-size:9pt;color:#232323;">statement </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">existence </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">restriction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:140%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#363636;">5.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#232323;text-decoration:underline;">Transfers</font><font style="font-family:inherit;font-size:9pt;color:#232323;">. Except as </font><font style="font-family:inherit;font-size:9pt;color:#131313;">otherwise established by rules </font><font style="font-family:inherit;font-size:9pt;color:#232323;">and </font><font style="font-family:inherit;font-size:9pt;color:#131313;">regulations adopted </font><font style="font-family:inherit;font-size:9pt;color:#232323;">by </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the Board </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">Directors, and </font><font style="font-family:inherit;font-size:9pt;color:#232323;">subject </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to </font><font style="font-family:inherit;font-size:9pt;color:#232323;">applicable law, shares </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stock </font><font style="font-family:inherit;font-size:9pt;color:#131313;">may be transferred on </font><font style="font-family:inherit;font-size:9pt;color:#232323;">the books </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation </font><font style="font-family:inherit;font-size:9pt;color:#131313;">by the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">surrender </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation or </font><font style="font-family:inherit;font-size:9pt;color:#131313;">its transfer </font><font style="font-family:inherit;font-size:9pt;color:#232323;">agent </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of the certificate representing </font><font style="font-family:inherit;font-size:9pt;color:#232323;">such shares </font><font style="font-family:inherit;font-size:9pt;color:#131313;">properly </font><font style="font-family:inherit;font-size:9pt;color:#232323;">endorsed or </font><font style="font-family:inherit;font-size:9pt;color:#131313;">accompanied by a written assignment or power of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">attorney </font><font style="font-family:inherit;font-size:9pt;color:#131313;">properly </font><font style="font-family:inherit;font-size:9pt;color:#232323;">executed, and </font><font style="font-family:inherit;font-size:9pt;color:#131313;">with </font><font style="font-family:inherit;font-size:9pt;color:#232323;">such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">proof </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">authority or the authenticity of signature </font><font style="font-family:inherit;font-size:9pt;color:#232323;">as </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation </font><font style="font-family:inherit;font-size:9pt;color:#131313;">or </font><font style="font-family:inherit;font-size:9pt;color:#232323;">its </font><font style="font-family:inherit;font-size:9pt;color:#131313;">transfer </font><font style="font-family:inherit;font-size:9pt;color:#232323;">agent </font><font style="font-family:inherit;font-size:9pt;color:#131313;">may </font><font style="font-family:inherit;font-size:9pt;color:#232323;">reasonably require. Except </font><font style="font-family:inherit;font-size:9pt;color:#131313;">as may be </font><font style="font-family:inherit;font-size:9pt;color:#232323;">otherwise </font><font style="font-family:inherit;font-size:9pt;color:#131313;">required by law, by the Certificate </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of Incorporation </font><font style="font-family:inherit;font-size:9pt;color:#131313;">or by these By-Laws</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation shall </font><font style="font-family:inherit;font-size:9pt;color:#131313;">be entitled to treat </font><font style="font-family:inherit;font-size:9pt;color:#232323;">the record </font><font style="font-family:inherit;font-size:9pt;color:#131313;">holder </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of stock </font><font style="font-family:inherit;font-size:9pt;color:#131313;">as </font><font style="font-family:inherit;font-size:9pt;color:#232323;">shown on </font><font style="font-family:inherit;font-size:9pt;color:#131313;">its books </font><font style="font-family:inherit;font-size:9pt;color:#232323;">as the owner of such stock for all </font><font style="font-family:inherit;font-size:9pt;color:#131313;">purposes</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">including the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">payment </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of dividends and the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">right to vote with </font><font style="font-family:inherit;font-size:9pt;color:#131313;">respect </font><font style="font-family:inherit;font-size:9pt;color:#232323;">to such stock, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">regardless </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of any transfer, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">pledge </font><font style="font-family:inherit;font-size:9pt;color:#232323;">or other </font><font style="font-family:inherit;font-size:9pt;color:#131313;">disposition </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of such stock, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">until </font><font style="font-family:inherit;font-size:9pt;color:#232323;">the shares </font><font style="font-family:inherit;font-size:9pt;color:#131313;">have been transferred </font><font style="font-family:inherit;font-size:9pt;color:#232323;">on </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the books </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation </font><font style="font-family:inherit;font-size:9pt;color:#131313;">in </font><font style="font-family:inherit;font-size:9pt;color:#232323;">accordance with the </font><font style="font-family:inherit;font-size:9pt;color:#131313;">requirements  of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">these By-Laws.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:139%;text-align:left;padding-left:61px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#363636;">5.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">Lost,</font><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9pt;color:#232323;text-decoration:underline;">Stolen or</font><font style="font-family:inherit;font-size:9pt;color:#232323;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">Destroyed</font><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9pt;color:#232323;text-decoration:underline;">Certificates</font><font style="font-family:inherit;font-size:9pt;color:#232323;">. </font><font style="font-family:inherit;font-size:9pt;color:#131313;">The </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation </font><font style="font-family:inherit;font-size:9pt;color:#131313;">may </font><font style="font-family:inherit;font-size:9pt;color:#232323;">issue a </font><font style="font-family:inherit;font-size:9pt;color:#131313;">new </font><font style="font-family:inherit;font-size:9pt;color:#232323;">certificate </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stock </font><font style="font-family:inherit;font-size:9pt;color:#131313;">in place </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of any previously issued certificate </font><font style="font-family:inherit;font-size:9pt;color:#131313;">alleged to have been lost, </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stolen, or </font><font style="font-family:inherit;font-size:9pt;color:#131313;">destroyed</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:9pt;color:#232323;">upon such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">terms and </font><font style="font-family:inherit;font-size:9pt;color:#232323;">conditions as </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the Board of Director</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">s </font><font style="font-family:inherit;font-size:9pt;color:#131313;">may prescribe</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:9pt;color:#232323;">including </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the presentation of reasonable </font><font style="font-family:inherit;font-size:9pt;color:#232323;">evidence </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">loss, </font><font style="font-family:inherit;font-size:9pt;color:#232323;">theft or </font><font style="font-family:inherit;font-size:9pt;color:#131313;">destruction </font><font style="font-family:inherit;font-size:9pt;color:#232323;">and </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">giving </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">indemnity as the Board </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of Directors may </font><font style="font-family:inherit;font-size:9pt;color:#131313;">require </font><font style="font-family:inherit;font-size:9pt;color:#232323;">for </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the protection </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation or any </font><font style="font-family:inherit;font-size:9pt;color:#131313;">transfer agent or registrar.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:140%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#232323;">5.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#232323;text-decoration:underline;">Record</font><font style="font-family:inherit;font-size:9pt;color:#232323;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">Date</font><font style="font-family:inherit;font-size:9pt;color:#131313;">. </font><font style="font-family:inherit;font-size:9pt;color:#232323;">The </font><font style="font-family:inherit;font-size:9pt;color:#131313;">Board </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">Directors may fix </font><font style="font-family:inherit;font-size:9pt;color:#232323;">in </font><font style="font-family:inherit;font-size:9pt;color:#131313;">advance </font><font style="font-family:inherit;font-size:9pt;color:#232323;">a </font><font style="font-family:inherit;font-size:9pt;color:#131313;">date </font><font style="font-family:inherit;font-size:9pt;color:#232323;">as </font><font style="font-family:inherit;font-size:9pt;color:#131313;">a </font><font style="font-family:inherit;font-size:9pt;color:#232323;">record </font><font style="font-family:inherit;font-size:9pt;color:#131313;">date for </font><font style="font-family:inherit;font-size:9pt;color:#232323;">the </font><font style="font-family:inherit;font-size:9pt;color:#131313;">determination of the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stockholders entitled </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to notice of or to vote </font><font style="font-family:inherit;font-size:9pt;color:#232323;">at any </font><font style="font-family:inherit;font-size:9pt;color:#131313;">meeting </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of stockholders, or entitled </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to receive payment of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">any dividend or other </font><font style="font-family:inherit;font-size:9pt;color:#131313;">distribution or </font><font style="font-family:inherit;font-size:9pt;color:#232323;">allotment of any rights in respect </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of any change</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:9pt;color:#232323;">conversion or exchange of stock, or for </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the purpose </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of any other </font><font style="font-family:inherit;font-size:9pt;color:#131313;">lawful </font><font style="font-family:inherit;font-size:9pt;color:#232323;">action. Such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">record date </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">s</font><font style="font-family:inherit;font-size:9pt;color:#131313;">hall not be </font><font style="font-family:inherit;font-size:9pt;color:#232323;">more </font><font style="font-family:inherit;font-size:9pt;color:#131313;">than </font><font style="font-family:inherit;font-size:9pt;color:#232323;">sixty (</font><font style="font-family:inherit;font-size:9pt;color:#131313;">60) </font><font style="font-family:inherit;font-size:9pt;color:#232323;">nor </font><font style="font-family:inherit;font-size:9pt;color:#131313;">less than ten </font><font style="font-family:inherit;font-size:9pt;color:#232323;">(I </font><font style="font-family:inherit;font-size:9pt;color:#131313;">0) days before the date of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">meeting, nor more than </font><font style="font-family:inherit;font-size:9pt;color:#232323;">sixty (60) days prior </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to </font><font style="font-family:inherit;font-size:9pt;color:#232323;">any </font><font style="font-family:inherit;font-size:9pt;color:#131313;">other </font><font style="font-family:inherit;font-size:9pt;color:#232323;">action </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to </font><font style="font-family:inherit;font-size:9pt;color:#232323;">which such record date </font><font style="font-family:inherit;font-size:9pt;color:#131313;">relates</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:139%;text-align:left;padding-left:60px;text-indent:17px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#131313;">If </font><font style="font-family:inherit;font-size:9pt;color:#131313;">no </font><font style="font-family:inherit;font-size:9pt;color:#232323;">record </font><font style="font-family:inherit;font-size:9pt;color:#131313;">date is </font><font style="font-family:inherit;font-size:9pt;color:#232323;">fixed, the record </font><font style="font-family:inherit;font-size:9pt;color:#131313;">date </font><font style="font-family:inherit;font-size:9pt;color:#232323;">for determining stockholders entitled to </font><font style="font-family:inherit;font-size:9pt;color:#131313;">notice </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of or to vote at a meeting of </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">s</font><font style="font-family:inherit;font-size:9pt;color:#131313;">tockholders </font><font style="font-family:inherit;font-size:9pt;color:#232323;">shall </font><font style="font-family:inherit;font-size:9pt;color:#131313;">be </font><font style="font-family:inherit;font-size:9pt;color:#232323;">at </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">close of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">busine</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">ss </font><font style="font-family:inherit;font-size:9pt;color:#232323;">on </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the da</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">y </font><font style="font-family:inherit;font-size:9pt;color:#232323;">before </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the day </font><font style="font-family:inherit;font-size:9pt;color:#232323;">on which </font><font style="font-family:inherit;font-size:9pt;color:#131313;">notice i</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">s </font><font style="font-family:inherit;font-size:9pt;color:#232323;">given, or, if notice </font><font style="font-family:inherit;font-size:9pt;color:#131313;">is </font><font style="font-family:inherit;font-size:9pt;color:#232323;">waived, at the close of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">business </font><font style="font-family:inherit;font-size:9pt;color:#232323;">on </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the day </font><font style="font-family:inherit;font-size:9pt;color:#232323;">before </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the day on </font><font style="font-family:inherit;font-size:9pt;color:#232323;">which the </font><font style="font-family:inherit;font-size:9pt;color:#131313;">meeting is held. </font><font style="font-family:inherit;font-size:9pt;color:#232323;">The </font><font style="font-family:inherit;font-size:9pt;color:#131313;">record date </font><font style="font-family:inherit;font-size:9pt;color:#232323;">for </font><font style="font-family:inherit;font-size:9pt;color:#131313;">determining </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stockholders </font><font style="font-family:inherit;font-size:9pt;color:#131313;">for </font><font style="font-family:inherit;font-size:9pt;color:#232323;">any </font><font style="font-family:inherit;font-size:9pt;color:#131313;">other purpose </font><font style="font-family:inherit;font-size:9pt;color:#232323;">shall </font><font style="font-family:inherit;font-size:9pt;color:#131313;">be </font><font style="font-family:inherit;font-size:9pt;color:#232323;">at the close of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">business on the day on </font><font style="font-family:inherit;font-size:9pt;color:#232323;">which </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the Board of Directors adopts the resolution relating to </font><font style="font-family:inherit;font-size:9pt;color:#232323;">such </font><font style="font-family:inherit;font-size:9pt;color:#131313;">purpose.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:141%;text-align:left;padding-left:60px;text-indent:16px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#232323;">A </font><font style="font-family:inherit;font-size:9pt;color:#131313;">determination </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of stockholders of record entitled </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to notice </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">or to </font><font style="font-family:inherit;font-size:9pt;color:#232323;">vote at a </font><font style="font-family:inherit;font-size:9pt;color:#131313;">meeting of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stockholders shall apply </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to any </font><font style="font-family:inherit;font-size:9pt;color:#232323;">adjournment </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">the </font><font style="font-family:inherit;font-size:9pt;color:#131313;">meeting; </font><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">however, that the Board of Directors may fix </font><font style="font-family:inherit;font-size:9pt;color:#232323;">a new </font><font style="font-family:inherit;font-size:9pt;color:#131313;">record date </font><font style="font-family:inherit;font-size:9pt;color:#232323;">for </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">adjourned </font><font style="font-family:inherit;font-size:9pt;color:#131313;">meeting.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:142%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#232323;">5.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">Dividends</font><font style="font-family:inherit;font-size:9pt;color:#131313;">. </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Subject </font><font style="font-family:inherit;font-size:9pt;color:#131313;">to limitations contained in the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">General Corporation Law </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of the State </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">Delaware</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">, </font><font style="font-family:inherit;font-size:9pt;color:#232323;">the Certificate </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of Incorporation </font><font style="font-family:inherit;font-size:9pt;color:#232323;">and </font><font style="font-family:inherit;font-size:9pt;color:#131313;">these By-Jaw </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">s, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the Board of Directors ma</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">y </font><font style="font-family:inherit;font-size:9pt;color:#131313;">declare and pay dividends upon the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">shares of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">capital </font><font style="font-family:inherit;font-size:9pt;color:#232323;">stock of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation, which </font><font style="font-family:inherit;font-size:9pt;color:#131313;">dividends may be paid </font><font style="font-family:inherit;font-size:9pt;color:#232323;">either </font><font style="font-family:inherit;font-size:9pt;color:#131313;">in </font><font style="font-family:inherit;font-size:9pt;color:#232323;">cash, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">in property or in </font><font style="font-family:inherit;font-size:9pt;color:#232323;">shares </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">capital stock </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#131313;font-weight:bold;">ARTICLE 6  - GENERAL PROVISIONS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;padding-left:17px;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#232323;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#232323;text-decoration:underline;">Fiscal Year</font><font style="font-family:inherit;font-size:9pt;color:#232323;">. Except as from time to </font><font style="font-family:inherit;font-size:9pt;color:#131313;">time </font><font style="font-family:inherit;font-size:9pt;color:#232323;">otherwise </font><font style="font-family:inherit;font-size:9pt;color:#131313;">designated by the Board </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">Director</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">s, </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">fiscal year </font><font style="font-family:inherit;font-size:9pt;color:#131313;">of the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Corporation shall begin on </font><font style="font-family:inherit;font-size:9pt;color:#131313;">the first day </font><font style="font-family:inherit;font-size:9pt;color:#232323;">of </font><font style="font-family:inherit;font-size:9pt;color:#131313;">January of </font><font style="font-family:inherit;font-size:9pt;color:#232323;">each year </font><font style="font-family:inherit;font-size:9pt;color:#131313;">and </font><font style="font-family:inherit;font-size:9pt;color:#232323;">end </font><font style="font-family:inherit;font-size:9pt;color:#131313;">on the last day of December in </font><font style="font-family:inherit;font-size:9pt;color:#232323;">each year</font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:77px;"><font style="font-family:inherit;font-size:9pt;color:#232323;">6.2</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:9pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">Corporate</font><font style="font-family:inherit;font-size:9pt;color:#131313;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9pt;color:#232323;text-decoration:underline;">Seal</font><font style="font-family:inherit;font-size:9pt;color:#232323;">. </font><font style="font-family:inherit;font-size:9pt;color:#131313;">The </font><font style="font-family:inherit;font-size:9pt;color:#232323;">corporate seal shall </font><font style="font-family:inherit;font-size:9pt;color:#131313;">be in </font><font style="font-family:inherit;font-size:9pt;color:#232323;">such form </font><font style="font-family:inherit;font-size:9pt;color:#131313;">as </font><font style="font-family:inherit;font-size:9pt;color:#232323;">shall </font><font style="font-family:inherit;font-size:9pt;color:#131313;">be </font><font style="font-family:inherit;font-size:9pt;color:#232323;">approved </font><font style="font-family:inherit;font-size:9pt;color:#131313;">by the </font><font style="font-family:inherit;font-size:9pt;color:#232323;">Board of Directors.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12.5pt;"><font style="font-family:inherit;font-size:12.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#131313;">10</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:60px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="sB65DEFE512AB04361BBCB9E3393C8E5F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:131%;padding-top:5px;text-align:left;padding-left:62px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#232323;">6.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Form of Notice</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. Whenever any notice whatsoever is required to be given in writing to any </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholder </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">by law, by the Certificate of Incorporation or by these By-laws, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">notice may be given by a form </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">electronic transmission if the stockholder to whom </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">notice is given has previously consented to the receipt of notice by </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">electronic </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">transmission.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:61px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">6.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Waiver of Notice</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. Whenever any notice whatsoever is required to be given by law, by the Certificate of Incorporation or by these By-Laws, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">a </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">waiver of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">notice either in writing </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">signed </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">by the person entitled to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">notice or such person's duly authorized attorney</font><font style="font-family:inherit;font-size:9.5pt;color:#444444;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">or by telegraph, cable or any other available method, whether before, at or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">after </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the time </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stated </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">waiver, or by the appearance of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">person at such meeting in person or by proxy, </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be deemed equivalent to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">notice. Any member of the Board of Directors or any committee thereof who is present at a meeting </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be conclusively presumed to have waived notice of such meeting except when such member attends for the express purpose of objecting at the beginning of the meeting to the transaction </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">any business because the meeting is not lawfully called </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">or </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">convened. Such member </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be conclusively presumed to have assented to any action taken unless his or her dissent </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be entered in the minutes of the meeting or unless his or her written dissent to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">action </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be filed with the person acting as the secretary </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the meeting before the adjournment thereof or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be forwarded by registered mail </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">to </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the Secretary of the Corporation immediately after the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">adjournment </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the meeting. </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">right to dissent </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">not apply to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">member </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">who voted </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">in favor </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">action.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">6.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Voting of Securities</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Except </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as the directors may otherwise designate, the Chief </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Executive </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Officer or Treasurer may </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">waive </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">notice of, and act as, or appoint any person or persons to act as, proxy or attorney-in-fact for this Corporation (with or without power of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">substitution) </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">at, any meeting of stockholders or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shareholders </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of any other corporation or organization, the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">securities </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of which may be held by this Corporation</font><font style="font-family:inherit;font-size:9.5pt;color:#444444;">.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:132%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">6.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;text-decoration:underline;">Evidence</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">of Authority</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. A certificate by the Secretary, or a temporary </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">secretary, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as to any action taken by the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholders, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">directors, a committee or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">officer or representative of the Corporation </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as to al l persons who rely on the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">certificate </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">in </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">good </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">faith, be conclusive evidence of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">such </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">action.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:131%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">6.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;text-decoration:underline;">Certificate of Incorporation</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">All references in these By-Laws to the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Certificate </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of Incorporation </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be deemed to </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">refer to </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Certificate </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of Incorporation of the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">Corporation, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">as amended or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">restated </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">and in </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">effect </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:134%;text-align:left;padding-left:60px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">6.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Transactions</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;text-decoration:underline;">with</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">Interested Parties</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">. No contract or transaction between the Corporation and one or more of </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">directors or officers, or between the Corporation and any other corporation, partnership, association, or other organization in which one or more of the directors or officers are directors or officers, or have a financial interest, shall be void or voidable </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">solely </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">for this reason, or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">solely </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">because the director or officer is present at or participates in </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">meeting of the Board of Directors or a committee of the Board of Directors which authorizes the contract or transaction or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">solely </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">because his</font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">her or their votes are counted for such purpose, if:</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:132%;padding-left:60px;text-align:left;text-indent:20px;"><font style="text-align:left;font-family:inherit;font-size:9.5pt;color:#181818;padding-right:18px;">(1)</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">to the </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Board of Directors or the committee, and the Board of Directors or </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">committee </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the Board of Directors in </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">good </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum;</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:132%;padding-left:60px;text-align:justify;text-indent:21px;"><font style="text-align:justify;font-family:inherit;font-size:9.5pt;color:#181818;padding-right:18px;">(2)</font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">The </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">contract </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">or transaction is </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">specifically approved in good </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">faith by vote of the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholders</font><font style="font-family:inherit;font-size:9.5pt;color:#444444;">; </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">or</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:134%;padding-left:60px;text-align:left;text-indent:18px;"><font style="text-align:left;font-family:inherit;font-size:9.5pt;color:#181818;padding-right:18px;">(3)</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board of Directors, a committee </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the Board of Directors, or the </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:131%;text-align:left;padding-left:60px;text-indent:18px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee, which </font><font style="font-family:inherit;font-size:9.5pt;color:#2b2b2b;">authorizes </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the contract or transaction.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#181818;">11</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:60px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><a name="sFCF55F967E0A36983664B9E339722436"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:134%;padding-top:5px;text-align:left;padding-left:65px;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#181818;">6.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#282828;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:9pt;color:#282828;">. Any determination that </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">any </font><font style="font-family:inherit;font-size:9pt;color:#282828;">provision of these By</font><font style="font-family:inherit;font-size:9pt;color:#5d5d5d;">-</font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">Laws </font><font style="font-family:inherit;font-size:9pt;color:#282828;">is </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">for </font><font style="font-family:inherit;font-size:9pt;color:#282828;">any reason </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">inapplicable, </font><font style="font-family:inherit;font-size:9pt;color:#282828;">illegal </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">or ineffective shall </font><font style="font-family:inherit;font-size:9pt;color:#282828;">not affect or invalidat</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e </font><font style="font-family:inherit;font-size:9pt;color:#282828;">any other provision </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">these By-Laws</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:136%;text-align:left;padding-left:64px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#181818;">6.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#282828;text-decoration:underline;">Pronoun</font><font style="font-family:inherit;font-size:9pt;color:#282828;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;text-decoration:underline;">s</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">. </font><font style="font-family:inherit;font-size:9pt;color:#282828;">All pronouns used </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">in </font><font style="font-family:inherit;font-size:9pt;color:#282828;">the</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">se </font><font style="font-family:inherit;font-size:9pt;color:#282828;">By-Laws </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">sha</font><font style="font-family:inherit;font-size:9pt;color:#0a0a0a;">ll </font><font style="font-family:inherit;font-size:9pt;color:#282828;">be deemed to refer to the ma</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s</font><font style="font-family:inherit;font-size:9pt;color:#282828;">culine</font><font style="font-family:inherit;font-size:9pt;color:#5d5d5d;">, </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">feminine </font><font style="font-family:inherit;font-size:9pt;color:#282828;">or neuter</font><font style="font-family:inherit;font-size:9pt;color:#5d5d5d;">, s</font><font style="font-family:inherit;font-size:9pt;color:#282828;">ingular </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">or </font><font style="font-family:inherit;font-size:9pt;color:#282828;">plural, as the </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">identity of the </font><font style="font-family:inherit;font-size:9pt;color:#282828;">person or </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">persons </font><font style="font-family:inherit;font-size:9pt;color:#282828;">ma</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">y </font><font style="font-family:inherit;font-size:9pt;color:#282828;">require.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:138%;text-align:left;padding-left:64px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#181818;">6.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#282828;text-decoration:underline;">Contracts</font><font style="font-family:inherit;font-size:9pt;color:#282828;">. In </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">addition </font><font style="font-family:inherit;font-size:9pt;color:#282828;">to the powers otherwise </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">granted </font><font style="font-family:inherit;font-size:9pt;color:#282828;">to </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">officers </font><font style="font-family:inherit;font-size:9pt;color:#282828;">pursuant to Article </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">4 </font><font style="font-family:inherit;font-size:9pt;color:#282828;">h</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e</font><font style="font-family:inherit;font-size:9pt;color:#282828;">reof, the Board </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">Directors may authorize </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">any </font><font style="font-family:inherit;font-size:9pt;color:#282828;">officer or officer</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s, </font><font style="font-family:inherit;font-size:9pt;color:#282828;">or any agent or </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">agents, of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">the Corporation to </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">enter </font><font style="font-family:inherit;font-size:9pt;color:#282828;">into </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">any </font><font style="font-family:inherit;font-size:9pt;color:#282828;">contract </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">or </font><font style="font-family:inherit;font-size:9pt;color:#282828;">to </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">execute </font><font style="font-family:inherit;font-size:9pt;color:#282828;">and deliver </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">any </font><font style="font-family:inherit;font-size:9pt;color:#282828;">instrument in the name of </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">and </font><font style="font-family:inherit;font-size:9pt;color:#282828;">on behalf of the </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">Corporation, </font><font style="font-family:inherit;font-size:9pt;color:#282828;">and </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">such authority </font><font style="font-family:inherit;font-size:9pt;color:#282828;">may be general </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">or confined </font><font style="font-family:inherit;font-size:9pt;color:#282828;">to specific instances.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:139%;text-align:left;padding-left:64px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#181818;">6.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#282828;text-decoration:underline;">Inspection of Books and Records</font><font style="font-family:inherit;font-size:9pt;color:#5d5d5d;">. </font><font style="font-family:inherit;font-size:9pt;color:#282828;">The </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">Board </font><font style="font-family:inherit;font-size:9pt;color:#282828;">of Director</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">shall </font><font style="font-family:inherit;font-size:9pt;color:#282828;">have </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">power </font><font style="font-family:inherit;font-size:9pt;color:#282828;">from </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">time </font><font style="font-family:inherit;font-size:9pt;color:#282828;">to </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">time </font><font style="font-family:inherit;font-size:9pt;color:#282828;">to determine to </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">what </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">ex</font><font style="font-family:inherit;font-size:9pt;color:#282828;">tent </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">and at what </font><font style="font-family:inherit;font-size:9pt;color:#282828;">t</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">i</font><font style="font-family:inherit;font-size:9pt;color:#282828;">me</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">and </font><font style="font-family:inherit;font-size:9pt;color:#282828;">place</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">and </font><font style="font-family:inherit;font-size:9pt;color:#282828;">under </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">what conditions </font><font style="font-family:inherit;font-size:9pt;color:#282828;">and regulations the accounts </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">and </font><font style="font-family:inherit;font-size:9pt;color:#282828;">books of the </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">Corporation, </font><font style="font-family:inherit;font-size:9pt;color:#282828;">or </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">any of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">them, </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">shall </font><font style="font-family:inherit;font-size:9pt;color:#282828;">b</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e </font><font style="font-family:inherit;font-size:9pt;color:#282828;">op</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e</font><font style="font-family:inherit;font-size:9pt;color:#282828;">n </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">to the </font><font style="font-family:inherit;font-size:9pt;color:#282828;">inspection </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">the </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s</font><font style="font-family:inherit;font-size:9pt;color:#282828;">tockholders</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">; </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">and </font><font style="font-family:inherit;font-size:9pt;color:#282828;">no </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s</font><font style="font-family:inherit;font-size:9pt;color:#282828;">tockholder </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">shall </font><font style="font-family:inherit;font-size:9pt;color:#282828;">have any </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">right </font><font style="font-family:inherit;font-size:9pt;color:#282828;">to inspect </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">any account </font><font style="font-family:inherit;font-size:9pt;color:#282828;">or book or document of the Corporation</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">, </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">except </font><font style="font-family:inherit;font-size:9pt;color:#282828;">as conferred by the laws of the </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">State </font><font style="font-family:inherit;font-size:9pt;color:#282828;">of Delaware</font><font style="font-family:inherit;font-size:9pt;color:#5d5d5d;">, </font><font style="font-family:inherit;font-size:9pt;color:#282828;">unless and unti</font><font style="font-family:inherit;font-size:9pt;color:#0a0a0a;">l </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">a</font><font style="font-family:inherit;font-size:9pt;color:#282828;">uthorized </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">so </font><font style="font-family:inherit;font-size:9pt;color:#282828;">to do by resolution of the Board </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">Directors or of the </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">stockholders </font><font style="font-family:inherit;font-size:9pt;color:#282828;">of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:139%;text-align:left;padding-left:62px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#181818;">6.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#282828;text-decoration:underline;">Sec</font><font style="font-family:inherit;font-size:9pt;color:#0a0a0a;text-decoration:underline;">t</font><font style="font-family:inherit;font-size:9pt;color:#282828;text-decoration:underline;">ion Headings</font><font style="font-family:inherit;font-size:9pt;color:#282828;">. </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">Section </font><font style="font-family:inherit;font-size:9pt;color:#282828;">head</font><font style="font-family:inherit;font-size:9pt;color:#0a0a0a;">i</font><font style="font-family:inherit;font-size:9pt;color:#282828;">ngs in these By-laws ar</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">for convenience </font><font style="font-family:inherit;font-size:9pt;color:#282828;">of refer</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e</font><font style="font-family:inherit;font-size:9pt;color:#282828;">nc</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">only </font><font style="font-family:inherit;font-size:9pt;color:#282828;">and shall not be </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">given </font><font style="font-family:inherit;font-size:9pt;color:#282828;">any </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">substantive </font><font style="font-family:inherit;font-size:9pt;color:#282828;">effect </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">in </font><font style="font-family:inherit;font-size:9pt;color:#282828;">limiting or </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">otherwise construing </font><font style="font-family:inherit;font-size:9pt;color:#282828;">any provision herein.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:145%;text-align:left;padding-left:62px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#181818;">6.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#282828;text-decoration:underline;">Incon</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s</font><font style="font-family:inherit;font-size:9pt;color:#282828;">istent </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">Provisions</font><font style="font-family:inherit;font-size:9pt;color:#0a0a0a;">. </font><font style="font-family:Arial;font-size:8.5pt;color:#282828;">In </font><font style="font-family:inherit;font-size:9pt;color:#282828;">the </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">event </font><font style="font-family:inherit;font-size:9pt;color:#282828;">that </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">any </font><font style="font-family:inherit;font-size:9pt;color:#282828;">provi</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s</font><font style="font-family:inherit;font-size:9pt;color:#282828;">ion </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">the</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">se </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">By-laws </font><font style="font-family:inherit;font-size:9pt;color:#282828;">is or be</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">co</font><font style="font-family:inherit;font-size:9pt;color:#282828;">me</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s </font><font style="font-family:inherit;font-size:9pt;color:#282828;">inconsistent </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">with </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">any </font><font style="font-family:inherit;font-size:9pt;color:#282828;">pro</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">v</font><font style="font-family:inherit;font-size:9pt;color:#282828;">i</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">si</font><font style="font-family:inherit;font-size:9pt;color:#282828;">on </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">the Am</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e</font><font style="font-family:inherit;font-size:9pt;color:#282828;">nded </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">a</font><font style="font-family:inherit;font-size:9pt;color:#282828;">nd Restat</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e</font><font style="font-family:inherit;font-size:9pt;color:#282828;">d </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">Certificate of Incorporation</font><font style="font-family:inherit;font-size:9pt;color:#6e6e6e;">, </font><font style="font-family:inherit;font-size:9pt;color:#282828;">th</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">General Corporation </font><font style="font-family:inherit;font-size:9pt;color:#282828;">Law </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">the </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">State of Delaware or any </font><font style="font-family:inherit;font-size:9pt;color:#282828;">other </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">applicable </font><font style="font-family:inherit;font-size:9pt;color:#282828;">law</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">, </font><font style="font-family:inherit;font-size:9pt;color:#282828;">the provision of these By-laws </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">shall </font><font style="font-family:inherit;font-size:9pt;color:#282828;">not be </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">given any </font><font style="font-family:inherit;font-size:9pt;color:#282828;">effect to th</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">extent </font><font style="font-family:inherit;font-size:9pt;color:#282828;">of </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">such </font><font style="font-family:inherit;font-size:9pt;color:#282828;">inconsi</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s</font><font style="font-family:inherit;font-size:9pt;color:#282828;">t</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">ency </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">but shall </font><font style="font-family:inherit;font-size:9pt;color:#282828;">otherwise be </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">given </font><font style="font-family:inherit;font-size:9pt;color:#282828;">full force and </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">effect.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s493B491BC7416A5600E0B9E339A2E010"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:78px;"><font style="font-family:inherit;font-size:9pt;color:#181818;">6.15</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:9pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:9pt;color:#282828;">RESERVED</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:left;padding-left:78px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9pt;color:#282828;font-weight:bold;">ARTICLE 7 </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;font-weight:bold;">&#8211; </font><font style="font-family:inherit;font-size:9.5pt;color:#282828;font-weight:bold;">AMENDMENTS</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div></div></div><div><a name="s62A933BF0AF4F8A54CB7B9E339AF34EC"></a></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:139%;padding-top:5px;text-align:justify;padding-left:62px;text-indent:16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">7.1 </font><font style="font-family:inherit;font-size:9pt;color:#282828;">By the Board </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of </font><font style="font-family:inherit;font-size:9pt;color:#282828;">Directors. These B</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">y</font><font style="font-family:inherit;font-size:9pt;color:#282828;">-Laws may be altered, </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">amended </font><font style="font-family:inherit;font-size:9pt;color:#282828;">or repealed </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">or </font><font style="font-family:inherit;font-size:9pt;color:#282828;">new </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">By-Laws </font><font style="font-family:inherit;font-size:9pt;color:#282828;">may </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">be adopted </font><font style="font-family:inherit;font-size:9pt;color:#282828;">by the </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">affirmative </font><font style="font-family:inherit;font-size:9pt;color:#282828;">vot</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e </font><font style="font-family:inherit;font-size:9pt;color:#282828;">of </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">a </font><font style="font-family:inherit;font-size:9pt;color:#282828;">majority of the dir</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">e</font><font style="font-family:inherit;font-size:9pt;color:#282828;">ctor</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s </font><font style="font-family:inherit;font-size:9pt;color:#282828;">present </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">at any regular </font><font style="font-family:inherit;font-size:9pt;color:#282828;">or </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">special </font><font style="font-family:inherit;font-size:9pt;color:#282828;">meeting </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">of the </font><font style="font-family:inherit;font-size:9pt;color:#282828;">Board of Director</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">s </font><font style="font-family:inherit;font-size:9pt;color:#282828;">at </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">which a </font><font style="font-family:inherit;font-size:9pt;color:#282828;">quorum </font><font style="font-family:inherit;font-size:9pt;color:#3b3b3b;">is </font><font style="font-family:inherit;font-size:9pt;color:#282828;">pre</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">se</font><font style="font-family:inherit;font-size:9pt;color:#282828;">nt.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#282828;">12</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:61px;font-size:1pt;"><font style="font-family:Arial;font-size:1pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:1pt;"><font style="font-family:Arial;font-size:1pt;"><br></font></div><div><a name="s8A477F52BD719A9BA20FB9E339C93735"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:132%;padding-top:5px;text-align:left;padding-left:61px;text-indent:17px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#181818;">7</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">.</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">2 </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">By the</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;text-decoration:underline;">Stockholders</font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">. Notwithstanding </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">any other provision of law, the Certificate of Incorporation or these By-Laws, </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">notwithstanding the fact that a lesser percentage may be </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">specified </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">by law, the </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">affirmative vote </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the holders of </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">at </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">least </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">seventy-five </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">percent (75%) of the </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">shares </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">capital stock </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">of the Corporation issued and outstanding </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">and entitled </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">to vote </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">be required to alter, amend or repeal any provision of these By-Laws or to adopt new By-Laws, unless such alteration</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">amendment or repeal has been approved by a majority of those directors of the Corporation who are not affiliated </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">or associated </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">with any person or </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">entity </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">holding 10% or more </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the voting power </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">outstanding capital </font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">stock of the </font><font style="font-family:inherit;font-size:9.5pt;color:#2a2a2a;">Corporation</font><font style="font-family:inherit;font-size:9.5pt;color:#464646;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:270px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#181818;">13</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>rxipc0211916.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc --><TITLE>rxipc0211916</TITLE></HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1316;">
<!-- Slide 0001 -->
<DIV style="padding-top:2em;">
<IMG src="rxipc0211916001.jpg" title="Page 1" width="1316" height="799">
<DIV><FONT size="1" style="font-size:1pt;color:white">THIS CERTIFIES THAT&#13;&#10; is the owner of&#13;&#10; CUSIP&#13;&#10; DATED &#13;&#10;COUNTERSIGNED AND REGISTERED:&#13;&#10; COMPUTERSHARE TRUST COMPANY, N.A.&#13;&#10; TRANSFER AGENT AND REGISTRAR,&#13;&#10; COMMON STOCK&#13;&#10; SEE REVERSE FOR CERTAIN DEFINITIONS&#13;&#10; Certificate&#13;&#10; Number&#13;&#10; Shares&#13;&#10; .&#13;&#10; GALENA BIOPHARMA, INC.&#13;&#10; INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE&#13;&#10; President &amp; Chief Executive Officer&#13;&#10; By&#13;&#10; AUTHORIZED SIGNATURE&#13;&#10; COMMON STOCK&#13;&#10; PAR VALUE $0.0001&#13;&#10; FULLY-PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK OF&#13;&#10; Galena Biopharma, Inc. (hereinafter called the &#8220;Company&#8221;), transferable on the books of the Company in&#13;&#10; person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and&#13;&#10; the shares represented hereby, are issued and shall be held subject to all of the provisions of the Amended and&#13;&#10; Restated Certificate of Incorporation, as amended, and the Amended and Restated By-Laws, as amended, of the&#13;&#10; Company (copies of which are on file with the Company and with the Transfer Agent), to all of which each holder,&#13;&#10; by acceptance hereof, assents. This Certificate is not valid unless countersigned and registered by the Transfer&#13;&#10; Agent and Registrar.&#13;&#10; Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized officers.&#13;&#10; Vice President, Finance &amp; Corporate Controller&#13;&#10; THIS CERTIFICATE IS TRANSFERABLE &#13;&#10;IN CANTON, MA, JERSEY CITY, NJ AND &#13;&#10;COLLEGE STATION, TX&#13;&#10; 363256 50 4&#13;&#10; ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS#&#13;&#10; DD-MMM-YYYY&#13;&#10; * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * *&#13;&#10; * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * *&#13;&#10; * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * *&#13;&#10; * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * *&#13;&#10; * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * *&#13;&#10; ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample&#13;&#10; **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David&#13;&#10; Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander&#13;&#10; David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.&#13;&#10; Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample ****&#13;&#10; Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample&#13;&#10; **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David&#13;&#10; Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander&#13;&#10; David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.&#13;&#10; Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample ****&#13;&#10; Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Sample **** Mr. Sample&#13;&#10; **000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares***&#13;&#10; *000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****&#13;&#10; 000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0&#13;&#10; 00000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00&#13;&#10; 0000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000&#13;&#10; 000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0000&#13;&#10; 00**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00000&#13;&#10; 0**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000&#13;&#10; **Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000*&#13;&#10; *Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**&#13;&#10; Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**S&#13;&#10; ***ZERO HUNDRED THOUSAND&#13;&#10; ZERO HUNDRED AND ZERO***&#13;&#10; MR. SAMPLE &amp; MRS. SAMPLE &amp;&#13;&#10; MR. SAMPLE &amp; MRS. SAMPLE&#13;&#10; ZQ00000000&#13;&#10; Certificate &#13;&#10;Number&#13;&#10; s&#13;&#10; 1234567890/123456789&#13;&#10; 0&#13;&#10; 1234567890/123456789&#13;&#10; 0&#13;&#10; 1234567890/123456789&#13;&#10; 0&#13;&#10; 1234567890/123456789&#13;&#10; 0&#13;&#10; 1234567890/123456789&#13;&#10; 0&#13;&#10; 1234567890/123456789&#13;&#10; 0&#13;&#10; Total &#13;&#10;Transactio&#13;&#10; n&#13;&#10; Num/No&#13;&#10; .&#13;&#10; 123456&#13;&#10; Denom&#13;&#10; .&#13;&#10; 123456&#13;&#10; Tota&#13;&#10; l&#13;&#10; 1234567&#13;&#10; MR &#13;&#10;A SAMPL&#13;&#10; E&#13;&#10; DESIGN&#13;&#10; ATION (IF ANY&#13;&#10; )&#13;&#10; ADD &#13;&#10;1&#13;&#10; ADD &#13;&#10;2&#13;&#10; ADD &#13;&#10;3&#13;&#10; ADD &#13;&#10;4&#13;&#10; PO BOX 43004, Providence, RI 02940-3004&#13;&#10; CUSI&#13;&#10; P&#13;&#10; XXXXXX &#13;&#10;XX &#13;&#10;X&#13;&#10; Holder &#13;&#10;ID&#13;&#10; XXXXXXXXX&#13;&#10; X&#13;&#10; Insurance &#13;&#10;Value&#13;&#10;  &#13;&#10;1,000,000.0&#13;&#10; 0&#13;&#10; Number &#13;&#10;of &#13;&#10;Share&#13;&#10; s&#13;&#10; 12345&#13;&#10; 6&#13;&#10; DT&#13;&#10; C&#13;&#10; 12345678 &#13;&#10; 12345678901234&#13;&#10; 5&#13;&#10;&#13;&#10;</FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- Slide 0002 -->
<DIV style="padding-top:2em;">
<IMG src="rxipc0211916002.jpg" title="Page 2" width="799" height="1316">
<DIV><FONT size="1" style="font-size:1pt;color:white">The IRS requires that we report the cost basis of certain shares&#13;&#10; acquired after January 1, 2011. If your shares were covered by&#13;&#10; the legislation and you have sold or transferred the shares and&#13;&#10; requested a specific cost basis calculation method, we have&#13;&#10; processed as requested. If you did not specify a cost basis&#13;&#10; calculation method, we have defaulted to the first in, first out&#13;&#10; (FIFO) method. Please visit our website or consult your tax&#13;&#10; advisor if you need additional information about cost basis. &#13;&#10;If you do not keep in contact with us or do not have any&#13;&#10; activity in your account for the time periods specified by state&#13;&#10; law, your property could become subject to state unclaimed&#13;&#10; property laws and transferred to the appropriate state.&#13;&#10; The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full&#13;&#10; according to applicable laws or regulations:&#13;&#10; TEN COM - as tenants in common UNIF GIFT MIN ACT-  . . . . . . . . . .Custodian . . . . . . . . . . . . . . .&#13;&#10; TEN ENT - as tenants by the entireties under Uniform Gifts to Minors Act  . . . . . . . . . . . . .&#13;&#10; JT TEN - as joint tenants with right of survivorship     UNIF TRF MIN ACT  . . . . . . . . . . . . . . .Custodian (until age. . . ). . . . . . . . . . .&#13;&#10; and not as tenants in common                                                           (Cust)                                                          (Minor)&#13;&#10; under Uniform Transfers to Minors Act. . . . . . . . . . &#13;&#10;(State)&#13;&#10; Additional abbreviations may also be used though not in the above list.&#13;&#10; For value received, ____________________________hereby sell, assign and transfer unto&#13;&#10; ________________________________________________________________________________________________________________________________&#13;&#10; ________________________________________________________________________________________________________________________________&#13;&#10; ________________________________________________________________________________________________________________________________&#13;&#10; _______________________________________________________________________________________________________________________ Shares&#13;&#10; _______________________________________________________________________________________________________________________ Attorney&#13;&#10; Dated: __________________________________________20__________________&#13;&#10; Signature: ____________________________________________________________&#13;&#10; Signature: ____________________________________________________________&#13;&#10; Notice: The signature to this assignment must correspond with the name&#13;&#10; as written upon the face of the certificate, in every particular,&#13;&#10; without alteration or enlargement, or any change whatever.&#13;&#10; (Cust) (Minor)&#13;&#10; (State)&#13;&#10; PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE&#13;&#10; (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE)&#13;&#10; of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint&#13;&#10; to transfer the said stock on the books of the within-named Corporation with full power of substitution in the premises.&#13;&#10; .&#13;&#10; Galena Biopharma, Inc.&#13;&#10; THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS,&#13;&#10; PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE&#13;&#10; QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS, PREFERENCES AND&#13;&#10; LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE&#13;&#10; COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF&#13;&#10; DIRECTORS TO DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE&#13;&#10; COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE,&#13;&#10; OR HIS LEGAL REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY&#13;&#10; CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE.&#13;&#10; Signature(s) Guaranteed: Medallion Guarantee Stamp&#13;&#10; THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks,&#13;&#10; Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED&#13;&#10; SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15.&#13;&#10;&#13;&#10;</FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>

</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>gale-20161231xex211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC9EDEDE331001B632CF4C8A223BD7D4B"></a></div><div></div><div><br></div><div style="line-height:132%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 21.1</font></div><div style="line-height:132%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SUBSIDIARIES OF THE REGISTRANT</font></div><div style="line-height:132%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;text-align:left;text-indent:384px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;"></font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Jurisdiction of Incorporation</font></div><div style="line-height:132%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Name</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Ownership Percentage</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/Formation</font></div><div style="line-height:132%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Apthera, Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100%&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Delaware</font></div><div style="line-height:132%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mills Pharmaceuticals, LLC&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100%&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Delaware</font></div><div style="line-height:132%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Galena Biopharma UK Limited&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100%&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;United Kingdom</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>gale-20161231xex231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s80B33D77B210FBA4A3FA6F9E9FC6BEC4"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-188847, 333-188849, 333-195260, 333-199517, 333-208330, 333-208331, 333-212674, 333-213908, 333-213493, and 333-213908) and Form S-8 (Nos. 333-151154, 333-153847, 333-175763, 333-174819, 333-182578, 333-183300, 333-190540, 333-210833, and 333-213248) of our report dated March 15, 2017, relating to the consolidated financial statements of Galena Biopharma, Inc., and the effectiveness of internal control over financial reporting of Galena Biopharma, Inc., appearing in this Annual Report on Form 10-K for the year ended December 31, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">/s/ Moss Adams</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">San Francisco, CA</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 15, 2017</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>gale-20161231xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0263FA7DEABB501216D76F9EA06FB77B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF INTERIM CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I, Stephen F. Ghiglieri, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. I have reviewed this Annual Report on Form 10-K of Galena Biopharma, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dated: March 15, 2017</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Stephen F. Ghiglieiri</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Stephen F. Ghiglieri</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Interim Chief Executive Officer and Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>gale-20161231xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6B1DB738FB47D3D077BE6F9EA1B87861"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the accompanying Annual Report of Galena Biopharma, Inc., (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. The information contained in the Report fairly presents, in all material respects, the Company&#8217;s financial condition and result of operations.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:45.8984375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Stephen F. Ghiglieiri</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Stephen F. Ghiglieri</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Interim Chief Executive Officer and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: March 15, 2017</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>gale-20161231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:7541b3fd5d1b4621a2e5be4b10a5dc8a,x:49494180c3394f9e8e34a933417e7f26-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:gale="http://www.galenabiopharma.com/20161231" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="gale-20161231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1PublicFloat">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gale:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gale:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan01-Feb28_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2Jun29_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-10</xbrli:startDate>
			<xbrli:endDate>2016-05-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2MAY8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-07</xbrli:startDate>
			<xbrli:endDate>2013-05-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Mar15_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-14</xbrli:startDate>
			<xbrli:endDate>2016-12-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug22_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_EmploymentContractsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LicenseAgreementTermsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LiabilitiesTotalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-06</xbrli:startDate>
			<xbrli:endDate>2016-07-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase2Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SecuritiesLitigationOptOutSettlementCase2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb23_us-gaap_LitigationCaseAxis_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_IndemnificationGuaranteeMember_us-gaap_LitigationCaseAxis_gale_SECLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SECLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb23_us-gaap_LitigationCaseAxis_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TitleOfIndividualAxis_gale_FormerEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:FormerEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase1Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SecuritiesLitigationOptOutSettlementCase1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec22-Dec22_us-gaap_LitigationCaseAxis_gale_SECLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SECLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-22</xbrli:startDate>
			<xbrli:endDate>2016-12-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec1-31_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec22-Dec22_us-gaap_LitigationCaseAxis_gale_SECLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_TitleOfIndividualAxis_gale_FormerCEOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SECLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:FormerCEOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-22</xbrli:startDate>
			<xbrli:endDate>2016-12-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-24</xbrli:startDate>
			<xbrli:endDate>2016-06-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec3_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-03</xbrli:startDate>
			<xbrli:endDate>2015-12-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-24</xbrli:startDate>
			<xbrli:endDate>2016-06-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_ShareholdersSecuritiesLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:ShareholdersSecuritiesLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_SECLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SECLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May24_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul13">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-13</xbrli:startDate>
			<xbrli:endDate>2016-07-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:LincolnParkCapitalLLCPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:LincolnParkCapitalLLCPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan12_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Nov18_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:LincolnParkCapitalLLCPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec4_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-04</xbrli:startDate>
			<xbrli:endDate>2015-12-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-03-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Mar18ToApr10_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-04-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-13</xbrli:startDate>
			<xbrli:endDate>2016-07-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-13</xbrli:startDate>
			<xbrli:endDate>2017-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb06_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:LincolnParkCapitalLLCPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul14_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2May24_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-24</xbrli:startDate>
			<xbrli:endDate>2013-05-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:LincolnParkCapitalLLCPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul14">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:LincolnParkCapitalLLCPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Apr10_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-10</xbrli:startDate>
			<xbrli:endDate>2015-04-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-12</xbrli:startDate>
			<xbrli:endDate>2016-01-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:LincolnParkCapitalLLCPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb06_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:LincolnParkCapitalLLCPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:JanuaryTwoThousandSixteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:JanuaryTwoThousandSixteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2016WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2016WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2016WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:JanuaryTwoThousandSixteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May10_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-10</xbrli:startDate>
			<xbrli:endDate>2016-05-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jun29-Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-29</xbrli:startDate>
			<xbrli:endDate>2016-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2May13_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-08</xbrli:startDate>
			<xbrli:endDate>2013-05-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec14_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:TwoZeroZeroSevenIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gale:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gale:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gale:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:TwoZeroZeroSevenIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:MidatechPharmaPLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MDAndersonCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec16_us-gaap_CounterpartyNameAxis_gale_MonosolRxLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:MonosolRxLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-16</xbrli:startDate>
			<xbrli:endDate>2015-12-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:MidatechPharmaPLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-24</xbrli:startDate>
			<xbrli:endDate>2015-12-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:MidatechPharmaPLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-24</xbrli:startDate>
			<xbrli:endDate>2015-12-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:SentynlTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-11-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:SentynlTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-19</xbrli:startDate>
			<xbrli:endDate>2015-11-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:SentynlTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-19</xbrli:startDate>
			<xbrli:endDate>2015-11-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:SentynlTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-19</xbrli:startDate>
			<xbrli:endDate>2015-11-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_ServicesProvidedbyCorporateCounselMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gale:ServicesProvidedbyCorporateCounselMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:TroyGouldPcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:TroyGouldPcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:TroyGouldPcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_ServicesProvidedbyCorporateCounselMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gale:ServicesProvidedbyCorporateCounselMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:TroyGouldPcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_ServicesProvidedbyCorporateCounselMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gale:ServicesProvidedbyCorporateCounselMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:TroyGouldPcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsandZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gale:AbstralRightsandZuplenzRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Nov19_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsNetMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gale:AbstralRightsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-11-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Dec24_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_ZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gale:ZuplenzRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-10-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-07-01</xbrli:startDate>
			<xbrli:endDate>2012-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-04-01</xbrli:startDate>
			<xbrli:endDate>2013-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-01</xbrli:startDate>
			<xbrli:endDate>2013-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="election">
		<xbrli:measure>gale:election</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="witness">
		<xbrli:measure>gale:witness</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="day">
		<xbrli:measure>gale:day</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="defendant">
		<xbrli:measure>gale:defendant</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="count">
		<xbrli:measure>gale:count</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="price">
		<xbrli:measure>gale:price</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="installment">
		<xbrli:measure>gale:installment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="products">
		<xbrli:measure>gale:products</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="dosing_strength">
		<xbrli:measure>gale:dosing_strength</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2016Q4YTD" id="Fact-13C3151252126362C26B8C0E45E47580">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2016Q4YTD" id="Fact-17A1A8CD7F8C432D13158C0E45D923FC">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2016Q4YTD" id="Fact-34A83DFD9168AC38E5C08C0E45E6FCA4">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2016Q4YTD" id="Fact-CC152175F866E682E3188C0E45CC1BEC">2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2016Q4YTD" id="Fact-42618F34E298187772518C0E45E67BC5">2016-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2016Q4YTD" id="Fact-B0837EA316A11A80F58C8C0E45DD858C">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2016Q4YTD" id="Fact-F4B7EF82BEB20215064B8C0E45E41778">0001390478</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q1PublicFloat" decimals="0" id="Fact-6169C3DC936B5736AD598C0E45DD42A4" unitRef="shares">38828222</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2016Q4YTD" id="Fact-E695F5A6D252BD2D54098C0E45E655EC">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2016Q4YTD" id="Fact-53263AA76274DB1A93778C0E45E8BFFA">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2016Q2" decimals="0" id="Fact-85BBD9A2E278356992078C0E45DD8725" unitRef="usd">85410521</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2016Q4YTD" id="Fact-DDC4405AFD1CD1EB358F8C0E45DD1ED7">Galena Biopharma, Inc.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2016Q4YTD" id="Fact-5D79E781D0784FB73B618C0E45CCB7E7">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2016Q4YTD" id="Fact-D2F02E404DF19F8922038C0E45E8768C">No</dei:EntityWellKnownSeasonedIssuer>
	<dei:TradingSymbol contextRef="FD2016Q4YTD" id="Fact-4B55E38391A8965CA6838C0E45E86F63">GALE</dei:TradingSymbol>
	<gale:AggregateIntrinsicValueOfStockOptionsExercisable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-35393D68996293E976798C0E45F40341" unitRef="usd">13429000</gale:AggregateIntrinsicValueOfStockOptionsExercisable>
	<gale:AggregateIntrinsicValueOfStockOptionsExercisable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-72753B6D8287385C42828C0E45CED17B" unitRef="usd">37000</gale:AggregateIntrinsicValueOfStockOptionsExercisable>
	<gale:AggregateIntrinsicValueOfStockOptionsExercisable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9F0C66BE37289CE3D17E8C0E45F449BA" unitRef="usd">56000</gale:AggregateIntrinsicValueOfStockOptionsExercisable>
	<gale:AnnualMaintenanceFee contextRef="FI2016Q4_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember" decimals="INF" id="Fact-CA5645896FAACFE7C82B8C0E45F2D367" unitRef="usd">200000</gale:AnnualMaintenanceFee>
	<gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds contextRef="D2013Q2May24_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-6" id="Fact-C605FD8AF882D36019AF8C0E46027FD0" unitRef="usd">20000000</gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds>
	<gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds contextRef="D2015Q4Dec4_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-6" id="Fact-A0A3EDD2E9BDA9C7B1858C0E46023C5F" unitRef="usd">20000000</gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds>
	<gale:AtMarketIssuanceSalesAgreementsPercentofGrossProceeds contextRef="I2013Q2May24_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="2" id="Fact-C19621B788CD8591219C8C0E461391D6" unitRef="number">0.03</gale:AtMarketIssuanceSalesAgreementsPercentofGrossProceeds>
	<gale:CashExcludingFromNetAssetsAcquired contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DEC84D8C19E6BADED4628C0E462DD660" unitRef="usd">168000</gale:CashExcludingFromNetAssetsAcquired>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2014Q4YTD" decimals="-3" id="Fact-03D2956F616FDAC42DA58C0E45CCDA0A" unitRef="usd">16556000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2F596ED564172ECB36358C0E4624056B" unitRef="usd">1161000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2EF69707195AA1046C688C0E45BA0D20" unitRef="usd">22220000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2014Q4YTD" decimals="-3" id="Fact-650C17D726EE4025B7B78C0E45B3DE30" unitRef="usd">170000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AC33CA79854B28D709BE8C0E45AC8F49" unitRef="usd">509000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A8FEACB6EA40A4E865528C0E45B1AC97" unitRef="usd">5047000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-A87E74F59AA8885E270E8C0E45E84824" unitRef="usd">-509000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2016Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-300815478D119060F0B48C0E45E800AD" unitRef="usd">-5047000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-077DA82039E4BCB100F0C80460AA47A5" unitRef="usd">-1136000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-6CA8A68C35ED864BF1EFC804336DD852" unitRef="usd">-88000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-5C2001CEBAC2E9298D7CC80422DFE7D2" unitRef="usd">-462000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-38CAF85D20C36B6EDD85C804444DD928" unitRef="usd">0</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-3DEA541644BD5E9B13C3C80400E4ED28" unitRef="usd">41000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-867B0B353694F749F0A3C80456B7F0F3" unitRef="usd">0</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-38C20F53FC10FA4B5433C804129CA4CB" unitRef="usd">-627000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-865CE7A6C19C994DB07EC8003BF2E447" unitRef="usd">-22220000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-9F3A109BDD0923FA2B8CC800380C63B2" unitRef="usd">-259000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-9F485C1949BBF527298BC80036EB1119" unitRef="usd">-1500000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-75EBB292C5C220FD0E6EC80033A5CC17" unitRef="usd">-5061000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-4EFC197D82F515C592D3C80032A156CA" unitRef="usd">-3543000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-34BFAA45115D128E7597C800394BDD6C" unitRef="usd">-98000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-1B2DB7E17865AD4AF7C0C80034AC6244" unitRef="usd">-9905000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-42701EC84263A7279B1AC8003AB44B19" unitRef="usd">-2000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-D42B3E193DE4B05BC50EC80035A78321" unitRef="usd">-1852000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0AE6BDE69ECA018294D3C7F041079531" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-5DE5718F7FCDF53C298DC7F012A7BBD9" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-E489D8F01D1FBF66A79BC7F004F0E36A" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-1A083F166DB594110D7BC7F01E921F53" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-2055B5225BD4C7A0765BC7EFEB1760FF" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-D371BAD68204A15390C5C7F02BE0EB35" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-5F3721CBED2572A322D4C7F0379766AD" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-CD47BE28EC08148ECB17C7EFF5FEECD3" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-81FCE163DB86CC29E816C7E61C45F851" unitRef="shares">19000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-A1B4F874EEC70A32E3F1C7E4E08DDA3D" unitRef="shares">18000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-472375FC91F798CB0D73C7E4D2195A9F" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-D5AFE9A9561470AC649BC7E4AB2AB16B" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-61FD650828735BE88053C7E3F055379D" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-2B23BF513502D42B26D0C7E4EE15D166" unitRef="shares">1000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-51403F1840130D564EAFC7E4BA71991E" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-7957195483331ED7CAEFC7E4FDB103CF" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-0C50F38DF301F81FBA71C7E50891E42B" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-FC4C337C0829420586E8C7E4C584A506" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassofWarrantorRightExercisePeriod contextRef="D2016Q3Jul13" id="Fact-32A04D34ABDF7B550C22C8F4BF9700AC">P5Y</gale:ClassofWarrantorRightExercisePeriod>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q4YTD" decimals="-3" id="Fact-70585DD9A6E72151E59FC7F0422275F2" unitRef="shares">12000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-18E89A71CC8F416D6DA0C7F014D8648F" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-398715A4289EBD4B7DD6C7F007BA68F9" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-053336BF0A880B677602C7F021806517" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-BD2EB74E320B56F4B362C7EFED83FD83" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-DAA3E822BAA3AF8C12E1C7F02E01EB05" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-6DDC4CDFAEF9067B0C95C7F03A20E192" unitRef="shares">12000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-EB717B8D3735AE173CEAC7EFF83FB8A4" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD" decimals="-3" id="Fact-52B7C0FA53AB47B38A4BC7E61E6BA723" unitRef="shares">9000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-22E67489B22AE4C85C58C7E4E41BB10C" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-511A4E8D70E7C090FC21C7E4D528F433" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-658F78B8032579969D71C7E4ADF6BEFF" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-ADE864608A625E47D660C7E4183C41F4" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-E89164531E857BF367FAC7E4F17EE79C" unitRef="shares">8000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-EAF6A2901CAF80A4B476C7E4BC9794FA" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-CB3EC792A024AA5A14BAC7E5004AD7D5" unitRef="shares">1000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-D39D9FE3FCAA0373B912C7E50B7FCCCB" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-396186CC2AA217665451C7E4C84EA263" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightGranted contextRef="D2016Q2Jun29-Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="-3" id="Fact-602D9D801F3E4F0123D6C856A5DD962A" unitRef="shares">50000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0C8DA012581F0331B141C7F03FDBBB0B" unitRef="shares">700000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-63A9BED59694C43E209FC7F00F6553F5" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-C13A31FE3F81C8738988C7F0015EA20F" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-B87B7231F3FC5D4EA142C7F01C185C6B" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-011EEC9A595C116EC5B1C7EFE7FC73A0" unitRef="shares">700000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-45B6D2D12650489A8F9AC7F028A3FFDF" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-92572E44A49B10CFE6FBC7F034FCA8F8" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-47D94DCBD783E7718550C7EFF3DD6077" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4E5D9D904A43A0F6D969C7E619AAB259" unitRef="shares">1482000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-87056902FA5C3ADCA219C7E4DD556D93" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-83D20BD9ADEB282E9D87C7E4CEF34542" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-C748E86E8900A9549F76C7E4A88F2A70" unitRef="shares">682000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-51B67F44720EE3A715C0C7E3C1DB8F5D" unitRef="shares">700000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-354C54FBB17EBDC06B6CC7E4EB794590" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-CE55F09A87A3FA152B3DC7E4B7D7F9F5" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-C87EED94C64148ED8300C7E4F9F01F46" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-58ED6670BB358C26B640C7E5067BBC68" unitRef="shares">100000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-2B1516A8D510C23BE7BDC7E4C2C775C0" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightIssuedDuringPeriod contextRef="D2016Q3Jul13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-93D2F47BF66EDBD96F74C6285063F406" unitRef="shares">700000</gale:ClassofWarrantorRightIssuedDuringPeriod>
	<gale:ClassofWarrantorRightIssuedDuringPeriod contextRef="D2017Q1Feb13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="0" id="Fact-1414918DC452A18A73E1C6318C7753A4" unitRef="shares">17000000</gale:ClassofWarrantorRightIssuedDuringPeriod>
	<gale:ClassofWarrantorRightMaturityPeriod contextRef="D2016Q2May10_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" id="Fact-EEC6FF54F99AA2907B7DC80C965443BD">P5Y</gale:ClassofWarrantorRightMaturityPeriod>
	<gale:ClassofWarrantorRightNumberofDaysAveragedforExercisePrice contextRef="D2013Q2May13_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" id="Fact-5838B31E8B975799B2B7C81D24054A56">P20D</gale:ClassofWarrantorRightNumberofDaysAveragedforExercisePrice>
	<gale:ClassofWarrantorRightTerm contextRef="D2013Q2MAY8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" id="Fact-BA3B9FD496BB360663398BBCDB76FA15">P7Y</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantorRightTerm contextRef="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" id="Fact-AEBA777598405678E9DAB9E69E4F1910">P5Y</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable contextRef="D2016Q3Jul13" id="Fact-0F90B1198F59AE5256C9C8F72EC34499">P6M1D</gale:ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable>
	<gale:CommonStockIssuedInConnectionWithEspp contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0148F36B9E4E40966A378C0E46240E3D" unitRef="usd">263000</gale:CommonStockIssuedInConnectionWithEspp>
	<gale:CommonStockIssuedInConnectionWithEspp contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0EDE975407F1F03D3B598C0E45B115D0" unitRef="usd">309000</gale:CommonStockIssuedInConnectionWithEspp>
	<gale:CommonStockIssuedInConnectionWithEspp contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CC3A53D3E583FC7EEAB48C0E46205B8C" unitRef="usd">95000</gale:CommonStockIssuedInConnectionWithEspp>
	<gale:CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="2" id="Fact-73E99C3A735F036C6763B9E84583EEE3" unitRef="usdPerShare">8.00</gale:CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2015Q4" decimals="-3" id="Fact-FB230D29ADF7BB02AB4C8C0E45F75955" unitRef="usd">6142000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2016Q4" decimals="-3" id="Fact-3CD93E1B37143B80C5FE8C0E46174400" unitRef="usd">1095000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContractResearchPayable contextRef="FI2015Q4" decimals="-3" id="Fact-3E5879CE52509C7B10A38C0E45F3A3D8" unitRef="usd">3294000</gale:ContractResearchPayable>
	<gale:ContractResearchPayable contextRef="FI2016Q4" decimals="-3" id="Fact-0745C38C92C062687FB58C0E45F4FAEC" unitRef="usd">3088000</gale:ContractResearchPayable>
	<gale:ContractualObligationDueinFifthYearandThereafter contextRef="FI2016Q4" decimals="-3" id="Fact-A4DAF441357DDCB88C1D8C0E4633C10E" unitRef="usd">8815000</gale:ContractualObligationDueinFifthYearandThereafter>
	<gale:ContractualObligationDueinFifthYearandThereafter contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_EmploymentContractsMember" decimals="-3" id="Fact-40F9ADA3F98F8BBD4C398C0E46316960" unitRef="usd">0</gale:ContractualObligationDueinFifthYearandThereafter>
	<gale:ContractualObligationDueinFifthYearandThereafter contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LiabilitiesTotalMember" decimals="-3" id="Fact-F1F0CBDBE0846ABD38588C0E46331E27" unitRef="usd">0</gale:ContractualObligationDueinFifthYearandThereafter>
	<gale:ContractualObligationDueinFifthYearandThereafter contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LicenseAgreementTermsMember" decimals="-3" id="Fact-F5D00F875ACFFBB360758C0E4633212B" unitRef="usd">8815000</gale:ContractualObligationDueinFifthYearandThereafter>
	<gale:ContractualObligationsCurrentDue contextRef="FI2016Q4" decimals="-3" id="Fact-F48DD2041396E1C793998C0E4635FBE8" unitRef="usd">20831000</gale:ContractualObligationsCurrentDue>
	<gale:ContractualObligationsCurrentDue contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_EmploymentContractsMember" decimals="-3" id="Fact-7EED22E6568F7917733F8C0E46335256" unitRef="usd">1601000</gale:ContractualObligationsCurrentDue>
	<gale:ContractualObligationsCurrentDue contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LiabilitiesTotalMember" decimals="-3" id="Fact-01DAFB6BD6EA6C789CF58C0E4634B1EE" unitRef="usd">2575000</gale:ContractualObligationsCurrentDue>
	<gale:ContractualObligationsCurrentDue contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LicenseAgreementTermsMember" decimals="-3" id="Fact-454F8A3621EB76EDF9EF8C0E46338583" unitRef="usd">18256000</gale:ContractualObligationsCurrentDue>
	<gale:DebtInstrumentCashFacilityFee contextRef="I2013Q2May8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-68CA96F7ABA0E6493EC18BBCDB74B11E" unitRef="number">0.01</gale:DebtInstrumentCashFacilityFee>
	<gale:DebtInstrumentCashFinalPayment contextRef="I2013Q2May8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-ABC5D03B1254B779570C8BBCDBBACD6E" unitRef="number">0.055</gale:DebtInstrumentCashFinalPayment>
	<gale:DebtInstrumentCovenantLiquidityCovenant contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="-5" id="Fact-F022DE013696B7A7FFFCB9E9CA7EBF46" unitRef="usd">18500000</gale:DebtInstrumentCovenantLiquidityCovenant>
	<gale:DebtInstrumentOriginalIssueDiscountPercent contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-2B3E1CCC65BA84310FFBB9DEE8DFE0FC" unitRef="number">0.06375</gale:DebtInstrumentOriginalIssueDiscountPercent>
	<gale:DebtInstrumentPlacementAgentFeePercentofFundsReceived contextRef="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="2" id="Fact-7BB0D17D7A35476CED48B9F4DC205AF7" unitRef="number">0.02</gale:DebtInstrumentPlacementAgentFeePercentofFundsReceived>
	<gale:DebtInstrumentPrincipalThatCouldBeRedeemed contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-3B251260B37C7D9B57E6B9E23EC0543D" unitRef="usd">1100000</gale:DebtInstrumentPrincipalThatCouldBeRedeemed>
	<gale:DebtInstrumentPrincipalThatCouldBeRedeemed contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-8D760BF1374B6BC0D48EB9E29E554D60" unitRef="usd">1500000</gale:DebtInstrumentPrincipalThatCouldBeRedeemed>
	<gale:DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="0" id="Fact-6F073CCA09C96A423466B9E46CA41F59" unitRef="usd">2500000</gale:DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection>
	<gale:DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-0E013ED9FD6F54E81968B9E2FC800F24" unitRef="usd">2200000</gale:DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold>
	<gale:DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate contextRef="D2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="3" id="Fact-C9D6329E80F814FCF771B9E5BE44D506" unitRef="number">0.075</gale:DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate>
	<gale:DebtInstrumentRedemptionNumberofDaysMaximum contextRef="D2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-EF63D120132BE7AE2DB7B9E56562751D" unitRef="day">20</gale:DebtInstrumentRedemptionNumberofDaysMaximum>
	<gale:DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-3F07F669CA5B9C32470AC8BDA886A3EA" unitRef="price">3</gale:DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate>
	<gale:DebtInstrumentTermInterestOnly contextRef="D2013Q2MAY8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" id="Fact-30DD6F628C682F985A108BBCDB79178F">P12M</gale:DebtInstrumentTermInterestOnly>
	<gale:DebtInstrumentTermInterestOnly contextRef="D2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" id="Fact-F21CC74BF9D56438E0F8C8ABCC361EC8">P6M</gale:DebtInstrumentTermInterestOnly>
	<gale:DeferredTaxAssetsLicensingDeductionDeferral contextRef="FI2015Q4" decimals="-3" id="Fact-42D9789B0EE63508527B8C0E4626BE63" unitRef="usd">9910000</gale:DeferredTaxAssetsLicensingDeductionDeferral>
	<gale:DeferredTaxAssetsLicensingDeductionDeferral contextRef="FI2016Q4" decimals="-3" id="Fact-C63779F22AFFB41956248C0E462509B6" unitRef="usd">10263000</gale:DeferredTaxAssetsLicensingDeductionDeferral>
	<gale:DeficitAccumulatedDuringDevelopmentalStage contextRef="FI2015Q4" decimals="-3" id="Fact-DD25990FCFA0C736116F8C0E45BB0326" unitRef="usd">-279383000</gale:DeficitAccumulatedDuringDevelopmentalStage>
	<gale:DeficitAccumulatedDuringDevelopmentalStage contextRef="FI2016Q4" decimals="-3" id="Fact-81EC311C4203EE7527008C0E45EC5D20" unitRef="usd">-302932000</gale:DeficitAccumulatedDuringDevelopmentalStage>
	<gale:DisposalGroupIncludingDiscontinuedOperationConsiderationNet contextRef="I2015Q4Dec24_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_ZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-FA9DBC884557576A97FF8C0E461EB097" unitRef="usd">2700000</gale:DisposalGroupIncludingDiscontinuedOperationConsiderationNet>
	<gale:DisposalGroupIncludingDiscontinuedOperationConsiderationNet contextRef="I2015Q4Nov19_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsNetMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-366D64698156A9F30F648C0E46151CAD" unitRef="usd">7533000</gale:DisposalGroupIncludingDiscontinuedOperationConsiderationNet>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-2732B22FDF490C282CA48C0E45C9CBCB" unitRef="usd">900000</gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue contextRef="FI2016Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-B5478E74B846E315D5498C0E45BB75E8" unitRef="number">0.05</gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-331F62E7FA85696FF06F8C0E45CE6D4B" unitRef="usd">352000</gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-3CCF887C70023B3DC9FD8C0E45C9D7AD" unitRef="number">0.03</gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-FF05E748B963DEE57A138C0E45C09AB3" unitRef="usd">680000</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-4575DE1DFBCAD8BF8A068C0E45AD4384" unitRef="usd">355000</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B9AD56F9897268BF93E18C0E45CCFB14" unitRef="usd">0</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsandZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-6" id="Fact-5142ADF6A333FF6187A88C0E45CA4276" unitRef="usd">30000000</gale:DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments>
	<gale:DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-1468B3243706EF42DFDF8C0E45B3CE43" unitRef="usd">0</gale:DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts>
	<gale:DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-C850D3E310A3B7C464488C0E45B1A432" unitRef="usd">1349000</gale:DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts>
	<gale:DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-FD182EF1A87D9A7380B68C0E45D5937E" unitRef="usd">0</gale:DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts>
	<gale:DisposalGroupIncludingDiscontinuedOperationTransactionCosts contextRef="I2015Q4Dec24_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_ZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-A307F62B24BC409CACF08C0E46150BF8" unitRef="usd">1050000</gale:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
	<gale:DisposalGroupIncludingDiscontinuedOperationTransactionCosts contextRef="I2015Q4Nov19_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsNetMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-48477BCFB1B746DE33B48C0E4613AB0E" unitRef="usd">815000</gale:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C6CE8CC7258F0D83DD2D8C0E45D9B57A" unitRef="usd">2295000</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition contextRef="FD2016Q4YTD" id="Fact-63A98CC9F9D1C269B2AF8C0E45D090E6">P2Y3M19D</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
	<gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees contextRef="FD2016Q4YTD" decimals="2" id="Fact-7BDE6D29FC0073EB8CFF8C0E45D7120E" unitRef="number">0.15</gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees>
	<gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement contextRef="FD2016Q4YTD" decimals="2" id="Fact-80C533D85B3779C713CB8C0E45D91CC9" unitRef="number">0.08</gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement>
	<gale:FairValueOfContingentPurchasePriceConsideration contextRef="FD2014Q4YTD" decimals="-3" id="Fact-3912F30DE567D6729C068C0E45C141C7" unitRef="usd">2716000</gale:FairValueOfContingentPurchasePriceConsideration>
	<gale:FairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q4YTD" decimals="-3" id="Fact-445C02BF37698EED95E28C0E45BF1A70" unitRef="usd">0</gale:FairValueOfContingentPurchasePriceConsideration>
	<gale:FairValueOfContingentPurchasePriceConsideration contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D6275CDF7597341035C38C0E45BCC411" unitRef="usd">0</gale:FairValueOfContingentPurchasePriceConsideration>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-7F47DA65947094B74D1EC7F83CE08070">P1Y3M22D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-702C1BACACB7D7F6E095C7F83BC7F06C">P1Y11M23D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" id="Fact-95A5E3B10039109211FCC7F83DAAD977">P2M5D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-5CB17313D4288E8419E8C7F83A0B24BB">P4Y2M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-F07DD1966A4187D97149C7F83E610BA7">P2M27D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-54999FFBEF0EB9937DD0C7F83ADCE917">P2Y8M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-B40A864239BB0FD53B498C0E45D796F2">P3M22D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-C9B9746C46E01D26640F8C0E46073FD8">P11M23D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" id="Fact-10B184D36893E46F2CFAC7F7E24569D9">P4Y0M11D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" id="Fact-1EEF826BA05B1491C172C7F7E16F450A">P4Y6M15D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-C7574BECC38839446F39C7F7E36E9E5A">P3Y2M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-81216A4CCD8AC4A18C93C7F7E4786E72">P1Y8M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C0F3DB8B77DBFDD80FA8C8045EEC47E0" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-61D6D5D279A33C948715C8042FDD756F" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-74FCF78B6B64789C6AB1C8041F91881E" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-D01773BDB11E47A8F8BFC80440733C0C" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-993B65EDAC279677DEBAC803FCB342C4" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-F2F31AA7D4E94AD259DBC80452CC772B" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-80E36B22D5CA3725AC9EC8040DA7FE69" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D84A8FE48045480E3B7DC7FF75772530" unitRef="usd">324000</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-A629BF2413F6E4C8A6FDC7FF6F780254" unitRef="usd">278000</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-91F996B0495D81B977BAC7FF6D4D845B" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-20D3E425C522D7F66E46C7FF66793128" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-96F46A74D6B840B8FE73C7FF640FA529" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-52D951D16F47BF64D5C1C7FF711A28A5" unitRef="usd">46000</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-7B7BA70A90DFBEEE307DC7FF68CEF245" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-4DA9B5CDE95D4EDC61ADC7FF7334F91F" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-CA080280F91F65206A51C7FF6B47EC2B" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E231BBB75DA0825602648C0E45C0BD9B" unitRef="usd">10296000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5C546E19AF4B02284B758C0E45BE2618" unitRef="usd">9886000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4" decimals="-3" id="Fact-2CC578F9E965A45B147EC8045C9F6CD2" unitRef="usd">5358000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-CCA10B8FE288D025A978C804285C6DDA" unitRef="usd">625000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-FA4AAF14A94CC4A53CDDC80419428DCA" unitRef="usd">2027000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-4C15124D80371A04D7F3C8043917AAF0" unitRef="usd">144000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-5FE923C90FBC06DE214AC803F4E8A4F9" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-43C87E21DC7C83360C8BC8044984ACAE" unitRef="usd">2000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-67CB1A7FC8224E5A9C8BC8040678F0B2" unitRef="usd">2560000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-E596E41578F00FC52342C80461D7147B" unitRef="usd">14518000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-A42A44C55FEE5E581179C80436AC0249" unitRef="usd">537000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-48F9C2E534CBD8007A6EC80426518D87" unitRef="usd">1565000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-F295EE82F72749A6CDD7C7FDD51129C9" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-C5827F0F429700F05655C7FDD23CB47E" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-E0E961F7438701CC821FC804477FB98C" unitRef="usd">144000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-4FB54DB9941A77250769C80404BF2B3A" unitRef="usd">10337000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-6A663621A654804C4F6FC8045A812EA7" unitRef="usd">2000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-33DF12A0E29EC57FA41DC804174C4024" unitRef="usd">1933000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-7F261ECC10A2D8E8A538C7FFD79EA394" unitRef="usd">1860000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-6A06E989276FEBE1547DC7FFD0AABCF8" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-DA76C87B97533CA1040AC7FFCF285B16" unitRef="usd">65000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-EB9799ABB0139D1EF637C7FFCA5619AF" unitRef="usd">529000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-765D3ECBA04B5306520DC7FFC89A7F84" unitRef="usd">753000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-A2511097914F5A5DE929C7FFD33EF75C" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-A597DD2EA46A291B711FC7FFCC83A377" unitRef="usd">432000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-904C317FDD2175282F2DC7FFD57F4721" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-7904F11DE4E7F3D68546C7FFCDD89674" unitRef="usd">81000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4" decimals="-3" id="Fact-4AA568DBD49577DC11A78C0E4620CFE2" unitRef="usd">14518000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6150ACABA53C8A05AEB28C0E45BAE00A" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C878AD43576BD9FDF8DA8C0E45B3F37C" unitRef="usd">14518000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DE71E36D4D2F2986C8DD8C0E45B9AF9E" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9E711A89AB1ADB3EC96B8C0E45BCBAE0" unitRef="usd">14518000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q4" decimals="-3" id="Fact-CC589279C258DE2C810C8C0E45F42773" unitRef="usd">1860000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E3E352EFA04F5F0322608C0E45E8B321" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DC097C3FBF158DE2B1D48C0E463332AF" unitRef="usd">1860000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4907D933F24805D7BB378C0E462F8183" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0D62F4891969B2D924648C0E462FA336" unitRef="usd">1860000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CD9A8CE92F6417EC941AC8045DBFA909" unitRef="usd">10296000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-C6E97CA94A1E2F258D02C8042C99838F" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-865AD678084A5FAB5DA0C8041C67E944" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-7C416E2C59141636E593C8043CBD2FEF" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-CD13BEDE56708B4A63DAC803F8C86476" unitRef="usd">10296000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-4DFA02E2A077BA56124BC8044E7797C9" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-9A5FFF77CF204C18C54EC8040A3C56B8" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9B40284FAD3D3F115C2DC7FE959863FC" unitRef="usd">9886000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-2BCFD9D2D1DC54020B2DC7FE8989E0DD" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-B41BC720D12E5F98924DC7FE86C61C24" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-3CC634B3D61B4B94BEC3C7FE7FB06125" unitRef="usd">5590000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-2681E310D47D5718862AC7FE7C90B018" unitRef="usd">4296000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-F701468EC1729431E7EDC7FE8C19B93E" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-A6BA3C8CBF0360843A7DC7FE81F2E258" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-457F69EFCE33AC854547C7FE90A062D7" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-2BFCA43CAFD757B9F565C7FE84C3F67F" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGrantedperShare contextRef="I2013Q2May8_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="2" id="Fact-0FD0F4996FA0CC61E095C84A07E18B1E" unitRef="usdPerShare">38.60</gale:FairValueofWarrantsGrantedperShare>
	<gale:FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BFC19A15443D5BD69D55B4C952BED295" unitRef="usd">1139000</gale:FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts>
	<gale:FutureMilestonePayment contextRef="FI2016Q4_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember" decimals="-5" id="Fact-0E2FD31F35ED26424AD18C0E45F3081A" unitRef="usd">200000</gale:FutureMilestonePayment>
	<gale:GALE401rights contextRef="FI2015Q4" decimals="-3" id="Fact-BFCDD576DF946931A5A38C0E46049C3F" unitRef="usd">9255000</gale:GALE401rights>
	<gale:GALE401rights contextRef="FI2016Q4" decimals="-3" id="Fact-4CD699DCBE087AFC42108C0E461E101B" unitRef="usd">9255000</gale:GALE401rights>
	<gale:GeneralAndAdministrativeExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-26717AF90DA50536715C8C0E46358786" unitRef="usd">16226000</gale:GeneralAndAdministrativeExpenses>
	<gale:GeneralAndAdministrativeExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B3B3D86C9DA4E23E887D8C0E45BB13D3" unitRef="usd">10609000</gale:GeneralAndAdministrativeExpenses>
	<gale:GeneralAndAdministrativeExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6908430594F0E8ABBE168C0E45AFE33E" unitRef="usd">12007000</gale:GeneralAndAdministrativeExpenses>
	<gale:InProcessResearchDevelopment contextRef="FI2015Q4" decimals="-3" id="Fact-9AF19CBA5639FD4BDB4E8C0E460793F5" unitRef="usd">12864000</gale:InProcessResearchDevelopment>
	<gale:InProcessResearchDevelopment contextRef="FI2016Q4" decimals="-3" id="Fact-40EA1CC0E9530EF3759A8C0E46207703" unitRef="usd">12864000</gale:InProcessResearchDevelopment>
	<gale:IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8BE6397547D95EBD9ABC8C0E4602D065" unitRef="usd">-6503000</gale:IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability>
	<gale:IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability contextRef="FD2015Q4YTD" decimals="-3" id="Fact-06C1EA5B45473D4D47468C0E45A4A3C1" unitRef="usd">-456000</gale:IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability>
	<gale:IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A0BEFD29E6EA399A55338C0E4611535A" unitRef="usd">-8728000</gale:IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability>
	<gale:IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9962ABDCA53BA8BFB6018C0E46040E8A" unitRef="usd">0</gale:IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities>
	<gale:IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-053184F5375BA0E5F9FA8C0E4608A3D6" unitRef="usd">0</gale:IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities>
	<gale:IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1506C0166475B47BACBC8C0E45F7DAEE" unitRef="usd">0</gale:IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities>
	<gale:IncreaseDecreaseinLitigationSettlement contextRef="FD2014Q4YTD" decimals="-3" id="Fact-207206CFF48D5AC1643F8C0E45B1B335" unitRef="usd">0</gale:IncreaseDecreaseinLitigationSettlement>
	<gale:IncreaseDecreaseinLitigationSettlement contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A3DD0F7377CAB2CCADEF8C0E45B19210" unitRef="usd">24000000</gale:IncreaseDecreaseinLitigationSettlement>
	<gale:IncreaseDecreaseinLitigationSettlement contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EEDA1CDD7BAA8BC41FB08C0E46222EC3" unitRef="usd">-25000000</gale:IncreaseDecreaseinLitigationSettlement>
	<gale:InterestIncome contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5075DB3DF8310E63C72F8C0E4613BB80" unitRef="usd">-1110000</gale:InterestIncome>
	<gale:InterestIncome contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BC575916BBB56931BC168C0E45CC68A7" unitRef="usd">-760000</gale:InterestIncome>
	<gale:InterestIncome contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EDD17C67929FDFA4F6868C0E45B32D03" unitRef="usd">-3508000</gale:InterestIncome>
	<gale:IssuanceOfCommonStockInExchangeOfOutstandingWarrants contextRef="FD2014Q4YTD" decimals="-3" id="Fact-107D44290228FD9E4ED68C0E45BF6E3E" unitRef="usd">6840000</gale:IssuanceOfCommonStockInExchangeOfOutstandingWarrants>
	<gale:IssuanceOfCommonStockInExchangeOfOutstandingWarrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4141CFEAD2EE2C304A368C0E45C149AD" unitRef="usd">0</gale:IssuanceOfCommonStockInExchangeOfOutstandingWarrants>
	<gale:IssuanceOfCommonStockInExchangeOfOutstandingWarrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-938C5A00C226FCEFEC488C0E45C198E7" unitRef="usd">0</gale:IssuanceOfCommonStockInExchangeOfOutstandingWarrants>
	<gale:IssuanceofCommonStockforLitigationSettlement contextRef="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-6" id="Fact-D5F0BF241BF0E851B7978C0E45AE9AE1" unitRef="usd">1000000</gale:IssuanceofCommonStockforLitigationSettlement>
	<gale:IssuanceofCommonStockforLitigationSettlement contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B44A6F1137D8021A31F88C0E45B2BEC1" unitRef="usd">0</gale:IssuanceofCommonStockforLitigationSettlement>
	<gale:IssuanceofCommonStockforLitigationSettlement contextRef="FD2015Q4YTD" decimals="-3" id="Fact-80FF862A7C94D37F0CCC8C0E45C8A9DE" unitRef="usd">1000000</gale:IssuanceofCommonStockforLitigationSettlement>
	<gale:IssuanceofCommonStockforLitigationSettlement contextRef="FD2016Q4YTD" decimals="-3" id="Fact-461B8361C034A9C334028C0E4622DF76" unitRef="usd">2650000</gale:IssuanceofCommonStockforLitigationSettlement>
	<gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B20CA44039F3990012CFCE8C65F91229" unitRef="usd">0</gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt>
	<gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2E4F7F4AEB4ED4CC7926CE8C66034B12" unitRef="usd">0</gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt>
	<gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-62F5412C6B88B2B21CE0B58BFF4AE100" unitRef="usd">8079000</gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt>
	<gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DA06A252BB2161B32826B58BF8F65A2E" unitRef="usd">8079000</gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt>
	<gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A33CFAB25ADCD3B2F5A1B58BF6808C3F" unitRef="usd">0</gale:Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt>
	<gale:LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments contextRef="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member" decimals="INF" id="Fact-78919C771F7D20ACB9F6C89CA9C20C2A" unitRef="installment">2</gale:LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments>
	<gale:LitigationSettlementAmountCash contextRef="FD2016Q4YTD" decimals="-3" id="Fact-209F6A77EE97A8ECD6AEB804032C34AF" unitRef="usd">950000</gale:LitigationSettlementAmountCash>
	<gale:LitigationSettlementIssuanceofCommonStockShares contextRef="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="INF" id="Fact-3C5B8C1350169AC7D23BC8E62548A293" unitRef="shares">24002</gale:LitigationSettlementIssuanceofCommonStockShares>
	<gale:LitigationSettlementIssuanceofCommonStockShares contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase1Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="INF" id="Fact-69D4C76C7AB9CCBF62BCB7F35A6376E3" unitRef="shares">14563</gale:LitigationSettlementIssuanceofCommonStockShares>
	<gale:LitigationSettlementIssuanceofCommonStockShares contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase2Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="INF" id="Fact-519BBC36D53D3571EBF1B7F4BC98648C" unitRef="shares">168337</gale:LitigationSettlementIssuanceofCommonStockShares>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase1Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-3" id="Fact-4FD9AFDCCDCB6573FE5DB7F30760658B" unitRef="usd">150000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase2Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-7C0CFBA2010871CDC734B7F3B79E0F48" unitRef="usd">1500000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LossContingencyDamagesPaidbyInsuranceCompanyValue contextRef="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-31FAD0BE4782900BC8358C0E45AF2C59" unitRef="usd">16700000</gale:LossContingencyDamagesPaidbyInsuranceCompanyValue>
	<gale:LossContingencyDamagesPaidbyInsuranceCompanyValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-68D6F115EC596D9916BDB80495C4C346" unitRef="usd">21700000</gale:LossContingencyDamagesPaidbyInsuranceCompanyValue>
	<gale:LossContingencyNumberofWitnesstoTestifyatTrial contextRef="I2017Q1Feb23_us-gaap_LitigationCaseAxis_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TitleOfIndividualAxis_gale_FormerEmployeeMember" decimals="INF" id="Fact-3E2EE6EC5CACED644FEDB9357B0DF9D0" unitRef="witness">1</gale:LossContingencyNumberofWitnesstoTestifyatTrial>
	<gale:LossOnWarrantExchange contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9B8448F96BBC504F0ACB8C0E45C8CBE9" unitRef="usd">-16556000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1D9F6155364C751A874B8C0E45ADB26D" unitRef="usd">-1162000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FB5A1807313B907E0F508C0E45F188A7" unitRef="usd">-22220000</gale:LossOnWarrantExchange>
	<gale:MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents contextRef="FD2016Q4YTD" id="Fact-463B60D3D19CB154EF288C0E4620E243">P90D</gale:MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents>
	<gale:MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance contextRef="FD2015Q4YTD" decimals="2" id="Fact-E6732CA44A6F6736D4328C0E45CC44D0" unitRef="number">1.00</gale:MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9D63ABF77CF5960749C88C0E45BC75BC" unitRef="usd">10717000</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-939678AB76CE26C766348C0E45BF5277" unitRef="usd">0</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2562216FA332AA846E008C0E46242C64" unitRef="usd">233000</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NumberofCommericalProducts contextRef="FI2016Q4" decimals="INF" id="Fact-575035691B634FFDC6C38C0E4617F8B8" unitRef="products">1</gale:NumberofCommericalProducts>
	<gale:NumberofCountsAgainstDefendants contextRef="I2017Q1Feb23_us-gaap_LitigationCaseAxis_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-51A4D926CAFF19C37D3FB9304DF1DDB4" unitRef="count">20</gale:NumberofCountsAgainstDefendants>
	<gale:NumberofCountsAgainstDefendantswithJudicialRulingofGuilty contextRef="I2017Q1Feb23_us-gaap_LitigationCaseAxis_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-A3533CF47F5E7A925A35B931E67EE048" unitRef="count">19</gale:NumberofCountsAgainstDefendantswithJudicialRulingofGuilty>
	<gale:NumberofDosingStrengths contextRef="FI2016Q4" decimals="INF" id="Fact-C524F43A46C6F91564928C0E45CAEF1B" unitRef="dosing_strength">6</gale:NumberofDosingStrengths>
	<gale:NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-23FB991D906719A9145DB9E4382B5D2F" unitRef="election">3</gale:NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal>
	<gale:OperatingLeaseExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-277F27E8A5D8068767818C0E45B00716" unitRef="usd">72000</gale:OperatingLeaseExpense>
	<gale:OperatingLeaseExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-03A1DC31CDD9B84504978C0E45ADD1FF" unitRef="usd">116000</gale:OperatingLeaseExpense>
	<gale:OperatingLeaseExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-52F309CFB9A620C7857C8C0E45AFCDBA" unitRef="usd">291000</gale:OperatingLeaseExpense>
	<gale:OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases contextRef="FI2016Q4" decimals="INF" id="Fact-38BE6B48D295FF373C4DC8E499A52C9D" unitRef="usd">0</gale:OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases>
	<gale:OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter contextRef="FI2016Q4" decimals="-3" id="Fact-01DBCCDD8D76564A2FA18C0E46339DD0" unitRef="usd">0</gale:OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter>
	<gale:OperatingLossCarryforwardsExerciseofStockOptions contextRef="FI2016Q4" decimals="-5" id="Fact-E43B70312D9F3CD9E4858C0E45CC15F6" unitRef="usd">1400000</gale:OperatingLossCarryforwardsExerciseofStockOptions>
	<gale:PaymentofCashDividendsforCovenantonLongtermDebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-17F28724367E8742498DB4B8777ADECB" unitRef="usd">0</gale:PaymentofCashDividendsforCovenantonLongtermDebt>
	<gale:PaymentofCashDividendsforCovenantonLongtermDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8E1467ACBCC1BD04AF63B4B87555B322" unitRef="usd">0</gale:PaymentofCashDividendsforCovenantonLongtermDebt>
	<gale:PaymentofCashDividendsforCovenantonLongtermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E737A4F5C52037FA8737B4B87330904E" unitRef="usd">17621000</gale:PaymentofCashDividendsforCovenantonLongtermDebt>
	<gale:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember" decimals="2" id="Fact-34D859113BC5239566758C0E45CE4937" unitRef="number">0.01</gale:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2015Q2Apr10_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="-5" id="Fact-A28BF17395DC2B8D74798C0E460267CA" unitRef="usd">5400000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2015Q2Mar18ToApr10_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="-5" id="Fact-74ACF3D432ADAE79FA518C0E46008B26" unitRef="usd">40800000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2016Q1Jan12" decimals="-5" id="Fact-962E5D60178E1A534F05C626AAD6547D" unitRef="usd">20200000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2017Q1Feb13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="-5" id="Fact-5C04291744073DB46DC4C63BDE61C1BF" unitRef="usd">15500000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:PurchaseAgreementConsiderationReceivableUnderAgreement contextRef="I2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember" decimals="-4" id="Fact-211937BBFEA299325EB3BA071C550196" unitRef="usd">29750000</gale:PurchaseAgreementConsiderationReceivableUnderAgreement>
	<gale:PurchaseAgreementConsiderationReceivableUnderAgreement contextRef="I2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member" decimals="INF" id="Fact-5C78A45F0F8476852061BA053351FBB9" unitRef="usd">12000000</gale:PurchaseAgreementConsiderationReceivableUnderAgreement>
	<gale:PurchaseAgreementContingentConsiderationReceivableUnderAgreement contextRef="I2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember" decimals="-6" id="Fact-0A92E6A6D8281EA5A167BA079EC5A781" unitRef="usd">26000000</gale:PurchaseAgreementContingentConsiderationReceivableUnderAgreement>
	<gale:PurchaseAgreementContingentConsiderationReceivableUnderAgreement contextRef="I2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member" decimals="INF" id="Fact-5A0356AF12EFC6990FD7BA0622C1B1A3" unitRef="usd">4000000</gale:PurchaseAgreementContingentConsiderationReceivableUnderAgreement>
	<gale:PurchaseAgreementContingentConsiderationThresholdNetSales contextRef="D2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-6" id="Fact-A79F85F2DAA6D5AFBF63BA080666D192" unitRef="usd">70000000</gale:PurchaseAgreementContingentConsiderationThresholdNetSales>
	<gale:PurchaseAgreementContingentConsiderationThresholdNetSales contextRef="D2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="-6" id="Fact-6389CCFA5C2E88EFCBA9BA07D65A9744" unitRef="usd">12000000</gale:PurchaseAgreementContingentConsiderationThresholdNetSales>
	<gale:PurchaseAgreementContingentConsiderationThresholdNetSales contextRef="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-CF0E170AD74B15BC2732BA06D003CA60" unitRef="usd">35000000</gale:PurchaseAgreementContingentConsiderationThresholdNetSales>
	<gale:PurchaseAgreementContingentConsiderationThresholdNetSales contextRef="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-DCCFADB4D2FDEC7CB393BA066D342215" unitRef="usd">25000000</gale:PurchaseAgreementContingentConsiderationThresholdNetSales>
	<gale:PurchaseAgreementPaymentofUpfrontFee contextRef="D2016Q4Dec16_us-gaap_CounterpartyNameAxis_gale_MonosolRxLLCMember" decimals="0" id="Fact-995036218AF81E6D19F3BA0861A8C4E9" unitRef="usd">900000</gale:PurchaseAgreementPaymentofUpfrontFee>
	<gale:PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived contextRef="D2016Q4Dec16_us-gaap_CounterpartyNameAxis_gale_MonosolRxLLCMember" decimals="2" id="Fact-37EDBFC7903808DE6A90BA08357335CF" unitRef="number">0.20</gale:PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived>
	<gale:PurchaseAgreementTerm contextRef="D2014Q4Nov18_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" id="Fact-CDB0980BFC6C93B5636A8C0E46021D3D">P36M</gale:PurchaseAgreementTerm>
	<gale:PurchaseAgreementUpfrontPaymentReceivableUnderAgreement contextRef="I2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember" decimals="-4" id="Fact-C6EA9BCF28110E26884CBA0769785474" unitRef="usd">3750000</gale:PurchaseAgreementUpfrontPaymentReceivableUnderAgreement>
	<gale:PurchaseAgreementUpfrontPaymentReceivableUnderAgreement contextRef="I2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member" decimals="INF" id="Fact-0C4C09B35B890561F353BA05893239F9" unitRef="usd">8000000</gale:PurchaseAgreementUpfrontPaymentReceivableUnderAgreement>
	<gale:ReclassificationOfWarrantLiabilityUponExercise contextRef="FD2014Q4YTD" decimals="-3" id="Fact-15AD9A6B70F7429625848C0E45C187E2" unitRef="usd">27026000</gale:ReclassificationOfWarrantLiabilityUponExercise>
	<gale:ReclassificationOfWarrantLiabilityUponExercise contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9C8C849C1B03B9B75BAC8C0E45BF1EAA" unitRef="usd">324000</gale:ReclassificationOfWarrantLiabilityUponExercise>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-FD9B8540998DBEABC599CE42E5EB8184" unitRef="usd">17622000</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5FB7C46B32454FEC0E44CE42E87EDCD0" unitRef="usd">0</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-AF51C24322E6C2CD64C3CE42EB8B3F94" unitRef="usd">0</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-146796296023C2812DF7CE42E3F5FF39" unitRef="usd">17622000</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-5D2ACAA2EAC34A675DD78C0E45F9B2B1" unitRef="shares">50000</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-EED8F431995E343B91BA8C0E45D07897" unitRef="number">0.15</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants>
	<gale:SharesIssuedforMilestonePayment contextRef="FD2014Q4YTD" decimals="INF" id="Fact-42C551C4A04734FC7C878C0E45F70033" unitRef="shares">219061</gale:SharesIssuedforMilestonePayment>
	<gale:StockAvailableforIssuanceSharesNewIssues contextRef="I2016Q1Jan12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-5C4BD6D7B4355D7CD1D5C62577D191CD" unitRef="shares">148295</gale:StockAvailableforIssuanceSharesNewIssues>
	<gale:StockIssuedDuringPeriodSharesOverallotmentOption contextRef="D2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="INF" id="Fact-913EECD68811564D6E9D8C0E46077490" unitRef="shares">91346</gale:StockIssuedDuringPeriodSharesOverallotmentOption>
	<gale:StockIssuedDuringPeriodValueAchievementofMilestone contextRef="FD2014Q4YTD" decimals="-3" id="Fact-88DC41208BDA0DBE9EF38C0E45DD3BD6" unitRef="usd">9340000</gale:StockIssuedDuringPeriodValueAchievementofMilestone>
	<gale:StockPurchaseAgreementAuthorizedAmount contextRef="I2017Q1Feb06_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="-3" id="Fact-EE696227B8A1879CCE10C648A958EF91" unitRef="usd">15600000</gale:StockPurchaseAgreementAuthorizedAmount>
	<gale:StockPurchaseAgreementAuthorizedAmount contextRef="I2017Q1Feb06_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="-3" id="Fact-2B7580F9E27AC27B0694C648A9581A86" unitRef="usd">55000000</gale:StockPurchaseAgreementAuthorizedAmount>
	<gale:Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-76A1070E7E4BA8B52DDEB58BF3D5C32B" unitRef="shares">3981208</gale:Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="2" id="Fact-568F040F658A941BC852C7F29960DA50" unitRef="usdPerShare">13.00</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="2" id="Fact-8F12304CB712AA98DC81C7F296942051" unitRef="usdPerShare">31.60</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="2" id="Fact-DC55A0CC1F15E97CF292C7F29C4E633B" unitRef="usdPerShare">13.00</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="2" id="Fact-7BD01BB0D25979A2D100C7F290B497B1" unitRef="usdPerShare">41.60</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="2" id="Fact-F7196A8DE059B49B39DDC7F29EE508EA" unitRef="usdPerShare">40.04</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="2" id="Fact-65A8969D7743B56E2C21C7F2932E135E" unitRef="usdPerShare">50.00</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="2" id="Fact-4993FBC6918CD13506418C0E45B11545" unitRef="usdPerShare">13.00</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="2" id="Fact-1C57D79162DA9205E1158C0E45EBE3E3" unitRef="usdPerShare">31.60</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="2" id="Fact-4FB8179111CE8A40213BC7F2718D8856" unitRef="usdPerShare">28.40</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="2" id="Fact-29035635B05FDA90E88AC7F26DC08BE1" unitRef="usdPerShare">13.00</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="2" id="Fact-5D0C4A4D072C9450F4E7C7F27361F4C3" unitRef="usdPerShare">41.60</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="2" id="Fact-F384968B9269387C09A1C7F275C6782C" unitRef="usdPerShare">50.00</gale:WarrantStrikePrice>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-3E9AF1ED42E0A58CFC66C7F722F21644" unitRef="number">0.6560</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-77D74B5C7F001F7C66FBC7F7222745CE" unitRef="number">0.7637</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-84354E54F93A172F2DB0C7F723ECFB3C" unitRef="number">0.4798</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-BB6CC8BE9FC683157DBBC7F72084D117" unitRef="number">0.7585</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-2BFB1961DC61C2D9A89DC7F724AF599B" unitRef="number">0.7141</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-A2E6198121FFC303E32FC7F721502F17" unitRef="number">0.7470</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-D4CCB13473802D621CAE8C0E45C83607" unitRef="number">1.0379</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-8EA5ECB1E09C0C497BF28C0E462FC20C" unitRef="number">2.0455</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="4" id="Fact-4BCDFF2549F9DAECFC90C7F77118238A" unitRef="number">1.2038</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="4" id="Fact-0733E670061DDCF54AFAC7F77025E5EF" unitRef="number">1.1782</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-6459E0FEC203DE32A915C7F7723D76D0" unitRef="number">1.3146</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-32E35DC8588A5352DB2AC7F7738ACC61" unitRef="number">1.6401</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-D56D26F00BDF306A1663C656F80C7DBF" unitRef="number">0.0077</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-566D7EB3AB24A7ADD8EFC656F7B20562" unitRef="number">0.0105</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-E0ED2410A092623AACFCC656F9013FF3" unitRef="number">0.0000</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-A4FE9FEC299235B1E2ABC656F70A6B63" unitRef="number">0.0158</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-772265482235E4C712A1C656FA481E0B" unitRef="number">0.0000</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-CDE820AAA69BB0A9F009C656F762BDD4" unitRef="number">0.0124</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-92E5A10A27ACA60267A18C0E46332578" unitRef="number">0.0053</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-4DCE3C66059B0B8C2E388C0E45C975BC" unitRef="number">0.0084</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="4" id="Fact-7A0E9754A28D75918C5BC656D57782EC" unitRef="number">0.0171</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="4" id="Fact-482BE196C8755B629155C656D5045F37" unitRef="number">0.0182</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-07E97E0A3EC90C8B665FC656D5CC7F3E" unitRef="number">0.0152</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-EA92272B1EC93A595245C656D615EFB9" unitRef="number">0.0110</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsGrantedNumberofShares contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="INF" id="Fact-3AB6570E2EB2DEFB802DC80A966F8D71" unitRef="shares">100000</gale:WarrantsGrantedNumberofShares>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-52A07B62097C52B384FF8C0E46205B96" unitRef="usd">1597000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8C22B423139700211A098C0E462073B9" unitRef="usd">840000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C7A1F3A02C17031DCB668C0E461497BD" unitRef="usd">5292000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-7987629A6DA1C9F960908C0E45D785DC" unitRef="usd">4292000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-4B2D4405BE9FADCE4D938C0E45F4A4BB" unitRef="usd">435000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-EC3A41A53F4D9385D8C88C0E45F54D2C" unitRef="usd">229000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q4" decimals="-3" id="Fact-B7C45AF8775F21BFA0548C0E462DC47F" unitRef="usd">296730000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q4" decimals="-3" id="Fact-7BC6198D58C9EB714A738C0E45D74734" unitRef="usd">335423000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="FD2014Q4YTD" decimals="-3" id="Fact-66F0EF61C9C6A927456A8C0E45F1B60E" unitRef="usd">134000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0489C78896A4EE3EDA528C0E45F5E558" unitRef="usd">134000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2E9B0E20B8845EAC6C1A8C0E45E49233" unitRef="usd">5253000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FFC1D689536C8E2479D08C0E45E67613" unitRef="usd">5253000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F7DA5DD955437BA48BD78C0E45E6B1D8" unitRef="usd">2896000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5798B5E35C56478D7ACC8C0E45EC2630" unitRef="usd">2896000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EEEEDA0CC938FADBD6ADB4D3E7D6088F" unitRef="usd">2264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CC885F66A8A47508AC81B4D3E0ACAF8E" unitRef="usd">2264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B962A812F0908C6B05D38C0E45E8BBA7" unitRef="usd">-10296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F72250B684940B96B8B38C0E45F63AD4" unitRef="usd">-10296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A5FCC2DA7A27E99B86F8B4D21793C2E3" unitRef="usd">-9886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-395E3295E153CD99E3C1B588BF203AFD" unitRef="usd">1139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-53137B4D0C77595F2F2BB587811EA398" unitRef="usd">1139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-A960A3A3FE62110FD568B5878F793C9E" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DFD5FC2024F9220787D2B4D20FA36741" unitRef="usd">-9886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-019FB715787861FEBA7B8C0E4609760C" unitRef="usd">484000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-39FE910D54EC1ECC8FDD8C0E46092F8C" unitRef="usd">4903000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-725C3F847465D0ABD4248C0E4611A436" unitRef="usd">5387000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-AC8C94FD2131CBD2526E8C0E46113A65" unitRef="usd">350000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-E09F930E629A3066BFCF8C0E460FFAA1" unitRef="usd">1591000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-5C378D39010CB0E824AD8C0E46093660" unitRef="usd">1941000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-D7FE79FE5FDD718322AC8C0E460924AB" unitRef="usd">298000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-17E781D2EC16DF6080388C0E4608C2C9" unitRef="usd">1966000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-B3E3A149DF3F38CA6B128C0E46113C3C" unitRef="usd">2264000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7DC2C26F96804D189AEE8C0E460544C7" unitRef="usd">-276000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-23CF5D301129CD8AE48C8C0E46207DF6" unitRef="usd">-248000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C9D35503C4FACE661DC78C0E45F7C547" unitRef="usd">-3054000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6CB3ACD01E2E05CDF9288C0E45C1B6A1" unitRef="shares">1778000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-264CEC53CDCCDA06D6DD8C0E45C73F90" unitRef="shares">663000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-6307AD810EC5FF8675958C0E45BF4CF9" unitRef="shares">1115000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4AF83B460B63844BF6D78C0E45C0F534" unitRef="shares">3131000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-F469EDB554D64CFBA36B8C0E45C16251" unitRef="shares">561000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-6B19A7786D5F5AFE42248C0E45BFEBC3" unitRef="shares">2570000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-8DD1E62CAFB9AB2897D18C0E4602983D" unitRef="usd">82144000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-8DC4F62CB2D24740EC4A8C0E460402EA" unitRef="usd">65811000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C24E6E84B6FD8B83DBEC8C0E4611E87E" unitRef="usd">53621000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-452BE020103C3D0F5F8F8C0E46115C91" unitRef="usd">37499000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6625F072F42407A4AA658C0E45BBCF7C" unitRef="usd">29171000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-23DF6697F1C901DFE1898C0E45BB617D" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0F713B52720434066A998C0E45BC29C2" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D03D88097BA12503D7928C0E45BB5B6F" unitRef="usd">29171000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-424E4B350C0098CDC7A38C0E462F9E86" unitRef="usd">33814000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5F66880A21981AA6EB428C0E462FCFE3" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-713505D5A52E9116C5E38C0E45CE989B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4795D1EE72189B79AA2B8C0E463326BB" unitRef="usd">33814000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-AA9D1FFC50090D4D40798C0E46246121" unitRef="usd">392000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="FI2016Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-32AF892D56FA0D23902E8C0E46269B46" unitRef="usd">813000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C9FE7DAC34F64440D0E98C0E46072A2B" unitRef="usd">392000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-038AC7BBB5687E938CF38C0E45D9C59B" unitRef="usd">813000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2011Q4" decimals="-3" id="Fact-0F2104FD4A1A23F307AA8C0E45B03885" unitRef="usd">47787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-AA071D0B4BF39EF9649B8C0E45C82C16" unitRef="usd">23650000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-62D258EC7A1B904D9D078C0E45BFDEDC" unitRef="usd">29730000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-07F8238607BC40F0BE9D8C0E46227FA3" unitRef="usd">18083000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3BC0A793BD8BB0FCEE878C0E45C07030" unitRef="usd">29171000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DEF3430F130B4E2A57D28C0E45BE270F" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-77C80253138901B4697C8C0E45B4530F" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6A346687A7DFD350DC0C8C0E45BC1DF6" unitRef="usd">29171000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4" decimals="-3" id="Fact-ADAE50C19ECDB4F37CF68C0E45F72302" unitRef="usd">17583000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E08628271251A0B8BD068C0E463390AF" unitRef="usd">16192000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-04C677AFC31A9B12113C8C0E4635CDFF" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-92A04018C603287489918C0E46302F80" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CFC3B703CFD9CD64CA8D8C0E4631893A" unitRef="usd">16192000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E8C94E4564312039A8868C0E46247C03" unitRef="usd">-24137000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5D010E1559ACAA87C21C8C0E45C127B0" unitRef="usd">6080000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FA7F27DAE46ED7D5300A8C0E462283E0" unitRef="usd">-11647000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-71F68D14308FAC6CD50F8C0E45A4E229" unitRef="usd">-3056000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8D53E50E20F2771D1A288C0E45CA248B" unitRef="usd">10749000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-53A4FBB408D69D2A843E8C0E45AD2F90" unitRef="usd">-1050000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-27343DD1C14C413DFCC28C0E45A628FE" unitRef="usd">-5832000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-75B760C0364C8AC4981F8C0E45AF4A11" unitRef="usd">-9358000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2A89160F734C88D8D9358C0E45C0D618" unitRef="usd">-11685000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="2" id="Fact-839F96543EC6ABBA6C95C858E0602361" unitRef="usdPerShare">79.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2013Q2May8_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="INF" id="Fact-76ACE486C9184F2F7E27C8198187FA42" unitRef="usdPerShare">49.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2013Q2May8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-9E08DBF31068C986DA2CCD97584D8306" unitRef="usdPerShare">49.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="INF" id="Fact-0730F50DB93D8C5E128A8C0E461123C3" unitRef="usdPerShare">41.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q1Jan12" decimals="INF" id="Fact-A5556A3B5854575381BCC624EE932EE0" unitRef="usdPerShare">28.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q2Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="INF" id="Fact-8934E94195B9F5424736C8115D45EF78" unitRef="usdPerShare">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q2Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="2" id="Fact-1D1270D3D229AAE6BF14C85710203D67" unitRef="usdPerShare">79.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q2May10_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="INF" id="Fact-22ED71D770070C087650C80CF3D2EB33" unitRef="usdPerShare">30.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-54EE8DEB1DB748210584B9E64D81F6D6" unitRef="usdPerShare">30.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q3Aug22_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-F42A14F1217CB4DC4F8EB9E8AA8A90A0" unitRef="usdPerShare">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q3Jul14" decimals="INF" id="Fact-C7A95683BD8839515612C62958FEA109" unitRef="usdPerShare">13.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q4Dec14_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="INF" id="Fact-D1C2FE654594B0222EE5C80C117538AF" unitRef="usdPerShare">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-EF117F7E5989456CF4E4B9E894144DE6" unitRef="usdPerShare">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q1Feb13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="2" id="Fact-F851D459DB8D21B512E8C6374205BF35" unitRef="usdPerShare">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2016Q1Jan12" decimals="INF" id="Fact-7DEC6BB5709DD9EDC4A4C6252998E9DF" unitRef="shares">0.60</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2013Q2May8_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="INF" id="Fact-B4564D15256BC1133105C84BCE18E153" unitRef="shares">9109</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2013Q2May8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-45AA2527D08999677CE0CD96343F70AD" unitRef="shares">9109</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="2" id="Fact-0853E548809006FFAD138C0E46040280" unitRef="shares">0.50</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q1Jan12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-E4F4DE3FE52683C5AF0BC6261DC94D0F" unitRef="shares">88977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-322EAD7918373AEA1C01B9DF5A9553FA" unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4" decimals="-3" id="Fact-8C3677164BAFAF586869C7F03E9FED48" unitRef="shares">428000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-447AA3F6CF7EB6224DEDC7F00C7F1B92" unitRef="shares">31000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-74E0CA606628DD9FBE31C7EFFE980044" unitRef="shares">152000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-DF00689D358703C8D913C7F0199CB10B" unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-84D2F01310F64082457DC7EFE6063E32" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-387205F46C8D97662AFAC7F02685A00D" unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-3C7B810F0157200FC56EC7F0328777F9" unitRef="shares">36000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-A26ED96D6F957E634605C7EFF1642AE8" unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4" decimals="-3" id="Fact-B29C88F66A9DC9717DACC7E617B6DDDA" unitRef="shares">1116000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-EB41A38FB69A9A2911D6C7E4DAA1BA63" unitRef="shares">31000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-CD762044E209CF3BC627C7E4CC59F86B" unitRef="shares">152000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-450836646C8C5DE0B907C7E4A640F979" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-89B0DF9A997AD2E8A69CC7E36AF7544F" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-68BC0B1DF23C24622CFDC7E4E85AFC05" unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-483F46FEC44954725EC7C7E4B435F42D" unitRef="shares">700000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-8F9CF8D4201E762F85BBC7E4F6684D4C" unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-9B288DE4C9869C10A7E6C7E5043AB6DB" unitRef="shares">24000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-E7AA1A6D40E93CFD39CAC7E4C061C8FA" unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4" decimals="-3" id="Fact-B0704F016E2A1C4D1FFFC7E620D58435" unitRef="shares">2570000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-963C9E7461FF2E4CDDA2C7E4E6909D95" unitRef="shares">13000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-62C4AF0A1C8D5DF4D40CC7E4D893E51F" unitRef="shares">152000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-BE4F613A12266D9EFB78C7E4B1FCD13B" unitRef="shares">682000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2016WarrantsMember" decimals="-3" id="Fact-E9F2DD88012B32FFAB3AC7E43CA7F747" unitRef="shares">700000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-6D35143E3F4B1803E071C7E4F4B84F0D" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-8054E993B67A288A208FC7E4BEFF644C" unitRef="shares">700000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-34DC37349536484A1E32C7E502B1B524" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-32EFB55F3EB3EC537E43C7E50DF6FE2B" unitRef="shares">124000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-F359090652B8B750DA33C7E4CAB5C1A4" unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="-3" id="Fact-C494F05FB5A915F32C58C854F0ACE674" unitRef="shares">15000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2016Q2Jun29_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="-6" id="Fact-3C85977D7CD11D5A47EEB9E7A26EEB56" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2016Q2May10_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="0" id="Fact-0DD8CBAF7EF2CA7EDE78C8529C2CE142" unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-6E11EA3FF69DD591CAD4B9E6167B967E" unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-D76D3225C0A7963E028C8C0E461E1826" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-6287AE61BF05706DEFF78C0E45E41FF6" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-FEFD2A8E890D961E19798C0E45D91789" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-69555BD465F8912D1A498C0E45DBD076" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-F777237757CFC1A9EBFC8C0E45D97842" unitRef="shares">275000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-FC361EF112D76A742A588C0E45D71EBA" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="INF" id="Fact-C2012CAE8D50E6E573878C0E4606FAA7" unitRef="shares">182692</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="INF" id="Fact-17B771842954C8FBD70D8C0E45D9597A" unitRef="shares">8129087</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-42ABD163CDC63EB88BE68C0E45D981FE" unitRef="shares">15224223</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-49DC1328B2E214B9A4998C0E45DB3CE6" unitRef="shares">8095337</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-C9CBAE393D7B6A37ADAE8C0E45D73882" unitRef="shares">15190473</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-522674471A59CBA165088C0E46083FEF" unitRef="usd">15000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-E749B0497EC7DAF9C57A8C0E46061B57" unitRef="usd">15000</us-gaap:CommonStockValue>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-EFC6C42892BD990BCBCD8C0E45B33526" unitRef="number">0.54</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-DA3730115F379234C2A48C0E45B0E569" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-B66F9B18260CF75BCED78C0E45AD7038" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-095CD06D5934662F67C78C0E45BA8A72" unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-9AEDF0C4EBD6E117359B8C0E4613737C" unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-DB6077700914DB67DC0D8C0E461198BD" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-993CD65BAFF72A8F79518C0E461590D5" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-A28F437A8F9187EDB8B28C0E4611B1E0" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-4B7AB891C2D2002470168C0E45B92ECC" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-B45391540909F2FF28D98C0E45B21FA8" unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-228E160B0D382649C38D8C0E45B2CBC7" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-7BEFE12E05B29FD0BD168C0E45BA6BF1" unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-E5B5A4CABA926829AE6D8C0E461318FF" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-6D9B5B27467E2B72AB7E8C0E4613C921" unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-25FC4315FD71A5AADADC8C0E46177EB9" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-4B9723E88C931E6B0C678C0E4615189E" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-CC298CF556351175703B8C0E45E88BEA" unitRef="usd">6651000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-FC029DF4D8E3C8AEBE7A8C0E45BA5DF1" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-02E01E0EFD8C691851C98C0E45B937C3" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-286FD4A75D8CB9CB632C8C0E45E89604" unitRef="usd">6142000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-58BDE41519ACDEE097138C0E45BDF532" unitRef="usd">6142000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-FBC8478260C7C0169AAC8C0E45B4F7D0" unitRef="usd">6142000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E1E9C96C00351E3B87BB8C0E462FBDE6" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9AF3D1994A6C22AB77988C0E46316133" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-BB1C9A5EB7E05B394F4E8C0E45E89B97" unitRef="usd">1095000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0ADCE7BB94887B3E56D08C0E463185F0" unitRef="usd">1095000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B926FC4DA47794D7AEF18C0E4631B97F" unitRef="usd">1095000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContractualObligationDueInFourthYear contextRef="FI2016Q4" decimals="-3" id="Fact-639E34386BC401FD957C8C0E46319D69" unitRef="usd">7586000</us-gaap:ContractualObligationDueInFourthYear>
	<us-gaap:ContractualObligationDueInFourthYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_EmploymentContractsMember" decimals="-3" id="Fact-CD0C066423EBAD5F660B8C0E4633B72A" unitRef="usd">0</us-gaap:ContractualObligationDueInFourthYear>
	<us-gaap:ContractualObligationDueInFourthYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LiabilitiesTotalMember" decimals="-3" id="Fact-B649D2B04789241DEDAA8C0E46316D91" unitRef="usd">236000</us-gaap:ContractualObligationDueInFourthYear>
	<us-gaap:ContractualObligationDueInFourthYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LicenseAgreementTermsMember" decimals="-3" id="Fact-586CA0DAFC6CF70FB5308C0E4631E482" unitRef="usd">7350000</us-gaap:ContractualObligationDueInFourthYear>
	<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="FI2016Q4" decimals="-3" id="Fact-D2426A77FED0138D75658C0E46351C8B" unitRef="usd">3233000</us-gaap:ContractualObligationDueInNextTwelveMonths>
	<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_EmploymentContractsMember" decimals="-3" id="Fact-32C0491275117C188DCC8C0E46355C2A" unitRef="usd">1601000</us-gaap:ContractualObligationDueInNextTwelveMonths>
	<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LiabilitiesTotalMember" decimals="-3" id="Fact-3D780DD296A88459E75A8C0E4631666A" unitRef="usd">1842000</us-gaap:ContractualObligationDueInNextTwelveMonths>
	<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LicenseAgreementTermsMember" decimals="-3" id="Fact-69249D28ADB4B76C5BC48C0E4631D348" unitRef="usd">1391000</us-gaap:ContractualObligationDueInNextTwelveMonths>
	<us-gaap:ContractualObligationDueInSecondYear contextRef="FI2016Q4" decimals="-3" id="Fact-2370B328F3907D2AED578C0E45F7EE62" unitRef="usd">596000</us-gaap:ContractualObligationDueInSecondYear>
	<us-gaap:ContractualObligationDueInSecondYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_EmploymentContractsMember" decimals="-3" id="Fact-4062F6F873A36249D9488C0E46331CE9" unitRef="usd">0</us-gaap:ContractualObligationDueInSecondYear>
	<us-gaap:ContractualObligationDueInSecondYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LiabilitiesTotalMember" decimals="-3" id="Fact-453164FD928DABC360488C0E46337570" unitRef="usd">246000</us-gaap:ContractualObligationDueInSecondYear>
	<us-gaap:ContractualObligationDueInSecondYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LicenseAgreementTermsMember" decimals="-3" id="Fact-D7EEA5112B6A92B5CC728C0E46310EE3" unitRef="usd">350000</us-gaap:ContractualObligationDueInSecondYear>
	<us-gaap:ContractualObligationDueInThirdYear contextRef="FI2016Q4" decimals="-3" id="Fact-08115376B0FB610C16CD8C0E45A3C1AC" unitRef="usd">601000</us-gaap:ContractualObligationDueInThirdYear>
	<us-gaap:ContractualObligationDueInThirdYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_EmploymentContractsMember" decimals="-3" id="Fact-5B9774DD072D1F57E7D48C0E46330BA2" unitRef="usd">0</us-gaap:ContractualObligationDueInThirdYear>
	<us-gaap:ContractualObligationDueInThirdYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LiabilitiesTotalMember" decimals="-3" id="Fact-8776EF77163FE189A2698C0E4631A3F6" unitRef="usd">251000</us-gaap:ContractualObligationDueInThirdYear>
	<us-gaap:ContractualObligationDueInThirdYear contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_LicenseAgreementTermsMember" decimals="-3" id="Fact-54A5791DEC64FF6D39228C0E4635A094" unitRef="usd">350000</us-gaap:ContractualObligationDueInThirdYear>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-83234F24178C756DCDBC8C0E45DD2801" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A1710B1DDD33D8F939518C0E45DD9863" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D544B857BCFF6FD7FAFC8C0E45EB7EE6" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D222624124A6B6A773B88C0E45EAB75F" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-953E7DBB672818281A478C0E45E42D42" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BFA7E4814E232095D7248C0E45F1C154" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2420FB3F2E010C624B088C0E45DBF48A" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-36FB27D2A2D98C59375F8C0E45DD8E60" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F436BB16B2DC8500BC548C0E45EA519D" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="I2013Q2May8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-B8C49174026E231A0BEE8BBCDB74CEC4" unitRef="usd">10000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-E3425BD2C87FD1054EACB9E7DEA0C590" unitRef="usdPerShare">12.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-F6D067040B64236F805EB9DF2ED10CE3" unitRef="usd">25530000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2013Q2May8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-D0C79B27E9A10E6CF2D48BBCDB7B1A52" unitRef="number">0.0845</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="2" id="Fact-5B33055E031BBFBD5411B9E0D405915F" unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="D2016Q4Dec14_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="3" id="Fact-2B093B50A298818EF333B9E4C02D1074" unitRef="number">0.075</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtInstrumentTerm contextRef="D2013Q2MAY8_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" id="Fact-1E47127ECA8A4F466BF68BBCDB673FDA">P30M</us-gaap:DebtInstrumentTerm>
	<us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="0" id="Fact-848A33261CC3181BBB9CB9F39A4105B5" unitRef="usd">1224672</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9EF25918F518E40DFFE38C0E45E608DD" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C0E97AB802F22BFF3C978C0E45E6683C" unitRef="usd">332000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EC1C89AD422163D226FA8C0E45E6F5AC" unitRef="usd">210000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-21FC7DC6823C9308B7C18C0E45E499D8" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2A7448DF6CD3830D315A8C0E45E40D4C" unitRef="usd">365000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0AD0B93BABC0DBCD91058C0E45E45B19" unitRef="usd">243000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-700F3FB506BF60AE75898C0E45F3993B" unitRef="usd">5418000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-ACF10C3ED18415560D528C0E45F3D2E8" unitRef="usd">5661000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BFD2904F8E2B88BE90078C0E45BE7B2A" unitRef="usd">365000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
	<us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="FD2016Q4YTD" decimals="-3" id="Fact-11D73E104498F19A20808C0E45CC0A37" unitRef="usd">243000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-FD436FA55D95269B3C6A8C0E45E42BE5" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C57E101FC6EA0F6F03BA8C0E45E431DB" unitRef="usd">33000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7FAF5836C73A610471448C0E45E4D9D0" unitRef="usd">33000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2015Q4" decimals="-3" id="Fact-AC6C0E3EC4B34DB6B2568C0E4624524F" unitRef="usd">95477000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4" decimals="-3" id="Fact-448A38A33A02A80994188C0E46236A76" unitRef="usd">117329000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-FFE523B3F2398CE4298A8C0E4610A89B" unitRef="usd">-5418000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-E1289E0D9680B5CCE49D8C0E45D52C9C" unitRef="usd">-5661000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2015Q4" decimals="-3" id="Fact-B5B80E65E602B4F50E868C0E462D8218" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-5AAC962F0B5F1802E2838C0E4624D114" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2015Q4" decimals="-3" id="Fact-372232E08AF08D16A58A8C0E462C4466" unitRef="usd">75221000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2016Q4" decimals="-3" id="Fact-55E7390525E7D4BA3EB38C0E462409B2" unitRef="usd">97168000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2016Q4" decimals="-5" id="Fact-FD2BB848CE172A7CF2D48C0E45CC6AB9" unitRef="usd">251500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2016Q4" decimals="-5" id="Fact-A110D36EBE3995FA60FF8C0E45CCAB1D" unitRef="usd">200000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="FI2015Q4" decimals="-3" id="Fact-BBCF05A61F3CCDBE4F568C0E462D6FBB" unitRef="usd">1430000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
	<us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="FI2016Q4" decimals="-3" id="Fact-1932674E112023914E418C0E46269440" unitRef="usd">58000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2015Q4" decimals="-3" id="Fact-82EC8F8BA8ED2FB540178C0E4622C9E3" unitRef="usd">3866000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2016Q4" decimals="-3" id="Fact-8D39EFCA20E92D6C3CD08C0E46247DD0" unitRef="usd">4083000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-35F2E4928D5AB8436C438C0E45CAE22D" unitRef="usd">2600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-89967DA98F3BF39965A98C0E45CEE53E" unitRef="usd">2500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2015Q4" decimals="-3" id="Fact-5D4E00D7E612F366C1478C0E4624B3AF" unitRef="usd">5050000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2016Q4" decimals="-3" id="Fact-2E052DA96A14711DA6D88C0E462422F2" unitRef="usd">5757000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-3" id="Fact-DCD5F0940061238F9BE08C0E462D3100" unitRef="usd">95477000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-2C458DF78699FB4A2D988C0E4626997E" unitRef="usd">117329000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="FI2015Q4" decimals="-3" id="Fact-7242AC57C90172742EFD8C0E45EA1ADA" unitRef="usd">5418000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
	<us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="FI2016Q4" decimals="-3" id="Fact-196F771876BF885C4EC08C0E45EA04B9" unitRef="usd">5661000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F7C1F4A394E4BC78903B8C0E461583B0" unitRef="usd">70000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0CC2312CE9B0B80E15218C0E4616E8ED" unitRef="usd">115000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2016Q4YTD" decimals="-3" id="Fact-ED6239009A9E18160FCE8C0E46152816" unitRef="usd">108000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-A52109754E73F9D73D178C0E45D01CAF" unitRef="usd">171000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6D3DE17EEDBBD8B22A448C0E45A6FA7C" unitRef="usd">96000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q4YTD" decimals="-3" id="Fact-709B781800C3D1EBB4338C0E45BE2FE6" unitRef="usd">86000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A0C1B8B4FE955C56CD448C0E45CA460A" unitRef="usd">107000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-3" id="Fact-21E6320BD1C8F628A6178C0E45B3D2F8" unitRef="usd">142000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E3E665A722FD19E453138C0E4624D680" unitRef="usd">392000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="FI2016Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-895C39FB0E3B13B208518C0E4626C93F" unitRef="usd">813000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-8F22390BFBE524D1FC2D8C0E462DF601" unitRef="usd">1491000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable contextRef="FI2016Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B795B81EBFD1B15FC7778C0E462CEA60" unitRef="usd">3115000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-0E275FF97BF60D18624E8C0E462C41DE" unitRef="usd">4434000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="FI2016Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-A6B7F0C14B1988B7D5A58C0E4626AA24" unitRef="usd">2944000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="I2015Q4Dec24_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_ZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-C73E023EAE3F1F3E319B8C0E4611E977" unitRef="usd">3750000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="I2015Q4Nov19_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsNetMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-446AD6699CD6B60CCEDC8C0E46136C7E" unitRef="usd">8348000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-8E7419202799CF59CD0B8C0E45CCCA62" unitRef="usd">1403000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-76BF400437F8E2CC8A908C0E45AD0381" unitRef="usd">1780000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-44061748543A24DBC6A78C0E45C9560F" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-94C448D3076B79C4BD4E8C0E45BB4ECA" unitRef="usd">440000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-9CE5B9179C41398FDE418C0E45A66253" unitRef="usd">921000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-5C105A8EA860B345FCB08C0E45BA2304" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-6B9C2BB9F5B11948DD6C8C0E45B30E6C" unitRef="usd">15118000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-48345AD515B3469639EC8C0E45B2C457" unitRef="usd">17655000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-00AF52B775361888587C8C0E45BC0E11" unitRef="usd">9562000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-278AA958A873ACA5FC588C0E462D24C6" unitRef="usd">9319000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-3881B3A696EB736EDFF68C0E45D0C0D0" unitRef="usd">9734000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-F85BD776ED757E05682C8C0E462D11A6" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D9A39DFA654D4B7F7A548C0E4622C449" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
	<us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-9DC43496A1F2E82B6C7D8C0E45A4C8F4" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
	<us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F93ECCF4BEA2216064AC8C0E45BE3424" unitRef="usd">-4549000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
	<us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-0C843A64AEFA2437CF198C0E45A55AA3" unitRef="usd">-4549000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
	<us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A480BFF023848A0A3B238C0E45BD3F0C" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
	<us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-13EA5EB494A5E2209B248C0E45B368BD" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="FI2015Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember" decimals="0" id="Fact-9C3F028E83561F6EA68A8C0E46153C12" unitRef="usd">97000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="FI2016Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember" decimals="0" id="Fact-7439720BDE1EF0D2957B8C0E46139B4B" unitRef="usd">20000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:EarningsPerShareBasic contextRef="FD2012Q1QTD" decimals="2" id="Fact-667A8F1CE2DC8B50F1748C0E45D089BB" unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2012Q2QTD" decimals="2" id="Fact-570E611D51A663680C228C0E45A3D3FA" unitRef="usdPerShare">-1.94</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2012Q3QTD" decimals="2" id="Fact-596D319792F48FCDFE018C0E46114F1C" unitRef="usdPerShare">-2.23</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2012Q4QTD" decimals="2" id="Fact-725BFDB41A4D109E34A38C0E460211CE" unitRef="usdPerShare">-2.51</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2013Q1QTD" decimals="2" id="Fact-CA13AB40DE1CF54259C28C0E45EAD8FB" unitRef="usdPerShare">-1.84</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2013Q2QTD" decimals="2" id="Fact-9DC8FB8990D12675649B8C0E46118FD6" unitRef="usdPerShare">0.59</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2013Q3QTD" decimals="2" id="Fact-3A21F481A629EA4EEA928C0E46041E15" unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2013Q4QTD" decimals="2" id="Fact-7B4151A9F24BEBD35FCD8C0E45D54398" unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-549529B76012A05E12368C0E45F7D9CF" unitRef="usdPerShare">-6.13</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-B0E8C569C6C62F8A8A258C0E4600E61C" unitRef="usdPerShare">-8.23</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-48DFE1520480D9A561718C0E45B17EC9" unitRef="usdPerShare">-2.36</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-F91F331C48A4C7EAC5818C0E45F42406" unitRef="usd">1535000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-893CA8EFA57E8B76E3848C0E45F3F0EF" unitRef="usd">975000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E1BB37DEC008BFDD55948C0E45BDB986" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5E105A8FEEDD750D65738C0E45BFFDB7" unitRef="usd">14518000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B3DF0589200FA5DB57F88C0E45BE2C1C" unitRef="usd">6142000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-746DF93B99AEF95B3EBB8C0E45BAF025" unitRef="usd">20660000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4B8D5F099CC5598924118C0E4631A318" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-986C596D9DB672D1E24C8C0E4631A7FF" unitRef="usd">1860000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DD7C0F03C6903F75B1FD8C0E462F60DD" unitRef="usd">1095000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-052AF9C715C2E68FB6C38C0E45E83E4A" unitRef="usd">2955000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2013Q2May13_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-80D4C2256CFDC01DFAD3C8186991D97F" unitRef="number">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2016Q2Jun29-Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-3D71970BA9EDAE4DF267C811B52CC513" unitRef="number">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-C72F072413836DC708FCC86750B5E79C" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-FBFFD3FBEC1279BDB88BC80E8E97692F" unitRef="number">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2013Q2May13_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" id="Fact-641E8F6EA2D2A4E8B251C819564D9963">P7Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2016Q2Jun29-Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" id="Fact-0124176867C08B4686C2C8102744A922">P5Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" id="Fact-6F3233AE5606AC5FFD55C80D6ADEB449">P5Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2013Q2May13_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-EDBBCEBD607FBA81650CC818CE50712F" unitRef="number">0.7534</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2016Q2Jun29-Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-006E7EC0A2058D4453C0C80FC6578F84" unitRef="number">1.0663</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-A7C705A275583C3C3135C80E1C33B005" unitRef="number">0.7713</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2013Q2May13_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-562EA75F87A7E23906B6C8189047E1B1" unitRef="number">0.0120</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q2Jun29-Jun29_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-E72C383718BE3903C37DC80FF94CC763" unitRef="number">0.0135</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember" decimals="4" id="Fact-4E170F32D0B71034B4FFC80E5B13FC90" unitRef="number">0.0126</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:GainLossRelatedToLitigationSettlement contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A88E1923CBC8287621468C0E45E4EC7F" unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
	<us-gaap:GainLossRelatedToLitigationSettlement contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8A14A3577A13B42E3E0B8C0E45BCC202" unitRef="usd">-5282000</us-gaap:GainLossRelatedToLitigationSettlement>
	<us-gaap:GainLossRelatedToLitigationSettlement contextRef="FD2016Q4YTD" decimals="-3" id="Fact-058192A7611809A344328C0E45DB7AA8" unitRef="usd">-2750000</us-gaap:GainLossRelatedToLitigationSettlement>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-3" id="Fact-0FB2DFB099B4CD5ABF288C0E45F7FFB1" unitRef="usd">5898000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-3" id="Fact-C7AC1B91754C1CB62DDA8C0E4613A149" unitRef="usd">5898000</us-gaap:Goodwill>
	<us-gaap:GrossProfit contextRef="FD2012Q1QTD" decimals="-3" id="Fact-1E95773B32A39928641A8C0E4600BA5D" unitRef="usd">2357000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2012Q2QTD" decimals="-3" id="Fact-EBDD2126E9071EA612A48C0E46040771" unitRef="usd">2914000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2012Q3QTD" decimals="-3" id="Fact-091E1A641D0E187F05ED8C0E461111A6" unitRef="usd">1454000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2012Q4QTD" decimals="-3" id="Fact-EC4066C098AF4C20B2198C0E45E88EEE" unitRef="usd">1229000</us-gaap:GrossProfit>
	<us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="FI2016Q4_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_IndemnificationGuaranteeMember_us-gaap_LitigationCaseAxis_gale_SECLitigationMember" decimals="-3" id="Fact-7C1EA04825C453AC8509B9BDA0335F92" unitRef="usd">750000</us-gaap:GuaranteeObligationsCurrentCarryingValue>
	<us-gaap:ImpairmentChargeOnReclassifiedAssets contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-5" id="Fact-CD0435F17F03D59D2EB38C0E45C1C4A7" unitRef="usd">8100000</us-gaap:ImpairmentChargeOnReclassifiedAssets>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2014Q4YTD" decimals="-3" id="Fact-274F3F81787530CE71B88C0E46241F95" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B09183B660AC8F687BCE8C0E45B3C710" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2015Q4YTD" decimals="-3" id="Fact-29D614EB9906DAB2CF658C0E45B15896" unitRef="usd">8071000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-D355450511CFE3D512A28C0E45B37DF8" unitRef="usd">8071000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2016Q4YTD" decimals="-3" id="Fact-012B1630973631C288128C0E45A4FCEB" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B0950113CA1D02C47BAF8C0E45AC4FD2" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E6FBDB611AA2AC65C75B8C0E45A57058" unitRef="usd">-28284000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-504C30769A2491E73ECB8C0E45F5C005" unitRef="usd">-38956000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D6DE9B5B7B23C04F16488C0E45A44DE2" unitRef="usd">-11101000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-442CA448B4FDCF78B4478C0E45E69921" unitRef="usd">-28284000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4F9772CD6132AF924D2E8C0E45A5C191" unitRef="usd">-38591000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2700520C767A36F42DB68C0E45B2F5F8" unitRef="usd">-10858000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2014Q4YTD" decimals="2" id="Fact-B93AB05E9C01AB98904A8C0E45C8BA97" unitRef="usdPerShare">-4.74</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q4YTD" decimals="2" id="Fact-4F84D22C530E6644E9868C0E45BD9B78" unitRef="usdPerShare">-5.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2016Q4YTD" decimals="2" id="Fact-B8B90B3D7093C6A83AB48C0E46059270" unitRef="usdPerShare">-1.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-512FED4DFFD22C9DC2118C0E45AD64A8" unitRef="usd">8322000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1417A7378CD75A139D488C0E45AFC50D" unitRef="usd">24946000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-782438E3637AF58E0AB68C0E45C7AB1E" unitRef="usd">12448000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8FC667E191BE6B7C57288C0E4635E2F3" unitRef="usd">-8322000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-0344AC48EE7D9FBA7E038C0E45D0118D" unitRef="usd">-8322000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A7F6CF104B67615843AE8C0E45EAB1B1" unitRef="usd">-24946000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2015Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-DFAED14CBF62D7C3AB108C0E45AFC18B" unitRef="usd">-24946000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9DB3A451B6A3F365D68F8C0E46151605" unitRef="usd">-12448000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2016Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-9DDAD215E320FE4BFB888C0E462D99C0" unitRef="usd">-12448000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2014Q4YTD" decimals="2" id="Fact-0B71FC0398690F5333238C0E45AB39E0" unitRef="usdPerShare">-1.39</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2015Q4YTD" decimals="2" id="Fact-060EC5956EFF954B879F8C0E45CAC8DE" unitRef="usdPerShare">-3.21</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2016Q4YTD" decimals="2" id="Fact-3979B128ECA4CC104D348C0E462FC1E6" unitRef="usdPerShare">-1.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-82438B9F3C8DEDC14D5B8C0E45F12467" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FF59431AF7A75795F9B68C0E4605F055" unitRef="usd">365000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5FED41BEF5CB31DB8D418C0E45EB31EC" unitRef="usd">243000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2014Q4YTD" decimals="-3" id="Fact-AEF5C89E39CCD4A68F3D8C0E46093719" unitRef="usd">17275000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FDCAEA27123B05B83B078C0E4607C77B" unitRef="usd">24029000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7BD7DD3CCB0821B7465B8C0E46109314" unitRef="usd">21852000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q4YTD" decimals="-3" id="Fact-66152B2495D70CC669E48C0E45FE345D" unitRef="usd">-12447000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="-3" id="Fact-87C569DFAD478B5A7A2B8C0E45F9E38C" unitRef="usd">-21603000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-903B1AA0657FD3D8D5508C0E4603F0B4" unitRef="usd">-7977000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C83782C57A99CC6238D28C0E4607FE73" unitRef="usd">3996000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CF2A5778847D746D3C808C0E45F9F0BD" unitRef="usd">508000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2016Q4YTD" decimals="-3" id="Fact-04F858627378187D711A8C0E4613FD7E" unitRef="usd">-1782000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-69CBE8915573C17088FE8C0E46049146" unitRef="usd">-996000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8B2460E7EE60B97381EC8C0E45F8C86B" unitRef="usd">538000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-83B3173550E04870D99A8C0E46002A5E" unitRef="usd">-1330000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2014Q4YTD" decimals="-3" id="Fact-96E2AFFF1DD8E095FFB28C0E46074A7D" unitRef="usd">-1283000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5A9FF64EC8FF8CDE48BB8C0E460FA4A5" unitRef="usd">-2375000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2E96CF0A9112571654D18C0E460050C0" unitRef="usd">-1575000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationTaxCredits contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6E4CB4A0054290E322618C0E46139128" unitRef="usd">-42000</us-gaap:IncomeTaxReconciliationTaxCredits>
	<us-gaap:IncomeTaxReconciliationTaxCredits contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A0A79A6DAEC4259E532F8C0E45F98809" unitRef="usd">276000</us-gaap:IncomeTaxReconciliationTaxCredits>
	<us-gaap:IncomeTaxReconciliationTaxCredits contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D66C670A5A2F1FC66EB98C0E4608EECD" unitRef="usd">217000</us-gaap:IncomeTaxReconciliationTaxCredits>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1529F5911C8A86DB5F6F8C0E45CC3410" unitRef="usd">-21000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DB89ADCA9B8E8D14B4F58C0E45ADC4E0" unitRef="usd">-289000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B2B83E281EA9ECDE7F498C0E46229C0D" unitRef="usd">-757000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A701F0A10DFEBB02B6888C0E462029CA" unitRef="usd">4044000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DB22530BCCC513DCC76A8C0E45BA8C9D" unitRef="usd">-3593000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-490B788596CD06DA6E9F8C0E45CCC066" unitRef="usd">-50000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2787107297ACF796CEA08C0E45CCE197" unitRef="usd">-2490000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
	<us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FE0E7294B9E78B33FF2F8C0E45BBC619" unitRef="usd">-2968000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
	<us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DDE5D3B88B3918A2773C8C0E45AF328E" unitRef="usd">-763000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
	<us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-EC65CCE589DEC2B2757E8C0E45C1708B" unitRef="usd">0</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
	<us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9E4B44B39F2DD429431A8C0E45C90103" unitRef="usd">21700000</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
	<us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5B3840DE4096364BD3B28C0E45BB878B" unitRef="usd">-21700000</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-983CB02A7E7E03B073F58C0E45BB0CA0" unitRef="usd">1078000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8697119238C6798090AF8C0E45C98431" unitRef="usd">245000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-11B43B1CE29E1F7681478C0E45C8028B" unitRef="usd">-892000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F4B0FED9CEA69C73C5998C0E45BDCC8C" unitRef="usd">201000</us-gaap:IncreaseDecreaseInRestrictedCash>
	<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="FD2016Q4YTD" decimals="-3" id="Fact-154A6FDC91B55FAA912F8C0E45BF9252" unitRef="usd">0</us-gaap:IncreaseDecreaseInRestrictedCash>
	<us-gaap:InsuranceSettlementsReceivableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-42A165387677E093AE8D8C0E45DB51AF" unitRef="usd">21700000</us-gaap:InsuranceSettlementsReceivableCurrent>
	<us-gaap:InsuranceSettlementsReceivableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-697C8FEF0996EA93F5158C0E45C9DD2C" unitRef="usd">0</us-gaap:InsuranceSettlementsReceivableCurrent>
	<us-gaap:InterestPaid contextRef="FD2014Q4YTD" decimals="-3" id="Fact-343577042B7D78B2532D8C0E45C78B92" unitRef="usd">800000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2AFC627EDDB4269C68008C0E45BDCFE1" unitRef="usd">541000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-46AC2B44A88E83BC6CA48C0E45BD2655" unitRef="usd">636000</us-gaap:InterestPaid>
	<us-gaap:InterestPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-49FF59980D533916DF998C0E45F79EEB" unitRef="usd">28000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-66A7A5C0EAAA77D7E15E8C0E45F3B587" unitRef="usd">0</us-gaap:InterestPayableCurrent>
	<us-gaap:LegalFees contextRef="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-E45BB1733E907976A982B7F284CD77BA" unitRef="usd">4500000</us-gaap:LegalFees>
	<us-gaap:LegalFees contextRef="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-F37CF5446AEF2CC0FCA7B9CDFA3F41D5" unitRef="usd">4500000</us-gaap:LegalFees>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-3" id="Fact-5496AF2F4941F8C62E298C0E46314006" unitRef="usd">68631000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-58E4FB04C903EC7310A38C0E45E42F46" unitRef="usd">37154000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-AA35BF2F19BAFE5F5DB48C0E46173E20" unitRef="usd">82144000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-32EB3A044B5CCE3DFDF58C0E45D90B0D" unitRef="usd">65811000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-0047C88F62FFA38B802C8C0E4613FF88" unitRef="usd">57071000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-CC3F8FBC909932035FFC8C0E460081B1" unitRef="usd">30398000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-3B73E8AF45ED815CFF9E8C0E45D96DC0" unitRef="usd">5925000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-C797EAA80D39714131B98C0E46245BAD" unitRef="usd">5925000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-510B2C40003C3A8829708C0E45F8DE79" unitRef="usd">6059000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2016Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-6129902E66159E12CF8B8C0E46266E7A" unitRef="usd">6059000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-1A157C7D5F069A296EB48C0E45DA5282" unitRef="usd">25000000</us-gaap:LitigationReserveCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5A90E38FF119172662928C0E45F99CD9" unitRef="usd">950000</us-gaap:LitigationReserveCurrent>
	<us-gaap:LitigationSettlementAmount contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase1Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-3" id="Fact-1A3DE347A2791942ABB6B7F2C429D00D" unitRef="usd">-150000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="D2016Q4Dec22-Dec22_us-gaap_LitigationCaseAxis_gale_SECLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" decimals="-3" id="Fact-3F6819C57433EDEE14C0B9BF99459042" unitRef="usd">-200000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="D2016Q4Dec22-Dec22_us-gaap_LitigationCaseAxis_gale_SECLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_TitleOfIndividualAxis_gale_FormerCEOMember" decimals="-3" id="Fact-096523D48899CB560389B9C69AC5A0F4" unitRef="usd">-600000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1CBC4801AC37C43510BCB8072E40B135" unitRef="usd">27750000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" decimals="-3" id="Fact-42DEC69DE9EFFB247AD3B7FBF4016004" unitRef="usd">5000000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" decimals="-3" id="Fact-C9BED2F5B1BF06F22C3AB7FBF1EAF76B" unitRef="usd">20000000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_SECLitigationMember" decimals="-3" id="Fact-71AC410E2DB73FC69BCBB7FD411521DD" unitRef="usd">950000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_ShareholdersSecuritiesLitigationMember" decimals="-3" id="Fact-C571FA89E1DEEB6491DEB7FBF5DCB99C" unitRef="usd">1800000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-E07CE6FC43A1FD61129C8C0E46176DC2" unitRef="usd">4739000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-96D31A53AC475CDDE8348C0E45CEA2EE" unitRef="usd">16397000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-6" id="Fact-5F1F2A38BF76080A3F8C8C0E45AD4A60" unitRef="usd">20000000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-6" id="Fact-A822893F668C64698A1D8C0E45B10D2C" unitRef="usd">20000000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-6" id="Fact-AE6064AEBAB059E207198C0E45B1C9E9" unitRef="usd">15000000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesPaidValue contextRef="D2015Q4Dec3_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-9F3F9AB2D41B5C060C888C0E45AF2308" unitRef="usd">3300000</us-gaap:LossContingencyDamagesPaidValue>
	<us-gaap:LossContingencyDamagesPaidValue contextRef="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-6A3CF6620DFAA3431C188C0E45B1B519" unitRef="usd">3300000</us-gaap:LossContingencyDamagesPaidValue>
	<us-gaap:LossContingencyNumberOfDefendants contextRef="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember" decimals="INF" id="Fact-3B49258F9EB597F9D314B920B2767E8E" unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B7FA710A9F3400EC2E3D8C0E45BA8A59" unitRef="usd">24260000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BD8D0F729F2DAD46E4568C0E45C952C8" unitRef="usd">43845000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-083E18C46E14736572AE8C0E45CA0C1B" unitRef="usd">34324000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6C33E513B29EC69190458C0E4622D766" unitRef="usd">-5528000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D8F12D0843DA5298426D8C0E45BB38EC" unitRef="usd">10395000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-19E57593A4EFF453483D8C0E45BF7E72" unitRef="usd">-1056000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0811B3E91EE0A05C5A198C0E45B004CF" unitRef="usd">-2472000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-64DC22D02BBDC65411148C0E45B3FC47" unitRef="usd">-354000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1A82626E64D69F6A2C458C0E45AD3F33" unitRef="usd">-6000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A15AFFC49BC5E3EDE0308C0E45CAB9B1" unitRef="usd">-42869000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-859AD8A96568BE954D268C0E45B3E611" unitRef="usd">-48160000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FB289E5FAA78478AEE4B8C0E45CAF0D9" unitRef="usd">-44915000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8CDEE464069F7058E7108C0E4622B831" unitRef="usd">-37037000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F7F078B4C309B74BEEB28C0E45C7CD57" unitRef="usd">-38802000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-71D40B66C96A15D4C1C28C0E45C16EE3" unitRef="usd">-33230000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q1QTD" decimals="-3" id="Fact-3723820E0B3C067F35A78C0E46009183" unitRef="usd">-10537000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q2QTD" decimals="-3" id="Fact-6630F098D93413BF6CDB8C0E45D096DF" unitRef="usd">-15660000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q3QTD" decimals="-3" id="Fact-294EA184766E208BEC7D8C0E4635C214" unitRef="usd">-18026000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q4QTD" decimals="-3" id="Fact-77C523F2F58E5606B8F58C0E46028580" unitRef="usd">-19678000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q1QTD" decimals="-3" id="Fact-12E7DC09E9A13A9A06C88C0E46096965" unitRef="usd">-16493000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q2QTD" decimals="-3" id="Fact-358716B40AEFB7E0DFA68C0E4607C3A2" unitRef="usd">5389000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q3QTD" decimals="-3" id="Fact-9E36B0D30ECC2C22CC6A8C0E45A6E129" unitRef="usd">-6929000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4QTD" decimals="-3" id="Fact-7DA6546E096AB98376B18C0E4635FC73" unitRef="usd">-5516000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F3136A4BBC04B05A99A28C0E45F52543" unitRef="usd">-36606000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-FA3A259678F240F742CC8C0E45DDB0E2" unitRef="usd">-36606000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-476E6AB5E6E2CBC4B7118C0E45BBF821" unitRef="usd">-63902000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-54E153559C8878DB47028C0E45E61344" unitRef="usd">-63902000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C297D0DE4F35AE9F77498C0E45ADC88D" unitRef="usd">-23549000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-CE5850A971680AFEB84FB4D44D6A8DF0" unitRef="usd">-23549000</us-gaap:NetIncomeLoss>
	<us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="FD2014Q4YTD" decimals="-3" id="Fact-AC4CAF8A3B305E3F8FFE8C0E45BFAF3D" unitRef="usd">2500000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
	<us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7D1325FB08B997A7FD428C0E45C04EBE" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
	<us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-58CA1F5577B918974EC88C0E45C8A37E" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-22B2EBF5AFF130055C2F8C0E45CCD602" unitRef="usd">15616000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0B8A360F166E2C5F117B8C0E46171566" unitRef="usd">-4371000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7D358ADAB5E6BB5B29B18C0E45F6E51D" unitRef="usd">21009000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:OperatingExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0E8779008C478FE5E4CC8C0E46337048" unitRef="usd">43900000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B7F0DF94EFDE50E6228E8C0E45E64A2A" unitRef="usd">34220000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1D25DE361BE5C0B1C1C68C0E45F2635A" unitRef="usd">31867000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-440DC93CC6F873172AA08C0E45B071E3" unitRef="usd">-43900000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-06FD5C454124D8E3F8118C0E461D8602" unitRef="usd">-34220000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9E412C1EA9B42B4907628C0E4600236A" unitRef="usd">-31867000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2016Q4" decimals="-3" id="Fact-F96382DDC128845F73708C0E46316C4A" unitRef="usd">974000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-4215800790FF8C8908B88C0E46319CD1" unitRef="usd">241000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2016Q4" decimals="-3" id="Fact-8E1980CF948BE209D9DE8C0E4631D53C" unitRef="usd">236000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2016Q4" decimals="-3" id="Fact-FF11BD3D5EE6ABFAB0EA8C0E45F7E52F" unitRef="usd">251000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2016Q4" decimals="-3" id="Fact-DCE17E3F31DFE770CBB68C0E4633545D" unitRef="usd">246000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BBC812BB18EF24FB16778C0E45A33EE4" unitRef="usd">1052000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0812A6E5548AEB915FCE8C0E45BA24D7" unitRef="usd">170000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-44DDC01D467F4D0463888C0E45A36333" unitRef="usd">509000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4A39ACD208AC698404978C0E45F60917" unitRef="usd">5047000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentsForLegalSettlements contextRef="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-47AA985886AD665038078C0E45AD2CFA" unitRef="usd">2300000</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsForLegalSettlements contextRef="FD2016Q4YTD" decimals="-3" id="Fact-348E48DB0C25A5FC4AC6B80561964982" unitRef="usd">2450000</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8D975ADAA48D624523988C0E46207B63" unitRef="usd">2415000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7FC9773A4B5E5385B2F48C0E46253E13" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B111E777C44A2966C69F8C0E4620C927" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D5746E07706CD8B5A0238C0E4624CBFD" unitRef="usd">3056000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8A21D8D33FD4768639E58C0E45BD1F92" unitRef="usd">534000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CEEA69217555A3FD51238C0E45AFEAB8" unitRef="usd">0</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5C30068C140281224AA68C0E46229549" unitRef="usd">57000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-800F4101757ACFD21AF98C0E46241BA9" unitRef="usd">153000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-58C4580CF47EACD097A18C0E45C6A8BD" unitRef="usd">6000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-8E334B4E9F6EE12B59F68C0E45DB3302" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-B9763A6117768F18DC788C0E45DB2B05" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-77E05362B425875A99928C0E45DB0E79" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-12ACAC03524B81EDCBB38C0E45DB93B0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2015Q4" decimals="INF" id="Fact-08122940F809F3CF96EA8C0E45D79446" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-BE890E7D7E666DC7FA1D8C0E45DA3D0E" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-7EABF5693C6914B937F58C0E45D9A5A9" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-39C734B0CE2AF389C4E08C0E45DB8EBA" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-19E389340D4DF73868DE8C0E46132187" unitRef="usd">1398000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-2A62D849DBCB6A0741EA8C0E4607156F" unitRef="usd">581000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2014Q4YTD" decimals="-3" id="Fact-CAA9E28314C6003C08F18C0E45C75726" unitRef="usd">15000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B0CB6759E63F281FFB268C0E45C84DF0" unitRef="usd">18000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1FDC8FCA78A049BAA0CE8C0E45C0FDD1" unitRef="usd">117000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1F063765773E1D59EA968C0E45C7F0FB" unitRef="usd">10704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0CDC42414817A1CA64058C0E45C0FB69" unitRef="usd">47416000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="-5" id="Fact-63396CBEA5233BE6064DC620510E35A6" unitRef="usd">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2DE8D4CEAA7E5F8D9A658C0E45BF150F" unitRef="usd">33534000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="-5" id="Fact-88E632C7E0D23C3C56BBC6201E1E311F" unitRef="usd">800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BAEA1333613BDE2EBAD98C0E45BCA834" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-78E4D4D55FFE51F2F52E8C0E45BFF3CE" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E9126349E702308D73EC8C0E45AD68B4" unitRef="usd">23401000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="-5" id="Fact-1D0EEB6C652DBD1C6C50B9DF870FA3DA" unitRef="usd">23400000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="D2016Q3Jul13" decimals="-5" id="Fact-1F6D2D55E18131D5C15EC629F7C512FB" unitRef="usd">11700000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q4Nov18_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="INF" id="Fact-86050E1015AE24A59B998C0E460555E2" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q4Nov18_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="-5" id="Fact-2DF54D32701BCC7CA6CF8C0E460F7708" unitRef="usd">4900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="-6" id="Fact-2461EBBD5D89F4D9EE7F8C0E4606FC85" unitRef="usd">38000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2014Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="-5" id="Fact-AA2508FFEC58A826C9938C0E461173B1" unitRef="usd">8500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2014Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-DE12B59CAD32C49223EF8C0E461194E9" unitRef="usd">2300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-BFAA29F93CEFD65035D38C0E46070706" unitRef="usd">2300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2016Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-166A0438AA49CDDB5D47C61D7CF3D804" unitRef="usd">900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-94CA8E6EAAF9320B5D858C0E46223661" unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
	<us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-517413CB614A1DE2AB538C0E45B35336" unitRef="usd">11283000</us-gaap:ProceedsFromSaleOfProductiveAssets>
	<us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AA2FA74F40DE4B4077938C0E45ACC534" unitRef="usd">-1050000</us-gaap:ProceedsFromSaleOfProductiveAssets>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6FA17019C8D3677DAF5F8C0E45B1F292" unitRef="usd">4342000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B15B134543B2671AC00F8C0E45A627AE" unitRef="usd">31000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0C6092C138D4631F7C3D8C0E45BA4AB7" unitRef="usd">261000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProfessionalFees contextRef="D2015Q4Dec1-31_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-96628141530D12665F3B8C0E45AF34D2" unitRef="usd">2000000</us-gaap:ProfessionalFees>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-C884AD45BF2CD9D65D5F8C0E45B368E4" unitRef="usd">335000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-BC08D4EA5D1D67DED8368C0E463A3105" unitRef="usd">199000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-33462BE8A8F3BDF577DD8C0E461ED382">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-C2CBEB5192D6209BD9D08C0E45F97916">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2014Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_ServicesProvidedbyCorporateCounselMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember" decimals="0" id="Fact-D76446AA676E009804148C0E4613DB0D" unitRef="usd">533000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2015Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_ServicesProvidedbyCorporateCounselMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember" decimals="0" id="Fact-88628B08CDDBBA597D108C0E4615FB79" unitRef="usd">577000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2016Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_ServicesProvidedbyCorporateCounselMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_TroyGouldPcMember" decimals="0" id="Fact-400638488E916109AE458C0E461380E5" unitRef="usd">209000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-88ACD43A46E2B04AB1D88C0E4620D00A" unitRef="usd">1766000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E8C59227CB678F8488688C0E45ADFB84" unitRef="usd">3911000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-120FC1999CCCB2843EED8C0E45BF1FC1" unitRef="usd">5579000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1834310078D7D766CF638C0E460624C6" unitRef="usd">27674000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AF420BFBFBC658BAEB868C0E45F7A36C" unitRef="usd">23611000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2639A53BF5C9D6B673388C0E463398A3" unitRef="usd">19860000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-63FBFF584F5585F340718C0E45D9F9AD" unitRef="usd">401000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-DD89F0DE88CBB6A7181A8C0E4609E174" unitRef="usd">18022000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:SalesRevenueNet contextRef="FD2012Q1QTD" decimals="-3" id="Fact-0856B8A21FD763E099108C0E46046AF2" unitRef="usd">2750000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2012Q2QTD" decimals="-3" id="Fact-7D153E73D69EB47A68F18C0E45E4CE28" unitRef="usd">3382000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2012Q3QTD" decimals="-3" id="Fact-5DE23A76557AC9C639B68C0E4605469D" unitRef="usd">2166000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2012Q4QTD" decimals="-3" id="Fact-8E95ABD437E4569E26F68C0E46028D5F" unitRef="usd">1436000</us-gaap:SalesRevenueNet>
	<us-gaap:SeniorNotes contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="0" id="Fact-E4EE222F302F8CEC5577B9F01E6783F3" unitRef="usd">17621702</us-gaap:SeniorNotes>
	<us-gaap:SeniorNotes contextRef="I2017Q1Mar15_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-D437FF56003939B0CDDCB9F426ECBA54" unitRef="usd">13671702</us-gaap:SeniorNotes>
	<us-gaap:SeniorNotesCurrent contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="0" id="Fact-CE9060698C55B5B377A3B9F12F5A0CA0" unitRef="usd">16397030</us-gaap:SeniorNotesCurrent>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-AADB3508FC71561E6AC78C0E45A6111C" unitRef="usd">4666000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B96FF1F672740B3B5AB98C0E45BCC93D" unitRef="usd">1931000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CB2CC2D420B79177190E8C0E45CABEA0" unitRef="usd">2264000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" id="Fact-59BE902F6AC0789F9A288C0E45D5FAFA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-1395D53CD37A045171388C0E45F1FFDD" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-A83EA3A7ECBA34DEF3AD8C0E45F12282" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-FE9C111F2CFD9F4711628C0E45A4456D" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-98212D19B53E7B990C7D8C0E46133317" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-1C08EFA952183C971DB68C0E45B1054F" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-D35DB6928E3FB2FD944E8C0E45F42D82" unitRef="number">0.7937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-D5C80AA998EF76354E718C0E45A4089A" unitRef="number">0.7397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-2C7CCA181B5BBF6E6E0B8C0E45ADBC80" unitRef="number">1.0262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-CF36619354832E82DF498C0E45A6B55F" unitRef="number">0.0201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-015FBD406A24E54C6B4A8C0E45F5A89B" unitRef="number">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-AFD6060DA118226C185A8C0E4600CE2F" unitRef="number">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-721EDF0090193855B9D78C0E45D7FAB7" unitRef="shares">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2016Q4_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-E6432222E58B7AFAD04B8C0E45D01810" unitRef="shares">20930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2016Q4_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-608EEF2E11C44E5CC5788C0E45F4FD39" unitRef="shares">1325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2016Q4_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-9238DD007446978E05BD8C0E45D78B8C" unitRef="shares">501000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2016Q4" decimals="-3" id="Fact-01E59C2D59816E92F2588C0E46040C71" unitRef="shares">329000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-09D90C996DA58A17BCB48C0E46048FAF" unitRef="usdPerShare">56.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD" decimals="-3" id="Fact-406D5A6145B18DE76DBA8C0E460230B7" unitRef="shares">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-232B377DB3805930F2F98C0E45B16480" unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1EA3F93589099C9028BB8C0E4602DA5D" unitRef="shares">146000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-8FE231ADD14B3A2A97268C0E45D728D1" unitRef="shares">561000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-033D831C3475B6D0966D8C0E45F5E080" unitRef="usdPerShare">21.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-D27878438EC6CE9F4D218C0E45CE8973" unitRef="usdPerShare">6.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2014Q4" decimals="-3" id="Fact-A5B374350F134A34B43E8C0E45D7C51B" unitRef="usd">610000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q4" decimals="-3" id="Fact-27AF49B822C15A01E6708C0E45DBEDE5" unitRef="usd">539000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-BA44EF060B2511C9E38B8C0E45CE7C55" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="-3" id="Fact-128082D7890A809E305B8C0E46045012" unitRef="shares">663000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="-3" id="Fact-B284ACAD1BBC6888B9ED8C0E4604EE2C" unitRef="shares">561000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-1A7F7E5F7D292EFE8F818C0E4602C850" unitRef="usdPerShare">51.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-66132E4BECE2A8917C758C0E4602C0F7" unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-1CFE879965CB8FB2DDF78C0E4602B00C" unitRef="usdPerShare">31.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-B826E59C8ABF740A46D48C0E4602AA04" unitRef="usdPerShare">50.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-D98F360501496A03449F8C0E4609BCD9" unitRef="usdPerShare">9.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2014Q4Nov18_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="INF" id="Fact-86906EF0514BB81D696E8C0E4607732F" unitRef="usdPerShare">40.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="2" id="Fact-47C79EC50D14F75C96F48C0E460602BC" unitRef="usdPerShare">31.20</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" id="Fact-CEECA606A8CCBE25EC008C0E45D72042">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q4YTD" id="Fact-304F2016776110E7B8128C0E45A6598B">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD" id="Fact-1DF701D28F95B0A7A5238C0E45A63547">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD" id="Fact-FD19014B4B8359F472B58C0E45A4B038">P5Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2014Q4" decimals="-3" id="Fact-9196E9E760EDF16D06C88C0E45D75075" unitRef="usd">509000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2015Q4" decimals="-3" id="Fact-207BE76DBB1074F1F4168C0E45F820EF" unitRef="usd">518000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2016Q4" decimals="-3" id="Fact-07058315C8DC1BE081568C0E45F5680F" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2014Q4YTD" id="Fact-05921470109B5F886E088C0E45F3D125">P6Y6M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2015Q4YTD" id="Fact-C7382AA6C7950BA604CE8C0E45D02CBD">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD" id="Fact-85CED32FCEFFA802B3368C0E45D0C056">P5Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2014Q4YTD" id="Fact-27107265E6A0BD7CD1F78C0E45F56F4A">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD" id="Fact-AEAACA758381C406D8C68C0E45CCEE0A">P7Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-3447A6ED33F1871AFB918C0E45D04A57">P7Y0M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-B9C7D1B86227D3DDF5F28C0E45D71B7B">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-F4B0ECC5C34097175BEE8C0E45D7799B">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_gale_EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-609A91EDEA17490FF88D8C0E45D092F8" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-6339AA1AB41FAC67F21D8C0E45CE5FEC">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q1Jan12" decimals="INF" id="Fact-F8990BA0268961ECD1EFC623D7EF63BE" unitRef="usdPerShare">22.00</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q1Jan12_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="2" id="Fact-9EE558615506A1B295D1C6394FB8501C" unitRef="usdPerShare">1.00</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q3Jul14_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5984460225278BA594B5C628AB6A1938" unitRef="usdPerShare">9.00</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesOutstanding contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-81DF51E0B52C972DCF4A8C0E45E6B7D9" unitRef="shares">5505035</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A806A21EC7C78F846DF98C0E45E23B68" unitRef="shares">6507317</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A3AC92B7D722748F93688C0E45F37059" unitRef="shares">8129087</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-16293A357544FF4D822CB4D452F1E205" unitRef="shares">15224223</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-65F329069A900390BF648C0E45E4E9FC" unitRef="shares">273351</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-DB493A731B93F130656DB4D30085BDF0" unitRef="shares">20403</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2D3FCFB19C1D3DC790558C0E45E8FD41" unitRef="shares">5732</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-48D13BB6CDB7C4B1AD078C0E45CEC98F" unitRef="shares">11566</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD" decimals="INF" id="Fact-730B9EDE333C4FAE07CB8C0E45D99395" unitRef="shares">29070</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-28722FAFAD4016969315B4D357B2BC9A" unitRef="shares">5477</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q4Nov18_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="INF" id="Fact-E62B5DD6E628323091BA8C0E4602C051" unitRef="shares">31561</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q1Mar18_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="INF" id="Fact-535F2F11796A11C8E5A18C0E4602C1AA" unitRef="shares">1217948</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q1Jan12" decimals="INF" id="Fact-4A8AB591A6C9EACCBEECC62394EC5B92" unitRef="shares">988636</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q3Jul13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5BBDA79A71A24BC20008C627CE16CAFC" unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q1Feb13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_gale_UnderwrittenPublicOfferingMember" decimals="INF" id="Fact-7ADE8CDF842FA72DCAE8C62ABCCA33A9" unitRef="shares">17000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q1Jan01-Feb28_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-3A48EC34BAB0ADABF639B9F83D813B51" unitRef="shares">3541077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-25C7C32723789A7DA2A98C0E45E2251D" unitRef="shares">331650</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="INF" id="Fact-0AF178B648F6EDC2F5DD8C0E4600F9C3" unitRef="shares">230000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="INF" id="Fact-F9683BAA36EE6762B17F8C0E460065AF" unitRef="shares">70000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A34356ACBCC9846CF3BE8C0E45DD5D8D" unitRef="shares">1607934</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="INF" id="Fact-44D574046864E6BBB3E1C61F09ABDA36" unitRef="shares">135000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="INF" id="Fact-2661902CD7C15B536B5C8C0E460FDE66" unitRef="shares">72000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-664ACE83548A6D194F11B4CE4AB35F86" unitRef="shares">2872803</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="INF" id="Fact-5C9009CF1AC9670C8C55C61EEDCF3055" unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="INF" id="Fact-B534F6C1FE830CD9730FC61D1C5B098E" unitRef="shares">334000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A6772DFEEE5E473F40C4B595F04C0E65" unitRef="shares">206903</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="D2014Q4Nov18_us-gaap_SubsidiarySaleOfStockAxis_gale_LincolnParkCapitalLLCPurchaseAgreementMember" decimals="-5" id="Fact-8A733F6B0CB74A9AE7FF8C0E4609D775" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B541CFC98163097319E58C0E45E681A7" unitRef="shares">172488</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-62BFE8D0D284F7F6B0B48C0E45EAC7F8" unitRef="shares">2270</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-347B762821A26CCA19BA8C0E46028EAE" unitRef="shares">8000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2368463C9C5C741E93E1B4D43B2AC88F" unitRef="shares">8342</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-424468EAC1765CBC94DF8C0E45DD4AF4" unitRef="usd">37742000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-EE2B2A98E64465BDDA298C0E45E43C83" unitRef="usd">37741000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6B69B876011CDF8D4D918C0E45DB1351" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DD37F79AAA18B02FF2CAB4D30C3F249D" unitRef="usd">95000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CC3BCD3A32871ACEB33CB4D305DAF1A3" unitRef="usd">95000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-29FAC521669EFCEEFF37B4D302ECEE1D" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D056BBB25EC34B6C4BC68C0E45DDDE0E" unitRef="usd">263000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-86908BEAF7B32BF4A4948C0E45D9BC6B" unitRef="usd">263000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9CDBBA6DB4410A0438A68C0E45F3042C" unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-088DA5337890DF2B30708C0E45F157D8" unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD" decimals="-3" id="Fact-482B755A001EAAB8ED7AB4D362C179FB" unitRef="usd">2650000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D660476AE67749966926B4D35BEC81E5" unitRef="usd">2650000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2016Q1Jan12" decimals="-5" id="Fact-8296191F83E5A4A3DBF2C62439377ACA" unitRef="usd">21800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2017Q1Jan01-Feb28_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-DE847DC3A21DD0C2F5E9B9FD72FAFE81" unitRef="usd">3950000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F0C82461993331E15CAC8C0E45CE3E17" unitRef="usd">10705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-54FEB1BD8F18518E71FE8C0E45D95103" unitRef="usd">10704000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F3DAB1259516783D70138C0E45DB4460" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FB186FC66CAD4137674D8C0E45EC36E9" unitRef="usd">47416000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-56063A865914AE36C8728C0E45D7CD17" unitRef="usd">47413000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D69FBA78642DEA985C188C0E4600396B" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D53C54FA527DC61B5B10B4CE586CC6C2" unitRef="usd">33534000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-52B91B45AD9C51AC6E03B4CE5173A264" unitRef="usd">33534000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-294A7DE7C5B5ABC8F4A6B4CE4DFE2C4C" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-3" id="Fact-CC7AC6490F23825C3502B5968B8DD3D8" unitRef="usd">557000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C2924C87218FA95225F0B595FB5FE8F1" unitRef="usd">557000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5B931277DC0D838E373BB595F60AAADA" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2016Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-969DE99B45E4755A6C8FB5960AD53301" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6376B6EE6EB8B994D61E8C0E45D08C6F" unitRef="usd">4342000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1C230E175E876A4141028C0E45CE426F" unitRef="usd">4342000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B7A3CF6FFA88A54E82F58C0E45D9135C" unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5EC7AAEFFAC9D98C541A8C0E45DD58D4" unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-446ECC419512F7A805ABB4D44695900B" unitRef="usd">261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-59863B33773FFAE29C79B4D43FB786CC" unitRef="usd">261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-89EEFD0D3EB20D868AB98C0E45B9F493" unitRef="usd">13513000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-A2F96392220A576127808C0E46041210" unitRef="usd">28657000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4" decimals="-3" id="Fact-95FE2AC77B4C3208471E8C0E45DBBE6A" unitRef="usd">5886000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-72255EFD4C83EB03B6A08C0E45EAD241" unitRef="usd">188600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-3DCA95496003EBA5CD3E8C0E45E83495" unitRef="usd">10000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-2519E4F3C1E61163DB2B8C0E45F56435" unitRef="usd">-178875000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-3E79E043B00F6E35874E8C0E45F90FBF" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4" decimals="-3" id="Fact-3A197084A3194BBD59B98C0E45D0A03B" unitRef="usd">37059000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FFDA1998A778123534EC8C0E45F65114" unitRef="usd">256377000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-62A6EC753EB0528C19568C0E45D9DF73" unitRef="usd">12000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-86D51FEDD8A9A80F0E2A8C0E45D0B37F" unitRef="usd">-215481000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-0C15BFACC0B3DFEA72CD8C0E45CE524B" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-3" id="Fact-FA0DF7623FBF22746D5A8C0E45EACFDD" unitRef="usd">13513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4EB054BC896E00A774A88C0E45DBE71B" unitRef="usd">296730000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B71263230E33FB94C0B08C0E45E6843C" unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C03774533A6D9F1723B88C0E45F61391" unitRef="usd">-279383000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-0927CE4D979683C5695C8C0E45E60F3E" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-3" id="Fact-6FD6EF088489C6134B8FB4D465D52954" unitRef="usd">28657000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4894AC5581764D902694B4D458EAE83D" unitRef="usd">335423000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-91295B3CADF13DDE0AE4B4D455884876" unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-47696823F677A43D94FAB4D45EAA6826" unitRef="usd">-302932000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-847035E37E159217448FB4D4625AE9EA" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:TreasuryStockShares contextRef="FI2015Q4" decimals="INF" id="Fact-ECC2E81860294ABFEAF48C0E45D9E72B" unitRef="shares">33750</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2016Q4" decimals="INF" id="Fact-FE4E0877A2150BDCC4148C0E45DAF2D0" unitRef="shares">33750</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-F5EA6CADCB75F8219ED28C0E4615967B" unitRef="usd">3849000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-BBBA72AFB958E9ACB1F48C0E461527A4" unitRef="usd">3849000</us-gaap:TreasuryStockValue>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DE2770CD9B8A1A655CF68C0E45CE0AA2" unitRef="usd">24200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-66E4F81050550D36CE648C0E45CC477D" unitRef="usd">21800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q4YTD" decimals="0" id="Fact-2025D3331AD4C6738ED18C0E45F5F9E2" unitRef="shares">5969418</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q4YTD" decimals="0" id="Fact-D9A2461E505B4AD784888C0E45C7F525" unitRef="shares">7763236</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-602AFED14351E1C2FDF08C0E45A65E1B" unitRef="shares">9958802</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<gale:ChangesInFairValueOfWarrantLiabilityTableTableTextBlock contextRef="FD2016Q4YTD" id="Fact-0DC8C2FDB7789B57825F8C0E462D7701">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;July 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(3,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;January 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(9,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(259&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;144&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(22,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(462&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;144&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;144&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:ChangesInFairValueOfWarrantLiabilityTableTableTextBlock>
	<gale:ContingentConsiderationPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-429EA3FBEA9EC2BC2A628C0E4600D358">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingent Purchase Price Consideration&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Contingent consideration is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:ContingentConsiderationPolicyPolicyTextBlock>
	<gale:OperatingLeasesFutureMinimumPaymentsDueTableTextBlock contextRef="FD2016Q4YTD" id="Fact-C022B09548A74758B7BB8C0E45AF7954">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s contractual obligations that may require future cash payments as of December&amp;#160;31, 2016 are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Operating&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Non-Cancelable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Employment&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Agreements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Cancelable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;License&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Agreements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2021 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:16px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December&amp;#160;31, 2016, 2015, and 2014 were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;$291,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;$116,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;$72,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:16px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:16px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;License agreements generally relate to the company&amp;#8217;s obligations with The Board of Regents, University of Texas M.D. Anderson Cancer Center and the Henry M. Jackson Foundation for our oncology therapies and the obligations with Biovascular Inc. and Mills Pharma for our GALE-401 asset. The company continually assesses the progress of its licensed technology and the progress of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; amounts will be due.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gale:OperatingLeasesFutureMinimumPaymentsDueTableTextBlock>
	<gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-A79A6C039FBCB39AE9208C0E462046DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock>
	<gale:ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-BD4901B22BD5E9720E7E8C0E45CCFD9B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of net deferred tax assets are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;97,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,866&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Licensing deduction deferral&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,910&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;117,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;95,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(117,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(95,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock>
	<gale:ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-E03DC1DD8B1BCAF131918C0E45CCD2C7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of net deferred tax liabilities are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In-process research and development not subject to future amortization for tax purposes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock>
	<gale:ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock contextRef="FD2016Q4YTD" id="Fact-C3F88518E943963E6B758C0E4605A4CC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock>
	<gale:ScheduleOfWarrantActivityTableTableTextBlock contextRef="FD2016Q4YTD" id="Fact-15F003622673C3E568B58C0E462F5B8A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of warrant activity for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015 (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;July 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;January 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;November 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;November 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantActivityTableTableTextBlock>
	<gale:ScheduleOfWarrantValuationAssumptionsTableTableTextBlock contextRef="FD2016Q4YTD" id="Fact-C0B0B49AE6C817F44B828C0E462FDDB5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;July 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;117.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;January 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;120.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;41.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;131.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;164.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;204.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;103.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;41.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;65.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;47.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;40.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;71.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantValuationAssumptionsTableTableTextBlock>
	<us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="FD2016Q4YTD" id="Fact-D8F499FFFDE7E545DA118C0E45E6C968">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2014, the FASB issued ASU No. 2014-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company has adopted this ASU.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-03,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Further, ASU 2015-03 requires the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 must be applied retrospectively. The Company adopted this ASU on January 1, 2016. There was no impact to the Company&amp;#8217;s consolidated financial statements upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In November 2015, the FASB issued ASU No. 2015-17, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or ASU 2015-17.&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ASU 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. Previous guidance required deferred tax liabilities and assets to be separated into current and noncurrent amounts on the balance sheet. The guidance will become effective for us beginning in the first quarter of 2017 and may be applied either prospectively or retrospectively. Early adoption is permitted. At the time of adoption, we will reclassify current deferred tax amounts on our Consolidated Balance Sheets as noncurrent. The Company adopted this ASU on January 1, 2017. There was no impact to the Company&amp;#8217;s consolidated financial statements upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In January 2016, the FASB issued ASU No.&amp;#160;2016-01,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt; Financial Instruments&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016-01 will be effective for the Company beginning in its first quarter of 2019 and early adoption is not permitted. The Company does not believe the adoption of the new financial instruments standard will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of our pending adoption of the new standard on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued Accounting Standards Update 2016-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation-Stock Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU 2016-09 includes several areas of simplification to stock compensation including simplifications to the accounting for income taxes, classification of excess tax benefits on the Statement of Cash Flows and forfeitures. ASU 2016-09 is effective for annual reporting periods beginning after December&amp;#160;15, 2016. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this ASU on January 1, 2017. There was no impact to the Company&amp;#8217;s consolidated financial statements upon adoption.. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2016, the Financial Accounting Standards Board issued ASU No. 2016-15 "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force." The objective of ASU No. 2016-15 is to provide specific guidance on eight cash flow classification issues and how to reduce diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years.  We are still evaluating the effect of this update.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. We are evaluating the effect of this update.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2016Q4YTD" id="Fact-6E9F38D796A9798953608C0E45D0736D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Accrued Expenses and Other Current Liabilities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2016Q4YTD" id="Fact-3623D9B5AEC485C7EF758C0E45F746C5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions and In-Licensing &amp;#8212;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, we determined there were no variable interest entities required to be consolidated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-5F31796D310863E9B8F98C0E4600458A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company considers all highly liquid debt instruments with an original maturity of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; days&amp;#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2016Q4YTD" id="Fact-AE258387A22AF64C26F28C0E461F5033">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Restricted cash consists of the minimum cash covenant as required by the debenture certificates of deposit on hand with the Company&amp;#8217;s financial institutions as collateral for its corporate credit cards&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-FF903E4421ACFDD964708C0E45AFF44D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Derivative Litigation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, granting final approval to the settlement awarding attorney&amp;#8217;s fees of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus costs, which was paid by our insurance carriers. The settlement included a payment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$15 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;60,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; outstanding director stock options. The settlement also required that we adopt and implement certain corporate governance measures. The settlement did not include any admission of wrongdoing or liability on the part of us or the individual defendants and included a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Securities Litigation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, granting final approval of the settlement awarding attorney&amp;#8217;s fees of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus costs, which was paid out of the settlement funds. The settlement agreement provided for a payment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to the class and the dismissal of all claims against us and the other defendants in connection with the consolidated federal securities class actions. Of the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; settlement payment to the class, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$16.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; was paid by our insurance carriers and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; was paid by us through a combination of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares of our common stock (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24,002&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares) issued by us on July 6, 2016. In addition to the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; settlement payment, the company paid &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in December 2015 in attorney fees outstanding as a condition of the settlement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In July 2016, we resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,563&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares) of our common stock, and in another case for &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares of our common stock (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;168,337&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements did not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and included a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On October 13, 2016, we filed a complaint in the Circuit Court for the County of Multnomah for the State of Oregon against Aon Risk Insurance Services West, Inc. where we are seeking attorney's fees, costs and expenses incurred by us related to our coverage dispute with a certain insurer and for amounts we were required to contribute to the settlements of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Derivative Litigation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Securities Litigation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as a direct result of certain insurer's failure to pay its full policy limits of liability and other relief. We are currently engaged in written discovery.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On February 13, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Miller v. Galena Biopharma, Inc., et al&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. On February 15, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Kattuah v Galena Biopharma, Inc., et al&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. Within the time allowed under the federal rules and statutes, the Company and the other defendants, former and current officers, will respond to the complaints through an appropriate pleading or motion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A federal investigation of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the high-prescribing physicians for Abstral (former commercial product) has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial began in January 2017 and is ongoing. We received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&amp;#8217;s Office for the Southern District of Alabama (SDAL), which is handling the criminal trial, and are cooperating in the production of documents. On April&amp;#160;28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&amp;#8217; pharmacy as well as their ownership of our stock. The criminal trial&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; which began on January 4, 2017, concluded with a jury verdict on February 23, 2017 finding these physicians guilty on &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; counts; sentencing is scheduled for May 2017. At the end of the SDAL case&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; SDAL dismissed count &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the indictment charging that the physicians conspired, through the C&amp;amp;R Pharmacy, to receive illegal kickbacks in exchange for prescribing Abstral. Though certain former employees received trial subpoenas to appear at the trial and provide oral testimony, only &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; former employee testified at the trial. We agreed to reimburse those former employees&amp;#8217; attorney&amp;#8217;s fees. To our knowledge, we were not a target or subject of that investigation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;There are also federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&amp;#8217;s Office for the District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral, the commercial product we sold in the fourth quarter of 2015. We have been in contact with the U.S. Attorney&amp;#8217;s Office for the District of New Jersey and the Department of Justice, and we have come to understand that the investigation being undertaken is a criminal investigation in addition to a civil investigation that could ultimately involve the Company as well as one or more former employees. Pursuant to the Company&amp;#8217;s charter, we are currently reimbursing certain former employees&amp;#8217; attorney&amp;#8217;s fees with respect to the investigation. We are cooperating with the civil and criminal investigation, and through our outside counsel we have begun preliminary&amp;#160;discussions with the government aimed at the ultimate resolution of the investigation regarding the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;22, 2016, the Company and its former CEO reached an agreement in principle to a proposed settlement that would resolve an investigation by the staff of the Securities and Exchange Commission (SEC) involving conduct in the period 2012-2014 regarding the commissioning of internet publications by outside promotional firms. Under the terms of the proposed settlement framework, the Company and the former CEO would consent to the entry of an administrative order requiring that we and the former CEO cease and desist from any future violations of Sections 5(a), 5(b), 5(c), 17(a), and 17(b) of the Securities Act of 1933, as amended, and Section&amp;#160;10(b), 13(a), and 13(b)(2)(A) of the Securities Exchange Act of 1934, as amended, and various rules thereunder, without admitting or denying the findings in the order. Based upon the proposed settlement framework, the Company will make a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; penalty payment. In addition to other remedies, the proposed settlement framework would require the former CEO to make a disgorgement and prejudgment interest payment as well as a penalty payment to the Commission. To address the issues raised by the SEC staff&amp;#8217;s investigation, in addition to previous governance enhancements we have implemented, we have voluntarily undertaken to implement a number of remedial actions relating to securities offerings and our interactions with investor relations and public relations firms. The proposed settlement is subject to approval by the Commission and would acknowledge our cooperation in the investigation and confirm our voluntary undertaking to continue that cooperation. If the Commission does not approve the settlement, we may need to enter into further discussions with the SEC staff to resolve the investigated matters on different terms and conditions. As a result, there can be no assurance as to the final terms of any resolution including its financial impact or any future adjustment to the financial statements. In response to an indemnification claim by the former CEO, a special committee of our Board of Directors has determined that we are required under Delaware law to indemnify our former CEO for the disgorgement and prejudgment interest payment of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; that he would be required to pay if and when the settlement is approved by the Commission. Any penalty payment that the former CEO will be required to make in connection with this matter (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$600,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; under the proposed settlement framework) will be the responsibility of the former CEO.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The litigation settlements are summarized as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" style="padding-left:0px;padding-right:0px;padding-top:4px;padding-bottom:4px;" rowspan="1"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Class action settlement in 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Derivative settlement in 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shareholders securities litigation settlements in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;SEC settlement in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;27,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Payable by the Company in cash as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Paid by the insurance carriers in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Paid by the Company in cash in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,450&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Paid by the Company in common stock in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;27,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&amp;#8217;s contractual obligations that may require future cash payments as of December&amp;#160;31, 2016 are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Operating&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Non-Cancelable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Employment&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Agreements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Cancelable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;License&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Agreements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2021 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:16px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December&amp;#160;31, 2016, 2015, and 2014 were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;$291,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;$116,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;$72,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:16px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:16px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;License agreements generally relate to the company&amp;#8217;s obligations with The Board of Regents, University of Texas M.D. Anderson Cancer Center and the Henry M. Jackson Foundation for our oncology therapies and the obligations with Biovascular Inc. and Mills Pharma for our GALE-401 asset. The company continually assesses the progress of its licensed technology and the progress of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; amounts will be due.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the disclosure provisions FASB ASC Topic 460 (&amp;#8220;ASC 460&amp;#8221;), &amp;#8220; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Guarantor&amp;#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others,"&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to its agreements that contain guarantee or indemnification clauses. The Company provides (i)&amp;#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&amp;#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&amp;#160;460. In 2016, the Company has incurred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as a result of these obligations as a result of its obligation to its former CEO as noted above. Accordingly, the Company has accrued this liability in its financial statements related to these indemnifications.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-F17A81E45165142F60D78C0E45F8D316">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2016Q4YTD" id="Fact-91E95F8510F6D7D577398C0E461E93C0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the company&amp;#8217;s cash equivalents were invested in money market mutual funds. The Company&amp;#8217;s investment policy does not allow investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-3F58D522AB7C1AEBACD08C0E461EC0A6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;font-weight:bold;"&gt;Significant Customers and Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;The company is engaged in the business of developing and commercializing pharmaceutical products. The company has recognized revenue from only &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt; commercial product, Abstral, available in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt; dosing strengths, and all sales reported are in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;The percentage of product sales to our customer that represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt; or more of revenue in at least one of the periods presented, is as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;There were no product sales during the year ended December 31, 2012.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;The following accounts represented 10% or more of total accounts receivable in at least one of the periods presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-0F03243B42EFABEAFF8B8C0E45F968A6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-89552D50DA07A344F8AB8C0E45E66ADD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Long-term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On May 8, 2013, we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; ("Loan"). The Loan payment terms include &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months of interest-only payments at the fixed coupon rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8.45%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, followed by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cash facility fee and a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cash final payment and granted to the lender &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-year warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,109&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$49.4&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. On May 10, 2016, the Company prepaid the outstanding principal amount and cash final payment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On May 10, 2016, the Company entered into a&amp;#160;Securities Purchase Agreement ("Purchase Agreement"), with certain purchasers pursuant to which the Company sold, at a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.375%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; original issue discount, a total of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$25,530,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Senior Secured Debenture&amp;#160;(&amp;#8220;Debenture&amp;#8221;) and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company's common stock. Net proceeds to the Company from sale of the&amp;#160;Debenture, after payment of commissions and legal fees, were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$23.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; The&amp;#160;Debenture&amp;#160;matures November 10, 2018, accrues interest at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per year, and does not contain any conversion features into shares of our common stock. On August 22, 2016, the Company, the purchasers and certain other parties entered into an amendment agreement, which provides for the amendment and restatement of the Debenture, an amendment to the terms of the Series A Common Stock Purchase Warrant issued by the Company to the purchasers pursuant to the terms of the Purchase Agreement, and certain other terms and conditions, as summarized below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December 14, 2016, the Company and the holder entered into a waiver (the &amp;#8220;Waiver&amp;#8221;) that amended the Securities Purchase Agreement dated May 10, 2016 between the Company and the holder, as amended on August 22, 2016 (the &amp;#8220;SPA&amp;#8221;). The Waiver provides that solely with respect to the calendar months of December 2016, January 2017, February 2017 and March 2017 (collectively, the &amp;#8220;Specified Months&amp;#8221;), the holder waives, subject to certain delineated exceptions, the requirement of paragraph (i) of the definition of &amp;#8220;Equity Conditions&amp;#8221; set forth in Section 1 of the Debenture, thereby continuing to allow the Company to deliver shares of its Common Stock in respect to a portion of its amortization obligation under the Debenture. Furthermore, the waiver sets out a Monthly Allowance for each Specified Month equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1,500,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and required the Company to withdraw all cash and/or cash equivalents in excess of eighteen million five hundred thousand dollars (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18,500,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;) from certain accounts and deposit such funds into an account in a form acceptable to the holder, such that the Company requires the prior written consent of the holder for certain withdrawals. The Waiver also grants the holder special redemption rights depending upon the price of our common stock, including the right to redeem the debenture.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Debenture carries an interest only period of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months, following which interest is due monthly and payable in cash or stock at the election of the Company. Interest deferred during the interest only period is added to and considered principal. Following the interest only period, the Company has the right under the Debenture, commencing November 10, 2016, to pay the monthly redemption amount of the outstanding balance in cash, shares of the Company's common stock or a combination thereof, if certain conditions are met. The maximum monthly redemption amount was increased from &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1,100,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1,500,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; under the amended Debenture; provided, that if the trading price of the Company&amp;#8217;s common stock is at least &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share (as adjusted for stock splits, combinations or similar events) during such calendar month, then such maximum monthly redemption amount may be increased to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2,200,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; at the holder's election and if the Company has already elected to satisfy such monthly redemptions in shares of common stock. In addition, notwithstanding the foregoing limitations on the monthly redemption amount, the holder may elect up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; times in any 12-month period to increase the maximum monthly redemption to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2,500,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;If the Company elects to pay the redemption amount in shares of its common stock, then the shares will be delivered at the lesser of A) &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; discount to the average of the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; lowest volume weighted average prices over the prior &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; trading days or B) a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; discount to the prior trading day&amp;#8217;s volume weighted average price. The Company may only opt for payment in shares of common stock if certain equity conditions are met. The Company, at its option, may also force the holder to redeem up to double the monthly redemption principal amount of the Debenture but not less than the monthly payment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The holder received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; warrants upon the closing on the sale of the Debenture at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$30.20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, maturing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from issuance, and in accordance with the terms of the amendment agreement, the exercise price of the warrant was reduced to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. Additionally, the holder received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The amendment agreement provides that, following November 10, 2016, the holder may elect to convert any portion of the outstanding balance into shares of common stock at a fixed price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$12.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share (as adjusted for stock splits, combinations or similar events). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s obligations under the&amp;#160;Debenture&amp;#160;can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company&amp;#8217;s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the&amp;#160;Debenture in cash. The Company&amp;#8217;s obligations under the&amp;#160;Debenture&amp;#160;are secured under a security agreement by a senior lien on all of the Company&amp;#8217;s assets, including all of the Company&amp;#8217;s interests in its consolidated subsidiaries.  Under the subsidiary guarantee agreement, each subsidiary guarantees the performance of the Company of the Purchase Agreement, Debenture and related agreements. The Company must also maintain as a compensating cash balance, the lesser of a minimum of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash or the outstanding principal and accrued and unpaid interest, which such amount is included in restricted cash as of December 31, 2016. The holder of the Debenture has the right, at any time and from time to time, to require the Company to prepay the lesser of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus accrued and unpaid interest or the outstanding principal and accrued and unpaid interest. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2016 the outstanding principal balance of the Debenture was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$17,621,702&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The current portion of long-term debt of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$16,397,030&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; is net of unamortized discounts and debt issuance costs of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1,224,672&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In January and February 2017, the holder of the Debenture redeemed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3,950,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of principal, which the Company satisfied with &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,541,077&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock. The outstanding principal balance as of March 15, 2017 is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$13,671,702&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Armentum Partners, LLC (&amp;#8220;Placement Agent&amp;#8221;) acted as the&amp;#160;placement agent&amp;#160;in the offering of the&amp;#160;Debenture and the Company paid the Placement Agent a fee equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the funds received from the sale of the&amp;#160;Debenture. The Company paid half of the placement fee upon funding and paid the other half during the third quarter of 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q4YTD" id="Fact-314EE01A37BC553147A98C0E45F52012">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Options to Purchase Shares of Common Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company follows the provisions ASC&amp;#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is being re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the Consolidated Statements of Comprehensive Loss for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, 2015, and 2014 (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,903&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;102.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;73.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The weighted-average fair value of options granted during the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015 was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.09&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.40&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s expected common stock price volatility assumption is based upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&amp;#160;718-10, which averages the contractual term of the Company&amp;#8217;s options of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; with the average vesting term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for an average of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the Company has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for options granted to its employees, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for options granted to senior management and zero for non-employee directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2,295,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company&amp;#8217;s operating expenses over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.30&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,325,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock were reserved for issuance under the Company&amp;#8217;s 2016 Incentive Plan, including &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;561,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares subject to outstanding common stock options granted under the plan and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;501,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares available for future grants.  On July 14, 2016, shareholders approved the 2016 Incentive Plan. The 2016 Incentive Plan replaced the 2007 Incentive Plan that expired on February&amp;#160;23, 2017. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The options generally will expire, unless previously exercised, no later than &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from the grant date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes option activity of the company:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;51.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;41.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;56.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The weighted average remaining contractual life of options outstanding as of December 31, 2016, 2015, and 2014 was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.02&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.63&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.35&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, respectively. The weighted average remaining contractual life of options exercisable as of December 31, 2016, 2015, and 2014 was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.52&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.51&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The aggregate intrinsic value of outstanding options as of December 31, 2016, 2015, and 2014 was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$539,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$610,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively. The aggregate intrinsic value of exercisable options as of December 31, 2016, 2015, and 2014 was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;,  &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$518,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$509,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company's common stock and the exercise price of the underlying options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2016, 2015, and 2014 was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$56,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$37,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$13,429,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The Company also has an employee stock purchase plan (&amp;#8220;ESPP&amp;#8221;) which allows employees to contribute up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of their cash earnings, subject to certain maximums, to be used to purchase shares of our common stock on each semi-annual purchase date. The purchase price is equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the market value per share on either the first or last day of the semi-annual period, whichever is lower. Our ESPP is non-compensatory pursuant to the provisions of generally accepted accounting principles for share-based compensation expense. The ESPP contains an &amp;#8220;evergreen provision&amp;#8221; with annual increases in the number of shares available for issuance on the first day of each year through January&amp;#160;1, 2015 equal to the lesser of: (a)&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,500&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares increased on each anniversary of the adoption of the Plan by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;of the total shares of stock then outstanding and (b)&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares.&amp;#160;As of December&amp;#160;31, 2016, an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,930&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock were authorized and available for future issuance under the ESPP. The Company has issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,070&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares under the ESPP through December&amp;#160;31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Stock Units&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; In addition to options to purchase shares of common stock, the Company may grant restricted stock units (&amp;#8220;RSU&amp;#8221;) as part of its compensation package. If granted, each RSU would be granted at the fair market value of the Company's common stock on the date of grant. Vesting is determined on a grant-by-grant basis. There were no RSUs outstanding as of December 21, 2016 and 2015.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-AC25C96AFB02709646988C0E46200B9E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Discontinued Operations - &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As described in Note 15, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. The Company generally considers assets to be held for sale when (i) the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) the assets are available for immediate sale in their present condition, (iii) the company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to the current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment for sale, the Company discontinues depreciating the asset and writes down the asset to the lower of the carrying value or fair market value, if needed. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-8C8BCD92261BD05C4F878C0E45BF37BF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Discontinued Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As part of the Company's strategic objective to focus its resources on its development pipeline, our management and Board of Directors decided and committed to pursue a plan to sell or otherwise divest the Company&amp;#8217;s commercial business during the third quarter of 2015. The Company&amp;#8217;s commercial business was comprised of two products: Abstral&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (fentanyl) Sublingual Tablets and Zuplenz&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film. As described in Note 14, both products were sold in the fourth quarter of 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company met the relevant criteria for reporting the commercial business as held for sale and in discontinued operations in the accompanying financial statements pursuant to FASB Topic 205-20,&amp;#160;Presentation of Financial Statements--Discontinued Operations, and FASB Topic 360,&amp;#160;Property, Plant, and Equipment. The Company assessed the commercial business net asset group for impairment pursuant to FASB Topic 360, as discussed in Note 1, determining that the carrying value exceeded the fair value of the assets, therefore the Company recorded a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; impairment charge as of September 30, 2015. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company entered into an agreement with a third party firm to assist the Company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, in the event the Company successfully completed a divestiture through the sale of its commercial operations to a third-party, the Company paid a success fee to the third party firm in an amount of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, reimbursement for reasonable out-of-pocket expenses and agreed to pay &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of realized future revenue and payment streams. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management. Under the terms of these arrangements, if the Company met certain sales and margin numbers in the fourth quarter of 2015 and successfully completed a divestiture through sale of its commercial operations to a third-party, the Company paid a retention fee to the three employees in a combined total amount equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$352,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash consideration received as upfront payment in the transactions. These employees will also receive severance payments equal to one month&amp;#8217;s salary for between four and seven months. In addition to these compensatory agreements loss from discontinued operations includes one-time termination benefits provided to employees that were part of the commercial business and did not accept employment opportunities at the companies who purchased Abstral and Zuplenz. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Sale of Abstral and related assets on November 19, 2015&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Sale of Zuplenz and related assets on December 24, 2015&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net proceeds from sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Less selling costs*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Proceeds from sale, net of selling costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;*Note selling costs related to the sale of Zuplenz and related assets are included in accrued liabilities and were paid in the first quarter of 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In addition to the upfront proceeds received from the sale of Abstral and Zuplenz and their related assets, the Company is eligible to receive up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$30 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in future milestone payments based on future net revenue of the products. The additional consideration will be recognized in the period that the net revenue milestones are achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale in the balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of assets included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current assets of discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of liabilities included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current liabilities of discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table represents the components attributable to the commercial business in 2016, 2015, and 2014 that are presented in the consolidated statements of comprehensive loss as discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cost of revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Additional channel obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amortization of certain acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general, and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(9,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(15,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment charge form classification as held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Loss on sale of commercial business assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Severance and exit costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Loss from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(12,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(24,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Additional channel obligations included in discontinued operations in 2016 is comprised of larger than anticipated rebates of Abstral sales for which we were responsible through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control and was partially offset by lower than expected patient assistance program reimbursement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;included in discontinued operations consists of all other expenses of our commercial operations that were required in order to market and sell our marketed products prior to our sales of the rights to these commercial products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the year ended December 31, 2016 we incurred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$9.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. See Note 6 for further disclosures related to these legal proceedings.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-1E224FFBFC106BF52CA78C0E460801B7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Earnings per Share.&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2016Q4YTD" id="Fact-0C87C84B37CF1DCE44828C0E4613E2BA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Earnings per Share.&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2016Q4YTD" id="Fact-64493EDB91DE6794AD358C0E45CA2762">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending Level 3 liabilities for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015 is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-32E4E94E4B28EAED519F8C0E45CA35F2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company follows ASC&amp;#160;820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;) for the Company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company categorized its cash equivalents and marketable securities as Level&amp;#160;1 inputs. The valuations for Level&amp;#160;1 were determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&amp;#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2016Q4YTD" id="Fact-13E158FB5E64C9A6A3E58C0E461E36E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The carrying amounts reported in the balance sheet for cash equivalents, marketable securities, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-B75B61761A98BCA703AF8C0E45CA5436">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company follows ASC&amp;#160;820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;) for the Company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company categorized its cash equivalents and marketable securities as Level&amp;#160;1 inputs. The valuations for Level&amp;#160;1 were determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&amp;#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company has not transferred any financial instruments into or out of Level 3 classification during the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or 2015. A reconciliation of the beginning and ending Level 3 liabilities for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015 is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The decrease in the estimated fair value of the contingent purchase price consideration during 2016 reflects a lowering of the probability and lengthening of the timeline for the potential approval of NeuVax, as these assumptions are now based principally on our Phase 2 combination trial with trastuzumab whereas previously, the valuation was based on our Phase 3 PRESENT trial, which was deemed futile by the Independent Data Monitoring Committee ("IDMC") in June 2016 and subsequently closed.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-A0911D4733044CF99DA38C0E460075B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:66px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant changes in the manner of its use of acquired assets or the strategy for its overall business;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant negative industry or economic trends;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in stock price for a sustained period; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;text-align:left;"&gt;&lt;font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in market capitalization relative to net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit (the &amp;#8220;First Step&amp;#8221;). If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment (the &amp;#8220;Second Step&amp;#8221;). Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&amp;#8217;s policy is to identify and record impairment losses, if necessary, on intangible product rights when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:60px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, and has determined that there has been no impairment to these assets as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-9CCFCB60516E978FE5E08C0E45CC7064">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of federal and state income tax expense are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Deferred expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total deferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of net deferred tax assets are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;97,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,866&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Licensing deduction deferral&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,910&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;117,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;95,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(117,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(95,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of net deferred tax liabilities are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In-process research and development not subject to future amortization for tax purposes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected federal income tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(7,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(21,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(12,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State income taxes after credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Unrealized gain on marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Changes in warrant value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6,503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,782&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;508&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effect of change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Income tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has incurred net operating losses from inception. At December&amp;#160;31, 2016, the Company had domestic federal and state net operating loss carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$251.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively, available to reduce future taxable income, which expire at various dates beginning in 2016 through &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company also had federal and state research and development tax credit carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively, available to reduce future tax liabilities and which expire at various dates beginning in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The income tax expense for the year ended December 31, 2016 relates to indefinite lived deferred tax liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;At December 31, 2016, approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Company's net operating loss carryforwards were generated as a result of deductions related to the exercises of stock options. If utilized, this portion of the Company's carryforwards, as tax effected, will be accounted for as a direct increase to contributed capital rather than as a reduction of that year's provision for income taxes. Net operating loss carryforwards created by excess tax benefits from the exercise of stock options are not recorded as deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&amp;#8217;s ownership may result in a limitation on the amount of net operating loss carryforwards and research and development credit carryforwards which could be utilized annually to offset future taxable income and taxes payable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Based on an assessment of all available evidence including, but not limited to the Company&amp;#8217;s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; deferred income tax valuation allowance has been recorded against these assets. The valuation allowance increased by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$24.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for the years ended December 31, 2015 and 2014, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company files income tax returns in the U.S.&amp;#160;federal, Massachusetts, Colorado, California, Connecticut, Georgia, Oregon, and Texas jurisdictions. The Company is subject to tax examinations for the 2012 tax year and beyond. The Company does not believe there will be any material changes in its unrecognized tax positions over the next &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12&amp;#160;months&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company has not incurred any interest or penalties. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial statements as general and administrative expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-3BCFABCF4495EA6BD8B58C0E461EB71D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&amp;#160;740-10, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ASC 740-10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&amp;#8217;s assumptions or changes in the company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-DA85E847A1710E6CAC5F8C0E46026383">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;License Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed asset through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In conjunction with the acquisition of NeuVax, the Company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&amp;#8220;MDACC&amp;#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&amp;#8220;HJF&amp;#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, clinical milestone payments including &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; upon commencement of the Phase 3 PRESENT trial of NeuVax and royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effective December&amp;#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&amp;#8220;ABIC&amp;#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&amp;#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On November 19, 2015, Galena Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) and Sentynl Therapeutics Inc., a Delaware corporation (&amp;#8220;Sentynl&amp;#8221;), entered into and closed upon an Asset Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;), pursuant to which the Company agreed to sell to Sentynl and Sentynl agreed to purchase from the Company, certain assets of the Company related to and including its Abstral&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (fentanyl) sublingual tablets product (&amp;#8220;Abstral&amp;#8221;). The assets sold and assigned to Sentynl pursuant to the Purchase Agreement included all of the Company&amp;#8217;s rights and interests in the Asset Purchase Agreement by and between the Company and Orexo AB (&amp;#8220;Orexo&amp;#8221;) dated March 15, 2013, and the License Agreement by and between the Company and Orexo dated March 18, 2013 (collectively, the &amp;#8220;Orexo Agreements&amp;#8221;).  The Company&amp;#8217;s future obligations under the Orexo Agreements were assumed by Sentynl pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Abstral, as well for certain channel liabilities related to Abstral for a period of time post-closing. In connection with the transactions contemplated by the Purchase Agreement, the Company assigned to Sentynl all of its rights to and interests in the Orexo Agreements. In connection with such assignment, Orexo released the Company from any future liabilities and obligations under the Orexo Agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The total potential consideration payable to the Company under the Purchase Agreement is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$12 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, comprised of an &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; upfront payment and up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, consisting of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; one-time payments based on Sentynl's achievement of "net sales" of Abstral in amounts ranging from &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$25 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$35 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills"), and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of myleoproliferative neoplasms (MPNs). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. We are responsible for patent prosecution and maintenance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December 17, 2015, Galena Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) and Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (&amp;#8220;Midatech&amp;#8221;), entered into an Asset Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;), pursuant to which the Company agreed to sell to Midatech and Midatech agreed to purchase from the Company, certain assets of the Company related to and including its Zuplenz&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film (&amp;#8220;Zuplenz&amp;#8221;). The assets to be sold and assigned to Midatech pursuant to the Purchase Agreement include all of the Company&amp;#8217;s rights and interests in the License and Supply Agreement by and between the Company and MonoSol Rx, LLC (&amp;#8220;MonoSol&amp;#8221;) dated July 17, 2014 (the &amp;#8220;MonoSol License&amp;#8221;).  The Company&amp;#8217;s future obligations under the MonoSol agreement will be assumed by Midatech pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Zuplenz, as well for certain channel liabilities related to Zuplenz for a period of time post-closing. The transaction was completed on December 24, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The total potential consideration payable to the Company under the Purchase Agreement is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$29.75 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, comprised of a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.75 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; upfront payment upon the closing and up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$26 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, consisting of four one-time payments based on Midatech's achievement of "net sales" of Zuplenz in amounts ranging from &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$12 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$70 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Through a separate agreement with MonoSol entered into on December 16, 2015 (the &amp;#8220;MonoSol License Amendment&amp;#8221;), (i) the Company and MonSol agreed to amend the MonoSol License in order to reduce the number of field representatives that the Company is required to maintain with respect to Zuplenz, and (ii) the Company agreed to pay MonoSol &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$900,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the upfront fee payable to the Company under the Purchase Agreement and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of any future milestone payments received by the Company under the Purchase Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December 24, 2015, the Company and Midatech closed upon the Purchase Agreement. In connection with the closing of the transactions contemplated by the Purchase Agreement, the Company assigned to Midatech all of its rights to and interests in the Company&amp;#8217;s License and Supply Agreement, dated July 17, 2014 (the &amp;#8220;MonoSol License&amp;#8221;).  As a result of such assignment, Midatech assumed all of the Company&amp;#8217;s obligations under the MonoSol License.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-035AC5292DE6B7DFFBB48C0E461E39A8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:LegalCostsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-3BBDEB61B83E87E554108C0E46171774">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Fees and Insurance Recoveries &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
	<us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock contextRef="FD2016Q4YTD" id="Fact-DEFA542E502805EC81008C0E462D3350">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of warrant activity for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015 (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;July 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;January 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;November 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;November 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants classified as liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in July 2016, January 2016, March 2015, September 2013, December 2012,&amp;#160;April 2011,&amp;#160;March 2011,&amp;#160;March 2010 and August 2009. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;July 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;117.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;January 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;120.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;41.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;131.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;164.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;204.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;103.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;41.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;65.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;47.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;40.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;71.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s expected volatility is based on a combination of implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, because the company has no present intention to pay cash dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;July 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(3,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;January 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(9,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(259&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;144&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(22,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(462&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;April 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2011 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;144&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;144&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;March 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants classified as equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,109&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$49.40&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, which equaled the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-day average market price of our common stock prior to the date of the grant. The warrants were valued using the Black Scholes model. The fair value assumptions for the grant included a volatility of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75.34%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, expected term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, risk free rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.20%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and a dividend rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The fair value of the warrants granted was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$38.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In 2016, we issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;100,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to the holder of the Debenture. The holder received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; warrants upon the closing on the sale of the Debenture at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$30.20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, maturing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from issuance, and in accordance with the terms of the amendment agreement, the exercise price of the warrant was reduced to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The fair value assumptions for the grant included a volatility of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;77.13%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, expected term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.5&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, risk free rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.26%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and a dividend rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. Additionally, the holder received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The fair value assumptions for the grant included a volatility of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;106.63%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, expected term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.5&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, risk free rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.35%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and a dividend rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In addition to the warrants issued to the holder of the debenture we have &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; outstanding warrants issued to service providers with a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$79.40&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as of December 31, 2016 and 2015. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="FD2016Q4YTD" id="Fact-270DA1A3A1B83CD3E4FB8C0E4620DBEB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Business and Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Galena Biopharma, Inc. (&amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; &amp;#8220;our,&amp;#8221; &amp;#8220;Galena&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Company&amp;#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax&amp;#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and the asset is ready to advance into a pivotal trial in patients with essential thrombocythemia (ET). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the generally accepted accounting principles (GAAP). Unless the context otherwise indicates, references in these notes to the &amp;#8220;Company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us&amp;#8221; or &amp;#8220;our&amp;#8221; refer (i)&amp;#160;to Galena, our wholly owned subsidiary, Apthera, Inc., or &amp;#8220;Apthera,&amp;#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, Inc. or "Mills."&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Management's Plans&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; -  We had cash and cash equivalents of approximately $18.1 million as of December&amp;#160;31, 2016, compared with $29.7 million as of December&amp;#160;31, 2015. We expect to continue to incur operating losses as we continue to advance our product candidates through the drug development and the regulatory process. In the absence of revenue, our potential sources of operational funding are proceeds from the sale of equity, funded research and development payments, debt financing arrangements, and payments received under partnership and collaborative agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On February 13, 2017, the Company closed an underwritten public offering of 17,000,000 units at a price to the public of $1.00 per unit for gross proceeds of $17.0 million ("February 2017 Offering"). Each unit consists of one share of common stock, and a warrant to purchase one share of common stock at an exercise price of $1.10 per share. The net proceeds of the February 2017 Offering were $15.5 million, after deducting underwriting discounts and commissions and offering expenses paid by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In addition to the proceeds from the February 2017 Offering, in January and February 2017 the holder of the Debenture redeemed $3.95 million of outstanding principal that was satisfied by the Company with 3,518,663 shares of our common stock. As a result of the redemptions, the Company was able to transfer $3.95 million out of restricted cash and cash equivalents and into unrestricted cash and cash equivalents to be used to fund the Company's ongoing operations. The outstanding principal balance on the Debenture as of March 15, 2017 is $13,617,702 and is maintained by the Company as restricted cash.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In addition to the funds raised through underwritten public offerings and the debenture, we maintain a purchase agreement with Lincoln Park Capital LLC (LPC) and At Market Issuance Sales Agreements (ATM) with future availability of $2.0 million and $19.1 million, respectively subject to certain terms and conditions. We may also continue to use the ATM, or other instruments, in order to fund our operations going forward.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On January 31, 2017, the Company announced that it is in the process of evaluating strategic alternatives focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in a transaction. While the Company evaluates its strategic alternatives, Galena&amp;#8217;s investigator-sponsored immunotherapy trials will remain ongoing.&amp;#160;With the confirmation from the FDA that the GALE-401 development program is appropriate for a New Drug Application (NDA) filing using the 505(b)(2) regulatory pathway in patients with ET who are intolerant or resistant to hydroxyurea, we have developed a clear path forward for GALE-401 in the treatment of ET. Subject to completing the manufacturing of the new formulation and the internal work to prepare the Phase 3 trial for initiation, the Company is evaluating the appropriate time to commence enrollment of the GALE-401 trial and anticipates making a definitive determination in the second half of 2017. The Company has focused on reducing expenditures in order to preserve liquidity while pursuing a strategic alternative.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We believe that our existing cash and cash equivalents, funding available under an amended LPC purchase agreement, ATM and other instruments, should be sufficient to fund our operations for at least one year from the date of issuance of the Company's consolidated financial statements. This projection is based on our current limited operations and estimates of legal expenses associated with the ongoing government investigation and legal matters pending against the company, and is subject to changes in our operating plans, resolutions of such government investigation and legal matters, uncertainties inherent in our business, strategic alternatives outcomes, and the need to seek to replenish our existing cash and cash equivalents sooner than we project and in greater amounts that we had projected. There is no guarantee that any debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate, our operations or to seek to merge with or to be acquired by another company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reverse Stock-Split&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On November 11, 2016 the Company effected a 1:20 reverse stock split of the Company's outstanding shares of common stock, outstanding stock options to purchase shares of our common stock and warrants to purchase shares of common stock. In addition, the number of shares of common stock and number of shares of common stock subject to stock options or similar rights authorized under the Company&amp;#8217;s equity incentive plan and employee stock purchase plan were proportionately adjusted for the reverse stock-split. Further, the per share exercise price under such plans were proportionately adjusted for the reverse stock-split. These consolidated financial statements give retroactive effect to such reverse stock-split and all share and per share amounts have been adjusted accordingly.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Discontinued Operations - &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As described in Note 15, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. The Company generally considers assets to be held for sale when (i) the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) the assets are available for immediate sale in their present condition, (iii) the company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to the current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment for sale, the Company discontinues depreciating the asset and writes down the asset to the lower of the carrying value or fair market value, if needed. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Uses of Estimates in Preparation of Financial Statements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company considers all highly liquid debt instruments with an original maturity of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; days&amp;#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Restricted cash consists of the minimum cash covenant as required by the debenture certificates of deposit on hand with the Company&amp;#8217;s financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The carrying amounts reported in the balance sheet for cash equivalents, marketable securities, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equipment and Furnishings&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years for equipment and furniture) of the related assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:66px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant changes in the manner of its use of acquired assets or the strategy for its overall business;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant negative industry or economic trends;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in stock price for a sustained period; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;text-align:left;"&gt;&lt;font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in market capitalization relative to net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit (the &amp;#8220;First Step&amp;#8221;). If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment (the &amp;#8220;Second Step&amp;#8221;). Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&amp;#8217;s policy is to identify and record impairment losses, if necessary, on intangible product rights when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:60px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, and has determined that there has been no impairment to these assets as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingent Purchase Price Consideration&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Contingent consideration is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions and In-Licensing &amp;#8212;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, we determined there were no variable interest entities required to be consolidated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Fees and Insurance Recoveries &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non- Employees&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&amp;#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial expenses include direct costs associated with contract research organizations ("CROs"), as well as patient-related costs at sites at which our trials are being conducted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&amp;#160;740-10, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ASC 740-10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&amp;#8217;s assumptions or changes in the company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015, we recognized income tax of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$243,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$365,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively. There was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; income tax expense or benefit for the year ended December 31, 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the company&amp;#8217;s cash equivalents were invested in money market mutual funds. The Company&amp;#8217;s investment policy does not allow investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$17,583,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in interest-bearing accounts above federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-6956B407E18F372CF2A98C0E46152B05">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Employee Benefit Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company sponsors a 401(k) retirement savings plan (the &amp;#8220;Plan&amp;#8221;). Participation in the Plan is available to full-time employees who meet eligibility requirements. Eligible employees may defer a portion of their salary as defined by Internal Revenue Service regulations. The Company may make matching contributions on behalf of all participants in the 401(k) Plan in an amount determined by the Company&amp;#8217;s Board of Directors. The Company may also make additional discretionary profit sharing contributions in amounts as determined by the Board of Directors, subject to statutory limitations. Matching and profit-sharing contributions, if any, are subject to a vesting schedule; all other contributions are at all times fully vested. The Company intends the 401(k) Plan, and the accompanying trust, to qualify under Sections&amp;#160;401(k) and 501 of the Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that the Company will be able to deduct its contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, invests the assets of the 401(k) Plan in any of a number of investment options. The Company made matching contributions totaling &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$108,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for the year ended December 31, 2016. For the years ended December 31, 2015 and 2014, the Company made matching contributions totaling &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$115,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$70,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="FD2016Q4YTD" id="Fact-7A017B3F1C5434A4D4478C0E45F9A2BB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-2B1A66D3AEBD04316CC18C0E461E45F4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equipment and Furnishings&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years for equipment and furniture) of the related assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2016Q4YTD" id="Fact-C901C3FC67091B0FC0638C0E45A43AD9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Selected Quarterly Financial Data (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following amounts are in thousands, except per share amounts:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;1st Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2nd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3rd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;4th Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(16,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross profit on net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(10,537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(15,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(18,026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(19,678&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-A515A3E3DD3AF15D081F8C0E4613547F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;From 2011 to 2016, the Company retained TroyGould PC as outside corporate counsel. Sanford J. Hillsberg, the Chairman of Galena, is a senior lawyer with TroyGould PC. The Company incurred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$209,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$577,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$533,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for services provided by TroyGould PC during the years ended December 31, 2016, 2015, and 2014, respectively. At December 31, 2015, Galena owed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to TroyGould PC. There was no payable to TroyGould PC as of December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2016Q4YTD" id="Fact-763CCAEE62BD73B46A838C0E461F2E5C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial expenses include direct costs associated with contract research organizations ("CROs"), as well as patient-related costs at sites at which our trials are being conducted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-4DA255CCCCC99247665E8C0E4617FD06">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-9B34B3769A253D27F8058C0E45D72833">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2016Q4YTD" id="Fact-8E473D1F9940E48797B58C0E45CED3FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of federal and state income tax expense are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Deferred expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total deferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="FD2016Q4YTD" id="Fact-25EBABC62BD7662BE4638C0E45C026EA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Sale of Abstral and related assets on November 19, 2015&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Sale of Zuplenz and related assets on December 24, 2015&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net proceeds from sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Less selling costs*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Proceeds from sale, net of selling costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;*Note selling costs related to the sale of Zuplenz and related assets are included in accrued liabilities and were paid in the first quarter of 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale in the balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of assets included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current assets of discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of liabilities included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current liabilities of discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table represents the components attributable to the commercial business in 2016, 2015, and 2014 that are presented in the consolidated statements of comprehensive loss as discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cost of revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Additional channel obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amortization of certain acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general, and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(9,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(15,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment charge form classification as held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Loss on sale of commercial business assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Severance and exit costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Loss from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(12,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(24,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-29101CFD56DAE71507F18C0E45EBDB4E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected federal income tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(7,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(21,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(12,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State income taxes after credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Unrealized gain on marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Changes in warrant value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6,503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,782&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;508&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effect of change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Income tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2016Q4YTD" id="Fact-584C391474CCF33C549D8C0E45D97230">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the Consolidated Statements of Comprehensive Loss for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, 2015, and 2014 (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,903&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2016Q4YTD" id="Fact-8D90391F399F7CC90D5B8C0E45CA5CCF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock contextRef="FD2016Q4YTD" id="Fact-AB7315F1894F5F0CF80AB7F772ADDB3C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The litigation settlements are summarized as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" style="padding-left:0px;padding-right:0px;padding-top:4px;padding-bottom:4px;" rowspan="1"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Class action settlement in 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Derivative settlement in 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shareholders securities litigation settlements in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;SEC settlement in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;27,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Payable by the Company in cash as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Paid by the insurance carriers in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Paid by the Company in cash in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,450&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Paid by the Company in common stock in 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;27,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-7C17155FC7F490FAD3CF8C0E45E8E6EA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following amounts are in thousands, except per share amounts:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;1st Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2nd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3rd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;4th Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(16,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross profit on net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(10,537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(15,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(18,026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(19,678&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-CE349AB3762BA52CF5588C0E45CECB59">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes option activity of the company:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;51.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;41.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;56.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-0AEB51B822FC09FE53348C0E45F3980B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;102.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;73.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="FD2016Q4YTD" id="Fact-63A1B053E610472BDF458C0E461759E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;The percentage of product sales to our customer that represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt; or more of revenue in at least one of the periods presented, is as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;The following accounts represented 10% or more of total accounts receivable in at least one of the periods presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2016Q4YTD" id="Fact-9E2248F25F5B8BFAB51D8C0E46015A6E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non- Employees&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&amp;#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-0A7FDC815BF3C02DE4578C0E461016E9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of preferred stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&amp;#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of common stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Issuances of common stock are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;November 2014 Purchase Agreement with Lincoln Park Capital, LLC - &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On November 18, 2014, the Company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the Company has the right to sell to LPC up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$50 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares of the Company's common stock, subject to certain limitations and conditions over the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;125,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company's common stock at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$40.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and the Company issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31,561&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the Company received initial net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting commissions and other offering expenses. In addition to the LPC&amp;#8217;s initial purchase of our common stock under the purchase agreement, during 2014, we received net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from LPC&amp;#8217;s subsequent purchases of a total of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;230,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock, excluding the commitment fee shares.  During the years ended December 31, 2016 and 2015 we received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; by issuing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;150,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;135,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock, respectively.  On February 6, 2017, Purchase Agreement was amended to the total value of common stock that the Company may sell to LPC from &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$55,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$15,600,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;At-The-Market Issuance Sales Agreements &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;- On May 24, 2013 the Company entered into At-The-Market Issuance Sales Agreements (ATM) with FBR &amp;amp; Co. (formerly MLV &amp;amp; Co. LLC) and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the gross proceeds from the sale of shares, up to a total limit of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in gross proceeds. The ATM is available to the Company until it is terminated by the Agents, or the Company. During the years ended December 31, 2016 and 2015 we received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; by issuing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;334,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock. During the year ended December 31, 2014, we received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in net proceeds from the sale of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;70,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock through the ATM. On December 4, 2015 we replenished the ATM limit up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in gross proceeds available for future sales of our common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;March 2015 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On March 18, 2015 the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,217,948&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; units at a price to the public of $&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;31.20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$38 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$41.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;182,692&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;91,346&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;91,346&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;182,692&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock for additional net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$40.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses payable by the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;January 2016 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On January 12, 2016 the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;988,636&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$22.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; ("January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$28.40&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;148,295&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;88,977&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;88,977&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. The underwriters did not exercise their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;148,295&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses paid by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;July 2016 Registered Direct Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On July 13, 2016, we closed the sale to certain institutional investors of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,400,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at a purchase price per share of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$9.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;in a registered direct offering, and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;700,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock with an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$13.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;per share in a concurrent private placement. The warrants are initially exercisable &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; day following issuance and have a term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses were approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$11.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;February 2017 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On February 13, 2017, the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and warrants to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock priced at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and accompanying warrant ("February 2017 Offering"). The warrants are immediately exercisable with a strike price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and will expire on the fifth anniversary of the date of issuance. The shares of common stock and the warrants will be issued separately and will be separately transferable immediately upon issuance&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The net proceeds of the February 2017 Offering were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$15.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses paid by the Company.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2016Q4YTD" id="Fact-01F4FC1AD09A9BF3F4E18C0E46142FB0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt; Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company evaluated all events or transactions that occurred after December&amp;#160;31, 2016 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the Company did not have any material recognizable or unrecognizable subsequent events.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2016Q4YTD" id="Fact-20D750E56C9FDF616C0C8C0E45F909BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2016Q4YTD" id="Fact-7DD0BDE89A4B3D852E738C0E4620C336">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Uses of Estimates in Preparation of Financial Statements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>gale-20161231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.galenabiopharma.com/20161231" xmlns:gale="http://www.galenabiopharma.com/20161231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2105100 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2405402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2305301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentation" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>2401402 - Disclosure - Business and Basis of Presentation (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentationPolicies" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies">
        <link:definition>2201201 - Disclosure - Business and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.galenabiopharma.com/role/BusinessCombinations">
        <link:definition>2102100 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsDetails" roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails">
        <link:definition>2402402 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables">
        <link:definition>2302301 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingencies">
        <link:definition>2107100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2407402 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail">
        <link:definition>2407404 - Disclosure - Commitments and Contingencies (Schedule of Contractual Obligations and Future Cash Payments) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail">
        <link:definition>2407405 - Disclosure - Commitments and Contingencies (Schedule of Contractual Obligations and Future Cash Payments) (Footnotes) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails">
        <link:definition>2407403 - Disclosure - Commitments and Contingencies (Summary of Litigation Settlements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2307301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementOfStockholdersEquity" roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical">
        <link:definition>1003001 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>1004001 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails">
        <link:definition>2420403 - Disclosure - Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails">
        <link:definition>2420404 - Disclosure - Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails">
        <link:definition>2420402 - Disclosure - Discontinued Operations, Assets Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails">
        <link:definition>2420406 - Disclosure - Discontinued Operations, Assets Held for Sale - Net Proceeds from the Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleNotes" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes">
        <link:definition>2120100 - Disclosure - Discontinued Operations, Assets Held for Sale (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails">
        <link:definition>2420405 - Disclosure - Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleTables" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables">
        <link:definition>2320301 - Disclosure - Discontinued Operations, Assets Held for Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.galenabiopharma.com/role/EmployeeBenefitPlan">
        <link:definition>2118100 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.galenabiopharma.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2418401 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements">
        <link:definition>2103100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail">
        <link:definition>2403402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail">
        <link:definition>2403403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables">
        <link:definition>2303301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.galenabiopharma.com/role/IncomeTaxes">
        <link:definition>2112100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2412406 - Disclosure - Income Taxes (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail">
        <link:definition>2412402 - Disclosure - Income Taxes (Components of Federal and State Income Tax Expense (Benefit)) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail">
        <link:definition>2412403 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail">
        <link:definition>2412404 - Disclosure - Income Taxes (Components of Net Deferred Tax Liabilities) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail">
        <link:definition>2412405 - Disclosure - Income Taxes (Schedule of Provision Computed by Applying Federal Statutory Rate) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesTables">
        <link:definition>2312301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.galenabiopharma.com/role/LicenseAgreements">
        <link:definition>2114100 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsLicenseAgreementsAdditionalInformationDetail">
        <link:definition>2414401 - Disclosure - License Agreements License Agreements (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.galenabiopharma.com/role/LongTermDebt">
        <link:definition>2106100 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDetails" roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails">
        <link:definition>2406401 - Disclosure - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.galenabiopharma.com/role/NetLossPerShare">
        <link:definition>2111100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareCommonSharesExcludedFromNetLossDetail" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail">
        <link:definition>2411402 - Disclosure - Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables">
        <link:definition>2311301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNotes" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes">
        <link:definition>2110100 - Disclosure - Other Income (Expense) (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails">
        <link:definition>2410402 - Disclosure - Other Income (Expense) (Schedule of Other Income (Expense)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseTables" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables">
        <link:definition>2310301 - Disclosure - Other Income (Expense) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyAdoptedAccountingPronouncements" roleURI="http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements">
        <link:definition>2102100 - Disclosure - Recently Adopted Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactions">
        <link:definition>2116100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2416401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RxiSpinOff" roleURI="http://www.galenabiopharma.com/role/RxiSpinOff">
        <link:definition>2103100 - Disclosure - RXi Spin-off</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RxiSpinOffAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/RxiSpinOffAdditionalInformationDetail">
        <link:definition>2403401 - Disclosure - RXi Spin-off (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2119100 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedDetails" roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedDetails">
        <link:definition>2419402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2319301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRisk" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk">
        <link:definition>2115100 - Disclosure - Significant Customers and Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskDetails" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails">
        <link:definition>2415402 - Disclosure - Significant Customers and Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskTables" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables">
        <link:definition>2315301 - Disclosure - Significant Customers and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation">
        <link:definition>2109100 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2409404 - Disclosure - Stock Based Compensation (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail">
        <link:definition>2409403 - Disclosure - Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails">
        <link:definition>2409402 - Disclosure - Stock Based Compensation (Components of Stock-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail">
        <link:definition>2409405 - Disclosure - Stock Based Compensation (Stock Option Activity) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables">
        <link:definition>2309301 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.galenabiopharma.com/role/StockholdersEquity">
        <link:definition>2108100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2408401 - Disclosure - Stockholders' Equity (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.galenabiopharma.com/role/SubsequentEvents">
        <link:definition>2121100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.galenabiopharma.com/role/Warrants">
        <link:definition>2109100 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsChangesInFairValueOfWarrantLiabilityDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail">
        <link:definition>2409404 - Disclosure - Warrants (Changes in Fair Value of Warrant Liability) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail">
        <link:definition>2409403 - Disclosure - Warrants (Fair Value of Warrants Classified as Liabilities) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsScheduleOfWarrantActivityDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail">
        <link:definition>2409402 - Disclosure - Warrants (Schedule of Warrant Activity) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.galenabiopharma.com/role/WarrantsTables">
        <link:definition>2309301 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsWarrantsClassifiedAsEquityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails">
        <link:definition>2409405 - Disclosure - Warrants (Warrants Classified as Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="gale_AbstralRightsNetMember" name="AbstralRightsNetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_AbstralRightsandZuplenzRightsMember" name="AbstralRightsandZuplenzRightsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AggregateIntrinsicValueOfStockOptionsExercisable" name="AggregateIntrinsicValueOfStockOptionsExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_AmortizationPeriodOfSellingAndDistributionRights" name="AmortizationPeriodOfSellingAndDistributionRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AnnualMaintenanceFee" name="AnnualMaintenanceFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_AprilTwoThousandElevenWarrantMember" name="AprilTwoThousandElevenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" name="AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" name="AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_CashContributionInCapital" name="CashContributionInCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_CashExcludingFromNetAssetsAcquired" name="CashExcludingFromNetAssetsAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_CashTransferredWithSpinOffTransaction" name="CashTransferredWithSpinOffTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchaseConsideration" name="ChangeInFairValueOfContingentPurchaseConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchasePriceConsideration" name="ChangeInFairValueOfContingentPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" name="ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightExercisePeriod" name="ClassofWarrantorRightExercisePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightExpired" name="ClassofWarrantorRightExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightFairValueRollForward" name="ClassofWarrantorRightFairValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightGranted" name="ClassofWarrantorRightGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightIssuedDuringPeriod" name="ClassofWarrantorRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightMaturityPeriod" name="ClassofWarrantorRightMaturityPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice" name="ClassofWarrantorRightNumberofDaysAveragedforExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightOutstandingRollForward" name="ClassofWarrantorRightOutstandingRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightTerm" name="ClassofWarrantorRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable" name="ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CommercialBusinessSegmentMember" name="CommercialBusinessSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockIssuedInConnectionWithEspp" name="CommonStockIssuedInConnectionWithEspp" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument" name="CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_ContingentConsiderationPolicyPolicyTextBlock" name="ContingentConsiderationPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractResearchPayable" name="ContractResearchPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractualObligationDueinFifthYearandThereafter" name="ContractualObligationDueinFifthYearandThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractualObligationsCurrentDue" name="ContractualObligationsCurrentDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_CustomerFourMember" name="CustomerFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerOneMember" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerThreeMember" name="CustomerThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerTwoMember" name="CustomerTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentCashFacilityFee" name="DebtInstrumentCashFacilityFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentCashFinalPayment" name="DebtInstrumentCashFinalPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentCovenantLiquidityCovenant" name="DebtInstrumentCovenantLiquidityCovenant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentOriginalIssueDiscountPercent" name="DebtInstrumentOriginalIssueDiscountPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" name="DebtInstrumentPlacementAgentFeePercentofFundsReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentPrincipalThatCouldBeRedeemed" name="DebtInstrumentPrincipalThatCouldBeRedeemed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection" name="DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold" name="DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" name="DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentRedemptionNumberofDaysMaximum" name="DebtInstrumentRedemptionNumberofDaysMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate" name="DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentTermInterestOnly" name="DebtInstrumentTermInterestOnly" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_DecemberTwoThousandTwelveWarrantMember" name="DecemberTwoThousandTwelveWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DeferredTaxAssetsLicensingDeductionDeferral" name="DeferredTaxAssetsLicensingDeductionDeferral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_DeficitAccumulatedDuringDevelopmentalStage" name="DeficitAccumulatedDuringDevelopmentalStage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" name="DisposalGroupIncludingDiscontinuedOperationConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" name="DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" name="DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" name="DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" name="DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" name="DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" name="DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts" name="DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" name="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_EquipmentFurnitureAndFixturesMember" name="EquipmentFurnitureAndFixturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" name="EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" name="EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedSales" name="EstimatedSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ExpirationDateOfSharesUnderSpinoff" name="ExpirationDateOfSharesUnderSpinoff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfContingentPurchasePriceConsideration" name="FairValueOfContingentPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsExercised" name="FairValueOfWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" name="FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsLiabilities" name="FairValueOfWarrantsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueOfWarrantsPotentiallySettleableInCash" name="FairValueOfWarrantsPotentiallySettleableInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueofWarrantsGranted" name="FairValueofWarrantsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueofWarrantsGrantedperShare" name="FairValueofWarrantsGrantedperShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts" name="FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_FormerCEOMember" name="FormerCEOMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_FormerEmployeeMember" name="FormerEmployeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FutureMilestonePayment" name="FutureMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_GALE401rights" name="GALE401rights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" name="GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" name="GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_GeneralAndAdministrativeExpenses" name="GeneralAndAdministrativeExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_InProcessResearchDevelopment" name="InProcessResearchDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability" name="IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities" name="IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_IncreaseDecreaseDeferredTaxAssets" name="IncreaseDecreaseDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_IncreaseDecreaseinLitigationSettlement" name="IncreaseDecreaseinLitigationSettlement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_InterestIncome" name="InterestIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" name="IssuanceOfCommonStockInExchangeOfOutstandingWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone" name="IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares" name="IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_IssuanceofCommonStockforLitigationSettlement" name="IssuanceofCommonStockforLitigationSettlement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt" name="Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_JanuaryTwoThousandSixteenWarrantsMember" name="JanuaryTwoThousandSixteenWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_July2016WarrantsMember" name="July2016WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsLineItems" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsTable" name="LicenseAndCollaborationAgreementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments" name="LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LincolnParkCapitalLLCPurchaseAgreementMember" name="LincolnParkCapitalLLCPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LitigationSettlementAmountCash" name="LitigationSettlementAmountCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_LitigationSettlementIssuanceofCommonStockShares" name="LitigationSettlementIssuanceofCommonStockShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LitigationSettlementIssuanceofCommonStockValue" name="LitigationSettlementIssuanceofCommonStockValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_LockUpPeriodOfSharesUnderSpinOff" name="LockUpPeriodOfSharesUnderSpinOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LossContingencyDamagesPaidbyInsuranceCompanyValue" name="LossContingencyDamagesPaidbyInsuranceCompanyValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_LossContingencyNumberofWitnesstoTestifyatTrial" name="LossContingencyNumberofWitnesstoTestifyatTrial" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_LossOnWarrantExchange" name="LossOnWarrantExchange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MDAndersonCancerCenterMember" name="MDAndersonCancerCenterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MIlestonePayment" name="MIlestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MLVCo.LLCandMaximGroupLLCMember" name="MLVCo.LLCandMaximGroupLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandElevenWarrantMember" name="MarchTwoThousandElevenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandFifteenWarrantsMember" name="MarchTwoThousandFifteenWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandTenWarrantMember" name="MarchTwoThousandTenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" name="MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance" name="MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MidatechPharmaPLCMember" name="MidatechPharmaPLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MinimumEstimatedSales" name="MinimumEstimatedSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_MiscellaneousOtherIncomeExpense" name="MiscellaneousOtherIncomeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MonosolRxLLCMember" name="MonosolRxLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff" name="NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_NetProceedsFromExerciseOfCommonStockWarrants" name="NetProceedsFromExerciseOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_NetProceedsFromIssuanceOfConvertibleNotesPayable" name="NetProceedsFromIssuanceOfConvertibleNotesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberOfSharesDistributedToSurrendersUnderSpinOff" name="NumberOfSharesDistributedToSurrendersUnderSpinOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberOfSharesRetainedByCompanyUnderSpinOff" name="NumberOfSharesRetainedByCompanyUnderSpinOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofCommericalProducts" name="NumberofCommericalProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofCountsAgainstDefendants" name="NumberofCountsAgainstDefendants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty" name="NumberofCountsAgainstDefendantswithJudicialRulingofGuilty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofDosingStrengths" name="NumberofDosingStrengths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal" name="NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_Numberofsharessoldbycompanyafterspinoff" name="Numberofsharessoldbycompanyafterspinoff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_OperatingLeaseExpense" name="OperatingLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock" name="OperatingLeasesFutureMinimumPaymentsDueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases" name="OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter" name="OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_OperatingLossCarryforwardsExerciseofStockOptions" name="OperatingLossCarryforwardsExerciseofStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_OtherWarrantIssuesMember" name="OtherWarrantIssuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PartnerCompanyTextBlock" name="PartnerCompanyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" name="PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PaymentofCashDividendsforCovenantonLongtermDebt" name="PaymentofCashDividendsforCovenantonLongtermDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" name="PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" name="PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" name="ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ProceedsFromTechnologyRevenue" name="ProceedsFromTechnologyRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ProceedsFromTechnologyRevenueUnderConditionOne" name="ProceedsFromTechnologyRevenueUnderConditionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ProceedsFromTechnologyRevenueUnderConditionTwo" name="ProceedsFromTechnologyRevenueUnderConditionTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_Proceedsfromsaleofsharesafterspinoff" name="Proceedsfromsaleofsharesafterspinoff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementConsiderationReceivableUnderAgreement" name="PurchaseAgreementConsiderationReceivableUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement" name="PurchaseAgreementContingentConsiderationReceivableUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_PurchaseAgreementContingentConsiderationThresholdNetSales" name="PurchaseAgreementContingentConsiderationThresholdNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementPaymentofUpfrontFee" name="PurchaseAgreementPaymentofUpfrontFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" name="PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementTerm" name="PurchaseAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" name="PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ReclassificationOfWarrantLiabilityUponExercise" name="ReclassificationOfWarrantLiabilityUponExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_RestrictedCashandCashEquivalentsFairValueDisclosure" name="RestrictedCashandCashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_RetainedPricePerSharesUnderSpinOff" name="RetainedPricePerSharesUnderSpinOff" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_RetainedValueOfSharesUnderSpinOff" name="RetainedValueOfSharesUnderSpinOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_RxiMember" name="RxiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember" name="SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SECLitigationMember" name="SECLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_SalesAndDistributionsRights" name="SalesAndDistributionsRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_SalesAndDistributionsRightsZuplenz" name="SalesAndDistributionsRightsZuplenz" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_SalesDiscountsServicesPercent" name="SalesDiscountsServicesPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" name="ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" name="ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" name="ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" name="ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" name="ScheduleOfSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantActivityTableTableTextBlock" name="ScheduleOfWarrantActivityTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" name="ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecuritiesLitigationOptOutSettlementCase1Member" name="SecuritiesLitigationOptOutSettlementCase1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecuritiesLitigationOptOutSettlementCase2Member" name="SecuritiesLitigationOptOutSettlementCase2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeniorSecuredDebenturesMember" name="SeniorSecuredDebenturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SentynlTherapeuticsInc.Member" name="SentynlTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeptemberTwoThousandThirteenWarrantMember" name="SeptemberTwoThousandThirteenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ServicesProvidedbyCorporateCounselMember" name="ServicesProvidedbyCorporateCounselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ShareholdersSecuritiesLitigationMember" name="ShareholdersSecuritiesLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_SharesIssuedforMilestonePayment" name="SharesIssuedforMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockAvailableforIssuanceSharesNewIssues" name="StockAvailableforIssuanceSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_StockIssuedDuringPeriodSharesOverallotmentOption" name="StockIssuedDuringPeriodSharesOverallotmentOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedDuringPeriodValueAchievementofMilestone" name="StockIssuedDuringPeriodValueAchievementofMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_StockPurchaseAgreementAuthorizedAmount" name="StockPurchaseAgreementAuthorizedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares" name="Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_TroyGouldPcMember" name="TroyGouldPcMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_TwoZeroZeroSevenIncentivePlanMember" name="TwoZeroZeroSevenIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantStrikePrice" name="WarrantStrikePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsExpectedVolatility" name="WarrantsFairValueAssumptionsExpectedVolatility" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" name="WarrantsFairValueAssumptionsRiskFreeInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsGrantedNumberofShares" name="WarrantsGrantedNumberofShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ZuplenzMember" name="ZuplenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ZuplenzRightsMember" name="ZuplenzRightsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>gale-20161231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20161231.xsd#BusinessCombinations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20161231.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20161231.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingencies" xlink:href="gale-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20161231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:href="gale-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20161231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="gale-20161231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/EmployeeBenefitPlan" xlink:href="gale-20161231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/EmployeeBenefitPlanDetails" xlink:href="gale-20161231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20161231.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20161231.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxes" xlink:href="gale-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:href="gale-20161231.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:href="gale-20161231.xsd#IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:href="gale-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20161231.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20161231.xsd#LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20161231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20161231.xsd#LongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20161231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20161231.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20161231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20161231.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:href="gale-20161231.xsd#OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20161231.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements" xlink:href="gale-20161231.xsd#RecentlyAdoptedAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactions" xlink:href="gale-20161231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:href="gale-20161231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RxiSpinOff" xlink:href="gale-20161231.xsd#RxiSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RxiSpinOffAdditionalInformationDetail" xlink:href="gale-20161231.xsd#RxiSpinOffAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:href="gale-20161231.xsd#StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20161231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20161231.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20161231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20161231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20161231.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:href="gale-20161231.xsd#WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20161231.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20161231.xsd#WarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20161231.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_4bc2eb0b-84ca-cbf9-99d8-76b29500d829" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_gale_ContractResearchPayable_4bc2eb0b-84ca-cbf9-99d8-76b29500d829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00eaf688-6963-ad8a-03b8-e257d107b9c7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00eaf688-6963-ad8a-03b8-e257d107b9c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c2ad5d03-49c6-819a-1ac6-e6584eea34ff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c2ad5d03-49c6-819a-1ac6-e6584eea34ff" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter" xlink:label="loc_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_1848E6F0ED7BB704E02CB8E4B4DD1EB6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_1848E6F0ED7BB704E02CB8E4B4DD1EB6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractualObligationsCurrentDue" xlink:label="loc_gale_ContractualObligationsCurrentDue_8f949782-cf2a-4f48-207b-8c0e6bd3e04b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_3f4a95be-b9ff-0d86-2259-f86b73eb6304" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_ContractualObligationsCurrentDue_8f949782-cf2a-4f48-207b-8c0e6bd3e04b" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_3f4a95be-b9ff-0d86-2259-f86b73eb6304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_11b0dba0-ca4d-52e4-44aa-00d7ecea976b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_ContractualObligationsCurrentDue_8f949782-cf2a-4f48-207b-8c0e6bd3e04b" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_11b0dba0-ca4d-52e4-44aa-00d7ecea976b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_a44b6131-f9c7-e567-f0aa-2764841daa16" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_ContractualObligationsCurrentDue_8f949782-cf2a-4f48-207b-8c0e6bd3e04b" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_a44b6131-f9c7-e567-f0aa-2764841daa16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_c1365bc7-eca4-ecda-2c56-808319876e4a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_ContractualObligationsCurrentDue_8f949782-cf2a-4f48-207b-8c0e6bd3e04b" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_c1365bc7-eca4-ecda-2c56-808319876e4a" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractualObligationDueinFifthYearandThereafter" xlink:label="loc_gale_ContractualObligationDueinFifthYearandThereafter_72C588C565A18C817716B8E2E6F895E3" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_ContractualObligationsCurrentDue_8f949782-cf2a-4f48-207b-8c0e6bd3e04b" xlink:to="loc_gale_ContractualObligationDueinFifthYearandThereafter_72C588C565A18C817716B8E2E6F895E3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_287c3286-b769-ce4b-45fb-5caef047aea9" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementAmountCash" xlink:label="loc_gale_LitigationSettlementAmountCash_6CE6DD19250E7146B4ADB80B5EF64739" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LitigationSettlementAmount_287c3286-b769-ce4b-45fb-5caef047aea9" xlink:to="loc_gale_LitigationSettlementAmountCash_6CE6DD19250E7146B4ADB80B5EF64739" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyDamagesPaidbyInsuranceCompanyValue" xlink:label="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_09EB7E92759D6400396697BBC1779C8E" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LitigationSettlementAmount_287c3286-b769-ce4b-45fb-5caef047aea9" xlink:to="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_09EB7E92759D6400396697BBC1779C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_bb554206-5063-699d-c454-15aed4affb4e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LitigationSettlementAmount_287c3286-b769-ce4b-45fb-5caef047aea9" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_bb554206-5063-699d-c454-15aed4affb4e" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_5E40FDF4EDB91248794597BCD8B83CC7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LitigationSettlementAmount_287c3286-b769-ce4b-45fb-5caef047aea9" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_5E40FDF4EDB91248794597BCD8B83CC7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_f5035bac-57b6-ced4-a27c-507fbcd9d0a0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LitigationReserveCurrent_f5035bac-57b6-ced4-a27c-507fbcd9d0a0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4ebca9a0-a1af-cff3-9b4f-76b294c13e83" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4ebca9a0-a1af-cff3-9b4f-76b294c13e83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6a60d556-a11e-4bed-09d1-f2c511f699d6" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6a60d556-a11e-4bed-09d1-f2c511f699d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_77f006fd-b727-9e55-3ff1-d8268898b4c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_77f006fd-b727-9e55-3ff1-d8268898b4c7" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_d8bb4f8c-0b6c-70b0-8758-76b294c35cec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_d8bb4f8c-0b6c-70b0-8758-76b294c35cec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_98fd51f5-5a5b-1d70-7b57-76b2954c26ea" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_98fd51f5-5a5b-1d70-7b57-76b2954c26ea" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d6e62e4f-fa41-c5ac-31c0-f175f0c219a7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d6e62e4f-fa41-c5ac-31c0-f175f0c219a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_df866d05-0665-6819-5031-77017d332796" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_df866d05-0665-6819-5031-77017d332796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed9fae98-3ae1-7659-630e-7314e2eeb5de" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed9fae98-3ae1-7659-630e-7314e2eeb5de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_9cda9080-a984-740f-5949-76b294aef966" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_gale_SalesAndDistributionsRights_9cda9080-a984-740f-5949-76b294aef966" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_d2d15cf5-8131-7ece-05bd-76b294caf386" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_gale_SalesAndDistributionsRightsZuplenz_d2d15cf5-8131-7ece-05bd-76b294caf386" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_532dc099-52b6-80d5-da7b-76b295d2d4af" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_gale_GALE401rights_532dc099-52b6-80d5-da7b-76b295d2d4af" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_5eb5cd7b-d4b6-2ad3-92c0-76b294becbba" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_gale_InProcessResearchDevelopment_5eb5cd7b-d4b6-2ad3-92c0-76b294becbba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_764ac536-ae18-42ab-58db-4d138c5c1d6c" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_764ac536-ae18-42ab-58db-4d138c5c1d6c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_83c4ac54-425f-5554-ad41-76b294c7c447" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_83c4ac54-425f-5554-ad41-76b294c7c447" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommonStockIssuedInConnectionWithEspp" xlink:label="loc_gale_CommonStockIssuedInConnectionWithEspp_c7ed6f3a-1e34-ad7c-171f-8c0e6b823dc0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_gale_CommonStockIssuedInConnectionWithEspp_c7ed6f3a-1e34-ad7c-171f-8c0e6b823dc0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PaymentofCashDividendsforCovenantonLongtermDebt" xlink:label="loc_gale_PaymentofCashDividendsforCovenantonLongtermDebt_FDC3EFFCBD9C8432DE67B4B9C3A4BD61" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_gale_PaymentofCashDividendsforCovenantonLongtermDebt_FDC3EFFCBD9C8432DE67B4B9C3A4BD61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_90cd6d89-f315-788f-d750-05a68667e398" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_90cd6d89-f315-788f-d750-05a68667e398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_2c1ca162-2947-99be-de5d-a58ee5d07618" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_2c1ca162-2947-99be-de5d-a58ee5d07618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b2683b18-afdc-1ebc-004c-5a4b0284f1f4" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b2683b18-afdc-1ebc-004c-5a4b0284f1f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7eefdb79-b488-fe99-9b8e-a51ddf6de5ad" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7eefdb79-b488-fe99-9b8e-a51ddf6de5ad" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8bb79809-c54b-b06e-b2e8-230e4404bbe5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8bb79809-c54b-b06e-b2e8-230e4404bbe5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ca1c93dd-7216-462e-21d0-48e47bcfcfe4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8bb79809-c54b-b06e-b2e8-230e4404bbe5" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ca1c93dd-7216-462e-21d0-48e47bcfcfe4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_4bfb598c-5b20-1fea-5801-a6da79e5a964" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8bb79809-c54b-b06e-b2e8-230e4404bbe5" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_4bfb598c-5b20-1fea-5801-a6da79e5a964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfSecuritiesNet" xlink:label="loc_us-gaap_GainLossOnSaleOfSecuritiesNet_16ae3da2-05c7-338b-5739-969b56f7a43d" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_GainLossOnSaleOfSecuritiesNet_16ae3da2-05c7-338b-5739-969b56f7a43d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_aa347117-ecf0-6b31-16d5-636a7c2499b9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_aa347117-ecf0-6b31-16d5-636a7c2499b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_5E40FDF4EDB91248794597BCD8B83CC7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_5E40FDF4EDB91248794597BCD8B83CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_7eaea36c-0f2e-a233-4f5f-e9bbb24cbfcf" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_7eaea36c-0f2e-a233-4f5f-e9bbb24cbfcf" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_02062355-baa7-b9b2-b5da-76b294da86de" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_02062355-baa7-b9b2-b5da-76b294da86de" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_5c7cc403-9251-319a-1e5f-76b295603ec3" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_5c7cc403-9251-319a-1e5f-76b295603ec3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_35950518-de38-091b-1ea1-23860fdcd45e" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_35950518-de38-091b-1ea1-23860fdcd45e" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IncreaseDecreaseinLitigationSettlement" xlink:label="loc_gale_IncreaseDecreaseinLitigationSettlement_1915a0a5-41cc-72b0-ab9a-8c0e6a86286f" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_gale_IncreaseDecreaseinLitigationSettlement_1915a0a5-41cc-72b0-ab9a-8c0e6a86286f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_311af4a2-f075-1e80-40f2-b85400721efa" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_311af4a2-f075-1e80-40f2-b85400721efa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_614b3ef6-9c49-a693-9832-8c3fd7bc9fcc" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_614b3ef6-9c49-a693-9832-8c3fd7bc9fcc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_1bd927a6-2dcc-dd7a-eeb4-e4afb99942de" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_1bd927a6-2dcc-dd7a-eeb4-e4afb99942de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_93e7d4d9-3ad7-19ee-b618-7decbe729ac1" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:to="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_93e7d4d9-3ad7-19ee-b618-7decbe729ac1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GeneralAndAdministrativeExpenses" xlink:label="loc_gale_GeneralAndAdministrativeExpenses_92723802-9902-bd99-5fbe-8c0e64c66fe7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_gale_GeneralAndAdministrativeExpenses_92723802-9902-bd99-5fbe-8c0e64c66fe7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_a7d41efe-9243-f43c-07e4-a4abed3c3bf8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_a7d41efe-9243-f43c-07e4-a4abed3c3bf8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_8f04eb90-8ce0-6eca-53eb-76b29552721f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_gale_LossOnWarrantExchange_8f04eb90-8ce0-6eca-53eb-76b29552721f" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_InterestIncome" xlink:label="loc_gale_InterestIncome_5c73155f-99ec-d7d7-61ad-8c0e6a064861" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_gale_InterestIncome_5c73155f-99ec-d7d7-61ad-8c0e6a064861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_a1422aa3-75c0-abab-ec53-596c709a6d9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_a1422aa3-75c0-abab-ec53-596c709a6d9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_cbccdc82-bbab-a298-aba7-ba75496b120b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_cbccdc82-bbab-a298-aba7-ba75496b120b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_124143f7-66bc-b09b-eaae-6c2b0283fa33" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_124143f7-66bc-b09b-eaae-6c2b0283fa33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_e66303ff-4dab-9bd8-8638-a8b98b882b3a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_e66303ff-4dab-9bd8-8638-a8b98b882b3a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6a60d556-a11e-4bed-09d1-f2c511f699d6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_96995b8c-dc23-082e-131f-ee13493ef95b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6a60d556-a11e-4bed-09d1-f2c511f699d6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_96995b8c-dc23-082e-131f-ee13493ef95b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_5d6e5be7-09b2-5c66-c6cd-e6c8786caa60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6a60d556-a11e-4bed-09d1-f2c511f699d6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_5d6e5be7-09b2-5c66-c6cd-e6c8786caa60" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9e4f1252-47bf-7ba6-fed7-01b1b8bd5d22" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9e4f1252-47bf-7ba6-fed7-01b1b8bd5d22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8712fd20-5d5a-b470-c9c7-0fe02bd6250a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8712fd20-5d5a-b470-c9c7-0fe02bd6250a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_39bfa8dd-40b8-99b9-9591-9bca53c0a576" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_39bfa8dd-40b8-99b9-9591-9bca53c0a576" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_0696fcb5-8243-9c23-f72b-76b294d1f47d" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_0696fcb5-8243-9c23-f72b-76b294d1f47d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_11a2b012-afeb-11b9-6d73-61f144f0140e" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_11a2b012-afeb-11b9-6d73-61f144f0140e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_1bd927a6-2dcc-dd7a-eeb4-e4afb99942de" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_1bd927a6-2dcc-dd7a-eeb4-e4afb99942de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_614b3ef6-9c49-a693-9832-8c3fd7bc9fcc" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_614b3ef6-9c49-a693-9832-8c3fd7bc9fcc" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_a3d3f20c-1775-18c1-0493-8c0e67bd2cb8" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_a3d3f20c-1775-18c1-0493-8c0e67bd2cb8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="extended">
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_64CAEF25750A891BBB95980267E086C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a28bb0f0-d2be-d6e6-cf74-92987a5fa93c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_64CAEF25750A891BBB95980267E086C0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a28bb0f0-d2be-d6e6-cf74-92987a5fa93c" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_70E693C56503010DEA4997FF6C9EBFF3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_64CAEF25750A891BBB95980267E086C0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_70E693C56503010DEA4997FF6C9EBFF3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_254a2ea6-203e-6d58-1c91-7d777f7fa7f6" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4ebca9a0-a1af-cff3-9b4f-76b294c13e83" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_254a2ea6-203e-6d58-1c91-7d777f7fa7f6" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4ebca9a0-a1af-cff3-9b4f-76b294c13e83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_d39e6781-80ba-8a9a-6ada-0a70854d4ef6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_254a2ea6-203e-6d58-1c91-7d777f7fa7f6" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_d39e6781-80ba-8a9a-6ada-0a70854d4ef6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_B3D1A2DFD4F9CACEA53FCE445ABA98C3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_B3D1A2DFD4F9CACEA53FCE445ABA98C3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b8476f99-9bab-21a6-d61d-02a9c0661176" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b8476f99-9bab-21a6-d61d-02a9c0661176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3ab57836-244f-310a-5a92-cb6b846a6a17" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3ab57836-244f-310a-5a92-cb6b846a6a17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f316d4eb-12c7-f1d0-fd3d-ba8b892345ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f316d4eb-12c7-f1d0-fd3d-ba8b892345ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_88730b7a-f2f4-51cb-d8a1-7a903025ce13" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_88730b7a-f2f4-51cb-d8a1-7a903025ce13" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6826a434-0eba-a280-99df-92eaa6c3f055" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6826a434-0eba-a280-99df-92eaa6c3f055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f1177a25-1e80-13fd-0827-beddb4de2232" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f1177a25-1e80-13fd-0827-beddb4de2232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87cdbec2-773d-bc5a-3050-f979513ecb7f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87cdbec2-773d-bc5a-3050-f979513ecb7f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_cf092b67-25e3-3adf-c63b-bf53b5afcbfd" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_cf092b67-25e3-3adf-c63b-bf53b5afcbfd" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_c586e793-bed8-8bf2-d6c9-8c0e63d66936" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_c586e793-bed8-8bf2-d6c9-8c0e63d66936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b782f46e-1b8c-4937-ee75-91eed84bcf8b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b782f46e-1b8c-4937-ee75-91eed84bcf8b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b6c76c51-9163-a2c4-e48f-4450dcc2ac29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b6c76c51-9163-a2c4-e48f-4450dcc2ac29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_01db0ee8-dc9d-9a44-534f-a2200747ef03" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_01db0ee8-dc9d-9a44-534f-a2200747ef03" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities" xlink:label="loc_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_d8a472a8-34e6-ad8d-b2a1-8c0e684447f4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_d8a472a8-34e6-ad8d-b2a1-8c0e684447f4" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability" xlink:label="loc_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_d34f7af9-1876-06d2-d965-8c0e6aa422ed" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_d34f7af9-1876-06d2-d965-8c0e6aa422ed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9535bc9d-9685-491b-9666-d4ee81b2fb72" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9535bc9d-9685-491b-9666-d4ee81b2fb72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7988daaa-e3da-5096-4bce-cb601f0ef813" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7988daaa-e3da-5096-4bce-cb601f0ef813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_36b06a4a-d67e-22f4-dada-9b80dd603885" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_36b06a4a-d67e-22f4-dada-9b80dd603885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_11289e28-2728-6877-19a4-d3db9fc50958" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_11289e28-2728-6877-19a4-d3db9fc50958" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_6c3ba8b6-e5bc-b9d4-9556-ba149aff7292" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_6c3ba8b6-e5bc-b9d4-9556-ba149aff7292" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_1f31ec91-1628-db92-3109-76b294b034ed" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_1f31ec91-1628-db92-3109-76b294b034ed" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_76800b74-ddd3-25fc-37d9-76b294c2f77f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_gale_MiscellaneousOtherIncomeExpense_76800b74-ddd3-25fc-37d9-76b294c2f77f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/RxiSpinOff" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/RxiSpinOffAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>gale-20161231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20161231.xsd#BusinessCombinations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20161231.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20161231.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingencies" xlink:href="gale-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20161231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:href="gale-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20161231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="gale-20161231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/EmployeeBenefitPlan" xlink:href="gale-20161231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/EmployeeBenefitPlanDetails" xlink:href="gale-20161231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20161231.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20161231.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxes" xlink:href="gale-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:href="gale-20161231.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:href="gale-20161231.xsd#IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:href="gale-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20161231.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20161231.xsd#LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20161231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20161231.xsd#LongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20161231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20161231.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20161231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20161231.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:href="gale-20161231.xsd#OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20161231.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements" xlink:href="gale-20161231.xsd#RecentlyAdoptedAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactions" xlink:href="gale-20161231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:href="gale-20161231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RxiSpinOff" xlink:href="gale-20161231.xsd#RxiSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RxiSpinOffAdditionalInformationDetail" xlink:href="gale-20161231.xsd#RxiSpinOffAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:href="gale-20161231.xsd#StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20161231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20161231.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20161231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20161231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20161231.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:href="gale-20161231.xsd#WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20161231.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20161231.xsd#WarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20161231.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4A182114A07807963386CDA01AFACBBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:to="loc_us-gaap_RangeAxis_4A182114A07807963386CDA01AFACBBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_4A182114A07807963386CDA01AFACBBE" xlink:to="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_4A182114A07807963386CDA01AFACBBE" xlink:to="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_85A64A5A8E780CA3B13FCDA01AFB77A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79" xlink:to="loc_us-gaap_MinimumMember_85A64A5A8E780CA3B13FCDA01AFB77A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1BDE1B4EECD2846C230CCDA01AFBE27D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79" xlink:to="loc_us-gaap_MaximumMember_1BDE1B4EECD2846C230CCDA01AFBE27D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:to="loc_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesDiscountsServicesPercent" xlink:label="loc_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AmortizationPeriodOfSellingAndDistributionRights" xlink:label="loc_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1379AD6E99C82EC6428ACDA01AFCA6D8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1379AD6E99C82EC6428ACDA01AFCA6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:to="loc_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:to="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:to="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_10EB15E4475B26F3C6258C0EA46A0AE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:to="loc_us-gaap_CommonStockMember_10EB15E4475B26F3C6258C0EA46A0AE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_62EDF6FECB442F701890C8991B6C1F63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_LitigationStatusAxis_62EDF6FECB442F701890C8991B6C1F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_62EDF6FECB442F701890C8991B6C1F63" xlink:to="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_62EDF6FECB442F701890C8991B6C1F63" xlink:to="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_29733047B807B9C85F75C8991B6CF102" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:to="loc_us-gaap_SettledLitigationMember_29733047B807B9C85F75C8991B6CF102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:to="loc_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:to="loc_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D39E37FD62C5E44460B1C8991B6DA6BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_RangeAxis_D39E37FD62C5E44460B1C8991B6DA6BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0EB9C96CCD2B2B58E44BC8991B6D7A3B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_D39E37FD62C5E44460B1C8991B6DA6BC" xlink:to="loc_us-gaap_RangeMember_0EB9C96CCD2B2B58E44BC8991B6D7A3B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0EB9C96CCD2B2B58E44BC8991B6D7A3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_D39E37FD62C5E44460B1C8991B6DA6BC" xlink:to="loc_us-gaap_RangeMember_0EB9C96CCD2B2B58E44BC8991B6D7A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_910B70FBF752CD69693CC8991B6DC450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0EB9C96CCD2B2B58E44BC8991B6D7A3B" xlink:to="loc_us-gaap_MaximumMember_910B70FBF752CD69693CC8991B6DC450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_9C4BBDA61C91A30D336AC8991B6D5062" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_TitleOfIndividualAxis_9C4BBDA61C91A30D336AC8991B6D5062" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_9C4BBDA61C91A30D336AC8991B6D5062" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_9C4BBDA61C91A30D336AC8991B6D5062" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:to="loc_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FormerEmployeeMember" xlink:label="loc_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:to="loc_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FormerCEOMember" xlink:label="loc_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:to="loc_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SecuritiesLitigationOptOutSettlementCase1Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SecuritiesLitigationOptOutSettlementCase2Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember" xlink:label="loc_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SECLitigationMember" xlink:label="loc_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9E8B731F0518859AC265C8991B6D4E97" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9E8B731F0518859AC265C8991B6D4E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80685275354ACB1E3DA2C8991B6E8B44_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9E8B731F0518859AC265C8991B6D4E97" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80685275354ACB1E3DA2C8991B6E8B44_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80685275354ACB1E3DA2C8991B6E8B44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9E8B731F0518859AC265C8991B6D4E97" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80685275354ACB1E3DA2C8991B6E8B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_57FA3B932280B1D965E3C8991B6EDAEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80685275354ACB1E3DA2C8991B6E8B44" xlink:to="loc_us-gaap_SubsequentEventMember_57FA3B932280B1D965E3C8991B6EDAEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyDamagesPaidbyInsuranceCompanyValue" xlink:label="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementIssuanceofCommonStockShares" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty" xlink:label="loc_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCountsAgainstDefendants" xlink:label="loc_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyNumberofWitnesstoTestifyatTrial" xlink:label="loc_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:to="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:to="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:to="loc_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="loc_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:to="loc_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter" xlink:label="loc_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractualObligationDueinFifthYearandThereafter" xlink:label="loc_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractualObligationsCurrentDue" xlink:label="loc_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_65B2D99517D3FEECEA02CD9DF143ECFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_us-gaap_LossContingenciesTable_65B2D99517D3FEECEA02CD9DF143ECFA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_E71A86D6A47E1015D076CD9DF14347B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65B2D99517D3FEECEA02CD9DF143ECFA" xlink:to="loc_us-gaap_LitigationCaseAxis_E71A86D6A47E1015D076CD9DF14347B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_E71A86D6A47E1015D076CD9DF14347B5" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_E71A86D6A47E1015D076CD9DF14347B5" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_52E5E9A99440892A6755CD9DF144B579" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:to="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_52E5E9A99440892A6755CD9DF144B579" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_98225C53F4EC77216574CD9DF1441E52" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:to="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_98225C53F4EC77216574CD9DF1441E52" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareholdersSecuritiesLitigationMember" xlink:label="loc_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:to="loc_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SECLitigationMember" xlink:label="loc_gale_SECLitigationMember_7D2CF656902D59D1B34BCD9DF144E570" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:to="loc_gale_SECLitigationMember_7D2CF656902D59D1B34BCD9DF144E570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementAmountCash" xlink:label="loc_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyDamagesPaidbyInsuranceCompanyValue" xlink:label="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_BCA587D009297D27AF62CD9DF1473F4C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_BCA587D009297D27AF62CD9DF1473F4C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_FE65500F6ED1BA0DCA7BCD9DF1476C31" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_FE65500F6ED1BA0DCA7BCD9DF1476C31" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4562393CF7F8AEFFBB8FCDA01B240063" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4562393CF7F8AEFFBB8FCDA01B240063" xlink:to="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:to="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:to="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:to="loc_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:to="loc_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:to="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:to="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:to="loc_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4562393CF7F8AEFFBB8FCDA01B240063" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SharesIssuedforMilestonePayment" xlink:label="loc_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_StockIssuedDuringPeriodValueAchievementofMilestone" xlink:label="loc_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares" xlink:label="loc_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt" xlink:label="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares" xlink:label="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone" xlink:label="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C86AB9CDDA2851396478CDA01B27E2A6" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_NetIncomeLoss_C86AB9CDDA2851396478CDA01B27E2A6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:to="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:to="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:to="loc_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:to="loc_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:to="loc_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_632F96B28E40966398EC8C0EA2974255" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_632F96B28E40966398EC8C0EA2974255" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1C8F7387B6674B285148C0EA2976646" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_632F96B28E40966398EC8C0EA2974255" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1C8F7387B6674B285148C0EA2976646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_16B13D468D24D5DE4BBE8C0EA298638A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1C8F7387B6674B285148C0EA2976646" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_16B13D468D24D5DE4BBE8C0EA298638A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_16B13D468D24D5DE4BBE8C0EA298638A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1C8F7387B6674B285148C0EA2976646" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_16B13D468D24D5DE4BBE8C0EA298638A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_C0CA4E1A27C1AF7D40918C0EA2983261" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_16B13D468D24D5DE4BBE8C0EA298638A" xlink:to="loc_gale_CommercialBusinessSegmentMember_C0CA4E1A27C1AF7D40918C0EA2983261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B717C3902340C899C2758C0EA1DBB576" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B717C3902340C899C2758C0EA1DBB576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9AEDB68A725C3E3340778C0EA1DB8E66_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B717C3902340C899C2758C0EA1DBB576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9AEDB68A725C3E3340778C0EA1DB8E66_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9AEDB68A725C3E3340778C0EA1DB8E66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B717C3902340C899C2758C0EA1DBB576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9AEDB68A725C3E3340778C0EA1DB8E66" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsandZuplenzRightsMember" xlink:label="loc_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9AEDB68A725C3E3340778C0EA1DB8E66" xlink:to="loc_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A2178D9222F2B687EEBC8C0EA1DC3E73" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A2178D9222F2B687EEBC8C0EA1DC3E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70CA5DD765FB86FAD4FE8C0EA1DC8D21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A2178D9222F2B687EEBC8C0EA1DC3E73" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70CA5DD765FB86FAD4FE8C0EA1DC8D21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70CA5DD765FB86FAD4FE8C0EA1DC8D21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A2178D9222F2B687EEBC8C0EA1DC3E73" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70CA5DD765FB86FAD4FE8C0EA1DC8D21" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_53BF9E81DAD9BD16C77B8C0EA1DDA926" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70CA5DD765FB86FAD4FE8C0EA1DC8D21" xlink:to="loc_gale_CommercialBusinessSegmentMember_53BF9E81DAD9BD16C77B8C0EA1DDA926" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:label="loc_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_411BB8E2723BE3C8E1939030BC37C0E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_411BB8E2723BE3C8E1939030BC37C0E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_411BB8E2723BE3C8E1939030BC37C0E3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_411BB8E2723BE3C8E1939030BC37C0E3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_45ED2B8E00D80722CCE09030BC373F73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75" xlink:to="loc_gale_AbstralRightsNetMember_45ED2B8E00D80722CCE09030BC373F73" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_41614CB08776271A1AEE9030BC38A31D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75" xlink:to="loc_gale_ZuplenzRightsMember_41614CB08776271A1AEE9030BC38A31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D64B4C4893AF0CC9A20C9030BC382077" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D64B4C4893AF0CC9A20C9030BC382077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3A20A706FF4437B54A6A9030BC384E9D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D64B4C4893AF0CC9A20C9030BC382077" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3A20A706FF4437B54A6A9030BC384E9D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3A20A706FF4437B54A6A9030BC384E9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D64B4C4893AF0CC9A20C9030BC382077" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3A20A706FF4437B54A6A9030BC384E9D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_36310E3A3BD481D17A8A9030BC38EA3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3A20A706FF4437B54A6A9030BC384E9D" xlink:to="loc_gale_CommercialBusinessSegmentMember_36310E3A3BD481D17A8A9030BC38EA3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_83D86983F44A3BF527758C0EA0B1BF56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_83D86983F44A3BF527758C0EA0B1BF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_83D86983F44A3BF527758C0EA0B1BF56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_83D86983F44A3BF527758C0EA0B1BF56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_7E466CC781193FE8372D8C0EA0B35A7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF" xlink:to="loc_gale_AbstralRightsNetMember_7E466CC781193FE8372D8C0EA0B35A7B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_5AC29A95F382EAC765C38C0EA0B37AA4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF" xlink:to="loc_gale_ZuplenzRightsMember_5AC29A95F382EAC765C38C0EA0B37AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_449054843718963862388C0EA0B396D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_449054843718963862388C0EA0B396D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AB7D52E5F207E7F014738C0EA0B3CA87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_449054843718963862388C0EA0B396D5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AB7D52E5F207E7F014738C0EA0B3CA87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AB7D52E5F207E7F014738C0EA0B3CA87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_449054843718963862388C0EA0B396D5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AB7D52E5F207E7F014738C0EA0B3CA87" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_53F636C9E369B8A5BB588C0EA0B30D7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AB7D52E5F207E7F014738C0EA0B3CA87" xlink:to="loc_gale_CommercialBusinessSegmentMember_53F636C9E369B8A5BB588C0EA0B30D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_302DDDDDF0A09FD1DFAC8C0EA0B4FD01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_302DDDDDF0A09FD1DFAC8C0EA0B4FD01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BB24C6CDE6205D573D4E8C0EA0B604F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BB24C6CDE6205D573D4E8C0EA0B604F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64A920E72662FCA0BFD6CED0E000D328" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64A920E72662FCA0BFD6CED0E000D328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64A920E72662FCA0BFD6CED0E000D328" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64A920E72662FCA0BFD6CED0E000D328" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_E295A9FF473C4850A6CCCED0E0013881" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_E295A9FF473C4850A6CCCED0E0013881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:to="loc_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MIlestonePayment" xlink:label="loc_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:to="loc_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:to="loc_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLossCarryforwardsExerciseofStockOptions" xlink:label="loc_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IncreaseDecreaseDeferredTaxAssets" xlink:label="loc_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance" xlink:label="loc_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="gale-20161231.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:to="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:to="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:to="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:to="loc_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:to="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SentynlTherapeuticsInc.Member" xlink:label="loc_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:to="loc_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MidatechPharmaPLCMember" xlink:label="loc_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:to="loc_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MonosolRxLLCMember" xlink:label="loc_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:to="loc_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F87F5921A6DE3F8EA5EBC8989D1EB5DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:to="loc_us-gaap_RangeAxis_F87F5921A6DE3F8EA5EBC8989D1EB5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_F87F5921A6DE3F8EA5EBC8989D1EB5DF" xlink:to="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_F87F5921A6DE3F8EA5EBC8989D1EB5DF" xlink:to="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4BAF9D7F11A1228BBD76C8989D1EFB0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340" xlink:to="loc_us-gaap_MinimumMember_4BAF9D7F11A1228BBD76C8989D1EFB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F6CDFC21829F6B5A0AE8C8989D1E4D65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340" xlink:to="loc_us-gaap_MaximumMember_F6CDFC21829F6B5A0AE8C8989D1E4D65" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments" xlink:label="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementContingentConsiderationThresholdNetSales" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementPaymentofUpfrontFee" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5327866B18A89C299A08CD967A9FE169" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:to="loc_us-gaap_DebtInstrumentAxis_5327866B18A89C299A08CD967A9FE169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82E17089906A47DECA8BCD967AA0963D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5327866B18A89C299A08CD967A9FE169" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82E17089906A47DECA8BCD967AA0963D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82E17089906A47DECA8BCD967AA0963D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5327866B18A89C299A08CD967A9FE169" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82E17089906A47DECA8BCD967AA0963D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_279F96B63DD38B1B326ACD967AA0BB38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82E17089906A47DECA8BCD967AA0963D" xlink:to="loc_gale_SeniorSecuredDebenturesMember_279F96B63DD38B1B326ACD967AA0BB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5666F450032D67BF7E88CD967AA06C37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5666F450032D67BF7E88CD967AA06C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8B16FEF63132F4920D06CD967AA0B69E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5666F450032D67BF7E88CD967AA06C37" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8B16FEF63132F4920D06CD967AA0B69E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8B16FEF63132F4920D06CD967AA0B69E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5666F450032D67BF7E88CD967AA06C37" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8B16FEF63132F4920D06CD967AA0B69E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D4E885C963396A98F2D7CD967AA1D39A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8B16FEF63132F4920D06CD967AA0B69E" xlink:to="loc_us-gaap_SubsequentEventMember_D4E885C963396A98F2D7CD967AA1D39A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8364604C7D845F49681FCD967AA2D929" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8364604C7D845F49681FCD967AA2D929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_86A9A815CCE6C3FBAADCCD967AA27B6B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_86A9A815CCE6C3FBAADCCD967AA27B6B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_D221578B82B6C39CBBD5CD967AA34716" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_D221578B82B6C39CBBD5CD967AA34716" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentOriginalIssueDiscountPercent" xlink:label="loc_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemed" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument" xlink:label="loc_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal" xlink:label="loc_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentRedemptionNumberofDaysMaximum" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" xlink:label="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesCurrent" xlink:label="loc_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_07EE9F2417C7430F31C7CD967AA529FA" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_07EE9F2417C7430F31C7CD967AA529FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7582695D55E46A38ED09CD967AA5AC47" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7582695D55E46A38ED09CD967AA5AC47" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" xlink:label="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:to="loc_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:to="loc_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ServicesProvidedbyCorporateCounselMember" xlink:label="loc_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:to="loc_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:to="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:to="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_TroyGouldPcMember" xlink:label="loc_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:to="loc_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/RxiSpinOff" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/RxiSpinOffAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1582412375EE7705DF008C142D7F3B85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1582412375EE7705DF008C142D7F3B85" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0C1481472551B429469C8C142D7F45D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1582412375EE7705DF008C142D7F3B85" xlink:to="loc_dei_LegalEntityAxis_0C1481472551B429469C8C142D7F45D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F243ABF5BE0C74B6D0848C142D803AF9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0C1481472551B429469C8C142D7F45D5" xlink:to="loc_dei_EntityDomain_F243ABF5BE0C74B6D0848C142D803AF9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F243ABF5BE0C74B6D0848C142D803AF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0C1481472551B429469C8C142D7F45D5" xlink:to="loc_dei_EntityDomain_F243ABF5BE0C74B6D0848C142D803AF9" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RxiMember" xlink:label="loc_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_F243ABF5BE0C74B6D0848C142D803AF9" xlink:to="loc_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CashContributionInCapital" xlink:label="loc_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenue" xlink:label="loc_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenueUnderConditionOne" xlink:label="loc_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenueUnderConditionTwo" xlink:label="loc_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MinimumEstimatedSales" xlink:label="loc_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedSales" xlink:label="loc_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberOfSharesDistributedToSurrendersUnderSpinOff" xlink:label="loc_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberOfSharesRetainedByCompanyUnderSpinOff" xlink:label="loc_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LockUpPeriodOfSharesUnderSpinOff" xlink:label="loc_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ExpirationDateOfSharesUnderSpinoff" xlink:label="loc_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Numberofsharessoldbycompanyafterspinoff" xlink:label="loc_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Proceedsfromsaleofsharesafterspinoff" xlink:label="loc_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RetainedPricePerSharesUnderSpinOff" xlink:label="loc_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RetainedValueOfSharesUnderSpinOff" xlink:label="loc_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:to="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:to="loc_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:to="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="loc_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="loc_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="loc_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="loc_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:to="loc_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:to="loc_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:to="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeStockPurchasePlanMember" xlink:label="loc_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:to="loc_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:to="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:to="loc_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C42EC9C83A07D88397AD8C0EA34AF1DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:to="loc_us-gaap_RangeAxis_C42EC9C83A07D88397AD8C0EA34AF1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_C42EC9C83A07D88397AD8C0EA34AF1DF" xlink:to="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_C42EC9C83A07D88397AD8C0EA34AF1DF" xlink:to="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_A541664BEF15310944278C0EA34A185F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A" xlink:to="loc_us-gaap_MinimumMember_A541664BEF15310944278C0EA34A185F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_ED8D91018908192FA8688C0EA34BD560" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A" xlink:to="loc_us-gaap_MaximumMember_ED8D91018908192FA8688C0EA34BD560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AggregateIntrinsicValueOfStockOptionsExercisable" xlink:label="loc_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_307F9C5441BE97D513C08C0EA34F66F6" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_307F9C5441BE97D513C08C0EA34F66F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LincolnParkCapitalLLCPurchaseAgreementMember" xlink:label="loc_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="loc_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="loc_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_UnderwrittenPublicOfferingMember" xlink:label="loc_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="loc_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="loc_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0412749D12BCD2794B81C8991B4BE0EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0412749D12BCD2794B81C8991B4BE0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A8249323DB863FA7A674C8991B4BCBC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0412749D12BCD2794B81C8991B4BE0EA" xlink:to="loc_us-gaap_EquityComponentDomain_A8249323DB863FA7A674C8991B4BCBC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A8249323DB863FA7A674C8991B4BCBC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0412749D12BCD2794B81C8991B4BE0EA" xlink:to="loc_us-gaap_EquityComponentDomain_A8249323DB863FA7A674C8991B4BCBC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DA888DCBA4F898BF894BC8991B4B6C24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A8249323DB863FA7A674C8991B4BCBC7" xlink:to="loc_us-gaap_CommonStockMember_DA888DCBA4F898BF894BC8991B4B6C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:to="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:to="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:to="loc_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:to="loc_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:to="loc_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_74B1EA9A6FD15DC228F0C8991B4D3D8D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_74B1EA9A6FD15DC228F0C8991B4D3D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7701BB4207D8E67F90ABC8991B4DA567" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7701BB4207D8E67F90ABC8991B4DA567" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_StockPurchaseAgreementAuthorizedAmount" xlink:label="loc_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_StockAvailableforIssuanceSharesNewIssues" xlink:label="loc_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightIssuedDuringPeriod" xlink:label="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightExercisePeriod" xlink:label="loc_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable" xlink:label="loc_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_July2016WarrantsMember" xlink:label="loc_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsExercised" xlink:label="loc_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_F2EB413F1512E76CF1C3C8970C8DB080" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_F2EB413F1512E76CF1C3C8970C8DB080" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_CEAE46697FEA82559E82C8970C8DFA78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F2EB413F1512E76CF1C3C8970C8DB080" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_CEAE46697FEA82559E82C8970C8DFA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_CEAE46697FEA82559E82C8970C8DFA78" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_CEAE46697FEA82559E82C8970C8DFA78" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_July2016WarrantsMember" xlink:label="loc_gale_July2016WarrantsMember_56526ABEDE4723B2B091C8970C8E0711" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_July2016WarrantsMember_56526ABEDE4723B2B091C8970C8E0711" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_8CDE6E4F62F317DA7AFCC8970C8E4935" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_8CDE6E4F62F317DA7AFCC8970C8E4935" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_892CDEFD70471851B76FC8970C8E96FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_892CDEFD70471851B76FC8970C8E96FC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_D7356535385ECEB877E8C8970C8E670C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_D7356535385ECEB877E8C8970C8E670C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_6D3F25EFC4AA6C4D46CFC8970C8FC27A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_6D3F25EFC4AA6C4D46CFC8970C8FC27A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_E840904F326AEB781AB7C8970C8F0993" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_E840904F326AEB781AB7C8970C8F0993" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_639A4E6A1AB6BF818542C8970C8FD7CB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_639A4E6A1AB6BF818542C8970C8FD7CB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_F757CD8296711AE553DEC8970C8FEA60" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_F757CD8296711AE553DEC8970C8FEA60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1CC7FA49E11984919E3EC8970C8F1D9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1CC7FA49E11984919E3EC8970C8F1D9B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0A13D595EBE0716D3709C7E347EED0C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_78D58EDC21B6EB17EEB7C7E347ED47B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0A13D595EBE0716D3709C7E347EED0C1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_78D58EDC21B6EB17EEB7C7E347ED47B9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3DE86F1F27BDF194BA04C7E347ED12BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_78D58EDC21B6EB17EEB7C7E347ED47B9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3DE86F1F27BDF194BA04C7E347ED12BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3DE86F1F27BDF194BA04C7E347ED12BC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3DE86F1F27BDF194BA04C7E347ED12BC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_July2016WarrantsMember" xlink:label="loc_gale_July2016WarrantsMember_3EA34BA7CE7EE745EDC6C7E36C2B9839" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_July2016WarrantsMember_3EA34BA7CE7EE745EDC6C7E36C2B9839" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_7A67200EDE47A31E2B75C7E859056AA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_7A67200EDE47A31E2B75C7E859056AA3" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_B170D5D5CCD454AB15F4C7E347EDC8B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_B170D5D5CCD454AB15F4C7E347EDC8B6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_6E9CD7CCFFCEB7902737C7E347EE9868" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_6E9CD7CCFFCEB7902737C7E347EE9868" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_3E89D248B1A5D4111E7CC7E347EE73CE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_3E89D248B1A5D4111E7CC7E347EE73CE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_8C1D3274C818F1673735C7E347EEF72C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_8C1D3274C818F1673735C7E347EEF72C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_9BE852AF32B6133C1360C7E70FCF3B36" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_9BE852AF32B6133C1360C7E70FCF3B36" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_C0775540CAD8CAD2405EC7E77D0A1D3F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_C0775540CAD8CAD2405EC7E77D0A1D3F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0A13D595EBE0716D3709C7E347EED0C1" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_261CF7E089CE7E722014CDA01941AA54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_261CF7E089CE7E722014CDA01941AA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FFFEE7EFCE383D026BC6CDA01942AB2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_261CF7E089CE7E722014CDA01941AA54" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FFFEE7EFCE383D026BC6CDA01942AB2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FFFEE7EFCE383D026BC6CDA01942AB2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_261CF7E089CE7E722014CDA01941AA54" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FFFEE7EFCE383D026BC6CDA01942AB2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FFFEE7EFCE383D026BC6CDA01942AB2E" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E0F0C94B0E890441E323CDA019423894" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:to="loc_us-gaap_RangeAxis_E0F0C94B0E890441E323CDA019423894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5E3636C94D0176B03144CDA01943415F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E0F0C94B0E890441E323CDA019423894" xlink:to="loc_us-gaap_RangeMember_5E3636C94D0176B03144CDA01943415F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5E3636C94D0176B03144CDA01943415F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E0F0C94B0E890441E323CDA019423894" xlink:to="loc_us-gaap_RangeMember_5E3636C94D0176B03144CDA01943415F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_5E3636C94D0176B03144CDA01943415F" xlink:to="loc_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF46B0A48BE8F0931142CDA01943AEFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF46B0A48BE8F0931142CDA01943AEFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7E84633AF18A99A9388CCDA019431272" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7E84633AF18A99A9388CCDA019431272" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightMaturityPeriod" xlink:label="loc_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>gale-20161231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_7034963499058AAD19C08C0EA447521B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_7034963499058AAD19C08C0EA447521B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7034963499058AAD19C08C0EA447521B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7034963499058AAD19C08C0EA447521B" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_7034963499058AAD19C08C0EA447521B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Purchase Price Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_858821EBF56DA5E9148E8C0EA09A4BB7_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_858821EBF56DA5E9148E8C0EA09A4BB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_858821EBF56DA5E9148E8C0EA09A4BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_858821EBF56DA5E9148E8C0EA09A4BB7" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_858821EBF56DA5E9148E8C0EA09A4BB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_EBC6823BCF18D979F60B8C0EA0947016_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_EBC6823BCF18D979F60B8C0EA0947016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_EBC6823BCF18D979F60B8C0EA0947016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_EBC6823BCF18D979F60B8C0EA0947016" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_EBC6823BCF18D979F60B8C0EA0947016" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927" xlink:type="arc" />
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_F66AD1671CA84541157F8C0EA3770F8A_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract_F66AD1671CA84541157F8C0EA3770F8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_F66AD1671CA84541157F8C0EA3770F8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_F66AD1671CA84541157F8C0EA3770F8A" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract_F66AD1671CA84541157F8C0EA3770F8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:to="lab_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:to="lab_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:to="lab_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:type="arc" />
    <link:label id="lab_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410_terseLabel_en-US" xlink:label="lab_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410_label_en-US" xlink:label="lab_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410_documentation_en-US" xlink:label="lab_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:to="lab_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:type="arc" />
    <link:label id="lab_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C_terseLabel_en-US" xlink:label="lab_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C_label_en-US" xlink:label="lab_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C_documentation_en-US" xlink:label="lab_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:to="lab_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:type="arc" />
    <link:label id="lab_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823_terseLabel_en-US" xlink:label="lab_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823_label_en-US" xlink:label="lab_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823_documentation_en-US" xlink:label="lab_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:to="lab_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:type="arc" />
    <link:label id="lab_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053_terseLabel_en-US" xlink:label="lab_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053_label_en-US" xlink:label="lab_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:label id="lab_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053_documentation_en-US" xlink:label="lab_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:to="lab_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:type="arc" />
    <link:label id="lab_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1_terseLabel_en-US" xlink:label="lab_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of commercial products</link:label>
    <link:label id="lab_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1_label_en-US" xlink:label="lab_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:label id="lab_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1_documentation_en-US" xlink:label="lab_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:to="lab_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:type="arc" />
    <link:label id="lab_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE_terseLabel_en-US" xlink:label="lab_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of dosing strengths</link:label>
    <link:label id="lab_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE_label_en-US" xlink:label="lab_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:label id="lab_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE_documentation_en-US" xlink:label="lab_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:to="lab_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_6307C5E7DAA3ED6A85878C1429C7FA69_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_6307C5E7DAA3ED6A85878C1429C7FA69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_6307C5E7DAA3ED6A85878C1429C7FA69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6307C5E7DAA3ED6A85878C1429C7FA69" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_6307C5E7DAA3ED6A85878C1429C7FA69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_38EF3C98D8A787A8C5098C0EA61F2A84_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_38EF3C98D8A787A8C5098C0EA61F2A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38EF3C98D8A787A8C5098C0EA61F2A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38EF3C98D8A787A8C5098C0EA61F2A84" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_38EF3C98D8A787A8C5098C0EA61F2A84" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:to="lab_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:type="arc" />
    <link:label id="lab_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D_terseLabel_en-US" xlink:label="lab_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, exercise of stock options</link:label>
    <link:label id="lab_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D_label_en-US" xlink:label="lab_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Exercise of Stock Options</link:label>
    <link:label id="lab_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D_documentation_en-US" xlink:label="lab_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Exercise of Stock Options</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLossCarryforwardsExerciseofStockOptions" xlink:label="loc_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:to="lab_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:type="arc" />
    <link:label id="lab_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A_negatedTerseLabel_en-US" xlink:label="lab_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in deferred tax assets</link:label>
    <link:label id="lab_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A_label_en-US" xlink:label="lab_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Deferred Tax Assets</link:label>
    <link:label id="lab_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A_documentation_en-US" xlink:label="lab_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Deferred Tax Assets</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IncreaseDecreaseDeferredTaxAssets" xlink:label="loc_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:to="lab_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:type="arc" />
    <link:label id="lab_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0_terseLabel_en-US" xlink:label="lab_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax valuation</link:label>
    <link:label id="lab_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0_label_en-US" xlink:label="lab_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Percentage Of Deferred Tax Asset To Establishes Valuation Allowance</link:label>
    <link:label id="lab_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0_documentation_en-US" xlink:label="lab_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Percentage Of Deferred Tax Asset To Establishes Valuation Allowance</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance" xlink:label="loc_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:to="lab_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, outstanding Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D9450D216664F8C5907D8C0EA2F479C0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D9450D216664F8C5907D8C0EA2F479C0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, outstanding Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D9450D216664F8C5907D8C0EA2F479C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D9450D216664F8C5907D8C0EA2F479C0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D9450D216664F8C5907D8C0EA2F479C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80E34C186FD58408D7228C0EA2F56671_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80E34C186FD58408D7228C0EA2F56671" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80E34C186FD58408D7228C0EA2F56671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80E34C186FD58408D7228C0EA2F56671" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80E34C186FD58408D7228C0EA2F56671" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_908773CAC61ACBAB1D3B8C0EA2F649E0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_908773CAC61ACBAB1D3B8C0EA2F649E0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_908773CAC61ACBAB1D3B8C0EA2F649E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_908773CAC61ACBAB1D3B8C0EA2F649E0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_908773CAC61ACBAB1D3B8C0EA2F649E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC_label_en-US" xlink:label="lab_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:to="lab_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:to="lab_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:to="lab_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs and non-cash interest</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Securities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfSecuritiesNet" xlink:label="loc_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE" xlink:to="lab_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD" xlink:to="lab_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD" xlink:type="arc" />
    <link:label id="lab_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D_verboseLabel_en-US" xlink:label="lab_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement payable in common stock</link:label>
    <link:label id="lab_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D_label_en-US" xlink:label="lab_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock for Litigation Settlement</link:label>
    <link:label id="lab_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D_documentation_en-US" xlink:label="lab_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock for Litigation Settlement</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D" xlink:to="lab_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock issued in exchange for services</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5" xlink:to="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent purchase consideration.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement insurance recovery</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Insurance Settlements Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8" xlink:type="arc" />
    <link:label id="lab_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B_terseLabel_en-US" xlink:label="lab_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement payable</link:label>
    <link:label id="lab_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B_label_en-US" xlink:label="lab_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Litigation Settlement</link:label>
    <link:label id="lab_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B_documentation_en-US" xlink:label="lab_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Litigation Settlement</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IncreaseDecreaseinLitigationSettlement" xlink:label="loc_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B" xlink:to="lab_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in continuing operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of commercial assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge from classification of assets held for sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities attributable to discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Assets Held-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834" xlink:to="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322_totalLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in discontinued operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in restricted cash</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of GALE-401</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for purchase of equipment and furnishings</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE" xlink:type="arc" />
    <link:label id="lab_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B_negatedLabel_en-US" xlink:label="lab_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash transferred with the RXi spin-off</link:label>
    <link:label id="lab_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B_label_en-US" xlink:label="lab_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Transferred With Spin Off Transaction</link:label>
    <link:label id="lab_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B_documentation_en-US" xlink:label="lab_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash transferred with spin-off transaction.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CashTransferredWithSpinOffTransaction" xlink:label="loc_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B" xlink:to="lab_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) continuing investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds received from sale of commercial assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for commercial assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F_totalLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) discontinued investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for repurchase of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2" xlink:type="arc" />
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21_terseLabel_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21_label_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Exercise Of Common Stock Warrants</link:label>
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21_documentation_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of common stock warrants.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21" xlink:to="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8_terseLabel_en-US" xlink:label="lab_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issued in connection with ESPP</link:label>
    <link:label id="lab_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8_label_en-US" xlink:label="lab_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Issued In Connection With Espp</link:label>
    <link:label id="lab_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8_documentation_en-US" xlink:label="lab_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock issued in connection with ESPP.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CommonStockIssuedInConnectionWithEspp" xlink:label="loc_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8" xlink:to="lab_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8" xlink:type="arc" />
    <link:label id="lab_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8_negatedTerseLabel_en-US" xlink:label="lab_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of RXi convertible notes payable</link:label>
    <link:label id="lab_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8_label_en-US" xlink:label="lab_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Issuance Of Convertible Notes Payable</link:label>
    <link:label id="lab_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8_documentation_en-US" xlink:label="lab_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of convertible notes payable.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="loc_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8" xlink:to="lab_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0" xlink:type="arc" />
    <link:label id="lab_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277_terseLabel_en-US" xlink:label="lab_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum cash covenant on long-term debt</link:label>
    <link:label id="lab_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277_label_en-US" xlink:label="lab_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Cash Dividends for Covenant on Long-term Debt</link:label>
    <link:label id="lab_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277_documentation_en-US" xlink:label="lab_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of Cash Dividends for Covenant on Long-term Debt</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PaymentofCashDividendsforCovenantonLongtermDebt" xlink:label="loc_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277" xlink:to="lab_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC413DA045DA8BDA2C0CCE4502C457C2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC413DA045DA8BDA2C0CCE4502C457C2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC413DA045DA8BDA2C0CCE4502C457C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC413DA045DA8BDA2C0CCE4502C457C2" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC413DA045DA8BDA2C0CCE4502C457C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received during the periods for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3" xlink:to="lab_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the periods for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5_label_en-US" xlink:label="lab_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5" xlink:to="lab_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as cost of equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as a cost of equity.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924" xlink:to="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with long-term debt recorded as debt issuance costs</link:label>
    <link:label id="lab_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5_label_en-US" xlink:label="lab_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Issued in Connection with Long-Term Debt Recorded as Debt Issuance Costs</link:label>
    <link:label id="lab_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Issued in Connection with Long-Term Debt Recorded as Debt Issuance Costs</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts" xlink:label="loc_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5" xlink:to="lab_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5" xlink:type="arc" />
    <link:label id="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA_verboseLabel_en-US" xlink:label="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal and interest repaid through issuance of common stock</link:label>
    <link:label id="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA_label_en-US" xlink:label="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock to satisfy principal and interest of long-term debt</link:label>
    <link:label id="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA_documentation_en-US" xlink:label="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of common stock to satisfy principal and interest of long-term debt</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt" xlink:label="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA" xlink:to="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA" xlink:type="arc" />
    <link:label id="lab_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9_verboseLabel_en-US" xlink:label="lab_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net liabilities distributed to common stock holders in the RXi spin-off, net of cash transferred</link:label>
    <link:label id="lab_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9_label_en-US" xlink:label="lab_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off</link:label>
    <link:label id="lab_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9_documentation_en-US" xlink:label="lab_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net liabilities distributed to common stock holders in the RXi spin-off</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff" xlink:label="loc_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9" xlink:to="lab_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9" xlink:type="arc" />
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325_terseLabel_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liabilities upon exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325_label_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liability Upon Exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325_documentation_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability upon exercise.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325" xlink:to="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325" xlink:type="arc" />
    <link:label id="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876_terseLabel_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued in settlement of contingent purchase price consideration</link:label>
    <link:label id="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876_label_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone</link:label>
    <link:label id="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876_documentation_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of contingent purchase consideration milestone.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone" xlink:label="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876" xlink:to="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of marketable securities before settlement</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2" xlink:type="arc" />
    <link:label id="lab_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE_terseLabel_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of GALE-401 milestone</link:label>
    <link:label id="lab_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE_label_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock In Exchange Of Outstanding Warrants</link:label>
    <link:label id="lab_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE_documentation_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of common stock in exchange for outstanding warrants.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" xlink:label="loc_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE" xlink:to="lab_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares issued to acquire Zuplenz rights</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73_terseLabel_en-US" xlink:label="lab_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future obligations for Zuplenz rights included in accrued expenses</link:label>
    <link:label id="lab_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73_label_en-US" xlink:label="lab_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73_documentation_en-US" xlink:label="lab_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73" xlink:to="lab_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E" xlink:to="lab_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross profit on net revenue</link:label>
    <link:label id="lab_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41_label_en-US" xlink:label="lab_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41" xlink:to="lab_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3" xlink:to="lab_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7" xlink:to="lab_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75CA57BEED2B16CACD66B8DDB0D9B6E7_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75CA57BEED2B16CACD66B8DDB0D9B6E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75CA57BEED2B16CACD66B8DDB0D9B6E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75CA57BEED2B16CACD66B8DDB0D9B6E7" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75CA57BEED2B16CACD66B8DDB0D9B6E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:to="lab_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:to="lab_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B_terseLabel_en-US" xlink:label="lab_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Cancelable Employment Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B_label_en-US" xlink:label="lab_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Contracts [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:to="lab_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subtotal [Member]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619_label_en-US" xlink:label="lab_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Total [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="loc_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:to="lab_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelable License Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:to="lab_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="lab_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases - 2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases - 2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases - 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases - 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:type="arc" />
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E_terseLabel_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases -2021 and thereafter</link:label>
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E_label_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years and Thereafter</link:label>
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E_documentation_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years and Thereafter</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter" xlink:label="loc_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:to="lab_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Second Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Third Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Fourth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:type="arc" />
    <link:label id="lab_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D_terseLabel_en-US" xlink:label="lab_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 and thereafter</link:label>
    <link:label id="lab_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D_label_en-US" xlink:label="lab_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Fifth Year and Thereafter</link:label>
    <link:label id="lab_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D_documentation_en-US" xlink:label="lab_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Fifth Year and Thereafter</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractualObligationDueinFifthYearandThereafter" xlink:label="loc_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:to="lab_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:type="arc" />
    <link:label id="lab_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306_totalLabel_en-US" xlink:label="lab_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306_label_en-US" xlink:label="lab_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligations Current Due</link:label>
    <link:label id="lab_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306_documentation_en-US" xlink:label="lab_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligations Current Due</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractualObligationsCurrentDue" xlink:label="loc_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:to="lab_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Inputs (Level 3) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance Liabilities</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:type="arc" />
    <link:label id="lab_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5_negatedLabel_en-US" xlink:label="lab_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">MIlestone Payment</link:label>
    <link:label id="lab_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5_label_en-US" xlink:label="lab_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MIlestone Payment</link:label>
    <link:label id="lab_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5_documentation_en-US" xlink:label="lab_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MIlestone Payment</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MIlestonePayment" xlink:label="loc_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:to="lab_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA_negatedLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in the estimated fair value of the contingent purchase price consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in the fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73E534C73B829D8CF0BD8C0EA639C522_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73E534C73B829D8CF0BD8C0EA639C522" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73E534C73B829D8CF0BD8C0EA639C522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73E534C73B829D8CF0BD8C0EA639C522" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73E534C73B829D8CF0BD8C0EA639C522" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uses of Estimates in Preparation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640" xlink:to="lab_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9" xlink:type="arc" />
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C_terseLabel_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C_label_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C_documentation_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration Policy [Text Block]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C" xlink:to="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and In-Licensing</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D" xlink:type="arc" />
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45_terseLabel_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45_label_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents And Patent Application Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45_documentation_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs [Policy Text Block]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45" xlink:to="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Fees and Insurance Recoveries</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9CD221C1437FCB374E448C0EA1B97A1F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_9CD221C1437FCB374E448C0EA1B97A1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9CD221C1437FCB374E448C0EA1B97A1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9CD221C1437FCB374E448C0EA1B97A1F" xlink:to="lab_us-gaap_EarningsPerShareAbstract_9CD221C1437FCB374E448C0EA1B97A1F" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares Excluded from Net Loss</link:label>
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1_label_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1_documentation_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" xlink:label="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1" xlink:to="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_95AEAAD59F3B802428A2C8980982E28D_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_95AEAAD59F3B802428A2C8980982E28D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_95AEAAD59F3B802428A2C8980982E28D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_95AEAAD59F3B802428A2C8980982E28D" xlink:to="lab_us-gaap_EquityAbstract_95AEAAD59F3B802428A2C8980982E28D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:type="arc" />
    <link:label id="lab_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5_terseLabel_en-US" xlink:label="lab_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 2016 Warrants [Member]</link:label>
    <link:label id="lab_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5_label_en-US" xlink:label="lab_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July 2016 Warrants [Member]</link:label>
    <link:label id="lab_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5_documentation_en-US" xlink:label="lab_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July 2016 Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_July2016WarrantsMember" xlink:label="loc_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:to="lab_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:type="arc" />
    <link:label id="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4_terseLabel_en-US" xlink:label="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">January 2016 Warrants [Member]</link:label>
    <link:label id="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4_label_en-US" xlink:label="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">January Two Thousand Sixteen Warrants [Member]</link:label>
    <link:label id="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4_documentation_en-US" xlink:label="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">January Two Thousand Sixteen Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:to="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2015 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40_label_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Fifteen Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Fifteen Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:to="lab_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:type="arc" />
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B_terseLabel_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 2013 Warrant [Member]</link:label>
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B_label_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">September Two Thousand Thirteen Warrant [Member]</link:label>
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B_documentation_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">September Two Thousand Thirteen Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:to="lab_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:type="arc" />
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F_terseLabel_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2012 Warrants [Member]</link:label>
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F_label_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December Two Thousand Twelve Warrant [Member]</link:label>
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F_documentation_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December Two Thousand Twelve Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:to="lab_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:type="arc" />
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A_terseLabel_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2011 Warrants [Member]</link:label>
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A_label_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April Two Thousand Eleven Warrant [Member]</link:label>
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A_documentation_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April Two Thousand Eleven Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:to="lab_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2011 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65_label_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Eleven Warrant [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Eleven Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:to="lab_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2010 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797_label_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Ten Warrant [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Ten Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:to="lab_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="lab_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC_periodStartLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Beginning balance</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Liabilities</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrant liabilities as of the balance sheet date.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:to="lab_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317_negatedLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants exercised</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Exercised</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Exercised</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsExercised" xlink:label="loc_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:to="lab_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368_terseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:to="lab_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_5FA5B4D1341E7420DCF5C89809831C89_periodEndLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_5FA5B4D1341E7420DCF5C89809831C89" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Ending balance</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_5FA5B4D1341E7420DCF5C89809831C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_5FA5B4D1341E7420DCF5C89809831C89" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_5FA5B4D1341E7420DCF5C89809831C89" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1AAE527B8C710621DA37CDA01B21A918_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_1AAE527B8C710621DA37CDA01B21A918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1AAE527B8C710621DA37CDA01B21A918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1AAE527B8C710621DA37CDA01B21A918" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_1AAE527B8C710621DA37CDA01B21A918" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="lab_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:to="lab_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:to="lab_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:to="lab_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:to="lab_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:to="lab_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:type="arc" />
    <link:label id="lab_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB_terseLabel_en-US" xlink:label="lab_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Debentures [Member]</link:label>
    <link:label id="lab_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB_label_en-US" xlink:label="lab_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Debentures [Member]</link:label>
    <link:label id="lab_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB_documentation_en-US" xlink:label="lab_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Debentures [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:to="lab_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:to="lab_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:to="lab_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:to="lab_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:to="lab_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:to="lab_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:type="arc" />
    <link:label id="lab_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5_terseLabel_en-US" xlink:label="lab_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under milestone achievement, shares</link:label>
    <link:label id="lab_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5_label_en-US" xlink:label="lab_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued for Milestone Payment</link:label>
    <link:label id="lab_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5_documentation_en-US" xlink:label="lab_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued for Milestone Payment</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SharesIssuedforMilestonePayment" xlink:label="loc_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:to="lab_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under milestone achievement</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Achievement of Milestone</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Achievement of Milestone</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_StockIssuedDuringPeriodValueAchievementofMilestone" xlink:label="loc_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:to="lab_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants issued in connection with common stock offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:type="arc" />
    <link:label id="lab_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358_terseLabel_en-US" xlink:label="lab_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period to satisfy principal and interest on long-term debt, new shares</link:label>
    <link:label id="lab_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358_label_en-US" xlink:label="lab_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock issued during period to satisfy principal and interest on long-term debt, new shares</link:label>
    <link:label id="lab_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358_documentation_en-US" xlink:label="lab_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period to satisfy principal and interest on long-term debt, new shares</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares" xlink:label="loc_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:to="lab_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:type="arc" />
    <link:label id="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959_terseLabel_en-US" xlink:label="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to satisfy principal and interest of long-term debt</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt" xlink:label="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959" xlink:to="lab_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:type="arc" />
    <link:label id="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8_terseLabel_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of contingent purchase price consideration, shares</link:label>
    <link:label id="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8_label_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone, Shares</link:label>
    <link:label id="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8_documentation_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone, Shares</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares" xlink:label="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:to="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:type="arc" />
    <link:label id="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0_verboseLabel_en-US" xlink:label="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of contingent purchase price consideration</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone" xlink:label="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0" xlink:to="lab_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in exchange for services, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in exchange for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation for directors and employees</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation for services</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of unrealized gain upon the sale of marketable securities, net of tax of $1,052</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_913EE2AEE83F759E7B8ACDA01B2796D2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_913EE2AEE83F759E7B8ACDA01B2796D2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_913EE2AEE83F759E7B8ACDA01B2796D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_913EE2AEE83F759E7B8ACDA01B2796D2" xlink:to="lab_us-gaap_SharesOutstanding_913EE2AEE83F759E7B8ACDA01B2796D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78DAFBFB828B2EC1FCCACDA01B277951_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78DAFBFB828B2EC1FCCACDA01B277951" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78DAFBFB828B2EC1FCCACDA01B277951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78DAFBFB828B2EC1FCCACDA01B277951" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78DAFBFB828B2EC1FCCACDA01B277951" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:type="arc" />
    <link:label id="lab_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798_terseLabel_en-US" xlink:label="lab_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical development expense</link:label>
    <link:label id="lab_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798_label_en-US" xlink:label="lab_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:label id="lab_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798_documentation_en-US" xlink:label="lab_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798" xlink:to="lab_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5" xlink:to="lab_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68A11C3FDD71920F10008C0EA4C4615F_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68A11C3FDD71920F10008C0EA4C4615F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68A11C3FDD71920F10008C0EA4C4615F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68A11C3FDD71920F10008C0EA4C4615F" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68A11C3FDD71920F10008C0EA4C4615F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:type="arc" />
    <link:label id="lab_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C_terseLabel_en-US" xlink:label="lab_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:label id="lab_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C_label_en-US" xlink:label="lab_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:label id="lab_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C_documentation_en-US" xlink:label="lab_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:to="lab_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:type="arc" />
    <link:label id="lab_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0_terseLabel_en-US" xlink:label="lab_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:label id="lab_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0_label_en-US" xlink:label="lab_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:label id="lab_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0_documentation_en-US" xlink:label="lab_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:to="lab_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:type="arc" />
    <link:label id="lab_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39_terseLabel_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:label id="lab_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39_label_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:label id="lab_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39_documentation_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:to="lab_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and furnishings, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rights</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:type="arc" />
    <link:label id="lab_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119_terseLabel_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC Purchase Agreement [Member]</link:label>
    <link:label id="lab_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119_label_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC Purchase Agreement [Member]</link:label>
    <link:label id="lab_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119_documentation_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LincolnParkCapitalLLCPurchaseAgreementMember" xlink:label="loc_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:to="lab_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:type="arc" />
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6_terseLabel_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6_label_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6_documentation_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:to="lab_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:type="arc" />
    <link:label id="lab_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2_terseLabel_en-US" xlink:label="lab_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2_label_en-US" xlink:label="lab_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2_documentation_en-US" xlink:label="lab_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_UnderwrittenPublicOfferingMember" xlink:label="loc_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:to="lab_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:to="lab_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9_label_en-US" xlink:label="lab_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:to="lab_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1_label_en-US" xlink:label="lab_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:to="lab_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955_label_en-US" xlink:label="lab_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:to="lab_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A_label_en-US" xlink:label="lab_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:to="lab_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:to="lab_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="lab_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase agreement term</link:label>
    <link:label id="lab_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC_label_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:label id="lab_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:to="lab_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, purchase of assets</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A_label_en-US" xlink:label="lab_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:to="lab_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:type="arc" />
    <link:label id="lab_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757_terseLabel_en-US" xlink:label="lab_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized under purchase agreement, shares</link:label>
    <link:label id="lab_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757_label_en-US" xlink:label="lab_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Authorized Amount</link:label>
    <link:label id="lab_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757_documentation_en-US" xlink:label="lab_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Authorized Amount</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_StockPurchaseAgreementAuthorizedAmount" xlink:label="loc_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:to="lab_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:type="arc" />
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB_terseLabel_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of gross proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB_label_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB_documentation_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:to="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:type="arc" />
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4_terseLabel_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum gross proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4_label_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4_documentation_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:to="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares availabe from warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, overallotment option</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:to="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of shares, net underwriting discounts, commissions and offering expenses</link:label>
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19_label_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19_documentation_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:to="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per unit</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:type="arc" />
    <link:label id="lab_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52_terseLabel_en-US" xlink:label="lab_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock available for issuance under warrants</link:label>
    <link:label id="lab_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52_label_en-US" xlink:label="lab_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Available for Issuance, Shares, New Issues</link:label>
    <link:label id="lab_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52_documentation_en-US" xlink:label="lab_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Available for Issuance, Shares, New Issues</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_StockAvailableforIssuanceSharesNewIssues" xlink:label="loc_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:to="lab_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issued during period</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightIssuedDuringPeriod" xlink:label="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:to="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise period of warrants</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Period</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Period</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightExercisePeriod" xlink:label="loc_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:to="lab_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period from issuance which warrants is exercisable</link:label>
    <link:label id="lab_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805_label_en-US" xlink:label="lab_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrants or Rights, Period from Issuance which Warrants or Rights Exercisable</link:label>
    <link:label id="lab_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805_documentation_en-US" xlink:label="lab_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrants or Rights, Period from Issuance which Warrants or Rights Exercisable</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable" xlink:label="loc_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:to="lab_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Loss Contingencies by Contingency [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87" xlink:type="arc" />
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C_terseLabel_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contractual Obligations and Future Cash Payments</link:label>
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C_label_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases Future Minimum Payments Due [Table Text Block]</link:label>
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C_documentation_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock" xlink:label="loc_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C" xlink:to="lab_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_34DA4B6DE10EF1E5DB8D8C0EA4E2E54A_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_34DA4B6DE10EF1E5DB8D8C0EA4E2E54A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_34DA4B6DE10EF1E5DB8D8C0EA4E2E54A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_34DA4B6DE10EF1E5DB8D8C0EA4E2E54A" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_34DA4B6DE10EF1E5DB8D8C0EA4E2E54A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions for Option Grants Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_32FD9D70EC5839B0DB998C0EA43E21C4_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_32FD9D70EC5839B0DB998C0EA43E21C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_32FD9D70EC5839B0DB998C0EA43E21C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_32FD9D70EC5839B0DB998C0EA43E21C4" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_32FD9D70EC5839B0DB998C0EA43E21C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A" xlink:to="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions Table [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E" xlink:to="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E" xlink:type="arc" />
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B_terseLabel_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B_label_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability Table [Table Text Block]</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B_documentation_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B" xlink:to="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development not subject to future amortization for tax purposes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:type="arc" />
    <link:label id="lab_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D_terseLabel_en-US" xlink:label="lab_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:label id="lab_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D_label_en-US" xlink:label="lab_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:label id="lab_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D_documentation_en-US" xlink:label="lab_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:to="lab_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:to="lab_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:to="lab_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future milestone payments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit memos for expiring channel inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz rights</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936_label_en-US" xlink:label="lab_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:to="lab_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_49C60957D5876DC25C618C0EA39879F1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_49C60957D5876DC25C618C0EA39879F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_49C60957D5876DC25C618C0EA39879F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_49C60957D5876DC25C618C0EA39879F1" xlink:to="lab_us-gaap_SubsequentEventsAbstract_49C60957D5876DC25C618C0EA39879F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:to="lab_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5_terseLabel_en-US" xlink:label="lab_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5_label_en-US" xlink:label="lab_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5_documentation_en-US" xlink:label="lab_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeStockPurchasePlanMember" xlink:label="loc_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:to="lab_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:to="lab_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:type="arc" />
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB_terseLabel_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB_label_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Zero Zero Seven Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB_documentation_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Zero Zero Seven Incentive Plan [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:to="lab_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Averages contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average vesting term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745_terseLabel_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to employees</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745_label_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annualized Forfeiture Rate For Options Granted To Employees</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745_documentation_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to employees.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:to="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6_terseLabel_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to senior management</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6_label_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annualized Forfeiture Rate For Options Granted To Senior Management</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6_documentation_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to senior management.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:to="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses weighted average period</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to outstanding common stock options granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting periods of options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options expire from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual term for options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual term for options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:type="arc" />
    <link:label id="lab_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB_terseLabel_en-US" xlink:label="lab_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value Of Stock Options Exercisable</link:label>
    <link:label id="lab_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB_label_en-US" xlink:label="lab_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value Of Stock Options Exercisable</link:label>
    <link:label id="lab_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB_documentation_en-US" xlink:label="lab_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value Of Stock Options Exercisable</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_AggregateIntrinsicValueOfStockOptionsExercisable" xlink:label="loc_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:to="lab_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:type="arc" />
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D_terseLabel_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</link:label>
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D_label_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</link:label>
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D_documentation_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:to="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instrument granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Warrants [Member]</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6_label_en-US" xlink:label="lab_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:to="lab_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duration of average market price used for warrant exercise price</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Days Averaged for Exercise Price</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Days Averaged for Exercise Price</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:to="lab_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate percentage</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate percentage</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate percentage</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants granted (in usd per share)</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:to="lab_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453_terseLabel_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued from warrants</link:label>
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453_label_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453_documentation_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:to="lab_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274_verboseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:to="lab_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity period of warrant</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Maturity Period</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Maturity Period</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightMaturityPeriod" xlink:label="loc_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:to="lab_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:type="arc" />
    <link:label id="lab_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A_terseLabel_en-US" xlink:label="lab_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expenses</link:label>
    <link:label id="lab_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A_label_en-US" xlink:label="lab_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Expense</link:label>
    <link:label id="lab_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A_documentation_en-US" xlink:label="lab_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Expense</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeaseExpense" xlink:label="loc_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A" xlink:to="lab_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A" xlink:type="arc" />
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C_terseLabel_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease payment due upon lease termination</link:label>
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C_label_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases Future Minimum Payments Due Upon Termination of Leases</link:label>
    <link:label id="lab_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C_documentation_en-US" xlink:label="lab_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases Future Minimum Payments Due Upon Termination of Leases</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases" xlink:label="loc_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C" xlink:to="lab_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:to="lab_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:to="lab_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:label id="lab_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A_label_en-US" xlink:label="lab_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:to="lab_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:type="arc" />
    <link:label id="lab_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A_terseLabel_en-US" xlink:label="lab_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Employee [Member]</link:label>
    <link:label id="lab_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A_label_en-US" xlink:label="lab_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Employee [Member]</link:label>
    <link:label id="lab_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A_documentation_en-US" xlink:label="lab_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Employee [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FormerEmployeeMember" xlink:label="loc_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:to="lab_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:type="arc" />
    <link:label id="lab_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F_terseLabel_en-US" xlink:label="lab_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former CEO [Member]</link:label>
    <link:label id="lab_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F_label_en-US" xlink:label="lab_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former CEO [Member]</link:label>
    <link:label id="lab_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F_documentation_en-US" xlink:label="lab_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former CEO [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FormerCEOMember" xlink:label="loc_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:to="lab_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A_label_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:to="lab_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03_label_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="lab_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:type="arc" />
    <link:label id="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954_terseLabel_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI</link:label>
    <link:label id="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954_label_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]</link:label>
    <link:label id="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954_documentation_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:to="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:type="arc" />
    <link:label id="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0_terseLabel_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI</link:label>
    <link:label id="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0_label_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</link:label>
    <link:label id="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0_documentation_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:to="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:type="arc" />
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42_terseLabel_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 1 [Member]</link:label>
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42_label_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 1 [Member]</link:label>
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42_documentation_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 1 [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SecuritiesLitigationOptOutSettlementCase1Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:to="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:type="arc" />
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94_terseLabel_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 2 [Member]</link:label>
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94_label_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 2 [Member]</link:label>
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94_documentation_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 2 [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SecuritiesLitigationOptOutSettlementCase2Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:to="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:type="arc" />
    <link:label id="lab_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E_terseLabel_en-US" xlink:label="lab_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member]</link:label>
    <link:label id="lab_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E_label_en-US" xlink:label="lab_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member]</link:label>
    <link:label id="lab_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E_documentation_en-US" xlink:label="lab_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember" xlink:label="loc_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:to="lab_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:type="arc" />
    <link:label id="lab_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57_terseLabel_en-US" xlink:label="lab_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Litigation [Member]</link:label>
    <link:label id="lab_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57_label_en-US" xlink:label="lab_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Litigation [Member]</link:label>
    <link:label id="lab_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57_documentation_en-US" xlink:label="lab_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SEC Litigation [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SECLitigationMember" xlink:label="loc_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:to="lab_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:to="lab_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96_label_en-US" xlink:label="lab_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:to="lab_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares cancelled</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829" xlink:type="arc" />
    <link:label id="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5_verboseLabel_en-US" xlink:label="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Damages paid by insurance companies</link:label>
    <link:label id="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5_label_en-US" xlink:label="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid by Insurance Company, Value</link:label>
    <link:label id="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5_documentation_en-US" xlink:label="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid by Insurance Company, Value</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyDamagesPaidbyInsuranceCompanyValue" xlink:label="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:to="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages paid</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable by the company in cash</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:type="arc" />
    <link:label id="lab_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E_terseLabel_en-US" xlink:label="lab_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement payable in common stock</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E" xlink:to="lab_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attorney fees</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:to="lab_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, amount</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:to="lab_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:type="arc" />
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D_terseLabel_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, issuance of shares</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D_label_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Value</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D_documentation_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Value</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:to="lab_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:type="arc" />
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF_terseLabel_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, issuance of shares, shares</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF_label_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Shares</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF_documentation_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Shares</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementIssuanceofCommonStockShares" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:to="lab_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:type="arc" />
    <link:label id="lab_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7_terseLabel_en-US" xlink:label="lab_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of counts against defendants with judicial ruling of guilty</link:label>
    <link:label id="lab_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7_label_en-US" xlink:label="lab_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Counts Against Defendants with Judicial Ruling of Guilty</link:label>
    <link:label id="lab_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7_documentation_en-US" xlink:label="lab_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Counts Against Defendants with Judicial Ruling of Guilty</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty" xlink:label="loc_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:to="lab_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:type="arc" />
    <link:label id="lab_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E_terseLabel_en-US" xlink:label="lab_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of counts against defendants</link:label>
    <link:label id="lab_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E_label_en-US" xlink:label="lab_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Counts Against Defendants</link:label>
    <link:label id="lab_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E_documentation_en-US" xlink:label="lab_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Counts Against Defendants</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCountsAgainstDefendants" xlink:label="loc_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:to="lab_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:type="arc" />
    <link:label id="lab_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C_terseLabel_en-US" xlink:label="lab_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of witness to testify at trial</link:label>
    <link:label id="lab_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C_label_en-US" xlink:label="lab_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Witness to Testify at Trial</link:label>
    <link:label id="lab_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C_documentation_en-US" xlink:label="lab_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Witness to Testify at Trial</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyNumberofWitnesstoTestifyatTrial" xlink:label="loc_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:to="lab_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor obligations</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Current Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:to="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Description [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26" xlink:type="arc" />
    <link:label id="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866_terseLabel_en-US" xlink:label="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing deduction deferral</link:label>
    <link:label id="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866_label_en-US" xlink:label="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Licensing Deduction Deferral</link:label>
    <link:label id="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866_documentation_en-US" xlink:label="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Licensing Deduction Deferral</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866" xlink:to="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:type="arc" />
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136_terseLabel_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash equivalents</link:label>
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136_label_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136_documentation_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:to="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500_verboseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Potentially Settleable In Cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A_totalLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A_label_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:to="lab_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706_negatedTerseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078_totalLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Net</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Net</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Net</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1AFD6B3A7513F5DCE0168C0EA3C1F2DA_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1AFD6B3A7513F5DCE0168C0EA3C1F2DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1AFD6B3A7513F5DCE0168C0EA3C1F2DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1AFD6B3A7513F5DCE0168C0EA3C1F2DA" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1AFD6B3A7513F5DCE0168C0EA3C1F2DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected federal income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes after credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6" xlink:type="arc" />
    <link:label id="lab_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D_terseLabel_en-US" xlink:label="lab_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D_label_en-US" xlink:label="lab_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation Unrealized Gain On Marketable Securities</link:label>
    <link:label id="lab_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D_documentation_en-US" xlink:label="lab_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation Unrealized Gain On Marketable Securities</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities" xlink:label="loc_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D" xlink:to="lab_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D" xlink:type="arc" />
    <link:label id="lab_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F_terseLabel_en-US" xlink:label="lab_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in warrant value</link:label>
    <link:label id="lab_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F_label_en-US" xlink:label="lab_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation Gain On Change In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F_documentation_en-US" xlink:label="lab_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation Gain On Change In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability" xlink:label="loc_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F" xlink:to="lab_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B" xlink:type="arc" />
    <link:label id="lab_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA_terseLabel_en-US" xlink:label="lab_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders Securities Litigation [Member]</link:label>
    <link:label id="lab_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA_label_en-US" xlink:label="lab_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders Securities Litigation [Member]</link:label>
    <link:label id="lab_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA_documentation_en-US" xlink:label="lab_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shareholders Securities Litigation [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareholdersSecuritiesLitigationMember" xlink:label="loc_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:to="lab_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503_totalLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503" xlink:to="lab_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503" xlink:type="arc" />
    <link:label id="lab_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81_terseLabel_en-US" xlink:label="lab_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable by the company in cash</link:label>
    <link:label id="lab_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81_label_en-US" xlink:label="lab_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement Amount, Cash</link:label>
    <link:label id="lab_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81_documentation_en-US" xlink:label="lab_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement Amount, Cash</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementAmountCash" xlink:label="loc_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:to="lab_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:type="arc" />
    <link:label id="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B_terseLabel_en-US" xlink:label="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable by the insurance carriers</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyDamagesPaidbyInsuranceCompanyValue" xlink:label="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B" xlink:to="lab_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:to="lab_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D_label_en-US" xlink:label="lab_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:to="lab_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47_label_en-US" xlink:label="lab_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:to="lab_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:type="arc" />
    <link:label id="lab_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2_terseLabel_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2_label_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2_documentation_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:to="lab_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:to="lab_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:type="arc" />
    <link:label id="lab_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD_terseLabel_en-US" xlink:label="lab_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sentynl Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD_label_en-US" xlink:label="lab_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sentynl Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD_documentation_en-US" xlink:label="lab_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sentynl Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SentynlTherapeuticsInc.Member" xlink:label="loc_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:to="lab_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:type="arc" />
    <link:label id="lab_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985_terseLabel_en-US" xlink:label="lab_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Midatech Pharma PLC [Member]</link:label>
    <link:label id="lab_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985_label_en-US" xlink:label="lab_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Midatech Pharma PLC [Member]</link:label>
    <link:label id="lab_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985_documentation_en-US" xlink:label="lab_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Midatech Pharma PLC [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MidatechPharmaPLCMember" xlink:label="loc_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:to="lab_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:type="arc" />
    <link:label id="lab_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C_terseLabel_en-US" xlink:label="lab_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monosol Rx, LLC [Member]</link:label>
    <link:label id="lab_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C_label_en-US" xlink:label="lab_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monosol Rx, LLC [Member]</link:label>
    <link:label id="lab_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C_documentation_en-US" xlink:label="lab_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monosol Rx, LLC [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MonosolRxLLCMember" xlink:label="loc_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:to="lab_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="lab_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:type="arc" />
    <link:label id="lab_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202_terseLabel_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202_label_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202_documentation_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:to="lab_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:type="arc" />
    <link:label id="lab_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD_terseLabel_en-US" xlink:label="lab_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD_label_en-US" xlink:label="lab_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone Payment</link:label>
    <link:label id="lab_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD_documentation_en-US" xlink:label="lab_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Milestone Payment</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:to="lab_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration receivable under agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82_label_en-US" xlink:label="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Consideration Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Consideration Receivable Under Agreement</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:to="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment receivable under agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2_label_en-US" xlink:label="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Upfront Payment Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Upfront Payment Receivable Under Agreement</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:to="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable under agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE_label_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Receivable Under Agreement</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:to="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:type="arc" />
    <link:label id="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834_terseLabel_en-US" xlink:label="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of one-time future milestone payments</link:label>
    <link:label id="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834_label_en-US" xlink:label="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Number Of One-Time Future Cash Milestone Payments</link:label>
    <link:label id="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834_documentation_en-US" xlink:label="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Number Of One-Time Future Cash Milestone Payments</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments" xlink:label="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:to="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration threshold, net sales</link:label>
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D_label_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Threshold, Net Sales</link:label>
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Threshold, Net Sales</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementContingentConsiderationThresholdNetSales" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:to="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of upfront fee</link:label>
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455_label_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee</link:label>
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementPaymentofUpfrontFee" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:to="lab_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of upfront fee, percentage of future milestone payments received</link:label>
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569_label_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received</link:label>
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:to="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations,Assets Held for Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:type="arc" />
    <link:label id="lab_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03_terseLabel_en-US" xlink:label="lab_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional Fees [Member]</link:label>
    <link:label id="lab_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03_label_en-US" xlink:label="lab_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Services Provided by Corporate Counsel [Member]</link:label>
    <link:label id="lab_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03_documentation_en-US" xlink:label="lab_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Services Provided by Corporate Counsel [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ServicesProvidedbyCorporateCounselMember" xlink:label="loc_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:to="lab_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:to="lab_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:type="arc" />
    <link:label id="lab_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260_terseLabel_en-US" xlink:label="lab_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Troy Gould Pc [Member]</link:label>
    <link:label id="lab_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260_label_en-US" xlink:label="lab_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Troy Gould Pc [Member]</link:label>
    <link:label id="lab_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260_documentation_en-US" xlink:label="lab_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Troy Gould Pc [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_TroyGouldPcMember" xlink:label="loc_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:to="lab_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Customer and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_31CF7F8FA3223B8F47D28C1429B73615_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_31CF7F8FA3223B8F47D28C1429B73615" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of the contingent purchase price liability</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_31CF7F8FA3223B8F47D28C1429B73615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_31CF7F8FA3223B8F47D28C1429B73615" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_31CF7F8FA3223B8F47D28C1429B73615" xlink:type="arc" />
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8_terseLabel_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous other income</link:label>
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8_label_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous Other Income Expense</link:label>
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8_documentation_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Miscellaneous other income (expense).</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8" xlink:to="lab_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE" xlink:type="arc" />
    <link:label id="lab_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A_terseLabel_en-US" xlink:label="lab_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RXi Spin-off</link:label>
    <link:label id="lab_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A_label_en-US" xlink:label="lab_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partner Company [Text Block]</link:label>
    <link:label id="lab_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A_documentation_en-US" xlink:label="lab_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RXi Spin-Out.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PartnerCompanyTextBlock" xlink:label="loc_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A" xlink:to="lab_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF" xlink:type="arc" />
    <link:label id="lab_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338_terseLabel_en-US" xlink:label="lab_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash excluding from net assets acquired</link:label>
    <link:label id="lab_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338_label_en-US" xlink:label="lab_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Excluding From Net Assets Acquired</link:label>
    <link:label id="lab_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338_documentation_en-US" xlink:label="lab_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash excluding from net assets acquired</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CashExcludingFromNetAssetsAcquired" xlink:label="loc_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338" xlink:to="lab_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of certain acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD_negatedTerseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge from classification as assets held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of commercial business assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A_negatedTerseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Severance and exit costs</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Severance and Exit Costs</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Severance and Exit Costs</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="lab_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:to="lab_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538" xlink:type="arc" />
    <link:label id="lab_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A_terseLabel_en-US" xlink:label="lab_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A_label_en-US" xlink:label="lab_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expenses</link:label>
    <link:label id="lab_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A_documentation_en-US" xlink:label="lab_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General and administrative expense.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_GeneralAndAdministrativeExpenses" xlink:label="loc_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A" xlink:to="lab_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034" xlink:to="lab_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E" xlink:to="lab_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924" xlink:type="arc" />
    <link:label id="lab_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72_negatedTerseLabel_en-US" xlink:label="lab_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72_label_en-US" xlink:label="lab_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Warrant Exchange</link:label>
    <link:label id="lab_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72_documentation_en-US" xlink:label="lab_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss on warrant exchange.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72" xlink:to="lab_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72" xlink:type="arc" />
    <link:label id="lab_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5_terseLabel_en-US" xlink:label="lab_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5_label_en-US" xlink:label="lab_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income</link:label>
    <link:label id="lab_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5_documentation_en-US" xlink:label="lab_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest (expense) income.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_InterestIncome" xlink:label="loc_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5" xlink:to="lab_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F5598215526C1FBC727C8C0EA30D8DF9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F5598215526C1FBC727C8C0EA30D8DF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of the contingent purchase price liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F5598215526C1FBC727C8C0EA30D8DF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_F5598215526C1FBC727C8C0EA30D8DF9" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_F5598215526C1FBC727C8C0EA30D8DF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_EFAF2F598E57D9E622B18C0EA30DFFDE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_EFAF2F598E57D9E622B18C0EA30DFFDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_EFAF2F598E57D9E622B18C0EA30DFFDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_EFAF2F598E57D9E622B18C0EA30DFFDE" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_EFAF2F598E57D9E622B18C0EA30DFFDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_043C5AA6FDFB6061B7198C0EA30E3C46_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_043C5AA6FDFB6061B7198C0EA30E3C46" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_043C5AA6FDFB6061B7198C0EA30E3C46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_043C5AA6FDFB6061B7198C0EA30E3C46" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_043C5AA6FDFB6061B7198C0EA30E3C46" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9DC9062C9F3FDD1DE0748C0EA30EDDA1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9DC9062C9F3FDD1DE0748C0EA30EDDA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9DC9062C9F3FDD1DE0748C0EA30EDDA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9DC9062C9F3FDD1DE0748C0EA30EDDA1" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9DC9062C9F3FDD1DE0748C0EA30EDDA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_41CD2CE5433C0279E5988C0EA30E7BB5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_41CD2CE5433C0279E5988C0EA30E7BB5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_41CD2CE5433C0279E5988C0EA30E7BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_41CD2CE5433C0279E5988C0EA30E7BB5" xlink:to="lab_us-gaap_NetIncomeLoss_41CD2CE5433C0279E5988C0EA30E7BB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted per share, continuing operations (usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share, discontinued operations (usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding: basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of unrealized gain upon sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax effect of reclassification of unrealized gain upon sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effect of unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_42C58974D3322F5964408C0EA39B5778_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_42C58974D3322F5964408C0EA39B5778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_42C58974D3322F5964408C0EA39B5778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42C58974D3322F5964408C0EA39B5778" xlink:to="lab_us-gaap_DebtDisclosureAbstract_42C58974D3322F5964408C0EA39B5778" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:type="arc" />
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33_terseLabel_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings [Member]</link:label>
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33_label_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33_documentation_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:to="lab_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:type="arc" />
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B_terseLabel_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Highly-liquid debt instruments maturity days</link:label>
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B_label_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</link:label>
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B_documentation_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:to="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576_label_en-US" xlink:label="lab_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:to="lab_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:to="lab_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:to="lab_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:type="arc" />
    <link:label id="lab_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589_terseLabel_en-US" xlink:label="lab_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prompt pay discount, percent of gross sales</link:label>
    <link:label id="lab_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589_label_en-US" xlink:label="lab_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Services, Percent</link:label>
    <link:label id="lab_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589_documentation_en-US" xlink:label="lab_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Discounts, Services, Percent</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesDiscountsServicesPercent" xlink:label="loc_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:to="lab_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:type="arc" />
    <link:label id="lab_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D_terseLabel_en-US" xlink:label="lab_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization period of license and distribution rights</link:label>
    <link:label id="lab_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D_label_en-US" xlink:label="lab_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Period Of Selling And Distribution Rights</link:label>
    <link:label id="lab_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D_documentation_en-US" xlink:label="lab_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Period Of Selling And Distribution Rights</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_AmortizationPeriodOfSellingAndDistributionRights" xlink:label="loc_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:to="lab_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest bearing accounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock [Member]</link:label>
    <link:label id="lab_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E_label_en-US" xlink:label="lab_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:to="lab_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:to="lab_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_146680F5E85B2FE09F408C0EA23C9055_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_146680F5E85B2FE09F408C0EA23C9055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_146680F5E85B2FE09F408C0EA23C9055" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146680F5E85B2FE09F408C0EA23C9055" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_146680F5E85B2FE09F408C0EA23C9055" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="lab_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="lab_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B747C7C9762B2820EC38C0EA23D9AAE_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B747C7C9762B2820EC38C0EA23D9AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B747C7C9762B2820EC38C0EA23D9AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B747C7C9762B2820EC38C0EA23D9AAE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B747C7C9762B2820EC38C0EA23D9AAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803" xlink:type="arc" />
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement insurance recovery</link:label>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7_label_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Settlements Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7" xlink:to="lab_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620" xlink:to="lab_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and furnishings, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916" xlink:type="arc" />
    <link:label id="lab_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D_terseLabel_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral rights, net</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D_label_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D_documentation_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D" xlink:to="lab_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D" xlink:type="arc" />
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1_terseLabel_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz rights</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1_label_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights, Zuplenz</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1_documentation_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights, Zuplenz</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1" xlink:to="lab_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1" xlink:type="arc" />
    <link:label id="lab_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8_terseLabel_en-US" xlink:label="lab_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:label id="lab_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8_label_en-US" xlink:label="lab_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:label id="lab_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8_documentation_en-US" xlink:label="lab_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8" xlink:to="lab_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8" xlink:type="arc" />
    <link:label id="lab_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8_terseLabel_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8_label_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research Development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8_documentation_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8" xlink:to="lab_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F_label_en-US" xlink:label="lab_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F" xlink:to="lab_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F" xlink:to="lab_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_539E36EF7910EC6FE15A8C0EA242477E_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_539E36EF7910EC6FE15A8C0EA242477E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_539E36EF7910EC6FE15A8C0EA242477E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_539E36EF7910EC6FE15A8C0EA242477E" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_539E36EF7910EC6FE15A8C0EA242477E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement payable</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828" xlink:to="lab_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_C55A1B3D868ECCB87BDA8C0EA243A9C9_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_C55A1B3D868ECCB87BDA8C0EA243A9C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_C55A1B3D868ECCB87BDA8C0EA243A9C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_C55A1B3D868ECCB87BDA8C0EA243A9C9" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_C55A1B3D868ECCB87BDA8C0EA243A9C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E" xlink:to="lab_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1A3CF61BFD73C006A6EA8C0EA2431195_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1A3CF61BFD73C006A6EA8C0EA2431195" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1A3CF61BFD73C006A6EA8C0EA2431195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1A3CF61BFD73C006A6EA8C0EA2431195" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1A3CF61BFD73C006A6EA8C0EA2431195" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868" xlink:to="lab_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D" xlink:type="arc" />
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D_terseLabel_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D_label_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration Net Of Current Portion</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D_documentation_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration, net of current portion.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D" xlink:to="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38_label_en-US" xlink:label="lab_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38" xlink:to="lab_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3" xlink:to="lab_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:to="lab_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 350,000,000 shares authorized, 15,224,223 shares issued and 15,190,473 shares outstanding at December 31, 2016; 275,000,000 shares authorized, 8,129,087 shares issued and 8,095,337 shares outstanding at December 31, 2015</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8" xlink:to="lab_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D" xlink:type="arc" />
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810_negatedLabel_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810_label_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deficit Accumulated During Developmental Stage</link:label>
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810_documentation_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deficit accumulated during the developmental stage.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810" xlink:to="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less treasury shares at cost, 675,000 shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC" xlink:to="lab_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9" xlink:to="lab_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8" xlink:to="lab_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45" xlink:to="lab_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192" xlink:to="lab_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192" xlink:type="arc" />
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93_label_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93_documentation_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="lab_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09_label_en-US" xlink:label="lab_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09" xlink:to="lab_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5_label_en-US" xlink:label="lab_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5" xlink:to="lab_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691" xlink:to="lab_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55" xlink:to="lab_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83_label_en-US" xlink:label="lab_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83" xlink:to="lab_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B_terseLabel_en-US" xlink:label="lab_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B_label_en-US" xlink:label="lab_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B" xlink:to="lab_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE" xlink:to="lab_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE" xlink:to="lab_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D" xlink:to="lab_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23_label_en-US" xlink:label="lab_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23" xlink:to="lab_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98" xlink:to="lab_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073" xlink:to="lab_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B_label_en-US" xlink:label="lab_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B" xlink:to="lab_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041" xlink:type="arc" />
    <link:label id="lab_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC_terseLabel_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:label id="lab_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC_label_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:label id="lab_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC_documentation_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:to="lab_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="lab_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28" xlink:to="lab_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD_negatedLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:to="lab_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC_negatedTerseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:to="lab_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_F1EA9C7B4BDEF055F6B0C7E347EF89F3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_F1EA9C7B4BDEF055F6B0C7E347EF89F3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_F1EA9C7B4BDEF055F6B0C7E347EF89F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_F1EA9C7B4BDEF055F6B0C7E347EF89F3" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_F1EA9C7B4BDEF055F6B0C7E347EF89F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:type="arc" />
    <link:label id="lab_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5_terseLabel_en-US" xlink:label="lab_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strike price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5_label_en-US" xlink:label="lab_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5_documentation_en-US" xlink:label="lab_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:to="lab_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC_label_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Liability Assumptions Expected Term</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Liability Assumptions Expected Term</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:to="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:to="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:to="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Federal and State Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Net Deferred Tax Assets</link:label>
    <link:label id="lab_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635_label_en-US" xlink:label="lab_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Components Of Net Deferred Tax Assets Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635_documentation_en-US" xlink:label="lab_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Components Of Net Deferred Tax Assets Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" xlink:label="loc_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635" xlink:to="lab_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Net Deferred Tax Liabilities</link:label>
    <link:label id="lab_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE_label_en-US" xlink:label="lab_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Components Of Net Deferred Tax Liabilities Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE_documentation_en-US" xlink:label="lab_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Components Of Net Deferred Tax Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" xlink:label="loc_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE" xlink:to="lab_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Provision Computed by Applying Federal Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:to="lab_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="lab_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan, amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for interest only payments</link:label>
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B_label_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only</link:label>
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B_documentation_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:to="lab_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments at the fixed coupon rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for principal and interest payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:to="lab_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash facility fee percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC_label_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Facility Fee</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Facility Fee</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:to="lab_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash final payment percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833_label_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Final Payment</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Final Payment</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:to="lab_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:to="lab_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original issue discount, percent</link:label>
    <link:label id="lab_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392_label_en-US" xlink:label="lab_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Original Issue Discount, Percent</link:label>
    <link:label id="lab_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392_documentation_en-US" xlink:label="lab_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Original Issue Discount, Percent</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentOriginalIssueDiscountPercent" xlink:label="loc_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:to="lab_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of secured debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal that could be redeemed</link:label>
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C_label_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed</link:label>
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C_documentation_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemed" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:to="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity covenant</link:label>
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D_label_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:to="lab_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2_terseLabel_en-US" xlink:label="lab_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock trading price threshold</link:label>
    <link:label id="lab_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2_label_en-US" xlink:label="lab_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Trading Price Threshold, for Redeeming Principal of Debt Instrument</link:label>
    <link:label id="lab_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2_documentation_en-US" xlink:label="lab_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Trading Price Threshold, for Redeeming Principal of Debt Instrument</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument" xlink:label="loc_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:to="lab_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal that could be redeemed, stock price threshold</link:label>
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8_label_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed, Company's Monthly Stock Price Threshold</link:label>
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8_documentation_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed, Company's Monthly Stock Price Threshold</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:to="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:type="arc" />
    <link:label id="lab_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311_terseLabel_en-US" xlink:label="lab_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of elections company can make in 12 month period</link:label>
    <link:label id="lab_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311_label_en-US" xlink:label="lab_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Elections Company Can Make in Year to Redeem Debt Instrument Principal</link:label>
    <link:label id="lab_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311_documentation_en-US" xlink:label="lab_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Elections Company Can Make in Year to Redeem Debt Instrument Principal</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal" xlink:label="loc_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:to="lab_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal that could be redeemed, company's election</link:label>
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1_label_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed, Company's Election</link:label>
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1_documentation_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed, Company's Election</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:to="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lowest volume weighted average prices during prior trading days used to compute average</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Number of Lowest Weighted Average Prices to Apply Discount Rate</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Number of Lowest Weighted Average Prices to Apply Discount Rate</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:to="lab_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Number of Days, Maximum</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Number of Days, Maximum</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentRedemptionNumberofDaysMaximum" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:to="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate applied to prior trading day's volume weighted average price</link:label>
    <link:label id="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7_label_en-US" xlink:label="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prior Trading Day&#8217;s Volume, Weighted Average Price, Discount Rate</link:label>
    <link:label id="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7_documentation_en-US" xlink:label="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prior Trading Day&#8217;s Volume, Weighted Average Price, Discount Rate</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" xlink:label="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:to="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE_label_en-US" xlink:label="lab_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:to="lab_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior notes, current</link:label>
    <link:label id="lab_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E_label_en-US" xlink:label="lab_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesCurrent" xlink:label="loc_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:to="lab_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement agent fee percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9_label_en-US" xlink:label="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Placement Agent Fee, Percent of Funds Received</link:label>
    <link:label id="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9_documentation_en-US" xlink:label="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Placement Agent Fee, Percent of Funds Received</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" xlink:label="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:to="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:type="arc" />
    <link:label id="lab_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3_terseLabel_en-US" xlink:label="lab_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral Rights and Zuplenz Rights [Member]</link:label>
    <link:label id="lab_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3_label_en-US" xlink:label="lab_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abstral Rights and Zuplenz Rights [Member]</link:label>
    <link:label id="lab_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3_documentation_en-US" xlink:label="lab_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abstral Rights and Zuplenz Rights [Member]</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsandZuplenzRightsMember" xlink:label="loc_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:to="lab_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:type="arc" />
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF_terseLabel_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of cancer patients affected by inadequately controlled breakthrough cancer pain (BTcP) (in percent)</link:label>
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF_label_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Cancer Patients Affected by Inadequately Controlled Breakthrough Cancer Pain (BTcP)</link:label>
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF_documentation_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Cancer Patients Affected by Inadequately Controlled Breakthrough Cancer Pain (BTcP)</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:to="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375_label_en-US" xlink:label="lab_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment Charge on Reclassified Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:label="loc_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:to="lab_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success fee contingently due to third party</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of realized future revenue</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retention fees contingently due</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retention fees contingently due (as percentage of consideration received)</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:type="arc" />
    <link:label id="lab_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E_terseLabel_en-US" xlink:label="lab_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RXi [Member]</link:label>
    <link:label id="lab_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E_label_en-US" xlink:label="lab_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rxi [Member]</link:label>
    <link:label id="lab_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E_documentation_en-US" xlink:label="lab_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rxi.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_RxiMember" xlink:label="loc_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:to="lab_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:type="arc" />
    <link:label id="lab_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A_terseLabel_en-US" xlink:label="lab_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash contribution in capital</link:label>
    <link:label id="lab_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A_label_en-US" xlink:label="lab_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Contribution In Capital</link:label>
    <link:label id="lab_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A_documentation_en-US" xlink:label="lab_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash contribution in capital.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_CashContributionInCapital" xlink:label="loc_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:to="lab_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from technology revenue</link:label>
    <link:label id="lab_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30_label_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Technology Revenue</link:label>
    <link:label id="lab_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30_documentation_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from technology revenue.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenue" xlink:label="loc_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:to="lab_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from technology revenue under condition one</link:label>
    <link:label id="lab_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E_label_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Technology Revenue Under Condition One</link:label>
    <link:label id="lab_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E_documentation_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from technology revenue under condition one.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenueUnderConditionOne" xlink:label="loc_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:to="lab_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from technology revenue under condition two</link:label>
    <link:label id="lab_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96_label_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Technology Revenue Under Condition Two</link:label>
    <link:label id="lab_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96_documentation_en-US" xlink:label="lab_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from technology revenue under condition two.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenueUnderConditionTwo" xlink:label="loc_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:to="lab_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:type="arc" />
    <link:label id="lab_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877_terseLabel_en-US" xlink:label="lab_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum estimated sales</link:label>
    <link:label id="lab_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877_label_en-US" xlink:label="lab_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Estimated Sales</link:label>
    <link:label id="lab_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877_documentation_en-US" xlink:label="lab_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum estimated sales.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_MinimumEstimatedSales" xlink:label="loc_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:to="lab_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25_terseLabel_en-US" xlink:label="lab_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated sales</link:label>
    <link:label id="lab_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25_label_en-US" xlink:label="lab_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Sales</link:label>
    <link:label id="lab_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25_documentation_en-US" xlink:label="lab_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated sales.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedSales" xlink:label="loc_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:to="lab_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:type="arc" />
    <link:label id="lab_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D_terseLabel_en-US" xlink:label="lab_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares distributed to surrenders under spin-off</link:label>
    <link:label id="lab_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D_label_en-US" xlink:label="lab_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Distributed To Surrenders Under Spin Off</link:label>
    <link:label id="lab_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D_documentation_en-US" xlink:label="lab_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares distributed to surrenders under spin-off.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberOfSharesDistributedToSurrendersUnderSpinOff" xlink:label="loc_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:to="lab_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:type="arc" />
    <link:label id="lab_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0_terseLabel_en-US" xlink:label="lab_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares retained by company under spin-off</link:label>
    <link:label id="lab_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0_label_en-US" xlink:label="lab_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Retained By Company Under Spin Off</link:label>
    <link:label id="lab_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0_documentation_en-US" xlink:label="lab_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares retained by company under spin-off.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberOfSharesRetainedByCompanyUnderSpinOff" xlink:label="loc_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:to="lab_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:type="arc" />
    <link:label id="lab_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458_terseLabel_en-US" xlink:label="lab_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lock up period of shares under spin-off</link:label>
    <link:label id="lab_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458_label_en-US" xlink:label="lab_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lock Up Period Of Shares Under Spin Off</link:label>
    <link:label id="lab_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458_documentation_en-US" xlink:label="lab_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lock up period of shares under spin-off.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_LockUpPeriodOfSharesUnderSpinOff" xlink:label="loc_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:to="lab_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:type="arc" />
    <link:label id="lab_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E_terseLabel_en-US" xlink:label="lab_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration date of shares under spin-off</link:label>
    <link:label id="lab_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E_label_en-US" xlink:label="lab_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Date Of Shares Under Spinoff</link:label>
    <link:label id="lab_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E_documentation_en-US" xlink:label="lab_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Date Of Shares Under Spin-Off</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_ExpirationDateOfSharesUnderSpinoff" xlink:label="loc_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:to="lab_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:type="arc" />
    <link:label id="lab_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293_terseLabel_en-US" xlink:label="lab_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares sold by company after spin-off</link:label>
    <link:label id="lab_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293_label_en-US" xlink:label="lab_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares sold by company after spin-off</link:label>
    <link:label id="lab_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293_documentation_en-US" xlink:label="lab_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares sold by company after spin-off</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_Numberofsharessoldbycompanyafterspinoff" xlink:label="loc_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:to="lab_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:type="arc" />
    <link:label id="lab_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175_terseLabel_en-US" xlink:label="lab_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of shares after spin-off</link:label>
    <link:label id="lab_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175_label_en-US" xlink:label="lab_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of shares after spin-off</link:label>
    <link:label id="lab_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175_documentation_en-US" xlink:label="lab_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from sale of shares after spin-off</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_Proceedsfromsaleofsharesafterspinoff" xlink:label="loc_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:to="lab_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:type="arc" />
    <link:label id="lab_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F_terseLabel_en-US" xlink:label="lab_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained price per shares under spin-off</link:label>
    <link:label id="lab_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F_label_en-US" xlink:label="lab_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Price Per Shares Under Spin Off</link:label>
    <link:label id="lab_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F_documentation_en-US" xlink:label="lab_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retained price per shares under spin-off.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_RetainedPricePerSharesUnderSpinOff" xlink:label="loc_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:to="lab_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:type="arc" />
    <link:label id="lab_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E_terseLabel_en-US" xlink:label="lab_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained value of shares under spin-off</link:label>
    <link:label id="lab_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E_label_en-US" xlink:label="lab_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Value Of Shares Under Spin Off</link:label>
    <link:label id="lab_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E_documentation_en-US" xlink:label="lab_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retained value of shares under spin-off.</link:label>
    <link:loc xlink:href="gale-20161231.xsd#gale_RetainedValueOfSharesUnderSpinOff" xlink:label="loc_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:to="lab_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>gale-20161231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20161231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20161231.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20161231.xsd#BusinessCombinations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20161231.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20161231.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingencies" xlink:href="gale-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gale-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20161231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:href="gale-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20161231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="gale-20161231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20161231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20161231.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/EmployeeBenefitPlan" xlink:href="gale-20161231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/EmployeeBenefitPlanDetails" xlink:href="gale-20161231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20161231.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20161231.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxes" xlink:href="gale-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:href="gale-20161231.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:href="gale-20161231.xsd#IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:href="gale-20161231.xsd#IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:href="gale-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20161231.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20161231.xsd#LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20161231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20161231.xsd#LongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20161231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20161231.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20161231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20161231.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:href="gale-20161231.xsd#OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20161231.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements" xlink:href="gale-20161231.xsd#RecentlyAdoptedAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactions" xlink:href="gale-20161231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:href="gale-20161231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RxiSpinOff" xlink:href="gale-20161231.xsd#RxiSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RxiSpinOffAdditionalInformationDetail" xlink:href="gale-20161231.xsd#RxiSpinOffAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="gale-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20161231.xsd#SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:href="gale-20161231.xsd#StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20161231.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20161231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20161231.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20161231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20161231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20161231.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:href="gale-20161231.xsd#WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20161231.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20161231.xsd#WarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20161231.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4DB56C668069FEF911AA8C0EA0BB56DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4DB56C668069FEF911AA8C0EA0BB56DC" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_04BC92E9B57DEF0CEA278C0EA0BC6E42" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:to="loc_gale_ContractResearchPayable_0196AE7F19958952D0B18C0EA1EF2798" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_F9B48C91D388A882BEF68C0EA1F0B47F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_90CD97165A288749B3D88C0EA1F099C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:to="loc_us-gaap_InterestPayableCurrent_CBE19B71D03C3096BE588C0EA1F1A4E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BA6255F378478BF5FCD88C0EA1EFE501" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_AB4E1304C631F43FB6DF8C0EA1F1141F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2EB68B09BE9AF98EC8028C0EA318F8B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2EB68B09BE9AF98EC8028C0EA318F8B6" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D63AF099FFA910A0823F8C0EA319618B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F894DDA0BBD5870403768C0EA1E436EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F894DDA0BBD5870403768C0EA1E436EE" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_E7C4C57E5AA28188EFEF8C0EA1E4FDCF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_78114F61183B49DEC505CDA01AF92BAC" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78114F61183B49DEC505CDA01AF92BAC" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4A182114A07807963386CDA01AFACBBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:to="loc_us-gaap_RangeAxis_4A182114A07807963386CDA01AFACBBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_4A182114A07807963386CDA01AFACBBE" xlink:to="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_85A64A5A8E780CA3B13FCDA01AFB77A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79" xlink:to="loc_us-gaap_MinimumMember_85A64A5A8E780CA3B13FCDA01AFB77A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1BDE1B4EECD2846C230CCDA01AFBE27D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_347E91C7B5EA2190C108CDA01AFBFD79" xlink:to="loc_us-gaap_MaximumMember_1BDE1B4EECD2846C230CCDA01AFBE27D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AB7E1D83FFA5788851C5CDA01AFB79C4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E4DB78322E7EE21391ADCDA01AFBE586" xlink:to="loc_gale_EquipmentFurnitureAndFixturesMember_7A495EDEB8B366CF1722CDA01AFB2C33" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_FBFCB96BE8FA3EB983F9CDA01AF92F2D" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_84526F913AA8F73C6B46CDA01AFBDD0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_InventoryNet_A07A2A9585A6F075B3CCCDA01AFC9576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_InventoryWorkInProcess_C553664E7DBB087969A9CDA01AFCC706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_InventoryFinishedGoods_DA97B1C677A56FB61989CDA01AFCF202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A7DE124785938021FDD1CDA01AFCAC26" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesDiscountsServicesPercent" xlink:label="loc_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_gale_SalesDiscountsServicesPercent_DEAD79C84A5A5EB8A4FCCDA01AFCC589" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AmortizationPeriodOfSellingAndDistributionRights" xlink:label="loc_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_gale_AmortizationPeriodOfSellingAndDistributionRights_1E403A465B13A25F4585CDA01AFC424D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1379AD6E99C82EC6428ACDA01AFCA6D8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1379AD6E99C82EC6428ACDA01AFCA6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FFCC2B5510ACB096A529CDA01AFBAA81" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9CA730433CB86666E0FBCDA01AFC848D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_9AABC8A56AC33EA1D2C68C0EA67A0C1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_UseOfEstimates_4D88E72BD296E9A58E758C0EA67A7640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_BB36B8F0EDDCA6BE7D488C0EA67ADB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9776E815A5BD00CBF8468C0EA67A3FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_698C1DBB8AEFE2A18B428C0EA67ACFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F052220369292B811358C0EA67A2F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_6FA4C6E5F6D6270B79A48C0EA67A2195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_E74518250800D4B588B28C0EA67B0884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_B9C295D698A66F5E38778C0EA67B1127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_46037599D57DD39CD30D8C0EA67B7F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_B7AA7573AF38A8F534D08C0EA67B880F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_63F3BAFA405E9F9752B48C0EA67BCBE9" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_BAC5B110C74414A6B6ED8C0EA67BE19C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_C61067B4FBE65426EFC88C0EA67B6801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_794091A057D54D3FFBB98C0EA67BDF0D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7B71A234AE71CFEF4AE88C0EA6809A45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_0C7F1BDA5EAEBA0F77938C0EA6817692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5B85AC2AAFE368A2181F8C0EA6811277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D5380C8DF82F326020608C0EA681BEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_F4B4E99E05717A5CDA278C0EA68154E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_98FB9B9C845ECAA6828C8C0EA6817777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61BD2576E2CB299626398C0EA6812FB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_E5C82E70D00BAA89EFD18C0EA6819C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03C3CF503A3AC6597ADD8C0EA6795E46" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5669EA3A2CCC712E2F698C0EA6825057" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_70A8C554A768589846C88C0EA2042461" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_70A8C554A768589846C88C0EA2042461" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_521A5612DC81B725639D8C0EA2048428" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8F498EDBCB16F4EAB1848C0EA469B513" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8F498EDBCB16F4EAB1848C0EA469B513" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_18F0A039D13B594969348C0EA46AC7DD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B08D716222246F72CD638C0EA46A48FF" xlink:to="loc_gale_ZuplenzMember_762746D3986615D4E3C38C0EA46AF98D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F32CFFC3F37C3974D9738C0EA46A2B0B" xlink:to="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_10EB15E4475B26F3C6258C0EA46A0AE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_EAF25968A2F0BBEDFDD88C0EA46A2E93" xlink:to="loc_us-gaap_CommonStockMember_10EB15E4475B26F3C6258C0EA46A0AE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0039A67266090EC73DCB8C0EA4696A7A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_F87A043E3D47B154D2648C0EA46B0EC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_5C09027BFFE9773D8A588C0EA46C4991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53BACBEE1C58A816D0C58C0EA46C6A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_DF56BDBCF036D5AB5CB18C0EA46CF82C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_DF825F24007529F056118C0EA46CAFE2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_43C02727F0A7A7F0E5218C0EA46C3611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_Goodwill_4853773F136D1EC41BA38C0EA46C9936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B1469AB3EA2018C3DD7E8C0EA46B0B17" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_3F6391C403881C06D62E8C0EA46C9EE7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7034963499058AAD19C08C0EA447521B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7034963499058AAD19C08C0EA447521B" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_DB0BC29A53B0EED4B0878C0EA4486909" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33B0A3048DFA9FCB74D68C0EA6415E9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33B0A3048DFA9FCB74D68C0EA6415E9F" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87754790136E63E3A6168C0EA64139B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C552CB32F2EBAE8344FFC8991B6C6C58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C552CB32F2EBAE8344FFC8991B6C6C58" xlink:to="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_62EDF6FECB442F701890C8991B6C1F63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_LitigationStatusAxis_62EDF6FECB442F701890C8991B6C1F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_62EDF6FECB442F701890C8991B6C1F63" xlink:to="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_29733047B807B9C85F75C8991B6CF102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:to="loc_us-gaap_SettledLitigationMember_29733047B807B9C85F75C8991B6CF102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:to="loc_us-gaap_JudicialRulingMember_8D26DB7F9082C713B454C8991B6C1DCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_B7D9D03A0EC42E6D5413C8991B6C6599" xlink:to="loc_us-gaap_PendingLitigationMember_259A8C11A4E5BE2BA6ADC8991B6C29D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D39E37FD62C5E44460B1C8991B6DA6BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_RangeAxis_D39E37FD62C5E44460B1C8991B6DA6BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0EB9C96CCD2B2B58E44BC8991B6D7A3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_D39E37FD62C5E44460B1C8991B6DA6BC" xlink:to="loc_us-gaap_RangeMember_0EB9C96CCD2B2B58E44BC8991B6D7A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_910B70FBF752CD69693CC8991B6DC450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0EB9C96CCD2B2B58E44BC8991B6D7A3B" xlink:to="loc_us-gaap_MaximumMember_910B70FBF752CD69693CC8991B6DC450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_9C4BBDA61C91A30D336AC8991B6D5062" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_TitleOfIndividualAxis_9C4BBDA61C91A30D336AC8991B6D5062" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_9C4BBDA61C91A30D336AC8991B6D5062" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:to="loc_us-gaap_DirectorMember_9A6422B7578F02EC1242C8991B6DA74A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FormerEmployeeMember" xlink:label="loc_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:to="loc_gale_FormerEmployeeMember_4B92B690D61B1361926FC8991B6D2F1A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FormerCEOMember" xlink:label="loc_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_57F63A1512C7D294671CC8991B6D09DB" xlink:to="loc_gale_FormerCEOMember_0749F5A8AAE400FF0B16C8991B6DA32F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_8BD529E42127FB3462E6C8991B6DB95A" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_DE3B9A05F38085003B76C8991B6D4954" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_8AE156BF2E2ACAD45A9AC8991B6D27A0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SecuritiesLitigationOptOutSettlementCase1Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_BAE97EC73583F65D9D4CC8991B6D5F42" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SecuritiesLitigationOptOutSettlementCase2Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_3289D4EF8F0924B3F2CFC8991B6D4A94" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember" xlink:label="loc_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember_7392E42058B75A5E9439C8991B6D7F6E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SECLitigationMember" xlink:label="loc_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6EA2B919C42F76E6A068C8991B6D4A03" xlink:to="loc_gale_SECLitigationMember_16B712B138BAF6D64EA4C8991B6DEB57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9E8B731F0518859AC265C8991B6D4E97" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9E8B731F0518859AC265C8991B6D4E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80685275354ACB1E3DA2C8991B6E8B44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9E8B731F0518859AC265C8991B6D4E97" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80685275354ACB1E3DA2C8991B6E8B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_57FA3B932280B1D965E3C8991B6EDAEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80685275354ACB1E3DA2C8991B6E8B44" xlink:to="loc_us-gaap_SubsequentEventMember_57FA3B932280B1D965E3C8991B6EDAEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_2877733B9FAEBA921097C8991B6E1301" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_0E29D84D6B6981AD5DF8C8991B6E063C" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_4CE8BDD04168FEEC77EDC8991B6E1D2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6E3399EF71AC9A629E50C8991B6CCA7B" xlink:to="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LegalFees_09F58F4FDD91D627C1D7C8991B6E0C96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_95FA85BB37E1113071D9C8991B6EC09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4370A4E75A74BEF55AB2C8991B6E0829" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyDamagesPaidbyInsuranceCompanyValue" xlink:label="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_4E2CEBF6B2F86FD11C33C8991B6EB4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_54F6484C83ACEC05CE08C8991B6E606E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_EB92F2D3C933EDF743C2C8991B6ECEB5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_4A07922D06924EC3934AC8991B6EA61E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_ProfessionalFees_7DD1FA7A91F42D94D3A9C8991B6E98B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LitigationSettlementAmount_256F3CBDD1BACC18CF73C8991B6E6CCB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_69909223CF31761C88A7C8991B6EB85D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementIssuanceofCommonStockShares" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockShares_E8BABCAA7477D6D3FF0EC8991B6E35EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_4C193C011019EF3B899AC8991B6FF32C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty" xlink:label="loc_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty_3EBD36A11AC3EE13F63DC8991B6F03D7" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCountsAgainstDefendants" xlink:label="loc_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_NumberofCountsAgainstDefendants_2FBFBDC16D996854027CC8991B6FEE3E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyNumberofWitnesstoTestifyatTrial" xlink:label="loc_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_gale_LossContingencyNumberofWitnesstoTestifyatTrial_8CAE5C8571F47AD43187C8991B6F463C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019E7892DFD1C5B9AA44C8991B6E308A" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_318A291DC5ADE3298AA7C8991B6FF026" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75CA57BEED2B16CACD66B8DDB0D9B6E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75CA57BEED2B16CACD66B8DDB0D9B6E7" xlink:to="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1DDE166899E5FC7369E3B8DDB0D9C12D" xlink:to="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:to="loc_us-gaap_EmploymentContractsMember_02B29B440B907183F3D1B8DDB0D9F40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="loc_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:to="loc_us-gaap_LiabilitiesTotalMember_0029BE25CD0F704F73C8B8DDB0D9B619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_327A1247960DAE38FBE1B8DDB0D9DFD1" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_DFA0D8B9DFFA3A5B67BDB8DDB0DAC47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2D95350A12C38F2D140AB8DDB0D9B7F9" xlink:to="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4BA4426EAF5AC86D44ACB8DDB0DA45B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9BA89EB5EA9F959BD6B9B8DDB0DA1C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3B05027630F540DD3609B8DDB0DAD3AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3E33C88FBECB41141477B8DDB0DA2DCF" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter" xlink:label="loc_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter_7F0A1F4B027DA23F6C8CB8E4C0243F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_79895EA889DA491B750CB8DDB0DA5F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_5B68509709A9E5738FE2B8DDB0DA3931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_C56A0EEDFBB8E059778AB8DDB0DADC79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_2474B0E5C1D9CA6B75ECB8DDB0DA4946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_78CF4FEC70206F08B120B8DDB0DA9E1A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractualObligationDueinFifthYearandThereafter" xlink:label="loc_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_gale_ContractualObligationDueinFifthYearandThereafter_5BFFD8CD5274F3A13095B8E32E73CC5D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContractualObligationsCurrentDue" xlink:label="loc_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1B72E73E826C7060DA70B8DDB0DAA0AE" xlink:to="loc_gale_ContractualObligationsCurrentDue_C855B35271C2A73FBE59B8DDB0DA5306" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC06ADCB71AEBA76275EC8991B55B90E" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeaseExpense" xlink:label="loc_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC06ADCB71AEBA76275EC8991B55B90E" xlink:to="loc_gale_OperatingLeaseExpense_E1C5BAF5D4F1D9628FADC8991B558E8A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases" xlink:label="loc_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC06ADCB71AEBA76275EC8991B55B90E" xlink:to="loc_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases_3D52CECE429F8FDF34F2C8E49919221C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AFA576F16A5AF6AB5B5ECD9DF1437667" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_65B2D99517D3FEECEA02CD9DF143ECFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AFA576F16A5AF6AB5B5ECD9DF1437667" xlink:to="loc_us-gaap_LossContingenciesTable_65B2D99517D3FEECEA02CD9DF143ECFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_E71A86D6A47E1015D076CD9DF14347B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65B2D99517D3FEECEA02CD9DF143ECFA" xlink:to="loc_us-gaap_LitigationCaseAxis_E71A86D6A47E1015D076CD9DF14347B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_E71A86D6A47E1015D076CD9DF14347B5" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_52E5E9A99440892A6755CD9DF144B579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:to="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_52E5E9A99440892A6755CD9DF144B579" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_98225C53F4EC77216574CD9DF1441E52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:to="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_98225C53F4EC77216574CD9DF1441E52" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareholdersSecuritiesLitigationMember" xlink:label="loc_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:to="loc_gale_ShareholdersSecuritiesLitigationMember_62BE35DAC50F1F473EBFCD9DF1448EBA" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SECLitigationMember" xlink:label="loc_gale_SECLitigationMember_7D2CF656902D59D1B34BCD9DF144E570" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_1958F8B3048A002A5664CD9DF1442A94" xlink:to="loc_gale_SECLitigationMember_7D2CF656902D59D1B34BCD9DF144E570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65B2D99517D3FEECEA02CD9DF143ECFA" xlink:to="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_us-gaap_LitigationSettlementAmount_4446E246BC81DBEEBBDDCD9DF144E503" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LitigationSettlementAmountCash" xlink:label="loc_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_gale_LitigationSettlementAmountCash_F0D78163441D40645393CD9DF146AF81" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossContingencyDamagesPaidbyInsuranceCompanyValue" xlink:label="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue_8130FBE5E949E7264846CD9DF147608B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_BCA587D009297D27AF62CD9DF1473F4C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_BCA587D009297D27AF62CD9DF1473F4C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_FE65500F6ED1BA0DCA7BCD9DF1476C31" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1307F0F94441E4918C88CD9DF1449149" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_FE65500F6ED1BA0DCA7BCD9DF1476C31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8CDF2987EC4F4EA1F2A0B7F714119AC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8CDF2987EC4F4EA1F2A0B7F714119AC9" xlink:to="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_44D2DACA1B4B2FB10DD4B7F714114B87" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock" xlink:label="loc_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8CDF2987EC4F4EA1F2A0B7F714119AC9" xlink:to="loc_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock_93FA554C3E21B04C3A4BB7F714110F8C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92DB29C5F8F8BC2B0DB68C0EA3E780A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92DB29C5F8F8BC2B0DB68C0EA3E780A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_931146BF22897255F5D98C0EA3E73295" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_931146BF22897255F5D98C0EA3E73295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_PreferredStockSharesIssued_BE39A7173A746DC473498C0EA3E743D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0A74AECD22E1F33D0C138C0EA3E8DFB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_AE0E4FBAA0FB16DF9E9C8C0EA3E8604B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_AE0E4FBAA0FB16DF9E9C8C0EA3E8604B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_93C2CD98DDF7A404ECBA8C0EA3E8879D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_93C2CD98DDF7A404ECBA8C0EA3E8879D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_CommonStockSharesIssued_D9705B60529BBCFD0DA38C0EA3E9DA45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_CBE195730BEDD8524DEE8C0EA3E9C1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34F736B6833EDFDE8ACF8C0EA3E763FA" xlink:to="loc_us-gaap_TreasuryStockShares_C91A9087222D5A0935FB8C0EA3E9D192" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_146680F5E85B2FE09F408C0EA23C9055" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146680F5E85B2FE09F408C0EA23C9055" xlink:to="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B747C7C9762B2820EC38C0EA23D9AAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B747C7C9762B2820EC38C0EA23D9AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_EC873C40F84A3178B7838C0EA23E1C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_A8188FEEF29F9E2499808C0EA23E7803" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_42FF75C7BBADC5B390C88C0EA23E82EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="loc_us-gaap_InventoryNet_42FF75C7BBADC5B390C88C0EA23E82EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_62A325472074835D74178C0EA23FE4B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_FA25A41C2623F431945B8C0EA23FB30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_588CBFBCE977E8CE13AB8C0EA23FE9F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A6A3011D37260B94FD548C0EA23D1EC0" xlink:to="loc_us-gaap_AssetsCurrent_E7B7F9D226EE363648028C0EA23FB620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3D987D386F353A1489638C0EA23FF916" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_gale_SalesAndDistributionsRights_8685C9770F75BACC1C138C0EA23F4B2D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_gale_SalesAndDistributionsRightsZuplenz_4AA3408CF905AF2DD2AB8C0EA23F0CC1" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_gale_GALE401rights_F1750DBB75A5FC4708888C0EA24080F8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_gale_InProcessResearchDevelopment_DF513579AAEA873A9F498C0EA240E3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_786EB65C6F260B9D03B68C0EA241B0B8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_us-gaap_Goodwill_786EB65C6F260B9D03B68C0EA241B0B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_646D8D57B8803AD8ADBA8C0EA2414C21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D5FA884727FB374157708C0EA23D89BD" xlink:to="loc_us-gaap_Assets_A9BE762DFC0A09DA492B8C0EA241024F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146680F5E85B2FE09F408C0EA23C9055" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:to="loc_us-gaap_AccountsPayableCurrent_F86C8C090A1D01F896698C0EA242AF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_539E36EF7910EC6FE15A8C0EA242477E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_539E36EF7910EC6FE15A8C0EA242477E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:to="loc_us-gaap_LitigationReserveCurrent_F27CF0C1B9BBB8F0FD9E8C0EA2438828" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_C55A1B3D868ECCB87BDA8C0EA243A9C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_C55A1B3D868ECCB87BDA8C0EA243A9C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:to="loc_us-gaap_LongTermDebtCurrent_B8FF853760097E339FF98C0EA243095E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1A3CF61BFD73C006A6EA8C0EA2431195" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1A3CF61BFD73C006A6EA8C0EA2431195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6320FF604DDEE3C9466A8C0EA24191E7" xlink:to="loc_us-gaap_LiabilitiesCurrent_64E31EBDC22724A597A18C0EA2449868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_50BABACD871CA470BCD48C0EA244083D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_2A30754DAD1D2793D0CC8C0EA2440F6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2D58661409AD9C8551058C0EA244FACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="loc_us-gaap_Liabilities_5F18EB5B40B7B1D3A3DE8C0EA244DC38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="loc_us-gaap_CommitmentsAndContingencies_10D42FB4B1F265825BE18C0EA24419C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:to="loc_us-gaap_CommonStockValue_18B01246D163B9FDD5B38C0EA2453FD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_AF1050305EE7DC5D74B18C0EA2465D2D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:to="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_DD48556D637C14AB80CB8C0EA2467810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:to="loc_us-gaap_TreasuryStockValue_6884D1FD0E2B23D125938C0EA24798FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_FA63401638AE5F6882658C0EA24513A9" xlink:to="loc_us-gaap_StockholdersEquity_C76296AA0E65FBE5F4658C0EA247D9A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_670384092F69AD8B078F8C0EA2416936" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2136F3E317AD1C384AA98C0EA247FFDE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1AAE527B8C710621DA37CDA01B21A918" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1AAE527B8C710621DA37CDA01B21A918" xlink:to="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F1A3EB6ABDEB38F56406CDA01B210510" xlink:to="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_CommonStockMember_B02CB1F8D3A83842F232CDA01B21BEEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_998D35E57937A8568EC4CDA01B21985C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_6CE7EC1C44FB3BDE5EA9CDA01B2299C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_RetainedEarningsMember_457C5B33C96FD7A76F3BCDA01B2210A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9E48E21594B7014F8C9ECDA01B213570" xlink:to="loc_us-gaap_TreasuryStockMember_E89F7E7AB90D840F8666CDA01B2283C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0E2AA5E5C2BC2C187751CDA01B22692E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98654395928717F93C74CDA01B236067" xlink:to="loc_gale_SeniorSecuredDebenturesMember_E27C92F208834164B640CDA01B23C4BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2F1C7EA3503F3ED349F7CDA01B232318" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_706A1D9B7E94B994BB8ECDA01B23CC25" xlink:to="loc_us-gaap_SeniorNotesMember_95BAC9C4C72AC658416FCDA01B2310EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_D789184A5767C110D9FFCDA01B24DC19" xlink:to="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_BF76A12462BEC5C8FA71CDA01B24F7CB" xlink:to="loc_us-gaap_SettledLitigationMember_7432309D200629DD33C0CDA01B24C79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4562393CF7F8AEFFBB8FCDA01B240063" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6D6756123681D766831DCDA01B21B3F8" xlink:to="loc_us-gaap_StatementLineItems_4562393CF7F8AEFFBB8FCDA01B240063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4562393CF7F8AEFFBB8FCDA01B240063" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_SharesOutstanding_B07B78DA5573851F0D7ACDA01B24B1E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AEAF57268C08789E8ECCDA01B259DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53968F56F51111FB49F1CDA01B25C789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1467E45172E3D9413E63CDA01B25F43F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SharesIssuedforMilestonePayment" xlink:label="loc_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_SharesIssuedforMilestonePayment_2E4AE7EC36A1EFD43C75CDA01B25B5A5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_StockIssuedDuringPeriodValueAchievementofMilestone" xlink:label="loc_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_StockIssuedDuringPeriodValueAchievementofMilestone_FE62095DCB4A286E6BF3CDA01B254E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_64B56E756ED9C51F6A0CCDA01B259E9F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares" xlink:label="loc_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares_D3DE89EC0525E764DD88CDBC32B88358" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt" xlink:label="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EFDDDE5AA4145A529568CDBAABB73959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_C390EF6FBE0BFD17F508CDA01B2593FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_33FA48DA212D6F28D800CDA01B2544B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3C59F946655C46380C2BCDA01B2602E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3F3ADD81098BA17C7277CDA01B267F9C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares" xlink:label="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestoneShares_F5E179DE016A2DC53337CDA01B2694F8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone" xlink:label="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_A8DA67A6B7A6A9762886CDA01B26BFB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_84DE6AA94DA4589CEE12CDA01B26DA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1533FEED5824F07793A1CDA01B266F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_EE3DDB0CA43A90FFF10FCDA01B266161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_B07DF7F8D4A8AD647C3ACDA01B26F378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_5F5B56330C0EF2398A12CDA01B270E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_E3EA87EBF18B4574998DCDA01B270BA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93CB18816E1519F6EE5ACDA01B2710A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FD5CCBDAC6DD64FB3405CDA01B27D9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39D77FC1585614EC7E09CDA01B271700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C86AB9CDDA2851396478CDA01B27E2A6" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_NetIncomeLoss_C86AB9CDDA2851396478CDA01B27E2A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_913EE2AEE83F759E7B8ACDA01B2796D2" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_SharesOutstanding_913EE2AEE83F759E7B8ACDA01B2796D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78DAFBFB828B2EC1FCCACDA01B277951" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46948FA60D7413BBF3D3CDA01B243178" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78DAFBFB828B2EC1FCCACDA01B277951" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5C77C4583CEAF85E1E248C0EA2B9C010" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_91979A5CDEF807657C2E8C0EA2B9565D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5C77C4583CEAF85E1E248C0EA2B9C010" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_91979A5CDEF807657C2E8C0EA2B9565D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:to="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_32E96F9CFA5CE12FA793CE69F3FAF4B7" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_156D25BCFBBE5ECA19FCCE69F3FC66F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32E7B6A7B1A13A8E7F14CE69F3F995FC" xlink:to="loc_us-gaap_StatementLineItems_F579DAD139C505014108CE69F3FC7EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_C6A734067A986B75ED1BCE4502AE278F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0358DF72C2085A8A42ABCE4502AE0EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8FA2A416B78F261144A7CE6992D622A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfSecuritiesNet" xlink:label="loc_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_us-gaap_GainLossOnSaleOfSecuritiesNet_368DAF8DE91E9F990965CE4502AE6CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_85B795FF8CF21370B7B5CE4502B3F36A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_us-gaap_ShareBasedCompensation_768F7F58832EF6C3E58CCE4502B39BDD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_D64262B170AB5D528029CE4502B4240D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5CCA6B1C2D774B359E47CE4502B41FBC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_376E4902B87B1304C97CCE4502B4FCB5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BBF26F719F9D6EA382B6CE4502AEEF4C" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_724577706B9DD1EA9DE2CE4502B40078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_DFD9DC64D101C034F0F3CE4502B47097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_A50D8C09CF8BC363FA77CE4502B472E8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IncreaseDecreaseinLitigationSettlement" xlink:label="loc_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_gale_IncreaseDecreaseinLitigationSettlement_EE8AFA02B5C86B4F565FCE4502B5BB0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D0AEA29509A80EDD3244CE4502B54846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6DF6A7F6BA983ED771DCCE4502B53622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_F70ED65EBD19CCE3A53ACE4502B56A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C7E7A51B3288A663CF07CE4502B5E439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_CC0F993F2B21FDDE710CCE4502B5F439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_E595BDD0F1824EA51B82CE4502B5EFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_4F59B77A270AD109EEE0CE4502B5D834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E9F137710C7D31D8D2F5CE4502B41A70" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5397672B985924D5DE5ECE4502B67322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F005588015324A38CD55CE4502AEA6D1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A894605F55F32C848471CE4502B6F44F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_52256E8F85CC3D8B3F3CCE4502BB6979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B2320512458E06D4ECBCE4502BCCD56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_F330A2A8594BA6E7DC8ACE4502BCB4FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7133715DEB74FCE9A83DCE4502BCF5BE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CashTransferredWithSpinOffTransaction" xlink:label="loc_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_gale_CashTransferredWithSpinOffTransaction_64121D3CB7D667C03D69CE4502BC524B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_03B17A9323222AA8CA4FCE4502BCF821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_F01EF952868E2D2B041FCE4502BDED8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_CB80B47AA48AF7C0777CCE4502BD25B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_E56890CED4628427003BCE4502BD6C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2599108253E767CC857ACE4502B60AC8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_C6521ED643382D062FFACE4502BD3FAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7B327AEADEEB6CD2B428CE4502BD2976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_D59088D87D6A4EB50984CE4502BE93CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5946341A9294AFBC90B7CE4502BE91B2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_1EC9629ADC5F2D0F0CC0CE4502BE5F21" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommonStockIssuedInConnectionWithEspp" xlink:label="loc_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_gale_CommonStockIssuedInConnectionWithEspp_8961CBE48F6F4F2D7F62CE4502BE95E8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="loc_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_gale_NetProceedsFromIssuanceOfConvertibleNotesPayable_261C691C1E2CB2B4FE9ECE4502BEC9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_05D0BFC95A3590C8A3B7CE4502BEABE0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PaymentofCashDividendsforCovenantonLongtermDebt" xlink:label="loc_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_gale_PaymentofCashDividendsforCovenantonLongtermDebt_8CE089F3B4A2A2431334CE4502C37277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_A7ACCBDD2DA058787A9ACE4502C4CFE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6A041382323944EE2703CE4502BD4356" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_898BD4AD475EB5572D86CE4502C4068F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32B6A840FFDD4C673C55CE4502C45358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A368A6CD6E0CB2B79222CE4502C4FE29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC413DA045DA8BDA2C0CCE4502C457C2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC413DA045DA8BDA2C0CCE4502C457C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_3B2277386C483AD8B5ADCE4502C499E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF2349931E7A79E39633CE4502C4E99F" xlink:to="loc_us-gaap_InterestPaid_E700DE1905F757CD4FCFCE4502C4B1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_90776B1C92017F1AF4DACE4502AD41B5" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_48D2E4B975E5DAFC7921CE4502C52924" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts" xlink:label="loc_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts_B6FE8F455637156B3CDFCE4502C5E1E5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt" xlink:label="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt_EB7A5DA411A6B221C925CE8B59DCE3EA" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff" xlink:label="loc_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_gale_NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOff_E06CE8FAB76F9145E919CE4502C528B9" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_59121EC782445BBF3B9BCE4502C59325" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone" xlink:label="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_gale_IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone_94103046D40FEBCE9A50CE4502C58876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_C769BF86B32546AE5C10CE4502C5B2A2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" xlink:label="loc_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_D04653AC7E2260737F14CE4502C66BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ADF7A03FA9FAA7813E6FCE4502C6B206" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_262C4477C1AEC2F8DECECE4502C52228" xlink:to="loc_gale_FairValueOfContingentPurchasePriceConsideration_E05F09BE2E81178DB494CE4502C68A73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_CFAD88340A8670DC10D68C0EA20CEF9D" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CashExcludingFromNetAssetsAcquired" xlink:label="loc_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CFAD88340A8670DC10D68C0EA20CEF9D" xlink:to="loc_gale_CashExcludingFromNetAssetsAcquired_75709A05BCC4F8487DB68C0EA20C3338" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_BDE15B5AA89FA799497A8C0EA30BF538" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_GeneralAndAdministrativeExpenses" xlink:label="loc_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:to="loc_gale_GeneralAndAdministrativeExpenses_8722ADCFFDED5BC1BC9D8C0EA30B521A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6F2409B91F9696683A958C0EA30A1F48" xlink:to="loc_us-gaap_OperatingExpenses_63769F0A5F108895B29C8C0EA30B5034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_OperatingIncomeLoss_CCA9AE60B0AEC93349AA8C0EA30C070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_3468381F5DFF5A2AF1E58C0EA30CC924" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:to="loc_gale_LossOnWarrantExchange_D47ADF3B7312194DFF818C0EA30DAD72" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_InterestIncome" xlink:label="loc_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:to="loc_gale_InterestIncome_BE4D8F27A9108695AA178C0EA30D99F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F5598215526C1FBC727C8C0EA30D8DF9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_F5598215526C1FBC727C8C0EA30D8DF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91A49AA337172BDD74068C0EA30CCDA9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_E6E969B6A32971A11F3D8C0EA30D7FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1504C192285916052E768C0EA30DE186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_EFAF2F598E57D9E622B18C0EA30DFFDE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_EFAF2F598E57D9E622B18C0EA30DFFDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_043C5AA6FDFB6061B7198C0EA30E3C46" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_043C5AA6FDFB6061B7198C0EA30E3C46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9DC9062C9F3FDD1DE0748C0EA30EDDA1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9DC9062C9F3FDD1DE0748C0EA30EDDA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_41CD2CE5433C0279E5988C0EA30E7BB5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_NetIncomeLoss_41CD2CE5433C0279E5988C0EA30E7BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7347A0272A459CBDB1EB8C0EA30FC355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_A3B5BDC75E652170F1208C0EA30F9F7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4B254B48B3B53823ED168C0EA30FC116" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_AA1BC949BF717853E8AE8C0EA30F02EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EF35FB4050446BC53D808C0EA30F0EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BEF8D29E1318A597E2A18C0EA30AD7EB" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4FE3C720FA6882A488868C0EA310577C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:to="loc_us-gaap_NetIncomeLoss_4FE3C720FA6882A488868C0EA310577C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3EC2ABCB4676CB46F0A88C0EA310E31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_D0684C1FDA6646167CCB8C0EA311201B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_A2B07E676F8F97710D728C0EA3119157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E953AEE5D56926B7D05F8C0EA311F88F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D02FF2B2C37521C50F408C0EA30F7F63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76B9FCFDCAA6E46C7CE28C0EA3114C20" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68A11C3FDD71920F10008C0EA4C4615F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68A11C3FDD71920F10008C0EA4C4615F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FE68546D5A3446E48D928C0EA4C5A249" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:to="loc_gale_AbstralRightsNetMember_BCD6B0316B579E2B93D08C0EA4C5F46C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C0112284A915118A31F58C0EA4C5F668" xlink:to="loc_gale_ZuplenzRightsMember_FD7D667AAF370A3EC6218C0EA4CAAEC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B3C71AC620583CDA163D8C0EA4CAA0F3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D44AAD01609C235944D38C0EA4CB95AF" xlink:to="loc_gale_CommercialBusinessSegmentMember_09A21855B9F49625F1068C0EA4CB6C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8DF823A5D66BF61EA8918C0EA4C47A20" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_91743B8BD515668EE6C38C0EA4CCDDFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DCA0F4DE5F852A185B008C0EA4CCABB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_1EC0B6565ED209437E6E8C0EA4CC549E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_CFD653F683F3DDD877878C0EA4CC4AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8BD0495440EFA4BB35AB8C0EA4CC99B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C46CC8CA3E6FA0B692EE8C0EA4CD9A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_888362EA4425DABD50CF8C0EA4CD7EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_7C3DDF107AC076D50DCD8C0EA4CDC88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_A4511835006E1EF7FB698C0EA4CDAA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_E97FB58EC16C4EFC87EC8C0EA4CBA3C9" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_FD07CF8692C17956B8A48C0EA4CDCAAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_CC361AC6551B7D2ADF448C0EA29742EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_632F96B28E40966398EC8C0EA2974255" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_CC361AC6551B7D2ADF448C0EA29742EC" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_632F96B28E40966398EC8C0EA2974255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1C8F7387B6674B285148C0EA2976646" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_632F96B28E40966398EC8C0EA2974255" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1C8F7387B6674B285148C0EA2976646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_16B13D468D24D5DE4BBE8C0EA298638A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1C8F7387B6674B285148C0EA2976646" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_16B13D468D24D5DE4BBE8C0EA298638A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_C0CA4E1A27C1AF7D40918C0EA2983261" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_16B13D468D24D5DE4BBE8C0EA298638A" xlink:to="loc_gale_CommercialBusinessSegmentMember_C0CA4E1A27C1AF7D40918C0EA2983261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_632F96B28E40966398EC8C0EA2974255" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1064C3A958A8D95F25958C0EA2985EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_DF5126FEF6A9104B649A8C0EA299E894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7FF2FA79E1F7A76666968C0EA2998404" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_7D8403B4E035B377AE5F8C0EA299EBFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_AB768299D0A8788108918C0EA2994AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_E715140357799552C40F8C0EA29A0ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_EC32095651D9C5977B8B8C0EA29AA492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_40D65D72493DD3EC6D988C0EA29AC8E2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts_790AB61C7C68F87A2C6E8C0EA29A6B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_612EC2AD1FCC7582B2798C0EA29818AE" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_CCD9AE04D9D0A958BA8C8C0EA29ADC73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6D4E3A9E08FB5558D5098C0EA1DB76F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6D4E3A9E08FB5558D5098C0EA1DB76F2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B717C3902340C899C2758C0EA1DBB576" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B717C3902340C899C2758C0EA1DBB576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9AEDB68A725C3E3340778C0EA1DB8E66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B717C3902340C899C2758C0EA1DBB576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9AEDB68A725C3E3340778C0EA1DB8E66" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsandZuplenzRightsMember" xlink:label="loc_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9AEDB68A725C3E3340778C0EA1DB8E66" xlink:to="loc_gale_AbstralRightsandZuplenzRightsMember_88FC7A7C0E5246205AE78C0EA1DB92C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A2178D9222F2B687EEBC8C0EA1DC3E73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A2178D9222F2B687EEBC8C0EA1DC3E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70CA5DD765FB86FAD4FE8C0EA1DC8D21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A2178D9222F2B687EEBC8C0EA1DC3E73" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70CA5DD765FB86FAD4FE8C0EA1DC8D21" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_53BF9E81DAD9BD16C77B8C0EA1DDA926" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70CA5DD765FB86FAD4FE8C0EA1DC8D21" xlink:to="loc_gale_CommercialBusinessSegmentMember_53BF9E81DAD9BD16C77B8C0EA1DDA926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8F697BB1F69E2D17B89D8C0EA1DB381A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1F0AAA06BC7B72E885E88C0EA1DECCDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:label="loc_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_us-gaap_ImpairmentChargeOnReclassifiedAssets_F76D667A4C90B5976A8E8C0EA1DEC375" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_6D41A6F2F3F825AB6BCC8C0EA1DEC890" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_F09AE8EEAF1B6B2884698C0EA1DE4C95" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_269F9DD5A8A7EC8960258C0EA1DEC774" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_FAC03A9ECBDE4606ACF08C0EA1DE8DAD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_843ED888039E1616785E8C0EA1DEE5E0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_A548E28B2CFBEC04A0698C0EA1E04CC0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C411E308A4B5C8CFE14D9030BC3745CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C411E308A4B5C8CFE14D9030BC3745CD" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_411BB8E2723BE3C8E1939030BC37C0E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_411BB8E2723BE3C8E1939030BC37C0E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_411BB8E2723BE3C8E1939030BC37C0E3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_45ED2B8E00D80722CCE09030BC373F73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75" xlink:to="loc_gale_AbstralRightsNetMember_45ED2B8E00D80722CCE09030BC373F73" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_41614CB08776271A1AEE9030BC38A31D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1E842FF7B04F802032199030BC37FB75" xlink:to="loc_gale_ZuplenzRightsMember_41614CB08776271A1AEE9030BC38A31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D64B4C4893AF0CC9A20C9030BC382077" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D64B4C4893AF0CC9A20C9030BC382077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3A20A706FF4437B54A6A9030BC384E9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D64B4C4893AF0CC9A20C9030BC382077" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3A20A706FF4437B54A6A9030BC384E9D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_36310E3A3BD481D17A8A9030BC38EA3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3A20A706FF4437B54A6A9030BC384E9D" xlink:to="loc_gale_CommercialBusinessSegmentMember_36310E3A3BD481D17A8A9030BC38EA3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_22F7F0802C15DEED56729030BC3707F3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_86E0665D1E6061CAF8619030BC3818FA" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_B4FF4AD13BFCFB9C1F7E9030BC38A706" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_70CF247C798846E58E9E9030BC38449E" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_2F21690BCAEC4260AC569030BC381078" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_AFA8B2AD6E76088905698C0EA19D810A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_AFA8B2AD6E76088905698C0EA19D810A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CA25B441D964320FD4F98C0EA19D658D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_76666ADD194554FBA9588C0EA0B0D6CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_76666ADD194554FBA9588C0EA0B0D6CB" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_83D86983F44A3BF527758C0EA0B1BF56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_83D86983F44A3BF527758C0EA0B1BF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_83D86983F44A3BF527758C0EA0B1BF56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_7E466CC781193FE8372D8C0EA0B35A7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF" xlink:to="loc_gale_AbstralRightsNetMember_7E466CC781193FE8372D8C0EA0B35A7B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_5AC29A95F382EAC765C38C0EA0B37AA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_079291222C176B537B648C0EA0B220EF" xlink:to="loc_gale_ZuplenzRightsMember_5AC29A95F382EAC765C38C0EA0B37AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_449054843718963862388C0EA0B396D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_449054843718963862388C0EA0B396D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AB7D52E5F207E7F014738C0EA0B3CA87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_449054843718963862388C0EA0B396D5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AB7D52E5F207E7F014738C0EA0B3CA87" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_53F636C9E369B8A5BB588C0EA0B30D7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AB7D52E5F207E7F014738C0EA0B3CA87" xlink:to="loc_gale_CommercialBusinessSegmentMember_53F636C9E369B8A5BB588C0EA0B30D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9BFCEB101368F8BF9FFC8C0EA0B0B5D9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_302DDDDDF0A09FD1DFAC8C0EA0B4FD01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_302DDDDDF0A09FD1DFAC8C0EA0B4FD01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BB24C6CDE6205D573D4E8C0EA0B604F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BB24C6CDE6205D573D4E8C0EA0B604F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3593F4FC071918DEA7E58C0EA0B67686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_EE658369625420D448918C0EA0B4664E" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_418E4AB269C5D77F30F98C0EA0B600D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_047C09ACC8BC6E41B82A8C0EA13F67DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_047C09ACC8BC6E41B82A8C0EA13F67DF" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_BDC3A871841E85E7D9DB8C0EA13F63B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="gale-20161231.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_EntityRegistrantName_3B9F728214B991D2E3DC8C0EA35DBB09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_TradingSymbol_B204B2E99D1E8BD4C9A68C0EA35EDFB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_EntityCentralIndexKey_2940E59D1D17D2F6BDB88C0EA35E7691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_CurrentFiscalYearEndDate_671B61B26E0AE65C9C8A8C0EA35EFD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_EntityFilerCategory_6CFA5992D8C4134ED2C38C0EA35FDD83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_DocumentType_55BE4F678B4903689C3C8C0EA35FDC6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_DocumentPeriodEndDate_48AF9062DC2B495645F98C0EA35FF7CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_DocumentFiscalYearFocus_B9A1577BFC3BE27347848C0EA35F8DFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_DocumentFiscalPeriodFocus_37FBB7C0F137530ECC988C0EA35FCF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_AmendmentFlag_4E1A7959435FB4E3037F8C0EA35F7C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_D3262CC8BDAFBCFE84228C0EA360AF9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_EntityCurrentReportingStatus_F3534BF128995D0EAB818C0EA3603A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_EntityVoluntaryFilers_6F2B523CFA423802D1008C0EA361C073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_EntityPublicFloat_FE52FB6C66F98D731CAD8C0EA361D80B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_30FB5AA019923A86847C8C0EA35D2D93" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_55B311C7EE76AA31E9078C0EA362D041" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_32FD9D70EC5839B0DB998C0EA43E21C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_32FD9D70EC5839B0DB998C0EA43E21C4" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_D5EF043D1436515007F68C0EA43EA5BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C07EEADCF4854B03BE2F8C0EA60146EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C07EEADCF4854B03BE2F8C0EA60146EC" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7E05E8C6B7FB312C03868C0EA601B939" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_EBC6823BCF18D979F60B8C0EA0947016" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_EBC6823BCF18D979F60B8C0EA0947016" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6C3DE9AEDB73F81526898C0EA0954707" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_58A37E7B6EC8A19D19A4CED0DFFF099E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_58A37E7B6EC8A19D19A4CED0DFFF099E" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_605428B5E6842DC64EC5CED0E000D540" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_55C114204E6FE1E980FDCED0E000198D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_115D5479907291D0803CCED0E000E3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64A920E72662FCA0BFD6CED0E000D328" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64A920E72662FCA0BFD6CED0E000D328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64A920E72662FCA0BFD6CED0E000D328" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_A2ED01DA9B3E6E28DA2ECED0E000536A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F1E71D76319BFC14A78BCED0E0008774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_E295A9FF473C4850A6CCCED0E0013881" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEF02DC702514FD09510CED0E000E73D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_E295A9FF473C4850A6CCCED0E0013881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC6BA63C8A8B8B01A983CED0DFFF39A5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7CC9A3E6FF4C062EA0DECED0E0012D48" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_4514926451383454BC03CED0E001D136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_54F139AE78EED25C16E1CED0E001349F" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_AF2028D0A5D3505F5300CED0E0017F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_618F8F637735A156D81BCED0E001DE0C" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_3C684A61A764AEEBECC1CED0E0020500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_CF80DB70685980FB8C41CED0E0020878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6277FEE4AC25275B0BF6CED0E0014CD6" xlink:to="loc_us-gaap_EquityFairValueDisclosure_07356879945C5EC1F987CED0E002B10A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_93F8D305A4FBDA18A5B78C0EA6328AB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93F8D305A4FBDA18A5B78C0EA6328AB0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_EA6F23E33B6AA1E771328C0EA6371E90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1441762D571214BE2BC28C0EA6383F91" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6328172CA13B3584AA9C8C0EA638CB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06B465EEC17463A44FC88C0EA63763F7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4659B78C4B0ADFDCD7FA8C0EA6388733" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FD487A41A54FDC9699E88C0EA63929CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MIlestonePayment" xlink:label="loc_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:to="loc_gale_MIlestonePayment_95B9EEDB1587E2E8A0868C0EA63952D5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_51955A2118A01BAA01638C0EA63920CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73E534C73B829D8CF0BD8C0EA639C522" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98B99191366ACD4788E68C0EA6380194" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73E534C73B829D8CF0BD8C0EA639C522" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_689CC56C2233B4D618FD8C0EA394C6C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_689CC56C2233B4D618FD8C0EA394C6C9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8B218901B027D01575728C0EA3956F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_689CC56C2233B4D618FD8C0EA394C6C9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C9E4AA6EBDC8114F6DA98C0EA3956927" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C9B2A3425424A509D0E68C0EA31CF216" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C9B2A3425424A509D0E68C0EA31CF216" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_272E10F034704FA95AD88C0EA31C3C13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38EF3C98D8A787A8C5098C0EA61F2A84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38EF3C98D8A787A8C5098C0EA61F2A84" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5715AEA137495DE2A35D8C0EA620F4F6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:to="loc_us-gaap_DomesticCountryMember_62ABAE4901D6A97030D58C0EA62004A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1677E02066429F5A35598C0EA62092A0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_27A49535D0185D851EE88C0EA620DA2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2AB84C161E88999C91C68C0EA620CB27" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_913C6C902320BB15A02B8C0EA620E9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1C625799E8F67E0ADD658C0EA61F9A43" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_A6D30D24CCA8F7CBEA858C0EA62193B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1D82669594F565CA9C688C0EA621F1C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_A66A76C86E2CFA6F38B88C0EA6214886" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OperatingLossCarryforwardsExerciseofStockOptions" xlink:label="loc_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_gale_OperatingLossCarryforwardsExerciseofStockOptions_19E3398886E6B1299A438C0EA621052D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IncreaseDecreaseDeferredTaxAssets" xlink:label="loc_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_gale_IncreaseDecreaseDeferredTaxAssets_5F4AF6F62C7F96BE3AC88C0EA621DA3A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance" xlink:label="loc_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance_A7BED463E75EEBEAE4FF8C0EA622B7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_15F6C78E8488A1A0CFC38C0EA621486B" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_15C656A39C79DEF7CEB08C0EA622C27E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B03ED521DA184C01EA588C0EA32A2BC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B03ED521DA184C01EA588C0EA32A2BC9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B9A7FEE9D6FBDD96C8D78C0EA32A4DF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_018814F7EB2279C6B0628C0EA32A1DE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_DD735116A6E4D5092D7A8C0EA32AB563" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5A3F1BEC81C534047DA58C0EA32A2AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B03ED521DA184C01EA588C0EA32A2BC9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EC1699A36C40C4924E028C0EA32A1769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_B638687AF453C1680D1B8C0EA32C1DAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_AB17842FA961DB8243338C0EA32AF20F" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C664488A40158406D6B08C0EA32C1094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_851FFDC02DF6470585E88C0EA32C7BAB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B03ED521DA184C01EA588C0EA32A2BC9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_851FFDC02DF6470585E88C0EA32C7BAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_D2682FC54E3BF02F98D48C0EA1FEB8CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C875FE528D623E10D8858C0EA1FE6DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_064930923E64A84464B58C0EA1FE0795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_045883D345F921D7F6548C0EA1FE6E26" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:to="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F9E05EE84AE0A3DF1B88C0EA1FE2866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_C74447299DB7D2A7FB5C8C0EA1FE178D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_464233F54E33067CCB8B8C0EA1FEBC3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_489875EC53DBEE6E891C8C0EA1FD3FF7" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_C9E4517154AE5DA736E68C0EA1FF5C95" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_36A0A9AD3D84901A55A38C0EA4D7E20F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36A0A9AD3D84901A55A38C0EA4D7E20F" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_EA1BC25B480AEB1998688C0EA4D7A227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36A0A9AD3D84901A55A38C0EA4D7E20F" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_B36C5117C97BC5332F448C0EA4D74228" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6BA5C2AC7DC88B8535CD8C0EA2D94A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1F2E9DBE06C50178B9938C0EA2D953F6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities" xlink:label="loc_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities_5A30177634F05AB47C8D8C0EA2D94E7D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability" xlink:label="loc_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability_EBC521BF1C6484FD87B28C0EA2D9316F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8A2C91C501E7A4597C858C0EA2DA931D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E5C2B6BED243B75D04018C0EA2DA0069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_73E48712AF182AB9BE298C0EA2DA8FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_FCC231E3F87B6E6EDBE08C0EA2DA2BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F57C5F39471B419ABD598C0EA2D9EB34" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_577C8B66D73F698B08928C0EA2DBF7B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_346EC5B8025651D58A1E8C0EA32251F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_346EC5B8025651D58A1E8C0EA32251F2" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_BD2344E6543BAF2F8B368C0EA3229208" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" xlink:label="loc_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_346EC5B8025651D58A1E8C0EA32251F2" xlink:to="loc_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_73B74F75F074218F49198C0EA3227635" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" xlink:label="loc_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_346EC5B8025651D58A1E8C0EA32251F2" xlink:to="loc_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_B843057CD71B97D6EB858C0EA32351FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_346EC5B8025651D58A1E8C0EA32251F2" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B9B48298294DAC87503C8C0EA3238811" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1AFD6B3A7513F5DCE0168C0EA3C1F2DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1AFD6B3A7513F5DCE0168C0EA3C1F2DA" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_CBDA5174F0EDC9DBEAA88C0EA3C156BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsLicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_468A36EAA65F0ACA8901C8989D1E2021" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_468A36EAA65F0ACA8901C8989D1E2021" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:to="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0E1ECF69A570A8704AADC8989D1EAF7D" xlink:to="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6D2DD4E9475120EE0527C8989D1EFE47" xlink:to="loc_gale_MDAndersonCancerCenterMember_F2D2BBF198A421A64326C8989D1E8FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:to="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_4EA7D665075A3EB87DDFC898EC3EE247" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SentynlTherapeuticsInc.Member" xlink:label="loc_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:to="loc_gale_SentynlTherapeuticsInc.Member_9AB809C5282ECE462C73C898EF6D85AD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MidatechPharmaPLCMember" xlink:label="loc_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:to="loc_gale_MidatechPharmaPLCMember_E320401878A989F68EB8C898F089D985" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MonosolRxLLCMember" xlink:label="loc_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_213D129C721A9ABFECE9C8998930FF62" xlink:to="loc_gale_MonosolRxLLCMember_A4D46A29A724D1AFCEE4C898F1B8332C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F87F5921A6DE3F8EA5EBC8989D1EB5DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:to="loc_us-gaap_RangeAxis_F87F5921A6DE3F8EA5EBC8989D1EB5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_F87F5921A6DE3F8EA5EBC8989D1EB5DF" xlink:to="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4BAF9D7F11A1228BBD76C8989D1EFB0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340" xlink:to="loc_us-gaap_MinimumMember_4BAF9D7F11A1228BBD76C8989D1EFB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F6CDFC21829F6B5A0AE8C8989D1E4D65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_18268B7EFFC01F66C7BFC8989D1E0340" xlink:to="loc_us-gaap_MaximumMember_F6CDFC21829F6B5A0AE8C8989D1E4D65" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_B243C3F706F8FEBDDCFAC8989D1E07EC" xlink:to="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_AnnualMaintenanceFee_322A5CAA59AC82386A9EC8989D243202" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_FutureMilestonePayment_C4971C6A7E6422248FADC8989D24A5CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_ABF209554351E7912D47C898E811AC82" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_E6751884EFABAAD0CF7AC898E85825F2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_5D55AF5F70DBFE1783E8C898E8DE87EE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments" xlink:label="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments_D1090FC0FA17504690C7C8989D242834" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementContingentConsiderationThresholdNetSales" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_9ED5B32B6FCB0A627892C898E91DD98D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementPaymentofUpfrontFee" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementPaymentofUpfrontFee_EAD05B7E4848FC6C0265C898EA63A455" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_22911E40042BB004E4F4C8989D24D6C3" xlink:to="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_786E740185A1E010AC3AC898EB082569" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_42C58974D3322F5964408C0EA39B5778" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42C58974D3322F5964408C0EA39B5778" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1DB6FC3F8C48059BADFD8C0EA39B74B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C435B568568F7FCCC4F5CD967A9FD708" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C435B568568F7FCCC4F5CD967A9FD708" xlink:to="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5327866B18A89C299A08CD967A9FE169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:to="loc_us-gaap_DebtInstrumentAxis_5327866B18A89C299A08CD967A9FE169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82E17089906A47DECA8BCD967AA0963D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5327866B18A89C299A08CD967A9FE169" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82E17089906A47DECA8BCD967AA0963D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_279F96B63DD38B1B326ACD967AA0BB38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82E17089906A47DECA8BCD967AA0963D" xlink:to="loc_gale_SeniorSecuredDebenturesMember_279F96B63DD38B1B326ACD967AA0BB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5666F450032D67BF7E88CD967AA06C37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5666F450032D67BF7E88CD967AA06C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8B16FEF63132F4920D06CD967AA0B69E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5666F450032D67BF7E88CD967AA06C37" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8B16FEF63132F4920D06CD967AA0B69E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D4E885C963396A98F2D7CD967AA1D39A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8B16FEF63132F4920D06CD967AA0B69E" xlink:to="loc_us-gaap_SubsequentEventMember_D4E885C963396A98F2D7CD967AA1D39A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_476657FA368B441D437ACD967A9F02BB" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_570BE277A69AFA1BE36CCD967AA17A93" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentTermInterestOnly_79C24C10B4533D4BD4E3CD967AA1528B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65237ACC0C1CD94458DACD967AA11BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentTerm_1A5062927C8BE7536DABCD967AA1AA3A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentCashFacilityFee_D064B125B95C49A5216CCD967AA22CDC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentCashFinalPayment_1884FC9B412520E05D7ACD967AA2C833" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_ClassofWarrantorRightTerm_0EC63218F05B56C5BBB2CD967AA221E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8364604C7D845F49681FCD967AA2D929" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8364604C7D845F49681FCD967AA2D929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_86A9A815CCE6C3FBAADCCD967AA27B6B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_86A9A815CCE6C3FBAADCCD967AA27B6B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_D221578B82B6C39CBBD5CD967AA34716" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_D221578B82B6C39CBBD5CD967AA34716" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentOriginalIssueDiscountPercent" xlink:label="loc_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentOriginalIssueDiscountPercent_49C28621833303FD600BCD967AA3D392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_FDD1E202154B681A6060CD967AA3CDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_D57982B428CB694AFF58CD967AA36D5A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemed" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_B917F474713516814D28CD967AA3680C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_F9AC419B2C93A02EA38CCD967AA3AC8D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument" xlink:label="loc_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument_900507E50BCBDC1C26AACD967AA3DFD2" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold_0F3153B20703FBBC4B30CD967AA37AB8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal" xlink:label="loc_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal_04706587919025F954DFCD967AA36311" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection_A6D18D776CCCCD8A75F5CD967AA401F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82B2C3E2AF332D965A47CD967AA4EEB5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate_34C48606098DFCD98603CD967AA4E7D7" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentRedemptionNumberofDaysMaximum" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_28510313C27A155A7FE2CD967AA475D5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" xlink:label="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_86464ADE13C2FAF4F6AACD967AA465B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8D9E61074AAC06B47CC1CD967AA4E3A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1A9E2D4022BE539C526BCD967AA48068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_SeniorNotes_DFA7F70CADAF286C33D0CD967AA496EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesCurrent" xlink:label="loc_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_SeniorNotesCurrent_7A12B8B1F1E2E5405E50CD967AA5119E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_BA7B61934C34244175FDCD967AA53BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_07EE9F2417C7430F31C7CD967AA529FA" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_07EE9F2417C7430F31C7CD967AA529FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7582695D55E46A38ED09CD967AA5AC47" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7582695D55E46A38ED09CD967AA5AC47" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" xlink:label="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9899CFBB46CD54FF920FCD967AA17207" xlink:to="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_FE94B4DF5959F527B8BECD967AA595C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_140EC491C960AAF764BD8C0EA139B042" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_140EC491C960AAF764BD8C0EA139B042" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_36D52EDA6F233E019DCD8C0EA139560B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45F598A4DAE480944EC18C0EA2E44C19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45F598A4DAE480944EC18C0EA2E44C19" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CB79F969C1123464D37F8C0EA2E4769F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:to="loc_us-gaap_WarrantMember_5FFF5F4378B665B1FEE68C0EA2E5AD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DD18985610B373AD9948C0EA2E44F64" xlink:to="loc_us-gaap_EmployeeStockOptionMember_494D89059F56634383818C0EA2E50D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9DEFE4FB14055B17A3888C0EA2E4EECD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FF6DC2B762337EF973608C0EA2E5E59E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26BD1F38532605B465648C0EA2E533F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9CD221C1437FCB374E448C0EA1B97A1F" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" xlink:label="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9CD221C1437FCB374E448C0EA1B97A1F" xlink:to="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_9A9A895644138BB4B29D8C0EA1BAD2E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1D3D81A844F129481AEB8C1429D36749" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1D3D81A844F129481AEB8C1429D36749" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_39D916B997834B2A25178C1429D3C3EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_60905327F879B47768EE8C1429B71518" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_60905327F879B47768EE8C1429B71518" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_A6CA0140CD33B65890878C1429B712F4" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_31CF7F8FA3223B8F47D28C1429B73615" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_60905327F879B47768EE8C1429B71518" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_31CF7F8FA3223B8F47D28C1429B73615" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_60905327F879B47768EE8C1429B71518" xlink:to="loc_gale_MiscellaneousOtherIncomeExpense_08DA61A1C382E852F1A98C1429B714C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_60905327F879B47768EE8C1429B71518" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_BA4BE2B9DE06240D6E018C1429B7FDEE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_6307C5E7DAA3ED6A85878C1429C7FA69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6307C5E7DAA3ED6A85878C1429C7FA69" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3F8E8957F62DD5F384208C1429C8E5F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_858821EBF56DA5E9148E8C0EA09A4BB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_858821EBF56DA5E9148E8C0EA09A4BB7" xlink:to="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_E507A1CCFB0A814F896D8C0EA09A9B69" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_34DA4B6DE10EF1E5DB8D8C0EA4E2E54A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_34DA4B6DE10EF1E5DB8D8C0EA4E2E54A" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_B4895172B0E3623089C18C0EA4E202F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0AA058B3616B5564CF878C0EA3A3ADD5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0AA058B3616B5564CF878C0EA3A3ADD5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_04D27B1BCBEDC38535788C0EA3A3A435" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ServicesProvidedbyCorporateCounselMember" xlink:label="loc_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_66A9C5A3ABEEC7939C458C0EA3A4204D" xlink:to="loc_gale_ServicesProvidedbyCorporateCounselMember_80281B6113880DCCF38A8C0EA3A47C03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B11C574CA22D3D2E02CC8C0EA3A4EEC8" xlink:to="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_TroyGouldPcMember" xlink:label="loc_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_94D66EBE505B6168EF9D8C0EA3A4DB8F" xlink:to="loc_gale_TroyGouldPcMember_243650546CB586EF4E0B8C0EA3A5B260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_16E48BB2C4846304E70F8C0EA3A3BB88" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1773A415E54DF6E1C2A98C0EA3A52C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9826503C3E4B6AB331388C0EA3A541D7" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3551AE60605DDA5CD3868C0EA3A5EB95" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/RxiSpinOff" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_03395DA9456524575BE38C142D8C3C23" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PartnerCompanyTextBlock" xlink:label="loc_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_03395DA9456524575BE38C142D8C3C23" xlink:to="loc_gale_PartnerCompanyTextBlock_F47BD40E49299D692A138C142D8D272A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/RxiSpinOffAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_A3BF083360688A11F2548C142D7F5A37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1582412375EE7705DF008C142D7F3B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_A3BF083360688A11F2548C142D7F5A37" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1582412375EE7705DF008C142D7F3B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0C1481472551B429469C8C142D7F45D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1582412375EE7705DF008C142D7F3B85" xlink:to="loc_dei_LegalEntityAxis_0C1481472551B429469C8C142D7F45D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F243ABF5BE0C74B6D0848C142D803AF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0C1481472551B429469C8C142D7F45D5" xlink:to="loc_dei_EntityDomain_F243ABF5BE0C74B6D0848C142D803AF9" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RxiMember" xlink:label="loc_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_F243ABF5BE0C74B6D0848C142D803AF9" xlink:to="loc_gale_RxiMember_8F3E45BD5DA1AAA656308C142D80D81E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1582412375EE7705DF008C142D7F3B85" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CashContributionInCapital" xlink:label="loc_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_CashContributionInCapital_7F1EA5ACAE44D3E548098C142D81C14A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenue" xlink:label="loc_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_ProceedsFromTechnologyRevenue_46EDDA80D131FE38FD4C8C142D81BF30" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenueUnderConditionOne" xlink:label="loc_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_ProceedsFromTechnologyRevenueUnderConditionOne_6E7B681C42A5C9C6D2F88C142D81C65E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromTechnologyRevenueUnderConditionTwo" xlink:label="loc_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_ProceedsFromTechnologyRevenueUnderConditionTwo_EF961EBD8F3BB7940EBF8C142D81DD96" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MinimumEstimatedSales" xlink:label="loc_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_MinimumEstimatedSales_C632871E682DCE3BE9448C142D82F877" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedSales" xlink:label="loc_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_EstimatedSales_0F53A87C6BEF9B6901128C142D836F25" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberOfSharesDistributedToSurrendersUnderSpinOff" xlink:label="loc_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_NumberOfSharesDistributedToSurrendersUnderSpinOff_1BFF48415D1D99BE5F5F8C142D83598D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberOfSharesRetainedByCompanyUnderSpinOff" xlink:label="loc_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_NumberOfSharesRetainedByCompanyUnderSpinOff_720D170E381040E19BD98C142D83CDB0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LockUpPeriodOfSharesUnderSpinOff" xlink:label="loc_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_LockUpPeriodOfSharesUnderSpinOff_BD4A3F3CFF08A1A729388C142D838458" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ExpirationDateOfSharesUnderSpinoff" xlink:label="loc_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_ExpirationDateOfSharesUnderSpinoff_4CE4588CD7B9D2C6AC208C142D83CF7E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Numberofsharessoldbycompanyafterspinoff" xlink:label="loc_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_Numberofsharessoldbycompanyafterspinoff_8680107E67EA0C42EE278C142D830293" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_Proceedsfromsaleofsharesafterspinoff" xlink:label="loc_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_Proceedsfromsaleofsharesafterspinoff_8540B52754FEF95B4CCE8C142D83E175" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RetainedPricePerSharesUnderSpinOff" xlink:label="loc_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_RetainedPricePerSharesUnderSpinOff_1BC906FF53DEA625F1858C142D83D18F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_RetainedValueOfSharesUnderSpinOff" xlink:label="loc_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_A6027646005C617BE63F8C142D813531" xlink:to="loc_gale_RetainedValueOfSharesUnderSpinOff_CD2FEF4159FD38E4D9D88C142D84D39E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_A1D21F3072548F59F07F8C0EA1ACE568" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_A1D21F3072548F59F07F8C0EA1ACE568" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_453055EFDA161A384EC18C0EA1ADCFDC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:to="loc_us-gaap_SalesRevenueNet_84BA39603E226D895DF48C0EA64A231E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:to="loc_us-gaap_GrossProfit_CD4A2E1DA4A06DAF34668C0EA64A6B41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:to="loc_us-gaap_NetIncomeLoss_A0D17E66175BBF58A7A58C0EA64A6CD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B82BF73359E7AAF648548C0EA64A07DA" xlink:to="loc_us-gaap_EarningsPerShareBasic_2D6659BBDFC2F6F61F288C0EA64A29D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DCEDC25DFA547491E2368C0EA68A2150" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DCEDC25DFA547491E2368C0EA68A2150" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_AA07B6959E50B051CFA28C0EA68A5897" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_124BFBADE33D71B6C9CA8C0EA1A4AB80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_124BFBADE33D71B6C9CA8C0EA1A4AB80" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_A23AFDED0C9A04663D748C0EA1A4B5D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_F66AD1671CA84541157F8C0EA3770F8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_F66AD1671CA84541157F8C0EA3770F8A" xlink:to="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EDE79A363058EB1327C78C0EA37873FE" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F415C594D13E470D67E48C0EA3789383" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_F9236DD5377F1186E5098C0EA37895AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_FC465DB687F0011EFD148C0EA37940A1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_EBE1B771EAEE7246E4408C0EA37905E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F392D40CCC9B0B64B4B58C0EA37956EB" xlink:to="loc_us-gaap_AccountsReceivableMember_8F812FADFBD3AB6281D68C0EA37A5E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:to="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_5E52C39E77F9D9F1C5F48C0EA37A914E" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="loc_gale_CustomerOneMember_327208EC3DE85CA9765F8C0EA37A8410" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="loc_gale_CustomerTwoMember_C7CBAE90033FCCBBF9D48C0EA37AB21C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="loc_gale_CustomerThreeMember_976B551A6C9529FE3CBD8C0EA37AF823" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1EE32208A506E57EAC448C0EA37A0FC6" xlink:to="loc_gale_CustomerFourMember_F9D4CA9875288A435F268C0EA37B8053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_DAB76F5E75B97A0006498C0EA377FE58" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:to="loc_gale_NumberofCommericalProducts_7171781254278AD8AA678C0EA37C7BA1" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:to="loc_gale_NumberofDosingStrengths_C38158735D5B51FAFC5B8C0EA37CA8BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6FD9BB817F057E6A97CA8C0EA37B4AD6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_AE438C87FF074F52EAE08C0EA37CDCBF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_41D7BB50B3142DBA937E8C0EA475E79C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_41D7BB50B3142DBA937E8C0EA475E79C" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0AB6A3A4E5C4F2D4C8418C0EA4759DAC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7CED73703027D94CD2928C0EA0D002FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7CED73703027D94CD2928C0EA0D002FA" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3DDDEC4CAA1D26C02B2A8C0EA0D1A953" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8CE1827C1FB76362ED9E8C0EA348773D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8CE1827C1FB76362ED9E8C0EA348773D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:to="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E52585996C1303ADB9A58C0EA349934D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeStockPurchasePlanMember" xlink:label="loc_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:to="loc_gale_EmployeeStockPurchasePlanMember_5FF39EC2DEB0A280F6B78C0EA349C4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C073DC99F879C1A143668C0EA349E3D6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_EFAD7592FE7FE62AAEF98C0EA34A912C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:to="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_AE44E668B70816DC64C68C0EA34A6FE4" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_94575848FDD9FB87B5328C0EA34A3EA0" xlink:to="loc_gale_TwoZeroZeroSevenIncentivePlanMember_EBC397309A0B2FC4E6528C0EA34A4FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C42EC9C83A07D88397AD8C0EA34AF1DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:to="loc_us-gaap_RangeAxis_C42EC9C83A07D88397AD8C0EA34AF1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_C42EC9C83A07D88397AD8C0EA34AF1DF" xlink:to="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_A541664BEF15310944278C0EA34A185F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A" xlink:to="loc_us-gaap_MinimumMember_A541664BEF15310944278C0EA34A185F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_ED8D91018908192FA8688C0EA34BD560" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_5433993502FFB73285078C0EA34AB95A" xlink:to="loc_us-gaap_MaximumMember_ED8D91018908192FA8688C0EA34BD560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0847CF4AFEFCFB9D057F8C0EA3484C30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63594B98B5CBA9A97AF98C0EA34B71A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_85865B0238FAB9612BB08C0EA34BE764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_CED0CE0ED4B9F74C874E8C0EA34B1C82" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_6453C889BB50778CE54F8C0EA34B4745" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_33E5351805A8A59F7DF38C0EA34C47B6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_41F1961C779DE320A7308C0EA34CEB26" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_24E602E8698B52E793FB8C0EA34C9209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87579F52C1097E7950148C0EA34C9B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3A62A57F11FC526E3EFD8C0EA34D8F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4AF02E2C40FBAB0EB5FB8C0EA34D5D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B444D422181E4A5CAE1C8C0EA34D143B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_C844467E786A1E7439FD8C0EA34D87A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D4A738EF2D428C0120088C0EA34D0A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E65AD44134AC0C88AA368C0EA34D15B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E77CAFC25E1D8CC7DB198C0EA34EB4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F5D4822F62929DB89818C0EA34E7A53" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AggregateIntrinsicValueOfStockOptionsExercisable" xlink:label="loc_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_AggregateIntrinsicValueOfStockOptionsExercisable_FA58FBB15128481312388C0EA34E1BFB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_C87A631D0601967FB3A18C0EA34E3D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_F0A4171E752D8052F50B8C0EA34E029A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_48ED304C8C2D775AC26B8C0EA34ECA8B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_1DDDC24FDBEDE6D225548C0EA34EB05D" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_F0C5D7FEC1234D49320F8C0EA34ECFC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_307F9C5441BE97D513C08C0EA34F66F6" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_307F9C5441BE97D513C08C0EA34F66F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FD94DA16FCF03F834C228C0EA34B781F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C6C2C866AC50191CDDEE8C0EA34FCC9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54FF962AE8958D5E0A328C0EA0C79EDD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54FF962AE8958D5E0A328C0EA0C79EDD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D70C2494B9D96FA9555E8C0EA0C98EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54FF962AE8958D5E0A328C0EA0C79EDD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8133BDA08404762549698C0EA0C930DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54FF962AE8958D5E0A328C0EA0C79EDD" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_753958C60C842DD532F68C0EA0C9458B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54FF962AE8958D5E0A328C0EA0C79EDD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A718A54DE5AFA4A7CF8D8C0EA0C95CE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63E8DC50E3ACCB21B8008C0EA21871CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63E8DC50E3ACCB21B8008C0EA21871CB" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_A8701AAE3E48E1B6D9288C0EA219D8D2" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_3912B846CE4BD2D662408C0EA21A9860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_F3BE07A1D88002D420D88C0EA219362C" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_84CF8F52028B54EACF378C0EA21A49A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E51A449714794C195B8D8C0EA21A3579" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AB1369C929F3DCB7051B8C0EA21B0297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F837FE63710A39BEF32F8C0EA21A46E2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FB95DC7D449A578092268C0EA21B1425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67BB9947C6601439318B8C0EA2192992" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8AA612CD8B1CBABA18DC8C0EA21BE468" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03F96997A4C119D294CA8C0EA21B7FA3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_445E67C99996115EF6558C0EA2F21661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D5476BBFD728E2295F2E8C0EA2F3D20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36BB53F2CF27003F78668C0EA2F3EACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_846B8DB2B7D7672CA0B08C0EA2F3D6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D9450D216664F8C5907D8C0EA2F479C0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3C61617B5DFE4ABCC1818C0EA2F2043C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D9450D216664F8C5907D8C0EA2F479C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C116CE45E3DC7157097C8C0EA2F471E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71D3C230C60FF7A24BD28C0EA2F48E9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3B25A06463C7F6EB44C78C0EA2F430DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9819B1BC448592D52CF78C0EA2F4C1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B2541B73D9D2485169B48C0EA2F5089D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80E34C186FD58408D7228C0EA2F56671" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DEBA122F82BECAD41628C0EA2F416FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80E34C186FD58408D7228C0EA2F56671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8E0EF2116AAF61FE9A0B8C0EA2F64DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4B94ED814AB241E9D0F98C0EA2F64D18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_908773CAC61ACBAB1D3B8C0EA2F649E0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D5BD0265434D33CA369D8C0EA2F2BDB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_908773CAC61ACBAB1D3B8C0EA2F649E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D22A2C5C880C6C8959EE8C0EA11D961D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D22A2C5C880C6C8959EE8C0EA11D961D" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9544E9DC6C7490BB938D8C0EA11D4D49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D22A2C5C880C6C8959EE8C0EA11D961D" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E58EF81B5A1D9C2825C98C0EA11DD0AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D22A2C5C880C6C8959EE8C0EA11D961D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75D51FF19EDFE8DA5B218C0EA11D43B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_28F20B3124F4B100CB4A8C0EA331B50C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_28F20B3124F4B100CB4A8C0EA331B50C" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17FAA530A0516F2C12178C0EA331DAAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_CA896F3719B236534D90C8991B4B32EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_CA896F3719B236534D90C8991B4B32EB" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_675952488431F7BE5CD9C8991B4B5563" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_LincolnParkCapitalLLCPurchaseAgreementMember" xlink:label="loc_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="loc_gale_LincolnParkCapitalLLCPurchaseAgreementMember_FC4879B502F6ECF57A03C8991B4B1119" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="loc_gale_MLVCo.LLCandMaximGroupLLCMember_1A06F8D7DB8FA412E954C904EEF035D6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_UnderwrittenPublicOfferingMember" xlink:label="loc_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="loc_gale_UnderwrittenPublicOfferingMember_89DA3FA79F5F8295022DC8991B4B31E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8C8D475F181B2073DE6FC8991B4BFCA9" xlink:to="loc_us-gaap_OverAllotmentOptionMember_FAF8AC22BB1143C13095C8991B4B8C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0412749D12BCD2794B81C8991B4BE0EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0412749D12BCD2794B81C8991B4BE0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A8249323DB863FA7A674C8991B4BCBC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0412749D12BCD2794B81C8991B4BE0EA" xlink:to="loc_us-gaap_EquityComponentDomain_A8249323DB863FA7A674C8991B4BCBC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DA888DCBA4F898BF894BC8991B4B6C24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A8249323DB863FA7A674C8991B4BCBC7" xlink:to="loc_us-gaap_CommonStockMember_DA888DCBA4F898BF894BC8991B4B6C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1A167A8362249B4C1936C8991B4B91D9" xlink:to="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:to="loc_us-gaap_MinimumMember_FA885D8623BC9F7DA9E8C8991B4B0955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F484C5A640D1516551BAC8991B4B84F1" xlink:to="loc_us-gaap_MaximumMember_566DEA04778428397EB5C8991B4B5A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CAD51361C85FC799D7F4C8991B4BB325" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_FB99151046882AFA7A10C8991B4B0A3B" xlink:to="loc_us-gaap_SubsequentEventMember_D565B6C302A3E6415E64C8991B4CB9C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C7B7BE742BD8B5975D9CC8991B4B2D12" xlink:to="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_32368DA1392542A61A31C8991B4C4702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3988B198B468AE92724DC8991B4D1EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_C44F3FDBFDAA3A756928C8991B4D40B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_52C165A0626349CC3A21C8991B4DEB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23F2FB8F1F5680DADCADC8991B4D4F2A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_PurchaseAgreementTerm_44C531A80FB4B243F3A2C8991B4EA9CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_007507A671067EA072A9C8991B4E0E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_SharePrice_7A204A540CD06B3043B8C8991B4D687A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_74B1EA9A6FD15DC228F0C8991B4D3D8D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_74B1EA9A6FD15DC228F0C8991B4D3D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7701BB4207D8E67F90ABC8991B4DA567" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7701BB4207D8E67F90ABC8991B4DA567" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_StockPurchaseAgreementAuthorizedAmount" xlink:label="loc_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_StockPurchaseAgreementAuthorizedAmount_E0FA50389CB67234C1D3C8991B4DB757" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_E03E8E0800EDCAE64405C8991B4DB2EB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_479B8A3B018D7FE17C11C8991B4D8FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F4F2D21ED0DC3B08CE9EC8991B4E97A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A094DADFB851CC78DB20C8991B4EB8AD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_70098231AAD5821395CAC8991B4E8A84" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_6EB5508EAD5055227CB7C8991B4EEE19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_5BA6DC758D8F8D092357C8991B4DF02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A8A3D698EB2D279B336BC8991B4F52E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_781D332738073C788EFBC8991B4FDB67" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_StockAvailableforIssuanceSharesNewIssues" xlink:label="loc_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_StockAvailableforIssuanceSharesNewIssues_F79B3C7E77AF86245A6DC8991B4E6A52" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightIssuedDuringPeriod" xlink:label="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B58A20D17779B3C0DA38C8991B4D5ADE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightExercisePeriod" xlink:label="loc_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_ClassofWarrantorRightExercisePeriod_F877AFC53F3D39E8CA4AC8F886BF04CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable" xlink:label="loc_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable_75A3F6783626C67AFFB7C8F72EA55805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_708650F77DAF5F76E080C8991B4C4399" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_098F23B843577A6F1B2DC8991B4E093C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_49C60957D5876DC25C618C0EA39879F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_49C60957D5876DC25C618C0EA39879F1" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_84851BD13404EB1D62DB8C0EA39837FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D0EFB30749450F51AA68C0EA1B451F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D0EFB30749450F51AA68C0EA1B451F6" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_443E4D3F92B7E1F53A608C0EA1B43338" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_95AEAAD59F3B802428A2C8980982E28D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95AEAAD59F3B802428A2C8980982E28D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7434B08FFE01ED6C149EC89809827E82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_July2016WarrantsMember" xlink:label="loc_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_July2016WarrantsMember_FEFD14E96E8CF6A8EB82C89809823BF5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_5298F4FBF033DCB7E018C89809825AD4" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_10CB31AEBFD5343ADC65C89809839B40" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_AE6F7EB0423CF6929A7FC8980983E65B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_E758CA602F42859ED070C8980983DD7F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_A16DAFC11758386A0B8DC8980983A58A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_54951835516685413693C89809831D65" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9C55513CA47BD0EF02EDC898098256EE" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_7B8BFA0AA4C78E16E9D2C8980983F797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F263FF97937F00DDC78EC8980982FF20" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE94B0BE0CCA1988CF93C89809839576" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_B379C1309CD2A0C6B500C8980983A6DC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_FairValueofWarrantsGranted_42870D8F8BC94B10FAD1C89809834B1F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsExercised" xlink:label="loc_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_FairValueOfWarrantsExercised_E3EDDD07FAC3245BAF5FC8980983E317" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_0A8214E80990B5AB2D99C89809833368" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_5FA5B4D1341E7420DCF5C89809831C89" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_4E99BB10E9554E95CA72C89809838C43" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_5FA5B4D1341E7420DCF5C89809831C89" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3179A1D73A7A8C39487CC8970C8B2215" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_F2EB413F1512E76CF1C3C8970C8DB080" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3179A1D73A7A8C39487CC8970C8B2215" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_F2EB413F1512E76CF1C3C8970C8DB080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_CEAE46697FEA82559E82C8970C8DFA78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F2EB413F1512E76CF1C3C8970C8DB080" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_CEAE46697FEA82559E82C8970C8DFA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_CEAE46697FEA82559E82C8970C8DFA78" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_July2016WarrantsMember" xlink:label="loc_gale_July2016WarrantsMember_56526ABEDE4723B2B091C8970C8E0711" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_July2016WarrantsMember_56526ABEDE4723B2B091C8970C8E0711" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_8CDE6E4F62F317DA7AFCC8970C8E4935" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_8CDE6E4F62F317DA7AFCC8970C8E4935" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_892CDEFD70471851B76FC8970C8E96FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_892CDEFD70471851B76FC8970C8E96FC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_D7356535385ECEB877E8C8970C8E670C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_D7356535385ECEB877E8C8970C8E670C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_6D3F25EFC4AA6C4D46CFC8970C8FC27A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_6D3F25EFC4AA6C4D46CFC8970C8FC27A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_E840904F326AEB781AB7C8970C8F0993" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_E840904F326AEB781AB7C8970C8F0993" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_639A4E6A1AB6BF818542C8970C8FD7CB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_639A4E6A1AB6BF818542C8970C8FD7CB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_F757CD8296711AE553DEC8970C8FEA60" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_BBD2F8B9C1438FDCB756C8970C8E0BF8" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_F757CD8296711AE553DEC8970C8FEA60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F2EB413F1512E76CF1C3C8970C8DB080" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1CC7FA49E11984919E3EC8970C8F1D9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1CC7FA49E11984919E3EC8970C8F1D9B" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_gale_WarrantStrikePrice_FCFC37932492A0526524C8970C8FD8F5" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_0DD4857EBB00FB35897DC8970C8FEFFC" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_0698644BA4771378223FC8970C8FDE07" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_A0788847226A91DD5F68C8970C8FCFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5B0BF6A3EF9CE7D1B4BDC8970C8F4F26" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_6279288DCEFBA7367CA9C8970C8FE420" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_B3E19A04E41918011F49C7E347EC2E7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_78D58EDC21B6EB17EEB7C7E347ED47B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_B3E19A04E41918011F49C7E347EC2E7A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_78D58EDC21B6EB17EEB7C7E347ED47B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3DE86F1F27BDF194BA04C7E347ED12BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_78D58EDC21B6EB17EEB7C7E347ED47B9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3DE86F1F27BDF194BA04C7E347ED12BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3DE86F1F27BDF194BA04C7E347ED12BC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_July2016WarrantsMember" xlink:label="loc_gale_July2016WarrantsMember_3EA34BA7CE7EE745EDC6C7E36C2B9839" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_July2016WarrantsMember_3EA34BA7CE7EE745EDC6C7E36C2B9839" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_7A67200EDE47A31E2B75C7E859056AA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_7A67200EDE47A31E2B75C7E859056AA3" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_B170D5D5CCD454AB15F4C7E347EDC8B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_B170D5D5CCD454AB15F4C7E347EDC8B6" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_6E9CD7CCFFCEB7902737C7E347EE9868" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_6E9CD7CCFFCEB7902737C7E347EE9868" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_3E89D248B1A5D4111E7CC7E347EE73CE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_3E89D248B1A5D4111E7CC7E347EE73CE" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_8C1D3274C818F1673735C7E347EEF72C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_8C1D3274C818F1673735C7E347EEF72C" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_9BE852AF32B6133C1360C7E70FCF3B36" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_9BE852AF32B6133C1360C7E70FCF3B36" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_C0775540CAD8CAD2405EC7E77D0A1D3F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_C0775540CAD8CAD2405EC7E77D0A1D3F" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4C1793F685C74B3A81F0C7E347ED4FAB" xlink:to="loc_gale_OtherWarrantIssuesMember_6F0D2BBAC1B2ACC9EA87C7E347EEB1CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0A13D595EBE0716D3709C7E347EED0C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_78D58EDC21B6EB17EEB7C7E347ED47B9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_0A13D595EBE0716D3709C7E347EED0C1" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0A13D595EBE0716D3709C7E347EED0C1" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9848C7BF0A522179DCA2C7E347EFCCDB" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_gale_ClassofWarrantorRightGranted_269D2DC7149A9A51E47CC7E347EFDB28" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_DB68DB5CBF0B4EED6EEDC7E347EF23AD" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_gale_ClassofWarrantorRightExpired_F00AD18FF47D54A0FFF0C7E347EF89BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_F1EA9C7B4BDEF055F6B0C7E347EF89F3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_80EFE0CDF4ECBBC0E59CC7E347EFE47C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_F1EA9C7B4BDEF055F6B0C7E347EF89F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398" xlink:type="locator" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398" xlink:to="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_0C07E17D72BE4C020AFEC7E34B13061A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398" xlink:to="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_5FAAA63AFC7B7C10C2DEC7E34B13AB0E" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_569D2E0B0B317D08AD2AC7E34B131398" xlink:to="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_F98992520291FA82A8B0C7E34B13295B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A379D924A0A1E4CB6261CDA0194118D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A379D924A0A1E4CB6261CDA0194118D8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_261CF7E089CE7E722014CDA01941AA54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_261CF7E089CE7E722014CDA01941AA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FFFEE7EFCE383D026BC6CDA01942AB2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_261CF7E089CE7E722014CDA01941AA54" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FFFEE7EFCE383D026BC6CDA01942AB2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FFFEE7EFCE383D026BC6CDA01942AB2E" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashMember_DB0953E7AC7E7625C7E9CDA0194201F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E0F0C94B0E890441E323CDA019423894" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:to="loc_us-gaap_RangeAxis_E0F0C94B0E890441E323CDA019423894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5E3636C94D0176B03144CDA01943415F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E0F0C94B0E890441E323CDA019423894" xlink:to="loc_us-gaap_RangeMember_5E3636C94D0176B03144CDA01943415F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_5E3636C94D0176B03144CDA01943415F" xlink:to="loc_us-gaap_WeightedAverageMember_4128940E36BB9710D559CDA0194369C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5BADE87615A09F456A9CDA01941F05C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF46B0A48BE8F0931142CDA01943AEFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF46B0A48BE8F0931142CDA01943AEFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7E84633AF18A99A9388CCDA019431272" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7E84633AF18A99A9388CCDA019431272" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice_B90D2B056602DE257687CDA01944C392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F2A4A8CF195652DAA92CCDA01944BE1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_E866E733AA0ACC8284E1CDA019447838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_24C403F9B369AB0D5142CDA019440F2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_CCDA2282FBB1549DB9EFCDA01944F675" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_B4D6818751B311DFA31DCDA01944D29A" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_WarrantsGrantedNumberofShares_930E2E4CE9D126C864A1CDA01944C453" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_ClassofWarrantorRightGranted_10FCAEB2823648D39335CDA01944A274" xlink:type="arc" />
    <link:loc xlink:href="gale-20161231.xsd#gale_ClassofWarrantorRightMaturityPeriod" xlink:label="loc_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_gale_ClassofWarrantorRightMaturityPeriod_024FD1966F94E7F2C35CCDA01944A3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF9D23B3FA59ADC3A7AACDA019431408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63C75A9C31F476BB72A6CDA019459434" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>coiimage.jpg
<TEXT>
begin 644 coiimage.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X0!T17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !(     0   $@    !  *@ @ $     0   ;"@ P $     0   &T
M    _^T .%!H;W1O<VAO<" S+C  .$))300$        .$))300E       0
MU!V,V8\ L@3I@ F8[/A"?O_B![A)0T-?4%)/1DE,10 ! 0  !ZAA<'!L B
M &UN=')21T(@6%E:( ?9  ( &0 + !H "V%C<W!!4%!,     &%P<&P
M                  #VU@ !     -,M87!P;
M                                        "V1E<V,   $(    ;V1S
M8VT   %X   %;&-P<G0   ;D    .'=T<'0   <<    %')865H   <P
M%&=865H   =$    %&)865H   =8    %')44D,   =L    #F-H860   =\
M    +&)44D,   =L    #F=44D,   =L    #F1E<V,         %$=E;F5R
M:6,@4D="(%!R;V9I;&4              !1'96YE<FEC(%)'0B!0<F]F:6QE
M
M      !M;'5C         !X    ,<VM32P   "@   %X:')(4@   "@   &@
M8V%%4P   "0   '(<'1"4@   "8   'L=6M500   "H   (29G)&50   "@
M  (\>FA45P   !8   )D:71)5    "@   )Z;F).3P   "8   *B:V]+4@
M !8   +(8W-#6@   "(   +>:&5)3    !X   , 9&5$10   "P   ,>:'5(
M50   "@   -*<W9310   "8   *B>FA#3@   !8   -R:F%*4    !H   .(
M<F]23P   "0   .B96Q'4@   "(   /&<'103P   "8   /H;FQ.3    "@
M  0.97-%4P   "8   /H=&A42    "0   0V=')44@   "(   1:9FE&20
M "@   1\<&Q03    "P   2D<G5250   "(   3087)%1P   "8   3R96Y5
M4P   "8   489&%$2P   "X   4^ %8!80!E &\ 8@!E &, ;@#] "  4@!'
M $( ( !P '( ;P!F &D ; !' &4 ;@!E '( :0$- &L :0 @ %( 1P!" "
M< !R &\ 9@!I &P 4 !E '( 9@!I &P ( !2 $< 0@ @ &< 90!N .@ <@!I
M &, 4 !E '( 9@!I &P ( !2 $< 0@ @ $< 90!N .D <@!I &, ;P07!# $
M,P0P!#L$3 0]!#@$.0 @!#\$0 0^!$0$, 0Y!#L ( !2 $< 0@!0 '( ;P!F
M &D ;  @ &< Z0!N .D <@!I '$ =0!E "  4@!6 $*0&G4H "  4@!' $(
M(()R7VECSX_P %  <@!O &8 :0!L &\ ( !2 $< 0@ @ &< 90!N &4 <@!I
M &, ;P!' &4 ;@!E '( :0!S &L ( !2 $< 0@ M '  <@!O &8 :0!LQWR\
M&  @ %( 1P!" "#5!+A<TPS'? !/ &( 90!C &X _0 @ %( 1P!" "  < !R
M &\ 9@!I &P%Y 7H!=4%Y 79!=P ( !2 $< 0@ @!=L%W 7<!=D 00!L &P
M9P!E &T 90!I &X 90!S "  4@!' $( +0!0 '( ;P!F &D ; #! &P = !A
M &P X0!N &\ <P @ %( 1P!" "  < !R &\ 9@!I &QF;I : "  4@!' $(
M(&//C_!EAT[V3@""+  @ %( 1P!" " PUS#M,-4PH3"D,.L 4 !R &\ 9@!I
M &P ( !2 $< 0@ @ &< 90!N &4 <@!I &,#DP.U [T#N0.Z \P ( /  \$#
MOP/& Z\#NP @ %( 1P!" %  90!R &8 :0!L "  4@!' $( ( !G &4 ;@#I
M '( :0!C &\ 00!L &< 90!M &4 90!N "  4@!' $( +0!P '( ;P!F &D
M90!L#D(.&PXC#D0.'PXE#DP ( !2 $< 0@ @#A<.,0Y(#B<.1 X; $< 90!N
M &4 ;  @ %( 1P!" "  4 !R &\ 9@!I &P :0!9 &P 90!I &X 90!N "
M4@!' $( +0!P '( ;P!F &D :0!L &D 50!N &D =P!E '( <P!A &P ;@!Y
M "  < !R &\ 9@!I &P ( !2 $< 0@0>!#$$200X!#D ( 0_!$ $/@1$!#@$
M.P1, "  4@!' $(&109$!D$ ( 8J!CD&,09*!D$ ( !2 $< 0@ @!B<&1 8Y
M!B<&10!' &4 ;@!E '( :0!C "  4@!' $( ( !0 '( ;P!F &D ; !E $<
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MQY2$C-M"!S@1QD<#N6/4U\W?MY^*+S1?!7@?1[+<&U'Q5I4[[0"6CL+A+C8
M>,LX7\J]@^"5_J7A2^UCX(:X6+^$_+ETJ=\DW6BSD_9R"3DM 08'_P!U3WKK
MOB_\'O"?QFTS1-,\5&54T'5K35[=H&V/Y]HVY5)_N-T8=Q0!ZI<R16UO)=R
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MO]1\&^,O%?P2U4(EII['5-(53D)!+*4NX%'\*1S%9HU_ACN%7HHH ^MJ***
M"BBB@ HHHH BGC,L31@[2>]?.]Q^RY\,KRYFO+FYU_S9W:1MGB'5$7+')PHN
M0 /0#@5]&T4 ?-O_  RG\*_^?GQ#_P"%'JO_ ,DUY'\:OV:OAGX>\'VVOP76
MO!-/U72Y)B^O:G+B%KN..0@/<$*=KGYARO4&ONZN"^*7A8^-OAUXC\)H2LNI
MV,\,1':8J3&?P<"@#XP^-?[-/@+P3HUO\5M&GUQSX7E234U_MS4GDGT9W O(
MU<W&]3&,3#:1DQX.17'_ !"^$'B*/Q UK\)_"NM:SH[VBF/4;KQ1J21--+&[
MJ\86\W/']Q2,*<YYP<C[;^&>O:?\3_A)I%SK4:RR:MIYM-0A(SMF"F"ZB;T(
M<,I!KE_V6[BXN?@MH>FZF_GWWAZ2\T69VY8MI=S+:*2><DI&N: /B"3X4_%3
MPSHR77B7P7J.JO"MP\SV7BG5XW;8 8E2+[3(29,[%YZ@EL"NR?\ 9LUZY^,>
MEQZSH%]-X/M KKJ">(M4>\MFEMAYNS=> C]X3&2%Y4$XK]+S;6Y;<8P3]*<8
M(2<E 30!^18^"7Q?GBU33=3\#ZI>B:\FCM)_^$FU-(DMD/!EC-Z2^],X.1]*
MH6_[,WB+3(YM1T7X0RVNM+AC./$M_F>0/%O&_P"U90,AD(;)Y '8Y_83RH^F
MT4>5'_=% 'YA>.?@MXJLM;T>^^'/A77M6TBYTV62YM[KQ'J<$L5ZLA7:TAO,
MA=HRJA<GU],_4OA#\41 YTWX?ZEO\QXU\[Q?JIQS+MD^6Y&Y1LCSTSOZ  X_
M4SR(?[@_*G^6GH.: /RXTCX5>-Y-5MK;Q'X"UG3[2XU""Q$@\6:L\C12D[[D
MK'<.J1QJI9@QR<J!SFI=5^!OQ N+;Q?<:=X=U33UTZVE&C(?$FJ7$EY<"X 1
MF'VQ0J^3D@'&6.<\8K]/_)B)R4&11Y,7'R#B@#\F$^$_QD41QR?#K5)C'"\L
MKGQ9J:>8V9!'&@%XV&P(RS<C)( KZ0O?V/OA'XC\,6'B;Q/;:Y9:[8V9F6:'
M7-2N;JQN&B_>?9W:=B60Y"C!#8&0>E?:WV> KMV#'I3O*C$9B"@(>WUH ^&?
M@E^S)I6J?#;2;KXG3^(%\0$2"8_V_JD,C1"1A \L:W15)7B"M(HX#$@ =*]>
MM?V7?AG8W4%]:W.O>;;R+(HD\0:I(FY#D;E:X*L,CD$$&OHE(TC!$:A0?2GT
M %%%% '_TOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>logo-verticala14.jpg
<TEXT>
begin 644 logo-verticala14.jpg
MB5!.1PT*&@H    -24A$4@   ?0   &0" 8   !8LY+&    &71%6'13;V9T
M=V%R90!!9&]B92!);6%G95)E861Y<<EE/   4X])1$%4>-KLG?E[(\=YYZMA
M97\-_,ORFN<)QE<2)YO!))O=)'ZR!./(DJR+M Y;LJT!)8^L>TA9IV-GP,2.
M-))E<BSYT&$!E*S1+7*DD2Q9<8C9W/8F ]FQX\0'D>?AN;\(^P<$M55] %W5
M57T #: ;_'ZD'H! -X[N1G_K6_6^;Q$"
M
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MD#__K]/[7OC)&A/=-5/,3>&V(]8=X6Y'L-OW:=NMT]8=[_CYC4]EV;JYUOH
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MKO^%UW/F7.3-IBOZG;;G'E=UEPOW;6$W-,*NZX*/$C@GZ[DJ(MZ@ 0X=W>T
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M$O(FS8G.6^&.50[=(X)!X]RJ+GCW8ZK> (V+%SY3MX%SFH(RJBYVZ#D $'0
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M MU4/$Z\Z[D_%]&]7EOL*75]WZ9W#G1B%I1QN7TJIZ_AO ( @@Y /\5\9JG
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M3Y75HOZM3[M$735&+OY-FR$CXIL!8^JZP+=>!,ZIW7G!4^;5+>+(00< @@Y
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M]5N>UHCZ#8ZHJ]/1@@+GFA$"Y[I(=Z-:-^]I0-2W[CZ[KG?G+A&7Z[<C* X
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M?_]L1T[=X]C-]VFPAML[A5Z/CWR%':-FT7;GO%%WD#GXNDO,>9K:>N!L:NY
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MC?&%UY@H\S%K.YB-: O.U"U'3RK;QS\66J#&[_W+K%G!S>I2+Z@=LRVTO(?
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MNK>A5/W:K?6;]N*L[[KO64]Z????;B%NTIK7G>L$7"_FYM]-;PE8YM(AY@!
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M:Y=;]=YKI-E4I(]IG+1B/77N>C-$P%QP65E7-+Q84.9C7\NQQW(1Q!QCYP!
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MNN5^9VQQE4K!JH+FY-QU&G+"%W.]^LXW9T6W3<FD1LSYL\?9YT.)5P @Z "
MD*)>93?S+5%W"_1_JO/-J1 8%V;"EZ:FH PM:,2\#G<.  0= !!=U+EX5EQ"
MJYE*51<T%V;"EZ904&;DO/OR&C'G+,"= P!!!P!T!G?I-4'4_:K'R;GK-&C"
M%\FA._.?>\6\SL2\@L,!  0= -"92^>.F!=P$9TQI8'3HWJ#YCSCZ8V=IZZ3
M<M#II- 0$!L6   (.@"@"U&O$5U5-IT##S7ABZ*@3)/F6Z_;ILH^ R9@ 0""
M#@"(0=2YH"YH1=UW#G2JF_!%R#\?^="].7:3D\2<$!21 0""#@"(5=1+Q*Q(
MIX'J4M;:@7%2T%Q5VCZO$/.J'7$/ ("@ P!BA'>]UX-%/2AWO4EV7CHB"_6D
MXA4Q=@X !!T T .7SH/C>-$9__2QX*"YFF*KO/1WQ1Z_!P! T $ /1#U6FCG
MK$U;:U85:Q>DOS%V#@ $'0#08U&OD+!5VY1!<TTQ(.[L>V0Q7\($+ ! T $
M_1%U[M*KH3=P!\U13Y>[6] ;<.< 0- ! /TE>#S=*^KUW=?OE-WW ==]3, "
M  0= -!GE\Z%=RKB9JI MX++G6,"%@ @Z "  8BZOI*<&GG\/,=NLO:?\W#G
M $#0 0"#$_4*<<_,YD]5X\XQ 0L $'0 0 )$G;OT6HCUY'6<@C((A , @@X
M2 A!07)5Q6.\H$P5[AP "#H (#DNO6Z+N@YY_#QK"SK<.0 0= ! PD2=N_#Y
MD [=<>=5[#D (.@ @.2).D\]JRB>4A64P00L $#0 0 )9EX2\)HB):V&"5@
M@* # )+MTN69V:J*=5:QIP" H , DB_J==(N.O,6]@@ $'0 0'I%G;OP:!.Y
M
M
M
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M#ETU" !@KY&UG<UDBH7=N0@V<#@!
M
M
M
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M^7TEB;)&I/(A2H;6B7I<E9N"U3UP_5A-Z'FKT@?=>#H_?JIB.<ZX>5J8(YJ
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M]6%?ZWXG_88W&I=[>=VT)VXY2/2%A@
M
M                                                   8$OZ_  ,
4XT7\[_IA+3      245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>logo-verticala15.jpg
<TEXT>
begin 644 logo-verticala15.jpg
MB5!.1PT*&@H    -24A$4@   ?0   &0" 8   !8LY+&    &71%6'13;V9T
M=V%R90!!9&]B92!);6%G95)E861Y<<EE/   4X])1$%4>-KLG?E[(\=YYZMA
M97\-_,ORFN<)QE<2)YO!))O=)'ZR!./(DJR+M Y;LJT!)8^L>TA9IV-GP,2.
M-))E<BSYT&$!E*S1+7*DD2Q9<8C9W/8F ]FQX\0'D>?AN;\(^P<$M55] %W5
M57T #: ;_'ZD'H! -X[N1G_K6_6^;Q$"
M
M                                                         !_V
MO;J>Q5X H'O.PBX   Q(R'/LYBA;^.T4]@@ $'0 0)J$_!03<L,4\J+]T +V
M"@ 0= ! :H3\%[8CIT5"#<)$W:&&O0- ]V2P"P  /17R5WZ>W_?*+\KL[GK;
ME5/V/S5O5((^=O.)'/8< '#H ( D"/G+/R]8CIP4+ &W+;GA7HO6-\Y_5]VS
M,273[-\E[$4 (.@ @$$)^<F?V4)."Z9Z4_L)P[XC"KO7G=]T(L]N$/D.  0=
M # 0(5_]J<N1$UO(J2W<6F$_[7TEFF^M"P" H , ^B3D*_]N"3EECMPPK+%Q
M4[AM)TY=(NX(N]%2?&] '"63[-__P)X% ((.P)YBY.Q[S.[IW3?O;O15R%_\
MMX*9?D9M1\Y%VBWFPGVE.R<;%[V[JGCI MMV&4<6@&@@RAV ](OY&E\<8>^Y
MD#__K]/[7OC)&A/=-5/,3>&V(]8=X6Y'L-OW:=NMT]8=[_CYC4]EV;JYUOH
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MKO^%UW/F7.3-IBOZG;;G'E=UEPOW;6$W-,*NZX*/$C@GZ[DJ(MZ@ 0X=W>T
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M$O(FS8G.6^&.50[=(X)!X]RJ+GCW8ZK> (V+%SY3MX%SFH(RJBYVZ#D $'0
MDL+H-64^T<H*-1TYUS:7*\^XA-D5_*8.9*/>==S"'A@X1^*+B _5H/"X</YX
M8_/3OR<(^NC5C^NCVS&&#@ $'8#$0&F=\!G3J$MPG2'QIBRFDFN/ZM[[$CA'
MNBDEZU/N51)P*K44  "AR6 7 ! _.X]?S<5\B@E5K258S2:AYD(M46?WS:4E
M:DUK:3VO62_$X^;[R(_3INMOU_OXKB>Y9FHW2-QCWJYUS/^\CZLF9)GTS*I&
MG=X)]+D# $$'8 ",?N1X3B_J=(H)6TT60=IL*D3;+8)N427B>K*X^CQ.A<=5
M MU4/$Z\Z[D_%]&]7EOL*75]WZ9W#G1B%I1QN7TJIZ_AO ( @@Y /\5\9JG
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M3Y75HOZM3[M$735&+OY-FR$CXIL!8^JZP+=>!,ZIW7G!4^;5+>+(00< @@Y
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M]5N>UHCZ#8ZHJ]/1@@+GFA$"Y[I(=Z-:-^]I0-2W[CZ[KG?G+A&7Z[<C* X
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M?_]L1T[=X]C-]VFPAML[A5Z/CWR%':-FT7;GO%%WD#GXNDO,>9K:>N!L:NY
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MC?&%UY@H\S%K.YB-: O.U"U'3RK;QS\66J#&[_W+K%G!S>I2+Z@=LRVTO(?
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MNK>A5/W:K?6;]N*L[[KO64]Z????;B%NTIK7G>L$7"_FYM]-;PE8YM(AY@!
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M:Y=;]=YKI-E4I(]IG+1B/77N>C-$P%QP65E7-+Q84.9C7\NQQW(1Q!QCYP!
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MNN5^9VQQE4K!JH+FY-QU&G+"%W.]^LXW9T6W3<FD1LSYL\?9YT.)5P @Z "
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MK$U;:U85:Q>DOS%V#@ $'0#08U&OD+!5VY1!<TTQ(.[L>V0Q7\($+ ! T $
M_1%U[M*KH3=P!\U13Y>[6] ;<.< 0- ! /TE>#S=*^KUW=?OE-WW ==]3, "
M  0= -!GE\Z%=RKB9JI MX++G6,"%@ @Z "  8BZOI*<&GG\/,=NLO:?\W#G
M $#0 0"#$_4*<<_,YD]5X\XQ 0L $'0 0 )$G;OT6HCUY'6<@C((A , @@X
M2 A!07)5Q6.\H$P5[AP "#H (#DNO6Z+N@YY_#QK"SK<.0 0= ! PD2=N_#Y
MD [=<>=5[#D (.@ @.2).D\]JRB>4A64P00L $#0 0 )9EX2\)HB):V&"5@
M@* # )+MTN69V:J*=5:QIP" H , DB_J==(N.O,6]@@ $'0 0'I%G;OP:!.Y
M
M
M
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M#ETU" !@KY&UG<UDBH7=N0@V<#@!
M
M
M
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M^7TEB;)&I/(A2H;6B7I<E9N"U3UP_5A-Z'FKT@?=>#H_?JIB.<ZX>5J8(YJ
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M]6%?ZWXG_88W&I=[>=VT)VXY2/2%A@
M
M                                                   8$OZ_  ,
4XT7\[_IA+3      245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>partnerchart020717.jpg
<TEXT>
begin 644 partnerchart020717.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 X4&AO=&]S:&]P(#,N,  X0DE-! 0
M       X0DE-!"4      !#4'8S9CP"R!.F "9CL^$)^_^('N$E#0U]04D]&
M24Q%  $!   'J&%P<&P"(   ;6YT<E)'0B!865H@!]D  @ 9  L &@ +86-S
M<$%04$P     87!P;                        /;6  $     TRUA<'!L
M
M   +9&5S8P   0@   !O9'-C;0   7@   5L8W!R=   !N0    X=W1P=
M!QP    4<EA96@  !S     49UA96@  !T0    48EA96@  !U@    4<E12
M0P  !VP    .8VAA9   !WP    L8E120P  !VP    .9U120P  !VP    .
M9&5S8P         41V5N97)I8R!21T(@4')O9FEL90              %$=E
M;F5R:6,@4D="(%!R;V9I;&4
M                             &UL=6,         '@    QS:U-+
M*    7AH<DA2    *    :!C8453    )    <AP=$)2    )@   >QU:U5!
M    *@   A)F<D95    *    CQZ:%17    %@   F1I=$E4    *    GIN
M8DY/    )@   J)K;TM2    %@   LAC<T-:    (@   MYH94E,    '@
M P!D941%    +    QYH=4A5    *    TIS=E-%    )@   J)Z:$-.
M%@   W)J84I0    &@   XAR;U)/    )    Z)E;$=2    (@   \9P=%!/
M    )@   ^AN;$Y,    *   ! YE<T53    )@   ^AT:%1(    )   !#9T
M<E12    (@  !%IF:49)    *   !'QP;%!,    +   !*1R=5)5    (@
M!-!A<D5'    )@  !/)E;E53    )@  !1AD841+    +@  !3X 5@%A &4
M;P!B &4 8P!N /T ( !2 $< 0@ @ '  <@!O &8 :0!L $< 90!N &4 <@!I
M 0T :P!I "  4@!' $( ( !P '( ;P!F &D ; !0 &4 <@!F &D ;  @ %(
M1P!" "  9P!E &X Z !R &D 8P!0 &4 <@!F &D ;  @ %( 1P!" "  1P!E
M &X Z0!R &D 8P!O!!<$, 0S!# $.P1,!#T$. 0Y " $/P1 !#X$1 0P!#D$
M.P @ %( 1P!" %  <@!O &8 :0!L "  9P#I &X Z0!R &D <0!U &4 ( !2
M %8 0I :=2@ ( !2 $< 0@ @@G)?:6//C_  4 !R &\ 9@!I &P ;P @ %(
M1P!" "  9P!E &X 90!R &D 8P!O $< 90!N &4 <@!I ', :P @ %( 1P!"
M "T < !R &\ 9@!I &S'?+P8 "  4@!' $( (-4$N%S3#,=\ $\ 8@!E &,
M;@#] "  4@!' $( ( !P '( ;P!F &D ; 7D!>@%U07D!=D%W  @ %( 1P!"
M " %VP7<!=P%V0!! &P ; !G &4 ;0!E &D ;@!E ', ( !2 $< 0@ M %
M<@!O &8 :0!L ,$ ; !T &$ ; #A &X ;P!S "  4@!' $( ( !P '( ;P!F
M &D ;&9ND!H ( !2 $< 0@ @8\^/\&6'3O9. ((L "  4@!' $( (##7,.TP
MU3"A,*0PZP!0 '( ;P!F &D ;  @ %( 1P!" "  9P!E &X 90!R &D 8P.3
M [4#O0.Y [H#S  @ \ #P0._ \8#KP.[ "  4@!' $( 4 !E '( 9@!I &P
M( !2 $< 0@ @ &< 90!N .D <@!I &, ;P!! &P 9P!E &T 90!E &X ( !2
M $< 0@ M '  <@!O &8 :0!E &P.0@X;#B,.1 X?#B4.3  @ %( 1P!" " .
M%PXQ#D@.)PY$#AL 1P!E &X 90!L "  4@!' $( ( !0 '( ;P!F &D ; !I
M %D ; !E &D ;@!E &X ( !2 $< 0@ M '  <@!O &8 :0!I &P :0!5 &X
M:0!W &4 <@!S &$ ; !N 'D ( !P '( ;P!F &D ;  @ %( 1P!"!!X$,01)
M!#@$.0 @!#\$0 0^!$0$. 0[!$P ( !2 $< 0@9%!D0&00 @!BH&.08Q!DH&
M00 @ %( 1P!" " &)P9$!CD&)P9% $< 90!N &4 <@!I &, ( !2 $< 0@ @
M %  <@!O &8 :0!L &4 1P!E &X 90!R &4 ;  @ %( 1P!" "T 8@!E ',
M:P!R &D =@!E &P <P!E=&5X=     !#;W!Y<FEG:'0@,C P-R!!<'!L92!)
M;F,N+"!A;&P@<FEG:'1S(')E<V5R=F5D+@!865H@        \U(  0    $6
MSUA96B        !T30  />X   /06%E:(        %IU  "L<P  %S1865H@
M        *!H  !6?  "X-F-U<G8          0'-  !S9C,R       !#$(
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M&$_Y]1^Y!]>K?SO[V?8/_#>?[4O_ $-L?_@!:_\ QNC_ (;S_:E_Z&V/_P
M+7_XW7Q]11_9&$_Y]1^Y!]>K?SO[V?8/_#>?[4O_ $-L?_@!:_\ QNC_ (;S
M_:E_Z&V/_P  +7_XW7Q]11_9&$_Y]1^Y!]>K?SO[V?8'_#>7[4I_YFV/_P
M+7_XW7=K^VS^TH?A?)XC/BF/^T%UQ+,2?8K;'D&T,I7;LQ]\9SUKX$KT]?\
MDB<O_8RI_P"D+5A7RG"JUJ4=UT1I3QM;7WW][/<O^&\OVI?^AMC_ / "U_\
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M< ]*EBAEF<10HTCG.%4%B<<G@<\"C^R,)_SZC]R#Z]6_G?WL^O/^&\_VI?\
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MUI=^O_ ZA["E_/\ @?&X\*>)SH][X@_LFZ&F:;-';W5P87$<$TH)1)"1\K,
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M106]U)&+J)KN.WN93!'*]N#YBH95*$D<-^=>15TTJT9W<7<RG"4?B05Z>O\
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M/V</B?;2S":*P^S6UC+J$MTE_#);)#!.;:13+&6'F),/+91]T]2!S5?7J/\
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M3R&3D;B[;L'@\YSR.M3'+ZR27M7_ $EY^5QO%4WKR'VU%^RUX8M[JWN]6O\
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M.0K,,=.:QO\ AG;]EW_HE]G_ .!-Q_\ %UC2XE@G+]W+?R_S+GE,G;WU^/\
MD?@'17[^?\,Z_LN_]$OL_P#P)N/_ (ND_P"&=?V7?^B7V?\ X$W'_P 76W^L
MT/\ GW+_ ,E_S(_L>7\Z_'_(_ 2BOW\_X9U_9>_Z)?9_^!-Q_P#%T?\ #.G[
M+W3_ (5?9Y_Z^;C_ .+H_P!9X?\ /N7_ )+_ )B_L>7\Z_'_ "/P#HK]_/\
MAG7]E[_HE]G_ .!-Q_\ %TO_  SI^R__ -$NL^/^GFX_^+H_UGA_S[E_Y+_F
M']CR_G7X_P"1^ 5%?OW_ ,,Z_LN_]$OL_P#P)N/_ (NE_P"&=?V7?^B7V?\
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M3GS(6*ED.6X!('Y5E6XD@XV]G+_R7_,JGE,D[\Z_'_(_GLHK]^_^&=?V7?\
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M5/,\J.\BLFM9[A@<G$KE6./F('/-9%S\ M<6UN=+MM5%W8S7-U<,T]U<+>W
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M;PY?<L4;-G9MR,9SQ2YE:X6/0Z*\<C^-_A0V#7MSI^J6CI>:=9R02VG[V/\
MM79]DFDVNRI#('!W%L@Y4C<,5O:5\4/#6L>+7\'6L=RER9+R&&XDC MKF;3R
MHNHXF#%MT6X9W*H/.TG!I*<7U#E9Z+6AJ/\ K(/^N$?\JSZT-1_UD'_7"/\
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M=OK7WM^R1\8O%GQX^._BCX]^,-!C\-:'IWAM-,>[5G^Q;HKGS3^^E 4L 6W
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MO^N<?\JX^OL<)_"CZ'B5_C84445T6,@K1U/_ %\?_7&+_P! %9U:.I_Z^/\
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M,<_F2QF5?G2-G)!.UR !7T-6D$MTB9-]0K1'_((/_7P/_0*SJT1_R"#_ -?
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MN1G;G*UYQ>?%#XE>+-.MV@#(L<33O/IUK=6OE7$^E7\DEA*LI8O):S1Q'>,
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M !_PH\_3O^?-O^_Q_P *_+B3XU?M:+]B>.;3)8+Z))A,MM'Y<:2*67S"2,'
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MMZ8KVCYO6O#? G_(QQ?]<Y/Y5[G7S>;+][\CUL'\!__0_8CQU_R,<W_7./\
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M_P"$<?\ Y^X_^^7_ ,*/^$<?_G[C_P"^7_PKHL'THP?2CZS(/91.=_X1Q_\
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ME@)N[DPR6UM,A169?-%S<JH56/R?,3UQ] $8.#VJH>I,BTO_ !Y/_P!=%_\
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MX8\'WWBS3&FU]K-MBV=M&\,\I"F1]OVA4&V.)6D=N@ ]2!6?S*^1Y,OQ'^.
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M:I?"?[,T%G]FU;Q%-;V^H26BP7%K DDL$,D$4UO!+;NTB@2"*7,A9'#2;BN
MU>RZ_KZ:EX*\2Y\/7?B>72M]I+86\9@&I7$:H62V+N,Q%VVEBW&&'S8Y\I\!
M>&/BWHVA> K'0;M-.TNUN[Z;6;74[:9)8H[CSY1#&IG)^S1,Z1P Y8!58_+E
M0W%7V"[L=/I/P$TS0M6TC6-$U-H)]'ETN2-#;1M$RZ;I[::5*C;@RQ.6+ Y5
ML8R!BO>^A]*\$^*,I^(WP?DFT32;^1]71_LB-IYNIX6PZ1RM;>? 1G&4<O\
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M0H]M#N'LY=C/7_CR?_KHO_H)JK70#0M3%LT?E#<74_>'0 BH?^$?U7_GD/\
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MU7_GD/\ OH4_J]/^8/:2['<?VEIW_/Q'_P!]"@:EIW:XC_[Z%</_ ,(_JO\
MSR'_ 'T*/^$?U7_GD/\ OH4OJ]/^8/:2[&UXBO+6>R5(95=MX.%(/%<76U_P
MC^J_\\A_WT*/^$?U7_GD/^^A752<(*W,934F[V,6BMK_ (1_5?\ GD/^^A1_
MPC^J_P#/(?\ ?0K3VL.Y/LY=A_AS_D*)_NM_*O0ZXW1M)O[._6>XC"H%89R#
/UKLJ\W%R3EH=%)66I__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>performancechartv2.jpg
<TEXT>
begin 644 performancechartv2.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X0!T17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !(     0   $@    !  *@ @ $     0   W>@ P $     0   K@
M    _^T .%!H;W1O<VAO<" S+C  .$))300$        .$))300E       0
MU!V,V8\ L@3I@ F8[/A"?O_B![A)0T-?4%)/1DE,10 ! 0  !ZAA<'!L B
M &UN=')21T(@6%E:( ?9  ( &0 + !H "V%C<W!!4%!,     &%P<&P
M                  #VU@ !     -,M87!P;
M                                        "V1E<V,   $(    ;V1S
M8VT   %X   %;&-P<G0   ;D    .'=T<'0   <<    %')865H   <P
M%&=865H   =$    %&)865H   =8    %')44D,   =L    #F-H860   =\
M    +&)44D,   =L    #F=44D,   =L    #F1E<V,         %$=E;F5R
M:6,@4D="(%!R;V9I;&4              !1'96YE<FEC(%)'0B!0<F]F:6QE
M
M      !M;'5C         !X    ,<VM32P   "@   %X:')(4@   "@   &@
M8V%%4P   "0   '(<'1"4@   "8   'L=6M500   "H   (29G)&50   "@
M  (\>FA45P   !8   )D:71)5    "@   )Z;F).3P   "8   *B:V]+4@
M !8   +(8W-#6@   "(   +>:&5)3    !X   , 9&5$10   "P   ,>:'5(
M50   "@   -*<W9310   "8   *B>FA#3@   !8   -R:F%*4    !H   .(
M<F]23P   "0   .B96Q'4@   "(   /&<'103P   "8   /H;FQ.3    "@
M  0.97-%4P   "8   /H=&A42    "0   0V=')44@   "(   1:9FE&20
M "@   1\<&Q03    "P   2D<G5250   "(   3087)%1P   "8   3R96Y5
M4P   "8   489&%$2P   "X   4^ %8!80!E &\ 8@!E &, ;@#] "  4@!'
M $( ( !P '( ;P!F &D ; !' &4 ;@!E '( :0$- &L :0 @ %( 1P!" "
M< !R &\ 9@!I &P 4 !E '( 9@!I &P ( !2 $< 0@ @ &< 90!N .@ <@!I
M &, 4 !E '( 9@!I &P ( !2 $< 0@ @ $< 90!N .D <@!I &, ;P07!# $
M,P0P!#L$3 0]!#@$.0 @!#\$0 0^!$0$, 0Y!#L ( !2 $< 0@!0 '( ;P!F
M &D ;  @ &< Z0!N .D <@!I '$ =0!E "  4@!6 $*0&G4H "  4@!' $(
M(()R7VECSX_P %  <@!O &8 :0!L &\ ( !2 $< 0@ @ &< 90!N &4 <@!I
M &, ;P!' &4 ;@!E '( :0!S &L ( !2 $< 0@ M '  <@!O &8 :0!LQWR\
M&  @ %( 1P!" "#5!+A<TPS'? !/ &( 90!C &X _0 @ %( 1P!" "  < !R
M &\ 9@!I &P%Y 7H!=4%Y 79!=P ( !2 $< 0@ @!=L%W 7<!=D 00!L &P
M9P!E &T 90!I &X 90!S "  4@!' $( +0!0 '( ;P!F &D ; #! &P = !A
M &P X0!N &\ <P @ %( 1P!" "  < !R &\ 9@!I &QF;I : "  4@!' $(
M(&//C_!EAT[V3@""+  @ %( 1P!" " PUS#M,-4PH3"D,.L 4 !R &\ 9@!I
M &P ( !2 $< 0@ @ &< 90!N &4 <@!I &,#DP.U [T#N0.Z \P ( /  \$#
MOP/& Z\#NP @ %( 1P!" %  90!R &8 :0!L "  4@!' $( ( !G &4 ;@#I
M '( :0!C &\ 00!L &< 90!M &4 90!N "  4@!' $( +0!P '( ;P!F &D
M90!L#D(.&PXC#D0.'PXE#DP ( !2 $< 0@ @#A<.,0Y(#B<.1 X; $< 90!N
M &4 ;  @ %( 1P!" "  4 !R &\ 9@!I &P :0!9 &P 90!I &X 90!N "
M4@!' $( +0!P '( ;P!F &D :0!L &D 50!N &D =P!E '( <P!A &P ;@!Y
M "  < !R &\ 9@!I &P ( !2 $< 0@0>!#$$200X!#D ( 0_!$ $/@1$!#@$
M.P1, "  4@!' $(&109$!D$ ( 8J!CD&,09*!D$ ( !2 $< 0@ @!B<&1 8Y
M!B<&10!' &4 ;@!E '( :0!C "  4@!' $( ( !0 '( ;P!F &D ; !E $<
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MR\#_ /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--_P#%T?\ "LO _P#T#?\
MR--_\77>44 <'_PK+P/_ - W_P C3?\ Q='_  K+P/\ ] W_ ,C3?_%UWE%
M'!_\*R\#_P#0-_\ (TW_ ,71_P *R\#_ /0-_P#(TW_Q==Y10!P?_"LO _\
MT#?_ "--_P#%T?\ "LO _P#T#?\ R--_\77>44 <'_PK+P/_ - W_P C3?\
MQ='_  K+P/\ ] W_ ,C3?_%UWE% '!_\*R\#_P#0-_\ (TW_ ,71_P *R\#_
M /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--_P#%T?\ "LO _P#T#?\ R--_
M\77>44 <'_PK+P/_ - W_P C3?\ Q='_  K+P/\ ] W_ ,C3?_%UWE% '!_\
M*R\#_P#0-_\ (TW_ ,71_P *R\#_ /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_
M "--_P#%T?\ "LO _P#T#?\ R--_\77>44 <'_PK+P/_ - W_P C3?\ Q='_
M  K+P/\ ] W_ ,C3?_%UWE% '!_\*R\#_P#0-_\ (TW_ ,71_P *R\#_ /0-
M_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--_P#%T?\ "LO _P#T#?\ R--_\77>
M44 <'_PK+P/_ - W_P C3?\ Q='_  K+P/\ ] W_ ,C3?_%UWE% '!_\*R\#
M_P#0-_\ (TW_ ,71_P *R\#_ /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--
M_P#%T?\ "LO _P#T#?\ R--_\77>44 <'_PK+P/_ - W_P C3?\ Q='_  K+
MP/\ ] W_ ,C3?_%UWE% '!_\*R\#_P#0-_\ (TW_ ,71_P *R\#_ /0-_P#(
MTW_Q==Y10!P?_"LO _\ T#?_ "--_P#%T?\ "LO _P#T#?\ R--_\77>44 <
M'_PK+P/_ - W_P C3?\ Q='_  K+P/\ ] W_ ,C3?_%UWE% '!_\*R\#_P#0
M-_\ (TW_ ,71_P *R\#_ /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--_P#%
MT?\ "LO _P#T#?\ R--_\77>44 <'_PK+P/_ - W_P C3?\ Q='_  K+P/\
M] W_ ,C3?_%UWE% '!_\*R\#_P#0-_\ (TW_ ,71_P *R\#_ /0-_P#(TW_Q
M==Y10!P?_"LO _\ T#?_ "--_P#%T?\ "LO _P#T#?\ R--_\77>44 <'_PK
M+P/_ - W_P C3?\ Q='_  K+P/\ ] W_ ,C3?_%UWE% '!_\*R\#_P#0-_\
M(TW_ ,71_P *R\#_ /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--_P#%T?\
M"LO _P#T#?\ R--_\77>44 <'_PK+P/_ - W_P C3?\ Q='_  K+P/\ ] W_
M ,C3?_%UWE% '!_\*R\#_P#0-_\ (TW_ ,71_P *R\#_ /0-_P#(TW_Q==Y1
M0!P?_"LO _\ T#?_ "--_P#%T?\ "LO _P#T#?\ R--_\77>44 <'_PK+P/_
M - W_P C3?\ Q='_  K+P/\ ] W_ ,C3?_%UWE% '!_\*R\#_P#0-_\ (TW_
M ,71_P *R\#_ /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--_P#%T?\ "LO
M_P#T#?\ R--_\77>44 <'_PK+P/_ - W_P C3?\ Q='_  K+P/\ ] W_ ,C3
M?_%UWE% '!_\*R\#_P#0-_\ (TW_ ,71_P *R\#_ /0-_P#(TW_Q==Y10!P?
M_"LO _\ T#?_ "--_P#%T?\ "LO _P#T#?\ R--_\77>44 <'_PK+P/_ - W
M_P C3?\ Q='_  K+P/\ ] W_ ,C3?_%UWE% '!_\*R\#_P#0-_\ (TW_ ,71
M_P *R\#_ /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--_P#%T?\ "LO _P#T
M#?\ R--_\77>44 <'_PK+P/_ - W_P C3?\ Q='_  K+P/\ ] W_ ,C3?_%U
MWE% '!_\*R\#_P#0-_\ (TW_ ,71_P *R\#_ /0-_P#(TW_Q==Y10!P?_"LO
M _\ T#?_ "--_P#%T?\ "LO _P#T#?\ R--_\77>44 <'_PK+P/_ - W_P C
M3?\ Q='_  K+P/\ ] W_ ,C3?_%UWE% '!_\*R\#_P#0-_\ (TW_ ,71_P *
MR\#_ /0-_P#(TW_Q==Y10!P?_"LO _\ T#?_ "--_P#%T?\ "LO _P#T#?\
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M^'W[)?P'^%_BNU\8^#] F@O],$ZZ;'<:A>7=II:W0Q.+"UN)I(+7S.0?*1<
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M_P!#9_Y(P_XUWE% '!_\(_XX_P"AL_\ )&'_ !H_X1_QQ_T-G_DC#_C7>44
M<'_PC_CC_H;/_)&'_&C_ (1_QQ_T-G_DC#_C7>44 <'_ ,(_XX_Z&S_R1A_Q
MH_X1_P <?]#9_P"2,/\ C7>44 <'_P (_P"./^AL_P#)&'_&C_A'_''_ $-G
M_DC#_C7>44 <'_PC_CC_ *&S_P D8?\ &C_A'_''_0V?^2,/^-=Y10!P?_"/
M^./^AL_\D8?\:/\ A'_''_0V?^2,/^-=Y10!P?\ PC_CC_H;/_)&'_&C_A'_
M !Q_T-G_ )(P_P"-=Y10!P?_  C_ (X_Z&S_ ,D8?\:/^$?\<?\ 0V?^2,/^
M-=Y10!P?_"/^./\ H;/_ "1A_P :/^$?\<?]#9_Y(P_XUWE% '!_\(_XX_Z&
MS_R1A_QH_P"$?\<?]#9_Y(P_XUWE% '!_P#"/^./^AL_\D8?\:/^$?\ ''_0
MV?\ DC#_ (UWE% '!_\ "/\ CC_H;/\ R1A_QH_X1_QQ_P!#9_Y(P_XUWE%
M'!_\(_XX_P"AL_\ )&'_ !H_X1_QQ_T-G_DC#_C7>44 <'_PC_CC_H;/_)&'
M_&C_ (1_QQ_T-G_DC#_C7>44 <'_ ,(_XX_Z&S_R1A_QH_X1_P <?]#9_P"2
M,/\ C7>44 <'_P (_P"./^AL_P#)&'_&C_A'_''_ $-G_DC#_C7>44 <'_PC
M_CC_ *&S_P D8?\ &C_A'_''_0V?^2,/^-=Y10!P?_"/^./^AL_\D8?\:/\
MA'_''_0V?^2,/^-=Y10!P?\ PC_CC_H;/_)&'_&C_A'_ !Q_T-G_ )(P_P"-
M=Y10!P?_  C_ (X_Z&S_ ,D8?\:/^$?\<?\ 0V?^2,/^-=Y10!P?_"/^./\
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MH **** "BBO&_CW\8-.^!?POU7XBZA:/J#6>R*WMD.WS;B9MD:LW\*Y.6/.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@)_]G1K?_(_>%_^N&H_^@PUWE '!_\ "=_]2[K'_@)_]G1_PG?_ %+NL?\
M@)_]G7>44 <'_P )W_U+NL?^ G_V='_"=_\ 4NZQ_P" G_V==Y10!P?_  G?
M_4NZQ_X"?_9T?\)W_P!2[K'_ ("?_9UWE% '!_\ "=_]2[K'_@)_]G1_PG?_
M %+NL?\ @)_]G7>44 <'_P )W_U+NL?^ G_V='_"=_\ 4NZQ_P" G_V==Y10
M!P?_  G?_4NZQ_X"?_9T?\)W_P!2[K'_ ("?_9UWE% '!_\ "=_]2[K'_@)_
M]G1_PG?_ %+NL?\ @)_]G7>44 <'_P )W_U+NL?^ G_V='_"=_\ 4NZQ_P"
MG_V==Y10!P?_  G?_4NZQ_X"?_9T?\)W_P!2[K'_ ("?_9UWE% '!_\ "=_]
M2[K'_@)_]G1_PG?_ %+NL?\ @)_]G7>44 <'_P )W_U+NL?^ G_V='_"=_\
M4NZQ_P" G_V==Y10!P?_  G?_4NZQ_X"?_9T?\)W_P!2[K'_ ("?_9UWE% '
M!_\ "=_]2[K'_@)_]G1_PG?_ %+NL?\ @)_]G7>44 <'_P )W_U+NL?^ G_V
M='_"=_\ 4NZQ_P" G_V==Y10!P?_  G?_4NZQ_X"?_9T?\)W_P!2[K'_ ("?
M_9UWE% '!_\ "=_]2[K'_@)_]G1_PG?_ %+NL?\ @)_]G7>44 <'_P )W_U+
MNL?^ G_V=?F[_P %&?C@?^$#TGX4:?:7>GW.O3B\O5N8_*+6EL?W:XW'(>;#
M9]8Z_5ZOYPOCWXGU7]IK]J:[L/#DGVB+4-1AT/2B,L@MXG\E9!Z(S%YCZ!C7
MT_"F#53$^UG\,-?\O\_D>#Q#B7"A[..\M/\ /_+YGWG_ ,$[?"__  @/PSU/
MQW?Z#J5S?^+;@>3+!;%T^PVF43#$C[TID)QP0%JM_P %%_"__"=?#O2?B!8:
M%J-K>^%+@QW$L]L8T^Q79"G<P+<K*(]N> &;GU_3'PCX8TOP5X6TCPAHB>78
M:+:0V<"]_+@0(I/J2!DGN>:A\;^$M+\>>#]:\%:TNZQUNTFLY?4+,A7</]I<
MY![$ URK.9?7_K?G^&UON.AY8OJGU;R_'_AS\U/^"=/QP,OPYU/X6:A:7FHW
M7AVX:YM!;1^:5L[H[F7&X$!)MY)Z?.!7Z+_\)W_U+NL?^ G_ -G7X"_LT>+=
M4_9T_:CLM+\3-]DCCOI_#^K DA DLGE%R3_ DJI)GN%]Z_HVKIXKP2IXKVD?
MAGK_ )_Y_,PX>Q+G0Y);QT_R_P OD<'_ ,)W_P!2[K'_ ("?_9T?\)W_ -2[
MK'_@)_\ 9UWE%?,GNG!_\)W_ -2[K'_@)_\ 9T?\)W_U+NL?^ G_ -G7>44
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M?_"=_P#4NZQ_X"?_ &='_"=_]2[K'_@)_P#9UWE% '!_\)W_ -2[K'_@)_\
M9T?\)W_U+NL?^ G_ -G7>44 <'_PG?\ U+NL?^ G_P!G1_PG?_4NZQ_X"?\
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MG?\ U+NL?^ G_P!G5FR\8_;;N*T_L/5(/-8+YDMMMC7/=FW' KLZ* "BBB@
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M#'VBK[6I_M>5*7VJ3_#_ (;\CY>'^S9@U]FI^?\ P_YG[14445\4?4!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >2?&;_D5[;_ *_$_P#1<E?,U?3/QF_Y%>V_Z_$_]%R5\S4
M?__7_<#X9?\ (CZ;_P!MO_1SUWE<'\,O^1'TW_MM_P"CGKO* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#@];_Y'[PO_P!<-1_]!AKO*X/6_P#D?O"_
M_7#4?_08:[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K$\2^(=,\)>'=4\4ZW)Y.GZ/:S7
M=P_]V*!"[D>^ <5MU^=W_!2#XI_\(?\ !VU^']A-LU#QG<".0 _,+*U*R2GU
M&Y_+3W4L*[<NP;Q%>%%=7^'7\#EQN)5&E*H^A^9OP<\/ZK^U)^U/;7?B"+SH
M=9U.75]34_,B6<+^:\7LI 6%?3<*_I"  &!P!7Y8_P#!,;X6?V7X2\0?%[48
M<7&MR_V=8L1R+6V(:9E/I)+A3[Q5^I]>WQ9C%/$^RA\,%;_/_+Y'E\/89PH>
MTEO+7^OS^84445\N>\,DCCFC>&90\;@JRL,@@\$$'J#7\V_B^PU/]DW]JN63
M3$<0^%M62[M5!(\[3I_G6/=WWV[F)CGKN%?TEU^2'_!3[X6^;:>&/C%I\66@
M)TB_8#^!MTULQQT ;S5)/=E'I7U7"6+4<0Z$_AFK?U^*^9\_Q%AW*BJL=XNY
M^L&E:I8:WI=GK6ES"XLK^&.X@D7H\4JAT8>Q4@U?KX0_X)Z?%+_A/?@3#X7O
MI=^I>"YC8."<L;5\R6S'V"[HQ[1U]WUX&/PCH5IT9=&>QA,0JM*-1=4%%%%<
MAT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMWK+^O7\CY?*/W^)J8I[;+^O3\R>BBBOBCZ@**** "BBB@#\_?\ @HO\+?\
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M'C_^)H /^$K\+_\ 08L__ B/_&C_ (2OPO\ ]!BS_P# B/\ QH_X1;PQ_P!
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M_ B/_&C_ (1;PQ_T![/_ ,!X_P#XFC_A%O#'_0'L_P#P'C_^)H /^$K\+_\
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M'L__  'C_P#B: #_ (2OPO\ ]!BS_P# B/\ QH_X2OPO_P!!BS_\"(_\:/\
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M_P#B:/\ A%O#'_0'L_\ P'C_ /B:\,]4/^$K\+_]!BS_ / B/_&C_A*_"_\
MT&+/_P "(_\ &C_A%O#'_0'L_P#P'C_^)H_X1;PQ_P! >S_\!X__ (F@ _X2
MOPO_ -!BS_\  B/_ !H_X2OPO_T&+/\ \"(_\:/^$6\,?] >S_\  >/_ .)H
M_P"$6\,?] >S_P# >/\ ^)H /^$K\+_]!BS_ / B/_&C_A*_"_\ T&+/_P "
M(_\ &C_A%O#'_0'L_P#P'C_^)H_X1;PQ_P! >S_\!X__ (F@ _X2OPO_ -!B
MS_\  B/_ !H_X2OPO_T&+/\ \"(_\:/^$6\,?] >S_\  >/_ .)H_P"$6\,?
M] >S_P# >/\ ^)H /^$K\+_]!BS_ / B/_&C_A*_"_\ T&+/_P "(_\ &C_A
M%O#'_0'L_P#P'C_^)H_X1;PQ_P! >S_\!X__ (F@ _X2OPO_ -!BS_\  B/_
M !H_X2OPO_T&+/\ \"(_\:/^$6\,?] >S_\  >/_ .)H_P"$6\,?] >S_P#
M>/\ ^)H /^$K\+_]!BS_ / B/_&C_A*_"_\ T&+/_P "(_\ &C_A%O#'_0'L
M_P#P'C_^)H_X1;PQ_P! >S_\!X__ (F@ _X2OPO_ -!BS_\  B/_ !H_X2OP
MO_T&+/\ \"(_\:/^$6\,?] >S_\  >/_ .)H_P"$6\,?] >S_P# >/\ ^)H
M/^$K\+_]!BS_ / B/_&C_A*_"_\ T&+/_P "(_\ &C_A%O#'_0'L_P#P'C_^
M)H_X1;PQ_P! >S_\!X__ (F@ _X2OPO_ -!BS_\  B/_ !H_X2OPO_T&+/\
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M6\,?] >S_P# >/\ ^)H /^$K\+_]!BS_ / B/_&C_A*_"_\ T&+/_P "(_\
M&C_A%O#'_0'L_P#P'C_^)H_X1;PQ_P! >S_\!X__ (F@ _X2OPO_ -!BS_\
M B/_ !H_X2OPO_T&+/\ \"(_\:/^$6\,?] >S_\  >/_ .)H_P"$6\,?] >S
M_P# >/\ ^)H /^$K\+_]!BS_ / B/_&I8/$GAZYF2WMM4M999#A42=&9B>P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% '!ZW_ ,C]X7_ZX:C_ .@PUWE<'K?_ "/WA?\
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M5_V;,%+[,_S_ *M]Y^]U%%%?%'U 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'DGQF_Y%>V_P"OQ/\ T7)7S-7TS\9O
M^17MO^OQ/_1<E?,U '__U_W ^&7_ "(^F_\ ;;_T<]=Y7!_#+_D1]-_[;?\
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M-X)B2V?0_&7@>/1_)4*3'<8@DC!'.V6!W,@_B')SUK-^#FF:%XM_91_:*O\
MQ/$GVOQ%KWCXZTTH#,DD3SQ1JQ;M!"D8C'1 !C% 'Z<]>117@'[*5]J^I_LQ
M?"?4->9Y-0N/"NC/,\F2[LUG$=S$\[F&"?<U[_0!P>M_\C]X7_ZX:C_Z##7>
M5Y?XRM-2O/&?A>'2K[^SI_*U ^;Y2S?*%BR-K<<^M:G_  C_ (X_Z&S_ ,D8
M?\: .\HK@_\ A'_''_0V?^2,/^-'_"/^./\ H;/_ "1A_P : .\HK@_^$?\
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M!_\ "/\ CC_H;/\ R1A_QH_X1_QQ_P!#9_Y(P_XT =Y17!_\(_XX_P"AL_\
M)&'_ !H_X1_QQ_T-G_DC#_C0!WE%<'_PC_CC_H;/_)&'_&C_ (1_QQ_T-G_D
MC#_C0!WE%<'_ ,(_XX_Z&S_R1A_QH_X1_P <?]#9_P"2,/\ C0!WE%<'_P (
M_P"./^AL_P#)&'_&C_A'_''_ $-G_DC#_C0!WE%<'_PC_CC_ *&S_P D8?\
M&C_A'_''_0V?^2,/^- '>5_.I^UMX*U+X"_M/7NM^&LV<=U=0^(=+D48"/))
MYC 8X CN$< #^$#UK][_ /A'_''_ $-G_DC#_C7Y[_\ !0_X-^(-:^%UE\3+
MG4_[5N?"4X24"V2%EL[QE1VRA);;*(^". 6/'.?I>%<:J6*4);3T_P O\OF>
M'Q!A?:8=RCO'7_,_1'X=>-=,^(_@30?'>D$?9=<LX;I5SDH9%!>,G^\C94^X
M-=G7Y._\$Y/'WB/Q3X)UGX70>(CI\GAF475K"UO'-NM;MB7VEL'"39)_ZZ"O
MTF_X1_QQ_P!#9_Y(P_XUY6:X)X?$3H]GIZ=/P/0R_%>VHQJ=_P ^IWE%<'_P
MC_CC_H;/_)&'_&C_ (1_QQ_T-G_DC#_C7GG8=Y17!_\ "/\ CC_H;/\ R1A_
MQH_X1_QQ_P!#9_Y(P_XT =Y17!_\(_XX_P"AL_\ )&'_ !H_X1_QQ_T-G_DC
M#_C0!WE%<'_PC_CC_H;/_)&'_&C_ (1_QQ_T-G_DC#_C0!WE%<'_ ,(_XX_Z
M&S_R1A_QH_X1_P <?]#9_P"2,/\ C0!WE%<'_P (_P"./^AL_P#)&'_&C_A'
M_''_ $-G_DC#_C0!WE%<'_PC_CC_ *&S_P D8?\ &C_A'_''_0V?^2,/^- '
M>45P?_"/^./^AL_\D8?\:/\ A'_''_0V?^2,/^- '>45P?\ PC_CC_H;/_)&
M'_&C_A'_ !Q_T-G_ )(P_P"- '>45P?_  C_ (X_Z&S_ ,D8?\:/^$?\<?\
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M_D?+YI_M&+IX9;+5_P!?UN?K%'&D2+%$H1$ "J!@ #H /2GT45\4?4!1110
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MQ%8I3(@Y8RC/SOG]_P"@ HHHH **** "BBB@ HHHH **** .#UO_ )'[PO\
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MC^Q_^RK\</@_X$^%^K>/;33]0^'.F6NE:3K<5]9M=FUMH4A\NX3<L<BOL5R
M%*MRA4%@?SR_X<B?%W_HH^A_^ ]U_A1_PY$^+O\ T4?0_P#P'NO\* /N?]C3
M]@3]GK]G;XC1>.[3XAV_Q#\91QRQ:: UM!';"1&$LD5O'+,[2^5N7<7(52WR
M\Y'ZO5^)?[(O_!+/XB_LX_M#>$_C-KWC72M7L?#WV_S+6VAG263[78SVB[2X
MVC:TP8Y[ U^VE !G%%?CK^TUXZ>?]I6Y\$_&_P"(.O?#/P_;:MH9\)S64_\
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M_P#LZ .\HK@_^$[_ .I=UC_P$_\ LZ/^$[_ZEW6/_ 3_ .SH [RBN#_X3O\
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M)W_U+NL?^ G_ -G1_P )W_U+NL?^ G_V= '>45P?_"=_]2[K'_@)_P#9T?\
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MQ-?3G_"=_P#4NZQ_X"?_ &=?-8O#2HU94I;IV/<P]95(1J1V9WE%<'_PG?\
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M??%/_A4GP%\1Z[:S>3JFI1_V98$'#?:+P%-RG^]''OD'^[7YJ?\ !-'X6?\
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M[IJU[:?UW]3YW+*DJ>,_?^]*2W3OO_7](_9RBBBOS0^X"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R^_X*:_"W^V
MO FA?%C3X<W/AV?[%>,!R;2[/[MF/I', H]Y37E/[&'[:WA'P#X3T;X,_$Q9
M[6&"ZFCL]5RK6T$,[;T2?)#*HD9QO&0H*YPH)%+_ (* ?M2:QK&N:I^S[X31
MK32=/>-=7N"/WEW,H6584_NQ(<%CU=AV4?-^9_\ PCMY_97]J9'3=L[[/7/]
M*_2\!@Z<LOA1QSLF_=UUUV_4^&Q>)FL9.KA%>R][Y;G]:,<D<T:30N'C<!E9
M3D$'D$$=0:?7X'?LW?MZ>*/@MX8/@?QCI<GBO1K4 :>?M'DW%HG>+<R.'B_N
M X*= 2N /J"+_@J7X);_ %_@744_W;N%OYJM?,8GA3&0FXPCS+HU;_,]VAQ!
MAI13E*S[:GZHT5^847_!4;X8'_7^#]83_=>W;^;K6G#_ ,%0/@NW^O\ #/B!
M/]V*T;^=PM<SX<QR_P"73_ Z%G>%_P"?B/TJHK\Z(O\ @IQ\ 9/OZ+XCB_WK
M6T/\KLUJ0_\ !2G]G>7 :WUR+/\ >LHC_P"@SFLWD&-7_+IE+-\,_P#EXC]
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MYF)#8!!3YS_9-_:J\0_LY>*)? 'C^.X;PA/<M'=VTBMY^EW(;:\L:'Y@ ?\
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M_MM_Z.>N\H _E8LO@%_P5TTVS@T[3KKQY:VEK&L4,,7BEDCCC0!51%6^ 55
M  ' ' JS_P *0_X+ ?\ 01^('_A6/_\ )]?U/44 ?S@_L/\ [)'[8?@[]M'P
M=\9?C?X4U-;.%]4DU+5]1OH+R9GN-+NK>-I7\^25V:1T7/)Y&>*_H^HHH **
M** "BBB@ HHHH **** "BBB@#@];_P"1^\+_ /7#4?\ T&&N\K@];_Y'[PO_
M -<-1_\ 08:[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X;XB?$C
MP9\*?"]UXQ\=ZG'IFFVHQN<Y>5R"5CB0?,[MCA5&>IZ FO+/VA?VF?A_^SSH
M/VKQ!+]OUVZ0M8Z5"X$\YZ!W//E19ZNP]0H9ABOP_P!7UOX]?MM_%.*UBC?4
MKHY\BVBS'IVF6Q(W,2<A$'&YVR[G ^8[5KZ+)\@EB%[:J^6FMW_E_F>+F6<1
MHOV=-<TWT_S_ ,CLOVB/VKOB1^T[X@B\#>#[2YL?#4\ZQV>D6P,ES?2;OD:X
M\O)=B>5C7**<?>8;J^Y/V4_V"=+\"_8_B!\:;>+4_$2[9;72SB6ULFZAI>JR
MS#L.40\C<<,/H7]FG]DKP+^SUIB:@H76?%]S'MNM4D3&P,/FBME.?+C[$_>?
MJQQA5^L:Z\SX@C&'U7 KEAWZO^OO9SX#)Y.?M\4[R[=%_7W!1117R1]$%%%%
M !1110 4444 %%%% !1110 4444 %%%% !16%I?B?PYKFH:GI.CZG;WM[HLJ
MPWL,,BO);R.NY5D4'*DCIGW'4&C5/$_AS0]0TS2=8U.WLKW6I6ALH9I%22XD
M1=S+&I.6('7'L.I% &[117(>*_B!X%\"V_VKQGX@L-$CQD?:[B.$M_NJQ!8^
MP!- '7T5\-^-O^"@OP#\,>9!H$M]XHN5R!]CMS%#N'K)<>7Q[JK>U?(/C;_@
MI/\ $G5?,@\"^';#0(6R!+<L]]./<']U&#[%&H _:*O)_&WQU^#WPZ\Q/&7B
M[3M/GB^];^<);D8_Z81;Y?\ QVOPUE\9_M:?M"2/!;7GB#Q';3$AX[))(;$?
M[ZP+' !VRU>J^"?^"=WQP\1>7/XIGT_PO V"RSS?:;@ ^B0;D/T,BT ?7'C;
M_@I%\*-&\R#P3HFH>))USMDDVV-LWIAGWR_G$*^0O&O_  4.^.GB3?;^&$L/
M"\#<*;>#[1<8/8R7&]"?=8UK["\$_P#!-_X2:)Y<_C36-0\2SKC<BE;&V;UR
MD9:7\I:^O?!7P0^$7PZ\MO!GA+3M-FC^[.L"R7/'K/)NE/XM0!^&4/@']K3]
MH*5+F[L=?\0V\I#)+J$CPV8]XVN&CA '7"5]!^"?^":WQ$U/RY_'?B2PT*)N
M3%:H][./8Y,48/N'8?RK]G:* /A_P3_P3]^ /A?RY]<M[WQ1<K@DWUP4BW>T
M5OY8Q[.6KZT\*^ _!/@>V^Q^#=!L=$B(P19V\<&[_>**"Q]R2:ZRB@#SSXD?
M"GP%\6](M]#\?Z3'JEK:SI<1!B4='0@G:ZD, X&UP#AE.#VKLO[(TG^R?[!^
MQ0_V;Y/V;[+Y:^1Y&W9Y?EXV[-OR[<8QQTK1HH \\^&_PI\!?"32+C0_ &DQ
MZ7:W4[W$H4EW=W)(W.Q+$(#M0$X51@=Z]#HHH **** "BBB@ HHHH **** "
MBBB@ HHHH *_.[]M']CFV^+=C<?$OX<6R0^-+2/-Q;H JZI$@Z'H!<*!A&/W
MA\K?PD?HC179@,=4PU15:3U7X^1S8O"0K0=.HM#\"?V/_P!K?5_@-KG_  KC
MXC&9_!MQ.T;K(K&;2;@MAW5#\WE[L^;'C(.64;MRO^]=A?V.JV-OJ>F7$=W9
MW<:RPS1,'CDC<;E=67(*D'((X(K\X?VUOV-(_B3;W?Q7^%UF$\66Z%[ZQC&!
MJ2(.70#_ )>% _[:#C[V-WR/^QI^V#>_!S4HOA?\3)I'\'7$I2&:0$R:5,S<
MG!Y\@M]].J'+*/O!OK<PP-/,*3QF$7OKXH_UU_/U/GL'BIX.I]6Q#]U[/^OZ
M7H?O#14%M<VU[;17EG*D]O.BR1R1L&1T895E89!!!R"."*GKX8^J"BBB@ KR
M?QE\"?@Y\0/,?Q=X/TV_FESNG\A8K@Y_Z;Q;9?\ QZO6** /SV\9?\$XO@YK
M?F3>$=3U+PW,V=J;UO+=?^ 2XE/_ ']KY/\ &7_!.'XPZ+YDWA#5=-\20KG:
MA=K.X;_@$FZ(?]_:_;FB@#^=TZ+^UO\ L_DM%!XC\-VEOU,#2RV'']XQF2W;
M\<URWQ-_:6^,GQ?\.V7A?QWKOVRPLW\TI%#';^>_\+3"%55RG\/& 23C/-?T
MEU^;?_!06+2/#?@2VN],^'UC>W6L2F*X\0-:1%['H0H=1YGF2\A6;Y1@XRQ&
M #\^?A[^UE\7OAK\-M3^&?A_4!]BNQMM+B3+7&G!R?-%LV?E#YXSG8<LF"<U
M]5?\$_O@W\3'\3/\9+K4;C1?#<J21>6>6U<G.<J^1Y2-\WF8R6&$/WB/@#1/
MAOJNLZ!<ZSY\=M, C6EK(K^9=AC@E"%*J!VW$;NWK7W_ /\ !/[XR?$Q/$S_
M  ;NM.N-:\-Q))+YAX;2",YRSX'E.WR^7G(8Y0?>! /V HHHH **** "BBB@
M HHHH **** "BBB@#R3XS?\ (KVW_7XG_HN2OF:OIGXS?\BO;?\ 7XG_ *+D
MKYFH __1_<#X9?\ (CZ;_P!MO_1SUWE<'\,O^1'TW_MM_P"CGKO* "BBB@ H
MHHH **^(?BO^U9XWT/XCW?PW^#/P^;QK=>'-2TW3]9N)[^"PA%SJ5NUU%9VI
MD.7G:$!S(P$29"L<GCL-6_:GM8_"7@'4/#7@C6M4\6_$A[J+3/#<ZQ:?>QOI
MX8WQNY+EEBACM]N&?+;LJ4#!@: /JZBOCO2OVQ_"EAX;^(]]\5_#NH>!?$'P
MK2TDUG2)GAO97341_H#64UNYBN!=/B./!4B0A7"]:ZCP3^T7J.J?$31_AA\3
M_ 6I?#O6O%5I=7NA"^N;2\BU".R"O<Q;[263RKB*-U=XGXVYPQQ0!].45\1#
M]M?1_P"R4^);>!]67X0R:B--7QB9K3[,2UU]B6[^Q^:;K[$T^%$VS.#NV;>:
M^Q?$7B#1O"?A_4_%/B*Z2QTK1K6:]N[B3.R&WMT,DLC8R<*BDGZ4 ;%%?'7A
M7]K<ZKJ7@NZ\9?#W6?!OA3XDW,-GX<UF_FLY$NKFZC::TBN;:":2:U:Y128M
MX.3@-M)P&^*_VNET:\\9ZGX4^'VL>+/!OPWNI[/Q'KMG-9QQ6L]FBR7JVUO-
M,LUU]D4GS]BC!5@NXB@#['HK)T'7-)\3Z%IWB70;E;S3-6MH;NUG3.V6"=!)
M&ZYP<,K CZUK4 <'K?\ R/WA?_KAJ/\ Z##7>5P>M_\ (_>%_P#KAJ/_ *##
M7>4 %%%% !1110 4444 %%%% !1110 4456O;VSTVSGU#4)X[6UMD:2665@D
M<:(,LS,V % Y))P!0D!9K\^_VJOVX_#OP?6[\#_#EH=<\9@&.63.^TTYNA\T
MCB28=HP<*?OGC:WS5^U;^W[=:W]L^'GP(NGM=/.Z*[UQ,I-/V9+3H43UE^\W
M\&T?,W#_ +*O[">N?$U[3X@_%^.;2O"TA$T%D28[O40>0S'[T4+?WOON/NX!
M#U]EE^14Z%/ZUF&BZ1ZO^NWWGS6,S:=6?U?!ZOJ^B_KO]QXY\&/V?_C!^UYX
MVN_%FN7TXTR6?=J>NWH+Y;C,4"G DD P BX1!@$J-H/[Q_"3X.> O@GX5B\)
M> M/%I ,-/.^&N+J4#!DGDP"S>@X51PH XKN]!T'1?"^CVGA_P .V,.FZ;81
MB*"W@01Q1H.@51P/ZGD\UK5Y6<9]4Q3Y5[L%LO\ /^M#ORW*88=<SUD]V%%%
M%>$>L%%%% !1110 4444 %%%% !1110 4444 %%9NK:SH^@6,FJ:[?0:=9P\
MO/<RK#$O^\[D*/Q-?(_Q _;M_9_\$>9;:=JDWBF]3(\K2XO,CSVS/(4B(]T9
MOI0!]E5SGC"TN-0\*ZM8VNL-X?FN+66--139NM&92!*/,^7Y3SSCZ@\C\>/B
M!_P4A^)VM^9:_#[1;/PS V0LTW^G70]""X2(?0QM]:^?6T+]JC]HP/JL]MKW
MBNT :57EWI9#:,GR@^R -Z+'R>PS0!C:%XY\>?LU_&*]U3PYKUKK%[8SM'<S
MVMR+NRU*%FW,)'1CN#]3DAT;GAA7*?%3XQ^./B]XXE\>>*+YEO58?9(X69([
M*-&W)' ,Y4*><_>+?,22<T?"OX.>./B]XXB\!^%[%EO58_:Y)E9([*-&VO).
M<94*>,?>+?* 2<5T?B;X>^-OV=_BY::'XKT"VUFYM)T>WM[FW^U66J0,VU=B
M,/G63I@?,K<<,* .ND_:)_:L^*<<'AC2?$.LZDT<:1"'283'.X VYD:T197+
M=RQ.>:ZGPI^P[^TEX^N/[1UK3H]$6Y.YKC6+D"1L]2T:>;-G_>45^XW@&&VC
M\(:5-;^'4\*-<V\4LFF(D2?99'4%HR(0$RIXX ]P#P.PH _+[P3_ ,$S_"]I
MY=Q\0O%MUJ+<%H-.B2V0'T,LOFLP^BH:^OO!/[*WP \ ^7)HG@VRGN8\$3WR
MF]EW#^(&X+A3_N 5]!T4 ,BBB@C6&%!'&@"JJC  '0 #H*?110 4444 %%%%
M !1110 44R22.*-I96"(@+,S'  '))/H*_/3_ALG5O\ A9OD_9K?_A#/M7D9
MV-]H^S[MOVC=G[W\>W;C'R]?FH _0ZBF1R1RQK+$P=' 964Y!!Y!!]#3Z "B
MBB@ HHJ*6>" ;II%C'^T0/YT 2T5BS>)/#MM_P ?&JVL6/[\\:_S-9,WQ#\
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MC.U0223Q]3@GP[T?X(?&K1;+QC8>'U:?2KAU5+EW:>TGV\[2'.-RD$$'GZC
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MI?\ A!_BPW6ROOQE/_Q5 'F4/[$WQ,;_ (^-8TB/_=DN&_G *UH?V'_%[?\
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MBIH/V<]8;_CYUB"/_<C9_P"96MB#]G"W'_'SKS/[);A?U,AH YMM8_9VLO\
MCT\-2MCIY497^<JU\"?'S]G+X?>/_%J^*/A4TGAA+L$WMI<)YD)D_P">L.V0
ME2W\2GC/(QR#^G$'[._A=<?:=1O)/]PQI_-&K9@^ O@*'_6"ZG_WYL?^@JM=
MN!S"MAI\]&5F<N+P=.O'DJJZ/AWX(?;/AEX2/A7QH(_&"V[ 64S--:R018P8
MF*R.)%'&SA2HR,D;0OJD_CS2&_X]O#%K'_OSW+_RD6O-/VQO@]\5?!&BM\1O
M@IJDYT.QBSJ6F+%%--;JHYN8G9&D:/'^L4DE/O#Y<[/(/V,_VG_">K:M%\,_
MC?:V<]W?28TW5[B) &D<\6]QP%&3_JWQU^5NQKTY917Q%&6,BU+NEO\ =9(X
M5F-*C46&DFNS>WWW9])3^,6E_P!7I-G#_N&X/_H4S5CRZY?SMB,+'GLBY_\
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M_A67@?\ Z!O_ )&F_P#BZLV7P^\(:==Q7UG8>7/ P=&\V4X8=#@N1^==G10
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M#O$7CAYM'MM12WNW_>FWDY6- /O9SU/?%>P?\,S_ !E_Z #_ /?:U]%_LS?
MSXA^"_'S^*?$]M_9UG!;2Q;2P+2O+@ 8'8=<^H% %72?V);KY6UG7(QZB+<P
M_(JO\Z]-TG]COP%98-]=R71'7$>,_P#?;2#]*^O** /$-*_9Z^&6D@".RDE
M_O/L_P#102NVL_AIX"L,>1H=LV/^>J^;_P"C-U=S10!1M-,TW3QML+2*V'I%
M&J?^@@5>HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** (;FVM[RWEL[R))X)T:.2.10R.C##*RG@@C@@]:_";]LW]CV\^#V
MHR_%#X902/X.N)0\T,>3)I4S-QSU\@M]QOX#A6_A+?N_52_L++5+*XTW4K>.
MZM+N-HIH95#QR1N-K*RG(*D'!!X(KULHS>IA*O/'5/==SS\RRZ&)ARRWZ/L?
MF]^Q1^V7'\1[>T^$_P 4KP)XK@41V%]*<#4D4<(Y/_+PH[_\M!S]_.[]+*_
MO]L']D?5?@3K9^)'PX69_!MQ.KJ8V8S:3<%LHC./F\LM_JI,Y!PC'=M9_N#]
MBW]L:W^+5E;_  S^)%TL/C2TCVVURY"KJD2#KZ"X4#+K_&/F7^(#V<YRBG4I
M_7L%K![KM_77MZ'F99F,X3^JXKXEL^_]?UJ?HI1117R!]&%%%% !1110 444
M4 %%%% !1110 4444 %%%% 'DGQF_P"17MO^OQ/_ $7)7S-7TS\9O^17MO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO0X,KS*:E]6Q.DUL^_\ 7XGW+1117R9]"%%%% !1110 4444 %%%% !1110
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MB9,L>&(^\?TK^$/P3UGX)>#;;P5X&N]'AM8COFGDT^=KBZF(PTLSB[&YC[
M# 4  "OHVBO5QV=XG$4XTZLKI?CZG!A,KHT9N=..K_K0X/['\3_^@MH__@NN
M/_DRC['\3_\ H+:/_P""ZX_^3*[RBO)/0.#^Q_$__H+:/_X+KC_Y,H^Q_$__
M *"VC_\ @NN/_DRN\HH X/['\3_^@MH__@NN/_DRJ5]/\2](CBOII].U2(3V
MZ26]M8W$<S1RRI&[*QN9 -BL7)*$8!SQS7I-% !1110 4444 %%%% 'DGQF_
MY%>V_P"OQ/\ T7)7S-7TS\9O^17MO^OQ/_1<E?,U '__T/W ^&7_ "(^F_\
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M25K":]6UBMWU#S_.%Z\;"0$1[-YV[,5[1=^/?CM\8_BQX\\$_!_7]-\#Z/\
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M3>"?$'A3P=XZUO4_#T_@W1O&7B_5-;T+0KF+[/-I^EW"Q)$)+;_EV>5HVE:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)/C-_R*]M_U^)_
MZ+DKYFKZ9^,W_(KVW_7XG_HN2OF:@#__TOW ^&7_ "(^F_\ ;;_T<]=Y7!_#
M+_D1]-_[;?\ HYZ[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^R;^V5\"K#X.ZEJMGH/Q2_M[3]?TV]U*ZU""Z>RM4FAN/]*DD82^8^2P8?=
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MQV76GW.C3VCCAHY_[3MDW*>H.QW&1V)H ]G^/_[46E_!;Q#X<^'/AWPOJ/Q
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M(_!?ACQ88F\06"W309"-N=& /4;D*G'L3BNHHH \O_X4Q\-?^@/_ .3%Q_\
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M[:_B;]I"XO+!O#6L^$8- AMUDE-\MU%<PS%W0Q"(1;8R 1*6SCY<<U]=444
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MBF62QTG3%E\Z0>;, TD\LG+$#"@L Q#!4^WZ* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)
M/C-_R*]M_P!?B?\ HN2OF:OIGXS?\BO;?]?B?^BY*^9J /_7_<#X9?\ (CZ;
M_P!MO_1SUWE<'\,O^1'TW_MM_P"CGKO* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***Q[/Q#H&HZC<Z1I^IVMS?V?^OMXID>:+G'SHI++SZ@
M4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >2?&;_D5[;_K\3_T7)7S-7TS\9O\ D5[;_K\3_P!%R5\S4 ?_T/W ^&7_
M "(^F_\ ;;_T<]=Y7!_#+_D1]-_[;?\ HYZ[R@ HHHH **** "BBB@ HHHH
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M)_9B^$M]^T1X<^.7B7QIXG\)1P7^LZ3K303:%J5N'5;J."T6-3:@*S,K*[,
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M ?P \&?"RTUB?PI]JO-1U*U>W\V[D1G"$9V+L2-0&8 G([#FO*/V%?@[XO\
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MPQ(%5@K<Y7&&#DKP'A'1_P!L']G_ /:!^.7B[P/\!_\ A86@_$?6X+ZSN_\
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MK)F-I4E0'*CJC<=J[;P_HMKX;T#3?#MB[R6VEVT-K$TA!=D@01J6( !8@<X
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MR"-G_P"NNN_X6;X'_P"@E_Y!F_\ B*^:?%7_ ",^L?\ 7Y<?^C&K!H ^M/\
MA9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*
M/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^
M(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@
M?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F
M^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+
MHH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)
M?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^
M@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^
MM/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09
MO_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y
M!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\
MA9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*
M/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^
M(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@
M?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F
M^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+
MHH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)
M?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^
M@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^
MM/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09
MO_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y
M!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\
MA9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*
M/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^
M(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@
M?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F
M^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+
MHH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)
M?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^
M@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^
MM/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09
MO_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y
M!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\
MA9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*
M/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^
M(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@
M?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F
M^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+
MHH ^M/\ A9O@?_H)?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ^M/\ A9O@?_H)
M?^09O_B*/^%F^!_^@E_Y!F_^(KY+HH ]S^(WBK1/%>E66C>'))=0O9+H,L45
MO,6VI%(2?N8  ]:\G_X13Q1_T![S_P !Y/\ "NA^&7_([Z;_ -MO_1+U]:4
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pipeline21027.jpg
<TEXT>
begin 644 pipeline21027.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 X4&AO=&]S:&]P(#,N,  X0DE-! 0
M       X0DE-!"4      !#4'8S9CP"R!.F "9CL^$)^_^('N$E#0U]04D]&
M24Q%  $!   'J&%P<&P"(   ;6YT<E)'0B!865H@!]D  @ 9  L &@ +86-S
M<$%04$P     87!P;                        /;6  $     TRUA<'!L
M
M   +9&5S8P   0@   !O9'-C;0   7@   5L8W!R=   !N0    X=W1P=
M!QP    4<EA96@  !S     49UA96@  !T0    48EA96@  !U@    4<E12
M0P  !VP    .8VAA9   !WP    L8E120P  !VP    .9U120P  !VP    .
M9&5S8P         41V5N97)I8R!21T(@4')O9FEL90              %$=E
M;F5R:6,@4D="(%!R;V9I;&4
M                             &UL=6,         '@    QS:U-+
M*    7AH<DA2    *    :!C8453    )    <AP=$)2    )@   >QU:U5!
M    *@   A)F<D95    *    CQZ:%17    %@   F1I=$E4    *    GIN
M8DY/    )@   J)K;TM2    %@   LAC<T-:    (@   MYH94E,    '@
M P!D941%    +    QYH=4A5    *    TIS=E-%    )@   J)Z:$-.
M%@   W)J84I0    &@   XAR;U)/    )    Z)E;$=2    (@   \9P=%!/
M    )@   ^AN;$Y,    *   ! YE<T53    )@   ^AT:%1(    )   !#9T
M<E12    (@  !%IF:49)    *   !'QP;%!,    +   !*1R=5)5    (@
M!-!A<D5'    )@  !/)E;E53    )@  !1AD841+    +@  !3X 5@%A &4
M;P!B &4 8P!N /T ( !2 $< 0@ @ '  <@!O &8 :0!L $< 90!N &4 <@!I
M 0T :P!I "  4@!' $( ( !P '( ;P!F &D ; !0 &4 <@!F &D ;  @ %(
M1P!" "  9P!E &X Z !R &D 8P!0 &4 <@!F &D ;  @ %( 1P!" "  1P!E
M &X Z0!R &D 8P!O!!<$, 0S!# $.P1,!#T$. 0Y " $/P1 !#X$1 0P!#D$
M.P @ %( 1P!" %  <@!O &8 :0!L "  9P#I &X Z0!R &D <0!U &4 ( !2
M %8 0I :=2@ ( !2 $< 0@ @@G)?:6//C_  4 !R &\ 9@!I &P ;P @ %(
M1P!" "  9P!E &X 90!R &D 8P!O $< 90!N &4 <@!I ', :P @ %( 1P!"
M "T < !R &\ 9@!I &S'?+P8 "  4@!' $( (-4$N%S3#,=\ $\ 8@!E &,
M;@#] "  4@!' $( ( !P '( ;P!F &D ; 7D!>@%U07D!=D%W  @ %( 1P!"
M " %VP7<!=P%V0!! &P ; !G &4 ;0!E &D ;@!E ', ( !2 $< 0@ M %
M<@!O &8 :0!L ,$ ; !T &$ ; #A &X ;P!S "  4@!' $( ( !P '( ;P!F
M &D ;&9ND!H ( !2 $< 0@ @8\^/\&6'3O9. ((L "  4@!' $( (##7,.TP
MU3"A,*0PZP!0 '( ;P!F &D ;  @ %( 1P!" "  9P!E &X 90!R &D 8P.3
M [4#O0.Y [H#S  @ \ #P0._ \8#KP.[ "  4@!' $( 4 !E '( 9@!I &P
M( !2 $< 0@ @ &< 90!N .D <@!I &, ;P!! &P 9P!E &T 90!E &X ( !2
M $< 0@ M '  <@!O &8 :0!E &P.0@X;#B,.1 X?#B4.3  @ %( 1P!" " .
M%PXQ#D@.)PY$#AL 1P!E &X 90!L "  4@!' $( ( !0 '( ;P!F &D ; !I
M %D ; !E &D ;@!E &X ( !2 $< 0@ M '  <@!O &8 :0!I &P :0!5 &X
M:0!W &4 <@!S &$ ; !N 'D ( !P '( ;P!F &D ;  @ %( 1P!"!!X$,01)
M!#@$.0 @!#\$0 0^!$0$. 0[!$P ( !2 $< 0@9%!D0&00 @!BH&.08Q!DH&
M00 @ %( 1P!" " &)P9$!CD&)P9% $< 90!N &4 <@!I &, ( !2 $< 0@ @
M %  <@!O &8 :0!L &4 1P!E &X 90!R &4 ;  @ %( 1P!" "T 8@!E ',
M:P!R &D =@!E &P <P!E=&5X=     !#;W!Y<FEG:'0@,C P-R!!<'!L92!)
M;F,N+"!A;&P@<FEG:'1S(')E<V5R=F5D+@!865H@        \U(  0    $6
MSUA96B        !T30  />X   /06%E:(        %IU  "L<P  %S1865H@
M        *!H  !6?  "X-F-U<G8          0'-  !S9C,R       !#$(
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M"_CO_P \-)_\!F_^+KX3HH_U?P7_ #Z7W!_:V)_Y^,^[/^'A?QW_ .>&D_\
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M]>F[6OW7"EB,3)-^V>GW]/\ AC*_X>%_'?./(TGG_IW;_P"+I/\ AX7\=_\
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M$&,>]3\%_D"RG#?R?F?G8?\ @G9X2[^.-0_\ X?_ (ND_P"'=?A'_H=]0_\
M .'_ .+K]%**?^L6-_Y^?@O\A?V1AOY/S/SK_P"'=?A+MXXU ?\ ;G#_ /%T
M?\.Z_"/_ $.^H?\ @'#_ /%U^BE%'^L6-_Y^?@O\@_LC#?R?F?G7_P .Z_"7
M_0[ZA_X!P_\ Q= _X)U^$1T\;ZA_X!P__%U^BE%'^L6-_P"?GX+_ "#^R,-_
M)^9^=?\ P[K\(_\ 0[W_ /X!P_\ Q='_  [L\)?]#QJ'_@'#_P#%U^BE%'^L
M6-_Y^?@O\@_LC#?R?F?G7_P[K\(_]#OJ'_@'#_\ %T#_ ()U^$1T\;WX_P"W
M.'_XNOT4HH_UBQO_ #\_!?Y!_9&&_D_,_.S_ (=V>$O^AXU#_P  X?\ XNC_
M (=V>$O^AXU#_P  X?\ XNOT3HH_UBQO_/S\%_D']D8;^3\S\[/^'=GA+_H>
M-0_\ X?_ (NC_AW9X2_Z'C4/_ .'_P"+K]$Z*/\ 6+&_\_/P7^0_[(PW\GYG
MYV?\.[/"7_0\:A_X!P__ !='_#NSPE_T/&H?^ </_P 77Z)T4?ZQ8W_GY^"_
MR#^R,-_)^9^=G_#NSPE_T/&H?^ </_Q='_#NSPE_T/&H?^ </_Q=?HG11_K%
MC?\ GY^"_P @_LC#?R?F?G['_P $_?"L>CW.DCQI?E;B:&8O]DAR#"KJ!C?W
MW_I6=_P[L\)?]#QJ'_@'#_\ %U^B=%)<08S_ )^?@O\ ('E.&_D_,_.S_AW9
MX2_Z'C4/_ .'_P"+I/\ AW7X2_Z'C4/_  #A_P#BZ_12BG_K%C?^?GX+_(7]
MD8;^3\S\Z_\ AW5X1Z?\)O?_ /@'#_\ %T?\.[/"7_0\:A_X!P__ !=?HI11
M_K%C?^?GX+_(/[(PW\GYGYZ6O_!//PG:W4%V/&VH,8)$D ^QP\[&!Q]_VIU[
M_P $]?"=Y>7%XWC:_0W$KRE1:0G!=BV/O]LU^A-%+_6#&7O[3\%_D/\ LG#6
MMR?F?G7_ ,.Z_"7_ $.^H?\ @'#_ /%T?\.Z_"6<_P#"<:A_X!P__%U^BE%/
M_6+&_P#/S\%_D+^R,-_)^9^=?_#NOPC_ -#OJ''_ $YP_P#Q='_#NOPCU_X3
M?4/_  #A_P#BZ_12BC_6+&_\_/P7^0?V1AOY/S/SK'_!.OPB.GC?4!_VYP__
M !=::_\ !/WPJND3:1_PFE^5FN(K@O\ 9(<@Q(Z!<;N^_/X5^@-%)\08Q[U/
MP7^0UE.&_D_,_.T_\$[/"9Z^.-0_\ X?_BZ;_P .Z_"7_0\:A_X!P_\ Q=?H
MI13_ -8L;_S\_!?Y"_LC#?R?F?G7_P .Z_"/_0[ZA_X!P_\ Q='_  [K\(\_
M\5O?\_\ 3G#_ /%U^BE%'^L6-_Y^?@O\@_LC#?R?F?G7_P .Z_".,?\ ";ZA
M_P" </\ \72C_@G9X2Z?\)QJ'_@'#_\ %U^B=%'^L6-_Y^?@O\A_V1AOY/S/
MS_'_  3]\*C13HO_  FE_M-R+G?]DASD1^7MQNZ=\UEG_@G7X2/!\<:A_P"
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MA* "BBB@ H[T4=Z /$?%/QOTKPW\0U^&T.CW.HZD+>TN9)$N;&VC1+R62*/
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MYQ_L75_^?&?_ +]-7W_#TH+#*[ZL^8S52]L[$']I:E_S]S?]_&_QH_M+4O\
MG[F_[^-_C4_]BZO_ ,^,_P#WZ:C^Q=7_ .?&?_OTU>Y[2GW1YUI^9!_:6I?\
M_<W_ '\;_&C^TM2_Y^YO^_C?XU/_ &+J_P#SXS_]^FH_L75_^?&?_OTU'M*?
M=!:?F0?VEJ7_ #]S?]_&_P :/[2U'_G[F_[^-_C4W]BZO_SXS_\ ?IJ/[%UC
M_GQG_P"_;?X4<]/N@M/S(?[2U+_G[F_[^-_C1_:6I?\ /W-_W\;_ !J?^Q=7
M_P"?&?\ []-1_8NK_P#/C/\ ]^FH]I3[H+3\R#^TM2_Y^YO^_C?XT?VEJ7_/
MW-_W\;_&I_[%U?\ Y\9_^_34?V+J_P#SXS_]^FH]I3[H+3\QBZG=M');W4TL
M]M.NR6,RN-R]B&!RK \AAT/XUXUXIT_Q!X=N$EAU.ZN=.N2?(G\UP<CDQR -
M\LBCJ.A'(X->OWEI<:7:2ZAJEO/#;P@$[86>5R>B1IU=V/ '3N2 ":\3U>#Q
M[XGO?MM]H]Y:VD>1:V:PR%(4/=CM^>1OXW/T&  *[\LJ+VONM6Z_UW_3?H<>
M/@^35._3^NW]=S"_MG6?^@C<_P#?^3_&C^V=9_Z"-S_W_D_QJY_PBWB?_H#W
MG_?B3_"C_A%O$_\ T![S_OQ)_A7TGM:7=?@>+[.IV93_ +9UG_H(W/\ W_D_
MQH_MG6?^@C<_]_Y/\:N?\(MXG_Z ]Y_WXD_PH_X1;Q/_ - >\_[\2?X4>UI=
MU^ >SJ=F4_[9UG_H(W/_ '_D_P :](^&7Q>\1?#W6OM4LTNHZ;<86YMI)"V0
M/XXRQ.UQV['H?6N"_P"$6\3_ /0'O/\ OQ)_A7:^"/A=K?B75$CU.UGL[-&
M8,A268G^",,/^^GZ*/? KAS*KA/82^L6Y;:_UW['3@X8CVL?9)\Q^F?AWQ%H
M_BK1[?7="N5NK.Y&4=>H(X*L.H8'@@]#6W7(>"O#$7A71HM-B"QJH&(XQB.,
M?W5'\R>2>3S77U^!UN3G?L]NE]['ZE3YN5<VX4445F6%%%% !1110 "B@44
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MT3LZ*XS^UK__ )Z?H*/[6O\ _GI^@H^JR#VT3LZ*XS^UK_\ YZ?H*/[6O_\
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M:C^P[3^\_P"?_P!:N#ZS Z/8R.4HKJ_[#M/[S_G_ /6H_L.T_O/^?_UJ/K,
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MC'VJ*VC:WT_?;O#(FUE+ML\^,AN>5;C'/TK;?#7X=6<#6MGX6TJ"%T$;(EC
MJE RN%("8(#(K8]5!Z@5VM 'SM\8/C3XL^&OCGP+X5T#P%J?BJT\57DEO<W=
MGY.RW58)I=H\R5/G!C#-N 7R\X8OA3\__M!?M*_%?X;>-?B%X<\):0;^PT'2
M?#=W!>A;8PZ=+J=]-!,]TLLJ22+(B ((U;:02:_0@@$@D9QTK'O/#GA[47NI
M-0TNUN6ODCCN#+ CF9(6+1K(6!W!&)*@Y )R* /A.?\ ;HN9]9\2:)H/@*:]
MFTS68M%L#+>K;K<W$FJ#2CYY>']Q^]/F(!YFZ,')#?+3M;_;EET.PUF^NO"-
MLQM-1_LBS@76(VNVO([X:?,UY:K"TUM;B7+)+M?>NWY0S@5]N+X*\&I?76J+
MH-@+R^EBGN)Q:Q>;-- =T4DC[<LZ'E6))4\BH+GP!X$O)=4N+OPYIL\NMJJW
M[O9PLUVJ8VB<E<R 8&-^<4 ?%EK^W#<ZGJVF:99>"EMSJ-OI)V7.I1K=I<ZU
M#.]NJ6JQEY88Y(")9588C82 '! X_P %?MI?$'4M/T"2^\.6>LZYXET[1Y8[
M*WO4M[*">\L+^^E;[08Y'(V6>TH5)1C@$X-?=&E?"'X<:-XPN_'EAH-JFMW<
M5M )S$K&"*TB:&)+<$8A7RV*D1X##K6_9>!/!&F^7_9WA[3K7R3N3RK2%-IP
MXRNU1@XD<<=F;U.0#YS^#_CSXP?$GQ5I?CR:U-KX!\2:7:ZA:0L(BL,5S;B5
M5,@^9I0[!3CT8D!=M?6U5K*RL]-M(=/TZ".UM;=%CBBB4)'&BC"JJJ   .
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MJ;;/DO-&:^M_^&,_BA_T$=+_ #NO_C%'_#&?Q0_Z".E_G=?_ !BO6_UBP/\
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MNXC.#P<=*Q_^%X_!'_H=]#_\#H/_ (JOB3QAX.\.>/O#TWACQ3 9;20[XI4
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M")?/!/\ >82_O S9(?+ [B35Z]^$'POU&33I+[PQ8SMI%N;2UW0J1%;D,/+
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M  (3_&C^Q+@#)N+4#_KX3_&ONG^R]-_Y]8O^^!2?V7IG_/I%_P!\"C_6BO\
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M?P;91WDULUUYDBIM5@I&X$YR?I7F_P#POG3_ /H$3?\ ?U?\*L?'#_D#6_\
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M(/LMM_SR7\A1]EMO^>2_D*GHHYF%B#[+;?\ /)?R%'V6V_YY+^0J>BCF86.
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M;E0L@MKYV^T0 @#'ENN#S7'V?[)'P4L[[1]5&GWDU_I%Q)=-<2W]Q)+?7#W
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M5QX/_P"@>OYG_&E_K7/^1?>']BQ_F/#/ ?@2[O+Q)YD*R)@NY&5@'H.QE/\
MXY_O=/JB*,0QK$I)" #)Y/%065A::=;):640BB3@*!Q5O KY[&XV=>?/-_\
M /4P^'C3CRQ"BC HP*Y#<**,"C H *.]&!1@4 %%&!1@4 %%&!1@4 % Z48%
M&!0 448%&!0 448%&!0 448%&!0 448%&!0 4444 ?_0_?RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#C?%WA9_$T$<"S)$$.2'C64''3A@1FN _X5#)_P _=O\
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H%KJRV4GFP"YB67RWZ$KN!QGOZ]ZZ0  8' %+10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>rxipc0211916001.jpg
<TEXT>
begin 644 rxipc0211916001.jpg
M_]C_X  02D9)1@ ! 0( E "4  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,?!20# 1$  A$! Q$!_\0
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M$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(HZXVCY^=9.[PPO'''/U/\
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MY:Q&CVUE6IV]T=[JKVAL''AEP\__ 'C#1T$D]%BW0+33Z]&UO'"H^O48&;3
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M22BI!2T HXXTD9&D9AS<NQ,:?4*,' R<ZT[G4J#K8VEG1--KG!SI=N)(! C
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M/CTHI'WY?34OM3;X=2VI@.#VT<]C39!'WD@_)34M79X56TI .;49;R9X-.F
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M*'&LOV3?$3X1_4?W'WK+WRW_ )T])U@V;%-!"VX:3O30R5"1 DN8XQEV*@9
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MR6U8 M]J*=V:.22-3-'-,X*#B&=IW]3%54AFSG\J#QC6K<O]T:[<<<0.>T#
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MEZ_KNMZKWU8:Y9ZJDJJJXQ4%,*FEK;A2BNK9I519>VC-B)8XXXXR.:L5[^<
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M^WJXDY^NKU,(O.O46WW&3HS=>E,PJ!8^F]#/O>"1OZMXKBEM^20?JCUM6?\
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MDEU!QRR?T\ZJDHY$^R-_/QIA5 $GG(5?XG.F%$<)#^\H_3CG_CI(1'!_J_\
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M0,=8P28!!V&"),%<;!YO-P.5:]R5\FX;XU?3!9%=CVX*3'"*(+Q11&%])')
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MB6@A-)(S/S9FBX\"2WJ)(.3Y]_.I ZJ94S3QK2T\4$<<=+#$@CCCB3"(H&
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MR*T2"(*L-HVY9]P7JQUMGEG_  BY(*R6MJI"R(D8E66G#K&Q<P@RAGD8<E8
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MGC]3C456<2'ZH!_ G3")BMK8+?2S5-75Q4U- C2RS2LJ)&BC+,S'P  "23[
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M(PLNY+#6M755!60%9):A3Z7IW5N4D06*!V107*,Q4$@#7L-2K^_L_:+A%*J
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M:62;YN0PIR#.[MDIZ5PIP/; \ZX=; B@Z"V6GR$ ;1N,0 !\63D2>9*X?:(
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MD3GRSCJ0WI@'JM7:73:GMEVI;G3[@JKM;H9*BKIHY3'(3/.,2R-*H]8/J(4
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M5):0?,TS*QXQJJF-L8/A6?CYR/<.N*EO>-OZS\58#V-D1CRND9))![9Q/?2
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MPM.ZP5U0NY8E22A5*@Q1"EYO_5@X;P$)))',X]]?=-2JT[C5P\$M'A'F1G?
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M=KK9;9N';E0*2Z0L:>H*4ZO)-&!R4+(P;BPR^%"Y89&? !Q*+Q/!LF>LG#W
M33%5QW)'9V(^W)LX ^VL$78&^%V[]8-H6S;VVI*:E_!ZNEFJ*VN9HHT#QR&9
M?2I+L&<848SQ!^VK"+OO23X(]O[ IN5ZO59?JLD96FS2P8'L",EC]?JH\^P/
MG60"+T#8-MVO:]%\G::&&@IN7(QP@^3]R3DG62*2T1&B(T1&B(T1&B(T1&B)
M+?GC'ZD_[-4*)6HJDM_6)]L'_AJ]%.J5J*K&,R9^R_\ '5Z*=5G4521_6/\
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MZ@^"#^OC0 @JK.&C_+EE_LGW'\-.5$!A)("/("^?YG_NTX"+/$Q_D\C^P?\
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MO[1UU=/474B"UHD=>OZ_V[+G=9[N2M.U=%TMD4T35C5\,LB2R1UQ6569""C
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M4B6".80R9E*JS<@<8A;S_#/WU])O++1+2ZN+1MFYYH-#G'Q")'EDQ'/F&/\
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M^/TU1ZHG$;D,>Q'N#]-8E5-R@QE HRK-Y4?3Z^-9!1.Y61?H0=8Y"J98F.1
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M0UEKV[;*.X7 W6N@IHXIZYE"FH<* TF![9/G^>OG=W4IUKBI4I,V-))#>PG
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M(452%;S&0K$RXR% &3DC.NXTNB+BX\$EP#A'D$]1S) V]YX7?:+0%W=>[DO
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M>"?7EL^#[:Z,U;2G48/#W-:3/F/F$X^4#MRO-FM8TJU,>#N:PNW>8^<3Y?E
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MQQE'7%H7/+:$ L 'F.'8E_K,'R\91)9[TT,ZK? DCW!:B-_E4/"F!!,&/KD
MCG[^?TT%:V!!-+&V#YCEV?-_MP@N+0.:30P&0?,<OSY_R\O&$5MGO4T5W6GO
M8IWJ9(VHW^55OE% 7DN/W^6&\GVY?II3K6S33+Z4[0=V3YCF#Z1CCF$I7%HU
MU$OH2&@[O,1N)F#_ )8QQS"77VF[U#W@TUY%*M3 D=$/EE;Y.0 \G\_GR2#@
M^V/UU*=:W:*6^E.TDNR1N&('I'<+&E7M6"CXE'=M)+O,1O&('^6,Y'=;%/;[
MA'=C/+<.[1?*I%\KV5'[8,2TO+W\C X^PQKB=4I&EL:R'23,].@CT[KA?5HF
MCL;3A^XG=)^&,-CT.956ZOW6';^TY[C/*L$=*#-W77F$9<<6*_O '!XCR?8$
M9UM:;0==7;*#!)=B%T5\_P .F']EYDNURNDE)6[JN<0J*BYR+26NLJ&CC$U&
MU-\M45KR*B\971B8U9@N<@' )/U%E"EN98TL"GE_.';MS6 2< _$0)C)[#SS
MGN$U7<NX^403_9:]JIIZ#H1U JY*..XW!JFU+-/54?!:[ML )'0DJ6X@!G1C
MDC. <YVW>&_7K6FUQ:T!\09VR. 8GG@$8^24O\-5)[M7I/X7*S\0Z&[9JB(U
M:9)9&6*,(H)E<D!1X&OG'M13\+6*[!T/] N^T[_#-^OYKJVO++M$:(C1$:(C
M1$:(N;]8MK2;E6U"/8MFWKV3+D7>M%/\MGC^3,;YY8\^V.(UZC0[P6IJ3=OH
M3'P-W3SSD1'3YKV?LY?MLC5W7U2VF/@;NW1//F;$=.>5HV^_=2K504U%1].+
M'34E/&L,,,>X\*B*,*H'R_@  #6Q5M]&K/=4J7KRXF232Y)Y^VMJM:>S]>HZ
MM5U&H7.)))HY)/)_B+JD99D4L K$>0#G!UY Q.%X,Q.$K441HB-$1HB-$1HB
M-$5$W)L2XW'<%%4T=ZKZ>CFGD:MB5X0%3M-P$>8R?ZSA]?;.O0VNHT:5!S*E
M)I< -I\W,B9APZ2O566JT*-L^G5HM+@!M,.YW"9AP'PSTYA6/9T-RI]IV:*\
M'-U2CB6K/I_K0@Y_E]/OGV\?;767SJ+KJJZW^ N.WGB<<YX[KIM2=;OO:SK7
M^&7';SQ..<\=\J8UHKKD:(L'1%YQZQT6U:[?-(EKO%.VY&K3#76:LOM;1)5M
M)%PB563DJ,KF-@J@!O(SYU]0T.I?4[)QKTSX.V6O%.F\MATN)!@D$2)),+[+
M[.5=2I:>\W%$^!MEE1M*D\M#72XD.@D$2)),+N&PK%6;8V38K3<*OYZOHJ*&
MGJ*GD6[LBJ S9;R<G/D^=> U&XIW=Y5N*3=K7.) [ G POF&K75*^OZ]U09M
M8]SB!C )P,8X[*?UURZE&B*B=9]S4^T-DRW:JM5OO4%//&6H:]PO=R<8BRC9
MD\Y QYP?;7H="M'WMX*#*CF$@^9O3_5D0WN9[+U7LU8OU&_%M3JNIEP/F:..
MOFRV&]S.,*:V'=*:\[6HZVDL=5MZ";DRV^LIEIY8_)\E%) S[_J#K1U&B^A<
MNIU*HJ$?:!+@?J>W"ZS5:%2VO'T:M<52/M-<7 X[GMPO-&Y.K5MZC]26?=MK
MOD>R[%/RM]HAM4TOXA4 D?,3X&.*X]*>??S]<_5+71JVEZ?%A48;BJ/,\O:-
MC?Y6^IZG[NB^V67L_<:-I4:95IFZK#SO-1HV-/V&9F3U=Z8Z1Z/Z?]1+;U'M
MM36VRGKZ>*";LLMPI&IW+<0V0&\D8(\Z^7ZEIE;2ZC:=<M)(GRN#AVZ+XSJ^
MCW&C56T;AS27"?*X.',<CY*TZZA=$C1%@* 20!D_7165G11&B(T1&B+!T10V
MV:BDJ#=?E:;Y;A7RI+ZN7<D&.3_IGQXUOW;:C?#WNF6B/0= O*:!7M*_OGNM
M+9MK5 [,[GB)=Z3C'136M!>K45NL!ML7<$J :.89;V_JV]];-M/O%./YA^:X
MJW\-WR*\%[$KJ>7I56UD-HI[; M^A[:1O(2Q%$P>0.X;B3^Z$91YQR^_WO4J
M;V:JVF^H7$TSV_G$"!$^L@_)>+9'@?4?DI7;CTMYK*ZT7 1U]'>J=J5VJ9Y%
MS(0#'W",OA9.#<^<G'!P%SD=5>TWTJ;:]+!IF< <=8Z9$B('U4HF2&G[2]K;
M44KMZA!QD)@X]O!.OBE0R\E>UIB&A3 'Z:XURHQ^FB(Q^FB*B]8^CMGZV[6I
M+#>ZFMI*2FN='=5>@=%<RTTPE1265AQ)4 ^,X]B/?1%1;U\&73N^=4M^;[EI
MZZ"X[WV[-MN]T=/*B4T\,O /,!PY+,1&@Y!L>G/')))%6;3\!6UZ6@NL%SWK
MO+<,U?LV78GS%RJJ9FIK8[HRK$%@55=.V &(.<DL&.,$5JKOA#VA7RWV22XW
MH&\;$CZ?3A9HL)0(& E7]GXF]9]1RO@>G1%5]P_ =MB\5-7-0[XWKM_Y[;M#
MM2OCM=;3HE9;J:+M=J0- ?+K^9Q@CSQXAF!(M^\? ]LZ:_FNV]?]S;)H:JCM
MU!<[5MZLCAAN$-"JI3!W:-I8R$549HG0LHP?<G1%U+8W2*T[ WEOO<M!4UL]
M=O"OAN%='4LABBDB@6!5B 4$+Q0$\BQR3YQXT17?'Z:(C'Z:(C'Z:(C'Z:(H
M6_+_ )U;/_6Y_P#93KDI\E<;N0DSDEP5SX'K(^W_ #URA9)Y  HX^WTQJ*IE
M1F0Q_P#1^X_7]/Y:R]5$Y,,)S]BOD:@56(EYCFWDM[#[#[:'")"9?]G]$_,?
MO]M7U46?S,8?IG)_U3IZIZ)D#N30^3Z25 _AY/\ PU>A46YC6"RE&-$60I.H
M2B<[!&"Y"#_2_P"6I/91&8D]@7_CX&F55@SM],(/]$8TA1(.6.3YUDJD3)SB
M=2#@@C5&"BUXXG[ ?^TY0D^!Y/\ X_QU20L4_-$(FQW .X>/CS@_?6 *J6XA
M@/,<BH&&^GC[Z9*)(XNA;@ S'D"23Q^VKD(@U!<< B*Q\-@>PTV]42A.T!RN
M%C)\@#\ITB46))GJ&XEFXJ<^_P!?^[3: D+*5,N2K.W(#WS[C[Z;0B0SR2OW
M58Y7PIS[_?2 ,(G4JG<9YMX]P3[:FT(F1-*)#,"V/MGW_7^.KM'"+8%4[ $.
M2/IJ;46LDK)(9,*8SX&5'C[G^>LB.B+:$H*^8T_PUA")M'C=^?;.!X7#?XG5
M@HG/V1'[R_X'4RJFEC25RPD&%\#D,9^YUE)")WY=C[8;^!&L942&A=?)4_X:
MLA%A693]M6 BT[]::7=%AN5FN<7S5MN--+1U4+,1W(I$*.N0<C*L1D'.L2$7
M#;=\#_36TV^EH*&LWQ1T5+$L,%/3[VND<<4:C"HJB8!0    ,#6.TJJS;8^%
MCIYM#I]N[9]JIKK3VW=LKS7JHDNU1+6UC.H5BU2SF094<3@^0S9_,=6$71MG
M[*MW3_:EIVUM^C6VV6U4L=)24D+$".)!A1Y\D_4D^222?)TPBJ&U_A_V=LJO
MW[4V:UU%%_3:9ZF]P)4R&&65T='D1,XB9@[9*XSX^PT "2N=V7X$>F.W+53V
MZTS[WMEMIEXPTM%O.Y10Q#).%190J^23X'N3I"*];L^'K:N].B53TKNIN]3M
M>>%8S+-<I9JY>,PF1_F).3,RR $%L^ !C'C5C$)*Y6?_ "?^UR,_Y3^KPS]?
MZ9R_^H]8[?5)7<KMTJL-[Z75'3VXP5E7MJJMAM$T=15RO42TY7B>4[$NS$>[
MDDY.LH$)*F+3M6VV3:M%MRGI%:RT=$EMCI:@=U3 D8C$;\L\QP !SG/G/OJP
M(A)51Z<] =E=(MJ;BVWLZTR;<L]]JZBNJJ:CJ9%[<LT:QN8223$.*CB%\+CQ
MC4 PJIKI5TMV[T:V-;-G[-MIM-@MX804R2,YRS%G9G8Y9BS$DDZ0 HM2Q=$M
MJ[9ZI;AZA6VDDM^YMPTT5-=9(JI^S6"( 1N\.>/<4#'/&?)^YU.#*BO'[)/J
MS?RP-7*([H7\L:C]3YTCNBP9Y",<B/T&K 1-^H_KJX1+$$C#(4ZDA5*^7(_,
MRK_$ZFY1-F..)PQ?*MX.!['Z:LDHG,Q#]US_ !(&IE$V\D<<@<1C!\-DY_@=
M6"42S*?HB ?ZND*K7:9F<2>!'[' QR^Q_EK*%%L-5. 27('U.=8[46N99.Z)
MV9@/;&?;['5@<)ZIUZEXQGDQ^@ /N=0-530>2*3NLYRWAO/M]M6 <*)QZF7/
M%78,1[Y\ ??4#0BQ'*].V YXL<^_[W_?J[0409VG.6PR#V!'N=(A%@5!0=MD
M1V'A01[C5CJBR>"1AN&74\B0<9^^L<HA1%.>9+!#X4>_C[ZN1A58@B$S8[BD
M1GCY\$G[_P#C[Z$PHF)(7-.7Q^5PBD'/L<:!V5BGX4X1(H]@H&J>5FEJY4^#
MQ/Z>-8PHG!.3^8!_];4A4(Q$_P!T/^(TR$*PT# 97UK]UTE1-X.LEDC&BDHQ
MHDK2\I45 \D-Q7_$>/\ CKDY 6*?_*XA^F<C_5&L?57T6'RA[8]G_*?M]]/5
M$N1>WAU'E?<?<?;419A]2<CY+>3_ ,M"JFF&).W[QGR?T_3^>KZJ)]P"IY>V
M/.=8JIB/(Y%_<KZ2?M_SUE\E%L;:'_H'2?ZI_P#9CKBJ?&5&\*4 \>VN)9+.
M/TT51C^.B(Q_'1$8_31$8_31$8_31$8_31$8_31$8_31$8_31$8_31$8_31$
M8_31%RGXE<KTKO'$4C.T?!5KHNY 69T50Z_4<B/X>^#KT7L\=NJ47$D0>A@_
M0KJM1_A+S3NBH@LUUIK30,EOALT*TI[$\C'O>\HB8E6XM(78N63D<9#8SKZG
M94W5Z3[BIYC4).0..D\B0($0?F%YJH8(:.BD7EI'Z%]0:I[>*T"NMDDM.C,'
MF02>,RJF2<9'DN 01RQ[:M-E3]N6C&/VF'Y/3'8G^WR6Q2/_ $U6.X7HWX86
MIY.B.VY*6%::"19G6%69@@,KGCDDDX_CKY[[4!XU>N*CMQ!&>^ N_P!._P ,
MWZKJFO++LT:(C1$:(C1$:(N8]:MI+NF.T@]/J;??8,OIJ+FM'\MD+[9!Y<L?
MRX_KKUF@WILS4B\-O,<,W;N?NC^J]O[,Z@; U8OS:SMX87[HGMQ'XRKWMJE%
M!MVUTWR"VKLTL4?R*2=Q:?"@=L/^\%]L_7&O.W3_ !+BH_?ODD[HB<\QTGF%
MY6]?XMU5J>)OEQ.Z(W2>8Z3S'12>M5:2-$1HB-$1HB-$1HBP?;1%P;>&XVH-
M^W1[5N.GVK% CI5RW*[#M-/E3WA3$2 J%R#GM9SG/UU]%LK45+&F*] UB8@-
M9G;GR[_*9G.-Z^KZ=9"KIU(7-N:Y<06AE,SMSY?$\IDG./$CMT7:[#4_.62W
MSFMAN1EIXW^=ITX1SY4'N*,G"M[@9/@^YUX*X;LK/9M+8)P>1G@\9'' 7S*[
M9X=Q49L+()&TY+<\$P)(X.!\EOZUUJHT18.B+A>^9]W/OI8+AW_PEKQ1_(Q5
M"40L[TP>(DR.Y$_S <.5"?O"/ ()U]"T]M@++?2C?L?N(\3Q=T.X \FR(F>D
MR087U/2FZ6-.WT(\3PZF\@U?&#X<(:&CP_#(@.+OLETD&%W0:^>KY8LZ(C1$
MW)!',8S(BN8VYH6 )4X(R/L<$C^>L@XMF#RLFN<V0TQ*7[:Q6*Y)8_B HZ*]
MKM_?=LJ-CWQY&C@:N/*BJP/9HJ@>GVQX8C!(&2=>TN/9NI4H^]Z74%>G&=OQ
MM]'-Y^[YKZ%=>R-6K;^_:-5%S2 !.WXV^CF<_=/>(76D974,IY*1D$'.=>,(
M(,%?/B"#!2M11&B(T1&B(T1&B(T1&B**L%15U'XC\U3"GX5DB18C*]R,8XO^
MN?/G6Y<MIMV;'3+1/H>H_P!EYS1:]W7]Z]ZI;-M5X;B-S!$.]9SGJI76FO1J
M(W='W=JWE, \J*8>?;^K;6U:F+BF1_,/S7#6_AN^17S^V=^%U/2"J%N$],L.
MXZ7MK6S1NZS"C<XB 4XRP.%*MS&<CZC]"ZC[PW5V>/!FD[@&(+QSG[R"(/"\
M9CP9/<?D5M4D4JT=VN5+4BOKZ&%:NFBIV,\4BJX;NR,/+QHR,0"6P>2$M&N%
MU*[A+*+QM:XD&<1B('0$X[2((\QSQ-&'.ZA>]-J>O;U"Q_>3/^).OSZ[#B%[
MFE\ 2MSW2LLECJ:V@M-1?*N+CPH*5T227+ '!<A1@$GR?IK9M*-.XK-IU:@I
MM/VC) QZ2?1=I8V]*ZN&T:]44FF9<02!CL 3GA4/;W6:LN6^*7;-VV;<]O5$
MU)+7--5U,$B10IX+OVV)52WI!.,G^!UZ*YT&G2LG7M"Y;4 <&P X$D]!($F,
MX7J[SV:HT=/=J%K>,JM#@R&M>"7'H-P$D#) Z+6_R^ T37Y=H7M]D*3G<0$7
M'M@X,X@Y=TP_7GQ_+YQC7-_Z;\_NIN6>\?\ T\\_R[HV[ND3SB5S?^DOWGN1
MNZ?O?_TO-,\[=\;-_3;/.)E3N[^J\.W;@E%;++<-SU"40NE4+6T1%/2$D+(2
M[J'+<6XHN6;B===9:,ZYI^)6JMI NV#=.7=L Q$B2<"0NKT[V??>4C6N*S:(
M+O#;OW>9_5N 8 D;G& )"1?.KM)3"TI8+17[MJ;C0?BR06PQJR4?C]J3(RCS
MR 5!ZF((QXUE;Z)4=XANJC:(8[9+I^//E\H/$9/ "RM?9VJ_Q3>U6T&TW^&2
M^3-3/E&T'B))X CNDW#K#0R4&WY-NVNMW367RE:OI:*A,<;BF4+SD<R,JI@N
MJX)R6. /?5I:'5#ZPNZ@I-I':2Z2-QF -H),P3/ &5:/LY6;4N&W]5M!M%P8
MYSI(W&8: T$F8)F(#<E8J>LE#4V7;U58+57[AK[[')+1VRG[<4RI%CO&0R,J
MIP8A#D_F( SJLT*JRM69=5&TVTB YQDB7?#&T$G<,C'&2JSV;K,KW%.]JMI,
MHD!SS)$N^':&@EVX9$#X<E$_6.@J-N6&OL]KKKQ<KW))#1V>/A%4=R+EWUD+
ML%C[95@Q)QG &<C4;H55MQ6I7%1K&4@"YYDMAT;8@$G=,B!Q\E&^S==EU7HW
M55M.G1 +GF2V'1L+=H)=OD%H XDF(1)UEM\NU[;<:&UW"NNMQK)+;3V-0D=5
M\W'S[L3\F")P[;EF+<<#()R,T:%6;<OHU:C6L8T/+\ENTQM(@2=TB!$S\BJ/
M9JNV[J4*U5K:=-H>:F2S8Z-KA D[I   F<8@K'^66@?:T-QBM5PEN\MQ:S+8
M0$%5\\N2T));@ %4N7Y<>'G/G3]A51<FBZHT4PW?OSMV'AW$Y.(B=V$_]-5A
M>&@ZJT4@SQ/$SL\,\.XW9)V[8G=B%E>LEO&U)[G+:Z^&ZPW 6=[$0AJOGB1Q
MA!#<#D,'#\N/$\LZAT*M[T*+:C2PMW[\[=G5W$XB(B9PA]FJ_OC;=M5IIEGB
M>)G9X8F7<;L$$%L3NQ"G-C;VCWE!7QR6^IL]UMM1\K7VVL*&2"3BKKZD)5E9
M65@RG!!UU^H:>ZQ<PAX>QXEKA,$21P0"""((/"ZO5-+=IKJ;FU!4IU!N8]LP
MX20<$ @@@@@B0K/Q_375+HT<?TT10FY"R3VTJ.3=\X'_ *:=9LZKC=R%F, (
M.)SGSG[ZY5DFV)1Q&IP&\Y_L_I_RUEZHG&C!0 >DCV_3452$?OMGV"'!'^EI
MPHAF[)( R&/I'Z_;_CIRBS@0<6^GLS'_ 'Z<J\) /!N\?9O!_A]/_'ZZOHIZ
MIN(,M1&I/G#-_CC_ +]4\(MU49C@#)^PUQRB7P6/\[>?[*^3I/958,W$80!!
M_M_QTCNB0<L?OJJ("EC@#)_34E$Y\OC\[!/XZ;BLEGG&G@*7/W;P-2"426F)
M&!A1_HC&K"*/I@9E16 \KS/GV)\:Y#A8!/1J:@'EGTCCG_2^IUC("O*6D;S_
M +,KC']9GQ_+^>D@91+$:P\E>10!Y'G/C[:Q)1)[2Q?M2S%C^8 ?3[?RU09P
MB4\D?$*BLS,/&3XQ]SJ041 \<'[+MY _*2QR1^NA!*BQ.XE(1$56'GEY\?\
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M4<:38M//[P_0N 'X@KR&K>70]-:[G]\?^TO 'XARZ9KRJ\2C1%![A.*FU_\
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MB2'PY)/V'C_;ID\*H%24&$ 4?IYTVHL&<2'UJ&/W!P=((1*%,)1F,G'V8?\
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MS&5CU68U[<0B!]0)7/Z??29,HA6[2<%&2#Q4'[?0ZISE59"B!@2?2WYB?O\
M?3E5*$8ERS^Q& #]!IPHDAV;,><2#P3]OUT]42GCXH./AE\C/_CZZ2JD@]]"
MX_J\$J#]3I$846UMIE2PT98@#!&3X\\B-<3QYB JP$B I-ID7EEU''\V2/'\
M=8[2>BS#7&('*'EC3F6=5X#DV3[#[G_ Z $Q Y0-)B!RFUK:=S %GB)G7E$
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MNY+.QP/+$GP/MK6O+VXOZOC7#I,1P  !P !  ] %IW^HW6J5O'NW[G0 ,
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M(/3^3] ,:H 1(XLY^I.KA1*%.WCEA!_I'4E(6>W&ON_+_5&@)56.Y&/://\
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M$1RT1'+1$<M$1RT1'+1$<M$1RT1'+1%#WX_YU:__ %N?_9#KDI]5QNY"Q&C
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MXIHS66Z."&0*D**9?4S2RX#R-Y9VP/) 4X UHU[FF[V@M*SP1A\GKQT X X
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MW$J?;1O*+N?PIN!_Y0#XK20".Y;O?^>@Y11O_E<\2]*>EBQVQ;NQWQ3 6YF
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MU47K$? CT'O?PU;=LURL-NL-/';J&K;=]&T-+<.\5C9I35N"#W&;CALKA@
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M<JF(GEX'OGZ:R!E1:**T]1RSC/G]57Z?S/OK(X6/5;$)$LC(W]0N%! \^/\
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MQW4W2TD-!T!ZF@TE1)$+C0+%+ Q4U!#A5P.RGGPK$<<'F/(\G6EXAJ:[8DN
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MD:E$52Q<@8Y'W/ZZ\@3)E>#)DRE:BB-$1HB-$1HB-$1HB-$1HB-$1HBP=$7
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MQKH($J)[?'Z25E6&:!^1R#S88]!U)"L*+K_BPLMNNFYH8K755-MM>U_Z20W
M3J(ZZ7LQ3FB1<$B015-(_+R#WQX])T)2%9;'UTBN'5FLV-/9Y:22FH0XN#SJ
M\$M<D44U30I@ \XHJB%^7LP9@ "AT4A<_P!F?%V;]2;<JJ[;-MIJ6_6^IKJ.
M.U;FBKZJ+LT<E7QJ8!$C1 I&5+ L%=D4_F!TW%56GHCUQJ^M$-/4K;MN6^EJ
MK7'<0EKW5'<ZN,2!"J34ZP(4P'(+9.&&/.<ZR:Z3E%V$2\#Q<<3[9^AU2$*S
M+Y>/Z8;P?MX.H L4H-C\_C_2 \?S'TT52&4-+@^?3D$']?H=7HBSEX_?UK]Q
M[C1%F!XYX4#G/'TAU_,N/&H1'"#*1,CT[QNWKC)X\U_7V\:R!!"JP\0E1C&P
M4GZCR"=.%$!UG3C,I0^V0?(/Z'_@=..%$S40LKECA)E'B5?RL/UU042X*SDP
M20=N3V\^S?PU".R2MQ),#BPRA^GVUA"JT:V?BQBA8$^QD^@_3^/Z:Y1W*I2!
M$%18FR$]V'U;^/\ '[:3U6/HMB1N2A)O$;'\OT4?4_J=8_)7E*D5CG/HCQ[_
M %(_X:BJ1$Q"X0 L?/V"_H=58I>%]*.<DG/-OH!]/T^FHJ@AI"<@HOZ^"?\
MEJRDI"E8W;Q@ !0H^I]_^6F824^J-5+QD\$#TI]_X_?6/'")E' 4D LSDL%&
MLU42#C&\DAR0"0![#46*9V^W_H/2^X])_P!YU@_XBHWA2/+^.N-5'+^.B+7N
M-%#=+?544X8P5,3PR!3@E64@X/\  ZY:51U&HVHSEI!'TRN>C6=;U6UF<M((
M^8,JOIL2F#4,DE=5RS03-/-(W &J)E27#@+@ /&A]./ Q[$Z[(ZD^'@, !$
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M1&B(T18.B*&VRE$GXK\D\KYKY3/W1C$OCD!X]O;6_=FJ?#\0#X1$=NGU7E-
M99,]\]R<XS6J%^[H_&X# \O$?FIK6@O5J)W:ADVM>$7')J.8#/MGMMK:M8]X
MISW'YKBJ_P -WR*^?NVKC^)=(2]7-%'/)?Z:GCBH:8(S,E&Q5654XN5"*W(D
M!>!))&0?T%>T!0U?]V# I.,DSR\"<F1,Q&9G 7BV']R1ZC\DR];/1U-[V_8:
M 5[5$B)$E$DTE1.T%0O<B::%3Z6C'/@O[CG)^FL*E*E6HT[R\=M@'F($M,$
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M_7(O\=(/9-[>Z/Q^W_\ 7(O\=(/9-[>ZU*BY4U=<+:L$Z2E9B2%/TXG7*&D
MDJ2"1"E1^RDXG\K>0?U^HU%R)XQKVBS#R?"_I]SJ*\+521H3VY,L /2_U(_7
M67*DIQXEG4'/GW5EU.$A*$[0QF.0<9/')A[?]VI$Y283<L; ]R(@./<?1AK*
M>B%*BD%1Q4CRWL#['4X188M2$1#UP9\?<'Z^?K^FKSE)270,>Y"1W!XP?8_H
M1I\U$(J59 )[4B^<_48_WZ<)RF*N>)Y.,JB*4#\@\B0?^/K]-4 ]%"F5KVE)
MB;F OAC]A^K?;]1JQU4E;$$42'"CO,/HHPB_^/YZAE5/,.(+SR#]<>!_#6/R
M5^:2G.1N03@H\+R_WXU54XRK"H=CESX3E[D_]VIRBR&=E55'!%&!R_Y:)*;*
MJ)!DYX^69CJHG@2P# 87Z%O&?X#41-J#)(S,>0'I7QX'\-$2FE&<*.9^P_YZ
ML*\K%/ 98S)*>*EB>(^O_/4)S 44%U,VI#O_ *<[IVH]2;;#?;556MJI$$C1
M":)HRX4D<B.6<9&?OK&)5E<DWA\)]KWQL[<%JFO-5;Z^YWK\:IKO! HGHRU-
M3TTT&.7KBDBIRKJ2,]P>,HIU2,JJP5'1*_T-QOL6WM]5-@VG>+L][K+?3T(-
M=%-)()*B.FK.X.U',X+-F-V7N/Q89''&.BBTZWX=:R>V5VTDW>8NFE=<9*^?
M;\=L457"2<U$M&E6''&F>4ME>T7"N4#@8(D(MD_#I:*">WW>VU4=LW=0[FJ]
MP0;@@H4$[K55<DU11RX(,D+QRM"06_=1QAD U=J2MW8/PY[-V1L>7;SV>W7&
M:JI:NBKKI\A%!5UD-2\C2J\BCGY$G$^KS@'5 5491] +[71[=M^Y=\/?[%MO
MD;1!^%I3U#3?+R4\,U7,'83O%'*_$(D09L,P) Q$6I4_"A;K58+;1;2OZ[/N
M*[:.U;M<+?;XQ^*TO96-9'0,H6>-@SQR9)7N2+Z@WB0B??X5=LV2HO,6TZJ3
M;-NOFV*G;%?0IW*J.2-D*TTP,DA*M 'F4*/#"4CQ@:L81/[N^':LOUWV5<K3
MN*V4E5MNPR6'A>=OI<X:B-S3DR<&E3MN#3+[$^&(U$3-1T(WC#?;G<;3U&HK
M+->K+16BYFBVXF1\LLRK+2\J@K 2M0P"E9 I4'R/&G116G<_1:GN'3C;.U=O
MU\FWCM:6@GLE7VA5"G>D 6(2(2O=0H"K#DI(8D,#@ZD(H.R_#]*-R4NXMP7U
M+Q?VW!^/5[T]N%/35 6V2VZ.F2(R.4C6*8MEF<LW+/AL BK5C^$FHV%7453L
M_>YMLM!>JZYT,=UM?S\=-35%%!2+1C]M&2D24Z!&+9"X4@XR4(G:[X5JT7"Q
MWJCW723[AI9KK57*NO=@CN$-PGKC3&1Q )D$7!:2)$ +808))R2A%/5/PUV'
M=WXBV]$H-P3U]@I;$S4EJ2C6E[$U3(L],.;F!\U"XXMZ6A5@?H+"JO']!J^X
M=,)MJWJ_-=KC46F2V55X^6$<D[/"T1G,08@,<\B <$YQ@' LX10E%T<MU-?-
MC5]9+'<DVKM^>PQTU52*RSB0TG[8Y)XL/E!X /\ 6'SX\R%%SN#X2YK5=+16
M6#<UL@EH::Z4O8O.VH[A 8ZRY/7^A.\@0H7[8/G*C.![:1"JZ%U!Z2W/>NQ=
MM6L;BIK9>['<K?=8KE#:@U.\]*W(#Y;NCBC>W$2>D?4Z<HH"Y?#M2=0[TETZ
MG7*+>TT-JDM,%/2TTMLIXXY96>=N"3L29%[*$%L8A'CU'2$6AMGX3[?05S5-
MUW!4[@63:)VI-%/3+'WLJ835L0QS,:810GZ$1Y_>(U$3\?P[76P[$VQMRT[T
M2H_#:&:CN<.X[.MSH+R\LG=DJ9J8RIQF,I=@RN1B1E(88(L(IV'H7;:;HE9>
MG4-UKH$LR4KV^\QK&*BFJJ:59H9D3' !9%&(L<>'H]M7:B@=Q?#37]2%N%9O
M;=D-YNU134MOIVH[0*6CI:2*N@K)4$#2R%VF>FC#LSD *H51@\HB[%:K':]N
MTSTMKM]-;J<NTG8HX%AC#'W/%0,GP//Z:JBYQ5=!J2X[:O\ 9)KD\L%XW=#N
MN3E2JP4QU=/4_+E2V&4_+A2Q^C$X\8.,(H7J-\+-%O"^WB[6F[4=BJ*VHL=6
ME*UHCJ*=)+;+4R+SB#H)!)\R01D8X#R<^"JO&R=D73;VT[C9;K=J&IDJFD$=
M5M^TBS]A70*2J+))^T!RPDR#[>/&LH15?IWT)NFV>HM)O+<.Y:3<%VHK9):H
MJNFLD=NJ:R-WB8R5TJR,:B0=E<8"("SL%RWB0BT+1\*=B^0VC;+Y=)]PV?;2
MW*2EH>+TO.JK*EI3.SQR Y2-Y(@OL1(Y/O@1126QOA\@V-<=AM2WFHJ*#9?X
MK3VNCE@\K25;+VJ<N6)(@1%16QEE S@CRA%I]-.@-\Z:;A6HIMRV.JM'XI77
M$P3;7C2N*U,\L[1_."HSX:8J&X?E&,:*J?W1TNO<V_+ANC9>ZZ?:]UN5#!07
M..MM:W""H$)D,$R+W(RDR"610Q9E8$!D/$'5441L?X8-K;(W!#<).W?5@L=-
M:(TO%''42]V.JJ:J6K,A']9++5NS!54 @8^@!%,]3>F%TWON/:E]L>YH-NW?
M;=54SPR55L^>BF$],8'5D[L9& <@\O?Z:I55'KOA5JYJ^SWFEW?13[FAK+G<
M+E7WJPQUT%?/6I3HS"G[J"(1I2PH@#-A5P2223(12E!T3WE9=X0[EMF]K305
M[6BFLM?"NU@::>.GJ9YD:*-:I>SD5#*1EQZ0?TU3E1:MO^%6QVVNM-^BN53_
M $VI+^^X*C<'K/S<DLK_ #,30&3MJDD$C4_@9"A3Y*XTA51UK^$*R46SML6)
MKW63_@NY3?'JWA7G64X/!:!QR\1"&*FBR/)%.IQYP*6HI*W?"G8J"MM=^@NM
M0F^Z2_R;@GW"0_\ G4LLC_,1M3]SMJDD$C0>/*J$.25U(6*1:?A6LVWK%M.&
MR5PLERMEBDV]<;A24,:&\T4E.8V2=5(RRR<)D?+%65AY#MJP.BR4IT<Z.7SI
M'1T5%47ZR7>V4-KCMT:V_;"6ZJ?MHBH\DZSN7\)Y7CY)SXQJ@*$PNOI.E0F6
MPX(_,/?2(3E,U$+0H'C(9 0<'V_[M49Y4A9$@SQ;T-]C]?YZ0HL.O"12/2#Z
M3C]?;1$MB8QEAE/[:^P_B/IIRJF0BF4D''+U!EU>$X3H=E1DD421L//'W_P_
MY:G7"2D(J2@NK>H'#,OW_4:<*)$G.-LE.:GPW$9_GC51*4!U#0R CZ9\C3YH
MF:B)#Z'Q"Q&?4,HW_C^6J$*UWKFB(B7DP;P#GW'Z-]OU.LHZJ2GJ66)6[<8$
MDI\<6\"(?^/\=0SRK*?8"E9AYEE)\G]?^&L>4X0B!#W)2#*?&![#] -/0*A+
M4M6XB/IC!]_J?TS]-3C*<K#RK"I 'Y?<#V'\=(E%B*,D]R7!?Z#Z*-4]@HG)
MIS,@[0#2>W(^Q_7]<:@'=5(BC6!"<@GW9SH<I$)#R-*P2/TK^\_U _35 1;7
M:54#(, ^_P#'6,K),2'N9 _*OD_J?H-4+!1-HO-%3VR".2JC1U!!4GR/)U'@
M[CA<8< ,K=_'[?\ ]<B_QUA![++>WNC^D%O_ .N1?XZ0>R;V]T?T@MY]JR+_
M !T@]DWM[H.X+>!_Z61?XZ0>R;V]T?T@MY_][(O\=(,Q"F]O=9%]H2,BJ3'\
M_P#EJACCT3>WNL?C]!G'S2?[?^6KL=V64@=4H7NB(R*E#_ '_EIL?V6.]@ZK
M OM"1GYJ/C]_/_+0,<> F]H,2C\=H 1FKC!/CSG38[LKN'= OE$1GYI,??S_
M ,M8EI'13Q&DQ*#?:%1EJJ,#^>A:X<A-[3P4?CE#C_TJ3_;_ ,M9;'=DWMYE
M OE$6X_,IG[><_[M8>BGBT^=RJ74V@H-Y[>>S25=1%#6'L2RT,_8F0,P P^/
M3Y\?<C('DZ[/3JM6UN&UZ8'ESD2/N6I<EE:GLGGLO&+UU1/<+-M[<%!'124\
MCQ21UB3)/#)-.>W"D\RC*+&>?%ACBG@YU]Z;38RE4O;1V[<!P6D&&Y):WK.)
M'4Y"\F=V&.Z*ZV>KAI>A/4AZ.2G,])7T',UR\^V>Z7 ,90@ EN8;U*W,G./&
MNEJTG5-=LQ4!AS7<'TCD'I$$8(B%NT\6U3YA>D_A=J'K.AVVIY(XH6E6:3M0
M($1,S.<!1X \^VOF?M.QM+5Z[ 28(YR> N]TW_#-^OYKJVO+KM$:(C1$:(C1
M$:(N8]:]V+M=+06Z@Q;$[YE ,EK6M^:P%]LCT\<_SY?IKUF@V9NS4BS-Q$?;
MV;>?OG\(7N/9G3S?&K%@;J(XJ%FV9[<S^$+4MGQ(=.Z6W4L-9O:FKJN.)4FJ
M?EI8^\X #/Q"87)R<#VSKFJ^RVKOJ.=3M2UI)@2# Z"9S'=<]?V,UU]5SZ5D
M6M),#<TP.@DF3'?JNKQNLB*ZG*L 0?N->.((,%>!(+3!2M11&B(T1&B(T1&B
M(T1&B(T1&B(T18/L=$7E7J%=ML;?WONI:6JJ;3N>NN$J5,]7<:.ECGI_E(N:
M21SJZ/"?';YH27,G%@ <_8-,HWMS9VY>T/HM:( :]Q#M[H(+""'#[<$ -VR"
M2%]ZTBWU"\T^U-1HJ6[& M#65'D.\1T%KF%KFO'V]K@ W;()(7H7IFE%%T[V
MREMAJX+>MMIQ3Q5_]>L?;7B)/]+&,X\?;7S3534-_7-8@NWNDMXF3,>B^0:V
M:SM3N3<%I?O=);\),F8].RLVNJ72(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+!
MT10VVJNGJ_Q7L4@I>W7RQR8;/<<8R_\ /_AK?NV/9X>]TRT$>@[?1>4T"YM[
MGWSW>CX>VM4:[,[G")?Z;NWHIK6@O5J$WQ4_);,OU1P$G:H)WXLW$'$;'!/T
MUMVC=]S3;W</S7#7.VDX^A7@>)[+>^A4LMLL8VY3S7Z"FJ*6FK&D-2JT97)>
M7U*'!/(1JS$ >#YU]^<RZM=<BO4\5PID@D<>?L,8Z20/5>/D&@8$9_HMX5V:
M$7YKDUI:T45:+W34@:!:@5(>**>F!*GO!'2'+HN6/(!ARQHOMRYYLG-W"H6^
M&3!@M@N#CGRR"Z 3C$@PN)N&[FF".?KV4;?8FW$;-N"*07*@JIO7,U?BE2=B
M(FC:,KZ#+R614R"K))],'6]:[;7Q;)PVN8,>7S$#S3,YB"">H(ZX4.<]_P U
MT"[)3[/VW9]JK55,B6X_YTTD4BFIK&8B250S$@CCX3/UP",G'FK9KK^N^^+!
MY\B(PWH/]_KF%SU'FG%+M^:W=A[5BW&::WUD9JWCE^920U'&*GP.9(8_FC;@
M/(P?RDHJL#KK]5N&,<2&QTB,G^Q';/:20N6E3<\PD]<.MO2^[5G _.W:[+*K
M5%;MS%/&WH$4B-,SJ9/2'577/ -D9(ULZ#[,ZRV7PUC3QOR>X, &.A@Q/"VK
MBYMZAB"3UC"KS]?>F=?N^VW"X[7W):::G_:/!\R)HG8EF5Y(V<$J1)+R R'#
M^?RKKM7^R6KMMWTZ5PQY..(/R!CG CLN$5[<U XM( ]5U+=53M_>UJLVY]NM
M276UVV!;;!\B3$*0A>0+0$%E*E1Q4*3[  ^^O&VMO<:;5=:73-KW9SF?D>(/
M>8[K9N"VN!5IF0,+E]GOTVTKS'44\Q-7#,90Z28:1?#$,H)!+9/@,1Q(;.),
M+ZM]H+VB6;8'7Y_KTYQTD].UQIOF<J!W?L3Y#>-"E@I9*BANE3^)T%'\P\-5
M H/://D&9XXF)E)!RRD^/&NRT^[#K.H;DB:8VDD M)YQ$0YP\H['JE2G+I9P
M4Y+=HKQ57&U4%]EIXK#+35-74?.&>5J2G,P8Q2!E#SNTY$ASQQ,@#!49M<9M
M31:VZK4035W!HVP YT1(S#0!+>N"8D@*CS2V8 Y^G_*E=BUWXMURV[4P%Z.W
MR5RQ4]&LO%&IA,TD,<J2<<RIG\\;/DY/D>_#J%JVAH]:F]H<X"2[LZ "01/E
M/9P$+EHNFX;'$KVO!"D=-"#&H.#]!]SKXD1DPO8M  PDF-8CG@O;)S[#TG_E
MJ*IP1QG]U#_(:2B;$20^ZJ8_OC\O_=JS*)SM1D?E0@_H-22B;"+ ?R@I]&QY
M75Y1/+&)L+[AOUU)A9!)E<HV#ED'@,/<#]1JH5@A95SG(]P1]/UTX428XWB;
MGCPOG*CP?XC_ ):'*J2TZ3MZVX29\'.@!"B DD7E0"/[(_Y?35P46>2!"65H
MY7^A7.?U_71$R97C4@@21X_*3@_[?^.K"B;6229\PJ5/UY'R-7 Y3*Q5+.Q:
M.2544_6%22?XZ@A0A-K;W52?3(A\Y<X/^SW_ )G5E(65I6G*QHW>5?' >@I^
MH/L-)A(6 *JG)6%0(P?ZHMY_C^G\LZ8/*F0G(:NG8DN2TJG'$J?!_CH059"W
M%,DRE@O%![G[_P S_P -8856,)&Q9FY2'QD^3_ :(L-*Y/&-0&_TOI_'2$3L
M-,D([DGK)\Y;ZG_@-"9P%82)JHR,1&.<C>W]D?S^V@"BPD7I 9O ^@\:*I<\
MD5'$H=EC=_" D#'W.@!<<*@$\!([QD8(I52/3AB"W@9QC^'G66V!*R(,3"3(
M$4B/D#(_CR?.,_\ @: $Y6.TQ,+<$8C&6!)_LC_CK!)"8GD,C)&?!)SQ_0>_
MC_#60'57U1WHQ.(>:"8CD(^0Y$??'OIM,;HQW5VN+=X&._3[TMX@'C61@I)+
M8SYP/.?T^FL9[+$ GA/+4P1RR1QLDDL>.:*P)3/MG[:A:Z 2,%9%I #B,'A:
M]1*SNO/(498D^ !K( #A09,!+[>,<B%S_:.- 9X5 )X2284FBYS(?)\*0?)]
MAH0X]$+7=DZU3"T?(/B+&<@CCC[YUCM<#$92#.V,IL/&\R\0S!0?(.?/CQI!
M'*Q(@P4^41!EN0_3&L40]0J1%^ZL<2CD6?P,?<GVU0TDP!E9 $G:.5A&$T:R
M*$DC89#Q$$$?<8]]""TP>4+2T[2,I+RP4Z]R2H6%/&2[@#S[>?UUD&.<8 RJ
MUCG':T&4ZTCC.8_!^WO_ (ZQA8)H1K(Q"-ZQ[J?<:LPJLB:-%'<E1Q]N0/\
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M%O5>A]N5LURL%NJZB6CFGGIXY'EM\ADIW)4$F-CY*'W!/TU\SNJ;:5=]-@(
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M@+2<&@ !]B>')<#SC'Z:Y*-:_HEU:JPO!!!W3Q(=]TP?FN:WN-4MR^XKTW5
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MF]IG>0?GP9_.3]ZZISM9J,.[Q"",\\$'\P3]Z@[!MBP0;BAGM^X5J*D22&*
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MFCD;BGO]N1)'_C^.LD61 TY*=YG(_*A/(#_;_P ])A59!$7H=>&?'&,\R?\
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M/BRWG/7WF2@N%+)5"V*\;=J<BC8*'D ]"*IY>WGV&N)QJ4O92W;0I!S71O\
M3S]!U)./1<M0 W+]Q[_DNM[AOE!!\/USD&ZJJU51IY96KK?0B7O2AI#C\F<\
MU8\P05X\B0,Z\):T75=9I4W40X$MPYT "!Z]NG7B%OM<!:F'05"=#]][PW%O
MVZR]1KM7V>[1VF$4UGCM:K%4T[!W,A/%@&)R2H*EN./92!V?M%IUA9VE,Z4
M^F7NE^[(<(QTQ'6#'UE8VU6JZHXUW$&.(Z?K[U4.OBVRNV3?_FMP"*&*_?\
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M0J L< [IDSGZ?-=Q3T.^MJK7L>UK^F3.1\OF/T$UM+<>W)[I/:;9;:BDFD#
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M#J>H-NVAV*!J,PT,-'')'VY0S9*Y"</O^K$9^F=>99IE:]FJ'2XN(.,?.?[
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M<+>++3HD5745]=5E41_2/5(S JRRNR C]Y2?'C7+7M]1:6,I/\0Y:&M;DC/
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M .D=\W51[)[=OZ5P[EIUKZTK<WJ*;,C&I?(XN0V <C/Z#Z:^E:W;V#[S=6U
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M4+.[92K!S&D!SFF"]DSY3QDP") @.$C"?V_<*Q[[<+3<9J>NDIHXI?FJ2!H
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M&7.GUJC6T;0EW8'YD_AP>V4X-MW*LMULK(+S!--2M-4FJDJ'E0AVY*? '(
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M,;2Z0<F('65)W;HG<(NI<6\4W-3T$:,U1)2R NKN@D5)RS#W5)V49SQ\>H^
M-:AK]']FG3C0+CP#Q .TEL#H2T$Q$YQU6K;^T] :0=*=;%Y,-!&(!VDM@="Y
M@)B)SCDF+DZ*W:KIJJP4^\*8/#?AN$R&,,Z3&8R<&C^I\IZB1]/3YUM#7Z#'
M-NWVQS3\*)P1MB0>G7$?7"VQ[46U-[;ZI9F'4O!B8!:&[9#NG7$?]V%UZ#;J
M&UTLU\N<TE32HW=J(JMH4;#\_4%*@X"@9(]@?H3KQ+KDBHX6U,!KN 6@GB,3
M/,\ \POGCKLBJYMI2 :XX!:">-N)DB9X!YCL%RBNZ2;AVA6W*JLG4FDL%LN%
MVDNBPU]%W&$AB*E6F:7,F$4D@CZ9/D:]E3UNTOF,IW-B:CV,#):Z,;IPT-QD
MXCY=5[^E[1V.I4Z=*\TUU6I3IBG+71C=,AH9Y<G$'K'5-5O3"\W."S5B]3[=
M%=+10SVZIN34ZREXIY1&,#N#MD! @.22W+R#K.GJUM2=5IFP<65'->&R1EHG
M^4SS/  $8A<E'7+2BZM2.EN-*J]KVLW$06-W?RG<#)<1  ;&(5BVSM+J1#7R
M2S]1K?=* .X>""W",]P2$..66(_*5/V)/CTZZR[OM&=3#663F.QDNG!&,0/F
M._U737VI^S[Z093TYU-\""7S@MQB!/(([B,Y6MNGIG?NH=EHI(][PQ7&AJTN
M%OK*7UK$Q5N)P!E@59L'[?XZY;/5K72ZS@ZU.Q[2UP."<B?E!'WKGT[7++1:
M[PZR/AO:6/:<$Y$_*"!]5&5/0'=.Y+Y%N*\;X@J-R4.(;?)248AA2#)[L3CR
MQYHS#/+*Y\9UN,]I;&VH&SMK0BD[+@722[$$=,$#$0>J[*E[7Z;:6YL+2Q(H
M/R\.=)+L;7#@#:0,1#NL*WW?8VX+_MZ[6NDW-2T]MN-'-2K&JF=(EE+ @$X+
M!59PIR/8> !C724-0M+6XIUWT"7L<#V)VQ]TD"<'KU*\Y;:K8V=U2N'VQ=4I
MN:X_9)+8(XP)(!.#R>I5-DZ$'>%/MZJAW73ULMHAAH6$+DQ5D$01TC;'Y LB
M1R<0&SCW]61WH]HO<G5F.MRWQ"79Y:YT@D=Y!+9Q\L0O2M]K!IS[BF^U+?%+
MGYY8YVX$CN2TN;,B.V(+NY>C5SNE)U CKMZ4E,NYBDTP2'TQ)$@CRP)R1E5'
MN,>V3K"UUVA1=9FG:D^!(&>2XSB/F>F>P7'9^T]M;/L#2LG.-O(&<DN.[$")
MR>F>8"E[OTKNF_\ ;$=%=MR1S6RJ@B$G8(=HW1?1(CX'J#Y/CC]LG&M&CK%#
M3;DU;>@0]I,3B03D$3P1CKWZKK*&OV^D7AKVML14:71. 03EI$\$8Z]X$K7N
MG1&JJDLE93;VJJ+>M'0&AGNQYRI7P!@S"2%I,CU,IRK#!;^&.2C[0,::M.I:
MAUNYVX,P"QT0(<&P< C(X'S7);^U5-AK4JMD'6CW[PS +'1 AP;!P",MR!\Y
MU*#IW<Z/J$=Q[AZAT%;=(F,$=-3@4R4RN8Q*J(78JSJ(Q^A;/N1KFJZG0?8>
MYVEDYK#DD^8N(G:20!(!D_3L%SU]8MWZ7^S[#3G-IG)<?,7$;BTD@-D-.X_(
M1P%8HK9?IZ>D:KW[05=<8(U[T<2Q1R)+,6BD"*V"2P2-3C#!2/WB-=8:UJUS
M@RS<&R<3)!:V")(GB7'L2.P*Z<W-DQSVT[!S62<$DD%K8<)(G@ESOY21V!4!
M>>E.\+)N&7<-EW]162KNJQ+71U=.)8JQXD8A_./4(Q@X RJ$G794-8T^O;BT
MN;,U&TYVP8+0XC'7$\3U,!=Q;Z[I5S:BQO-/=592DL+706!Q$CKC=Q,P3 4=
M7_#]N.[VZ\M<-[1W"XWM8(+A<&A,:RTD;JP@6-?"# ;U9)/(@^,G6S2]IK.A
M4I"C:EK*6XM;,PX@C<2<GIB($ K;H^V-A:U:(M[(LIT=Q8V9(>X$;RXY.2,1
M @$9PK;O_I)_3;;"V6KN5*@J*):(U$C%728-W 45<*<X P?91]==/INM"PN?
M>:;#AVZ.A$1DG/K/4KH-(]H1IEW[Y1IGRN+H&06D;8),GJ3/4E5V7I/=K962
MW'<&]*2JJ*^R1V"J%0G:6H4!RWJ^F0V?;/OY\Z[$:S0JL%&TM2 RH:@C,<1C
MTCO'"[9OM!;5V"WL;)S13JFLV#.TF(QZ$1S'&%J4WPYW>W;.>RP[K@J*R2MI
MJM[I4PMSEDBDB[:\,D#BL2H,LV?LOG.P[VIMZUW[RZW(:&N :",!P=.?4N).
M!\SB-MWMI:U[X7;[0AH:]H8"( <';C,9DN+C@?,XB<I-B76U[TO-VIMX4LTV
MYDA61,A60PQ.G)<9YC)(XCCC'N<:ZZIJ%O6LZ5!]L0*$Q_W$&#VQUS\EU%75
M;6OI]&VJ69 MBZ.OQN#H/8P)DS,\*7W7TOK]\]-[QM:[[CS+6%##61J<0JO$
MCD@*\U\?E)(]CG6A9:O2T[4:5];T,-F1WF>L&#Z@>BZW3]>H:3JU'4K2VPR9
M:>I,\$@P?4">D*#AZ9[QH(JBJJNJ5-/;64K48MYA' /ZL2]\]M@01R \8QKL
MGZKIU1P93T\A_3S3F,8V#<(Z?5=L_6])JN;3I:614Y;YYS&);X8W"#Q.>5#;
M)Z>[QVK$UILG5:R=IYII8Z-K5',1([O(^/VF2>0;^ 4^/!UNW^J:=>'Q[K3G
MR  3O(P  /LQQ'U/JNQU36=)U!WO-YI-20&@N\0MP UH^S'$?4C.5;=K;7W.
MM#3Q1[]I+O)%"'^8ACXF6-^XT;E<OX]3 8/J"@Y\8UTUY=V+GN<ZS+,\$\$0
M")@>DXQ,=5Y_4+[375'/=8.IYX)X(VAPF&]A,C!,1F5 #IGO*DW1>ZJP=0;=
M;9+I*KU]*U$M1RJ$C16D"DCBQ1D)4Y'J'CVUV'[6TY]M29=V3GBF/*=VWRDD
M@3F1(,'G!]5VIUW2:MI0IWVGOJ"D"&.#BWREQ($YD @@.P<'U4CT<Z/7?I/6
M24D>ZOF-O-*M4;;VU5Q*582'GQ&5)[9QX'C'\=;7-=M]9:*AMXJQ&Z3$2(Q)
MR,]UI^TGM-:>T#15=:Q7 +=TF-L@C$G(&[OS*GJ+:.X+<R1T.X*:C[./F$1W
MEY.(_P S!_8MD,P\8P,'SG775+RSJ2ZI1)GC@8G@1VX!RNIK7]A5)?5MRZ?A
M.!@G@1VX!S/5;%!;+A4W"Z4LNY::MJ5I9HC"DIB:*23AY*K[$'.&!R.8&/OQ
M5*M)M.G4;0+1(,Q,@3U/Y<&)^7#6KT6TJ55EL6C<TR1((;/4\R.D08)^3,.W
M=S496D;<<5' J"..&$Y;D22HRP\GW]@,@?E&,:Y'75G4E_NY<>23VZ\'^\=R
MN1U]85 :GNI<Z9)/$" >#^<QW*UH+=N.\,\U'NN+_-Y7B5D(DY+X\GTX4X \
M8/L3D<CKD=6LZ$-J6QR >W?US^'X+E?<:?; ,JVA\P!R(SGUDY^7:,!6VNV]
M::NK-543U,4\LBX"5DD:,^4 "J&P,E%\#[M_:.NEIW-9K=C&B #]D$QGK$]3
MGY=@O/4KRX:SPV,! !^PTF,\DB>IS\NP4G36^FH*.GIXHY'B1 JM*S2,1^K-
MDG^).M.H]U1Y>[D]A'X#A=?6>ZM4=4> ">P@?<,!<((Q\><>$Q_^;!O2<#_Y
M<+KBZKB7H"'N,2G%55ACR<XU2@7-S8=Y[.K+W3[;BLESM=RK)KA UUJY:9Z"
M>8EY@RI$_?C,A9P T;#D5)QA@"I2[G8-SVG=-+N&R);-P5TMJBMEPIZ^>2A1
MGBD>6.>)ECEXCE+*&C(/@KALJ0V65%IQ[%WAMK9^VK7:7L5\@@:K>_6^ZJT,
M-Q:=FEQ$P23M!978@.K J #Y\C!5;>P]GWG8]FW#/!066BKKA6BMI+!15+Q6
MZDQ'&A02"+.7*-([)$!R;PI\L<@HG.DEFW5M+;,]LN]!9NY#+4U%+);J^:19
M7EJ)IN$A>!"BCN!>0YD^3CZ:A'=50O1'HT_3R@C>\[>VW27Z!&1;M:99*F:;
MN,[R9:6%#'DL!A<\O.<>!HU"NL+&JG."6^Y.3K,E8JO;HM=YOE)<K9#1VJ:@
MJXC&M34R.'@!7#%HPA#D')&&7Z9Q[Z[.SJVM!S*[G.#FF8 $&#B#(CL9!^O"
M[_3ZME;/IW+W/#V&8 $&#B'2-L\&6N^O";O6V)_Q.R7:@CAKKA:XI:9172E"
M\<BH&82!6XOF-3GB<@L/&<ZRM[IGAU;>J2UE0@^43!!,")$C)Q.,'HL;:]I^
M%7M:Q+&52'>43!:3 VDB6^8XG! .82K9:KSM[;]-!1"@J*SO2SSP.S10CN.[
ME(F"GB%+8')?('TSXE:K;W5PY]0N#8 !P3@ 2X2)D#,'![J5Z]K>7+GU2YK8
M !@./E ;+A(DD"3!P>Z96Q[AH;)>9Z&2VTMZN=3\PD?J:GI_"(<'CZG*J6)X
MX+'R,9SR&XM*E:DVJ'&FP1TW'D]\"3$3(;UGC8?=6-6O0;7#G4J;=I. YV21
MUP)($;I#1@SP_M6UW.S4LU+)1V^EBP766*KEJ99IF)Y22LT:<B?&3[G]!C7'
M>UJ-=P>USB>Q : !P&@%T?T]<K6U"XH7+VU6/<X\06M8 T<!H#G0.?0>IE9I
MJ&^W6\VF:Z06^G@MTCS<Z2H>1JB1HFC& RKVUP[$@EB3@9P,F.JVM"E4;0+B
M7@#( @2#T)W' $P.I69K6=O1JLMBYQJ #S  - <'<@G<9  ,- $GDP(FX;(K
MA57NDHZ>A2@O-:E;4U<DA%1"X[?+"A2'/[,%#R7B6]CCSNTM0I[:3ZA=OI-+
M0,;2,QF<<^809CUQNTM5I;:-6L7;Z+2QK1&T@[HDR-H\WF$'<!SG%X)9B3P]
MS_:UY[A>5&%JW66[+2QO;(:6:1),O#52M'S0@_E=0>)S@^5(/MX]]<U 4"2*
MY('0@ P?4&)^\+;MQ;.)%R2!T( ,'U!(D?(@CG/"KK[5N5?9KV*B:FI+G<JE
M*Q.P6DBIY(Q&(AD@%Q^Q4L<#.3@# UV8O:-.M2V N8P%N8!(.[=W ^(P,PNV
M&H4*5Q0\-I=3IM+<P"X.W;NX;\1VB3$"3RMVR6ZZO>*R[744M+4201TT5-22
M-,B(K,[,795R69O;'@*/<DZU[FI0%%MO;DD DDD 22  (!. !WR2M6ZKVXH,
MM;4D@$N)< "20   "8  [Y)/2%8IXBQY%V.0#X\:ZT&,+J%S[>O3,WFH>LM<
MU3%6U%935-2);K/#"1$T9&$4,"<1@#P /?WUZ6PU44&BG7 +6M<!Y&D^8'J2
M,29]>%Z_2];;:M%*Y:"UK7M;%-CG><.')(,2Z3S/"OY(.?&->;7CUP/JE_\
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M6'>0YK@3$B09&#(G) G(SQ$31;OZ?R[OW1:*LW<5E@I#)5BN:(QMP\E$QG+
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MNS]5J-88(:&DF8:X0\"1Y0XC).9DA1^X-W].=I;ELUFFJKM4+>"TJW"-@M-
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MF5<*0&/U^I/D:\O<:7J%"J^BX3M,<X,&,2<C"\5=:+JEM6?;O&[:2/B$&#&
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M$C_SLW_^ EUC_P#737_U/J[DA+C^+=U;/^1'K&?&/_=47_U/K&54@_%G)_\
M 2ZQ_P#KIK_ZGUEN4A'_ )V;_P#P$NL?_KIK_P"I]-R);?%LYC"_Y$>L?@^_
M]%%_]3ZQE$C_ ,[-_P#X"76/_P!=-?\ U/K+<D+*_%K(IS_D2ZQ_^NHO_J?4
ME%F3XM7=F/\ D1ZQC/G_ -U1?_4^FY$D?%HX_P#W)=8__737_P!3Z2D):_%N
MX5Q_D1ZQ^1C_ -U1?_4^I*0DGXM9/_@)=8__ %TU_P#4^K*0L?\ G9O_ / 2
MZQ_^NFO_ *GU=R0EM\6SLJC_ "(]8_ Q_P"ZHO\ ZGU)1(_\[-__ ("76/\
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M92,'.&'CWU[:XHG7+A])U0@4:U1KR# \,DO$^@AS9GM\E]$NK<^TEW4HOJN
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M7.IAT$PZI3PZ 8,G!XQYEB#=$.S[9N.Q4VVY$K]Q6RFJK(DM..Y!/4QI2U
M(\^K]J N?#'.,G5-HZ^J4;I]?RT7N;4S@AA+V_AY3/4*FP?J5:WOJER"RW>]
MM6#@MIN-1A/;'D),9&)@*-O;T%BZ>]8+';+!+20)54<,50T8 B1%I@$?QG)*
MY8#ZL/?.=;5OXMQ?Z;<UJP)(>2)Y)+\CT@P/0=%N6HKW6IZ/>7%P'$MJ$B>2
M34R/0 PWT'3A7G>&V]V[AHZRR7NW[=I;6\P@KY=O6NH-9)&KHW%))"57N><-
MY/I.O/V-UI]JYMU;/J%\2T5'MV@D$20W)V]O5>6TR]TNR>R]LZE5U2)8*M1F
MP$@B2UH!.WM@94GL-J&;KYONEBVUQIJM;6IBJ8SF#$<BNP&#C)48\@$+GR"-
M:>H^*W0K1YKY;XN0>9(('X^IDPM#5O';[-6-0W/F;XV0?BDM($R.^>2"86.M
M.X[Y=;WL2DHXS;+O%N"0TM0M&\T:X@< %6QR;SY'IQ]O8FZ%:VM"A=U*AWTS
M2&X;@#\0ZB8'W_-9>S-E96UM?5*QWTC1&X;@#EXG(F!ZYGOVD;5<M\TMXII]
MSSQ;DIJ=0[6R.P)'+AO9T<,<8X?;\P4?J-:M2TM]%S;(&D3C=XI(QT(@=_ND
M^ATZ]'1GT'-T]IHN=@/-8D8Y!$"9G[I/H;7U$WM+M'I>NXZ3;M :<)&BT->2
MHCEDE6&,G QPP[$GP<8^YQU&EZ>V]U+W.I6=.<MZ@ N/69D #G/R71:+I;=0
MU?W"K<.W9.YN9#6EYY,[I  &<_)<.6SU?PV7R@3<5CI-XM=.W1V::.1Q#1AI
M!\S3(CYX_G!5\$E5"G[#WQKT_:NB\V=4T?#EU00)= \CR1$\0X2 "9]3]/-U
M2]M[>H;"NZW%*7500-SX'[MY(B>(<V0 3([GT)9YJ.?:-5+6;2IX*NF#\*!*
M?D99!@>D<<X+$+D^^"?;7S2L*C;IK:=R2UT>:>!ZYZ#*^05S59>L93NR6NCS
M3P,\YY D^G'*\V=)=[TO2RQ6RZW2TR266\V.IIZM1&.U5U5/-))'@MX9F1Y$
MQ_HKY]]?5=:T]^L5ZE"A4_>4ZC2,Y:U[0#QP 0'?4K[;[0Z74UZXJ6UM5'BT
M:K'-SEC'M:UW' #@UT^I6QLV-=OWG<:U>W9):]]G!Z\M%EC52SS3M-@KD*K$
M+GW7MCWP-<5^XW-&@:=8!OC^7/V6M:T-YY(S'63W7!J;C>4+8T;@!@N89G[#
M6L8&X/)&8Z[CW3>VKKU$H.BU'+:8+?\ @L%LCGJ1'91\TL"*O[1&:3C)(O+F
M,@>!R'GQK*[HZ15UAS;@N\0O($U/+N,X( EK3$&)S@]UG?6^@UM>>RY<[Q2\
MALU3LW$GRD!LM:8VF"<^4XRK'3V_:4&UMC[?H?G*6XQJ]99=QVF$-)4LL7*4
M\9%*RDEY 8\^2/ UU3JM^ZYN[NM!88;4IN.&R8;D&6\ AWKE=&ZOJC[R^OJ^
MUU,PVK2>8#070W+3+8AI#NDY6Y8[_?MA;NLEFW#9+-?)*GYA;9<C;32UM/-&
MI=FD"\@4(SZD/ZG UPW-M:ZE:5;FSJOIANW>W?N80XP )C([.^DE:]Y9V6K6
M-:\L*]2D&[=[-^YCFN, -F"'#L[Y"2NPT_4JJJ"D/]'ZR:H$<;F4*8T)/O\
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M'CYKKKFS?96H?3NI @%H.<DS@&!@Y'^K/>4%INU5&$J;18I4*HK@RR/X5D;
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MP+MQGGNO)7@(N'AS]Y!^+OZ_V]%NK%&ISP5L^_+SG6LM)$W:IX))L<8XU+L
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M_P!X/Y'&D_32^NUXAI(VX)('I_O!^>6G3:KWW1T/?F2A[@'%HHD4NWJ R"6
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M.Y+Y5U=-1P1W>0U=5412%YI)<!(\Y8\0JC 4#B->7U&\MKFWI4Z;B33$ $0
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MRR=YG=6!'< D'%LDV%"N@;.VM1['VI:=OV]YGH;93)2PM4/R<JHP,D #^0
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MJU+:"U^ X9YG+8_W6VUK1:OVF<A>C_AIGDJNA>T)YA&)):0R'M* OJD8^
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MP/08(YUQ9Z>LIY:9M\2SR.\L;B9W2-AR9&CP9!D<P3X.? P>/OFZX>QP>+0
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MSR;P6HAIY.34/S7&,,>6 09"<<FR,Y)/N3XQA<W%6O2+1;02/BC,8_RCH(Q
MCB%Q7=S6N:)8VS@N'Q;9,",_".@@Q  XA:=#MNEI*&FJ:/=@I*6(PQO^'P%
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MH-;1U>\=R_\  =>G'"WG:[J#N:G?H.#R(B(]$J+IKMZEITB6B9>+,PQ.X;U
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M=UE;UZE>H14=&.(Y5"ZTV>S+L_<\<U\GA>+<G?B$D!E6IF9:@=E0&R@&6RY
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M]T7*K^:@HXJ94% W(EGGD)#B,)),0K>0@4M@C7V?2VC3B=18P-H,:023.[&
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MU,]9).28S]VQ6!<X/GG*?V-3VRX6D6FZV]:JQ3QBG>VNZJ[#B2A)^CYP05)
M(8A\.5&O?NNJ5S[U1?MJ#,C\?IWF.T8E9T2TB'B6J(ZH?##N"VT]!':=[<+1
M"BTU'07R=J*:!6QA%>,8EP752Y X^ 3XUVNE>UEG4<_WNTEYRYS1N!]8/''
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MD6^J.N&46EC1+2 [<7"' 9.#N)!=P0.%VS?:/0;767W5*W8:;0'-(#@XO$.
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M<R01ETGKS'"C=[;1K>C%$N_-N6"#:#VJI@6IIZ>H=H;A#)(D;12)W&'@L2&
M^WL1K:T^]I:\_P#95Y6-85 8) EA )W [1VB/Z+=TO4:/M-4_8FH7!N!5:[:
M2T!U-S07!S3M!S$03^!7?DME^W1;:J*Y216R"824TE&M,LJ31'(Y9+9PRMC'
MCV)\9U\W-6ULZC7407D009((/W1@B?\ A?(37LK"JUUN"\B'!VX@AV,1$8(G
MZQT7G3J;T,LNW>J'3JUT=BI)Z&YS50F6FIU0S!(P64JSX)4>I<X&2?MKZ?I/
MM#<W6FWM>I6(<P-B23$G!D#J<%?:-"]JKR]T?4;FK7<'TPR)),2Z 9 X)P>L
M!+ZMV2IZ46#9;T]H@LEKAW13ULB44(<?,A&!**"S,O;48!\E@<^,::+<,UFO
M=!U0U'FBYHDQY9')P 9.?2/57V>NJ?M!<7H?6-6HZ@]HW&/+(P3  .XY["(S
M*VNH77V@W1TYW7;I;M6I)/031QPRV:51,2&5%Y]O"''%F)('(8'C7#IGLW5M
M-0MZS:;8#FDD5 8X),3GJ&@9CG*U]&]D:]CJEK<-I-(:]I)%1IC@DQNDYD-
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MYDJJAJDD!P46%T##*D\F\<W)/J(+(<$*V,-PJT?W0AL=.L]^!T ' P<@D+B
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M]O21G&=>>K:%7=!I7-%K8S)_ $LX =CKD=87E+GV9N7P:-Y;L;&9=Z< FG@
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M!R_D@:]DRYHU]4U!DAK7M(#B1M<8;U@\]><#$E?0&7="XUK5*8+6-J,+6N)
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MW<E60_O +ABF,'QY/T(/V.M@UM8$$- B>(^O7I^<CN%M.KZ\(=M:(!P([2<
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MD=2K1832[:I:FGHMN7F2&25I0&2-AG#?E]8P#VU_[:D^YQT]QONW-=5KL!
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MXI,_.<K<B/@Y]A['['7"N,)M@58@^^JH4#WT0)R3U+^H\D:*IK542XCQ);Z
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M,=EQB*C1//ZPL[:O<%@2LL6Y[F]C@6Z6Z&2@NU#^(HR4\322@TT0"02,<$,
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M&]W8',09&.^!!3\-XE:5;?%LJ*CF,IBCEEBY01R&,D.>* \?H3X\'[^-<;J
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M[&&8<0#+LYY,3C/=3.Q:^\]-]_TVQ[C::C<5EO%,U5;%N8$E13NA]:LYCRR
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M'#L@<0& Y9UJZRS274V'3ZNTQMG?F&>7+0!Y7<[R9,<+2]H*>AOHTSI=<-)
M9N#Q,,AL.8 WRN^+>3)B=JZ7!N=FD6J78<@=I>PLQB"OC!\C,8., #_$?09\
MJZT !8;OI,3C\_URO$NL0UIIF_$1,3CI_FYG^_REK(ETK*6"OMUIM-J$T2JL
M-1%(DR*,>@D >.7(C].)UIUS08XTJU1[X/((()[Y)Z1/K*ZZZ-LQ[J%>J^H0
M3D$%I/<23TB?65'W>_7V*M-)4V2DN A<2#A32R1\@ T?$GQER2@/[A4DY!&M
MBA;6I9XC*I;..0#'!GY<D?:! &5N6MG9.9XM.NYDB/B:#'#I Z-'F(^T" ((
M48UYK<.IVO0]HJ4+&V2$<">;-Q]R!)Z"ON6]?MXUMBA3D'WAT_ZQSP,^HS/0
M>7E;PMZ4@^].G_6.> )[EOF!X \O*Z= SO30N\?9=D5FCSG@<>5_E[:\D\ .
M(!D+PKVM:\AID3SW3[>E%7[^3K!<: 0XP?<>QT18C&&R?IYT18Y'EG/G159<
M9'(>WU'VT466],:K]3Y.BJ2C 9!\J?<:(LB/U8]Q[Y_3118=LN3]-$2E(<<3
M[_0Z(C'&,GZGQHJD:J)9'<&?WA[_ *ZQ46)/!"CV&JB1JJI: 9R?8>=1$DG)
MSHBQHB<'IC_5C_LT43>BJ-5$:(C1$:(C1$W5C-+, <$QMY!Q]#JCE8.X*\7]
M8*U&ZI[Z[UPK5J::>,T=/'3K.C2"*$JF#.",XC\B/V8^^OM&B"H--M]E,%IF
M3,&)/^7Y_:7DKL#QW_K^JK+1T3)7PFHJ(82H+I'2"18W/S'%D4E020L><A?]
M;P-=N/%\KMH)_P!7(\N#SW/?Y+2$"0IS?550U-)0C<=]NEN4)6PK&2U.GR':
M<"50A97/=XQ!F9.2EAX Y:Z?36UA6J&SH-<9;V/FD8S!&,X!@_<N4PX //?[
MOUA5ZGM9MM?'=+#:Z.INT4,4L=QY=JY1N(T$>*0<E]7H# $^AR_($EAW-:KX
MM)U&\J%K"3Y>61)GSX.,QCD;8Q"P'D(+,Q^N$KYAZ^\32RU'S-P:281I/,93
M)("QBSGW!5*<DL?.4;WD)U@!2IT@&"! X$0($_B7<>H^R%"Z3)Y3]JJF-1-%
M2U$KT_"&0*4[Q<KD>M2P$97*$8/@.7',L>"J W:7CS9],>AC,YGY;< ">,1U
M3$,T\[5,DCM,XFG:5R3)Z?>.7)P4D+=H\ OGD6(0N5&3FA@:&B!CT^8]1SF>
MD20 5?4\+-#57,TE7;;>&N-!.(TJ:,SM\O*,N"DIQA4PM*"Y *K)SRO<8CAJ
M4;0.;6J':X'! R#C([GXL=2(S G)I(D-/*T4M%ELU/0U,#T]MN9@K?E:.W2G
MY>6<PKE&J1Z_"_\ 1]MP00?1R.MUU>]K%[(WMEDEW,;N=O'/61]85 ;'WJS[
MEJ:66&A@I;C<;A9J>GC>W5%13]X29BFY-W&?DW[0$-E,@H!CZZZ6T87UWOJ,
M:VK)W &(R(@ 0,<9ZS*Y7QAOV>BB%BITN'-JNK[4M9(E94_**\T2B67B%4L!
MQRD R9!X/@#6^7512C8"0/*)@<#TYR?LK7P>3A6""IQ\/O4H=R.OIXJ^@6*6
MX/C@.8P<+,^"%X$>?);VUJ!LZ]93Y26ND-'H?\HG,]%OTQ-M4CN%Z2^%ZL:X
M=$-N534L-%WEF<00 A%!E?& 23_MU\T]IV>%J]=FXN@\GG@+O-.Q;-^OYKJV
MO++M$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$
M:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(L'1%$[>JFJOQ/E1I1]NMEC'!./=
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MI51PUE?1"C:14>6(*D@C*>ME)'Y@3D>/<#Z9U@7:;M+J;#N .#)$SB?0_/\
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M]2/1:5Q4U%[0RDW81&0\20.G(DR?,>I'2$BFM>W:JIGJJ;</X8!B>&)5^7[
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MU-"N9&B6I51)R#%F\,,!ESG'CQXQJMNKDS-K)XX.(CTZ'OGYJLO;P@DV6X\
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M^"($<O'#>I^1Q4/4PTP5O6:V;8I[A'.]<URB8JRQ_A[&-B"B1N"%/IR5/V+
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MO1^ZWP$BO]S!.#  '<'+!T;YA'"?H+A9;I+'!3;;>6>89CB:O9)"Q!P"3[2
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M:OY7=VX,CG,PTC#O\T-(/*C9[WMU)2AV]&X')2(JTLC!?+!1[,K$YC'L[@G
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M]5]Y]^;MBJ\,Q$TQ&T^LYRI/6HO0JN]1@#T^W-E.8_#*G*C'G]DWCSK>L?\
M%TO]3?S"U[C^"_Y%>#MDUDM9T55WK)*JL&YHW3O',D3"B;@$Y2*,C'[OD#R
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MFPOIRP)X^DG'C412U=T1V1=4,,VW:5:<[?EVM\M 6BA2V2%2].L:$*J^A<$
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MAFHP>09G+2@\V 4-@>#XD(O45HM5)8;316R@@6EH**".FIX$&%CC10J*/T
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MV[ J]KVBQQVJIMU/9JZIN-KJ[;<JFEK:&HJ))))WBJ8W$J\VEDY+RXD'!&
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MJ[_!<;;<JFEK::NJ68U$L51&XDC[G)@R*>)!QQP!J(K9T_Z?[?Z7[=BL6VZ
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M@:E"C3;L>=L@G=P(,MF""9].,(X.$P4NM^0K+M)\U->I+,+A(M46@@+KZY?
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MI)C-%<8)P*>J</W'26/"_F_*I9F.74$MKSU36J[MPO*#'4W"-I&1B 0<\=8
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MKY!!P$**>Z<?#?MCI)N:T76P5%>HM>VOZ,Q05,JR"2,U1JGGD?')IGD9BQ\
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M3_,<\R, &,P>DQE97-S;U#$;CW&/Q593XA.G,V[**X7C8UYLYB$;)''()D)
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M/>'2Z[WWX?ZO8-GW')MV\O8HK5!>J0.##(D2)R&"&"MQ()4A@K'!!QJHO/\
M#\#U[J(-WRJFQ]H-N#8MQV@*';-#4=M99Y8I%JIIY/VDY_9L"& *C !;).HA
M73>L7PP2=7;ZU1-?5ME,=ER[:1XH2\L-7\[25<%2 2 R(](N4)!;.,CWU825
M)].>F74%NM_^43?=UVV\J[;?;T5MV[!4+&K-5).TY>8Y/,J?1CTX4 MY;4A5
M=J/N=9+%&BB-$1HB-$352"U-,  Q,;@ ^Q\'601W"\<]9IXHNK>X"LJ0.M9'
M&9H%5F#&%&X2>S'*@^E77P/"G7V+1&%VFTHR8/W2<CI@]2#GJO'7O\=_ZZ*
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M? /S']OZA.;]W#==NI;]JVNF@N]]G@EH[K7M22RR3RSG IZ>HB8R0$ ,&0^
MS >?.FF65*Y<Z_K.+:33N:) B.I:1#AV/496-5YIM%)@\W7Z]!_55K>6UXHH
MME6#:Q%/60)64ZO8ZV2*HJJ@RI#)4]F3S(59)%/GVC\2 >!VFFWIJ5+J_OA(
M.WXP"  "0V1@3(CY_"2N*JT ,8T<=NJ?WQ>%BO-53K41+2T$"T'SRQ(LDJ4^
M%92 51?9LAN0RYPHS@K"V)HBJ1YGG=$G[6?4GTB..5QU7[G?+'W)ZX8J.@.^
M:2&E[]2MTMD?RL"GDLI? 4A5 Y8P<!%\8R/.K;PS7[5[G0-KS)[1ZGCZE<M+
M_#5!ZM7ISX8%*]!-F EBWR66Y>^>;9SX'UU\R]J"#K5S'&[^B])I_P#AF?KJ
MNI:\LNP1HB-$1HB-$6#HB\BUEQFONX;E?[97]/;;N>GNT< J7L4QE3E5&))!
M4N>$A/!E,@7PWIY*2#K[2RDVWH,M:S*[J)83'B-C#-Q&P9$3(:3QF")"_0M.
MBRUMJ=E<,N7V[J9,>*V#%,.(V#S-B00PNX\VTB0O5MF6X):J5;K)3S7$(!/)
M2(R1,WU*JQ) _0DX^YU\=KFD:KC0!#.DY,>I$ _<O@=R:!K.-L"&3@.()CU(
M !^<#Y+BU)>YIMO';-XVA77B=)YI+E1PV>'L6I#R$)IHV3A.O+!7!=B"['V*
MZ]X^W:VX]]M[EK! #27NFH<;MY!W-,<_"!@#NOIE2U:VZ_:%K=MI@AH8XU';
MJIQN%0@[F&)#OA:##1SN74MA"[+L:UK=J6*FN:4_!H!&L0 !(C#*F50E0O)5
MR 20/ UY'4?=S>U#;N)9/,D_."8)S,$Y(@E>$U8VIU"J;9Q=3)YDGYP3!(F8
M)R1!.5R>EO4UQVC2[:NVT;E>*BFC<W$)9*?A9Y2,1+30.G;E0'(4KS](#,3D
MZ]B^@VE=.O*%RU@<1M_>.FH/M%[@=S2>L[<X 7OZELRC>NU"VNV4VN(V?O7S
M5;]HU'@[FDCXIV^;  75[ MZEZ?4BW.AI1?#;PLM'@"$R\,<" 2 "< @$@9(
M!(UXZY-L+]QH//A[L'K$\]Y[3GNO W9M&ZF\V[W>%OP[[43R)R3V)@GKE<G:
M\RWW9]%8JW:EVO-314Q%55R6*G+6NL(7M10T\BB-D Y*"O(*H3+'ER'LA0;;
MW;KJG<-8'' \1WG9G<7/!W \&#!)F (A>^%LVUOGWM*Z93:]WE:*KXJ,SN<Y
M[3N!."08)=NAHB%UP+>*GI_QJ[?1RWZ2V8EH'P:9J@Q>8SYQP+>/?V^NO%S;
MLOIIO(I!^'?:V[N?G&?FOGTVK-2FE4<*(?AWV@W=AW^J,\<]%R2MODNX]ITE
MH;:MWOE504O%KG4V*G,E#</24B6GD4)QP"I9,JJA,MYY#V=.W;:W3K@7#*;7
MGX14=#J>9<7@DSU@Y)G&(7T&E:ML[U]T+IE)KW? *KX?2R"XO:2Z9R [+C/E
MQM75KZMYJ^G%:IMU'5W^2UL&H) 'II*@Q>8R&.&0MD8)P1[GZZ\?;FV9J#3O
M(I!_Q<.#9YQP8SCA>!M3:4]48?$<VB*@\PPX-W8..#&<<'@+EE[OU5NFQ0TE
M%M>[7VOMT"K2WVXV6G[L5P!SVGAD51&AP SH %]@P.#KU]O;LLZQJ5;AE-KS
MEC:CH-/C<'-))/4-,D]HD+WEK:4["X-6M=,I,J$[J;:KX-*(W!S22X]6M=)/
M)$2%U'?4=UJ>GMT6EM]-7W9J,D4;QK-&\F 2 CX#X\E0V 2!G7D=/-!M_3+W
MEK-W,P8^8R/4C@2O"Z4ZV9J=(U*A93W?%):0.DD9'J1P)A<ROU^J]V4M*;3M
M:Y7FXV]8EMVX+G9X"[UBL>[%,DBJ84\+RD0* >04@J,^KM[:G9N=[Q<-8Q\[
MJ;7N@,(P6EI(<>8:2<1.#CV]I:4M/>X75TRFRINWTF5'0*9'E<TM+@]W,-<7
M2(W2"8ZAU&L3;FV-=K8+7'>'J80HHGJS3!VY C$H4E"".0;!\J->2TNX%I>T
MZ_B; T\QNC'\LB9X(G@KPVC70L=0I7'BFF&GXMNZ,'[,B0>")X*Y1TML];MS
MK#/!?-KS6VX7"BJJ^GK9+Z]PB3,L7>2-.TBH68HS$^3@>3KV.KUZ=UI(=;7
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M(]G4]W@B+V^.CWS4S1/-WHL!W*>EL<N*\O5[<6]U^IW3]1?9/8\U33)\TV[
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MP0AA@BQ\-OPY;IZ+[TM%7>125-'2=.H+')64LP*+7?B575RP1J</VD6=%5B
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M_ I(8JEZB*>&@1NZ*@EE!B9!&&+DNP/E"BM'1_HSU'VOOZS4U-8[ELK:]/\
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MJU34]1%=0U/>:JD,8DJ*B2-XVAE10H(B5E".H()7/T..BN:U;4'NOV@@L(+
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M( F9$@"/G&#5_AAM--:JG<T)EOC7."&@I)H[U:X[>R0QI(( $5V+>DL.;'R
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MGH$:JGXKE(8@SE0C'#\!Y_(Y^FMW_P!6,M[1[K&P+6R29P,Y)($STGYA<1M
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MKH8V42A)Z9V59$YH6C;!PP*EAG6*R5YM^\MOWEKDM!?+97-;&*UXIJV*0TA
M)(EXL>V0 ?S8]CJ@J%:<W4C:5/3W&HEW39(H+:R+72O<H E*S_D$IYX0MD8#
M8SGQJRHMZ_[UV]MRGBENM^M5KA:.-UDK:Z*%2KMA""S $,? /U/@:Q!52-P;
MQL&TXZ62^7RV6:.J?MT[W&MBIQ,W]E"[#D?(\#/OK.5$N[;UV]M?B]XOMLM*
M^@@UU;% #S)$?YV'YBI ^Y!Q[:P*H6\ERI)ZBH@BJH))Z95::))5+1!@2I8
MY4$ D$^X!QK(*%,2WVVP65[S)7TXM$=.U6]<)5:$0A2QDY@X*A03D'&!H>$"
MKNW^K%DN/3NQ;LO,]/M*@O2K-2)?*N*G9DDR8,EF #NG%^&<CE@^0=8K)3=W
MW99-O5-!3W2\VZV3U[]JCBK*N.%ZE_[,89@7/D>%SK.5BL73>5@L-9#27.^6
MRW54TJ01P5E;%"[R/DH@5F!+, <#W.#C6)*J:_I:C;EW!;JFD-!26BGIZEKC
M/4P=J19 Y;TA^<801^6D50>0XDX; *%*I-Y[?K]NO?Z:^VRHL2*SM=(JV)Z5
M54X8F4-P 'U\^-60@4E8[S;[_:([E:ZZEN=OJ%S#5T<RS12#/NKJ2"/'T.L5
M5K2;NL=-?X;!/=[>EZGC,T5K>KC%4Z?VUB+<R/U QHBY_P!-^O-OZI]3MZ[8
ML5O,]MVM-\E47O\ $*9DGJP(R\<<"N9>($F.ZP"ED=1Y&DJKH\E_MC1PR+<*
M0Q23_)QN)TP\X)4Q Y\OE6'$><@^/&@45+W;UTVQLK?5AVQ=JR&G-SIKA4O<
MI:F*.FH/E%@:1)V9AP+"IC(!_GC(R160[NC_ *06*@HZ7\1H[O25%3'<Z:J@
M,*+&(ROI+\Y _<\-&K <3R(RN2*L[]ZY[6V/T_W3NR*NI]Q4NW /GZ6S5<,\
MT;EU3ML V$;+>S8]CI**YV7<]EW3\X+3=J"ZM1S-35!H:J.812CWC?@3Q8?8
MX.B)G<V\;!M-Z**^7RV69JL]JG6XUL5.9V_LH'8<CY'@9]])4A,4]ZVWM>:@
ML$%=:;3-Z*:CM:30P-Y4LD<<((/E58A5'L#CVT1;EGW78]P5URHK7>+?<*Z@
M;MUE)25<<LE,Q]A(JDE#X/AL:BR2=P;EM&T[<UPO=UH;-0*P0U5PJ4IX@Q]A
MS<@9/T&=58PD73>5AV_0"LNMZMMOH6A-0*BLK(H8S$.(,@9F X^M?5G'J'W&
MBJD?GJ6IHTKXJF&6@DC$J522 Q&/&>?(>../.?;&B+@&T?C MV\K-?MPV_:U
M;+M2VM=.S=HKM0.]2E#'(\C_ "XF[J<S$0@()(97/%3G24A=;M75';MTVEM6
M]5MTH[&NY:6GJJ"FN=7%#+,98UD6-06];@. 0N= 558:ZMIK73-45E1#24Z$
M!I9Y B*20HR20!DD ?J0-%C"PU[M],;A%/74T34,(GJD>9%,$9!(=P3Z%PK'
M)P/2?L=%5SRMZ^;;L>X;+9KX39JR^7ZIL5K,U732)5&&$R]_*2GA&P'$!L/R
M9%*@L-)56[TCZY;9ZLVNEJ+?5PT-QJ)*U%LM950_.\*:JEIGD,2L6X%H6(./
M8C/G11;O4CJSMCI;4;8CW!<$HFW'=4L]"'=5'>9'?DQ9AA $.6^[*/=AI,*K
M4Z;=;-M=0JFJI:>LAM]UBN=RM:6JMJ8EJIS15,E/+*D0;DT9:-B#CP/?&A**
MT-NBR'<7X$EXH/QSM=\VKYJ/YH1_V^UGGQ_7&-)11?4WJ?9>DFSI[]>Q4U$7
M?AI*6AH(>]5UU5*XCAIX(\CG*[D*!D#W)( )$*BINSNN5TN&^;;M7>'3V^;!
MNEWBGGM,M;4TM=35G94-+$9::1Q%,JGEP? 8!N+-@C5E5=)HMWV"^7"Y4-NO
M5NK:^VG%;34U9'))3'[2JK$H?]8#4"BTWZE[16FKYGW59$2VQ1SUKFY0A:5'
MQVWE//"*P(P6P#D8]])1;5XWSMFS6V.MN>X+5;J.6)9TJ*NNBBC9&(57#,P!
M4E@ ?8DC[Z*K7W!O&P;3I*>JO=\MEFI:A@D,]PK8J=)6(R K.P#$C'@??64J
M%%[WEM_;4'?N]]M=JA*))W*ZMB@7B[<4;+L!ACX!^I\#5D*+?@N5)55,M/#5
M035$2)+)%'*K.B/G@Q .0&P<'V.#CVU942J*NIKE2155)4155+*O..>"0.CK
M]PP)!'ZC1%$VG?>VK_3W">V;BM%R@MV16RT=?#,M-C)/=*L0F,'\V/;4D*K:
MM&Z+-N"IKJ>UW>@N=10R"*KBHZJ.9Z=S[+(%8E#^C8U915:W=9]MWOJ3;=G6
MFKAO%36VNMN?S]OJ8IZ:(4L\$,D+LC$B3E4(<?0 YP<:DI"M\]ZM]**XS5]+
M"*&,2U?<G1?ET()#29/H! )!; P#I*0M?<6[Z?;<5&L,2W.KJ*BEC-+!5P1R
M)%-,L7?/<=<HI;)QEFQA0S8!P)62YO2_%EL*OJ+,:&M^;IKEN6NVN];WH5BI
M)Z6*IEDEE)?TQ,*63BW[P*G&#G11=9L=XMVX+;37*V5M-<Z&I7G!54<RS12+
M_:5U)##^!T1<E?XJ=CU57PH:IZ]4W@-F5+QR1!::J[<DAF?+_P!2.TX#?4J<
M# )U9PJNFT^\K!<=L?CU'>[;46$*TAND59&]-P7\S&4-PP/J<^- BV;'=K?N
M"VT]RMM?37&VSCE#5T4ZS12C[JZD@C^!U291<3W;\3.Y=L=0K7L^3HQN>INM
MX6MDM/9NMJ$=;#2E3+*"U2. XR1L _%CRQC(.,5%U>S;WM-P6FIZVLH[7>GI
MC45%FGKX'J:8JJF5'".0>V6 9@2H^^"-654_;=^;:W%;);E:MPVFY6V!Q%+5
MT==%+#&Y( 5G5B <D#!/N=%$NU[NL5[HJZLM][MM=1T#O'5U%+612QTS)^=9
M&5B$*_4-C'UTE2%1>K/Q';2Z:],8]W4M=1[GIJJMAMMN@MESI@M;4RRK$J+,
M[B-0I;D[%L(H)/MJ2JK79M]6NL:S4-?6V^U[CN5&E6MC>XP2U(!4,P4*W[4+
MY'- 5.,@XU90J5I=U66:ZR6F&\6^:[A7=J".JC:<*A"N>V#RPI(!\>"1G1%S
M[JY\0VV^CNZ=GV2]0UDT^XZGM=^F56CM\/=A@%34$D%8N]401Y'UD_0Z<*KH
M%UW+:-L?*O>;K0VE*F=::%JZI2 2RGVC0L1R8_11DZ%$S=]\[=LENIJ^OOUK
MM]NJI>U!5U5=%%%-(20%5V8!CD$8!SHHDW_>-AVO&9+S?+9:(PJL7KZV*  ,
MW%3EV'@MX!^I\#5E50-TZR[;H>H5/L&.JCJMW5%FEO-)0=^.-9XU<(D8<G\[
MDY P?2K-[#6*B7MB][;ZX[&L.X9+537&WSLE;#272E25Z*JB9D92K A)H9%D
M0D>0RM@ZR D(G-W=7=L[ W=L_;M[N"4ESW7534=N21E56:.%I&+EF& >(4>^
M7=5'DZA54]3;LL=1?JFQT]XMU1?:9!)/;8JN-JF%#[,\0;DH\^Y&-%$[>KY;
M]NVZ>XW:OI;900#E+5ULZ0Q1C.,L[$ ?S.JBJ]ZZO6.WW78-%22"\0[PK:BA
MH*ZW31RTX,5)-5,Y<-@J5@91QSY(^F=1%N]*^HE%U7Z:[:WE;*:HHZ&_4$5P
MA@JN/=C209"MQ)&1^AT1;<74/;&+PZ[AM4HLJLUS6*NB<T0 )/> 8F/P/WL:
M%55#H3UNI>M_3;^G*6MMNV*9GDI9*VX4TQ>E"!Q-+VG983@^8W/)<>K&DJ0N
MB?B]$]3'2QU<!GEA^92(2J7>+('<"YR4R0.0\>1YT14"T=?]HW?>^X-K27*E
MM]1:9+?'%5UE9 D%Q:L@,T2TQ+_M#Q'L/?Z9&@.4*LM-NZ-KUN.CK*4VVDLJ
M02/<:FJ@[,JR1EV; <O&$Q@F4+GW7(\ZRE15^^]=-J;>K-E$7*EN%KW16U%'
M37BCK(7HX.Q2S5+R22\N/#C RY!."1GZZQ)55WMMVH-P4,-QM=;37&WU*]R"
MKI)5EBE7^TKJ2"/U!UD"HM-MTV5=PK8&O%O%]:+OK;#5Q_-&/^V(N7/C^N,:
MDJA#[RV^FX/Z.O?+8M_=!*MJ-9$*HKC/(0\N>,><XU)RHL_THLO](TV^;Q;Q
M?7C[PMAJX_FC'_;[7+GQ_7&-92$54Z1];]L]8]LVBZ6FLAIJVXT9KA9JFIB-
M=##S9 [Q*Q(4E3ZL8\^^L>46YU"ZNV7ISN;9MHO):G3<LU5!'722QQ4U)\O2
MO4N\S.PPI6,C(^I&?&B0IN?>%A@VX-PRWNVQ6 QB875ZR):0H3@-WBW#!^^=
M9!%#7+JO:+3O#8EBB#W([R:K2@KJ*1)*<""F-0S%@?4&48!7/G4)0+2N?6K;
M=+U!VUM"DJXKO<[W5UE$6M]3%,M#-34QJ'2<!LHQ52 N,Y]QC0%9*ST&[K%=
M*ZY45%>K=65EL_\ 2ZGIZR.22D_]:J&)C]C^;&K(6*V;/N6T;CAJ!:KK0W-J
M5PDXHJE)NTS*&4-P)XDJ00#[@@ZQZJK=(QK((4:JQ1HB-$6)!B"0GR.#>W\#
MJ Y0\+QAU<HI-S]>;S9.X6=JZG<BJ5F2G@=(U-0JR!D:-,Y/!HR//USK[5HE
M3W3167,='1'4B3MD003TD%>0NQNN7#U"I]-':;W76V[4\M10VZT_,4%1*U4T
M0NE/3NC25#+$6=,/+C@/+EX &;U,.VWU[9M6WJ .J5-KA@'87 @-$P#@<\-A
MT@8"UW-:XB.!_3JIS9VYTW#OBYM>:^E9]R<;%-<!(4=$4&58)A(J#':58G*Y
MY,!E?).M#4+)UM8TJ=)A+:4U(QDG!(@GK+@#$#JN2G4<ZH9.78_7Y)^XVU=O
MW%H332M)"P@>.0XX.H< JH.  7D^H)[C,,L@5L6.-Y2W" #G'T_V[\ <$D<9
M&UT.Z+I5CV3:.IJ+9+L\\MVMD;7*"[T%28JRA! "B)CCTEU8D852Q/@><>1J
M7]?1WFM;88_!8X2UWS'Y<F.J[2G2;<#PSR.O9<J@^&^JL^_+G2[1ZFVFGN=/
M'-%43URM2S<7]$T192P=AE.?^NA'N->U/M52KV;#?6!+,$1D3R#!B.L?(K6]
MT#'EE.H)'T4]T6^%_;=]I:N5MX-?H0HBJK/86^6@E7!>)9'+9='"97P,@@^
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MU T44/N;IYNJNW!NJ[7?:EYO6VTN^QKE?: T,DSW6AIJ!Q5*L6,U/:F,3R1
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M5"*L4:13S<>XS-&SX7TDTZ'P/.K4U2BU[B:&[.&@@G;,F6MF(F!.?,5Q> 7
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M0';8,$2.TQ.%Y+V=KV5M<U*UY$M8XLW;MI?B [;!@B1S$Q.%6OAVHMZT=IN
MW8MP6%TIVA-X,1JGJ.!%2V8_)B+!.'/UX!SXQKM?:=^FOJL]PVSYIV;MNV?(
M,_:B=VWRKNO;&II%2M3_ &86R-T[-VP-D;!YOM1.[;Y9XS*NO4+8$._K?0I^
M(55HN-NJUKJ"XT?$R4\R@J#Q8%6!#,"I&"#KH=,U)VG/>=@>QXVN:9@@YY$$
M&1@A>:T?5WZ34>?#%1E1I:]KIAS20>0009 ((X4#M_I+<H]U6S<&Z=X5VZZR
MU"3\/BDI(*2"!I%X.Y2(>IN.0"3XR?&NQN=9HFVJ6EC;-HMJ1N,N<3!D"7'
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M>'9].>_W)%)MNJO%[N=XJ*BJVMMZLOM=%+5FH,,H@GC+E4II582,6*GDGIY
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M-?1K*GJU4MH.M7-:[$CQ&#/4Q+0/7;ZE?6-/I:Y6++9UF]C'8EOBTQGJ=LL
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MXQY78%KZNVX7CII?J-X&F$U/Q,25L=&3ZE\":165/]8@_P".-=/HM7P-1HU
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MG*DNF=TA_P I&PBM--$[31%RU,J31AII$A>:,@?G5>)=, /^[Y&N'5&/]PO
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M\WNH-935$;^:Q)1&'D5'\<<^HCU,OD'VE2G:V+V7]P7O+SNW>&W:YI'P%NZ
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M99PK$CU/_:^@T1-DY;[G51+E(1 I/@?;ZG]-1$T>3#!\*?W0??\ B=5$[#A
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ML%;O$>,'R/I_+6*A3?LW'O#E] <9T43D?<5P<J1[>01HBPQD1F!53C^RV/\
M?HBU1<*>::6!2LL\8!DB1E9D!]BP!\9^F??524ZB)+&P+"''D*A*G1$GBJ9[
M3,Q_AR_V_P#?H$0#,6P3& /.%/JQ_/66$2GDBY!BCLQ&22.7G^/MK%58,O<S
MAXU^GY@3JA$N$Q\\,S29&"![?[/&A1!5D!"QB/!QY./]VH$2"WGS,!^BC62)
MWT21YS*S+_'&-8*IINV& [9R?."-9A1*0QHP)BQ_Z9J%%BJGHZ9HS)+#")&"
MIS<)R8^RC.,G]/?6*J?[8/++.K?5LD_X@Z(A.X%X^F5&\JRG&3_NT1)23+$
M\7'N/8C11*<1N"SGML!GN#Q_C^G\=$34-9%5TZ5$4T51 W@3PN&0_3W'C40I
MT''\=51",(\D#TG\RCZ_P_719((\ @\E/L1]=%$D@@\D/&0>Q^_Z'1$ZCBK4
M_NR#P1^NG"J;:)D/GQJRJEQN4/W7ZC442I(5;!C/O]#H"D)H J?/@Z)"?$B3
MCBV"X]\'SJ<(FI8NV.1("CZGQC5E(2HZ@KZ7\K_NT([*I3P*XY)_AG22$325
M2TT\4$DJ1O,2(XW<*SD#)XCW./TT,(MU8U'E0,_?6"(#,K8P2![L=$2"47)0
MJ7)P,G5^:+/AD_;84_QU$1)+PP/W/N#YT1***ZY;#?7(TRB:J.?$!/R?Z.LA
MZHFEAX#E(0H_4XU2469)QC@O@?4Z0B;2$O\ H/N=643W):=? R_ZZQY1,'E(
M<G.3]]9<*)V.'^V<?I]=8HL22 ^E1A1]/OHH4C@6.!Y.KP@2V I0&;#2'PJC
M[Z3*I3$D@B5YIY%4 %G=SA4'\3[ :+%9CFCEB69)$>%@&$BL"I!]B"/!T626
MS A0P.!Y"'V_B?OI")+N7]_?]=6(19A8N,H0%!P';ZG]/OJ'")01(FY?UDG]
MIO./X:(FVG4^>7,M[<3G.BQ3G&5E" *F?)^I'_#158[:KC+N[_?.!_L]]%4@
M+$\F&P3]1[G_  T46':*20@1C(^G#R!HHD%4)_JF'\!C6:J6G"-6;,J$^![Z
MQ*)',$ K.K ^V<>= B#R;'.,2>?H?^>LD2Y3'%A0[0\1YY' _P!OC6")!=HQ
MG*,#]0<$_P##6818B>)G!"NI_-X''_;['4*+76ZQ5#1=NLHY!-R,?[=27 ]^
M.#AL?7'MJ"$3Q"N?VK,I_4<?]O\ WZS^2B<*+'$<,)>1_*Y+$C^.N-5-]]5
M':9#],C _P =9PHGE,A]E4$^V6UB54Y,'R!E?2,> = A3!R#ZIL?X#62)V)D
M#\C,<*,^XU@JFN2$G]H3_P"G:SA1')/[PC_T[3*H3K,HA4=[\QS^8:Q'*B;"
ML?:3(_@#K)$I1)D <#_K C6)53DTC"0@QD@>/20=10IAS$S>0 W^D,:R"BSV
M\#TNP_VC51')U_=#_P #@Z*H616.,X/V/@Z*)<V13R8]^#>_\-8CE0KQ'UQ
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M[X_0]?1<$M=NDL\][J=MR4MVH6M#K64R[1ECBDD+JJ4'%OVG&3FPX*?V?'+
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M'[=V2!@8R%4,RX.%/(BKW4CK!>]Y["IJ7<=OLE??H++U&LM3>:>C>)^5OA,
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MG?PY]>*CHIT<V!-N98#L:MVK?KA3SJA^8_$:&NJ)Y("Y."):=B47&>4+8SG
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M]\ D'_'VUR1A0IT>1E8@1_$:Q1/ R)#^15+?K_W:F)623F3]/\3HL2@=PL
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M>O.52&T[0>6./U^ODN71)0UWQ8[*IK5:JE*JB:B-;-/+R-4%HE;NB/![9"$
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MW-0V6B:HD2H:G=G+54LC$MGB"B$#RJ,1D :X=:JM@:-;U2]H=N>8$3CRM Q
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M"J%C$OE#@CZ-_P ]11*8]H8D]?Z?]^B)+,)",,4Q[#Z:JJR%D8^I0_\ I?\
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MV#R'+QR[OGWY?77T?WRYI_N:)!H_S>\P8XGXQ!CILQQ'1?6OVA=TIH4' V_
M=[V0=HP#.\08Z;,<;>B]!TM;>3LB*KDMT,>X#;Q*;>'Q&*GMY[7+/MS].<^W
MUU\U>RV]\-,//A;HW==L\QWC*^15*=I^T#2%0FCOC=&=F[XH[QGA>>WVE970
M7(PU#[J$9<6YMA+VN]CEPX]CVY>.7=_7G]=?2Q>W(/@R/!GXO><QQ,[^8Z;/
M3;T7UX:A=@^[AP%O,;O>S.WB9W\QTV>FWHO0%PKKVNQ)ZN*V0R;A_#S*+<7#
M1FI[>>WG/D<O'N,_<>^OFU*G;&]%-U0BENC=UVSS]V?3LOD=&E9G46TG5"*&
M^-T9VS\4=#&>,=EP*3:=FHV-RM5/45VZHDYP6Z?8JQ1-,/4$/[!>V.1_-W?3
M[\CC)^CB]N:G[FN0VB>7"X),<3\9W&.FW/$+ZR-0NZO_ $]RX-MR<N%T20TX
M)^,[C'39GB.B[YNVKO$.Q[A/;[=%5WCY0E:)@)4+D>I<9'/&3XR.6,9&=?.;
M)ENZ]8VJ\BGNYX,=#UCYYCGHOD^GT[5VH4V5ZA;2W?%P8Z'K'3,&.<PN"Q[5
MM%IJDN>W:>>Z;IB*M!05.R%IXFD4C"E^Q'V!D_GYCC[^<8/T4WEQ6::-VX,H
MGEPN-Q@]8WNW?+;GC"^KNO[JX8;>^<&6YF7"Z+B >L>([>?\NWS<8Z>FUS@9
M&#KY.OB"SHB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HBC+)-7S?/_
M #T?;XU<BP>D#E$,<3^OU\ZV[AM)NSPC/E$_/JO/Z15OZOO/OS=L57AF(FF(
MVGUG.5)ZU%Z!0V\IQ2[1O<S!BL=#.Y" $X$;>V?KK9M03<4P!G</S7#7,4G'
MT*\.;,L^UVZ7-56.LN=5 +[3RB>XQ?+34]0M&59HFB8@AB_$JX*GEP((.=?;
M]2K7S]4V7C&M/AD0W(+=\YGM$R((B5X\;?!\H^T.?DMFOGNU9N.Y[AL55)3R
M4ZP""KI*F6"..1WBC7E3PAB!'3M'&"!VP WU)UKLH6[*#+*Y&3N)D F "<.,
M<ND_S<+!Q>7FJPY';]=E/UM=:NIMRO-9:Z@05=0T=?9Q':H[7WX 60T35TG[
MM14$NOU(5A@<M=8RG=:,UC*PE@P[S%\'G=L'5C<'H#U6TXLKD[<..1@#Z3Z]
M%5Z3>&X-E554G=^7=ZHP5E%<XIIXZ[M1,9QPD#22AJF;B'4(I(4 L,#7;U;&
MSOVMC(B01 +9,-F/*(8)(,GT"UFU:E!Q:.O=7VT]7)+L]+!M#95QN%\DF%/*
M*9U^1MTA;MR/(ZMSSQ9BHD5>.%)\CST-;0S0)]_N6MI@;A/Q.$2 !P?6)E;C
M*X+OW;/,?N"@:'I[46^JIJ2Z7"0;@>#L0SR5L:-%-%42K'--42OW'8+*C8AR
M"%89]M;E34_$876S)I Y&TY!:"0&@1!(/Q=86MX.PP\^8^O7U_V6O7]/+'%:
MZN"DK;D\%3'\M2I<2()(*C@(9'--5E"Z2*8\21^HA'^IQK)FJW3WA[F"1DP)
M!$[@-S9 (,X.,CHAH, P?Z?@>BL=#<MR=.UJJ:X[>NVY-KW2OJZF"X6B1I?P
M_BRQQA8Y#Z(BA)*R<1R&1X )TWTK/52'V]9M*JQK06N$;CR<CDSP1.%M-+Z$
MAS9:>H_7'S5=O'6"HW-/^'[;-+9;%7=RBY1\?F*TL'B#=[^KXB7MX17!&1ZL
MG&NPM-";;M]XNI>YL.CH(@Y'/PSF#P<0M5]P7#;2P#^*:L5$DUA;<&YYI**U
M_+RS4MJFIC6?.2/E)^=!-^T5*6H82<ERO%B <'7)<UGFO[EI^:A,%T[=L?##
MVX)J-Q!@R,JTJ>UOB5<#MW^G8)%^NMXWO;8+-;JN68V>U%:R&%)+4/Q2*5#-
M*\8'859$F& S>58^,YUG8T:%@X7%T!+W".*GD(, &=T@CH.5E4>:H#&\ ?+/
M=3^T:J@N^]^G_-Z>H:WSTZPKR<QP@E1$0N1S=8GBB$LI)'I 7+:ZV\IU+>SN
MID;@>V<Y^0)!.UL=9.%*)WUF3R"%ZPC]-%3I'XSG'OX]1R?.OE;OC,KU[>$\
MJA5  P!]-8'E9)$A+L(Q['RV/MHB<'M]L:BB;;]J_']U?+?K^FJB<SXU%4V/
MVKY/E%/@?<_?67 5"5-6T]+"145$4 \E#*X7./<#/OK#JA342257&8!NVPRG
M 9R/OD??64@+%+FD6E3&.)_=0>"3H,HLK"TZ=R0Y?V8#ZC_EI,*IN27#"*,9
M;ZX_=&K'51*CC$.&8@\?/G\H_P#'WU.50A^55B11P@/L2/?]<?\ /5XPJDLW
M ]N( R'W).<?J=/FL4(5I2.0[SM^Y]__ !]SIRBU*FBBB)R4,A'+B/ZM1^H_
M\$ZR!E0A-+3M&P:I9G4XP'\?X'Z?P/\ CJSV4CNMZG?M(5A)9/K W@K_  ^W
M^[6!SRLDIDCE(/F-_=6'C_V^B(CED&5<9*^Y7_?C1$K]F3W%;@#^9E^GZD:B
MJ6W<A;$@S_I+_P M.432*A<X/OZE9?I]QG51/B0LO"0=P>P;Z@?J/KJ$1D+)
M-Q8:/B<-Q\$:>JQ29(F[;!&SX\*Q_P!QU90)Z&J69563(;'C[_\ ?J$1PJFZ
MJGXQM(OTPW)?^.@*Q6>93^L&!_:7VT52FE.(\^M>7^_]=(53H17_ "MC]&_Y
MZQ0IJ2-DEC)'OGSJS*@60Y4Y!(/Z:L+)9-06F7F XXGW]_<:FU1/<(Y!E ?X
M9\ZF0JFU6,2OY<' ^@_74,E1.!T4$<F(_LD:F43<:PO)+@E?(P/Y:R\R)PX3
MP(SG]3J(LAI5]@$'ZC&HBRW"0CE)AOKCR-$26_9^R?S/G1%G,@\LW$?Z1\?X
M:(C,3'R//W]AHB2XD]E_*?['MJRB$!B_,X7/T'G3E5*[J'(5>!^Y&=(42#%(
MYS^?/USG5D*K*L(1AFY_Z(\ZG*BSW4=<*>U_NT@HD"!\Y'D?<>W^.K(53G=5
M1ASW&_\ 'UU(E1)8B485N(_LGQIPJLH)%\#V_7VU%%DF($<O)^O'VT1!+L1P
M<$#V"G'^S1%@%F.&CR?X8T1*XQHWYB#]O^\:(AGD;V*LOV'G1$GZX,7G],C1
M$F58T:,MD$DCCG/TU42FD0J0.2#[#&H$3#=ONIY<^#]!^FN15; 2-1E@0/U/
MG6$E$RTW&H/;7B. \^Y]SK("1E18+ESY))_72(0I,<3-(Y /G SI*B=[87\S
M#^"^=25DFUEX]PKA!R/G/_'64(D!RY] R/[3>W_?HL2L4M/SC60^2<DNWL-"
M4"<EJ%@5A'ZY "<_^/;2)Y5321,4 =L>/*K_ ,])41*0D00>.7@ #0*)T.R>
M$PA_M>Y'\-%DF'50X!/^DS,<Y^PU4*<!>4X0>_[S?\M3A1)4(A,CMS;]TM]/
MX#]=!G"JP\LC85!Q+>Q8?[<:L*)($<))\RR?4GR?^[3E1%0W).,S8##S GGE
M^A^_^[0>B+0:F9R6IBT:C.0GG^1/U_A_MUG/=8QV3E/11S, A038Y<3_ %;#
M_P ?S&H3"0MURD_I3,3)[K^OW_[QK'A9)*-W&$<H"RCV(/N/N-/DB4BM3MR(
M)@]W*C\OZXU.51A*F19LLF%!\@#\O_C]1JC'*J1%(23%*,/],_O#3U"Q3G9:
M)>ZA\KX53]_X_;4F<%9+"2+5(2P\_O*WN#IPH4VZO W-/VB_O+]<?\=9"#@H
M.5MQR+V RL"7_P!@UQG)53']4V?96/D?8ZRY6*<^FHB;7]DX3V5OR_I^FJB<
M(R"#YS]-1$W&2A,9\X\C/VU54M@&&",@_311-/ZH)HW\X1@?'N"#JH?A*\L=
M1WHK/U)WS(%BIFK\QS+F0I/^Q17)4D]MWB22'NQ$9&01Z<Z^GZ52?7L;<<AI
M],9Q\P"0Z'??E>5N7!M:I^NGZX57VW>;MLBWU-HKZV:%KU; M''.DEU3\5DE
M?M2HF.RPC2#R%;TJOMYUVU_0H7[_ !K>)8Z"9#/( )!^T"2>HR5KTZCJ(V/X
M/USW6+_08L7X_MKO5UI:B26>V4D#4/RLR@)#QH(?VKK45 [P=L+Q4 G U;2N
M16-G?$"I.'&'2/M?O'8!8WRP),DJOIM+34I<=1Q'T['E;UHZP?@*-;[^::^6
M2VS1TQDEPL](O!8PPF.(R#*LV5=R3ZO5D :X;G0O>2*]IY'/!,=#DF(^+X8R
M!](1EP1Y:@D#[PININ6X^I*P1VG;UTV_MJV5]+537*[2/";CS<QR%HXSZX1'
MA@B<AR\GW..O\"VTJ7UZS:E5[7 -:-VV,C)&'3R3&%S.WU6@,;#.I/7]>BKU
M)T\L=59:>*HJ[C%;Z6$4]9';AWI*BHX-#&PIJ7FR)&HD)=_4!(A]QC785M4N
MJ=<N93;YC+9Q D.(W.@$DQ@8D'HN(4J;FY/]?P'YE.573V:X25-';+G(-Q"G
M[$]5'<(Y7DGEGB626">-Q(A9868=X!0&49'D:XF:CL:#<,_=$X&T@ !I@$$1
M )^SGDPL30+I\,Y^?7T/]U9[OU<FM#U<>[MDW&WWF*?Y.'YJ1?D:^3EVXWC=
MFYD\55F$8;.6(\ZT*6B^.6^X7(=3<),?$T1)D=!VF.BV'W :?WM/S?@5SRKW
MKN7?,L""I6HECJA34U-;()8(J)I41X$X1A9(0)X2A=E=?6P)49&O0T["TTUC
MC$ B9=!D#!R?*989@$'L"M-U2K7< ?\ A6BCK[/TYN]HJ[E*M5<(':X7DO9X
MKB8*<X3Y):Z,^5IJ@ D^X4@ >G745*5YJ['-HB*9AK1O+)(SNV'J]O'0GKE;
M;2VV+9R1DXGZ3Z%0EL:\4U_M.X]P5 J'F6H%355=1-*DKQO)&Y2GF"DJ].LD
M9)';*D?4#79UF6S[=]E:C(+8@ '(!@N:3$.@_P T_5:C7/#Q5<9G]?DI8TU@
MBZ0;^%UEJ:>WUMTMIK:VBC^9JCF4KS?N,%*CCQ 0!4"D*"1K48Z[&K6C;8 O
M:U\ X''&/G.9)Y/*VJ6WW>I/4A>C/ALIZ2GZ*[9%!)/+1O$\D3U,8CD*M(Q'
M)59@#_ G7@/:4U':M7\4 .G,9$P..%WU@ +=NU=-UYE=BC1$:(C1$:(C1$:(
MC1%C&B+.B+&-$6=$6,:(LZ(L8T19T18QHBSHBQC1%G1$:(C1%'7ZOK+9;7GH
M;9+=ZE2H6DAECC9@3@GE(0O@>??6S;TZ=6H&5:@8.Y!/X $K;M:-*O5#*U04
MV_S$$C[F@G/R50CW9O:HW#:E79,]+:'9HZYYZZE+Q@XXR)QE.>/G*X\@Y!R,
M'NS9Z:VA4)N@:@RV&O@]P9;UZ&<=>9'HCI^D,MJI-Z'5!!;#:D&)EIEHB<09
MP1!$&1T#7FUY)&B(T1&B(T1&B(T1&B(T1&B(T1&B(T115@IJFF_$?F*I:KN5
MLDD?&0MVT.,)Y]L>?'ZZW+E['[-C8AH!]3W7F]%M[BA[U[Q6%3=5>YL$G:TQ
M#,\$=A@2I76FO2*O=1#C8.Y"&9#^&U/K0>5_9-Y&MZP_Q=+_ %-_,+6N?X#_
M )%>'=DT;4G12HBCK(;I2P[EAFDDH(6; 2D+KW/2ISR*L<^%[>ONFHU'5-8:
M7-+2:1 DCJ^,9/R'>5Y  ^ZF/YOZ*3VC5QTE3)+:W[K_ "K0&"-RLLU.8>/'
MTN2"55QD8.5.,'75WS14\E809F3P#,SQ',?>L*1V>9O*=I]B<+G07*TDWNS?
MC5"[4\\CUM730T\!X)(9"(T7DQS( WYU. 1YX&ZD74G4:X+*FQXD !I+W9.!
MN.!QCA<[J0:0YAD3]<(J-T;7ONRZ.M$]335UNE1:J&[[A-42LY%5VVJ5C:1P
MDBA! &C9L  @Z-LM1L[DTV-!:\8AFWX?)(:2!)&2X@@<JO?2J,!(,CN>>O,?
M@B?:F\=R6E*6GGI+1MNHI4GM<RR+1Q":%FECDEB4<_8.J(.0 !<LX3)Y!>Z=
M:/WO::E8$AT^;!P0TS',$G$\0)A<894>V 8:?IQPFY^D-BEJ9*&HOU0]==)V
MC4Q%(84EDC*U$?-E9WC+J!D $!&/T9CFS6KMK1493 8T<<F ?*>0 0#]21Z!
M3P63 =G\$U3;)$ZP77=]754U?55!I::&"=6YK KO&621,-'#R 3#CFJ%L$9U
MD[4P#X%@T%@$DD=3 ,0>71G&"8Y4-''[P\_K\$O_ "8WW;M.*G:5\6K>.C_#
M:"$SB&;G*6-4987RA0=N164,QXIRSF,YX_VQ9W3]NI48\VYQB< >4 C(/!!X
MG'4+E%$@32,G[OGZ+=MC6F@WH[[P6BH[A;EEK;C%$YC/- LJ@1]HQSJ##&!(
M A0%>1D'$GBJMN:EK&F@NIO@-GUD<[I:3)D9!S !D*,+/$_>"(Y_7"CUHYNJ
M%PM-1:+?4PVV*IN4$E;>[I^*)PJH$=A\RCAX%5F[:J.2_IKDIN.B4JE.Y=YW
M!AVM;M,L<8\I$.[DX^:.=XS@&XYY,K;IJ&&U;<:V)65$M,T=,;M7U%3)+#4S
MPQ\08^X045%!.#Y/($YRNN U'UKGWA[ ")V@  @$]8YD_P"W58N,,V-/S^:S
MTG6G7JIMIA'))%3UJ)4K!&Q1&,8C52P9@<,D3>_O$QUN:O)TVKNY+<2<\SQ
M[D?56VCWAL]PO9T4?&"(EN1XX\?ZQU\6.7%>R9P$X/IJ+)-Q>>3?VC_N\:*)
MPG )/L/.HB1"/0"?=O4?YZJJ)6*1L?KC0*+'()A$')@,?H/XZ(M.YV>BO%.*
M>X4=-<8G89CJX5E3 \_E8$?0:<JJF5_P]].+A\J\&SK;0FFG^81[<'HPDO\
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MQ45NAN5%454DLKQEHDJ$9D0Q^LNP&%"^2Q 'G7I- JU*5X32:7/+'@0 <EI
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M,#3:B<B=Q&J$,0!C*^#K& BRU,Q(PV?XGSI(1(*HI]3Y/V4:J)0G"C 7D/\
M2.=0A$O)E'H8H?[.I,*)LP.HRQ"C[DZLA5*618?8EO\ 8-2)4614 ^,=O]5T
MA5),+MY'K!^NJ"$6% C.2_D?1/?5Y1+^:7E^0?Q'OJ;2B08^Z<J_(GZ,?.@,
M(@0%,%B$_C[Z3*)?S"CQCG^K:D%1)=EF_>*G[-[:L0JL?+N?./'WSXU=R)0F
M$:X+=S]#[#4VHL&59% 8%?\ 5]O\-(A$D0%R>#!A]AX.K,(EJ&A&78J/[(^N
MIRB/F<$X0 'ZCP=(1(_9N?!*_P 1G5R$2UISXPX /U)UB2BS*'$3(O)LC&3H
M(43*5+NBLV"2/.1]?KK*!T529I T1PBY'J&/T\ZH!1.)(CLGH&&('N?KJ$$(
MO*5F^(KJK)TMN75JLV]M"X;&M53<9*NU4,]9#=4HJ2KFIYI4=^43R*D+2<#Q
M#8P&!UCE17CJQ\3 V!O_ &C;K;;:6Y[9EAIKCN6[.[ VR@JZA*2BF7'@\IG+
M,&]HXW/TT*JA=^=2^M]@ZRV'9EK3IX8=R0W6JMM35T]P[D$-'VCQG"R %V$Z
M^4\95OTT(A10M?\ $7OB;?6^;!!NOI'M./;5T2UB'=E=405-2_R=/.\X43+^
MS+SLH./W#DYSJ2D*RR]2.K6Y^K&[-J;,I]BO!MRWVFHJ);R:T?-S5<,CD1O$
M2$0&+ )5C@CWUE)1=*Z+=1$ZM[ HMQM;WLUP,]307"VS3"1J.LIIW@J(>8 #
M*LD;88 <E*G SC5W(KI&T<0*9,CJQ'%?8?SU225"E,@<$-CSX&/I_P"/OK&2
M,K$X!*YE:>H>X7H[=>ZZ&US6:NNIMS04R2I4PAJIJ:.0LSLK^H+D87PQQ[8/
MKJ^FV8>^VI%PJ-9ODP6F&!Y$  C$P9/&>5[NYTBP%2I9T'/%9E/Q)):6NBF*
MCA  +<$P9.0)YPWMW?\ ?JBW[3O-\CM36F_3"G5*-)8Y:1W5VC+%W977]F5)
M].,@^V=976F6@J7%M;%V^D)S!#@" 8@ @YD<SPLK[1;$5[JSLR_Q: )\VTM<
M 0'1 !:<R.9B.5)U'5.&DZEP65OE*BP2VKYS\1@EY%9^4IX$@\>/;@E/CSE=
M:HT=SM.-R)%4/V[2(\OESWF7#Z%:K?9]S])=>#<*XJ;=A$>6&"<B9W/;Z057
MML=9;I=KYMNGN-MIJ2CN<U='-QY<J9DG$=/[G'J+*K9'YF&,>VNQN]!H4:%=
M]*H7.8&$<09:2_IT@D>@S*[6^]F+:WMKFK0JESJ8ID<0Z6%U3IT@EOH#,K7@
MZX7&INEN9K=31VNHO<]&TWJYI1"&%XYSYQR/?5CXQQ/W\ZY7>S]%M-X#SO;3
M:Z,07[G M^7E('65RU/96@VG4:VJ[Q&TFNC$&IN>US.)@;"!UW?<K9M[J"+M
MN3<]OK#24%#15,-/15$DH5ZD-W%D)+'!_:1.%"^X&NFNM+\"VMZM.7/>"7",
M-B".!_*X3/5>=OM%]VL[6M1W/?4:YSP!(;&TC@2/*X23U*U*7>^X+Q6S;?IZ
M"DI]Q6_NFZS5"R?)PK@_+M'@AF$QXD#.559,^0,\U33[2@P7;WDTGQL C<?Y
MP>@V9!QDEL8)C8KZ586M(7U2HYU"I'A@;=YR-X.('AY!QYB6Q@F&;9OB_P"Y
MZ>MK+/98^_;(.-71UQ97:M5AW*2-A@950WK\KEXO]+%JZ;:6CVLNJN'GREL1
ML(P\CG)CR\P'>BM71K*PJ,9?5S%0^1S8@4R#MJ.',$QY<$ /]%LKU+KJ^US;
MHMU DFSZ:2/NRS1NM5)  ?F)T7Z+$Q4<2"6$<I'[N9^R:5.J+&L^+AP,01M#
MOL-)[N$YF!+9ZQF-"HTJPTVXJ1=.!@ C8'8V,)ZEXG(,#<R?M1:]I7VKW!:I
M+C-3I2TE5*7H4P1*U-X"/)GV+^7"C&%90?.==/?6].UJBBQTN:/-VW=0/0<3
MU()&(70ZE:T;*L+:F[<YHAYQ&_J&^C?AGJ02,0I?)UHKJEK3QO"XFC\I_P!(
MI]L??5D'"B7',(E>)3RA!\D^X'V_@-0#J5.%B', 9?>-3@?Z(^FLCE$M8V$^
M8@"&7)7Z'S[Y_GK#IE1.S-'- RIXP#Y]CG4RJFUE( #X\^S#V.LH18[+-.AC
MP#YR#['QI@!5//,LJ\5'I'NI]_YZ@"+77E%*_'+)@>GZC6>"%$YZ94'[RZBJ
M:C<Q!@?*!B.7U'GZZI$J)X^I3^HUBJL1']DG^J-4\HB7S$X_0Z)"4&R ?TSJ
M(L2@/!(I.,HPS_(ZQZK \%>0>KK6ZFZG[SCBLUTAN]3,8X:Z.Y&&.2<PP=ME
M7L@%03&2O<_</GZ:^M:**SM/H_O&[!D@MDQ)G[7SZ=5Y.[+17?(,_/\ V58:
M$24=3+3T%1FHJ/7VJT$3Q&.H,:EL$(1R5L\G]U.!KNFO >UKGC'^7@RV?GQ'
M ^:T0"1 "WZV"@V[3TU;N"U5+VTUM;\K/54SI!!"8Y^8<9GY=QORGMKC\^/W
M3K47UK@&G9O =M;(!$DAS8_DXZC<9^&5RB&'SC]?K^ZS:YJNZT%=;;%>;=3M
M5!7AL%1#\W<908$[!6N/$9#A6!R"%0#&5X#BNJ;*9;6NJ3G 3+P=K/B,^3/R
M]29ZRLOBD,(SP.OWJ<EH+K1WN5IUD[,L<T?9+=E^\S2F,EL> W=4@</ GB7]
MS75LK4'L&V-P(]1  G\N_P!DGJN0M+>1]/U^N$Q:J.\UUSJFM\TE4D:!6+.)
M'4$EHPN7!CXG+MX_:<XR,]H@;=>I;,IL\9L'\^_3/8=H,_%*XF-<]Q(Z)JRK
M51K5QU,TU1/%W86$=1VQW&#*>*@-Q#R.C+#D%!(@RI'$9W9IRUS  #!DB<8^
M4P!!=U@G/) $&'?K]%9_ ]P14=/7&=(G@=9JBY54?<I8 K5#)))&3AE5Y89"
M,GTO&.)[>N$7%F:OA@$@X#0?,?AP#TD CY@F<KD(?MGH/U^OR5?NFX=OA;G)
M<[A2[CJZXU:4E5;\TM/(_;C5T2D[3E)#[";P!D8)Q@=O1MKO>QMLTT@W;+7&
M7 22"72)'4MS\LRN(U&ESMV>Q''W0G]PV>NMDM;QH;@'2*)Z!G!A,$7;J0@+
M-(W<,9."OH.3RR=2A7HO:PO<)!.[K)EL]!$C@Y[*;2<PL50I+7>YY):.MBMZ
MUCRU$<=T$<C#,F6+! 57N20OC@W@CRP.=1I=6MPVFX;@/Y9CCI.3 (Y'T0D
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M=.YZB2[7R:FKGABN<,U%65*\6@CDC1%,#QE4'#"JQ09:0Z^@ZI:7ELRJ+&@
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MK3=K<L(/[HQ!/1TP2#V!_P"5X]HBW/\ J_HIW9%.MREDXTLC44%(*B2:IJ<
M(8D*P ,0HD.0BY(!+?0'73:@[P1N:?.3  ZF3)[P.2L*3=Q@\)D;NN>[[U99
M6CK[7MQ[Q;ZFFH4C6=3%41/&2)J?$A<.&!9^0Y8]L:Y#8T+"@\DAU4,>"3(\
MS2#P[$$'@1A<SGFH0!@2,?-2MUK:#;&W+39C;JVV7&H)6M@J+I2W"M>.%DHA
MF5D>%E*L"T.8R?/D?7KJ%.ZOZKKGQ 6MXAKFMETO. 0[D&'97(\LI-#-L'KD
M$]OT%&6BDW>L-?>-D7NHOO;B6WT]IMY<?ATTK\68T\@ *!5')7#LC,&+,5).
M_4?8#PZ&J4=A)W%Q^V ,#<.I/!$ B1 E<=,5(W4C/I\_1*NV^]S6^OD-=M(?
MC,$C&&H>FDAGD,*!>^4XF-Y'?B555 Y*<#\NK0TRQJ,#J5SY"!(D$>8_#,R
M!R9X(]575*FZ8R%IQWG<.W*F&VWBV27L-/WZ:6J)Q"TQ95(,0+/X$4DR\LAR
M3X)!US^[6-Z#6H/%.!! Z[>>>.H88XCHN,/J-\KA]ZEI:CJ?NVSM'\I6[7M5
M10]^&58VI*>VU%*PY<F&)'Y@9"%FY.WV36H/V+950016>'$$?$7-<,>@@\D
M0!ZKEFN\1D#[AA(VKNFQ6[<E''-</Z0455.*>HN1@C^7JV9DA!/[+N2R?MCZ
MTX(A!_.P=CC=VEW<V[GTF^&6Y#9,@#S=]H&.#)..! 6-.HQKH=F>?UW3-ZIJ
MC9]XLERLM/>;))WKK5"&:X"ZMV*>%8D,4@8P(&XCTR<F#'Z^VLK9[-1IU*-R
MYKL4V_#LRXDF1&XD3R($+*IY"'TY'/KPM^.ZR;@VW4UM5:)!?;2*:GN<)J(N
MY/(4#-(L</F/B9 KJ!@%AC\Q&M;P!:73:3:@--^XM,'&8 EW,@2#SCT6#B7-
MF,B)_NM;I7)"O57; XU$J"KC><U"HX8=J+AQ<CED22Q#&?W#CQK<U<$:76,Q
MB !/<S(^0)^H2U,UF'U"]FHS?*P\\\N/DGW]SKXP8W&%[)G"SCEJ+-(A_JU_
M08UD41-@1/DX\?74'*),8,RJSCTX\+]_U/\ RU3A$5#]N+/N0? ^_G09*)2I
MR(9\$CV7Z#1$B63C)&%\L21@_J/KH HEK&$))\D^['456(I><LB'(A;!)'N?
MX:$1E14?J[U)I>GUDGI*6:&3<E7232VVC8$@JB%I)W\$".)0TC<B >''W8:P
MW*JL?"ML%]E=):6XU[2RW_=%0^Y+I/4J!.\]2JL.YX_K!&(PWT#<P,# U6HH
M[:N[[MU3^)RZ-;[G44^P]E6R:WS4D9Q'<;I-,8WE;!]20B":-0P_.KL/<'6!
MYPBFOB?Z@5?3WI+>:FT5?RFX+B@M5DG! (K)LJLN2" L2+)*21@"(^_@'DF!
MZHNFT\),Z02LTI7$;M(<DJIQYQ]6()/\]93C"QY7D[X8[O>K9U/^9NUSN$='
MN&[;IM2VDL&IJB>CKC,U=X.!(Q:>/EC)2.,'PJ@<'59KT9UDW(-J]/[C)!0T
MMYN->!;K7:*O!CKZZ8\((74^"I8\F\>$5R? .LR0 HN"[9^&G;&R^J.TMMV"
MZ77;U^HML7"Y7:\V"H%))6SSU-)&9.W@Q*#)'*P7ME>*HI'I7&,9A56#=$_5
M&T]3-K[6M]VM_46GMD<FYJR"LC%HK6BCY04\4T\7*%B\LC.@$,?(TS<F &2(
MS"(V-USM6T^IW4^'?B5>PXJFZ6Z6G:]JOR4):UP*RM6Q%Z="S1$J'D4MXP,Y
M  D<J*]]8ZB#<6S*"QVVXQ=K>5;%:8ZFEE#@T[AI*QHG4D?^DL-0,CZD:SG=
MA8\*,Z_;5V_/#L>[WJV4E7:;+>H*-X)XP8TI:S%$>)QE.$DM,X*X(,0((]Q"
M,2%58)]C;BVS723;5W//AU519]S2/7T("D9$<F1/"Q'C/.1?] XU8@2$6S1=
M28Z2[4MEW+;9=JW:K=8Z6.JF66CKI"3Z*6I&%=\+GM.$D(]D/G0.[HKQE95^
MX_PP?^>LN%928)W@+DME"V.1_3QYU2 5$[/VYHR&7@Q\ K]"=8<(5DKP(4.&
M7Z-[?R.B)$D#-*%93A03_/Z?\=60K*2':(^KROMR^W\=7"2EI*[<R3R!].#Y
M! _\'4@*+!J# I)57C7SY'D?\]-LJ\)4$B]M<QJ2?.03YT(1)E/;!:-/)\<.
M7N3]M )Y*DIR*2/@ L?@>/+'4(5E)ED5@$$8]1^Y]OKH!ZI*=[N/:-/\-2/5
M$V\[O(JC  ]1XC'\-4 (EYED_M-_CIA)61$P.20GZDXU)52RZ8P[<S]U'D:9
MZ(L\4(S&HD/V;WU/FB;:63VSQ_0#&J(19C$OT!X_K[?[=#")1CA.,OP/U"^1
MI)1#CM>4C##^V3G4Y1--,Y()8ZR@!%2NI/738'2".)M[[MM-@EF&8::JG'S<
MW_K.!<R/_P"FJ=8$QPBH,?Q1R;C9OZ$=(^I&\H&\PUYM$=HHY1]Q)7RPL1^H
M33<40>K/7>H_])^@=OH4]\7+?E*CX_A%!(,_^G: HL+UCZWT)S6] $K81Y86
M7>]#4.1_HI-'#D_ID:%$3_%Q9-O$_P!/=@]0.F\*CUUUWL#U="#^M11-.BC]
M6XC0.A%U+8/4S:'5"T?BFS-R6K=-",!JBV5:5 C)_=<*<H?T8 Z3**Q&5RV>
M1SKD@(G$9I<\HP_ZCQ_MUB<<(L]N$/\ G/\ #/C_ !U),(B02E?0!P_]5Z")
MRB:621/ /C[:S(")X8(S(JJ/O['6'R18#Q#\N5/]IAG2"B;>-G;(D#G^.L@?
M1%CA*GT8:N%$A)Y(Y&0GP?4,C_'2 43O>)]U4_RU(53<,P0A3&/0P\^<XSD:
MI:HO*=G^'_JU3])KITGJKOLVW[*NM1<HJN\435D]T-%65<T\L<<3HD2RE)FC
M#EB%_-AO;7'!X25/3_!OMS?DW4&LWRU545.Y)?D*2&S7>MI8*&U0P+!10-$D
MB)*Z8>4\U8<Y&QD:RVH%9;)TGW:^YNCVY-RW:V5]WV=M^Y6N[U$!E_S^HJ(Z
M9$FCY*, _+EF#8P7\9T#2553JSHAONV]0NH-[M&V.ENY[;N>\_B\$N[8ZEJR
M!?E*>#M'C3NO',!888_G.H6D**9/3_J_M/JAN?=VU?Z!M'N2W6B"J@NE17**
M2>DADC;MK%%ZXBTI(#%20HSC/B0471>C/3=NE?3^BV^UQ-WKC455?<;J8NU\
MY6U,[SU$JID\%,DC<5R<*%&2?.LP .4E7B.)EE*JIPPSX'N1[_\ #64A1+4%
MFP'5 #Y8^?Y#4*$2(5,L_2ZVVN:D+7"ZUU'25CUT%NJIT^6CG,C.'XJBLW%G
M+ ,Q .#[@:[ZMJ]:JUP#&M<YH:7 '<6P!&20)  , 3]2O3UM?KUF. I,:]S0
MQSP#N+0 V)+B!( !@"1(X)3-FZ8V^T?A49N%SN=!;"11TE?+&\$!963*JL:\
MB%9E!<M@,?KYUE<:O6N/$(8UCG_$6@@G(/))C(!,1,*W?M#<W?B.%-E-U2-S
MF@ASL@Q)<8!(!.V)(3UZZ3[;O J>Y3-1Q314\)BHBL**L,KR+Q"KX+&1U;^T
MK$:PH:U>6^V';B"XR[)\P#3,GI ([$2L+7VBO[3;M=N+2XRZ7$E[0TR2<QM!
M;V< 4BIZ06>^P7!:@UD25:U4;-%/P*=ZH2=F4X\,LD:E?MCZZM/6[F@6%D';
MMY$SM:6 '.003/=96_M%>VYIEH;Y"PB1,[&%@!SD%KCN'5.U_2^PUM94@+.$
MD64,J2!4024R4S*HQ](XDQ]CY_37'3UBZI@ 1B,QGRO+Q/\ W.,^F%QTO:"]
MI!H:02-N2,^6HZH)SU<XSW&$[:NG]EM$O".F%6$IZ:'-<%FX=D.$<9'YSS8E
MO<DY\:PK:G<U\EVW+CY9'Q1(P>,"!T7!<ZS>7)^/;EY\LM^,@D8/PB  .@4A
M:]O4\-]N5X7N]^O$*RJ[94]I65"!C[,<_KK3JW+WT:=N8AFZ/^X@G\EU]2[J
M5;>E:NC;3W$=_,03/W84A9=O4NWS7/"T@^=K)*Z19&R3(^.6/'A?2-85[E]S
ML#_LM#1\AQ]5;J[J78I^)'D:&".PF)]<K1I=HT%'L^7;41G%MD@FICEP9.,G
M+EZL>_K./'VULOOJM2[%Z8W@@^DMB,?1;534Z]6^&HNCQ 6NXQ+8C'T$Y4G0
M4:6ZAIZ2$MVH(DB3D<GBJA1D_? UIU'FJ]U1W))/WY77U:KJU1U5W+B2?F3*
MVHXB_DGBH]V.N$F%Q+,D@X%$'I^N?K_'0#JHHW'R]0 H_*, ?VD_Y@XUR$R%
MB3E/IA)LH<QNN<_V?/O_  \ZQYY1.3.*>11%DQG/+_F/T_30">54F1<J74X.
M/Y$?KJA5*IU[Z!,>< %3]-0X1$S]B2.,'E'Y)?Z_S_34'FRBRZ!_(/%A[,-7
MA$W"^9) V P.,#5*);1\3R7 /U'T.B)-,W.+/U)R1]M#@H%B13"K,GY<'T_;
M]1_RT&43D)!B3!SX'MH>4"Q,<1M^HQH$2\8]M1$F;Q3R_P"HW^XZG"Q=PO'O
M6?\ S;K#N7NR2@\UG@EA5$ 4TK%@9 .60\<J^3XY#/C7V'00'Z73 '>>?YAT
MXX(/'3NO(7@_ZAT_K":>XSV';=+406B4WB]+4TELB%1$TD#A"RRO%-^<.T95
M$(P2GGV&N,4/>KAS#4BG3VEQ@Y$P1+>(!DGG*P:=K=Q&3,?W3>VH)=Y76YUM
M\@O=ZEEJ+9/,JUHMA2&KI6@<RR$B%PH<^F,JQ;Z?36=X]MBRG0MG-9 >)C?)
M8[<($;@3')D0K3!JDN>"1CK&"F=P;IM%ZN==(UQ2Q4D%0L5-<41334.'D@++
MB(2PRDTX\RB1'/'!1BK#*TLKFWI!SV^(2)+23)P'1S#AYND$9F1(4>]CWDC$
M<+85^I^T;<M.M-7[IL\%":BHD>(UE-<IZESQ(8YD3@#DQJR\73/LYTVZ-?UB
M[<*+BZ /A+0T?<9/!,R#W"R_?@2<C[^5%SWC<^XY)+5:K<UHX3]Z>>C+$3-#
MQ5SB8 IX,LD*\B2PSC()UN4K>PMFBO<5!4Q !Z3,?#SF \Q@>BX0Y[\ ?=^O
MN6Q:=\[FK*^-J+:F;O/,BU%6D$DLT9F0J)Q&%$:2*_(N&5@'89&.6L:VFV+6
MD/N/*!(!( P9VS))!'!!X!]%R,J5'N^'/Z_%9N5/NX+1W;?-\FLG<A>WS6NX
M!V_$9HI,(PID&.!5CQ50K.RLP92P(E)^G2^AIM'?!#@X?9!&?,>LC),AH@$&
M$>UY$UC'^WHI&AJK5O3:MPM L]SK[M35,4%.M-<:6W5L4,SM3$B942+ 2/*P
M>LC(P3[CK:[+K3;@7(J -<"3(<YL@!W!)=R<N,?1<K#3JM+-LGIP#G]<*,I]
MY7'9]RO")35]RV_'>+G65-.X6G1Z>!!$!WJG,@8R8PR\1R+>^=;SK"A?4F.:
M\-J;& ').YQDX;Y8 Z&<+@;5-(EIR)./P2][PQVR= *29**:B-3')3S\NXG9
M<F XRAD!!1@,X*CZ Z6#C5IN+B-X,'IU$.[QU"QK ,$#CE+J:-+K\/\ OJF2
MFFGG:]4*0B*%$D:-)>*'"+D_M%E.<9\^/IKFI5!2]H+5Y,>1Q,DD D3U/8CT
M7.S%J_YA>G/AEBFAZ$[/CJ(VBFCI"CHPP00[#!&OF?M.6NUFY+#@N_HO0Z?_
M (9OZZKI^O+KL4:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%0
M^NM=2VWI+N6IK;;37:ECILO1UDQBBD'-?S,"#@'!P/)Q@>3KT7L]3J5=4H,I
M/+'$\@21@\#CTS@<E>K]E:52MK5M3HU#3<78<T21@\ XSQG F3@+B?27IQLC
M=6Y%I:A.G]SCB@-0E-MNX5CU",&7#<7EP%&?/CW(U[S6=4U*SM][#7:28FHU
M@:1!Q(;SVSW7TWV@UG5["U\5AN6$F":K*8:00<2&S/;/$KU1KY"O@ZJG4RJO
M-)M65[(L_P QWHEFDI(%GJ(J<N!*\4; AW"Y(!!_@QP#W&E,MWW(%S$08DD
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M5A-PS1RLS]L^/2 3[?\ M]900(0)TSA!GMJ!]SYTB54B.9_+8"ESGV]OL-"
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M))=)#EE()^H.K!'"J.VA]I,?HPU)*+!@;Z8;^!SJRBQ^TB^C+_LTP5$B6:3
M8'DR^0#]?N-4 *)8G#@'BC ^0<8TA5-3S1QLLG;&?RD GS_[;0 E1.((\\G4
M\_T/@?PU(*0DO+%%(&*GBWCW_>_[] "@PA0CMS=3C]U>7M^I_75RJA7BB9U*
MD*/4,MXQ_P"WU,J)+$5"X,86,_3SD_QU8A.4N.J81_NKQ\$@ >VFU$Q/)),H
M<EN"^<?5A]?Y:R  1.^D+]  -15(C@DDE;*<4/J ;QGZ'_AIN"B<J!''">3Y
M;'I5!DDZ@DHLQN,A^(+'R"?/'^&I")GN-*TBJ? 8Y.?O]!_MU8CE%CEB1HT&
M#@'P/8>=6.J)EXF96C'H4R\#GW./?_=G6<]5%OHRPJ%C7&/WC[ZXB">58222
M3DG)^YU1A5 !8X R?MI*J<[:QGU^3_8'_'4F>%)29)"_CV ]@/;0#NJD>^LD
M3=72F2'G^7CY!U <K$Y2/F%;M.@*Q."&!'D']=6.ZB#F*:-?W/./T_367(56
M9(V2-RGA#X;_ $<_76,CJA6Q+Q"@1'!'CE]Q^OZ:P&>55KQOW9')&"H"E3]-
M<A$!%DGL DD]L>_^C_W:<IPA4#Q#(P3ZLC]=.J)+2$*5;\Y& 1]=%$XT6 "N
M P&,_?\ CHJD.W=4)CBQ."OV^NG")3(5)9!Y/NOW_P"_1%AB)2@!^N3]_&G"
M)[4534IR"H)!"LV1_ ZA"P<O+N_GI;KU/W[!#%QJ:?F8RU-%W*AXJ>.6H2!0
M<NRPDGG)A>3*H&<G7T_37/I:?;N^R3G)@ N+6EW:7=!)B3PO+W+0^M4 Y_V5
M8VAM"OOUAN]YOCT(EI;6*&GEO2Q5_*O2;E35+F/$I0"<$Y(\MQ.NSU.[91JL
MM[*?,Z3MEOE+8<W.)EI^Z5K4J0<UU1_ QGO],PHW=MYI=Q6J.PV\P4&TZ:-J
M=*"E44L5342!1.\U'4E2)(JEUD4J051O \9&Y96[[:J;FX\U<P9.2 .(>R1#
MF @S@GE85:H</";AOI_8^JN-NZ64=NJS<MW5BQ5LTL=8EKIAFK5Q#%R$LP_:
M(%<,> 9O!7+8)UT5;6JE1OA6+?*)&X\1)X;QQ&8'R7.RV:P36/TZ_5-5FP8]
MHURWS8;UL4$U53S7RT0U2U,,5/"SNU5VY&+21L<QE3G!!(&<8Q;J'O@-MJFT
MD-.QT023  D#!',_)9>'L&^W^HY^J@Z??4]38;>U3M9MPT3(GS-OJ_\ .H&J
MF3N02QP3 F)@\I4\/1F:-?88UV%336-KN+*^SF",';,$%S>00,3F&DK6\9S0
M!MGO_P )ZLW7N:]W 6ZUT5PJ]S5%.X8B=JB6IJ8IH)V[3DB&!"KR%6C(/%O?
M(&L:=E94&BK=. I@\1  (<T2/B<00 0[J%S-JU:AVTQD_P#/T^BLT/2W9-N2
MXI6UM;=KA<9)):R\&L,DCRER_HC#%"L; J>0/(Q^?!UUS=9U*IM?2VM8S#6@
M "..>9([<2N4T*+3#I)ZE4G=O3BNVG36ZL2MI:ZU351EH:VFBBACCF$*1T_*
M-RB12*K33!B'($>01XUWMEJ=*]+Z#J9#HAP)))&[<[(ES@<-C'/5:;Z#J8#I
MD=PK#8:RT=0;]8(+_#:*NXP21TE;55M)/<*JLH"B_)<JD8C[[2D2D#P5P"/2
M===>4;K3J3ZMF]PIF2 "UH#Y.^&_%M P#S/S"VJ;Z=<M%7GCJ21T^J@+)8KM
M9]UTMCN4Q>CM\-145M3&T$M%)DO4SRF*#!&(68!QAN<@4>,Z[&ZN:%2T=<41
MYGD!H(<'8AH$N_S=.($E:S:3M_AN/?Y=^GHE7:XPR=#M]]BKEH9Z6YVJ5)$
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MVE^]M,$GZJ9Z/?%'LRVS+!4;<J=IQH0\USI&6LI\!#''WN**RHBL /'@*O\
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M4G"8Y.PTS]X*^Q:GI>JZY;^#<BNQK3NB*+VS!R=AIGY2"O6X.1KXNOSXJWU
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M"& QW4(XQYDX5M^)*XR6Y.FEKAM%?>HZ_=M))-06ZG#]]:6*6JCC.<*B]Z*
M\G(10AR1CSD[. BONQMIU^VVN%XO5<ESW1=YQ+6U$0(AA09$-+ #Y$,08XSY
M9FDD(!<@4 =5"HCJ=T7MG5O<&V*FYW*OH(K*]2)HJ!Q'\_!41*DU-(_YT1^"
M<BA#$ KD!CK$CJ$]%T2FML5KI(*6E@BIJ2%%BAB@0)'&BC"JJCPH    \ #5
M!")1&#K)%!;VV5:]_P!B:U7:.0QK()Z:JIY#%4T<Z_DG@E'JBE4GPZ_<@Y!(
M,+050JGMO?5VVC>+=M/J!(C7"MF--:-S4\/;H[L0,I%*!XIZLJ#F,X20@F(^
M3&F();RJNF-$R?F&-9[@B1HL4XL[*,>X^Q\ZFV5DF:\QO2N<=LCW^HT (*Q=
MPN6],HWMG5OJY;%C*1R7"WWM5]L_,T*1R%5^W<I&/+ZL6'N-8@P81=/[;9:4
M9)SX'W ^FN2>B(7C,2WNN.(/_C_QXTX1+^9<X@9LMC)SYROWU"WJ$2I'&>YV
MUR/?'C(^VH!T1$#12@R%67E[>?8?;5,C"),ZI&?V;D<_<<?;[MJ E$\D484<
M9%P!XSG4DHF&B"RGBZ&)3ZO/U^_\-9@X1/=L8SW$Q]\ZQE$P(BK=[DO _0GV
M'WUE/1$\ZJB\C(A'Z'.L43?86(]WN*6;\ZJ#[?I_#22<*)UC$%!#EF;\H \'
M4RJFS%'$ R\G?][)QRUE)/*)U98R 5C!'W))U(*)7S!'Y55?X#4A$EII&&"Q
M/\3I "R6!&[>RD_RU9"Q*4*=A^8A1^IU)[(CA&ODL3_JC3**E]7^JMJZ.;#K
MMRW"EFKFC>.FHK;3>JHN-9*P2GI85^KR.0H^PR3X!U#(55(Z.=.[WL):C=VZ
M*:+<G5;=-3 ]^GIZB-4MM(7PE+3\SXI:93CBOJE<,WDD8@"+JEKML]AL*0]^
MOOU130M_G%6R-55)')@&8*J\B3Q'@ >-98:BY'T#Z\7WJ5NV_;?OUDIJ2>B1
MIXZZTNTE/3E)##-25.69HYHYEE17(43B*1U55 Y8S.$5NW9LCIIM+<E=U.W3
M\C0U5-VIYKG=ZUHZ*GEC0QI4"-V$2SA,()>/<XJJ@^,:D*KD-1\>E+O>JGH>
MBG3'=G5R6$LANE%3BWV@,#C'S<X^_P!E ^QU$66W;\85^3O473?IGM>-O(@O
M=^J:R0?Q:#TG5DHD_P"4'XM]L1_,7+H_L3>D*CDR;8W+)22D?Z/S.03]M-Q1
M;NW_ (^-FTEZAVWU5V[N+HW>ZANTD.\*+C0U!(_Z.L3,97W\MQ'ZZB+JN^>G
M=!OW;]DJ-MUU+;9[3 \FWY8T2HMM/*\0BBJQ OID:&,OVO/!2Y.#XQ8)1<PV
M7=K9\+UCK;1=)*Y8*RIX;=VF;BM1/3V^F"4_?:::011M,W[4J9$3+I&@,F00
M.U%V#-+O;;MKWEMCY.HN51:6FL=PN"3"#M5*1R#N(I5N+!8R1^88\8\YSF5%
MR?JK;ZC:6YJSK7TXIY;E>+*SVS>-@I$93?J&#Q( C !JNF!+Q./SKRCR0PU@
M<Y"+NNUMVVG>^VK7?[-50W.SW.FCK*.LA\++$ZAE8?;P?8^0<@^VLAZ**4*Q
M,/!9?X^=7*+'9S^5U;^>-655@P.ONI_PTD+% =D\ D:8*S2_F' \GD/](9U(
M"A26J%"DM&H'Z>--JB:X)*.3JRL?*X;\NLLA$XCQ%<EFC9?S?I^NL<HN2638
MG2&'JE*+74V=M[4-1+<UL*WAI&HIY >[4I;^Z4AD<.Q,BQJ?63G+$G'T3*QL
MO971JAZA21[:K;%+NFSO-4"S4]Z-0;2\F1,\5"962E8\F#,D:'U,/&3D%<J/
MLNQ.B=J-/N.WUM@-ON4M3:J!S?FEH1)4$K/#11M,88I),L"D 5CDC ]M9XX1
M6"Q?Y):[=MAI[/>-K5>Y=H4,]LM\%)=8I:NW4H18YHB@D+<0L2A@X...?!R=
M881:FX=K]);ALN"BN]PLE/M.Y5LVYJ687IJ9)Z@.:F6LBG256P&<R%D?BH;/
M@8U3PIE:&UKCT)V]''66K>^VYUM#R52U=1N[YXT9J$$#,9)JE^"NH50">.?8
M9.L0854;<K;\/U\MKWRIW-MJEI/Q:JJ$O%LW2*+C6U"HU2$J(:A.!E"([Q*P
M#$!RN3RU>.%!*F;M9NAEBV+'<*Z3:5)L^X6V.P)4U=R@6@J:1)'D2!79^#D2
M.[\@>?(DDY&0&4*V+%TIZ5VNLJ%A@HJZYSTU)='FN-ZFN%8*2GG6>FD$LTSR
M"G6:-7&"(RR^<ZL!$G<?3_I1N^I:Y7"*SR56\JF@GBN-+<VIGNLU*KM1O#+%
M*IDDC5GXF,Y*XSD 8NT<HH&][&Z&VNYV_;%UOU!1W>CJGJ*:AK=Z5,=QAFFB
M5#Q+58F = HX9XG((&3G4QPBF:E^C>WK;3=-ZJ];4ML4-9"1MNHO,,<YG[ZS
MQAXVE$CR--PD/+)=B.7+/G*1&U5;O4B/I9;=YVR\;YNNW;3N2**&:C>\W=*2
M8I!.987"-*O,),68$@@$L/8D:GEX45:O%LZ ;CKF_$[[M87B]UM+>^=-N9:.
MIJZA:=H*>I0Q3HY8PR,H9?#AO/+WT=$JA="VQ3[%Z:;;N]OM%5:;/:J"J;\5
M9Z]28JF4*2:J:1R_=</'YE;D04^F-8P BA*RT]*);IM_8U15;?%XVU2N+;8F
MN:+74=.:9H7 C[G=,9@9E8-D%<$YP"+A%6^G&U^A$T[6#:-]L5_-=;9+?^!I
MNV2[134?$!XQ2R5,BE J@>%\ >X&H(1;U1TJZ)[-NAV]>)K6EXW!0FU06^^;
MAEFK*BD9@33TPJ)VD6,LBY2+ )0>^!IZ*K:O6T>C])U5@:XU-FH-YW"LCND=
MCEO9@^<JEQPJC;^\(Y9AQ4B0Q%LJ#DD A 44G?J#IA=*'J-%=:VQ/2W"..FW
M?WKHJ!%$0BC6J/<'8_9X49X$_P ?.KA,J!L]AZ+[:O5-:(=Q6IKK5S45=36Z
MX[NEJY9)(W6:DEBBGJ7/YBK*5'J!'YAJ8"*8W3TLZ;;\WA>*6XTM'6;@_P Q
MKJ]*.YRT]5"\"R+23NL,JNA"R2*LG@LOIR0H R !"G55VJZ<]'*K;=EKJFZ0
M?AL;UE5:[D^\*L%@8U^:[55\UR= D +*'*J(R2!@G2 $5UVO9-C[:DVU;[!)
M;K<R6^=;+14M;@34K,DDTL<?/]L"W!FE(8Y;/+UG.6&X3E6::_6S\52T27"D
MCN;T[5AH'J$$Y@5N+2!,\N 8@%L8'MG5X52[3>:"\VVGK[?7TUPMU1'WJ>MI
M9EEAEC_M*ZDJP]_(.-3G*B19;Q;]R6Z"[VBOI+I05*YAJJ*=)H9D!(]+J2I\
M@^0?<$:L]%5OM*.WR7SGP!]SI"B3&GR^%)])/O\ 8Z'*+,XRH4>&/L?M^N@5
M68S@<",%1_B/OH5$F=2P 3Q)]#[>/KH/5$N-@RC QCQQ^VHB;G!SZ/S-X(^X
M_P">LAZH4X&Q!(T8SA&*@#_1.H?5#PO'_62N0=6]S4J.D1-5"LD3$A)&DC01
M\E("DMA@'97!/CD#X'U_0J1=IM%Q'0Y] 3.><=0"#UA>.O"?'?\ KHJY5P_T
MPZ?_ "P>2JALE8DZ1/6O!!'#-RA<.!@LRE%XQQ^H>H! 20>WI$V&H^(W'B C
M@$RV"([#.2<>O5<,E]*/Y?ZJ6OLU0-O[:O5CCIZ2\;>L]' +I16:,2"!D:%I
M4DJ&C(*3(\7$@D=Q3@>3KIK/:Z[KVMV996>X[2XQ/(!#0[H9GK'*YGN):Q[<
M%H']OS71=DW>@W_&N[KA5"&2RT'_ *.0Q&!I6,:,RU3NO)1W%08C3V/N3]?/
MWMO5TUYL:;9-1WD.8@F( ,'!/)^Y;E(LK_OG=!GZ=?JN1V^Y-U"NL&_9Z>2[
M72NF:AI:>K$:4EH8$]NGBRWJ<HT04D%0TK.0<$:]O6:=+IG1Q#&M <2)FIW)
MQ@ @SU@ !=?N=5=XAYX_V^Y>E.EG3M%V]:'EF@BG^218X'I%CE[:RC+XD3GA
ML#R0N1QRH\ ?+-3U(U*S]L[9GG$_0QCZ_-=U;VL-$P"N9=7]G+8)J69::WWJ
MTFCE6034ZI3R0R2CT"0 )RY*B AD9>:G#J&QZ72+YMT7,<YS7R",DY'6,\<\
M$&",&%H7- 4C(R"H7HU64UIW96=+7K:^MAJZ-[A005L:)+;JD@R?*ACR5E>+
MA)[8SY]R==IK=.I<6K=<#0"';7$$PX<;NA$&0L;:=QMW=<CT/^Z:WSN2XQO2
M]/K#5I7!GDH[FR4U,\5SJY& =)8I)%9.V0%/ \6+9&,#33K.AL?JMVV!RT2X
M%H'!! (,\YR/58UGN'_3TSGKZG_90/4*PT-\39UBM=)1)%2QU5# J4[VR:8-
M4"(S!A^R7E)%,P#MAAQP&/ON:3>5:'O5Y7+BXP3)#A@3&?-P1P,=PN*N-VQC
M1Q].J5O'<(K-Q5:?-2M#0)\I#)6%GEAC0B$<LCD9&*@97CR.<%_+:Y["R++9
MI($N,XX,^;Y0/68'0<+AJ.W/^6%LM<&3H3U JV2FG(N= DD]?'WPTBR$.N>)
M+%3X!+-C..0((!E('7;2F)'E=QC$8^6/0=X6S3)]VJ?,+T_\-=5)7=#=HU$L
M,%-))2EC%3H$C7,C>%4> -?+O:9@I:Q<,!)@]<G@+T=CFW8NFZ\TM]&B(T1&
MB(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T15OJ-=9[)L>\U]-=Z2Q34]
M.TBW&NB,L5/C&6*#\WC.!YR<>#[:[32Z+;B]I4GTS4!,;6F"?2>GJ>R[G1J#
M+K4*-&I2=5#C&QI@N] >GJ>TY'*\Y=*[->;OO&2HBW+9;_NM(Q5"LW58J]*T
M4_/'*G65U14R<9C48R,^^OI^L5[>C:!CJ#Z= XBE4IENZ.';023_ *B?1?9=
M>N;2WL0QUM4I6Y.W;1JTBS='#RUI<7?ZW&>B]8Z^.+X"M>X6^ENM%-1UM-%5
MTDRE)8)T#HZGW#*?!'\=<E.J^B\5*;BUPX(P1]5S4:U2WJ"K1<6N&008(^1"
MC[?LZPVEJ,T5EM](U&&6F,%+&AA#'+!"!Z<DG./?6S5OKJMN\2JX[HF23,<3
MG,=%MUM1O;C>*U9SM\;I<3,<3G,=)X4QK277(T1&B(T1&B(T1&B(T1&B(T1&
MB(T18.B*&VTU"QNOR2RKBOE$_=^LOCD5_3VQK?NQ5'A^)'PB([=/JO*: ;$^
M^>Y!P_?5-^[^?&Z/\O$*:UH+U:K_ %!?M[#W&P0R8MU0> !);]FWCQYUO6(F
M[I#_ #-_,+6N?X+_ )%>&=L7"EJ>A$LZ6ZDM]/)?T7M4DLC+YI" )$9F9LX_
M(5;D3X7(R/N][2>W6PUSRXBF<D#^?H8 'SD1WZ'QPS;&?YOZ+7H(Z&II+W01
M<Z&X5,3"DJ99CR[D:@&(2C(5R%1.>6&66-B6'HM9]9CZ59_F8TY;'0_:C&,D
MQCJX".>)KI!;UZ*>Z:R)#<-TVNJI"RQU#37A(8G<54"KVY(((E+O%/\ ,R1O
MW<J#D'QQQKIM;:XTJ%5AP1#.FTG(), %NT$1F/JMJV^([OKZCM\YZJ$L57;K
M-U&C3=%NK[K)%=2IM=/6)654C&3#(S\R9U!\=HM(Q9?3]<]E<4ZU;2@^T>&#
M9DD$#CH(@'_, T1RL6$"N!4SGA2<TUMHOBNWJETMU95UKR5IMX,H2"/_ #-B
M.XOABI3P.+#&<_PX2VL[V5MS:/ :(W=R=W3I@\XRN:H&BZ?(G)_)=8N]NM?_
M )N%S[EFOLH-/4*U%::IH^U,9) W[_@<F(*GER!488C7AK6O6_;=-Q>T?#EP
M!!  ].PY$1S(6^&_]*X$&<\*+Z+;=W?2=1[I'U*@W!4[@>UTWR5915O^;14X
M$BX98V4%PW(<F#<2V3@L">T]H;K3GV=,Z.6"F'.D%OFW8SF3$1@$?@EJ*HJD
M5P9C]?KHJ-US>Q46S]S05EFJ1W-P V^HIZDAC-BJ+22\B0T>0X"JH/GW/'.N
MY]EQ>/OJ)IU1 89!'3RX$1GCJM&L&!SA&9_NL7NX6:U='.EM-<Z&II+XUG[T
M5TJ,+2L@<\(G#-^U*@\N/%PF5+*0V-<MI1KU=9OS0<"S?EHY^8[=ID$Y ,I5
MVBE3!'FCE;6VYELG3>2JEI:R512F2O1JKYB:NHWYPQ0TE0,QTS+4LA=1PP0&
MX^//67L5M8(ID R #$!KA!)<WEP+1CF>ZP;_  9(^?J.D=LJE[0I*>@V^;C<
M.U);ZBECBM=%&&5I9S+)SD0<CQ<2*092PY%P  6!'K;Y[JUWX%'#@27NQ@0(
M!P)$<-C $DF%J QE6+HP].G4K:RQPE4DJ81B,'R$8J,KXPBG [?_ $9 Y1J<
M/KKM;8\V%<N/ /XY^\]_M#AQ&%RVP_?L^87MF/$D$+!.V@4X3.<'D=?##AQE
M>U;PL3>E1(/S+_M'VT'99+$7K_:'W8>!]A_SU3V1$Y*@.HRX]A_:_30919B
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M@-+S4I^\ ?\ ;I,H4J.EDR6('(_8@X'VT+@B:>*2%Q&JGU_E_P!'_P ?35W
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MT@IEY#0?FNB7BY6_=]+<]OS,MDH<BFMM2)7$E+/$L:1%Y..((0JH)"">7('
M)\>0I"O8OIW8!<X^9P@06DDG$Y,S'9;#GLK$TR8'3YCCY#NJ3MZ"2UT^X=CW
MQ(9;TMCJJ^S?*QU%Q5D>$2<('D/&57X<\CW:/QG.O273Z5R^WU6S)\+>T/G:
MW,Q) ^$B8^10"-U)_,&.OKCT5>MU747/8B]^.JX6N?E ]?*D324<^ 8DA3U)
M"DD9&5SY?\OG [FM29;:CN:035'V<@.;U+CRX@SGMRM,Y8#V_(J=Z/5BU'4_
M::QJTN+C$>+X[D!)P?8-@8SGPA/MD9QK4UND6Z?<;C'E/R/Y3][@L[<'QV?,
M+W"K\*: Y]!!'MC'J/G7P/)<5[5G"/ZU@?W5]OU.BS6&/9)?]SW;]/UU>468
M_6>9'O[#[#0]E4F5NQF0#(/NH^_WT&<*'"7$O%<YR3Y)^^A534IX/A3Z&\O_
M *(^_P#/5"B?!&/IC_9K%5,1'#@G\A\(?MK(J)4XYH$!PS'W^WZZ@1*5PJ'(
MX\!Y&B)$(,1]7@2'E_ GZ:IRBPK]LM+CP_D_Q'MISA$B'*5"+[ (1_CY'_'5
M/"!;6L%81HJE)(4/@XU")1+[JR>&3!^Z>-2(40(@Q!20$^X!\'25%S"X=+[K
MLF[27CIY406R.63N5VTZST6JN)/JDBXJ31SG))>,%'.>Y&2>8GR54QLKJI:=
MX7*HLDBS6/=E&G.LVY=.*5L*YQW% )6:$_2:(LA]L@@J*""BN$U0R0'U$@D
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M%>+'/V&L9"(BBD<'D.+*<') T) X1*:G#*5:1 #]CG4E$F,)Q(:0E@<'BO\
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M5-7>J.KGODZ,9VH8Z8O(AB)]4E0RQI,%D8GQP! 9CKKVU'>)[VUVUM)S13'
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MQPAG-3#// G?J)BHR T?)5,F0#CQC4N-8M8VV],"B'9S'E(:3#1Z@P3MA8>
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M((SCLAJ.<T!IP/IE273"EM=3O[I_'1Q0"*EJHY$$/,01R&5B,G :0J)."L^
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MRHNKQTT=/3QFY202O-*X:=I:69N#1C@RLI)R$)]E?7*^OIMR\"[M@S))(:"
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MX/< ,X["#'K@D'Y"?LK-H<X0FFN(L51=[1>;D+G4PTLL<]M@1D>&01LS(:M
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MB6/PQVU:ZNZ(/./,E/$Z?^Q?34D'A52=HZN;<NM_MUC=;Q9[K7H_R27FRU=
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MU0NR4\"HHY,!D.V#]_IC)1,[1ZS7^3JNFP;_ &_;USKA1R5=5<-HW&:I2V<
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MU\?H,?;5)[(%F<XC/W]P/N=0<H4 &4 MX4^0O_/5X469/3Q;^R?]GUU J4L
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M?!0PQ3P2E:I'>&I*R*1!(B>IUD.%XKDDD>&]CW^AO>R]&QA<2'#$ MD'S G
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M4/=12G<]; MMH ](*BH@/"8Q&$2>G,LJR 8'(B.,^<ZRIVFEM9-(GPVG<3,
MY$S&?*".<22.BR)K..<DX4I6;':RW3\1WO:3?]RW2I>MM%!6%Y$IJ>8(\DU1
M&5&725>(C)\*23X7QJC4W7#/ TZIX=)@ >1 )+9  /8@S/4_-9/IFCFL)<<C
M_=:M5M6W;QN%&=LM4;>O9$K&@R'MM?41AA'[L!'(25]397/[N?)VV7U:QIN-
M[%6EC/#V@Q/22.<8,=5PAK*L-&'?@?[*K;"W=#M"XR?-LALE3VK;4T[TAKI)
ME0,M-3KW0D"E6S/R '@#WSKM-1T\Z@S=2_B"7 @[0)RYV)<?Y8GE8TZII$CI
M]ZEM^4L5VVY9J^V[NHZY7MD=!4O*?PUF:6IE9:OMP(47N&G9,JV6*K]_/7:/
M4\.M4M[BB9!+A'G^%H!;+C.-TY$ 2LG@.8'@YX[=\J1Z:7BIAZG;&HY:"H@K
MA+$\T,Q454,+3R+&S/@B554!'\*_D-G!.FIT6G3[JHUX+((!$[20 2.D$\CD
M<A96YBM3 [KV:?\ Y'1^Y]!]_P#6.OB?VU[%GPIUOIK%<DIN7V7_ %E_WZH4
M)2SJ*I#^2@]\G_@=4(@H4SP/C^R?;2>ZBPLG[=<Y1L?7Q]?IJQA)7-I^G^Y-
MC25,_3ROMWR$U1+5/MB^JR4:22OSD--41*9*<%R[%&66/+MA4SKCR.%5O0[Z
MW;0TK273IO<6EXAFCLEVHJT X]AW'@)]OMK*9"BC:/KU;WDF-^V=O7:5#303
M5-3=+Y9#'1TL<2-)(TD\4DBJ J,0V<'P <D XARJY-T;7>76Z7<>XC9[OT_L
M6Z*YFN-TN*&GN]3;X>4-'0T41]4$?:)>2H;BW.:41*>0E61N,IPI7HWONT_#
M[TQM'3/<]JW'3WO;?=M]/';MNU]PCN$ E=X*BGD@B=61XV7(9@RL&5@,9-:=
MJG*Z/!U/W7N2WO-M7IM>1EBL<N\)X[+&1]&X?M9\?H8E/C^&KNE5(M=GZLUU
M1%/?-U;2LR<P6H+-8IZKT@^QJ*B=2<C(R(UQ]-4!Q"DA.=;K?4[@78^V4A:I
MH+SN>D%P7!(%)3)+6N&(_=9J:)//ORQ]=1V55T9&[C$,2DW[WC'+]<:SX6,K
MF?5#=MXI=[;)V-9JQ+)5;D%=537PPK,]+34D<;R1PQN"C32&5 O,,J*)&XL5
M U">@57+^MG1#:45FMM@ECNV\-W[PK?PJBN=]NU17STL;#N5=6$9Q%&((%D=
M2B* YB 'D:Q(& I/5=:LG1/IK9J2*EM6PMKV^DA011\+/3$!1C +%,LW@>Y]
M_)\ZY-H:%)E2Z]*=DRC";,VZD:GRYLU+EO\ ['_MUC '*LRE?Y+=E&0+!LS;
MJ$>>Z+/3>G]1^S]]-HY*LKD"]!]@['ZO1V*38VV+EM'>-/5UD5#5VBGD>WW&
M +),(B4R()XW+\,XCDC/' DP..,JRK?/\*O3RHK4F2UUUIMKDM5[?M5VJJ6U
M5WG*_,4J2".3!\XP%.?4&'C69 Z*!5[;_P )U+;K#9[/5]0-YU,-BITH+%+:
M;C^$&UTJY&%%. )I'4A7DE#%@HXA/.<=G=)5RVU\.>Q]M7H7RLI:_==\0_L+
MINZXS7BHIAXPL)J&81#.3Z%!\GSJAJLKI+<JH@,2(D]@3Y)^WZ:SPU1+)6%1
M]!CP -3E$A%,Q,C^%/@+^GZZIQA$Z2$&?8#6*),8(!+?F)R=4JK+MP7P,D^
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M);-4TL+2=R7#TZS1,\K+%R;@@Q$N% SF0045NEW-O^,(9>FL%4>7%Q;]T4Q
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M1&B(90ZX/CZYT524;ED'PP]Q_P =4J++KR7WP1Y!^VB(1^0P1AA[C0A$.G(
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M/?7=Z0VU=<.][:'-#7D F)<&G:)&9)B/7H5Z/06V;KIWOS0Y@8\@$D2X-):
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MT.95>>A=GXAR6B(XZR.BV:LOIAPP0/PX^]6G;&]*7==CAW/=3%43[>I)9KK
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MQ'_/1%D@9_JB?Y_]^GU1848/B$*?OXT^J)9,GT"@?J<ZF$6.+?O/@?8#&B+
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M.)DC+3,_>[A5@>,8(5R!YPVDHN<T/Q")NVJN4G1CIS?-^372I%3-N*X+):;
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MJ= Z:TW3:-HL]>**.6HME Q:ID/<B0S\ G+/+'(L".2CRZZTC_U^LU*M&L7
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MZ90O3]0]NS#(I9KC %D"EHG!;*@,3A0/_6C^<87VUUNK/FQJM/Q!IGN/[_\
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MM,-/+M6EI!'5=Z"3C4U<H8SRJA?N1\EY91@0 HP!D'7EZU-VH>)7K8J$R,C
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M_P!84O,=JBFI:VU"%JJEGFIZCBDR,T3"2GEEC.>#@KRY*5(8#P31E%P;I_\
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M6J#C)DY21,$ECX@%#QP03VMGHU&S9XSO/4:-TD\1GRCM (D.F01,X6I4K.J
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M4]OIDN-YK*.V3T,MMI*VZ&2&@2DF$U/%$N!Z%<*"7Y.555Y\0!IL*2%U$3Q
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M$8*Y^G_'60*Y ,)(IT,D2\&XMPS)D^<^^DJPE04BM^8 ,8P<.2!GF /]FA*
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MZ=Y^G4_>LA84AQ*U8_ALV^]/2T-;>+[<K+3 B*T3U,:4ZY7B?,<:R>_J_/\
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M)_>-_AIXA[)"/PI/[QO\-/$/9(6M<-NQ7"G,+RN@)!RH&?&GB=U"T.$%1?\
MD_IO^M3_ ."ZOB>BX_":C_)_3?\ 6I_\%U-_HGA-1_D_IO\ K4_^"Z;_ $3P
MFH_R?TW_ %J?_!=-_HGA-1_D_IO^M3_X+IO]$\)J/\G]-_UJ?_!=-_HGA-1_
MD_IO^M3_ ."Z;_1/":C_ "?TW_6I_P#!=-_HGA-1_D_IO^M3_P""Z;_1/":C
M_)_3?]:G_P %TW^B>$U'^3^F_P"M3_X+IO\ 1/":C_)_3?\ 6I_\%TW^B>$U
M'^3^F_ZU/_@NF_T3PFH_R?TW_6I_\%TW^B>$U'^3^F_ZU/\ X+IO]$\)J/\
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M'^3^F_ZU/_@NF_T3PFH_R?TW_6I_\%TW^B>$U'^3^F_ZU/\ X+IO]$\)J/\
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M2FVC2>-K>! /YCU*T7V5"HXO<,GU43-\+VRIXF1EN $DK22E:K!E!5UX'QC
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1]&/_ 'GE^Y_T-4!8%[5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>rxipc0211916002.jpg
<TEXT>
begin 644 rxipc0211916002.jpg
M_]C_X  02D9)1@ ! 0( E "4  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 4D Q\# 1$  A$! Q$!_\0
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M?/MX?2,7X/0G/E:Z*]F '$R?==THJ]\:][>]?U 5C/5YBT>G7W?IXXQQ]O\
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M:UI\;(H*/ZHXL*7ZZ[TF8OI"@#!8' ]8&0Y!Y>UO?WC:DZ=^T^?=Y4$#Z?\
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M1)"0"IET))X+ 4"4JT1L>*"6H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MR2_]*\,PE.,Y+=L:AXS$[5C5;[Y*94P%(80XB,M+I(4H-=M?%6SQ(5]>Z#-
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M>\4ARF]^M9QS<ZRM8A MXQV#?6H.47U<*X35R$ODQ6&T-.!;B51RW[O+:R
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MI]NB7*[VN_R+9&*/9OE"%)0\)"4E)XJ>#;:'=?C!M*O"MDA7G/2K <EP+?\
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M@AS^]HXJ.@[7ZM&#E_1NSLVIB+>FKGDF/I;8D+7[+*:<N,?W7%("CVE)/O$
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MYT9<J(TN,^M]IADH4MP)?:<4\@I=;)3K?+B04@)8]?V(6:V#$+ICEQMN276
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M:O\ ';<F6*+"2T&YS9XA]I2=!*5MGBIO6N2$J3HJ7R"D7KTY79?63)LTAPL
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M! 8%Z<NH_2V1;I=BSC'[C=39#:;C/O5F>67G?E"7,]I0VT^@ DRSM!.MI\$
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ME>E;4A*@"W^GV1#Q+!;-\MM+5C>6O9*MX1SI]+C\QWL@<O=(]K Y>?Q#X\^
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MR*\1Y631K+:KY;'53[O CF(B5<DMN^5.JC <0M14I"I*$J)*:#0E=3LQZJG
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M[BAL%!V 107[(K]CN'V*Y9I>DLVN-'@!R;/?CZ>3'1R6&U  K5HK5IOR>2R
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MB,\ EH'2CR3K0 3K1\!H=:.@F6YCU*NF7XQ-@V^YFW6RV0I+[JDJ0T57!FX
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MIF>]'1N.7G5AQ+2PE2>TA:E(YH(H-C-^O&3].;1G6&S<F9>R.)=[9:++ELN
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MAU-S[IE=KMAK>4W*^/%RP3(E[CVB(Y<VF)MP<B/QRV$!AQ>FBIM7;2=%8(/
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MEAUA(<5^,KB%>.))/D"@Q76Y]0+!U=SBVJZCW"9:+%BK>2L0GK7 2E;CKDY
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M/]$:#4Z86_HIDEUEVO$KXSD4UI^/<U1W<AEW \HSO)J0T'GE@I0XKRMO:22
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M<BZ\7"WW?(;*Q>K&Q%MD2U.Q$LW1U-O>;*5]UI:A[ZTH_&1X/_?00&%8KFV
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ML^G;JQ%Q^Y-.S;:Y/ZA8Y=;9?S!CJC*@3Y >EL/2'"\OO)0X\_$Y-H20AQ!
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M'3[K;U ZUVVWJQ)C&K3)BXW:;K='+PQ(>;>G3HHDIC,I;<26VTH*275%9_"
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M]WB7_P ,6NYVBOSP^J@^+)Z<K%8KO;G&;U?G,?MD]=TMV+N2T?)T20HJ5R2
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M_E+?/VEO[N@?,I_\I;Y^TM_=T#YDO_E+?/VEO[N@?,E_\I;Y^TM_=T#YDO\
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M= ^9+_Y2WS]I;^[H'S)?_*6^?M+?W= ^93_Y2WS]I;^[H'S)?_*6^?M+?W=
M^93_ .4M\_:6_NZ!\R7_ ,I;Y^TM_=T#YDO_ )2WS]I;^[H'S*>_*6^?M+?W
M= ^9+_Y2WS]I;^[H'S)?_*6^?M+?W= ^93_Y2WS]I;^[H'S*?_*6^?M+?W=
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MOO\ ;;9<\7M=L9M-UBW.YP)TY#?!;$!N*V\VLO2XZ03)=D\EI4HH;9!X*V5
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MN)[[GP20 ESQYVD/G*>K&7PNI5_QK&7;5 ?=O<UDS;LU(FI;;C62!+3P:#Z
MDJ6^4D)*4ZVK1425!K]5\ZOO4;H-T;O5OG_-U697G'%7)J,MT$L2BA;C"7&G
M6UA)) )"@2D$?6:"M.^IB]9]C_3J.U*@P)]U;L5WN2+6^M+S"U9';X;C!',D
M-K0X^A25>3Q4#XV*#LOI2O=PR+T^X9<;I.D7*?(B+4[*E.EUQP]YP;4HDD^
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MH*!0$T'Z(H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MU#]2;=895[85C2(CM[OL./#1#+DR/%MK[[1=4TY,:]IWV@ISLD*;3^*ASEM
M7_JMU(O$6)T=O]AN[+-KN]U[LR.B,L_*3)M4N2VPCFI"DEQ3:0D*&^:F]CW2
ME08>A'6Z^Y_D-NMUVEV&[MW;&(V3-NV!#B!;2ZX$>R/<G%\SY]USW"HM.[0-
M#0?G6_\ 4[-;?T[ZNXH,HNR+GD-QR&\6.[>UN>T6Z!#ESFYK;#F]MI:$)E*
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M2W$DR(UV8G;2AJ&A+#*DMNI2%!U:2Y[RE;)(63(?2]ELN/DL9F'C5S.31)\
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M/4AFN0X>Y-M,:PV6^VR)9OEB!<XC\I+,R7*7'=;24/-G@D=IY"COFA:?ARV
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M@4"@4"@4"@4"@4"@4"@4"@_*OJ$O'43/O419ND6)9'9L=L\W$WLBEN7:S?*
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MEMU2W''$N,-N-LD*6HG3:'7$)&])2K0    ?,KH#T^FH=2[B\)278CL):1S
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M7^N@:_K_ %T#7]?ZZ!K^O]= U_7^N@:_K_70-?U_KH&OZ_UT#7]?ZZ!K^O\
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MB/L% T-[UYH&A]E H'$?8*!H?90- _4*!Q'V"@]H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H/"0/CXH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]
MHH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB
M@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!
MR'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(
M?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]
MHH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB
M@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!
MR'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(?:*!R'VB@<A]HH'(
M?:*!R'VB@<A]HH'(?:*!R'VB@ @_ [H/:!0*!0*!00V4XX<HMJ(@NERM/%P.
M=^UR.PZ= CB5:/NG?P_0*"J?0Z?RWS'][_V*#SZ'#K7SWS+][_V*#WZ'3^6^
M8_O?^Q0/H=/Y;YC^]_[% /1TG_Y]\R_>_P#8H'T.G\M\Q_>_]B@?0Z?RWS']
M[_V*!]#IW_Z;YE^]_P"Q0/H=/Y;YC^]_[% ^AT_EOF/[W_L4#Z'3^6^8_O?^
MQ0!T=(_^??,OWO\ V*!]#I_+?,?WO_8H'T.G\M\Q_>_]B@#HZ1_\^^9?O?\
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M/2O=A=G\?8R'Y/P67C$>S7-,6!&:<GJ,Z5(D(;0VE*8^TOE/)*5>ZXKP5 +
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M7_+4#V[JE_F?$?WK+_EJ )O5/Z[/B'[UE_RU ]MZI?YGQ']ZR_Y:@>V]4O\
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MJ![;U2_S/B'[UE_RU ]MZI?YGQ']ZR_Y:@";U3UYL^(;_P!:R_Y:@"=U2/\
M\Q\1_>LO^6H'MO5+_,^(?O67_+4#VWJG_F?$/WK+_EJ![=U2_P SXC^]9?\
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MY&B$XG'+Z[;F[,PRZN%V(0>;[AYIDQW@.8*UMK:65H+2TGCR"1PSK!EF'9[
MP2&Y:XELL\F/96+0Y[,T[*ABVI?5.0V%E\K+A4H$)[/%M:5'EM0"ZSLESB^>
MA*^9?<,G*,LNV'.7YN=;80B^PER&E[M-)"B?=]X!9/+SOZA05:T=1LTPW)KY
M>[3?6LQL]QS-RU-6MN,E0G;QYN4AYEY*CQ*W64<4H'#3BO!)! 7/TI]:,HZJ
M2+@F]3[9=HPM4"X*=A.1RY$DO=SNQU)84M*4#@."7"'D\5!8.P:"BGU/Y+:Y
MO4%BY9%#4]";D&&JWV^/+C0^-R;BHY$R&G(ZPEY"5IFI0CF%N)<+:%)H(:'Z
MD\PEV^?<T(A76X6/YPQ(MT<90\0RT;4H2'!&7VG VB6ZM?:\*#'NE/O$AV?T
M]7^5/3U:EIRV-FR&,@3[+>8[>V'4BU0B $M$I.E;Y=KP3O0!)%!Q7&^N^79L
MG#_E#-&VGXN66=4^1;4Q/8)+<F-,_N9$AMP@MN/-(2AM]#;S96WS"BI!H):W
M^IO,U8VS,:R.RW9ZXV>)<+PXU;=(PQ]ZX1H[K<A(7LAII]]7!XA85#<4KW"0
MD,%ZZR9!9NJ=@N$'*XV0XTJ Y"NV8L10B-"BINR&P^&-]MY6U)87(;_!HVMS
MB4H*:#L7J ZGW3"LAL5L;RFV8%:95LN-P7?KK%2^V[)C]GM0P%J"05!QQPC\
M=26B$:.U *+CW7+J-=+_ &.\7%46UVZ1D5EL4K&5V_2VA-M,>4\I3RE<PMMY
M[21H )24J!)VD(WU4W[(H74FX0+?E#UM:DXO;W(-L/\ >S)%]C(7("0I*E\4
M+0% $>ZH D T$=FWJ+Z@8C<)F/2+U;X[=NN]YAJR:6U$BA\QH\)^,RL/.):!
M4)CA4$:6M$<\ #R("^=?,LNLGIOT9O4N^1\+FSLEM+UPGIY*C1>Y%?4XD\^.
MT<CH%P:!XE0\$4%$G>IG,VL==E/Y/9;2NVV>9<+/(>MO)&9O,SY$=E#">>PE
MQMEA7!G:RJ6VI/N !0>=0>NN4W2SYA"=OT)J;,9R:V2\/CQN,ZQQHL"4N/-+
MJ5<]J4TSM2M-J]K;X:(!4&*\>H_.;+TYM\N==;=C%\9G2H]TLBTQS*@):B-N
M1FF79*T,2^:%)?42XTIU+A2UQ*%:#MO5/JE<+5B/3^9%O$?%+=DLUAFX9'<H
M80FVLKB.OI):=5Q:6XXA#0[I(07-'DK0(<QZ(Y'?.I_J$LF1WZ>B8W$PAY41
MMJ*IJ,ZHW63&$YE*B2@2&6&G/K]U8 /'5!657G-+CU:GP(.=2&+C#RS)^*GF
M$R#"C)M\=R.P6B>/$["DE0_%Y<1M7(!NXSZJ,]R;+\00ZFU6I-QC8XZBT/K9
M:^46Y\9IV4ZV%K,A7!3CB&^TDH26%=PZ)*0Z-ZDNL6<=,,BM]LQF-%FO7Z I
MRU)?CE80_#<,B<'""/"X07P!^"T?7O5!RR_=8,DS(VC)6[RG%;?<G<>O#-R2
MQV5IM$G('FF&WBM7$)5'[*U[ )+A23Q.J# KJ!F.(=.KBS+N3-\M%W@Y?+9M
MTR(H*B+A7<):!="PMP*2^L*!(_%1QX@$$.E6#J_GS/4&(9#C&06R[7/*;=%L
M$2&W'=1\FR'$QN#ZU@%QP-E*BX0CW@1QT>08LTZR=0(&7S)C7;L-ML[^+HDX
MW+B,OO/&Y3E1I"')"%J2"A/%22WL!0\E0.J#GSGJOS-^XY*FSWF%<&U6:9/B
M&5 CI]C>:ND2*VDL-/+=0DMRE\D2%)<*F]@(&T@)U77/J?BTZ^N+G1<J%INV
M06*/;!:@TY.5#M:Y\=TJ;5ON*6D-$) 24GPD*\D-?%?4=E]WBPXLS+K%%LLN
MZP(\K,![(^FVAV)(?6VOLK4P@+=89;;4M14D/Z6"HH4H)^PWW)D>A)-SM%TF
MS[U[&ZMVZ6U#AD+C>W*$E^.DDK"_9^ZI !*@0G7D"@TI>:=/>G4>ZRNCU_;_
M  S-M9NMPB2UW*R6MA^<ADSI&UJ1[2EM;BCR6"4IYN[2G= A];L^O-R:@6O)
M;=-M=M9R.9\NLVQ#B;XQ;_8.SPTK@@%4MYI:VP0HL$H"?@ C<?\ 4EE-QL5O
MX9O8[I:[DQ8'KAF,: A,:P.34R#(94.1;V.RP$=T[;,A/<Y;2"&>S^H?-[C+
MNDIW([>FPXYC5SO"[A$LADB]!B?+B1Y"4AP:;6AIMTI;4 H@E*TH500V-]<<
MLS',L>@S<R;C6RUYG"BKF),)29[4FS2W1&>7&<4PH=]L(0$*/O.(!*EI!H)+
M ^O^3B#A[(NMJM4A#.+1(>&&&2_>(TYB,9,II:EEP):[KW$IVE'LCG<)WM(7
MKT^=5LWRO*,<8R6YP[G$R3%7[^AJ/;Q&]B=:F-,AM"@HE25(>23RV>2"1H'B
M J'4#U,=0<4SN]8Q%@Q)+UMG/V4N^R%7<F7(E=A(T=% 2E27C]I!]V@I'53,
M<D+66MLY&JSL+LN91X]N9!;;E2XUW80E\>_R4Z$**R$D:2%:XI4:#]-]*<ER
M:[W#J9C-ZNZ+A/QR[)A1+PB&AE2T/0(\E)4T-I)0M]21]H2G?G9(?FOH9UIO
M'3#I+8;-+N]O5<[A9,7NT SFPF5<I-QN3K5P5HJY/*2GAR4/*2>2OC0= ]*U
MTN$OJ==V94R5(9199)2E]U2P",DO" =$_'@E W]B0/@!00UT]3F96N1D\BTW
MFT93<8DG)HSN-1X)+EG9@.N)C2GN"NXH>XCF#H.=Q(;XD'D&6\>HC-K"U<V;
M%D-JSZVHN#-@MV11(">Q)N4^(3#0HM*+9#4I+:5E!UPE("O>020C97JASZ?C
M=CN+KL;';;<KC*M;UU?:C1D1Y$&(A,E 7*6EK\)-]J2GD=EN*KCY5R2'4_3_
M -2<WZGYI>G[[<;=$M5LM5I4;5;X>T.2)<%J0XZ'UGGP2HD)3H>%>22!04/,
M.N.6S)>3V^/E4*+<I#N26I>-Q883-L<>'$E+BW KY<]K4RP>2QVU"6WPT4@J
M"RR<ANO2#TG].5V6Y6^VOK8MC,F3+[4=2TO-]QWM+>VPA]:B=*?(05$[/)2:
M"NV_U6WCY,09-T@(ES;7C,BTMSH2(K]P=DW1Z)/4VREYP+ 0V@_@UK2D*"PH
MI4DT%7PKK9E6(XS=X=GS&SWIY*,KD/0[DR5''E1KFZ([LEQ!4YVU\R@\TZ.T
M*1I"%[#6O76W(<BA0KD_D[KT:)9,QBN6V2W&#%T?8A1GV&RY%>4U(4E#BSW&
M"DZ;<'!M27*"T8AURNN ]1KQ#R++8AL$G)Y[,A5RX-HMS8LT63#80HJ]P+/=
MX)/X_!6MGE005CZNY5=,KM%WN=P3>I5XMV%W1C'5I+2&ER&):GG&$\MIY.I"
M-G:05@$'B*";L'J&S>[V*,BVY79<@F72#8I4B;$M@[=@F3;FQ%=A.("_)#;K
MI2APAU*HZBO8( "]M]1\@G^FKJ]+O3D>[W?%SD-K3*7'[*9J8H<#:W&T$ %2
M>(5P(!()''>@&.P]4<U7U;@LR;G$=QJ7FEPQ-%I1 "5-L,VUR4V_WN147.XR
M4GQQ*5:UR'(A5^N5UR5/6V[6F#F3EO#Z\,=MUL6V%)9YWA]M]]*.0*P.*0OZ
MCW$!7@)%!6\M]3?43&VQ;%W*UQ7K9\NMIO4]$:,U=I,&X&.RRM+BT@;:"5N(
M8!<47$EL #B0[MULZC7'$[=T^2K([=@C5_NP@W"Z7!M#J(J/8)+_ !07.*$K
M+C*4A2QKX[&R!0<2>]1?5.7BE]R1AZ"TBQXM:;BJ$FUZ1*7-F2XZIRE+6"VP
MAF.B4$;'A1"E<?-!N-]>>H5YL;,:VY':QQEWL-WAB/&G./LP[>S);2LLJ,?G
MW7%-J+9*2E.O=7OB"R=:\VNDW&/EJ1;+F]+59KW'6;>XTB$J;:+H^MH);65+
M0VY%1HGDOBM0/)7$@(*U>JK-)&*VUAR]17GI-WCQKCD#0MHB0FW(#KX2Q*+W
MLRNZZUQ0'TMN(2H)6A2UH40LMH]2.8O9?TV;O%VM+$6\P[67X-G:9D+D.29#
MK*G2TZXAY3*PEI2'(Q=#7X0N)4D!5!^K[->H&0VYJ?;)K%P@N[[<F,X'&UZ4
M4G2AX.B"/^Z@W:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#&Y'
M:>)[C:%[24'DD':3\1_4?LH/6FD,-(;;0E#: $I0D:  ^  ^J@QKA1W(RHZF
M&U,*'%310"DC["/AJ@R!E ! 0D C6M?50? AL!];P9;#RTA"G.(Y*2/@"?K'
MD^*#TQ63(#Y:1W@G@'.(Y!/QUOXZ_10??!/#CH<=:UKQJ@\0RVVA*4(2E*?@
M   /&J#Y8C,QN?::0US45KX) Y*/Q)U\3^F@^/8(Q,@]AK<@:>/ ?A!K7O?;
MX\>:#(W'::2E*&TH2D: 2  !K6OU 4"/&:BM):9;0TVD:"$)"0!^@"@^&X,=
MI"T(8:0A:^XI*4 !2M[Y'[3OZZ#U$-AON\&6T]T\G-) YG6MG[3H:\T'K<1E
MEE+3;2$-)3P2A*0$A/V ?9^B@/QF9*4I>:0ZE*@L!:00"#L'S]8H/OMIW^*/
MCOX?70>+9;<6E:D)4I.PDD D;^.OU"@^'XC$E'!YEMU/(+XK2".0\@^?K&OC
M0?3S#<AI3;J$N-J&BE8V"/T@T'RN&PYV>3+:NR>3>T@\#K6Q]GCQXH B,AY;
MP:0'5I"%+XCDI(^ )^L>3XH/'X4>4GB\PVZG:5:6@*&P=@^?L^J@^WX[4IE;
M+S:'6EC2D.)"DJ'V$'XT'T$)2=@ '6OA]5!X&6PM2PA(6KXJT-GQJ@^#$84\
MVZ64%UL%*%E(Y)!^(!^K>A092D*(V =4'PMAMQ!2IM*DD:(*01K[*#Z+:#\4
M@_'ZOM^- X)!!XC8V?A]M *$JWM(.];V/LH,;<-AHN%#+:"XHK64I Y*.MD_
M:? \_HH,G;2#OB-[WO7UT&#Y.B^SK8]F:[#A*EM]L<5$G9)&M'9\T&P$A*=
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MV5GL.$J6UVQQ42=DD:T=GS09%1&5O-/*:0IUH$(<*05(!^.C]6Z#*E(0-)
M^P4'M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MBGD@A0#KBPEEI!?6DD=Q/;4LA8;9UGO>&7Z[61S)U3I$W(76H;$QA"G0XO(
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MM\^"XJ4J=<)6ZA7#AQ*3^-06I[K'D5P=Z>M6Z"P@W^)(FRRU;)$[M):?CMZ
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M9N@NM H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MZ6_[^@?2!EWYL[O^]+?]_0#U R_7^#*[G_\ &EO^_H'T@9=^;.[?O2W_ ']
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M@X'U!_ZYO1[_ &7R7_Q+;0=\H% H% H% H% H% H% H% H% H% H% H% H%
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MXVM(4E0WYT00:#<H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M\W./ONI;=='!&P?=YJ(V!L_&@@?I4N7YNLO_ -Q#_F:!]*ER_-UE_P#N(?\
M,T#Z5;EO_!UE_P#N(?\ ,T#Z5+E^;K+_ /<0_P"9H'TJ7+\W67_[B'_,T#Z5
M;EO_  =9?_N(?\S0/I4N7YNLO_W$/^9H'TJ7+\W67_[B'_,T#Z5;E^;K+_\
M<0_YF@#JK<B/\'67C_\ L0_YF@?2I<OS=9?_ +B'_,T#Z5;E^;K+_P#<0_YF
M@?2K<OS=9?\ [B'_ #- ^E2Y?FZR_P#W$/\ F: >JMR _P '67_[B'_,T#Z5
M+E^;K+_]Q#_F:!]*ER_-UE_^XA_S- ^E2Y?FZR__ '$/^9H'TJW+?^#K+_\
M<0_YF@?2I<OS=9?_ +B'_,T#Z5+E^;K+_P#<0_YF@?2K<M_X.LO_ -Q#_F:!
M]*ER_-UE_P#N(?\ ,T#Z5+E^;K+_ /<0_P"9H'TJW+S_ /(ZR_\ W$/^9H Z
MJW(C_!UE_P#N(?\ ,T#Z5+E^;K+_ /<0_P"9H!ZJW(#_  =9?_N(?\S0/I4N
M7YNLO_W$/^9H'TJ7+\W67_[B'_,T ]5;D!_@ZR__ '$/^9H'TJW+?^#K+_\
M<0_YF@?2I<OS=9?_ +B'_,T#Z5+E^;K+_P#<0_YF@?2K<M_X.LO_ -Q#_F:!
M]*ER_-UE_P#N(?\ ,T#Z5+E^;K+_ /<0_P"9H'TJW+?^#K+_ /<0_P"9H'TJ
M7+\W67_[B'_,T#Z5+E^;K+_]Q#_F:!]*MR_-UE_^XA_S- ^E6Y?FZR__ '$/
M^9H'TJ7+\W67_P"XA_S-!$=?KDY=_2WU-F.P)5L<>Q&[*,2:$!YK^Y'O"@A2
MD[_J)H+'T2_P-X)_J&!_PS=!=:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*#@?4'_ *YO1[_9?)?_ !+;0=\H% H% H%
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M)[KWUZR/I?>+LW9;/:I\"QXVK)[@J>^ZAUYE$CMJ8:"!H+*0HA:M@$ %)!V
MJN;^K>[XADU\:9LUNNUH89OR8:V!*0DOVV([((5)6V&G"I3#C:T-!7:5\5K(
M(H-M'J1S6P93+A9'8+$NW6N\Q[3/5:GWUON&3;_;6E,I6 -MC3:@K\<GD.&N
M)"T^GOKG?^J\HMWS'$VEJ79XE\AOM-NM)2V^3^ 4'=*<*0$D/('!>U:"2GR%
MG]3/_5OZK?[)W;_@W:"5Z)?X&\$_U# _X9N@NM H% H% H% H% H% H% H%
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M$K6%'XJ"E [V:#XP[ ,9Z>0'H.,6"W6"(\YWG&;=%0RE:] <B$@;(  &_@
M/ %!!.].NGF!0[O>$XQ9K2TXZB?-DQ[>D*4XVYW$.^XG?)+A*P1Y"B5#SYH*
M-TJZ(=/,/RJ?*9N\+)KW.28J4OQH3:M0I0=<4I$=IL.O-R%MJ6ZL%06$?BGX
MAT&]]&, R5Y+MUPNPW)8=?>W*MK3FUO$%Y1!3Y*R 5;^) )\B@^KOT8P+(')
M+ERPVQ3UR9#4M]4FWM++KS;?:0XK:?*@W^#V?Z/N_#Q0;LCIIB,NQW"SO8Q:
M5VJX!H2X1@M]I_M(0VUS3QT>"&FTI_Q0VD#7$:#>M&)6/'\<;Q^VVB%!L:&U
M,IML>,E$<(5OFGM@:TKDHG8\[.][H(>W=(,&M%XM5TA8C98ERM49$.!+9@-I
M<BLH24H0VH#W0E)4D:^ 40- F@SYCCF'7>=:7\GMMGF2RM<&WKN;#:UE3HVI
MILK&_?#0)2/CV]_T? :L#'<$ZAV=5ZCV>RWNWWQE;JY:H;;B9C;S;;:RHE/O
MA;;+23OXI;0#X2*"7Q_",>Q7'U62SV6#;;.KGSA1XZ4-+Y_CE2=:45?63O?U
MT%!L/3GH[=WLDQ"TXECSPMSD9NZQ&+4D-H< +K"%+X<5+0'"H **FPX/Q0H;
M"TM='\&CWFWW5K$+(U<K?&3$B2F[>TE;#*4E*6TD)\)"5*2!]04H#0)H*=<O
M3%B]UZD6?*G%E#-H>BR(-K;@1$-QE1VBVRAMX,AY#*?QNR%\>7V E)#H+?3_
M !=@PBC';6@PF8\:,4PF_P  TPON,(1X]U+:P%) \)/D:-!"6*%T]SMJ\P[=
M:;3=(UOE3K7-2;<"R'7E\IK6U(XKYN#\+Q)!6DA7O @!JX_:.EV,W"%CEEM^
M.PIB'9D5B%#CM\TN%MMR4CW1X46RR5@^2.&]^*"TV+!\=Q><]+L]CM]JE/QH
M\1UZ%%0TI;+"2EALE(&TMI)"1_1'@>*#&KI[BY86R<<M197%D0E-^Q-\2Q(6
M%R&B-?B.+ 4M/P41L[-!I.])<(D9!-OCN(V1Z\3D*;DSG+>TIYY*FRTL+44[
M(4V>!W\4^#L4$2YAO3'IW#M<4V/'[,W ??N]O81$;2MMYMD]U]E('(K2UX*D
M[/'0^&A0:[UQZ99_U&BL/P[9>LNL:D]B0_;E..1%\$/A"7E(XI6E*VW./+:2
MI)T"103MKZ2X19')[D#$K+#7/D-2Y19M[:2\\VYW6UJTGR4N?A$GZE;4/)W0
M?,["\%S*!>K')LMENT5-P[]RA&,VXE,U2$.=QQ.O#Q2M"N1][2DG?F@]1T?P
M=JZVBYM8C96;A:&$1K?):@-(7$:1O@ALA/NA/)7$#\7D=:V:"L8)T-Z9X+C;
MO3^#CULE-FV147%$FWMJ<GM(*D-./J" E:N:%J_0K:@ 3N@N,/IEB,&T)M<?
M&+0S;A!=MHBI@MAOV5U7)UCCK7!:O*D_!1\G9H/(W3/$865JR9C&K4SD1 !N
MB(38D>$=O^^:WOA[F]^4@#X 4&Y?<+Q[)G77+Q8K==7'83UM<7,B(>*XKQ27
MF"5 [;64(Y(^"N(V#H4&M<^G&*7IY+D_&[5,=2^S)2MZ$VHAUE"D-+V1^,A*
MU)2?J"B!X)H)"V8M9K-(1(M]JA0GT1&K>EV/'2VH1FBHM,@@?WM!6KBGX#D=
M#S0:#/3O%8\^?.;QRU-S)ZWG)3Z8386^IU"$/%9UM16EIM*M_C!"=[T*#0^C
M# ['>H^4#&+' N=LBI:9NGL33;D9AMLH2 O0X)0WM(/U)V!H>*#*F-AO4)=R
M)A6R^]V&W"EN.Q4NI>BNH#R6BI2=+;4E85H$I\_;0:5UZ5=.H$F\Y'<,2L")
M#[;[UPN#]O:*UH6TI+ZEJ*=D*;*@O_&!.]T$I:;+BF218E_@6VV36KBJ/=F9
MZ(R"7EAH)8?"M;*@WQ"5?$)T!XH/</Z;XI@"YR\9QNUV!4Y87)5;H:&"\1OC
MRX@; Y*T/@.1U\305KU,_P#5OZK?[)W;_@W:"5Z)?X&\$_U# _X9N@NM H%
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M;\J5R*OC0?73GT__ #2ZP,7U3):LN/XW"Q^V=R0EQ4]YML(5-<;2D!MQ+0#
M/DD%?@#6PLE[Z'?*6:7>\PLINUGM]\<9D7>TPPUVYCS3 80KN%/-"2VEM*T
MZ7VT_#:^05?(O239KU#MC;5^GLK@6BT6=#<AAF3&DM6\R"V)#"T\7@OVE14E
M7NA2&U  IH/FR^C[&[%A-WQIB]7146XV=ZSK>XL(6AMR?(FE:4H;" H+E+2
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M!]0?^N;T>_V7R7_Q+;0=\H% H% H% H% H% H% H% H% H% H% H% H% H%
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MVV@(2-E.SH)'DT&]]"G6O_2,N/\ !UJ_\E ^A3K7_I&7'^#K5_Y*!]"G6O\
MTC+C_!UJ_P#)0/H4ZU_Z1EQ_@ZU?^2@?0IUK_P!(RX_P=:O_ "4#Z%.M?^D9
M<?X.M7_DH'T*=:_](RX_P=:O_)0/H4ZU_P"D9<?X.M7_ )*!]"G6O_2,N/\
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MO_2,N/\ !UJ_\E!M8/Z>\LMG5BS9UF?5*;G4NSVZ9;H,5ZR1("&DR5,EQ1+
M!4?P"/CO_NH.ZT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&O<'WXT%]V-&,N0A!+; 6$
M%Q7U)Y'P-_::VZ5:WO%;VVQ\SYQ_1NT:TOJ5KJ6VUGS.,X_7$*!;NLT<PH<V
M\6J198<N1(C,NN.I?VID.=PE+>R "TKZOAY^%>CU>Q7WVT^GU(O:L5F8Q,?F
MQCSB/YH_V>MUOIO4]2^CTNK&I:L5M,8FO%]NWFV(YW1_7CRML7,K+-NR;;'N
M#3TM:>24HV4K]P+TE>N)5P4E7$'?$@ZUYKC7Z'J=/2]:])BO_P!\>/.,QC.,
M9X\O/:G;>KTM&>HOIS%8_P!.9CF/,1F)C.,9XSE6K]U:CVB]JM35O+TI,MV*
M5/2FH[>VV&'B>2S]8D) 'QV#]5=3I^S7UM'U[7Q&V)XB;3S:U?$?^V?]';Z3
MZ?OU'3QU-M3%=L6XK:T^ZUZ1Q$?>DS,_K#6:ZU1)CMG3$M4EXSXK<OM+?9;>
MX*6I&FD%6WBDH)/#8T4D$\@#NMV'4I&I.IJ1&R9KG%IC,1$\S$>V)SB-WSG.
M,2W6^F=73C6G5U8C9::YQ:8S$1/NF(]D3F(C=CG,3C$RMUZS*S8[+:C7*X-1
M'W6G'TI<W_>T?C+) T$C8&SKR0/B17%Z?H>IZJLWT:3,1,1_6?$?N\]TO;>K
MZRDZG3Z<VB)B./O/B/UF?M'Q$SXAI/\ 4O&HL9I]^ZMLH<4M.G$+2ILH*0ON
M)*=MZ*D \@/*D_:*WU[5UM[36NGG&/MSG,QB<XG.)\9\3]I6J]D[A>\TII3,
MQCQ,3$YS,8G.+9B)GC/$3]I;DK+[:QV B2TZX\]V4HYA.]/I86?/^*M0&OK/
M@5HIT6M;.:S$1&?_ .LVC_.(RK:?;NHONF:S$1&?'WI-X_SK&?VY:4/J;C,\
M0U,79IQ$O19<X+"""KBDE13I(4H$))T%'PDFM]^T];I[HOIS&WSXSXS/&>9B
M.9B.8^<+.IV3N&COB^E,37S'&>(S,8SF9B.;1&9K'G#8C9U9IUDN%UB2C*AP
M6E/NJ:;5LH".84D$#D"GRDCPKZB:UV[?U.GK4T-2N+6G$9F/.<<_;$^8GF/E
MIOVKJ]+J-/IM6NVUYB(S,><XQ.,XF)XF)YCYA$V;J_CEWDOL*E&$MM"74^U(
M* I!C(D;WK0(0LGB3OW%'6ANKFOV3K-"L6BNZ)S''/.^:?[QY\<Q'ET.I^G>
MOZ>M;Q7=$S,<<XF+SI_O/NCS'',1G/#>A=1[)<;U;[7%>>>E3>^$#L+1VU,I
M0I:7 H H/%Q! (\@@_6-U]3M?4Z6C?7O$1%=OS$YW3,1,8S$\Q,3CPJZG9NL
MT=#4ZC4B(K3;\Q.=TS$3&)F)C-9B<3Q/]6V[G-A9?4RNZ1TO)2ZHME7O -O)
M97X_0XI*?ZR*TQV_JK5W1ISCC_6LVC_.L3/[-%>U];:N^-*<<<_^ZLWC_.L3
M/[0S67*[5D1D"WS$22P 5\01[IWQ6-@<DGBK2AL'1T3JL-?H]?IMOK5QG_\
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M1)1(^3ITEN,CFT4N)*W.V"4_$^]]0V3]6ZW?V3U'XJ_1SC?2)GSQQ&?/[?\
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M,1&*SS$SYCC.8B?Z@=2/F) 9D>Q"X*]D=FO-I<4E:6FPGDH)2A9_I?%7% \
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M3N_1]-WL^UMQG&%-N+( TL*&COSL?U?"F.,F_G#U5Z6N2Y'CQ5/O-J(4.82
M!KSL_P!?P_148-V9P]8N[S\EMGV);?,<OPBP"$[T213"8EF;NC9MRIBTE+:0
M21\3X.JA.>,M.5D9@%H2XCC/</ND*"O'UDZ^!'V5E$983?'D=R)*9CD9I@NN
M(/UN!(4- ^-_$^?A3;.,IBR6:<[J$JXJ3R /%0T1^BL6;)0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*#S=![0>$ZH(J?>BRZZW&8,E3(Y.K*N*&P!O15]OZ*,
M9G[))EP.M(6/ 4D* /Z:,F2@4"@4$-F;5M?Q*]-7AXQ[4Y#>1+=3\4M%!"R/
M!\ZW]1_J-7NAG6KU6E;IXS>+1MC]<\.EVVW44ZW1MTL9U(M7;'ZYX^WS^JI(
MR7#\9ML?E8G;5&4IQE:7K46@RE9;2LKVD#BK;>];V!\/=.NS/2]PZO4G&K%Y
MXGB^<XS,8Y\QS]L?UC/H)Z+NO7:ML:\7MQ,8U(G.(M,8Y\QBV/&/ZQF+@WS!
MW+/[)+QIAF/"=?DO,,6_OLQ2A;J M:DIT"M+"C_5H'QK=O4Z?N<:OJ:>O,S:
M*Q$S;$VS%9Q$3/.)M']>8YRO:O2]XC7]72ZF9F\5K$S?;:V8K.(B9YBLWC^N
M9CG.-ZZW'#TWF6U\@19IEH<7<'40^3I*6VGT>Z$[63W$*V/@1L^1L:-'2[A.
MC6WK37;B*QNXYFU9YSQC$Q^L<>%7I]'NLZ%+>O-=LQ%(W8CF;4GG.(QMF.?,
M<>&@UEN&*NT/V3'HR"&/9C,>B!"& )*8JV%$).B.ZH#^CHZV HFK$]%W&-*W
MJ:T^<XBV9GV3J1:.8^W[Y^,QA;MV_NT:-_5ZB?.[;%LS;V3J1:,S'G;'ZYCQ
MF(AD%YZ=2+4Q"3CJ7XZG4.Q(/R.2J1WD+*'6T%/O)6EI8Y'QI(!UXK'T.[UU
M9U)UL3B8M;?XVS&8F<\3$VCC]>/EA^&[[36MJSU&)B)BUO4CV[9C-9G/$UFT
M<?><QGE.Y->L0NE@LMWN-N3>XD])3 0()D+6%M*<*0C6P.#9)!T/=\^0*YW2
M:'<-'7U>GT;^G:GYO=MB,3$9S^\\8^_#E=#TW=-#J=;I=#4].U/S^_;$8M%8
MG.>>;1$8YYXX1=NZB8+;2_=X,(QI4U225(MZFGI*%-EX. $ J04 J)^LCR.6
M@;FKVSNFKCI]6V:U_P 68K,3MQ\XG/&/_HO:W9^\Z^WI=:^ZM,_SQ-:S%MFV
M<3.)B9QC_P"F43<.H>'N7*,V_C"9-MMZWUL36X7=2VA#+$GNMI"?Q"'@HGZB
M@'R2*NZ7;.X1IVFNOB]]N8W8S,VM3;,S/GVX_K,>(ET-'L_=8TK6IU.-2\5B
M:S;&9FU]/;,S/YLUQ$?:9CQ$MR;,Z>,7NZRWH((DM*CN\8),:<XAT.*2C2?P
MCH<4/A]>];(5K1IT[O;1T].M_P LQ,>[W5B:XS//MK-8_P L9XF,U]+3[[;I
M]+2K?\LQ,>_W4B:S6)GGVTFL?Y8SQ,9G\-A8]E,=-P1C<2"Y;)3\&,ER*E*V
MDMN*3X24CCY*CKZMDCX[KF]=J=7T=O2G7FT7BMIYG$YB)^_/Q_ESX<CN6IUW
M06G0GJ;6C4K6UL6F8G=$3YS.>,<_..?"*8R#IM :]E1#@1FXX$LLF#Q#7<4Y
M')UQ\$!MQ*A]2!Y]W57+=-WG4G?-K3GVYW><1%_O^L3'WMXY7[='W_5GU)O:
M9M[<[_.V*ZD?/ZUF)^;>.7PU*P2[83=Y,''X$N-9F7)JH$B(E'DL]P$@@^%H
M \^? T1M.A-J=TT>LTZ:NM:)U)BNZ+3/BV/T_+/_ -O.65M/O/3]?I:>MU%J
MVUIBNZ+3/BVV8\Q^69GC^L<3F=M74;%7,:G2)5L?1%4LF?$<MZO=*FDO*6XD
M@#100K9\J^ !((K5':^NCJ:4I>-W\L[H^+36(B8GSGCCQ^W+1'9NY1U=*:>I
M&['LM%X^+32(K,3YBT3&(XCS,XY?619?B:L=N%O$QRW,3E2&W3!C@.*65H2Y
MH*21R<+Z %$>]W00?K&/3=%U\=135V[IKMF-T\8Q,QXG.*Q6<Q\;<?HQZ/MW
M<XZK3U]D7FFV8W3QB(F8\3$XK%)S$3QMQ,?#89FX8NQ6O(6K>P\W!4B!"XQ>
M<AIQ*^TEA T3R"]@#ZO)WKS6JVGW&-?4Z2UYB;9M;G%9B8W3:?C$QS_IYX:;
M:7=HZC5Z&VI,3?-[>[%9B8W3:9\8F.?U\8SPB<3Z@8=:&FD1K8U8I$YU2766
M(O I'M+K#/=\ @K4A0"2/!)'@>:N];VWN.O,S?4G4BL<3,Y_EK:V.9SB)C,_
M/[\.AW#M'=>HM,ZFK.K6D<3-L_R5O;;S.=L3&9^8C/GAHX=EV(*LEKD2\8C6
M,WG;J6TP/P8"TNI;2M12-J4WW$Z ( 41X"ANQUW1=PC6U*:>O.IZ?'YN>-LS
M,1F<1$XGG$SC/F.+7<>W]TCJ-73TNIG5]+C._GB:S:8C,XB+8GG$SC/F)QN7
MK-L5P['C'M=A9EVQ]A<J1#CQP@+28JWTDH*=+*DM:._@!Y^&JTZ'0==UW4;]
M?6F+Q,1$S.>=\5GG/&)MF/O\*_3=L[EW+JM_4:\UU(F*UM,YQ,:D4GG/&)MF
M/O\ 'EGNN7=/YEPDM3X$=^3&><=_"P0M3DE/;2XA/@E3HVTDCZR //$ZU:/1
M=VT].MM*\Q%HB.+8Q6<S$S]J^9B?]L\Z=#M_?-/2K;0U)BMHB.+8Q2=TQ,_$
M5_-,3\9F>,\_;F469S!,@N;N,]R$JYN,2;<(X[DESOH:*UH*?QB=$_'\4'9\
M&L8Z3J8Z[1T*Z_NV1,6SQ$;9MB)SX^/Z^&,=#U<=QZ?IZ]3B^R)K;/%8VS;$
M3GQC,?U\?#+CD3"KAEX7"MJ1.89[4);L/@SQCNK2LQU%/DI6\>1!^)!'VUCU
M5^Y:?28U;^V9S;%LSF\1,;HS\Q7C_*?LPZS4[OH]#C6U/9:<VQ;,YO6)B+QG
MYK6,?IQ/V5RW99A4J:_:Y6'MP8$IT*=<7 VCNB8[%0IP!.DCFGP2?^T4/@%&
MNIJ]'W*E(UZ=3NM6./=\;*WG'/,XGF/TC](=G6[?W;3TZ]1I]7-KUCB-_.)T
MZZDQ7GF<3S'^&/O$++ FXCU 9N=HM)3#==BK;4_%CH;<<C+6&W"V2D@H46P@
M^-^$D:]TURM33[AVV=/J-?W1$QQ,S,1:(S&<3',9S']?UAQ-72[IVBVEU74^
MZ(M$XF9F(O$;J[HB8YC=F.<<S$_S0@K%U+L&1X]"BWBQAF(XXVF#;D1G)"VT
M)[Q0I0X )XHCJ5L$@ $;^&^AU':NKZ77M?I]7-HB=ULQ$3,[<Q'/.9M$8G__
M )U>J[)UO1]3?4Z77S:(G?;=6L3,[<Q$[N<VO$8F(S_M+0,LQ7(XU@L,*P^T
M62Z+=2RDPPB,V&VP\E0&M:/($$? [WH@BJ>IT?7=+;6ZK4UL:E,9]V;3F=N/
MOQCG/F/&8Y<_6[?W+H[Z_6ZNOC5T\9]V;3NF:3&?.8QSGS'C,<L%SR+!K+=Y
MB)]EB^T1DN0UN1K<70U%0AE"RX>&DH ?0DCR.)T-@$#9I=-W/7TJSI:LXMBW
M-L9M,VF,<\S,UF?CG^F=VAT?>.IT:3H:TXMBT1-\9O,VF-ONS,S-)F/$Y_7$
MS-9:+3TVQ<W>VV",[(@J#,1IAH)4E;[J&SY ) )*2K6R>(_15#HO7[KU/X?6
MUIB+<VF9^*Q,_,XXC./W<SM\]3WKJ_PNOKS%;\VF9SQ2LVCB9B,Q&<?;/[JT
M<IP5I$[VZQQA,E<3-5&MY4VXXJ2M#:5.*2D<U.MJ/G7E.R?@3U?P?=+33TM6
M=M?RYMS$12)G$1,\168CCXG&/,.U^ [S:=/T=>=M?RYOS$12)F8K$SQ%;1'&
M>)Q$>82U@=Q"ZW2X!&-Q[>U9([4A,N3"2RD-O(4ZK0*04ZVHD'ZU$_6:I=37
MN&CITSKS:=69C$6SS68K]^<\8Q\1$.?U=>Z:&CIYZF;SK6M&V+3/-)BL>)G.
M>(C'Q$0R6')<+^5TRHEN%NNC[80E3EO++RVNR7$*^&^);9.C_P#6^)T1JL>H
MZ3N7I;-2^ZD3_>S&=V)CSYBUN?WSXG+#J^B[MZ,Z>KJ;].)^+Q:(MNBLQY\Q
M:W/_ +LQQ.4_B&;1LR=NGLD=]MB&ZTA#[R"E+Z7&&WDJ3O\ 0X/'_P"FN=UO
M07Z&-/U+1,VB>(^,6FLQ/]8<KN/;-3ML:7JVB9O%IQ$^)K>U)B?ZU6.N6XQ0
M*!0*!0*!0*!0<S]0U\Z7V+IO+>ZO.65.'..);<;OK0=:<<\E*4MZ*E+\$@)!
M5X-$3A\=#>FO2_"\:C7GICC-HL=IOL=J6B3;8/LZI32D\FRKD O6CL!6M?8*
M$*]@?6#H_P!=.J++EIELRNH.*L2VFHMPBO1)T1AQ8;?4A#B4\VU%M *D\A^+
MY&ZE$8F7<*AD4"@4"@4$5=+,JY*4"XCMJ1Q*5M!13^E)^HUE%L(F,L3./J9E
M..!YM3:UE1"V I>B-$<][I-D1$P\587W(Z8ZYZ_9VTZ;2E !_P#5Y'Z]?93=
M\HFN>,OKY!+\I,B6\F0L$;26P$D $ :_[]TW<8-O.66VV46Z2MQ+G)!2I*6^
M.@D%94!_W;U43,SY3$8;28?&>N3R)*F@WQU]A)W_ .^H3CG+Y@V],)V4M*ME
M]WND:UKP/%"(P^YD,2^Q[Q3VG4N^!O>M^/\ WT)C+!-M*)KRG%J(Y-=H ?$'
MER"@?M!%3$X1,9:#&-+;0PA<@.I94E066@'!H[T%?4#_ /GK+<C;#=>M ?C3
MF2Z0)2N6^(]WP/U_"L<RG# _CR?:^_&6F*H!)2A*!QY#?DC](.JRBW&)-L9R
M-620PZJ0U+"9+F^ZI36TJV?'C?C7U?UU$SG@Q\MN+;5,/M.K?6\M#7;*ECRK
MSO?_ /"L4X?*;4@VQ<):RI"@K:M:/D[_ /=0QQAKKLKTF5%?DR^Z8ZMI2EL)
M!^W?Z34[L,=K ,7[7=2AY*V5J)[3S06$@@ :/QV-?&IW3)MPF8C BQVF0HJ#
M: D*4?)T*Q91PS424"@4"@4"@4"@4"@4"@4"@4"@4"@4"@UYDUJ$UW'5A(^
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M(5Y%!ZU(;?!+:TN '1*3N@=Y/GWD^#H^?@?LH,8N$8__ %0U_P#YBB,LX4"
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M(;2@DA(!/QT*#TI!()'PH,:XC+BMJ:0H_:4B@\]B8  #+8 ^'N#Q092D%)!
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MFLQ/,3"BWG%.F;N(Y%D[]]G2,91[?'6TS(YM1'GU]N26$\>7<6K8'(J'ODI
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MU:Z==&)G2MI<UK:T6MH9K3F)F)\XG&,XC&)6',<#QO/3:;?(O#T64Q#>1'3
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&YM-N)?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836686896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Galena Biopharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GALE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,410,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,828,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6834969312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 18,083<span></span>
</td>
<td class="nump">$ 29,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">18,022<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Litigation settlement insurance recovery</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">37,499<span></span>
</td>
<td class="nump">53,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and furnishings, net</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_GALE401rights', window );">GALE-401 rights</a></td>
<td class="nump">9,255<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_InProcessResearchDevelopment', window );">In-process research and development</a></td>
<td class="nump">12,864<span></span>
</td>
<td class="nump">12,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,898<span></span>
</td>
<td class="nump">5,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">65,811<span></span>
</td>
<td class="nump">82,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,292<span></span>
</td>
<td class="nump">5,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement payable</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Fair value of warrants potentially settleable in cash</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">16,397<span></span>
</td>
<td class="nump">4,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">6,059<span></span>
</td>
<td class="nump">5,925<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,398<span></span>
</td>
<td class="nump">57,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">5,661<span></span>
</td>
<td class="nump">5,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent purchase price consideration</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">37,154<span></span>
</td>
<td class="nump">68,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 350,000,000 shares authorized, 15,224,223 shares issued and 15,190,473 shares outstanding at December 31, 2016; 275,000,000 shares authorized, 8,129,087 shares issued and 8,095,337 shares outstanding at December 31, 2015</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">335,423<span></span>
</td>
<td class="nump">296,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeficitAccumulatedDuringDevelopmentalStage', window );">Accumulated deficit</a></td>
<td class="nump">302,932<span></span>
</td>
<td class="nump">279,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury shares at cost, 675,000 shares</a></td>
<td class="num">(3,849)<span></span>
</td>
<td class="num">(3,849)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">28,657<span></span>
</td>
<td class="nump">13,513<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 65,811<span></span>
</td>
<td class="nump">$ 82,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeficitAccumulatedDuringDevelopmentalStage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deficit accumulated during the developmental stage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeficitAccumulatedDuringDevelopmentalStage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_GALE401rights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>GALE-401 rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_GALE401rights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_InProcessResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_InProcessResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6396582&amp;loc=d3e15243-108350<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821404000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">15,224,223<span></span>
</td>
<td class="nump">8,129,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">15,190,473<span></span>
</td>
<td class="nump">8,095,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">33,750<span></span>
</td>
<td class="nump">33,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837441456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 19,860<span></span>
</td>
<td class="nump">$ 23,611<span></span>
</td>
<td class="nump">$ 27,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_GeneralAndAdministrativeExpenses', window );">General and administrative</a></td>
<td class="nump">12,007<span></span>
</td>
<td class="nump">10,609<span></span>
</td>
<td class="nump">16,226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">31,867<span></span>
</td>
<td class="nump">34,220<span></span>
</td>
<td class="nump">43,900<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(31,867)<span></span>
</td>
<td class="num">(34,220)<span></span>
</td>
<td class="num">(43,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement</a></td>
<td class="num">(2,750)<span></span>
</td>
<td class="num">(5,282)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnWarrantExchange', window );">Change in fair value of warrants potentially settleable in cash</a></td>
<td class="nump">22,220<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">16,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_InterestIncome', window );">Interest expense, net</a></td>
<td class="num">(3,508)<span></span>
</td>
<td class="num">(760)<span></span>
</td>
<td class="num">(1,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Change in fair value of the contingent purchase price liability</a></td>
<td class="nump">5,047<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="nump">21,009<span></span>
</td>
<td class="num">(4,371)<span></span>
</td>
<td class="nump">15,616<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(10,858)<span></span>
</td>
<td class="num">(38,591)<span></span>
</td>
<td class="num">(28,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">(11,101)<span></span>
</td>
<td class="num">(38,956)<span></span>
</td>
<td class="num">(28,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations</a></td>
<td class="num">(12,448)<span></span>
</td>
<td class="num">(24,946)<span></span>
</td>
<td class="num">(8,322)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,549)<span></span>
</td>
<td class="num">$ (63,902)<span></span>
</td>
<td class="num">$ (36,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted per share, continuing operations (usd per share)</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (5.02)<span></span>
</td>
<td class="num">$ (4.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Basic and diluted loss per share, discontinued operations (usd per share)</a></td>
<td class="num">(1.25)<span></span>
</td>
<td class="num">(3.21)<span></span>
</td>
<td class="num">(1.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (usd per share)</a></td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (8.23)<span></span>
</td>
<td class="num">$ (6.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding: basic and diluted</a></td>
<td class="nump">9,958,802<span></span>
</td>
<td class="nump">7,763,236<span></span>
</td>
<td class="nump">5,969,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,549)<span></span>
</td>
<td class="num">$ (63,902)<span></span>
</td>
<td class="num">$ (36,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Tax effect of reclassification of unrealized gain upon sale of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_GeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_GeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_InterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest (expense) income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_InterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on warrant exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840248112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Settled Litigation [Member]</div></th>
<th class="th">
<div>Senior Secured Debentures [Member] </div>
<div>Senior Notes [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Settled Litigation [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Settled Litigation [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Senior Secured Debentures [Member] </div>
<div>Senior Notes [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th">
<div>Treasury Stock [Member] </div>
<div>Settled Litigation [Member]</div>
</th>
<th class="th">
<div>Treasury Stock [Member] </div>
<div>Senior Secured Debentures [Member] </div>
<div>Senior Notes [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,505,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2013</a></td>
<td class="nump">$ 5,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (178,875)<span></span>
</td>
<td class="num">$ (3,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 10,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedforMilestonePayment', window );">Issuance of common stock under milestone achievement, shares</a></td>
<td class="nump">219,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValueAchievementofMilestone', window );">Issuance of common stock under milestone achievement</a></td>
<td class="nump">$ 9,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt', window );">Issuance of common stock to satisfy principal and interest of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">37,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Stock based compensation for directors and employees</a></td>
<td class="nump">5,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation for services</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,507,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2014</a></td>
<td class="nump">37,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215,481)<span></span>
</td>
<td class="num">(3,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">47,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock warrants issued in connection with common stock offering</a></td>
<td class="num">(10,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt', window );">Issuance of common stock to satisfy principal and interest of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Stock based compensation for directors and employees</a></td>
<td class="nump">2,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(63,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,129,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2015</a></td>
<td class="nump">13,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(279,383)<span></span>
</td>
<td class="num">(3,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,872,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">33,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock warrants issued in connection with common stock offering</a></td>
<td class="num">(9,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares', window );">Stock issued during period to satisfy principal and interest on long-term debt, new shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,981,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt', window );">Issuance of common stock to satisfy principal and interest of long-term debt</a></td>
<td class="nump">8,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock Issued During Period, Value, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan, shares</a></td>
<td class="nump">29,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Stock based compensation for directors and employees</a></td>
<td class="nump">$ 2,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,224,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2016</a></td>
<td class="nump">$ 28,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (302,932)<span></span>
</td>
<td class="num">$ (3,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to satisfy principal and interest of long-term debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharesIssuedforMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued for Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharesIssuedforMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodValueAchievementofMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Achievement of Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodValueAchievementofMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period to satisfy principal and interest on long-term debt, new shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_Stockissuedduringperiodtosatisfyprincipalandinterestonlongtermdebtnewshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65880886&amp;loc=d3e23524-113945<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827466928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Tax effect of reclassification of unrealized gain upon sale of marketable securities</a></td>
<td class="nump">$ 1,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6838701984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss</a></td>
<td class="num">$ (11,101)<span></span>
</td>
<td class="num">$ (38,956)<span></span>
</td>
<td class="num">$ (28,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and non-cash interest</a></td>
<td class="num">(3,054)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred taxes</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">2,264<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">4,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IssuanceofCommonStockforLitigationSettlement', window );">Litigation settlement payable in common stock</a></td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
<td class="num">(22,220)<span></span>
</td>
<td class="num">(1,161)<span></span>
</td>
<td class="num">(16,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(5,047)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">892<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="num">(1,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable', window );">Litigation settlement insurance recovery</a></td>
<td class="nump">21,700<span></span>
</td>
<td class="num">(21,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncreaseDecreaseinLitigationSettlement', window );">Litigation settlement payable</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(757)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(3,593)<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in continuing operating activities</a></td>
<td class="num">(33,230)<span></span>
</td>
<td class="num">(38,802)<span></span>
</td>
<td class="num">(37,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss from discontinued operations</a></td>
<td class="num">(12,448)<span></span>
</td>
<td class="num">(24,946)<span></span>
</td>
<td class="num">(8,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss on sale of commercial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification of assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale', window );">Changes in operating assets and liabilities attributable to discontinued operations</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">2,968<span></span>
</td>
<td class="nump">2,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in discontinued operating activities</a></td>
<td class="num">(11,685)<span></span>
</td>
<td class="num">(9,358)<span></span>
</td>
<td class="num">(5,832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(44,915)<span></span>
</td>
<td class="num">(48,160)<span></span>
</td>
<td class="num">(42,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of GALE-401</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of equipment and furnishings</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) continuing investing activities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
<td class="num">(2,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Net proceeds received from sale of commercial assets</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="nump">11,283<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid for commercial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(534)<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) discontinued investing activities</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="nump">10,749<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(1,056)<span></span>
</td>
<td class="nump">10,395<span></span>
</td>
<td class="num">(5,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">33,534<span></span>
</td>
<td class="nump">47,416<span></span>
</td>
<td class="nump">10,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from exercise of stock options</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">4,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NetProceedsFromExerciseOfCommonStockWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockIssuedInConnectionWithEspp', window );">Proceeds from common stock issued in connection with ESPP</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of long-term debt</a></td>
<td class="nump">23,401<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PaymentofCashDividendsforCovenantonLongtermDebt', window );">Minimum cash covenant on long-term debt</a></td>
<td class="nump">17,621<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(5,579)<span></span>
</td>
<td class="num">(3,911)<span></span>
</td>
<td class="num">(1,766)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">34,324<span></span>
</td>
<td class="nump">43,845<span></span>
</td>
<td class="nump">24,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(11,647)<span></span>
</td>
<td class="nump">6,080<span></span>
</td>
<td class="num">(24,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of period</a></td>
<td class="nump">29,730<span></span>
</td>
<td class="nump">23,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">18,083<span></span>
</td>
<td class="nump">29,730<span></span>
</td>
<td class="nump">23,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the periods for interest</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the periods for interest</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity', window );">Fair value of warrants issued in connection with common stock recorded as cost of equity</a></td>
<td class="nump">9,886<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts', window );">Fair value of warrants issued in connection with long-term debt recorded as debt issuance costs</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt', window );">Principal and interest repaid through issuance of common stock</a></td>
<td class="nump">8,079<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReclassificationOfWarrantLiabilityUponExercise', window );">Reclassification of warrant liabilities upon exercise</a></td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants', window );">Issuance of common stock in settlement of GALE-401 milestone</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of shares issued to acquire Zuplenz rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfContingentPurchasePriceConsideration', window );">Future obligations for Zuplenz rights included in accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrants issued in connection with various equity financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockIssuedInConnectionWithEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued in connection with ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockIssuedInConnectionWithEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with common stock recorded as a cost of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Issued in Connection with Long-Term Debt Recorded as Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncreaseDecreaseinLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncreaseDecreaseinLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in exchange for outstanding warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IssuanceOfCommonStockInExchangeOfOutstandingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IssuanceofCommonStockforLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IssuanceofCommonStockforLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to satisfy principal and interest of long-term debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_Issuanceofcommonstocktosatisfyprincipalandinterestoflongtermdebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NetProceedsFromExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NetProceedsFromExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PaymentofCashDividendsforCovenantonLongtermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Cash Dividends for Covenant on Long-term Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PaymentofCashDividendsforCovenantonLongtermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReclassificationOfWarrantLiabilityUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability upon exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReclassificationOfWarrantLiabilityUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11374-113907<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2611-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827356592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CashExcludingFromNetAssetsAcquired', window );">Cash excluding from net assets acquired</a></td>
<td class="nump">$ 168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CashExcludingFromNetAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash excluding from net assets acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CashExcludingFromNetAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818144208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Business and Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Business and Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax&#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and the asset is ready to advance into a pivotal trial in patients with essential thrombocythemia (ET). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers. </font></div><div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the generally accepted accounting principles (GAAP). Unless the context otherwise indicates, references in these notes to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer (i)&#160;to Galena, our wholly owned subsidiary, Apthera, Inc., or &#8220;Apthera,&#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, Inc. or "Mills."</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Management's Plans</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> -  We had cash and cash equivalents of approximately $18.1 million as of December&#160;31, 2016, compared with $29.7 million as of December&#160;31, 2015. We expect to continue to incur operating losses as we continue to advance our product candidates through the drug development and the regulatory process. In the absence of revenue, our potential sources of operational funding are proceeds from the sale of equity, funded research and development payments, debt financing arrangements, and payments received under partnership and collaborative agreements.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, the Company closed an underwritten public offering of 17,000,000 units at a price to the public of $1.00 per unit for gross proceeds of $17.0 million ("February 2017 Offering"). Each unit consists of one share of common stock, and a warrant to purchase one share of common stock at an exercise price of $1.10 per share. The net proceeds of the February 2017 Offering were $15.5 million, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the proceeds from the February 2017 Offering, in January and February 2017 the holder of the Debenture redeemed $3.95 million of outstanding principal that was satisfied by the Company with 3,518,663 shares of our common stock. As a result of the redemptions, the Company was able to transfer $3.95 million out of restricted cash and cash equivalents and into unrestricted cash and cash equivalents to be used to fund the Company's ongoing operations. The outstanding principal balance on the Debenture as of March 15, 2017 is $13,617,702 and is maintained by the Company as restricted cash.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the funds raised through underwritten public offerings and the debenture, we maintain a purchase agreement with Lincoln Park Capital LLC (LPC) and At Market Issuance Sales Agreements (ATM) with future availability of $2.0 million and $19.1 million, respectively subject to certain terms and conditions. We may also continue to use the ATM, or other instruments, in order to fund our operations going forward.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 31, 2017, the Company announced that it is in the process of evaluating strategic alternatives focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in a transaction. While the Company evaluates its strategic alternatives, Galena&#8217;s investigator-sponsored immunotherapy trials will remain ongoing.&#160;With the confirmation from the FDA that the GALE-401 development program is appropriate for a New Drug Application (NDA) filing using the 505(b)(2) regulatory pathway in patients with ET who are intolerant or resistant to hydroxyurea, we have developed a clear path forward for GALE-401 in the treatment of ET. Subject to completing the manufacturing of the new formulation and the internal work to prepare the Phase 3 trial for initiation, the Company is evaluating the appropriate time to commence enrollment of the GALE-401 trial and anticipates making a definitive determination in the second half of 2017. The Company has focused on reducing expenditures in order to preserve liquidity while pursuing a strategic alternative.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We believe that our existing cash and cash equivalents, funding available under an amended LPC purchase agreement, ATM and other instruments, should be sufficient to fund our operations for at least one year from the date of issuance of the Company's consolidated financial statements. This projection is based on our current limited operations and estimates of legal expenses associated with the ongoing government investigation and legal matters pending against the company, and is subject to changes in our operating plans, resolutions of such government investigation and legal matters, uncertainties inherent in our business, strategic alternatives outcomes, and the need to seek to replenish our existing cash and cash equivalents sooner than we project and in greater amounts that we had projected. There is no guarantee that any debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate, our operations or to seek to merge with or to be acquired by another company.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reverse Stock-Split</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On November 11, 2016 the Company effected a 1:20 reverse stock split of the Company's outstanding shares of common stock, outstanding stock options to purchase shares of our common stock and warrants to purchase shares of common stock. In addition, the number of shares of common stock and number of shares of common stock subject to stock options or similar rights authorized under the Company&#8217;s equity incentive plan and employee stock purchase plan were proportionately adjusted for the reverse stock-split. Further, the per share exercise price under such plans were proportionately adjusted for the reverse stock-split. These consolidated financial statements give retroactive effect to such reverse stock-split and all share and per share amounts have been adjusted accordingly.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 15, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. The Company generally considers assets to be held for sale when (i) the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) the assets are available for immediate sale in their present condition, (iii) the company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to the current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment for sale, the Company discontinues depreciating the asset and writes down the asset to the lower of the carrying value or fair market value, if needed. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Restricted cash consists of the minimum cash covenant as required by the debenture certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The carrying amounts reported in the balance sheet for cash equivalents, marketable securities, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years for equipment and furniture) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div></td></tr></table><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit (the &#8220;First Step&#8221;). If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment (the &#8220;Second Step&#8221;). Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible product rights when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets.</font></div><div style="line-height:120%;text-indent:60px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, and has determined that there has been no impairment to these assets as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Contingent consideration is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Fees and Insurance Recoveries </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations ("CROs"), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015, we recognized income tax of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$243,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$365,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively. There was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> income tax expense or benefit for the year ended December 31, 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The Company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$17,583,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in interest-bearing accounts above federally insured limits.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827346944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Adopted Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company has adopted this ASU.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-03,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Further, ASU 2015-03 requires the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 must be applied retrospectively. The Company adopted this ASU on January 1, 2016. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or ASU 2015-17.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ASU 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. Previous guidance required deferred tax liabilities and assets to be separated into current and noncurrent amounts on the balance sheet. The guidance will become effective for us beginning in the first quarter of 2017 and may be applied either prospectively or retrospectively. Early adoption is permitted. At the time of adoption, we will reclassify current deferred tax amounts on our Consolidated Balance Sheets as noncurrent. The Company adopted this ASU on January 1, 2017. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2016, the FASB issued ASU No.&#160;2016-01,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"> Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016-01 will be effective for the Company beginning in its first quarter of 2019 and early adoption is not permitted. The Company does not believe the adoption of the new financial instruments standard will have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of our pending adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2016, the FASB issued Accounting Standards Update 2016-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation-Stock Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU 2016-09 includes several areas of simplification to stock compensation including simplifications to the accounting for income taxes, classification of excess tax benefits on the Statement of Cash Flows and forfeitures. ASU 2016-09 is effective for annual reporting periods beginning after December&#160;15, 2016. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this ASU on January 1, 2017. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.. </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2016, the Financial Accounting Standards Board issued ASU No. 2016-15 "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force." The objective of ASU No. 2016-15 is to provide specific guidance on eight cash flow classification issues and how to reduce diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years.  We are still evaluating the effect of this update.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. We are evaluating the effect of this update.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 6.G.2.b(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26874127&amp;loc=d3e31034-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=6368906&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 1.N.Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26874127&amp;loc=d3e30840-122693<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818093584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company categorized its cash equivalents and marketable securities as Level&#160;1 inputs. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 3</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 3</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company has not transferred any financial instruments into or out of Level 3 classification during the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or 2015. A reconciliation of the beginning and ending Level 3 liabilities for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The decrease in the estimated fair value of the contingent purchase price consideration during 2016 reflects a lowering of the probability and lengthening of the timeline for the potential approval of NeuVax, as these assumptions are now based principally on our Phase 2 combination trial with trastuzumab whereas previously, the valuation was based on our Phase 3 PRESENT trial, which was deemed futile by the Independent Data Monitoring Committee ("IDMC") in June 2016 and subsequently closed.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827346944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Accrued Expenses and Other Current Liabilities </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818152464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 8, 2013, we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> ("Loan"). The Loan payment terms include </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months of interest-only payments at the fixed coupon rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.45%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, followed by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cash facility fee and a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cash final payment and granted to the lender </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,109</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$49.4</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. On May 10, 2016, the Company prepaid the outstanding principal amount and cash final payment.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, the Company entered into a&#160;Securities Purchase Agreement ("Purchase Agreement"), with certain purchasers pursuant to which the Company sold, at a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.375%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> original issue discount, a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25,530,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Senior Secured Debenture&#160;(&#8220;Debenture&#8221;) and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company's common stock. Net proceeds to the Company from sale of the&#160;Debenture, after payment of commissions and legal fees, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> The&#160;Debenture&#160;matures November 10, 2018, accrues interest at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per year, and does not contain any conversion features into shares of our common stock. On August 22, 2016, the Company, the purchasers and certain other parties entered into an amendment agreement, which provides for the amendment and restatement of the Debenture, an amendment to the terms of the Series A Common Stock Purchase Warrant issued by the Company to the purchasers pursuant to the terms of the Purchase Agreement, and certain other terms and conditions, as summarized below.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 14, 2016, the Company and the holder entered into a waiver (the &#8220;Waiver&#8221;) that amended the Securities Purchase Agreement dated May 10, 2016 between the Company and the holder, as amended on August 22, 2016 (the &#8220;SPA&#8221;). The Waiver provides that solely with respect to the calendar months of December 2016, January 2017, February 2017 and March 2017 (collectively, the &#8220;Specified Months&#8221;), the holder waives, subject to certain delineated exceptions, the requirement of paragraph (i) of the definition of &#8220;Equity Conditions&#8221; set forth in Section 1 of the Debenture, thereby continuing to allow the Company to deliver shares of its Common Stock in respect to a portion of its amortization obligation under the Debenture. Furthermore, the waiver sets out a Monthly Allowance for each Specified Month equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and required the Company to withdraw all cash and/or cash equivalents in excess of eighteen million five hundred thousand dollars (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) from certain accounts and deposit such funds into an account in a form acceptable to the holder, such that the Company requires the prior written consent of the holder for certain withdrawals. The Waiver also grants the holder special redemption rights depending upon the price of our common stock, including the right to redeem the debenture.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Debenture carries an interest only period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months, following which interest is due monthly and payable in cash or stock at the election of the Company. Interest deferred during the interest only period is added to and considered principal. Following the interest only period, the Company has the right under the Debenture, commencing November 10, 2016, to pay the monthly redemption amount of the outstanding balance in cash, shares of the Company's common stock or a combination thereof, if certain conditions are met. The maximum monthly redemption amount was increased from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> under the amended Debenture; provided, that if the trading price of the Company&#8217;s common stock is at least </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share (as adjusted for stock splits, combinations or similar events) during such calendar month, then such maximum monthly redemption amount may be increased to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2,200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> at the holder's election and if the Company has already elected to satisfy such monthly redemptions in shares of common stock. In addition, notwithstanding the foregoing limitations on the monthly redemption amount, the holder may elect up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> times in any 12-month period to increase the maximum monthly redemption to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If the Company elects to pay the redemption amount in shares of its common stock, then the shares will be delivered at the lesser of A) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> discount to the average of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> lowest volume weighted average prices over the prior </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> trading days or B) a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> discount to the prior trading day&#8217;s volume weighted average price. The Company may only opt for payment in shares of common stock if certain equity conditions are met. The Company, at its option, may also force the holder to redeem up to double the monthly redemption principal amount of the Debenture but not less than the monthly payment.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The holder received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> warrants upon the closing on the sale of the Debenture at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30.20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5 years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from issuance, and in accordance with the terms of the amendment agreement, the exercise price of the warrant was reduced to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. Additionally, the holder received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The amendment agreement provides that, following November 10, 2016, the holder may elect to convert any portion of the outstanding balance into shares of common stock at a fixed price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share (as adjusted for stock splits, combinations or similar events). </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the&#160;Debenture&#160;can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company&#8217;s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the&#160;Debenture in cash. The Company&#8217;s obligations under the&#160;Debenture&#160;are secured under a security agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries.  Under the subsidiary guarantee agreement, each subsidiary guarantees the performance of the Company of the Purchase Agreement, Debenture and related agreements. The Company must also maintain as a compensating cash balance, the lesser of a minimum of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash or the outstanding principal and accrued and unpaid interest, which such amount is included in restricted cash as of December 31, 2016. The holder of the Debenture has the right, at any time and from time to time, to require the Company to prepay the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus accrued and unpaid interest or the outstanding principal and accrued and unpaid interest. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2016 the outstanding principal balance of the Debenture was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$17,621,702</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The current portion of long-term debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$16,397,030</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> is net of unamortized discounts and debt issuance costs of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,224,672</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In January and February 2017, the holder of the Debenture redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3,950,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of principal, which the Company satisfied with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,541,077</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock. The outstanding principal balance as of March 15, 2017 is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$13,671,702</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Armentum Partners, LLC (&#8220;Placement Agent&#8221;) acted as the&#160;placement agent&#160;in the offering of the&#160;Debenture and the Company paid the Placement Agent a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the funds received from the sale of the&#160;Debenture. The Company paid half of the placement fee upon funding and paid the other half during the third quarter of 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827342192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval to the settlement awarding attorney&#8217;s fees of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus costs, which was paid by our insurance carriers. The settlement included a payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">60,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> outstanding director stock options. The settlement also required that we adopt and implement certain corporate governance measures. The settlement did not include any admission of wrongdoing or liability on the part of us or the individual defendants and included a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval of the settlement awarding attorney&#8217;s fees of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus costs, which was paid out of the settlement funds. The settlement agreement provided for a payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to the class and the dismissal of all claims against us and the other defendants in connection with the consolidated federal securities class actions. Of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> settlement payment to the class, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$16.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> was paid by our insurance carriers and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> was paid by us through a combination of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares of our common stock (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,002</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares) issued by us on July 6, 2016. In addition to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> settlement payment, the company paid </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in December 2015 in attorney fees outstanding as a condition of the settlement. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In July 2016, we resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,563</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares) of our common stock, and in another case for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares of our common stock (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">168,337</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements did not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and included a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 13, 2016, we filed a complaint in the Circuit Court for the County of Multnomah for the State of Oregon against Aon Risk Insurance Services West, Inc. where we are seeking attorney's fees, costs and expenses incurred by us related to our coverage dispute with a certain insurer and for amounts we were required to contribute to the settlements of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as a direct result of certain insurer's failure to pay its full policy limits of liability and other relief. We are currently engaged in written discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 13, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Miller v. Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. On February 15, 2017, a putative shareholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Kattuah v Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Within the time allowed under the federal rules and statutes, the Company and the other defendants, former and current officers, will respond to the complaints through an appropriate pleading or motion.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">two</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the high-prescribing physicians for Abstral (former commercial product) has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial began in January 2017 and is ongoing. We received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&#8217;s Office for the Southern District of Alabama (SDAL), which is handling the criminal trial, and are cooperating in the production of documents. On April&#160;28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. The criminal trial</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> which began on January 4, 2017, concluded with a jury verdict on February 23, 2017 finding these physicians guilty on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> counts; sentencing is scheduled for May 2017. At the end of the SDAL case</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> SDAL dismissed count </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the indictment charging that the physicians conspired, through the C&amp;R Pharmacy, to receive illegal kickbacks in exchange for prescribing Abstral. Though certain former employees received trial subpoenas to appear at the trial and provide oral testimony, only </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">one</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> former employee testified at the trial. We agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we were not a target or subject of that investigation. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There are also federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office for the District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral, the commercial product we sold in the fourth quarter of 2015. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and the Department of Justice, and we have come to understand that the investigation being undertaken is a criminal investigation in addition to a civil investigation that could ultimately involve the Company as well as one or more former employees. Pursuant to the Company&#8217;s charter, we are currently reimbursing certain former employees&#8217; attorney&#8217;s fees with respect to the investigation. We are cooperating with the civil and criminal investigation, and through our outside counsel we have begun preliminary&#160;discussions with the government aimed at the ultimate resolution of the investigation regarding the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;22, 2016, the Company and its former CEO reached an agreement in principle to a proposed settlement that would resolve an investigation by the staff of the Securities and Exchange Commission (SEC) involving conduct in the period 2012-2014 regarding the commissioning of internet publications by outside promotional firms. Under the terms of the proposed settlement framework, the Company and the former CEO would consent to the entry of an administrative order requiring that we and the former CEO cease and desist from any future violations of Sections 5(a), 5(b), 5(c), 17(a), and 17(b) of the Securities Act of 1933, as amended, and Section&#160;10(b), 13(a), and 13(b)(2)(A) of the Securities Exchange Act of 1934, as amended, and various rules thereunder, without admitting or denying the findings in the order. Based upon the proposed settlement framework, the Company will make a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> penalty payment. In addition to other remedies, the proposed settlement framework would require the former CEO to make a disgorgement and prejudgment interest payment as well as a penalty payment to the Commission. To address the issues raised by the SEC staff&#8217;s investigation, in addition to previous governance enhancements we have implemented, we have voluntarily undertaken to implement a number of remedial actions relating to securities offerings and our interactions with investor relations and public relations firms. The proposed settlement is subject to approval by the Commission and would acknowledge our cooperation in the investigation and confirm our voluntary undertaking to continue that cooperation. If the Commission does not approve the settlement, we may need to enter into further discussions with the SEC staff to resolve the investigated matters on different terms and conditions. As a result, there can be no assurance as to the final terms of any resolution including its financial impact or any future adjustment to the financial statements. In response to an indemnification claim by the former CEO, a special committee of our Board of Directors has determined that we are required under Delaware law to indemnify our former CEO for the disgorgement and prejudgment interest payment of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$750,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> that he would be required to pay if and when the settlement is approved by the Commission. Any penalty payment that the former CEO will be required to make in connection with this matter (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$600,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> under the proposed settlement framework) will be the responsibility of the former CEO.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The litigation settlements are summarized as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" style="padding-left:0px;padding-right:0px;padding-top:4px;padding-bottom:4px;" rowspan="1"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Class action settlement in 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Derivative settlement in 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shareholders securities litigation settlements in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SEC settlement in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the Company in cash as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the insurance carriers in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the Company in cash in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the Company in common stock in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Commitments </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&#8217;s contractual obligations that may require future cash payments as of December&#160;31, 2016 are as follows (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Operating</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Leases</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-Cancelable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Employment</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Agreements</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cancelable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">License</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Agreements</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,586</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2021 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">974</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,256</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December&#160;31, 2016, 2015, and 2014 were approximately </font><font style="font-family:Helvetica;font-size:10pt;">$291,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica;font-size:10pt;">$116,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica;font-size:10pt;">$72,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License agreements generally relate to the company&#8217;s obligations with The Board of Regents, University of Texas M.D. Anderson Cancer Center and the Henry M. Jackson Foundation for our oncology therapies and the obligations with Biovascular Inc. and Mills Pharma for our GALE-401 asset. The company continually assesses the progress of its licensed technology and the progress of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, </font><font style="font-family:Helvetica;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> amounts will be due.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the disclosure provisions FASB ASC Topic 460 (&#8220;ASC 460&#8221;), &#8220; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Guarantor&#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others,"</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to its agreements that contain guarantee or indemnification clauses. The Company provides (i)&#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&#160;460. In 2016, the Company has incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$750,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as a result of these obligations as a result of its obligation to its former CEO as noted above. Accordingly, the Company has accrued this liability in its financial statements related to these indemnifications.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818152464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Issuances of common stock are as follows:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">November 2014 Purchase Agreement with Lincoln Park Capital, LLC - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 18, 2014, the Company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the Company has the right to sell to LPC up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares of the Company's common stock, subject to certain limitations and conditions over the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">125,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company's common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31,561</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the Company received initial net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting commissions and other offering expenses. In addition to the LPC&#8217;s initial purchase of our common stock under the purchase agreement, during 2014, we received net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from LPC&#8217;s subsequent purchases of a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">230,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock, excluding the commitment fee shares.  During the years ended December 31, 2016 and 2015 we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> by issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">135,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock, respectively.  On February 6, 2017, Purchase Agreement was amended to the total value of common stock that the Company may sell to LPC from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$55,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15,600,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">At-The-Market Issuance Sales Agreements </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- On May 24, 2013 the Company entered into At-The-Market Issuance Sales Agreements (ATM) with FBR &amp; Co. (formerly MLV &amp; Co. LLC) and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the gross proceeds from the sale of shares, up to a total limit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in gross proceeds. The ATM is available to the Company until it is terminated by the Agents, or the Company. During the years ended December 31, 2016 and 2015 we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> by issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">334,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock. During the year ended December 31, 2014, we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in net proceeds from the sale of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">70,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock through the ATM. On December 4, 2015 we replenished the ATM limit up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in gross proceeds available for future sales of our common stock.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On March 18, 2015 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,217,948</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> units at a price to the public of $</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$41.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,692</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">91,346</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">91,346</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,692</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock for additional net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the Company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">January 2016 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On January 12, 2016 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">988,636</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$22.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> ("January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$28.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,295</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">88,977</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">88,977</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. The underwriters did not exercise their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,295</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">July 2016 Registered Direct Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On July 13, 2016, we closed the sale to certain institutional investors of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,400,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at a purchase price per share of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;in a registered direct offering, and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock with an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$13.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share in a concurrent private placement. The warrants are initially exercisable </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">one</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> day following issuance and have a term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses were approximately&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">February 2017 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On February 13, 2017, the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and warrants to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock priced at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and accompanying warrant ("February 2017 Offering"). The warrants are immediately exercisable with a strike price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and will expire on the fifth anniversary of the date of issuance. The shares of common stock and the warrants will be issued separately and will be separately transferable immediately upon issuance</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The net proceeds of the February 2017 Offering were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827369424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company follows the provisions ASC&#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is being re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the Consolidated Statements of Comprehensive Loss for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, 2015, and 2014 (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,903</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">102.62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average fair value of options granted during the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.09</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, respectively.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the Company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the Company has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for options granted to its employees, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for options granted to senior management and zero for non-employee directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2,295,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,325,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock were reserved for issuance under the Company&#8217;s 2016 Incentive Plan, including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">561,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares subject to outstanding common stock options granted under the plan and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">501,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares available for future grants.  On July 14, 2016, shareholders approved the 2016 Incentive Plan. The 2016 Incentive Plan replaced the 2007 Incentive Plan that expired on February&#160;23, 2017. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The options generally will expire, unless previously exercised, no later than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from the grant date. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted average remaining contractual life of options outstanding as of December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.63</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.35</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, respectively. The weighted average remaining contractual life of options exercisable as of December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.52</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.51</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, respectively.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic value of outstanding options as of December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$539,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$610,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic value of exercisable options as of December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">,  </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$518,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$509,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company's common stock and the exercise price of the underlying options.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic value of options exercised during the years ended December 31, 2016, 2015, and 2014 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$56,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$37,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$13,429,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> respectively. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212;&#160;The Company also has an employee stock purchase plan (&#8220;ESPP&#8221;) which allows employees to contribute up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of their cash earnings, subject to certain maximums, to be used to purchase shares of our common stock on each semi-annual purchase date. The purchase price is equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the market value per share on either the first or last day of the semi-annual period, whichever is lower. Our ESPP is non-compensatory pursuant to the provisions of generally accepted accounting principles for share-based compensation expense. The ESPP contains an &#8220;evergreen provision&#8221; with annual increases in the number of shares available for issuance on the first day of each year through January&#160;1, 2015 equal to the lesser of: (a)&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,500</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares increased on each anniversary of the adoption of the Plan by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;of the total shares of stock then outstanding and (b)&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares.&#160;As of December&#160;31, 2016, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,930</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock were authorized and available for future issuance under the ESPP. The Company has issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,070</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares under the ESPP through December&#160;31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Stock Units</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; In addition to options to purchase shares of common stock, the Company may grant restricted stock units (&#8220;RSU&#8221;) as part of its compensation package. If granted, each RSU would be granted at the fair market value of the Company's common stock on the date of grant. Vesting is determined on a grant-by-grant basis. There were no RSUs outstanding as of December 21, 2016 and 2015.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818051824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015 (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">January 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">November 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">November 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in July 2016, January 2016, March 2015, September 2013, December 2012,&#160;April 2011,&#160;March 2011,&#160;March 2010 and August 2009. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">July 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">117.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">January 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">120.38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">131.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">164.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">204.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">103.79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65.60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">47.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">40.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">71.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected volatility is based on a combination of implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the company has no present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015 were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">January 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,852</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(278</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(259</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,886</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(22,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(627</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,358</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,109</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$49.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, which equaled the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-day average market price of our common stock prior to the date of the grant. The warrants were valued using the Black Scholes model. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.34%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, risk free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In 2016, we issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to the holder of the Debenture. The holder received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> warrants upon the closing on the sale of the Debenture at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30.20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from issuance, and in accordance with the terms of the amendment agreement, the exercise price of the warrant was reduced to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">77.13%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, risk free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.26%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Additionally, the holder received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">106.63%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, risk free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.35%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition to the warrants issued to the holder of the debenture we have </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> outstanding warrants issued to service providers with a weighted average exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$79.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as of December 31, 2016 and 2015. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90193-114008<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Freestanding Contract<br> -URI http://asc.fasb.org/extlink&amp;oid=6513800<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 55<br> -Paragraph 63<br> -URI http://asc.fasb.org/extlink&amp;oid=6924035&amp;loc=d3e23176-110880<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90205-114008<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90198-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837092624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">561</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827342992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of federal and state income tax expense are as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total deferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax assets are as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">97,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,866</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Licensing deduction deferral</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,910</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">117,329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">95,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(117,329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(95,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In-process research and development not subject to future amortization for tax purposes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected federal income tax benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,447</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State income taxes after credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,375</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,283</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Changes in warrant value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,728</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(456</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effect of change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,852</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,029</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has incurred net operating losses from inception. At December&#160;31, 2016, the Company had domestic federal and state net operating loss carryforwards of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$251.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, available to reduce future taxable income, which expire at various dates beginning in 2016 through </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2036</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company also had federal and state research and development tax credit carryforwards of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, available to reduce future tax liabilities and which expire at various dates beginning in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2023</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> through </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2035</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The income tax expense for the year ended December 31, 2016 relates to indefinite lived deferred tax liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At December 31, 2016, approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Company's net operating loss carryforwards were generated as a result of deductions related to the exercises of stock options. If utilized, this portion of the Company's carryforwards, as tax effected, will be accounted for as a direct increase to contributed capital rather than as a reduction of that year's provision for income taxes. Net operating loss carryforwards created by excess tax benefits from the exercise of stock options are not recorded as deferred tax assets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership may result in a limitation on the amount of net operating loss carryforwards and research and development credit carryforwards which could be utilized annually to offset future taxable income and taxes payable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Based on an assessment of all available evidence including, but not limited to the Company&#8217;s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> deferred income tax valuation allowance has been recorded against these assets. The valuation allowance increased by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for the years ended December 31, 2015 and 2014, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company files income tax returns in the U.S.&#160;federal, Massachusetts, Colorado, California, Connecticut, Georgia, Oregon, and Texas jurisdictions. The Company is subject to tax examinations for the 2012 tax year and beyond. The Company does not believe there will be any material changes in its unrecognized tax positions over the next </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12&#160;months</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company has not incurred any interest or penalties. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial statements as general and administrative expense.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827356592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">License Agreements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed asset through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In conjunction with the acquisition of NeuVax, the Company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, clinical milestone payments including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> upon commencement of the Phase 3 PRESENT trial of NeuVax and royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective December&#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&#8220;ABIC&#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 19, 2015, Galena Biopharma, Inc. (the &#8220;Company&#8221;) and Sentynl Therapeutics Inc., a Delaware corporation (&#8220;Sentynl&#8221;), entered into and closed upon an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell to Sentynl and Sentynl agreed to purchase from the Company, certain assets of the Company related to and including its Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (fentanyl) sublingual tablets product (&#8220;Abstral&#8221;). The assets sold and assigned to Sentynl pursuant to the Purchase Agreement included all of the Company&#8217;s rights and interests in the Asset Purchase Agreement by and between the Company and Orexo AB (&#8220;Orexo&#8221;) dated March 15, 2013, and the License Agreement by and between the Company and Orexo dated March 18, 2013 (collectively, the &#8220;Orexo Agreements&#8221;).  The Company&#8217;s future obligations under the Orexo Agreements were assumed by Sentynl pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Abstral, as well for certain channel liabilities related to Abstral for a period of time post-closing. In connection with the transactions contemplated by the Purchase Agreement, the Company assigned to Sentynl all of its rights to and interests in the Orexo Agreements. In connection with such assignment, Orexo released the Company from any future liabilities and obligations under the Orexo Agreements.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The total potential consideration payable to the Company under the Purchase Agreement is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, comprised of an </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> upfront payment and up to an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, consisting of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">two</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> one-time payments based on Sentynl's achievement of "net sales" of Abstral in amounts ranging from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$35 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills"), and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of myleoproliferative neoplasms (MPNs). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. We are responsible for patent prosecution and maintenance.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 17, 2015, Galena Biopharma, Inc. (the &#8220;Company&#8221;) and Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (&#8220;Midatech&#8221;), entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell to Midatech and Midatech agreed to purchase from the Company, certain assets of the Company related to and including its Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (ondansetron) Oral Soluble Film (&#8220;Zuplenz&#8221;). The assets to be sold and assigned to Midatech pursuant to the Purchase Agreement include all of the Company&#8217;s rights and interests in the License and Supply Agreement by and between the Company and MonoSol Rx, LLC (&#8220;MonoSol&#8221;) dated July 17, 2014 (the &#8220;MonoSol License&#8221;).  The Company&#8217;s future obligations under the MonoSol agreement will be assumed by Midatech pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Zuplenz, as well for certain channel liabilities related to Zuplenz for a period of time post-closing. The transaction was completed on December 24, 2015.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The total potential consideration payable to the Company under the Purchase Agreement is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$29.75 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, comprised of a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.75 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> upfront payment upon the closing and up to an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$26 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, consisting of four one-time payments based on Midatech's achievement of "net sales" of Zuplenz in amounts ranging from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$70 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Through a separate agreement with MonoSol entered into on December 16, 2015 (the &#8220;MonoSol License Amendment&#8221;), (i) the Company and MonSol agreed to amend the MonoSol License in order to reduce the number of field representatives that the Company is required to maintain with respect to Zuplenz, and (ii) the Company agreed to pay MonoSol </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$900,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the upfront fee payable to the Company under the Purchase Agreement and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of any future milestone payments received by the Company under the Purchase Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 24, 2015, the Company and Midatech closed upon the Purchase Agreement. In connection with the closing of the transactions contemplated by the Purchase Agreement, the Company assigned to Midatech all of its rights to and interests in the Company&#8217;s License and Supply Agreement, dated July 17, 2014 (the &#8220;MonoSol License&#8221;).  As a result of such assignment, Midatech assumed all of the Company&#8217;s obligations under the MonoSol License.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818056576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Customers and Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Significant Customer and Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;font-weight:bold;">Significant Customers and Concentration of Credit Risk</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">The company is engaged in the business of developing and commercializing pharmaceutical products. The company has recognized revenue from only </font><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">one</font><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"> commercial product, Abstral, available in </font><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">six</font><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"> dosing strengths, and all sales reported are in the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">The percentage of product sales to our customer that represented </font><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">10%</font><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"> or more of revenue in at least one of the periods presented, is as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">There were no product sales during the year ended December 31, 2012.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">The following accounts represented 10% or more of total accounts receivable in at least one of the periods presented:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6327-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808543488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">From 2011 to 2016, the Company retained TroyGould PC as outside corporate counsel. Sanford J. Hillsberg, the Chairman of Galena, is a senior lawyer with TroyGould PC. The Company incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$209,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$577,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$533,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for services provided by TroyGould PC during the years ended December 31, 2016, 2015, and 2014, respectively. At December 31, 2015, Galena owed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to TroyGould PC. There was no payable to TroyGould PC as of December 31, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827347744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Employee Benefit Plan</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company sponsors a 401(k) retirement savings plan (the &#8220;Plan&#8221;). Participation in the Plan is available to full-time employees who meet eligibility requirements. Eligible employees may defer a portion of their salary as defined by Internal Revenue Service regulations. The Company may make matching contributions on behalf of all participants in the 401(k) Plan in an amount determined by the Company&#8217;s Board of Directors. The Company may also make additional discretionary profit sharing contributions in amounts as determined by the Board of Directors, subject to statutory limitations. Matching and profit-sharing contributions, if any, are subject to a vesting schedule; all other contributions are at all times fully vested. The Company intends the 401(k) Plan, and the accompanying trust, to qualify under Sections&#160;401(k) and 501 of the Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that the Company will be able to deduct its contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, invests the assets of the 401(k) Plan in any of a number of investment options. The Company made matching contributions totaling </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$108,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for the year ended December 31, 2016. For the years ended December 31, 2015 and 2014, the Company made matching contributions totaling </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$115,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$70,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818039296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Selected Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following amounts are in thousands, except per share amounts:</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,493</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,516</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss) per share, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross profit on net revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,537</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,660</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18,026</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(19,678</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827347744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations,Assets Held for Sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Discontinued Operations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of the Company's strategic objective to focus its resources on its development pipeline, our management and Board of Directors decided and committed to pursue a plan to sell or otherwise divest the Company&#8217;s commercial business during the third quarter of 2015. The Company&#8217;s commercial business was comprised of two products: Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (ondansetron) Oral Soluble Film. As described in Note 14, both products were sold in the fourth quarter of 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company met the relevant criteria for reporting the commercial business as held for sale and in discontinued operations in the accompanying financial statements pursuant to FASB Topic 205-20,&#160;Presentation of Financial Statements--Discontinued Operations, and FASB Topic 360,&#160;Property, Plant, and Equipment. The Company assessed the commercial business net asset group for impairment pursuant to FASB Topic 360, as discussed in Note 1, determining that the carrying value exceeded the fair value of the assets, therefore the Company recorded a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> impairment charge as of September 30, 2015. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company entered into an agreement with a third party firm to assist the Company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, in the event the Company successfully completed a divestiture through the sale of its commercial operations to a third-party, the Company paid a success fee to the third party firm in an amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, reimbursement for reasonable out-of-pocket expenses and agreed to pay </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of realized future revenue and payment streams. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management. Under the terms of these arrangements, if the Company met certain sales and margin numbers in the fourth quarter of 2015 and successfully completed a divestiture through sale of its commercial operations to a third-party, the Company paid a retention fee to the three employees in a combined total amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$352,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash consideration received as upfront payment in the transactions. These employees will also receive severance payments equal to one month&#8217;s salary for between four and seven months. In addition to these compensatory agreements loss from discontinued operations includes one-time termination benefits provided to employees that were part of the commercial business and did not accept employment opportunities at the companies who purchased Abstral and Zuplenz. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Abstral and related assets on November 19, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Zuplenz and related assets on December 24, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net proceeds from sales</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,348</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Less selling costs*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proceeds from sale, net of selling costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*Note selling costs related to the sale of Zuplenz and related assets are included in accrued liabilities and were paid in the first quarter of 2016.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the upfront proceeds received from the sale of Abstral and Zuplenz and their related assets, the Company is eligible to receive up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in future milestone payments based on future net revenue of the products. The additional consideration will be recognized in the period that the net revenue milestones are achieved.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,491</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,059</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,925</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial business in 2016, 2015, and 2014 that are presented in the consolidated statements of comprehensive loss as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,734</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,886</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(355</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge form classification as held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on sale of commercial business assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance and exit costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,349</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,448</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations included in discontinued operations in 2016 is comprised of larger than anticipated rebates of Abstral sales for which we were responsible through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control and was partially offset by lower than expected patient assistance program reimbursement.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general and administrative expense</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of all other expenses of our commercial operations that were required in order to market and sell our marketed products prior to our sales of the rights to these commercial products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the year ended December 31, 2016 we incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. See Note 6 for further disclosures related to these legal proceedings.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=SL51724579-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818001424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"> Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated all events or transactions that occurred after December&#160;31, 2016 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the Company did not have any material recognizable or unrecognizable subsequent events.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820835968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 15, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. The Company generally considers assets to be held for sale when (i) the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) the assets are available for immediate sale in their present condition, (iii) the company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to the current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment for sale, the Company discontinues depreciating the asset and writes down the asset to the lower of the carrying value or fair market value, if needed. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Uses of Estimates in Preparation of Financial Statements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Restricted cash consists of the minimum cash covenant as required by the debenture certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The carrying amounts reported in the balance sheet for cash equivalents, marketable securities, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment and Furnishings</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years for equipment and furniture) of the related assets.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div></td></tr></table><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit (the &#8220;First Step&#8221;). If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment (the &#8220;Second Step&#8221;). Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible product rights when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets.</font></div><div style="line-height:120%;text-indent:60px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, and has determined that there has been no impairment to these assets as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentConsiderationPolicyPolicyTextBlock', window );">Contingent Purchase Price Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Contingent consideration is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and In-Licensing</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock', window );">Patents and Patent Application Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Fees and Insurance Recoveries</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Fees and Insurance Recoveries </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations ("CROs"), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The Company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company categorized its cash equivalents and marketable securities as Level&#160;1 inputs. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentConsiderationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentConsiderationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents and Patent Application Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840267536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 3</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Level 3</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending Level 3 liabilities for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,095</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837112832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818068096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock', window );">Schedule of Litigation Settlement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The litigation settlements are summarized as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" style="padding-left:0px;padding-right:0px;padding-top:4px;padding-bottom:4px;" rowspan="1"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Class action settlement in 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Derivative settlement in 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shareholders securities litigation settlements in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SEC settlement in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the Company in cash as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the insurance carriers in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the Company in cash in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the Company in common stock in 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock', window );">Schedule of Contractual Obligations and Future Cash Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s contractual obligations that may require future cash payments as of December&#160;31, 2016 are as follows (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Operating</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Leases</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-Cancelable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Employment</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Agreements</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cancelable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">License</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Agreements</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,586</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2021 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">974</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,256</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December&#160;31, 2016, 2015, and 2014 were approximately </font><font style="font-family:Helvetica;font-size:10pt;">$291,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica;font-size:10pt;">$116,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica;font-size:10pt;">$72,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License agreements generally relate to the company&#8217;s obligations with The Board of Regents, University of Texas M.D. Anderson Cancer Center and the Henry M. Jackson Foundation for our oncology therapies and the obligations with Biovascular Inc. and Mills Pharma for our GALE-401 asset. The company continually assesses the progress of its licensed technology and the progress of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, </font><font style="font-family:Helvetica;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> amounts will be due.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Payments Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OperatingLeasesFutureMinimumPaymentsDueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14472-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12021-110248<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14453-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12053-110248<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14394-108349<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6775037008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Components of Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the Consolidated Statements of Comprehensive Loss for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, 2015, and 2014 (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,903</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">102.62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817952000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantActivityTableTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015 (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">January 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">November 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">November 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock', window );">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">July 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">117.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">January 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">120.38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">131.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">164.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">204.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">103.79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65.60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">47.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:normal;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">40.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">71.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock', window );">Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015 were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">January 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,852</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(278</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(259</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,886</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(22,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(627</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">April 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2011 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,358</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantActivityTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantActivityTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808563376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock', window );">Common Shares Excluded from Net Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">561</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827459712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Federal and State Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of federal and state income tax expense are as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total deferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax assets are as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">97,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,866</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Licensing deduction deferral</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,910</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">117,329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">95,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(117,329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(95,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In-process research and development not subject to future amortization for tax purposes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Provision Computed by Applying Federal Statutory Rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected federal income tax benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,447</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State income taxes after credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,375</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,283</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Changes in warrant value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,728</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(456</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effect of change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,852</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,029</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Components Of Net Deferred Tax Assets Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Components Of Net Deferred Tax Liabilities Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6835564512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Customers and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">The percentage of product sales to our customer that represented </font><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">10%</font><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"> or more of revenue in at least one of the periods presented, is as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;">The following accounts represented 10% or more of total accounts receivable in at least one of the periods presented:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#ffff00;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6327-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820760608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following amounts are in thousands, except per share amounts:</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,493</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,516</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss) per share, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross profit on net revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,537</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,660</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18,026</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(19,678</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827422384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Abstral and related assets on November 19, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Zuplenz and related assets on December 24, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net proceeds from sales</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,348</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Less selling costs*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proceeds from sale, net of selling costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*Note selling costs related to the sale of Zuplenz and related assets are included in accrued liabilities and were paid in the first quarter of 2016.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,491</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,059</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,925</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial business in 2016, 2015, and 2014 that are presented in the consolidated statements of comprehensive loss as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,734</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,886</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(355</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge form classification as held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on sale of commercial business assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance and exit costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,349</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(12,448</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6838979072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation (Additional Information) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents', window );">Highly-liquid debt instruments maturity days</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Interest bearing accounts</a></td>
<td class="nump">$ 17,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gale_EquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gale_EquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797945712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,898<span></span>
</td>
<td class="nump">$ 5,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837756144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 17,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">$ 14,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
<td class="nump">$ 6,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">16,192<span></span>
</td>
<td class="nump">29,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">17,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">33,814<span></span>
</td>
<td class="nump">29,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,955<span></span>
</td>
<td class="nump">20,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">16,192<span></span>
</td>
<td class="nump">29,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">17,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">33,814<span></span>
</td>
<td class="nump">29,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 1,095<span></span>
</td>
<td class="nump">$ 6,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RestrictedCashandCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827451152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail) - Unobservable Inputs (Level 3) [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Beginning Balance Liabilities</a></td>
<td class="nump">$ 6,142<span></span>
</td>
<td class="nump">$ 6,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in the estimated fair value of the contingent purchase price consideration</a></td>
<td class="nump">5,047<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Ending Balance Liabilities</a></td>
<td class="nump">$ 1,095<span></span>
</td>
<td class="nump">$ 6,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6660645744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractResearchPayable', window );">Clinical development expense</a></td>
<td class="nump">$ 3,088<span></span>
</td>
<td class="nump">$ 3,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 4,292<span></span>
</td>
<td class="nump">$ 5,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6839483488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 14, 2016 </div>
<div>USD ($) </div>
<div>election </div>
<div>day </div>
<div>price </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 10, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 12, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 08, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 15, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 22, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 13, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 29, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,570,000<span></span>
</td>
<td class="nump">1,116,000<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,534,000<span></span>
</td>
<td class="nump">$ 47,416,000<span></span>
</td>
<td class="nump">$ 10,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentTermInterestOnly', window );">Term for interest only payments</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payments at the fixed coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term for principal and interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCashFacilityFee', window );">Cash facility fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCashFinalPayment', window );">Cash final payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="nump">$ 30.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentOriginalIssueDiscountPercent', window );">Original issue discount, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of secured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemed', window );">Principal that could be redeemed</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCovenantLiquidityCovenant', window );">Liquidity covenant</a></td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument', window );">Common stock trading price threshold | $ / shares</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold', window );">Principal that could be redeemed, stock price threshold</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal', window );">Number of elections company can make in 12 month period | election</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection', window );">Principal that could be redeemed, company's election</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate', window );">Number of lowest volume weighted average prices during prior trading days used to compute average | price</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionNumberofDaysMaximum', window );">Number of trading days | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate', window );">Discount rate applied to prior trading day's volume weighted average price</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,621,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotesCurrent', window );">Senior notes, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,397,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,224,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived', window );">Placement agent fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,671,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,541,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Trading Price Threshold, for Redeeming Principal of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockTradingPriceThresholdforRedeemingPrincipalofDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCashFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cash Facility Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCashFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCashFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cash Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCashFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCovenantLiquidityCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCovenantLiquidityCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentOriginalIssueDiscountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Original Issue Discount, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentOriginalIssueDiscountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Placement Agent Fee, Percent of Funds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal That Could Be Redeemed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPrincipalThatCouldBeRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal That Could Be Redeemed, Company's Election</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal That Could Be Redeemed, Company's Monthly Stock Price Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPrincipalThatCouldBeRedeemedCompanysMonthlyStockPriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prior Trading Day&#8217;s Volume, Weighted Average Price, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionNumberofDaysMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Number of Days, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionNumberofDaysMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Number of Lowest Weighted Average Prices to Apply Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionNumberofLowestWeightedAveragePricestoApplyDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentTermInterestOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term, Interest Only</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentTermInterestOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Elections Company Can Make in Year to Redeem Debt Instrument Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofElectionsCompanyCanMakeinYeartoRedeemDebtInstrumentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6841057728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 22, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 06, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 24, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>defendant </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 23, 2017 </div>
<div>witness </div>
<div>count</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Total number of shares cancelled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue', window );">Damages paid by insurance companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payable by the company in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IssuanceofCommonStockforLitigationSettlement', window );">Litigation settlement payable in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember', window );">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember', window );">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_SECLitigationMember', window );">SEC Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_SECLitigationMember', window );">SEC Litigation [Member] | Indemnification Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Guarantor obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue', window );">Damages paid by insurance companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payable by the company in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IssuanceofCommonStockforLitigationSettlement', window );">Litigation settlement payable in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Attorney fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockShares', window );">Litigation settlement, issuance of shares, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Securities Litigation, Opt Out Settlement, Case 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Litigation settlement, issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockShares', window );">Litigation settlement, issuance of shares, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Securities Litigation, Opt Out Settlement, Case 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Litigation settlement, issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockShares', window );">Litigation settlement, issuance of shares, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Director [Member] | Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Total number of shares cancelled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Maximum [Member] | Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling [Member] | SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling [Member] | SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty', window );">Number of counts against defendants with judicial ruling of guilty | count</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofCountsAgainstDefendants', window );">Number of counts against defendants | count</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling [Member] | Former Employee [Member] | SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossContingencyNumberofWitnesstoTestifyatTrial', window );">Number of witness to testify at trial | witness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member] | SEC Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement, amount</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member] | Former CEO [Member] | SEC Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement, amount</a></td>
<td class="num">$ (600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IssuanceofCommonStockforLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IssuanceofCommonStockforLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LitigationSettlementIssuanceofCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LitigationSettlementIssuanceofCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LitigationSettlementIssuanceofCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LitigationSettlementIssuanceofCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Paid by Insurance Company, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossContingencyDamagesPaidbyInsuranceCompanyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossContingencyNumberofWitnesstoTestifyatTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Witness to Testify at Trial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossContingencyNumberofWitnesstoTestifyatTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofCountsAgainstDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Counts Against Defendants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofCountsAgainstDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Counts Against Defendants with Judicial Ruling of Guilty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_SECLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_SECLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gale_FormerEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gale_FormerEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gale_FormerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gale_FormerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824664320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Summary of Litigation Settlements) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="nump">$ 27,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementAmountCash', window );">Payable by the company in cash</a></td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue', window );">Payable by the insurance carriers</a></td>
<td class="nump">21,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payable by the company in cash</a></td>
<td class="nump">2,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IssuanceofCommonStockforLitigationSettlement', window );">Litigation settlement payable in common stock</a></td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember', window );">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember', window );">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_ShareholdersSecuritiesLitigationMember', window );">Shareholders Securities Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_SECLitigationMember', window );">SEC Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IssuanceofCommonStockforLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IssuanceofCommonStockforLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LitigationSettlementAmountCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement Amount, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LitigationSettlementAmountCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossContingencyDamagesPaidbyInsuranceCompanyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Paid by Insurance Company, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossContingencyDamagesPaidbyInsuranceCompanyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_ShareholdersSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_ShareholdersSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_SECLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_SECLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824743152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Schedule of Contractual Obligations and Future Cash Payments) (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases - 2017</a></td>
<td class="nump">$ 241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases - 2018</a></td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases - 2019</a></td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Operating Leases - 2020</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter', window );">Operating Leases -2021 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2017</a></td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2018</a></td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2019</a></td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2020</a></td>
<td class="nump">7,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationDueinFifthYearandThereafter', window );">2021 and thereafter</a></td>
<td class="nump">8,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationsCurrentDue', window );">Total</a></td>
<td class="nump">20,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_EmploymentContractsMember', window );">Non-Cancelable Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2017</a></td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2018</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2019</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationDueinFifthYearandThereafter', window );">2021 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationsCurrentDue', window );">Total</a></td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_LiabilitiesTotalMember', window );">Subtotal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2017</a></td>
<td class="nump">1,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2018</a></td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2019</a></td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2020</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationDueinFifthYearandThereafter', window );">2021 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationsCurrentDue', window );">Total</a></td>
<td class="nump">2,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_LicenseAgreementTermsMember', window );">Cancelable License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2017</a></td>
<td class="nump">1,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2018</a></td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2019</a></td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2020</a></td>
<td class="nump">7,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationDueinFifthYearandThereafter', window );">2021 and thereafter</a></td>
<td class="nump">8,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationsCurrentDue', window );">Total</a></td>
<td class="nump">$ 18,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractualObligationDueinFifthYearandThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Due in Fifth Year and Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractualObligationDueinFifthYearandThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractualObligationsCurrentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligations Current Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractualObligationsCurrentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Future Minimum Payments, Due in Five Years and Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_EmploymentContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_EmploymentContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_LiabilitiesTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_LiabilitiesTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803929280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Schedule of Contractual Obligations and Future Cash Payments) (Footnotes) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OperatingLeaseExpense', window );">Operating lease expenses</a></td>
<td class="nump">$ 291,000<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases', window );">Operating lease payment due upon lease termination</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Payments Due Upon Termination of Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OperatingLeasesFutureMinimumPaymentsDueUponTerminationofLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6842472528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2017</div></th>
<th class="th"><div>Jul. 13, 2016</div></th>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Dec. 04, 2015</div></th>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
<th class="th"><div>Nov. 18, 2014</div></th>
<th class="th"><div>May 24, 2013</div></th>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Feb. 06, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,534,000<span></span>
</td>
<td class="nump">$ 47,416,000<span></span>
</td>
<td class="nump">$ 10,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 28.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses', window );">Proceeds from issuance of shares, net underwriting discounts, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,534,000<span></span>
</td>
<td class="nump">$ 47,416,000<span></span>
</td>
<td class="nump">$ 10,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExercisePeriod', window );">Exercise period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable', window );">Period from issuance which warrants is exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,872,803<span></span>
</td>
<td class="nump">1,607,934<span></span>
</td>
<td class="nump">331,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightIssuedDuringPeriod', window );">Warrant issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gale_LincolnParkCapitalLLCPurchaseAgreementMember', window );">Lincoln Park Capital, LLC Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementTerm', window );">Purchase agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued during period, purchase of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gale_LincolnParkCapitalLLCPurchaseAgreementMember', window );">Lincoln Park Capital, LLC Purchase Agreement [Member] | Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockPurchaseAgreementAuthorizedAmount', window );">Shares authorized under purchase agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gale_LincolnParkCapitalLLCPurchaseAgreementMember', window );">Lincoln Park Capital, LLC Purchase Agreement [Member] | Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockPurchaseAgreementAuthorizedAmount', window );">Shares authorized under purchase agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gale_LincolnParkCapitalLLCPurchaseAgreementMember', window );">Lincoln Park Capital, LLC Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gale_MLVCo.LLCandMaximGroupLLCMember', window );">MLV &amp; Co. LLC and Maxim Group LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds', window );">Percent of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds', window );">Maximum gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gale_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesOverallotmentOption', window );">Shares issued, overallotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses', window );">Proceeds from issuance of shares, net underwriting discounts, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gale_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses', window );">Proceeds from issuance of shares, net underwriting discounts, commissions and offering expenses</a></td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightIssuedDuringPeriod', window );">Warrant issued during period</a></td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockAvailableforIssuanceSharesNewIssues', window );">Stock available for issuance under warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements, Maximum Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements, Percent of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrants or Rights, Period from Issuance which Warrants or Rights Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantsorRightsPeriodfromIssuancewhichWarrantsorRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockAvailableforIssuanceSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Available for Issuance, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockAvailableforIssuanceSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Overallotment Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockPurchaseAgreementAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockPurchaseAgreementAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_LincolnParkCapitalLLCPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_LincolnParkCapitalLLCPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_MLVCo.LLCandMaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_MLVCo.LLCandMaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818451872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Components of Stock-based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,966<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">4,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,264<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="nump">$ 5,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824626048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Schedule of Warrant Activity) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember', window );">July 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember', window );">January 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Other Warrant Issues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6806160976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">2.01%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">102.62%<span></span>
</td>
<td class="nump">73.97%<span></span>
</td>
<td class="nump">79.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">5 years 11 months 4 days<span></span>
</td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825110064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Fair Value of Warrants Classified as Liabilities) (Detail) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember', window );">July 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 6 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">117.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">1.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember', window );">January 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 28.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">120.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">1.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 41.60<span></span>
</td>
<td class="nump">$ 41.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 years 2 months 19 days<span></span>
</td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">131.46%<span></span>
</td>
<td class="nump">75.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">1.52%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">164.01%<span></span>
</td>
<td class="nump">74.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 31.60<span></span>
</td>
<td class="nump">$ 31.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">11 months 23 days<span></span>
</td>
<td class="text">1 year 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">204.55%<span></span>
</td>
<td class="nump">76.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.84%<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 months 22 days<span></span>
</td>
<td class="text">1 year 3 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">103.79%<span></span>
</td>
<td class="nump">65.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.53%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 27 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837144928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Additional Information) (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="nump">$ 21.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Averages contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees', window );">Estimated annualized forfeiture rate for options granted to employees</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement', window );">Estimated annualized forfeiture rate for options granted to senior management</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 2,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">2 years 3 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares subject to outstanding common stock options granted</a></td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term for options outstanding</a></td>
<td class="text">7 years 7 days<span></span>
</td>
<td class="text">7 years 7 months 17 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term for options exercisable</a></td>
<td class="text">5 years 6 months 7 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 6 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AggregateIntrinsicValueOfStockOptionsExercisable', window );">Aggregate Intrinsic Value Of Stock Options Exercisable</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 13,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan, shares</a></td>
<td class="nump">29,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember', window );">2007 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">1,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares subject to outstanding common stock options granted</a></td>
<td class="nump">561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting periods of options granted</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gale_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">20,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants', window );">Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards', window );">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued', window );">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity instrument granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AggregateIntrinsicValueOfStockOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value Of Stock Options Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AggregateIntrinsicValueOfStockOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annualized forfeiture rate for options granted to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annualized forfeiture rate for options granted to senior management.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gale_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gale_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824960480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Changes in Fair Value of Warrant Liability) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">$ 14,518<span></span>
</td>
<td class="nump">$ 5,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">9,886<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="num">(324)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(22,220)<span></span>
</td>
<td class="num">(1,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember', window );">July 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(3,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember', window );">January 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">5,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(5,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">10,337<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(9,905)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">10,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(1,852)<span></span>
</td>
<td class="num">(627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="num">(278)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_July2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818239984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Stock Option Activity) (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares, outstanding Beginning Balance</a></td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options activity, Total Number of Shares, Granted</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options activity, Total Number of Shares, Exercised</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options activity, Total Number of Shares, Cancelled</a></td>
<td class="num">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares, outstanding Ending Balance</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Total Number of Shares, exercisable</a></td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 51.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Granted</a></td>
<td class="nump">9.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">31.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">50.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">41.50<span></span>
</td>
<td class="nump">$ 51.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, exercisable</a></td>
<td class="nump">$ 56.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824635664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Warrants Classified as Equity) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2016</div></th>
<th class="th"><div>May 10, 2016</div></th>
<th class="th"><div>May 08, 2013</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 14, 2016</div></th>
<th class="th"><div>Jul. 13, 2016</div></th>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 28.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,482,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,570,000<span></span>
</td>
<td class="nump">1,116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantsNotSettleableInCashMember', window );">Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="nump">$ 30.20<span></span>
</td>
<td class="nump">$ 49.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice', window );">Duration of average market price used for warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate percentage</a></td>
<td class="nump">106.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.34%<span></span>
</td>
<td class="nump">77.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate percentage</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGrantedperShare', window );">Fair value of warrants granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsGrantedNumberofShares', window );">Number of shares issued from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Warrants granted</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightMaturityPeriod', window );">Maturity period of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantsNotSettleableInCashMember', window );">Equity Warrants [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 79.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Days Averaged for Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightNumberofDaysAveragedforExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGrantedperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted, per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGrantedperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsGrantedNumberofShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsGrantedNumberofShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantsNotSettleableInCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantsNotSettleableInCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6595432816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) (Schedule of Other Income (Expense)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">$ 5,047<span></span>
</td>
<td class="nump">$ 509<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818534304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">3,131<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818437072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components of Federal and State Income Tax Expense (Benefit)) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6809437552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components of Net Deferred Tax Assets) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 97,168<span></span>
</td>
<td class="nump">$ 75,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">4,083<span></span>
</td>
<td class="nump">3,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">5,757<span></span>
</td>
<td class="nump">5,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Other</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeferredTaxAssetsLicensingDeductionDeferral', window );">Licensing deduction deferral</a></td>
<td class="nump">10,263<span></span>
</td>
<td class="nump">9,910<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">117,329<span></span>
</td>
<td class="nump">95,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(117,329)<span></span>
</td>
<td class="num">(95,477)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeferredTaxAssetsLicensingDeductionDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Licensing Deduction Deferral</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeferredTaxAssetsLicensingDeductionDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817999312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components of Net Deferred Tax Liabilities) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">In-process research and development not subject to future amortization for tax purposes</a></td>
<td class="nump">$ 5,661<span></span>
</td>
<td class="nump">$ 5,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liability</a></td>
<td class="nump">$ 5,661<span></span>
</td>
<td class="nump">$ 5,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836969872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Provision Computed by Applying Federal Statutory Rate) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected federal income tax benefit</a></td>
<td class="num">$ (7,977)<span></span>
</td>
<td class="num">$ (21,603)<span></span>
</td>
<td class="num">$ (12,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes after credits</a></td>
<td class="num">(1,575)<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(1,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability', window );">Changes in warrant value</a></td>
<td class="num">(8,728)<span></span>
</td>
<td class="num">(456)<span></span>
</td>
<td class="num">(6,503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(1,782)<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effect of change in valuation allowance</a></td>
<td class="nump">21,852<span></span>
</td>
<td class="nump">24,029<span></span>
</td>
<td class="nump">17,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Income tax credits</a></td>
<td class="num">(217)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(1,330)<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="num">(996)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Gain On Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Unrealized Gain On Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818070448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Additional Information) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal operating loss carryforwards</a></td>
<td class="nump">$ 251.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State operating loss carryforwards</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OperatingLossCarryforwardsExerciseofStockOptions', window );">Operating loss carryforwards, exercise of stock options</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance', window );">Deferred income tax valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Percentage Of Deferred Tax Asset To Establishes Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OperatingLossCarryforwardsExerciseofStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Exercise of Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OperatingLossCarryforwardsExerciseofStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6842568096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements License Agreements (Additional Information) (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 24, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2015 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member', window );">Sentynl Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementConsiderationReceivableUnderAgreement', window );">Consideration receivable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement', window );">Upfront payment receivable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement', window );">Contingent consideration receivable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments', window );">Number of one-time future milestone payments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member', window );">Sentynl Therapeutics, Inc. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales', window );">Contingent consideration threshold, net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member', window );">Sentynl Therapeutics, Inc. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales', window );">Contingent consideration threshold, net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember', window );">Midatech Pharma PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementConsiderationReceivableUnderAgreement', window );">Consideration receivable under agreement</a></td>
<td class="nump">$ 29,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement', window );">Upfront payment receivable under agreement</a></td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement', window );">Contingent consideration receivable under agreement</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember', window );">Midatech Pharma PLC [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales', window );">Contingent consideration threshold, net sales</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember', window );">Midatech Pharma PLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales', window );">Contingent consideration threshold, net sales</a></td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_MonosolRxLLCMember', window );">Monosol Rx, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementPaymentofUpfrontFee', window );">Payment of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived', window );">Payment of upfront fee, percentage of future milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember', window );">M D Anderson Cancer Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FutureMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FutureMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FutureMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Collaboration Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement, Number Of One-Time Future Cash Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementConsiderationReceivableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Consideration Receivable Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementConsiderationReceivableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Contingent Consideration Receivable Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Contingent Consideration Threshold, Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementContingentConsiderationThresholdNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementPaymentofUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Payment of Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementPaymentofUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Upfront Payment Receivable Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=gale_MonosolRxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=gale_MonosolRxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824689760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Customers and Concentration of Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>products </div>
<div>dosing_strength</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofCommericalProducts', window );">Number of commercial products | products</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofDosingStrengths', window );">Number of dosing strengths | dosing_strength</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofCommericalProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Commerical Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofCommericalProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofDosingStrengths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Dosing Strengths</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofDosingStrengths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803416768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Troy Gould Pc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related party</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=gale_ServicesProvidedbyCorporateCounselMember', window );">Professional Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party expenses</a></td>
<td class="nump">$ 209,000<span></span>
</td>
<td class="nump">$ 577,000<span></span>
</td>
<td class="nump">$ 533,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_TroyGouldPcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_TroyGouldPcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gale_ServicesProvidedbyCorporateCounselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gale_ServicesProvidedbyCorporateCounselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6660421120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contribution</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost recognized during the period for defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824937824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Mar. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Sep. 30, 2012</div></th>
<th class="th"><div>Jun. 30, 2012</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,436<span></span>
</td>
<td class="nump">$ 2,166<span></span>
</td>
<td class="nump">$ 3,382<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,229<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
<td class="nump">2,914<span></span>
</td>
<td class="nump">2,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,516)<span></span>
</td>
<td class="num">$ (6,929)<span></span>
</td>
<td class="nump">$ 5,389<span></span>
</td>
<td class="num">$ (16,493)<span></span>
</td>
<td class="num">$ (19,678)<span></span>
</td>
<td class="num">$ (18,026)<span></span>
</td>
<td class="num">$ (15,660)<span></span>
</td>
<td class="num">$ (10,537)<span></span>
</td>
<td class="num">$ (23,549)<span></span>
</td>
<td class="num">$ (63,902)<span></span>
</td>
<td class="num">$ (36,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share (usd per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
<td class="num">$ (2.23)<span></span>
</td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6658481664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Details) - Commercial Business Segment [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentChargeOnReclassifiedAssets', window );">Impairment charge</a></td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement', window );">Success fee contingently due to third party</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue', window );">Percent of realized future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees', window );">Retention fees contingently due</a></td>
<td class="nump">$ 352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived', window );">Retention fees contingently due (as percentage of consideration received)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsandZuplenzRightsMember', window );">Abstral Rights and Zuplenz Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Retention Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentChargeOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -URI http://asc.fasb.org/extlink&amp;oid=29634951&amp;loc=d3e1756-110224<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2459-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentChargeOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsandZuplenzRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsandZuplenzRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840279776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities held for sale</a></td>
<td class="nump">$ 6,059<span></span>
</td>
<td class="nump">$ 5,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total current assets of discontinued operations</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,115<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,944<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities held for sale</a></td>
<td class="nump">$ 6,059<span></span>
</td>
<td class="nump">$ 5,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6841084032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification as assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,071)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss on sale of commercial business assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,549)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations</a></td>
<td class="num">(12,448)<span></span>
</td>
<td class="num">(24,946)<span></span>
</td>
<td class="num">(8,322)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,734<span></span>
</td>
<td class="nump">9,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,780)<span></span>
</td>
<td class="num">(1,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Amortization of certain acquired intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(921)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment', window );">Research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(355)<span></span>
</td>
<td class="num">(680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="num">(9,562)<span></span>
</td>
<td class="num">(17,655)<span></span>
</td>
<td class="num">(15,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification as assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss on sale of commercial business assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,549)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts', window );">Severance and exit costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,349)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations</a></td>
<td class="num">$ (12,448)<span></span>
</td>
<td class="num">$ (24,946)<span></span>
</td>
<td class="num">$ (8,322)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Severance and Exit Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationSeveranceandExitCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2611-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6827439440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (153)<span></span>
</td>
<td class="num">$ (57)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6826373248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Net Proceeds from the Sale (Details) - Commercial Business Segment [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 24, 2015</div></th>
<th class="th"><div>Nov. 19, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsNetMember', window );">Abstral Rights, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal Group, Including Discontinued Operation, Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Disposal Group, Including Discontinued Operation, Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(815)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet', window );">Disposal Group, Including Discontinued Operation, Consideration, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_ZuplenzRightsMember', window );">Zuplenz Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal Group, Including Discontinued Operation, Consideration</a></td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Disposal Group, Including Discontinued Operation, Transaction Costs</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet', window );">Disposal Group, Including Discontinued Operation, Consideration, Net</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_ZuplenzRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_ZuplenzRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??5=CUQN[M/S:^",H6?MV%_ )02P,$%     @ PH-O2IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MIGV9A=?U[IL,NS=-M>F_I3'=?U7D[#]02P,$%     @ PH-O2MF-P6RX 0
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M4F@CW@@CA39"03:<%MF"1?^OM,B%D&DX:W#6,L"QE6G+:,M!UJL$*FN,4%5
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MZF?RN\-<<H!+27+):9*P8Y))#L@<)[7+!F3D*.3:._,R"' I22XYO!Y2FZ)
M%XQLA0I%ZR>UN4T)A\'DP'HHR?60 _N#153;*4C&IQOLYX8PYAS G)RR+1P
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MYPA"CP7>XFO@A;>="P%2YCUKX3NX'_W)>(_,+#67H"S7"AEH"ORP/1RS@(^
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M$*;IM"5G=/YE8_]K1 =>2G+E1ZCU'VPQ)-0N'#_YLYG&;#(<]O,/8LLW+OX
M4$L#!!0    ( ,*#;TI^7W>!M0$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;'U388_4(!#]*X0?<'39ZJZ;MLGM&:.))ILSGI_9=MJ2@TX%
MNCW_O4![M6KC%V"&>6_>#$,VHGFV+8 C+UIU-J>M<_V),5NVH(6]PQXZ?U.C
MT<)YTS3,]@9$%4%:,9XD;YD6LJ-%%GT74V0X."4[N!AB!ZV%^7D&A6-.=_35
M\2B;U@4'*[)>-/ 5W+?^8KS%%I9*:NBLQ(X8J'-ZOSN=TQ ? YXDC'9U)J&2
M*^)S,#Y5.4V"(%!0NL @_':#!U J$'D9/V9.NJ0,P/7YE?U#K-W7<A46'E!]
MEY5K<WJDI():#,H]XO@1YGK>4#(7_QENH'QX4.)SE*AL7$DY6(=Z9O%2M'B9
M=MG%?9QNTL,,VP;P&< 7P#'F85.BJ/R]<*+(#([$3+WO17CBW8G[WI3!&5L1
M[[QXZ[VW@B>'C-T"T1QSGF+X*F:W1##/OJ3@6RG._!\XWX;O-Q7N(WS_A\+C
M-D&Z29!&@O2_)6[%O/LK"5OU5(-IXC194N+0Q4E>>9>!O>?Q37Z'3]/^19A&
M=I9<T?F7C?VO$1UX*<F='Z'6?[#%4%"[<#SXLYG&;#(<]O,/8LLW+GX!4$L#
M!!0    ( ,*#;TJ)G$ ELP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;'U386_<( S]*X@?4!+NUE:G)%*OT[1)FW3JM/4SES@)*L0ID$OW
M[P<DS=(NVQ? QN_YV9AL1/-D6P!'7K3J;$Y;Y_H#8[9L00M[A3UT_J9&HX7S
MIFF8[0V(*H*T8CQ)KID6LJ-%%GTG4V0X."4[.!EB!ZV%^74$A6-.4_KJ>)!-
MZX*#%5DO&O@.[D=_,MYB"TLE-7168D<,U#F]2P_'?8B/ 3\EC'9U)J&2,^)3
M,+Y4.4V"(%!0NL @_':!>U J$'D9SS,G75(&X/K\ROXIUNYK.0L+]Z@>9>7:
MG-Y24D$M!N4></P,<ST?*)F+_PH74#X\*/$Y2E0VKJ0<K$,]LW@I6KQ,N^SB
M/DXW_&:&;0/X#. +X#;F85.BJ/RC<*+(#([$3+WO17CB],!];\K@C*V(=UZ\
M]=Y+P=,D8Y= -,<<IQB^BDF7".;9EQ1\*\61_P7GV_#=IL)=A._>*/Q'_OTF
MP3X2[/];XE;,>Y5LU5,-IHG39$F)0Q<G>>5=!O:.QS?Y$SY-^S=A&ME9<D;G
M7S;VOT9TX*4D5WZ$6O_!%D-![<+QQI_--&:3X;"??Q!;OG'Q&U!+ P04
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MCS@\P%3/%TJFXK_#!:0/#TI\C@*EC2LI>NM032Q>BA*OX][JN _C#4\FV#J
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M/-MIS";#FW[^06SYQL4O4$L#!!0    ( ,*#;TIL<8^HLP$  -(#   9
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M].%E4_]K1 ]!RN8JC% ;/MAL**A]/+X/9SN.V6AX[*8?Q.9O7/P!4$L#!!0
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M^P02QX*F],WQ)-K.!0<K\YZW\!W<C_YLO,46EEHHT%:@)@::@MZEQ],^Q,>
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M.8*P.ZU4G!J[5!W1HP+:>!)G)(FB ^%T$+@J?.RLJD).A@T"S@KIB7.J?I^
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MXZ;W=JZ6M[PLC!S7-B7;OZ+Z U!+ P04    " #"@V]*;./8J=,!  "<!
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M4&D[3<Q<3K=R"K3HYP<'+Z]>_A=02P,$%     @ PH-O2NP9_UJW 0  T@,
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M<>'XP9_--&:3X;"??Q!;OG'Y%U!+ P04    " #"@V]*6'$W6[@!  #2 P
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M/ASO\6RG,9L,;_KY!['E&Y=_ %!+ P04    " #"@V]*L/^;[;(!  #2 P
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M)&T6V9;:3-,F;5+4:=UO8E_'J'QX0.+N[<=7/3>+UC^&>SGG< Z&<M3FV?8
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M<Y-N62J<'O(#(M,KKO\ 4$L#!!0    ( ,*#;THQ%#]D^ ,  +D5   9
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M@&$Q=:-L-S%XDK;G'5*%RH4[AG'%**^$<GP_&$8(6RT' ,<,X>$" (RBMP
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M)_I,A/M(+>993YJU,_]4M4+-WHLH#3-TUT:3IAPU>*'!;Q6'M2+Z)T$*8*;
M3@ILXJ-EAF#K-HB<!I$QB-^484&6HV9C--VH";9;JQ*'".]B-TKL1(D=*)&%
M,FJ2199=FE@D:TV81(F;)'&2) Z2V"))5EDPWEDD:TW\'LC&";)Q@%CEEIM5
MDL#"6"OP.V<D=5*D*XK8VOTR7>U^C'?V85^+DJ5H)$&+"Z@?Q&^$7YM.>"<F
MU5TV-ZYB3((R#)Y43;5Z@^<!A4KJ;JKZ?'R)QH%D_?3(HOFE+_X"4$L#!!0
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M$X+:XSH3^-Z*NH/[@:&U0( ^(:@^$;F1B"TL# 3P%P3^[E.\%P3^U:P"G5H
M_ 6!OT;I F3%B&VJ!#!*:IUUQU82,,)N+P&,DH+1'5PKZO?6N1!@.RL!CI+
M4:.1 9Q),6)TT7&3VJ>Z!ULKZM:LKQQL 8Z2P%&#UB(!:%*/*!DP)"F&W*.O
M%;D3"I4,&)(40X!#"1B2(QA2@"%%,*2]T[Y_U -/1P& % &05L ' $.-..<I
M (8B%B#MK*H/RC_G,7!>40 >1<"C0S>.#P]'KVK0NQJ*'+"@*D".&D&. N0H
M@AP=N?42JP\( ZA1!#4A&C) C1I!C0;4Z $O2&ZUO_)\X*A/: ".)L )4;8
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M8=Y,UL!;)LT8VR*KNK^S[6M5%_G02T,E3W_TKZ=S]WKMOXF3H1ENP(<&_-:
M:6\#,300OQK(;O(]LVZJG],Z7:_*XCHK^__6)6V+@MV+9C&W[<5N[;KOFME6
MS=6WM1)Z%;VU'0V8IQ[#WV'8#1$UO=^&X&B()TZ:\_$ &XH0'(\@X"1$UUZ,
M)A'C#B3L0'8=R%$'B;4*/49UF'._"HQ92[6A(,D3S$1!)@HP65I,%&4B$WM-
M*2A>+# 3#9EHRD0N+"::#'+'++8;BG'0B"&-&-!@%HV8TK!9  ASU%@">22
MA[7F3PD9A*O86K,-!8WJ:$1E":DL 16!.V +K/I%N&*8PSA8@&8&4, _GT'O
M>&0\0 \#**C6&780)@*J?0"%S ;;# ,^0XJ940]QC8(MA $/(:7*_/[0ERH
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M31MRS>(DA 9C<?9@3K\R]\VX8'#2=IJ9N>R[;K_0HATN%#+>:L5?4$L#!!0
M   ( ,*#;TK!LUQ\$P4  .D=   9    >&PO=V]R:W-H965T<R]S:&5E=#4R
M+GAM;)69ZV[J1A2%7P7Y 6+/%3L"I"2H:J56BD[5T]\.3 (Z-J:V$T[?OKZ%
MXKW7@/,G8.>;F3TS>RUO/(M34?ZH=L[5LY]Y=JB6P:ZNC_=A6&UV+D^KN^+H
M#LU_7HLR3^OFLGP+JV/ITFW7*,]"&44VS-/](5@MNGO/Y6I1O-?9_N">RUGU
MGN=I^>^CRXK3,A#!YXUO^[==W=X(5XMC^N;^=/5?Q^>RN0K/O6SWN3M4^^(P
M*]WK,G@0]VO;->B([WMWJBZ^S]JIO!3%C_;BM^TRB-J(7.8V==M%VGQ\N">7
M96U/31S_#)T&YS';AI??/WO_I9M\,YF7M')/1?;W?EOOED$<S+;N-7W/ZF_%
MZ5<W3,@$LV'VO[L/ES5X&TDSQJ;(JN[O;/->U44^]-*$DJ<_^\_]H?L\#?U_
M-L,-Y-! GAM(<[6!&AJHJ0WTT$"?&PC=K58_E6YMUFF=KA9E<9J5_?8>TS:+
MQ+UN5G_3WNP6N_M?LSQ5<_=C9:Q=A!]M1P/SV#/R@A%G(FQZ/P\AT1"/DC67
MXP&>.*$(LN;(/,9!*#A/U;57HWG.<0<:=J"[#O2H@Y@L5,^8CCGT,S7SB$R6
M0T((LN1K#FGIF:^!X1H0;D+"18S!@U@XB.4=:(4[F,,.YM-W)88=Q!-V)69K
M.8_HIG FPF$D,(R$AT'W_;%G[.6^>]9*1%BJ$1A%4*TB2'K&\5B" %TH.@Z"
MM&<<Z L/0H(N#!T'0=8S#I:^4"!-?:%B\0L]/5$%%J1 :J.I.D"7>6ACZI8
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M.S/WS7 @-#QH=1P/NZ++B=OJ'U!+ P04    " #"@V]*X\S\8F@%  !R'P
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M-O;X71(U[" #'63&039W4"3.*HR:W&AZJ\$P) <A.0!!#B3W("@K8$@!0@H
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MRHK,*6<)J#!*8^)D#,@0IC2#H1,0.@&@"P=ZU"17<9(L<: !%2:NJH)\X9S
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M\Q?>-A2Z3MO]-W[BN8:;2G2.C<AK^]?9'&LEBI9%EU*P]^::E?9Z;ODO83B
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M/1>N#;F%XDW785'?YO-_4$L#!!0    ( ,*#;TIIVBP4[0$  -D$   9
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MS&00J*3>[M2>VVFSAF2]>TC0])IE_P%02P,$%     @ PH-O2M^:ZQP; P
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M=)OR;B!%W7]P!,-7S_(_4$L#!!0    ( ,*#;TILW,U""0(  (8%   9
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M1"WYK[UVE1N!4['S\LEG.M&AZT"['LR<4KZT2OGBT-")WA@+E /1;CUW=@*
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MY$UVFQ,KPCCU#N*"=P0H-=\2_ 7O!?RXI.->N3"@2FFF(?* PRFLDK8R3U.
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MTNCLA;M%:%#B!#-4PT% JL4'3TOBF)J_@0[OBT<Q@^6DNGNFZ,X[F6*],XI
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MN8REIX8<P^UH/(<_>2 3&.;!-BI=G "ZDTV,A#%FS;W*21A$ZBL4-F0)3L_
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M%3L*85FAZ4B1WQP/5?7#_O4)MQ7<F;J*IH(*]6#"Z[P"=:#4OL7:@3WKCC4
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M%7#&R!S8"7%^&_"F^=# -Y%MTN5UUIM$.[3LYML"L087NBP6+A^O@W&AUS*
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MOE -ETZK>3=,2[M[RU-*Q*TR7,'I<NDJ"- -X>:OKF->4 &S+![ME:K"RIN
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M-C=V.@G(*>_7+#+);?K&Z'P<SR[&?>)1PJ6"]S4C&,63TUEOE<H6AL3MU2E
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M;4,\["7!H3U?)YX=<##6_?7/G,Y;S!0LL+=)?Z'[AM2B+=LV*)3\PV=7X[*
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M^P:33N2K"3VZ+1O'L@[KZCZ4N,3EKGHWFBG5M/FT&T<V1_Q2%$M:"LX*G E
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M>WVG"9%H%2?)FA,<TZ4T#N7@HCQS;9]DA6&@@&J?/(56&=.C(2KI2"?E=?^
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M^\463$'@<"J7HW0-*\H^@C'\"Y\_B1OF>"DP2^@Q4I4U-@BQ;RK'! FW%)(
MSTXUG-;AR]'.3&: 2,L>;;+ZOU^C%8R*2*%X>HNE )VH0T3M:F&AV+^I/;&
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M:6VS026Q>B#NCZ[;,)@&3.6G9'_28"M=VT5-XE+I&<<:E,G$F(&SZW..&Y@
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M=4O^VIKR7_OE'6''S)6%B--SH21W]1GBRYI ^.OJ$Y9YR?%3TTX+>L5GKG)
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MIM7^ETR*JN# $W?[U;U1FG[+HI=^EYX3C[8LX-O-%@+UI#+I_R=KR\(1!@N
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MXIF^_+/U;F7K2JC8:O\E!%!NCS*KMWJ,K7$2<0,#VA1 E\,H5<1DD<//P7V
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MNI\/NJ<'/<P'/="#_!K(N.8G(:SY6GO M>=[[0'8GB^V!V1[OMD>H.WY:GO
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M_#/\RYH)W&7X..?;9URG?KE_HO0P;LGN^GKS/^]UZI\(-ZTH3[\!4$L#!!0
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,*#;TK4Q2_J[P   "L"   1
M          "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,*#
M;TJ97)PC$ 8  )PG   3              "  ;<"  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ PH-O2AJ= [FK @  !PH  !@
M ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,*#
M;TI?H1C('@0  ,T3   8              "  =D+  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " #"@V]*IKAOK6 "  !$"   &
M        @ $M$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ PH-O2J,&A%LD!   VA(  !@              ( !PQ(  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,*#;TK>SH.93 8  #8B   8
M              "  1T7  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " #"@V]*V8W!;+@!  #5 P  &               @ &?'0  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ PH-O2L/<4#K%!@
M:"8  !@              ( !C1\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( ,*#;THD]/,]NP$  -0#   8              "  8@F
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #"@V]*HGYD
M.+8!  #2 P  &               @ %Y*   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ PH-O2H9IFGJS 0  T@,  !D
M ( !92H  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #"
M@V]*^"KK[+4!  #2 P  &0              @ %/+   >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,*#;TI^7W>!M0$  -(#   9
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M970Q-BYX;6Q02P$"% ,4    " #"@V]*46I0FK0!  #2 P  &0
M    @ '3-P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M ,*#;TJ1/CHYM $  -(#   9              "  ;XY  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ PH-O2@V/J1&U 0  T@,  !D
M             ( !J3L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " #"@V]*;'&/J+,!  #2 P  &0              @ &5/0  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,*#;TJL.]/(MP$
M -(#   9              "  7\_  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ PH-O2C9,R?^U 0  T@,  !D              ( !
M;4$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #"@V]*
M0R:9#;,!  #2 P  &0              @ %90P  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,*#;TK@L)JZM0$  -(#   9
M      "  4-%  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ PH-O2GQ,'+"X 0  T@,  !D              ( !+T<  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #"@V]*H$1URK0!  #2 P
M&0              @ $>20  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( ,*#;TH.MSTJRP(  " ,   9              "  0E+  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ PH-O2M9%RN+"
M 0  -P0  !D              ( !"TX  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " #"@V]*$^ZH];<!  #2 P  &0
M@ $$4   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,*#
M;TJ#1G9$PP$  #<$   9              "  ?)1  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ PH-O2FSCV*G3 0  G 0  !D
M         ( ![%,  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " #"@V]*>3YA7-(!  "<!   &0              @ 'V50  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,*#;TID]U22M@$  -(#
M   9              "  ?]7  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ PH-O2@/WZ=K@ 0   04  !D              ( ![%D
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #"@V]*[!G_
M6K<!  #2 P  &0              @ $#7   >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( ,*#;TI8<3=;N $  -(#   9
M  "  ?%=  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MPH-O2K#_F^VR 0  T@,  !D              ( !X%\  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " #"@V]*?W+>"$@"  !Y!P  &0
M            @ ')80  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( ,*#;TIMEK*RL0$  -$#   9              "  4AD  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ PH-O2C$4/V3X P
MN14  !D              ( !,&8  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " #"@V]*I*/M>@P"  !Y!0  &0              @ %?
M:@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,*#;TI9
M]%OJ# (  /4%   9              "  :)L  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ PH-O2HZ_)Y+&!   @A@  !D
M     ( !Y6X  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,*#;TJX-5 U* 8  %<C   9              "
M 8J!  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ PH-O
M2M1:,%!3 @  AP<  !D              ( !Z8<  'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " #"@V]*WZ<^IH@%  !K(@  &0
M        @ %SB@  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( ,*#;TK5V$_T*P(  .$&   9              "  3*0  !X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ PH-O2L&S7'P3!0  Z1T
M !D              ( !E)(  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " #"@V]*;=U5*>D#  !]$P  &0              @ '>EP
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,*#;TKCS/QB
M: 4  '(?   9              "  ?Z;  !X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ PH-O2N'L+KK/ @  50H  !D
M ( !G:$  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #"
M@V]*^<9CQ(P#  !!$   &0              @ &CI   >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( ,*#;THXV+E[[0$  -L$   9
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M970V,2YX;6Q02P$"% ,4    " #"@V]*XH$^A=4"  !J"@  &0
M    @ $:M   >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M ,*#;TIL202>9 (  -L'   9              "  2:W  !X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ PH-O2@7XE^8, P  '@X  !D
M             ( !P;D  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    " #"@V]*KU1E!N\"   P#0  &0              @ $$O0  >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( ,*#;THLMD%L& (
M /(%   9              "  2K   !X;"]W;W)K<VAE971S+W-H965T-C8N
M>&UL4$L! A0#%     @ PH-O2FG:+!3M 0  V00  !D              ( !
M><(  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #"@V]*
MWYKK'!L#   A#   &0              @ &=Q   >&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;%!+ 0(4 Q0    ( ,*#;TI9F; F+P(  +D&   9
M      "  >_'  !X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%
M  @ PH-O2LJ@;'<O @  "@<  !D              ( !5<H  'AL+W=O<FMS
M:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " #"@V]*5;ON1Q #   !#0
M&0              @ &[S   >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+
M 0(4 Q0    ( ,*#;TILW,U""0(  (8%   9              "  0+0  !X
M;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ PH-O2G5*^XX6
M @  >08  !D              ( !0M(  'AL+W=O<FMS:&5E=',O<VAE970W
M,RYX;6Q02P$"% ,4    " #"@V]*W(-4MNFI  #&E0( %
M@ &/U   >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " #"@V]*1H=W
MB%D"  !>#   #0              @ &J?@$ >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( ,*#;TI]2L@'<04  +PO   /              "  2Z! 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #"@V]*3<[,[5P"  #0*P  &@
M        @ ',A@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #"@V]*SA;>=@X"  #7*@  $P              @ %@B0$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     4@!2 ' 6  "?BP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>242</ContextCount>
  <ElementCount>404</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1004001 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation</Role>
      <ShortName>Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Recently Adopted Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements</Role>
      <ShortName>Recently Adopted Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LongTermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Significant Customers and Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk</Role>
      <ShortName>Significant Customers and Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Discontinued Operations, Assets Held for Sale (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Business and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies</Role>
      <ShortName>Business and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/RecentlyAdoptedAccountingPronouncements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Warrants</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/NetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Significant Customers and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables</Role>
      <ShortName>Significant Customers and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRisk</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Discontinued Operations, Assets Held for Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Business and Basis of Presentation (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Business and Basis of Presentation (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LongTermDebtDetails</Role>
      <ShortName>Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LongTermDebt</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Commitments and Contingencies (Summary of Litigation Settlements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesSummaryOfLitigationSettlementsDetails</Role>
      <ShortName>Commitments and Contingencies (Summary of Litigation Settlements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Commitments and Contingencies (Schedule of Contractual Obligations and Future Cash Payments) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsDetail</Role>
      <ShortName>Commitments and Contingencies (Schedule of Contractual Obligations and Future Cash Payments) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Commitments and Contingencies (Schedule of Contractual Obligations and Future Cash Payments) (Footnotes) (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesScheduleOfContractualObligationsAndFutureCashPaymentsFootnotesDetail</Role>
      <ShortName>Commitments and Contingencies (Schedule of Contractual Obligations and Future Cash Payments) (Footnotes) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Stockholders' Equity (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Stock Based Compensation (Components of Stock-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation (Components of Stock-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Warrants (Schedule of Warrant Activity) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail</Role>
      <ShortName>Warrants (Schedule of Warrant Activity) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail</Role>
      <ShortName>Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Warrants (Fair Value of Warrants Classified as Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsClassifiedAsLiabilitiesDetail</Role>
      <ShortName>Warrants (Fair Value of Warrants Classified as Liabilities) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Stock Based Compensation (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Warrants (Changes in Fair Value of Warrant Liability) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Warrants (Changes in Fair Value of Warrant Liability) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Stock Based Compensation (Stock Option Activity) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail</Role>
      <ShortName>Stock Based Compensation (Stock Option Activity) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Warrants (Warrants Classified as Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails</Role>
      <ShortName>Warrants (Warrants Classified as Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Other Income (Expense) (Schedule of Other Income (Expense)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OtherIncomeExpenseScheduleOfOtherIncomeExpenseDetails</Role>
      <ShortName>Other Income (Expense) (Schedule of Other Income (Expense)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail</Role>
      <ShortName>Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Income Taxes (Components of Federal and State Income Tax Expense (Benefit)) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfFederalAndStateIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes (Components of Federal and State Income Tax Expense (Benefit)) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes (Components of Net Deferred Tax Assets) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Income Taxes (Components of Net Deferred Tax Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetail</Role>
      <ShortName>Income Taxes (Components of Net Deferred Tax Liabilities) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Income Taxes (Schedule of Provision Computed by Applying Federal Statutory Rate) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetail</Role>
      <ShortName>Income Taxes (Schedule of Provision Computed by Applying Federal Statutory Rate) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Income Taxes (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - License Agreements License Agreements (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LicenseAgreementsLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements License Agreements (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Significant Customers and Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails</Role>
      <ShortName>Significant Customers and Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2418401 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Discontinued Operations, Assets Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2420404 - Disclosure - Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2420405 - Disclosure - Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="gale-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2420406 - Disclosure - Discontinued Operations, Assets Held for Sale - Net Proceeds from the Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Net Proceeds from the Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gale-20161231.xml</File>
    <File>gale-20161231.xsd</File>
    <File>gale-20161231_cal.xml</File>
    <File>gale-20161231_def.xml</File>
    <File>gale-20161231_lab.xml</File>
    <File>gale-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001390478-17-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-17-000020-xbrl.zip
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M :RU3:=E6G=@@ON#A,-O6?AQ#Q2ZM.+,%8#/,LX6D+\@)A+;,]&GK)^EPPR
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M\@>^$%1ML\T$M].]<Q6]#*ZBVW$5/017T<O@*KH=5]'#<-5%6$"ZG06D>["
M0PC."CQE[:PHE)M%TEW62.[GR).<W#!YU>3B].7I715O_IX/DM^Y],7CZUN_
MM]5X6/I.N+;U^_JW#7"UJUXY)D=Q?>O7#ONMCUGO<WIX]MVM/%5#SE(V/?%^
M>)><^.YL9#O]5M[O,H+E+W_[[,O+^%]S"YE_T<P7?-;IWN6=I=]8#>O\1Q;>
M-;GT"-HZ F;7P+,0"BPGX^2.K;%>G.A;^M[BZM;O[ P7P\QYI-W#CT]ACZHW
MKB3UFE?>]_)FMA3VXNK6[RR"MG8[!8)+WSQSSQ/6W&T-FX/E6F)RP_9JH@MQ
M[\V_^H->UKD9W"[GM?G[UG^GE>6_& "VE0".[<;-3V/M^BF[GJOV>C4R1(WF
MX I31S''A!-,!!7$$6&50X'QP"17Z-6OUXUV'\A3>OGDBV[8ZZ5?0>#?:/\S
M:_3"2.UO\G%IL%'.RZ@<H\1C6,KHXUX3&MVK7Z\F@<*J+TU6XKO-X=WC#1\+
M4Q/A=_T-ED*94=1'K[%0QE$5N$-C/(CH#'OU:_SG:!5+OU*]C+3.31?A' 8Z
M2!Z5$$$H$BA6HT7 %1L '^FIJF4\?F5Q$:/U;4X21@16D;) M,)*2DDXGN!!
M6L=?S>VC+OW2XC+2^>(-OFZ1HC(8BH7!P!DH CN,&<(K^/G5KQ!F_N?\=].K
M)Y\+A7_CLG1>N?VFT\I^_&?VL,%W([,R1$5LL 01S)%@CU* I53S'M;2+RTL
MHWMWU^U\'G2;?Q;&MO]A.$B)II0FFUM32F'*/_#'X==VWHSM;F/PZJ=6ULSO
M0/+^^@K-K%-@H1WU3E-AN:3">*XG^&$$N/2GI N*ETZ<!ZH44820N66O6-D"
M#".1^Y3==WL#N)J2A!NQ<A":1VZ$!\UB/?&<(3WA(\X3*_\SF?-U7YI?3<S;
M6<\!>]UT>YN0E5/0:<9(023S%AM-@9:C12@;HWGUJVDVP8U,1S]:/Q5OGUW2
MW.?F5S)#J_EUC,I2R#("*FZMUX8$(A7E0FN"Y".#@ZS-$+"PPXHSC$ GS"YK
MYMOSB_J4W>1I-[ S2&.>-\"/]XXQQ$WTV'D<+.4J3E:#@Y>O?OT-#%&G\9/-
MN_? *'>-__-3F@\]NYKYC\XOZ._=-K@UC=X(DYNP#?=2!ZFP![2P:"6U D\T
M((@HK.A]=_;K"U^8__P_LG;[/SO=[YW/8#*[G:SUIM\?0C2U 6)(1"0PQ'S$
M.BI-"*(3QI$BZ:'Y92SYTF0Y7WJ-)%J?'^Z^=MN;*&$+(D(5U: #M>#."/7X
M>1$%!;J8MV&T@+EWIP^.MH5O;GK9#;#N&U!0X ;ES;\WVL/LPW4A]!_NBZQ\
M^)$2\?W47Z*\*#9>U)2/K^BLO>144R^4UH)H&K04<BS?D2'*\"(C8\J(!B7Z
MEY^?M+X] L97 R:)Y,!U'K2FI(H[!MISS('!8VD7 :/R+* 2JZ'2$3DA;*"2
M*.T"!4C"A%Q,6[,(%1?[@*K3&3;:[QHYK+63MI1BEE5I2_8O8.1_O85OM$?B
M--UA>^<-V-8>R)1++^@E@YM-^K[, /OF?9SUHPP7C(/H1&-<#-*!91]#2SP5
M<A%:@M ,N!6KGH(T>-?H_9D-DGP7FV1I7(4!_!0[9_WQ8/O?>MU^.E[8S++6
MO-8;9Q3?-1YF"@(^#[_V\U8.6BR];HS7&1R\_;OKOG[[%C#0*CY0;+G!O\MH
MN!*S6!"(1Z],! \ H$98FY%V%XC(Z%$U%J9XV![4O:)I5#=Q<"P99&CPG@1M
MO=%.6JSX!$O4\7@Z+(%#G3KO=*^7X^G-8=F)S'(3!DV/K82 !%QQC0G6(]=<
M@%^,O9C!TR0M@5XCNAF:JD%]1)1K]&_#C_$.<^QU[]YG@U'!AFG^>YCWP'G;
MUG[YX!3S"J *PAH?/!,C-2^(]T*4A /"PBG1UZ]GNO3;1N<&-&=LY+VQVISQ
MOO_1Z"7/J5^X"ZTW'=?M=$9)S7_D@]N_-R"B&O8#O#(YHTD9P?<JW*@UL"+J
MB>;@.& 1O0&+Y@V?.%4>^+\,*Y_5_P< X;CH66/Q2>1:! \F TL2G*6"CC4
M >=8E"P^Q@(_(^RL\1Q(B$)+)+'FQF#$A!/CG(0U")XOZ4?X#YT0/:GVY":E
M(X:]YFVCG\%O0!N."U&V%AW!D</22R("A .$6VG'\9JE/M"RFI#K8%^YOKV"
MMH;MC:/4&?#:.;-$>8FT';N$QJG(=,DE1/IL0%O#LT;%8)P5P3!D&,1,G(]]
M>(N-TR7_CR,FCP?;QY3OWHAVTY+1R?OLP^./_Y'#T_#&A[?9MZP]UV/Q\9XW
MG?OAH%_<0"O\H'F<07C-0!4:HY3B@4@4)C$G4X0MXNQJ>WXH [Y_Q(FC(XXB
MI#!G4GF,-1(H(LLFB$/(^ K$;<UMVV%NK%7?YHVO>3L?Y-GV-A%)Z8TBB.K
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M!WAWX^P\DS: _^J0P@S^ AY/O!YY#,'Y$TCZNKP%CBY@0;U5PH%-"@H+6+#
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M>Y^SYK ';)=]A8OP4[\$J#74ZNB9%F![!!*"4JW YG@K1?(U %"YDM)IE4^
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MS^)(7183[1B'28,"8(,9HGP:,ZP<+]2UYQ*"B[ $25ANXC6>$9*VBL5 /=N
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MXXF+7855J14XF]H(#QZZCEH@/9[WX:7BOC0V@>VRV(_ PUG15*O1CMD3T<M
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M+OZM*C_"!^8,"A^M]RR'E.SB2<.PCEFJ*IG<6HB7*?D72XEBRD(*ELGB>YG
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MZ?1A,+HA@SF]+TWOFQ/4@\_W.7JAI3A+"- \!,$M*7QIE<0LT$GR"%Y5?A!
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MU@.XMBSM=':FJM3A:H:R%:$3^N&/;?+-E[MF[I/=8[_"[-]WOJ6&H3>V&-Y
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M!B%Z9;)=#/*%55_RIS_KU0&R,PGVM%(P4L>,PB.ZE%%YD>:+ZI5WE&-7"([
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M<*:\B#-T0DH![4)BXUQ5I7L%JQ@)NS,R'M_^/KSKP([?]/#&LH>8/4/T,A0
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ME $E)#65Z\^[A\H?"^C%-#_</TR:GX:CT@_T;O!M!L,05SN?^IH/,VIA(<;
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MY36[/E-N&)*Q33R#[-+X(<^V1R#IH*:Q"J$CP\L,U9 $!:6/HEFB9:_4VVF
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MAJKQ-G;M  2YH(_&$J]LCV2?2N#VUL-^E28 &GFLVL(8.(>W'4.3^#$VL1?
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M8Q4G]IW9(4'+9V8RS*W\E<[<KBYKCBV9HN X/.[,NKB1[VB8)^?J&R:^9!S
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MLPG'7'[4Y9#4N_UA5[:LJ8BRV;7FO-'77>699\AT*= ;'LK.5Z.=-W1HNX!
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M\7O[H7&2SKUH!: "7M,\F!&;\X,HJJ[Y\0W_AGT'3O+K[UMH]"6<!QGW>_#
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MZ2QCD)I6#R=<3"@GE"^C]-WV'2&8$\P)YL.#>1^;WX1UPCIA?7A8?RN,!&D
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M*G#D\'-2I.P]:&ZPP6<Y_(-WX8#\9+Y(@UD X[@/N"C)LILG ?44-PT;^@=
MM\'[QP6[++[[%58ER,9%#DOS6QB'\V+^A_?(2.\4:])B#^#;O"A:O*'(NJG)
MFJ);FF4QX"OF6(.?CPM\M4^QC1BP@<F 81O<:1\R1J04:%%X$9?<@J9DRY$!
M0H#QY]XC\#W *04 ,:)SOI?-N$5%\PIU=3'OI=U5]9E7.2]ET)PF$=AZ&?<6
M@)#/D@(&.\F^?_]B%A^XNGL).EOWK-B,/,RN/5W\WGYHG*1S+UHQ*P6\IGDP
MLRTX/XBBZIH?W_!OV'<PG/SZ^^$,_A!.\AE\A#E5QAS88I&WR(+W]8</Z_;7
M<E#M[<?&AA/Y%>/N::-IVPYF.29)_>YY*W&KK5K-Z96W\Z=]/4V>)D^3O^C)
MG\EICL$%>9KA2F^>IE4?253/T/+I\(4/NC](6Y30.S!SFF<T!O:^9LW11E9:
M_%UYGRM#RXK%#B: 1?SPA.&VR*LH>!F8A><<$O<AF!),7\BUOR?Q.]N+P79G
M\<*A8=6=+Z*$>8:#&YIYEP8LV#)042*2*"%1<DQ ?"YN\R3W(F(U8K6>66W
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MM@A3XC3BM..:;TW34XD,N$%E9I_4(3N"J//R,(E?$(.ED^Y[U$_L#,57<#Z
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M8R=ST+V/W SGC)=A6\<97 =DOAD.^CJ/6 Q7=M1',)4G18?RCI>.+#H^AW,
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M%<RS!I,D8Q ?FY\MSOQL<U^2!9A&LLIS;VMI)?(?\"_P6_.+\.%[X.+EWU_
MT4^,O_R*][X/<R">7\[H+X67>G&>I"MBU/1]9%ATW1&]SG)ZGS!$D%:2&853
M]8 @ +'Z,S,8\:Z?XPE<Y>>M/Z-@@9^#6T!K7 F:CR@CL]&;'B!7":26'F%V
M&LI*-#COZG%Q, ?DG7F,]FLIROW(0\NNE++U>E>V9L:]#;]?JN:U6]FL[L'^
M1")D?K((& %Q<#@BOS)WP_@^R(#HI6I(D HLI(+\A$2MKP.BHZC+BNDT2#$:
M@V/UBQ0_WS(-LQQ[4$=EX#Z898QN,\R%R5H849@40(+'1;D0+(KSKKP>9AO.
MRY&\#5\^MV0*%P;5E,K59Q.\@XED^4K<J'YC"D"!9Y6&/<P%EO,>GL$PU1 <
MGUV4:Y$%ZTL%U@%H<@X>! L9@_ZKU,EV0,+X 73+"0+ZF(XI T]Y:[%G7K:D
M=/?<^2=-X?N*ZP!=47D745[Y-=FJX;%V 8)D^><:-L"$<S1_W(]X/:AJ=*!N
MDWO0R2@;4@1Y]+A),\_WTP+5_RQ$8\"[+6.+R/+X5-#5L1]Z$4P1E'8)RSK2
M6*[<EB5^1E-6G__\0Y&]N_.\Q?O2<V,/!W/.9L81V'W@HV9+008V7VY%B?_U
MI__^KS^W[ERDP0SL"V J$&;)//@C 5'Y6/ZWN8=)$?CR*9C^^&;L(/O\5?[G
M%^<-%T[@!_"/WXT%S=0%5U8$51%D<:SRCJ;;//PPUAU)4-_\M*;EGG+C=NFS
M9Y7D493BB_7X\F%Z!P/27V5O;&6CO9AAE8' :\ ("3+NIS#[:H/\"'/\M ?/
M&()K 'LH C]6'<U1-$TR&,^H\ ?)YB^#9W88(BND8Z*ZI!V'Q.M!3K8.4W/C
M1BZAJDJ+EKVP -$' H3Y5EEQ^R^T:=I"#Z16!H8HDU9E?&QM%GXYB[1B@2P$
M7;A(0;>$"_90O,3+2C>+?4 #Z]Z+ROA8VP"9@R)%JR KK[OU(O1144^!XKQ'
M%QG%;^UHX%;-0P)7Q5^;F!I&OAB;H.\$MP7?_,H0FP:3RL>&YQ>H]*(0A"B,
MP&1_[WX!=F\!];&/L"M>L$[Q<KNI-,^ "$"C.<@/I'WZ-<BY>9&#F\U-P>E?
M79R5AY:W,V=YP60%-TD"ID4Y(''RT+X 8Y^PMF@6PRJ"P1$R(S!E*C'"U0$V
MC-MN0>OFN]2;!"W_ 6W"F+$>#++<D,L:HVJ5F6:E6F<[=6D(VI%%2!]KBS,I
M%?8D6"09LQ">XM*#!>M.(?FD+-VBO/<0JM)8T1U%%$U+LP73M4S;X6NA:O-F
M_XKX4!FZ(^EC\U3J%/['\^5U#^4+;Y-H4K[A<TLHV07X&O/:-%^AZW-R]B"7
M_#6:H_-4E[U'JW8WVIUKU 0/ZI!=B#OA=]Y=*6-0.MT6X M5TK@*M]7N-]P$
MJX?Z*?P/_K9@H4$_*%B(%QV<2>'7VL)O 1Q\L 38X#_PEA1C:$50^EK,4]I;
MS+YHLK!(_;Z@196: B/.O 7U[44CSKOWPHCMH@!Y^QU(%G[K>::3A+G),#7@
MF7R6E=D1H$IPKPN5!4CIE'EHI5I'=OI;'.(OG]'/>D9"'T%X71J,06>B# 7\
M(EPK]JM6 T,A!4RS$KJE&0E+A 'U.#\DG/"BX0G\=SVS(VZ!)BF;>2U5T(K)
M6>Y/#L(EJ#=4T;1()AG7S'V$@H]MHZ(=E+W?I,4+8L ^VZ/91S>O!+WY.BI>
M<1!^;[\F3D#(1BL9M0+?WC/L;)=V;>1@:]Z%<3E(K\B3^H<R89S]4F[5"CP0
MHDI6A86*O$46O*\_;$3)M^_]-ON VM9J'OMOW99#TF!$!VX>K]POO/)VZ;2O
M/ZO1'[87O[,X2B4;Z"@$$>ZEA&N&JW1>:.P51#Z@O-$S*NA 0F[WZ/X)9M-:
M^BPG":,7;",3V@GM0T![]V4%^R/RZ?&/V?#$GL2>PV5/Z5IT49_G^NI@+6<2
MV"])B0_GV.U31)3WQO"KB;?DH',Z\_T4\38#;T-@/$+L12-6[+'N+2'V51;+
MA1HF5E<,1]*L>_H,1BX)>M=D.$C\# 4UG=D$!)8+!DMG9;NN RL4/]A#3=N#
M-*JO223UMQMU4L5^O"CT94LQPAWA[A!'O[O:GM>-._+EET:"0^X)N2?/J_S.
M:F]>AX0AL%PQ6*3.[./K ,M>A6A?Q)=1?W5'NLVHZ'VXFV52CGE<(@W*8Y5Q
MLG948JTZZ);L1CP0*M+QE8Z/KY3'+Y#TS8'A]@$5@?^N?<@CQPZ)[2O](+RO
MSU;M=>SC_1$@1\<\Z)@''?/HRMVEV-,08D\71C@ZYK%''BV=[1@ IQ+A7@OQ
M_Y^];WUN&TGR_+S[5R!\W;?R!<3F^^&>F0A)EOK<T=WVVIZ9V/L& D418Q#@
MH #)ZK_^,K,*+SXD2@)(@,R-G;9(XE&5E;]\558F)\_SV0YFS^-A3S[;P6<[
M&@9VSA1?V4"N:>+&<66*,V(9L7RVHTF(Y7P0/MO!6]S/VN+F?)!2;0(&RQ&#
MA;%2O3:ND5'-9SM.0B0=9X[YAN+KM7 XZ@) C@(P[NJ=8'WBN&-?GL]VL'OR
MK!@C^R?LRS-8=B/'@,]VO%0=;S_;\<QN04_V\/-I/X*N?W[?OO9-N]?M]R[[
MW>N;B\OKBYN;\:7NVS<9CO?0+NB0/=@^J;YDGNH16J#DVHJ_YO7TLGP'MDS,
MJ!8VR8N%L[EGI$N-9@6=-D@/)L"0?\&.5!:U1\&N5??S@%JLW?OP(!E/I>NX
M5NAB+ZP+SS,6\+Q0=7V#/Y+&.>GSYM:=,*9"^(; 9FC49EHW5\WH\H+F5UO9
M,\_&[\4T>EG#J_%D,.B^'[3?7[1'%[U^_V9\H3GX>CB\>/^^=@VO=N$8[<NT
MV_W):+8E2^FW *6G"!<&$N_1=:GT6,Z!&V/O9>@??>-WZ\$8TP&MGFG<"X/R
MT @A46!8AA=8ONH/K+K:/62MF%5WPH_?9T'HZ-Z+POCMMRL36\/0P99(=3.\
MA8M5LZ.D2:R'1\1":<3XC^YJ".^>!B%H1J$ZV<_<$/L-A_#8N:BF>>$/G;8!
M=WC5",:S-[\!\=Z\50V]\&]C:3T0Y9"],_%7_KL[W0KFLX OYR2?2= *&9U3
M!S(]*4E]*6GAO@O,T8R7@4\=$*M9O'&K/]B]1](SFDRJ8W6J-7?YS^]5T2TZ
M6QIK$8"=^F?:%3#M4:JTJ5XX [O"D^94F 9U^ ?X'W1@ 941M=->[3X>:2XF
M,;&T7 53!660%!5P<07+J]I>SBQ;=;2>"=7]O(KA#UI5\*>>@(N]01-Q@C.X
M!4&9]=].EJ7\]V./V@JDY3F='+ZW0IP&=5];QJ$]MZ0PXB5^+/^5$[/3GE2P
M0')NA<KTI@9RP0+0"4]$L\_"M3+$=VQX*+&GO6M7I=KZD]:ZE_OJQ[8,;3)T
MVJK+;[%W_#(4J6 (X@A,?1^=W[P46J!5GC6@+3#RRT^(-]W:*_-\_W.MO\U+
M6;0#,\_N2];=^%."T(O4)#Q[L_[EF[>F4B"V"+'Q=8IL, #A3QEC<UMXB3(#
M\V, %\LQ"305(&38ZHTJ$=!!Z-X25[M2QL)PP/U#GH>)Z#/XU0"^.S 'O;;9
M;E=A8'P1OAN$!BT^U7:8PL+"GQE?G/WOK+?URL_4U/HM87ZO GY0%34R"9_C
MUO^2!5G? O<;6\0'MA".3-1RPMG4OQ>K9^B'9'1,:0?\,@,(IDH>>W?#\X&I
MJ"<]4M,3M]C&7 AL#8^E.:PEO/"[BQ&1Y[0&?@:3]5K]"EVFKQLID7U%!BM&
M-A)C5<LN<& MVPYC(3,3%\1&!39#%0)C"1-!\T?YR&F3>8P16;JQ//Q]!_(2
M;?&9T$0@R;S=V"!5?1'?QD"+;G>#B%<?<L*8E+*6T0'\AKP7DJ0O*@,8$G"D
MHTS/1,J;6GX# ]ZYCL#FL*$*[&774@0@C?\E^,ES?/[1&C+*5];7?L$N]]*X
MP#G@3+^0697JG'\J\:(D+SEP>=#I!VY1/VOO6M=DY@82J5M4?V\P=M!=DA0!
MD?%B884N=NV>"G H7VG<',1":'9H*SV#W^EOLG!PS?#S'*P,$:X&ONXM%Q!G
MG.$5.=7V3_JZH->H,S2QK8Y</6XBJ7AXWO "_HCN,4"]?73$4<D[@C5<KPWS
MRZ>+_!A5"$J-/4,H#1QL+-059* !.)?@\2=HL#$,[UAA+KR0DE21\U?+CZWP
M 3^-3.-&3,/T(TW@=PNFKSZ>8400PPEW\#JU$/GQPGO=F8N$H7?E!V_F5XF6
M!0 FX^F_]% 3/#H"V8VH*[[;8JFAB#>'XM^Q&Z92!\0:R"UK.3?.W+<)W!T!
MOHB;Q$UR8[N&>Z,'W$?1\,X-SI"@Y$'2 ?%@!%]TN*2S0;2AL!!3DN21Z\?H
M%2&?8:AI54CA1'"A,MF.NR %B0<ORRV696#G>#URO+88!9J"Z%!_JGAK860M
MXR8.<7!8)TI12[,^3$VB%P>/IT4!+KG X5*<%Z6[L&!Q5U;. $J#35*)/?=#
MQQRTJ[+IE'(B-G%6%P3!X836/2Z7<EOAZI^  O0WWG2'4*$=+>(]2:M&<@]Q
MK0TF<';O@)%A$=0[@E@JA>]Y%BBCLRHH-JZ.9&^5%9O +]UPHSF)92!=>'X,
M+#*#&<O,=E#74=4Q9*,%?@-HI?I<6O(D0H]N)S&57Q&]3%)I\Q =DWN0MY%0
MFWHYTT(+#6369)C)6EJ>+$A%^!RH()K,WXH8P[U%6#&Q()%BT%Z_Q"D*%=V@
M0+<>BXKGK-IBIH[UN[I,'CT")XN/%0LM?Q)$EF8H-,PN.(B)\S4O# '0(1F8
MP*>I(Z$V.:@87C6NNW2_5[8G8.:J!"H#/9V7BY4;A;K.4P8'^)I)14 2;8";
M-'")/"H\K>&*KB]N%^B'@A85(8JW7%'(C92$MUN.HP+6VGJ68)7@K6FT$'13
M.OAM#RK:=&!KY0"V0=V9A$OA8\6_-3<2#<0 B4#W)(3)05]'+_7L\Q'.J>61
M7M24,W>*$2!]+?QFBFD)KI(BH0AF("]FJ<3*_ H#'FDL1*0$U\("3S]>/#+.
M>XLV&4,!%JBCI'4E6KE3F59NGAV1\5QBKJ>\]W-B>A/3 J1<Q1Q1:"51<ENL
M<$R:73/Z>85W7)E5[:R 1N-6)>19)G:M<88>C?,O<&.0-U-)(Y<>6+!F'A62
MY) +;\+BLG=H:+U-Y M9"$5'A22"KWYY&B,+0/M4Y&!2#<MUS6YUIFN4LUA
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MKUP-!)K4";VQ/L2SX93?](&^I_Q?S\4Q^S3#1TAF2<P=R6]Z/W%#0A0*E*K
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MP'L#Y"_"5\T,\4B3@T?R)#6SO5NO&;=#3*7[1$SEU=V5#PK"CCD9EA;Q/19
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M!.Q^+G#)]**"Q?^ ;FJP0*=9A+8KD20MXQ\ZBJ&4F]P4K\8"<2@5YJ (P4/
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M/@*=D4OQ*ZS9GY;0#L(')"86N:4U)+,+.[O(I.M*5O?2LFVQI,"4;0>QK\J
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M"%63J<@7Q0,G6% (L.NB:(BR<P=5U7#^H=>N\A"MGQPJ@QN%C/"$1'IN(NW
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M_4"L@LN4+B?<;\'==D%%M8PO0AA_@'@WAO3461S2NB(BO$#&H*I6G@T,I>8
MXP%S#\TX^;@P3O[^RT^Q/+^UK.6[]RXH0!CC+Z"*EO(#L24\YWT.AA]3'GF?
M#N4K$.O2"^QO?_O/__A+\JQK*_1Q#)]$^&5NA>(3&([V0WHI*2+X\%G,_OKF
MYCWRTG_W_^?K^S>&Z\ 70)+SSG6WV[^YN;RYZK2'ES>#[M7%:'S5ONX/V^-V
MYW+TYF\K<CG/!%]=5*I_B'OC<["PMKNFCXGU*J2XMLC;[?YDI'^\5Z^<!IZC
MWH$=JFFG"&AG$/'*T4R#YBK52H?^-6<F638"/E+F(97!4VQ.(C0"TPB6!2!
M8A./$>#J&%3KV08=0G81B8>;BR^7QL67*^-KL'1MHSML&\D.<G=#2*,"W9P
MD(9+7-1*1] I=P1*FEY:$F;Z")64Q1ZCS (K$];>1>F2W6%%4>A.8W+%4*HE
M=T<@+^: #E"->",*4H49X9Q;F"]W*PP_)KVD3W0D[Y2D",%<Q1>!4G,]>GO-
MQJA,DB#V'+#2P8";"O 7<@,WG$P9PXC=P$%M%"^2[USX0)RW]F1B8K0J0)/X
M:.?#C( $:"4^0J9/Z=7%B[39A:_1W]";D1(Q.$[*5_J.QH2DL1!1P*I0AI?R
M.,(0G#.P+YZIF9[0)H\IGN>HG/;5>'0U[E_V1E<WG?=7U_W^N*M43J=WW;V\
M8)53)[G-*H=5#JL<5CEEJ)QZB(6&2[19X'G!/?$(+1$>HT6&B%0H,F4)[V$;
M4XCO.OI#3CC%)RS/CKVTM\IV'$V%;<42([?"#55,!0.BFLNG@J+"Y^E[SUSD
MGB"&:3GR[;L74SBCQ:0$>F;/V&W[\R6V1.Z>PHXGIEKF^04_YQ_J!^'"\@I[
M1AV\)GVP6G1;>)Z^YJ]OVF_HLUQ:=O+Y^9;3O>M$<_@3YJ1WH\"D\:RE%.^2
M/WY>W5W*!I7/2$UWJ(8;$XMWSVE50QIU?GQZ"VSCUIZ>4N^5]Q_V]OV.OO%'
MQ<8ER(?Q,^7#EE3]P5,G- M[S.O[OA6G\ML@?D18%>GR0>P7;!4S\]7PG,@3
M9#LDNV&<X1EDJAE'U2[%ZX39:.>:M<^35D"/.F5_[RU/Z)_:,T2?>AF']MR2
MHN!<EX7:4HG;P/RWKCD85=^_JC:):EPUJ)Z:@S'Z"$8[9F=W_<(8+5?['K&2
M_:A#L97KV*H]UMH@=3 LKS_K$T0[%D2R6\7@V@U<PV&/P56UNJN1D;HW/?@U
MB"RO&M:J^@!A/9':,SN]BA3A<PAZ+"AFQ_)0ITY/ *L=<S2J04F08\'JL\\M
M/IU/N3&3\L9RPW]87BQ^<ZVIZ[F1*^3OPL*4?^>C_UG@L0]X""9AR;_[P10/
MF^!P/OC+.(*? ]^&NRAUXSE)F,-^?]*[?G\YZ;R_'HXF_8OWO0$E80ZN+KJC
M8;?R),S])<U<&&&!3,DIHJFX=7U<(%4&5*5D_88-V8V>X66KD9XXP3,Z4A_2
M66.C5P\SV3'-I&-R_J?\=]&,<;,#$^,LJ7.*).?K-"U?9S)IC=N#]G#<[0YA
M?N-!>=D[_5*R=\;#PZ;/=#E]YCEZMT89#+T#I,_4<VN:/JV=)D##P2#+85=A
M>+BQ:H,&CW(^7GVQ%J/]NP0>R)CW"PR!.A;"D.L_]IR)6/_1DA'; (XXTV9A
M1=U 3S5>=VEY>+[!-'ZU_-@*'S+,*<NWM+W24HM.U9*4Y=65>D79J'H&1H;F
M<%!>$+,.7%&OG88C%E!7<\N_I7. = 9*1NZ"JD',T/:Z0]LK"2:HV@VW5*LB
MV8)7!83H=)6C"SJ\Q!!^LM//8?/(JZ[K-FB7UX1K1TJ=4.\%-E2>9:BLUN9Y
MCH5RZJV[AF:G7UZ!1M;#K(=9#^]3#YOM_H@U,6OB.FABPXJ,9VR8<3'KF@<=
MN)CU2BY'>U+>08$7$[<V'%GS1(\J<C@VYHCD]E%4<:[G%WSL=:_[UY/^=?^R
M.[Z^N'X_Z$QNDL2/WN"F^L2/*D"S2_6M;+_,>,EV%!>L><G0\R6XDB23BR]7
MF<H>=]MFOH+6EE6BA)6L&*HT<R6OC+/<_5B:"YZ9^_EMFK^C!Y(V&1S]+(V9
MZX,]@361+$F5=/!%^>0?*N)D427C\X7&-%T4"BSOBQ^BO!\"GX1ES_7/F%*D
M2CNIPL'/>Q LN,0RR7Y,Y7QB2<E*^8OF+C@TX.8\J'&ZTIB&P3?A@XB_]\%?
MHK*UH<"RM7?"DRV=W^32OAN-QA%  GQYF@7T\K2?%>7;6;6(QKG/9#)UVN,J
MN8\FF]M4RB4D9(TFC7_'@:H[3?6!J>8;%2]2U8-5^I>+6$'5FK )?)?CDI<7
M9'^,9 <@47<SB52]:YEMA!N9$DN8*4'91@*EE??M( P#L"M4)AZ5U-/5P+'@
M-C(]/F.101^_%Z^G[P%HV=M,RSP58W^=C@3D4,P\84= &]^Z)3H4I-94@%Q(
MPB 8^KC'FS0AJ=L =F9 N:D*<U')KD '0K8O4NG4;ZA*K+2[0%XEVD#=VR"$
M"QS#A?6P+3DWL&(^2/=4[:EEU;7>P)34:R6-5?&F.4AURD#]H*OQ(S+7KJ7J
M_(Z(1+@@^3^UJ,<'2+^\.DXJ]2^780!:+:]UE39ZB?!LD8+/Y^+*E".= "MR
M!E'2. "&DP>,(VY1F\%=_XJ=6^J%83Q&T*0P8:$L'KPH L91F%,T7Z=FMT#-
M]#FH,C/MG6).QR"1>F%B[B-)79FJ_:G [^AZ)]<$@8P%W>OD')N@Q#!,#XGR
M0+=AV4H/EBD=M[-A1/1Z)S$0?+5>L"8H'7!IZ,V!(SPSN0;K3"X+C1X0[22/
ML=T"/  <BW2)"B;;J#-60]@QUDK%-W/KDM#:Z*5V"$P;+LK3%1=O<YQW&XWQ
M'^=?L=26U!:ZNE%2"W034?,SVCP13>D4+:HVIN[? L/%,0'!0"3 Z$$L2;-X
M":S+5 G<!RJE&=O8,H)@0B-.;TR+U&+96B.D3C<YC((>7:(610Q/([3T ,]2
M76B@'/L.:S*%-80I8C5/F.'C#O%VI_8IIW.CI_IQ=I-8UA]\&874QD&J.W=I
M2]"[[@S&-Y>#ZV'_:G(QO.A=#W2-Z.O>\+KZM@1[<9'41[RW4.$WYP,!BZ1T
M-'*$7%O+5ZLE(V^C$!9 P#R0K%BHRLFIGZ*W8:8Z%"OG N08<O"J^C(WZRXS
MJ\8,0!8NF3^Y+Y?6@_X&(&!;2Z0-^4*H]E"R?5=VCRI"FLD&T!ZQT)TZX#LY
MA^&>HX(S?"N*0Y'3IAI00-X$.2^&QV.<7H#&AJLVM/?8 1R7H\'EL#,:=BXF
MX\NKBU&[=Y&&< ;]WI!#.+6+@W (AT,X',+A$ Z'<#B$PR$<#N%P"(=#.!S"
MX1!.F2&<>LC&AHOUE>XJV(461)N/RS/#H_[$1-8TB",%LLT>1QX&3S&^CJ8
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M'D<!S_OT?0+ Q6[TC]QEO_]^F0T2WC:/ FO*I5C.OWLSQ<:&V1Z7_U@FISP
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MVN=MA6-2*3'1O3Y>5*I;K#[K@\589PK$?>2BPJ*43  2J?QF2IVZD\+3GI\
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MX U4#X S'T6RF$DZSCWN#\BV,^W6THX'?7H07RKLHNIQ#[HDIGS& J-C4^Z
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MG\WY$^Y0BU<I%)@LDZ[U_!ZXM(]ML2L5-S,)"VA-SSW[2L"B^/,9H.7U][D
M%/KLNX[UM,$F-AQT+R_/KZ\'G8NK8?>B-S@?=>--[*9SW;^L?!/+(_V@7Q'2
MZX]X[WLG!#W(2C8R34+%Y3DBLIB*R_O9VUE-&RBCCMGYP KOMW/OMWP9PK8
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M18&..%ICS&LI'%0AA:52OS[B:1HCV@MI+WRM>%Y?+F^"E8A?LZ5LW*<MD+;
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M#@V3*>X043CU X5TT1Q!IOSW]XUVNXW_*__1F2HK$5>D[C^7T%,AEU'!C'[
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M51G4*F=1&'*&9H:.0]=?'R3U)W4T9TB'&)K]&GM\]\HP3A'C.OX!4$L#!!0
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M/&#"N$V<A(?' L\/%[+UV?OW[T_DUZ0I<W4-!=JSDW_=#"=2]$>__L6RY%3
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MJK[_&!EN[UGW--)@E&@GKS=VZ!>O]_%@C[OXY'/MV^E)&SL,C->++SH(\EZ
M]SS?:OKYDZ]OS[V9[41_3=OAL&FIY&_ITB]N49"ER] /OKZ.?_&[\-K0?%"<
MTOU;-5U\;"Z^V<G<1>VXKFY7S=HQ:1>8@\ZNG?S:VJE?_!:N:TMYN5)*6EU0
M[>@V-(Y/Q]3+O[7<<YV #CV_=FRRJU^_6$;C+4KWR?V)J^ZB.G!B;7I9B.I
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M$]#6Y._9'['VS]2>\;EJ'5++9+9;9/OF3@66PA(<E6@CN +64P,H"P8PJWV
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MJY6*9.[@.I)'3O3,'8-0[6!],RK!I2UG)];.;^>++'/G\U1(]CR56:WNDB/
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M160=C;AC[0A0V,(5KQEOC>F@8>54K0]?S9X)E$O/^K6JW-=R,MFB4STT*9S
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M!W\-1.-L\3"ZG*;-<35=ZM[7WL[KARSN6UAK:[\"<>V)TQA 9@4@1!K !%%
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M 3K5"[5!>X.$D7'.KY_51N*%:@CZ9^>ME:]**\YZ:!OG%2TF9!F0*<A"2N0
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MMHC!Z<WHZ$Z!W]53[!"IP8[BL^MTYK/L8/1-]4P"I*?"$V^MA)8A;J#=?33
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MI*Z%@_LU^#P'@.Q,.\;WJPCBY97-KK+Y-#V\13C:-B$&2FP A!%ACW40MS*
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M6CBH$#=0>6[#6@:KT6/4IDK(V*)[:^OIE.C>T^ ;H;_W8_8UFZ\Z.I[8=I9
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M XR@K/#PFM-QQ]7THOF6<;#-$/V3::,,@GF-!.LCT#IL6DZ(K=X]G9!8E3F
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MNC_I,D$>02:#D,H9@AA0AK+=IP>X:$S"-Q'-WC<)6ZIC;&$PQ3+;%_&R'>:
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M8V(, 5MC6ES,)V66+C*;5?]^QMY]/#C:,*&>*,\\0X9[R;3#RNR(;15N'FI
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MUOZPN!-[2!"2$#H" $%:AW^&=9,8(86TB%AF&N4!:"K7ON"W$UHG&A%LL.>
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M#1$W?]FP-%BQ3Z38NX7HHO-$ D !=S380MH::!!3:F<5>=O"@'P=#L]SH#C
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M.4\<T)4W0",&QFTYG IST2$69[8+ME[A=8K,QX3^1[Z\>=SD=&.A;L\)Y#P
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MJ791%R(E'K3M4&8ES<%$X'7<J06.@X6?L[%YHFYQ\^%^MGAJ MWF%,GX7#"
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M)2M[B^JUX\VR6T0&RR5)5U)/'/GU,]& @8PK@1F*J.B49X-918.$-M^^/]\
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MQC!OR?S>@6N[LI]BYGOF\\_E_6Q33O;$JF_XE@"8%(P0K0CG$'.!$*[M$>M
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M,KD,W5%UHM3:NA25)OG^D7X _);7*YQB$$,O].P@PHGCN0"!SF($/(*5Y$;
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MCM*E7'EMG"[/#Z] W>T?LNJVH&/5C#TI^.TI*^J3VW-#SP8HP""%T,-I"*.
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M/KTF@1H8D]9!.H)^RJK]]W>TL>YAL66/33PU-Z( Q_. $Z0X 3Y!.(:1E_8
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MXY^<N$HSJ5]?:9O,6B1>8@>V"T+/)H%OIZD7V@.2U(/$C,+RVY]%8V-3&BO
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M/\!L [>K.F<;Q/CEE0>XV92'!M6[<I>S0ZOP4]W<!+"R/>0A$M@>]" *@QC
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MU$^92C[-FY)%,:7KD1T)7([*O<+:B+;IXGL9BJ;-F]),JU0^KG)\)?W$N.O
M('3<%$5. MR UI/MV3_7]B/?C12/KLB8-*QE%P]A*!]?D>*63]5FH%5,W"XQ
M:ATA2ITJ-G:DY0)U(PJGF?ME")UNIUX_]J+.F6S1-CQI'Z/4=1WD^!X@*/&
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M2)41%7E)R(B(*+"W# U1<:#4UI)4%.37]6/6+W=%8>![<1"[$7  NY@(]%-
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M.GZ2HBR*/3] +NX;,.,L#F/A):NF\:90B^/34+#GG>L.6=.PMKV0VI/32KG
M>G<&ME4RI9^7<A='9ZB@13D#PQ*KY!F85ELVZV!<;"DM1LFIM;5F0BU8;.NV
MJ#(W_20""-Q]SK=_%+M^4Y5OJ=8#@IKELDOVW]7MK]NJKOM=6 ;$)PDOR78(
M1I!$0>"$ Q!/K,S0X/"FMTA;5'SI=\=QL;RT!2:A<89X%P@J\U,N%V/@#K2
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M;]-/QZGZ&1.**TVPJ_I@5[4![.>%SB(+$^@YV(WC!H.#H3]T]P@A)L)A1=>
MAJ-*GTB^U:!,0MNTT2L01>9@5EMR_U8UR1P\2X20.?A6BR"Z>!<+((*\G(H?
MNFFU('QH-ZDR. W'!H^A>+4=EB8\6J'0IS[V4Y(@&$"4T"2),NH$2.C 2MM@
MAH/&H2B_@<._.(6EAQ965>.%04*UQ8I#G;V6,"%+[=@089!B[>%!E.H1D>$E
M'5)109%)6R."JCGO1H-1/"E$@KH;MVX'O#TJNOCSOARVRX8?Z_#QU<\B#J%/
MHSCQ(R]"$<-)>4$%C3T"PS!QA!XXFQB2Z6J(-IB\K+9L0 _1A?TY* Z(E171
MJ..D0Y(M/AL7N(XN?UV 8U]>OO3ESS\.B.TN50Z%MKA63\ T[&*5X#J"8+$0
M/(4'K0O4DQA].IQ/Q_FHY[$&N LG3:CG9TG@ARSEB*B;><.&I9/Z0H_):!IJ
MMDL1:KTVQA(K5BDP(:=R0?34@U@'R;7@*:R!J#/']IH8MN-,7I<Q(L]?J7(D
M7.BXO"]6>_["UJ>JKE&UX57?Q699%G7V?/B?S]?%CUW&2/AC$038PQ!!E[\6
M0S/7P3C(8AJ[@>L&62)51:5_=-.G[!U@_@E^*G?E79,Q@>_%;K=N&D5)5FGK
M9U],\>8E7O+,_9ASWH3M!5Q>\W0$&/Q^W9P.<^"@0?Z?$Q>ERC)[KD#5F)?L
M$%*#]KTN7#7,I-#NT-5CL<WY2)^*O"YJNM_MM\7G<L,;RWW-GYL^<WA?-!/X
M "3U*4M- ^03S\T<]M\PR'H@#DW$7R(T,_R$@LO]M,V7NWV^!E<WZTY\V[MR
MK34 Y?4]Z(V1V"PPY!J!O9[YO2*GQ@->T +NF>\@#^0#!EI&C"?SB<1FS?R^
M4=N8D?'1R.T6)8I.;:V8Y=N";13#!E:3S5VY1<:W8LT?*O^:;W?/UVPU4S,1
MY\H-;^I&T!=^@-E $2:N0ZA+0IPE.$$.@0'Q2!B(OM(U>AQSLME! PTV< P.
M_-[#FSA3?8^M,XFI-J+MR$/UF5,9FI!ZOC=^FWM=U4P(#E]\%B1IZ,9>YA _
M\GPG29';(W \ZL@LYW6.:SBO//T]RJW@M5(]3N5,LZQ-\ Y 68(XUSI=@D4%
M(1SC"[LU<91E@O(XGCWY[4_R\+BNGHOB>[%]*KN:\XQE3BM4/? F%TT&#M>-
M6]@_7=U^*Y;5W88_W-4>0Z&JWM5'F508!"3%*$)QD#I9EOJ=LKLN#G @=S=\
M-I23KNX?'JM-LRSA=QOY98!?;KAIX-BVOA>.ZC[KY&Z6W8^UV</J^[:]5: S
MJ[VO\X9_+\#!-OX7#];U%06-?19M\VIVF-!V\%R3Q([09 $/)[>7Y_6,?-@[
M .PV!>"?^7;5J&_;M++FS1U:U'6]?VC_[-6N 0D30A,W"Z&+4^0E7HC2'B1V
M(%6+=9- ,QS@CH U%Q9;X.#7MOZIO9Z@&LJF<9UL_++.:^I!ZSA&=<: QIJ+
M-CWIO%E?@,$D<.QP>V*4#J<(!:9)O6];-)K6^),A: 8?C(D[QX'Q&"1D:\&G
MDBT,7P*+0QRZE+HIP90D&(:9YPX!T<^BL;%&,QS3"Z@C'0(]Q/$!1;=/U(/(
MC.[0$SA>+FY>Q8W>"BM#A1SUDN'!D%_M#0FF#!8( T:Y%F[?=KS^V:R^%;MR
MVU3,'3;[#J<B'L4ICAV"PL1/,P=G:1M\ GXNB=Y[V\/$D 8ORASO;O%2E@/.
M%SOE,YT22I!X1@),N,*.;]V(9:];<1EC3_B" QN^'?QJ=U]LOU9LM %%5FR*
MVW+WYK8]#@EU A^[@1^%;N@X,8UZ.$Q9,JFK#Z9 &$[2ALW/#B/XROZUY#T(
M8_R+2:D5U,OI:@>Y[:3/08.7J'MO6'(>J<KPN4L7IIUFAP*;-_/U18UI>!75
MYOZ&"(\,S7VW+]6N>",RA%&*/>)D3N:[,782B#V(8N('F>N[?IH(2H&NX<Q]
M^</]TB:;:B^8<I VI%."[)WYJG7S;\='K-VJRNRLE>E9.BS).A OUUTO%U\.
M<F+"1HZ]C 3(\1Q(23^^$[E0O&^ISE$G+ /HFZ_(;689(/J\&L[+L>+6U-7/
M]()VXVE4H;Y>WF6ZE\[%OV('TW?],+9GJ00?IVKPC7!J0>F]&;LJT[-Q3)PY
M?<SS$DM((821#RF*LQBY#O+P@ 5FCGA34V,(#,<?FI?;Y@SWY6OE90U(O2L?
MFCK6WVI^GR9;Y\L_?F%VLI'J_MR%/TC#_^7G:E6LQ^BF-H>IQ*XY?#4^CKU]
M\FXBJ&ESSI@ -X>3] 6[\\Z2WWD1#8."K F'1-U>L#$\:K?Q;*@TPZA8S[Y[
M-FV+^G+#HT 3! 94G\K\IER?B. T3=+4"SW'2UT*$P\FF=-#\=)0:&?;* ##
M0;.##<H->#-^@@&\3-,V4\X0B(@V^$'RZ+!SP>4+%UR]X0(=$=&8;V3:YUG@
M(\5F>?*^TA80%5D[%0]-.\&"<&C<Q&K"22UWG("+VV*[+5;7^8]^]+*H^S_M
MKM^@_+'<Y6M>MOZMJ OVN^_A9H6+IV)=/?*/HREC7Q#H9L@+LR!Q(,G<-$VB
MI#WPP#'T/*E>45/B,APZ+S>_//)F7W4-MAW*YJQB=< )-M4.U/N;_RJ6.["K
MP&W;P2%_J+:[\E]M$LT+RG?Y#_"XWSY6P@_&S^)GL:,E6UTL%Y5[O$S'?X C
M.R[ \&\Z4R[ D3'@V_%4.+*GO?$T[3&51D^<.<J:P]]V''?-8GDU_]>F%HHN
M-\OJH7B)<Y'Y$0I=-T9IG*'0]ST:!/V0@><EBUW%@,O%%J6!I(+%@$E83G[=
M\IYWJUXZN."OY596>NB4DW#C3.K2Y(;>><3U+8X$U'(4M7;)WSA33NB9!G[D
M[[-D^[K<L(0.+O^Y+^NRV<#*GH_^5Y.[+QA7*8QB+XJ<U"$H]C'*6AA1&L%8
MZ'C?V. 3GO+WB,$QY O>R_/H#[KM"L$]"G,^$5.^6=VA>)"BS1.&+Z6(,7I&
M.XTYQPX]-6?>R>LE1G@4U=TW!H<_RGKA)M2!;$3L^EF8!FF4^IW*1Q#%6.B5
MM;%C&%;1M[Y7\#M')JF3RAR*R>$4],FIG@IS1G3M!#5GY&LLF7:HU&@K*KU3
M;+SF\'_<%@6N'O)RL\B<!,=NY+'_"R(:>PA'?C]ND%"I-ACC1YM!ARY CQ'\
MWJ+4H$F2'*NKDSEZQ^N4#+.3:=8+PB352XUL>W5,T1X!11O#E% !Q'_L']?%
MYE^?BX>;8KN((R\.(NRG212Y(0Z(CX8!:)J(/U0K]VL-JU4'!OS>PI$Y]I:D
M1Z#0P!PS<D(S'2D2)_SFR%$[MQ<F2>PH_H5YIP[8U3BPX-A<$7@UVO^2VW9L
M#C27]9IWY:YNFZ8(3>I(?0]1BGSJQ\A/XP"G\3">ESE2UY751S%=N=6_V]AV
M(U%9/(Y@4' W;1+RY/12CC<S6V*G:#FW]S6:2CO2+@UVO-[-TL2,< ^4HV&Z
M?(Y ZH5IE$"/.EE&,,4X&08BJ2\C. J_?F*E45H4JK F)C*&"1NG+K,L\WYF
MY(RPC*#/#D498\#K%BUCN1BQ#?6)_<$E$[)ZD;E!E,+,)Y#Y-T$^QC'IAF2B
MY4K5VXT::)9-< X/-/C&;SM)<*J\XV2&3AV;XB),3K7--+ DM\,D3ZX=FJ3'
ME/?WE53YD=4I5#W<E)MFS7UH=7VY8DE7>5OR(T)8U\6N[K:Y5G"S.BK;:&X#
M%2O^JA_[%X3]R!-;(_+7<&D20R?PB8^#.'/# 'M1,( F*%11NIF@FL[!^).(
MO*1TR?^A. !3T\BY_"FGLA_ E8HZ?639Q?'K",?&@=:Z_LQ@U;C_R$#067@!
MALE!!.:%4<4WXS&!F#'S5+$KZLQ-QHFX-3>LL1DZ'W3W?+EA\EW4N[;M_]6V
M>>2=@6^N_#"4Y=VF6"U"Y*2.%V>4DC2.?9S L%\VH"!-W9$YO$XHIB-7]?#
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M-IS@S1-3\FHK>1G1@!^TR[<!%QA6[ :QM1+=\JE'E25]\^&$6-8^=>U58M*
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M(A;)Z+P\:*X9U.69&58[+_&Z"Y^&.$@\CT9>ZJ4X2]+$[0'',/1G6M3(POQ
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M"3FS'!W!GAU+TC$&5-IFTA@%N69_%U</>;E91 1Z6>JF*/!H')$(.E'2#Q=
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M<$0_H0@,,6^M @Z8+]J-.%=%Z[4[0R!(S^D'N6#\,5T@$5;G=(5:^#3@$K$
M*4G5J4!HBG$+ IXQTZH)9JR! .9U$'PO8:,2FE G]8+,IQZBAWWT5'RS6O?
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MS5\Q^E+LOK._6"]2@L/,][*(HLR!D1<GJ==$]M3%.$W$*TG,09AK\;KKD5Z
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MEH!NEP_E:K\NK^\^E>MB5ZYNQ+4&G[?%IBF6;3+$SR]^TM[FZW.#&<8!$7?
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M]/S*.S-WY(:1NCP9*MK0I,TX :>#VK]5NX?37UGX:<I+3S_.XXBR)/=)@."
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M]%N]J;NSC3?W+XUB/CC. PQI[B5!Y-$D]_S!*!]-YXM=O2O6<D-70U-*NGY
M)?WF?!:_HJ'GMHB4&Y*.R*&:IG<J?HILD/2?>G C#T(O,W5A^&F)XGD,/&TY
M4SMY#%6NUBJVNTVY)?7C4[%Y/D[K\=(6T\C+(QA 2!,8(#]L3=&,!FF Y*_(
MTC3@>B[M?U7@]JG:_%S?W:G<9*1+ET1A.093:N+3(P(])+F9?XNDJ5SC- )Y
M>J7CX4F[WN],2\0S7IXK#4U)F4%):.Q";?$AT>U/_)][;KC<KI]9M2DVRZI8
M?]C<U=O'[D+=EYT^"'DI3F ,\]C#7NP3AH)V/27)4)Q!I:V$;A",V+5X@ T.
MN $M=@7XZ2^;8K^J=N7J?/DS9E#DJLSIXZ&F_V_1?X)S-@TU2GQ*-3.ZB,\\
M*E?'/IYM<73'J+H>*]U)U)7@MSSKMU?9X8*_(LOR]J$L19<[6G$5:L]K/"Z.
M-T=/,"4ARE(_B_P\B_.40MKM1_=#EH38UU/S^> ?,1?H7&+6#Y4/SE^!WGW0
M^M]V$!T9.&ERT>Z GT]HE'/2?*"[RVCJ#]&,DMQH 9)*D?-[7.:68&?(T-GT
M/$.L:EVSW2:F#MGGXEL_98;+37E7[;K%W3UWZ.@$^M+LML5RMZ T#6/?3U"2
M1S3V8$#3_G#2 .$XD3IE>@08CE-MCURQ9]8AZW+I:R:$JV6A8<==7YYPV,,"
M+?BI1_ZG*W $_R(=#?C'[KW5)OI21Z[[Z,TC*8SAZ.ONW;&X591H5HIVFO5W
MB!88HI3E.:0)PY3"A&0T':Q&E"F=1V!JR['8]KBTQ%:?/R5%'84Z/=GLH;VM
MFY.HXCFRWI<^8YIGI6_FWKPM8I984E2JML#E!>U'3NX;MCT_R_R(I3D.@A22
M!'M),-CV::YT!I8=BZYG8P0Z+<TR95))N48D44^_6H#MW%,+<48Z=IFZ]]7,
M$O6STC1;/KVM;%89LS-87L0H9#[.2>:3.(R\**4H'HP&*"<JS6F&ID9I3EO:
M'_J^SZ&-X:U5^NP/8><T0-4>A$IS/"O1,G9&:3"IR)'T07;E7<G-KG2&L C[
M:18%#,'$IS@+HC ,!T0L\)2NPG")PW')-D!7/.3.)?%RPC<7SA67EWK4/]3,
MG@'5%U1UC #.0W)'\?3UR7NCL:LJUOU0_5RFR(F?0(C"A$0>B6 0Y=ZQH$T3
MJ*/+AB;G.-=GBTTUL1V12$U=':;^YE-VRG$G(926R)^7)MIRZHS\6>5,5>E>
M#-W/0<")..LT12R*0XXF\ZC?7T@2$)^B7$?OK!B>WURA75[5E&]T2C7U[_74
MX?QT4(9)"36T&I!Y::)=U\XHHP/^+ W;%R1)HBC+4.3Y<19Y"4VP=[#JP4AE
M>M'4UBCSBRL7@_#W:;0RT+;*H(/!]*R&ROK#86F:YR5EQMZH#6L569+>J[^]
M+S;5/]IALCCOI5Y7J_8/7#]O^ ,Z;/F[OCOL73CT/C;''D?^MT^.J43+9;UO
MCY2YX9^WK$Y;(/.41"1.\QBA(/.S+&=Y=YJSGT>,$J7)R=F!=UQ8XGU3;<JF
M.\ >%TW5'@!\ZJGB^0)SXT_VQ(*YX7:7"$Y=;2=/C\ZV3\&IN^)A.&Y6.WI\
M>H"I^)W3 V6/7H/![0D/.1T[L!>2UFR?L7EDP?G2\_I8B=D"53@5L6@>\F_]
MM@1QL]9OY0XU3;EKT/(_]Q4O&A9IG'H0>3$F)&)9E*44=]?,!!X1<]S29U98
ML.6Z6Y\C!.4 L;O:;B,VM+4H0='#5#BDP0:_ES/7%-0J-C4(5@_H@( '.#[0
M 01H&E853L$8F5V] S%,GUW)$SC?I>*-Q&>;Q!D<H&'3F]K-HZ8XO72Z4^WR
M1K5/Y=>2?V/A>TE$0@3C#&44QBR(8=>>$L LSIG2F1H.S#O.%4+!MAT4Q1DH
M!TQ+3DI-2[+B/-6+/<7O;RD61XE?CH:;N2ME3B]-9[D+T#QJ>Y<.OI[T<LVE
M V4E=;-KKN]^J>M5<UNO5PO*8C](>)F?B O*(IQ$$/6(8)[!2.'P\3'@2*F!
M^1GD'):8D'"MONK1L"[#;B(PDAZWX$6@6OA X)^M-K\FVHY(:X?OAU-K?4_U
M9=N070?Z3<NG;;FLADD@]%AO=_T$T2)E+& HA;G/4I0F_'\P&<!ED>=8RDV0
MC:/JIY"$:"S+[4Y<"3,,7$'%1\2;^TJ<&M.-:9T)OU$8K>< YZ$;*1V<^M$=
M$77BR6P3PP7V[>0(&^']X=*%%:?U,X<]SJ4FV96&(DU9B(M2-BO*R]MU_21F
M A<IY:9#'.5>&.,P35$>LT-FPXRJ7D+D'M$X26, U^K)Z@A/82YYA.!(3.#/
M)""CS=2<A(W.-6P**P3S"I_> L((891;8S F\]P2Q'A1FL$*Q8C.UI.\"<Y&
M<;^4&[']H3US[[':5$U[5^O7PWT1"*=))HXT]U"69IGO9= ? $8(>VY'<J;H
MQDG,M^6:_\7[*W#?P;UJ-:)X@=C9^,TX@-;'<*,$;:3DW?O2G_)[ZLV[]Z%-
M/9A[)PQV!G2V8OW##>JL.:X_L+/+O8/<<OWR"J+VLML\]6.?I[PX32&,XX!$
MWI#PD)=3M<V[;J&X7E.O-S\?;^2J7MT$Z"Q?: 7%>HYP'0_7>>& _W"5V@27
M>9OQ;2<!F 3RAQ-](V?UA=Z<8UEQ__#X5%1;,3*YOOM8;^X_\G2RZEJR/M>X
M[#!S9'>+G(2!!^,D]BDD,4Q3G.'!/HI@H#$NL&=\G++_B!?P<=WVONSZ$)?K
MHFG:!N=N\K\9NA(?RO4*W-5;P*,^<MDH3>T%4; ?GGF\_P[\JET_V 8EVV_U
M[NUJLJ@V0EFN-\-?7XCK(6.:!A$,*0USDE"8#6A(IG8ZJ2L,CHLT@0;PMUB\
MLNU";?WX6&[;C4%?#KO(+B_0ND_]\G3*YGP' 9K'R^[<RTM9WAFKMA?F;LNO
M_"M.:+%9Y=_$65#-KEFDT$,X\4E*DHQE*0I(D@^8$IPBA^MR>H#&FOWKL;63
M1"5'QU6BD>W8&"DT=E?E'(9CI/';RZ )'[H.OED%S<V:G/O@C;4DIQQ$ZTMR
M;W)I847.+$8_UH*<H:^:ZW$V&)8>51^&[6*3TYMPFM]*/CCX7'Q#N]VV^K+?
MM;=9UI_*)]&ML[G/^2_LGA>$4(AR+Z)B4A?&&489&?!1DH8JY]Z,ATJI1E<_
M(:>MT=NA]^I4*.J#%VISJ2-&2VY:=9Z!4LO0+V9)NV"]K>K-5;M=E@^UN#=7
MX-0?L*O!37'QF'4WDR>V^+\TN3)ZC.<Q'IO []>3,Q,QKY8\#F<I'([@Q3G+
M: !S/_0S%,,T#U"WNA=ZB*8Y5A(7]8]W+A4'2),=:GV&FG??8GTRY_1.&GCQ
MYAMFRHKT25S#8DF_#'X\M#IA0>1!#'T&$Y@D6;OYL;?GLTCJ; ]S*XXG++M]
M:-U,1(?L7Q0/L]+G3TYQQJ%.37..R[D#J,E4YRP]%W3'G-)Y*(\%/UX?6V2)
M&5GU&=H\T8LVS][XX:R+X7B+#YN;;;TLFT:\M0M,<S_&,4(9%'LR8 2'*S,]
MS&*YLX?&P.%8P<RV.8P2"#FAFTL,U*3P7)_[\=S4X^E&Z+A=$?3HVQFXD?M@
M#(B^(*ICA&\>LCN*I_7X+X?"XM@[O93-(DN#@(_B&*,YC3'Q,8%TL!D'/I(^
M&,[8DF/Y/>UXUFEAMT2GQ(+5J$RJB>A (CK;-JZRTF3.IL)*TJBLZJT4G7]$
MAT'/GPV7@-XCX=P2CS7R9K"$8\^7VL7C93@KL$C"-(',0S'SO2R#,0X@.=CQ
M0J4K!-0_W?&22'=IP+&[O%02'0/2-*< K/)E.O2?>+RO,LZ7YFT>A:8!_O?&
M]8I,*.O&2>LU(0BB//&PAW("PS"":"@_B9=ZN99R*'R^8^TXOA!KCD93,53H
M4M0,1TSIJL:$^S_4-G68$#@S^=#QX)R :+,A*R&_U9OZI;%>LPY3D=!'PE08
MIGX:8$K3R$L&NX0BI3UQYM8<CR\O;WM37*RPP*V<^HQ+JYH6G6([R%$/[T^3
MK6.\R]@%J;+']CR$RZ(_M:OG4DW4AI;U3^6Z;9NN/U:[ZK[OK-OMUNU*[R*,
MDBS,?!93QF(4(.;G\<$V#"(58;-CT;&X'3&!Y@!*3=(L,2LG:^.3JCB/)@Y%
M[)O&>HRB"^R$YMOW:78B;U+,79 XN\S/0^8L^U2[?%85U@:ZK3E_*[;;0JQ0
MB#-\[LL%C5)$68C3T ]\&'%SV="]0A%-53; &EB1>O7,#Z%NP8A5OKNBVH*O
MQ7K?[H;[HT/;@*=ZQ\FOBO7ZN1>^MF&3_\*R:!X4IKHUN998+7#(KY:T#3L+
M>T1@@.2>+(7% />DZ:T #.3U#Z"X"J:%9CKO_Z:_YR;[S<B9P0R_H0.UM0=%
M08P_;'A95C:[KMA=X#RB&0M2<09VEL 8(3\=+$#(8NEE6<7/=5Q'#FB&B?LK
M<;N1@C*HLB2AGPX)4A/. S<=$H>L* BE0W;T%/+ TF%JI9]K,97(EYZ>TT9-
M/F8@BKK(:_.G07%I8O=0;L^._Q<LCF$6^'$<),1GF*1!.JR'T(PRI4E%0U..
MQ?)<=<I!@VXSQ[WH7WO:B^,WFQ(\;:ME"=95\:5:5[OGD>?L+U)Y:?K>3@SF
M,5*TY<SK27V;'!G/[R_R)(<)Q D* YCZR/=9.+0RT)2A1&6A4-_***T&FXNS
M^@KEBP56#6?TK1)J<29_)M/W.M/VTI3.0YTL^"$[3:_(C-Z.<]+M:.2VCUL:
M<7E7;\ON[WTNOI7-K]6FWO)T.-0N:+-Z^2GY?^[YCW\M=P\U_\E7_E?:NYT7
M?NQ%Q(=!D,703[PXR--A@8'F?J:D<G/"[5@WC[O6EP<W3_:L@R^MHX.4[H2K
M)OO8)WX&Y#1Y3I!=#F"_VPM_=/5D)_SP"'0>@,X%<.+#U9 C6B:N %<9\2QQ
M2.LN@7243+E;WFD,+Z2B.3Y)\TANLV3FXI[\F6#42, <69_G<;DI[ZK=(F>(
M!8P/0_(XI3!/@@ ?9D1%R[/*J%S7AO.YRR%C#;.74PC0=[2\*Q;Z1,[IQ3;P
MXLV7T)05>Q7KPHM"$B.4,,IPXB4^3GW8&\Y#$EDN--\U-VU].+>D;I2+I;F>
MTYMFQR'ES*?(U?AGE$%*H)<$!+*04>K3W$NC 1^ER%=/<6.@<MT8IGU&V?]_
MI)5T[.:H#J/X[>Q(*S7FI6?,R]U)UWWD$QJ0/(["D'A!"O.X/^J8VT@QCI5F
MR94^V7$&%^?87=Q"XV;B]I2"2Y.U6E3-XQ73Q/YZ4M:  =E'/2^V&_XZ-3?E
M]O:AV):X:*JE./.@6N]WY>K0I1WA((YPE.$0QV$6A#GUAU$H([Z?J"1-6S8=
MI\3A]0!<D]IS]473M,"KN ?$&L5R<Y13L*LVOS@@!!PB:#%>@19E=Z1+AW.R
M?2&2_%U0+ML1F(>F6?>J=OO<VA[><URO(+4P%VD8I8@+<H"B&!),L9_C YXP
MCA=?R^V76F] 81.'ROM\"EGZM3Z^PJO^%1;"V73O]]MK2#_MFY._I7BGG,.0
MV5H-&B-6;M9VKEIQ_EZ56_QSF]LY0[/1E(]IZ.8AVB/XJ3Q!9(=9%_-&YY A
MGFHP)6F<)W'@IQ[S V] !EE*323>#:()Q/Y0*O>*?V8>R:;F.XJFCOI/'T;C
M/'#FO/M>_ON[3^H[N7/Q9YH]M,)D:0[1]"&88T9Q[+'!O*$=MBU-HRP0$N>$
M11"SU$^S.,PSE ]6O2!G:AG$U-H$V6%S.IG2*K]9(C FW,IDBE6F'4RBS&KF
M1'_&1)KF>4BD-6_49D@469*5MK^5U?V#F( 1]U'=E[_M'[^4V^N[%L'U?M?L
M^//&4;T&D[,P9CCR8B^*$DSBD&8'G?5RN8V/CB$XGC\>4/]<=+!?S"$WH#X"
M_Q?PY;5@JJFAJQC)B>0,PJ.FG0-@T",&'611O-YVP3F!/;FLZM%[06T=QVL>
M(NS:R7K4=T!CYR6I'Y^VY4.Y::JOY;%R/JF/*]%HNMR615/2LOOO89:=>@%C
M 0Y(F/(RF<0>BP[ 4I:$RKLSW<)Q+.4OP.L<.SE"0.2T>F:Q4-/M%CQX&8P7
M$QFG<Q#379!C3/$%[1XQ?O/0\3$=?FNW[IA<V]#W3^5R731-=5<MVPD1M/H_
M^VXK@9@S0=?D ZNWM\6ZY,FI7.ZWU:XJ^]T*W)U%F), 88*C)$W$OYF'^BX3
MW\M#GRJ<&C4#M%)29'SZU&LGA #M-_Q!6%?_X$7FO3@C;O\D*G_NB/CA8[']
MO>RN#&T.7MG+**X? ?-,,X>PN\I WST-1^>Z>7;A'N"N@-O^<3BZ>#5LJ>->
MSB=IF45+,YF-](C,/\F-181"\ALU-J9)\2\')?ZW>BW&8,,YC=>;(SBTK1K^
M(\K_N+GO<OH1+_62+"(^HRA)HL1/4D+ZA6G?YZ\3MC$6<H_2\1#I+Z\2'A<^
MAVENA*":9;EYQ=-ZDCN)=N\?.#T*MSWW=O 2]&Z"SD_0.3J_5&<<,HU,-]YC
M,N]$-R(/DGEN[,A,-O834%& O33GZ9AE#*:I[]$T&*!"/TYMS?8Y ^@XN8GI
MI/+NKERVDTO;?X;QGE38)QKIV8[XS,9XL\EX)@$:<UBG\CS,.\^-0X'KH9QZ
M/*8:Q FD.8Q#E.<QC1,8)#BE7LP&I"S+F,4I39<PQYG+?)GI7F>U>0[JI((\
MS7#.6F#G/)";33XSB-*(8S>59V+>V6P4!AR/U]2C8;,+8Y$F&#+"*$$HR:.$
MI"0_I-&(!)[279TV#"J-I'1/XUV.T$_Q/K7V.B:LLNJP)V(>,GW*G&&K@S3Q
M\Q92/9<TVA44^9*5.EI^V8GM&/Q-WF^/W0]10.(,IA$-PT"<R)9$0_<#Q'&:
M9I)OH.:GNWOG!"!P1#19I]';Q%QXI0R9G,=+9.I$;?7I,GE1/I??=IB[]OO"
MISAA).151Y1Y,<2(,CI82R/LJ4S ZMIP/(?ZL=[<_\Q_[Q$(@&KY7ILV'8%Q
MPYBAP@A0H$4UJ<8<N)$6&74VYZ@R&EY<E!E=5J2N(+M=/I2K?3MEMW]\++;/
M_(OJ?M/.\6UV:+FL]^VE,S?UNEJVTWE?^&\QS B&"<XSAL(<PRQDD%#D^8C!
M@ 54^J8R-^8=J], &ES?@1YV^^41.#@B!P-T_EX*\.=?R=&"<UGH9A(7-0W\
MT4.B<#O;]*'1N\3-48CD+GK3(NV-O#5"!&9P;9QC!^O1GF:U@OMF*XX>V3W?
MK(7IS4J<LO\D'G3\_)E_$/I6-0N$T]RGW!Y#<9IE6>R3N+>,4TB4;H&W8<]Q
MJAL@7H$69+NQ\0#S"@B8?$3+@4IJJ%6JY0KVL5E62UP6"'92RDNP=J&LM\GY
M/$I\JQ[5[IY02XHG[-+ZL:@VBSRB.,W"(,C3/ _\$/J(#I;S.%,ZS=6&O3DH
M7@?5EN:ID&VH>8YX=J!Y[U$\KNH=>=-1/0W69ZYZ.A[)JIXV6U(3'@<S;+_=
M5#LQC;M9L>J;^*KYM11;\1<IBF"<TQQG.$P2POPT" :S 0FE-K1;,^98[PX0
MV]>PQ=D\M(<%_;T#J#(ZMD*NQ/3$V+RJZ=N1T@,\@ 2Y/<#)F%6891B;8;TY
M!7.FY:8/)-@X-UE@D\@93 U8=:=V], YG/_^6&W*#[ORL5DP1DB X]CW$,$>
M3% <#',0&*%,ZFH@QQ!F.@\N' "M!RYG7A4BY6!"W$V0QID4GUU\',Z.NXG3
MN#/D,O%R,TU^8,_65+EZ.&:0$T=PTF3*7)=3J?SY:_&M>MP__EKL1-OL<]\G
M6Y-ZTU2<<[1>_UMU_[!^_ECQ_+X2"]L?-LUNV[X=#6I(T3SP/"_^(PJ K_PC
MQ3VV610'"8-^R%&Q-"0)CI(!**6>U"[Z">$YSKL=Y)_7+6:P$NT?U1$U>.R=
M!:OB6;)7=LI02B3?^4=1+3'W_H#!H7YW!/A<@\$GP)T"G5>@<ZMMA0(GC@'4
M .%3.^)IOSCQ;OYQ5TCJ\X^_7L*?\CF0*PB<,'^N6)@VS#,H)"8FH)[-*Z=Z
M;<M7_NGU]OFW<K= 7HH"!.,L1@GSTAB'A/0F"(Q3I>4JI0]VG/0'+,H[*-78
MD5M?<D:,6AX]P&CWK8Q]5\B1@@MK0EI,S6/Q1P_Z=]=P:/NO_/K_K=[^_F%S
MLZV79=,L2!R'21+E*<78RU*80#0,=@A)/3TA4#,QDB3PQ_\/CHL/ L!3ATQ3
M(10)5-0*=]QIJ\;?>MIZ4%?@E^WH=QR_S8^,I.@1.C-QT73BG,R8<*(L.*P2
MBZ7EZI>Z7C4+BF"*?9*D*8H3AA,?9@=C+/ "+<%1,S&6X("['A:X%[@TY4:1
M/D6Y<<><MMP,D$"+:5JU>4&/C-KH\3DSM=%TXIS:F'!BW*/WEZ:\VZ\_5G?E
M J4T]X,HS6(89E[@,TK]P3(B@9T>/05[KGM6FEWU* ZM ?L6$UA77U6'159H
ME9.DL1E5TZ=WNO$ZC$" G$DOWI$UG5X\#<[GH6%6/9+MQ=-F2Z[Y@O^K::]F
MW&]VS6VY_5KQLNVFY _J9K>@.:(I)%F$8A3G.$,1.XP6Q7YK^08+(S/N^XT?
MGW;@J7CN;L'=BY?NJ<,F3N*X%S5">SJDRIR^(;,R#1&CD:K8]"!P@0.P*S!
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M[_T+C\^\\'JL3/^F:^*N39\'U?Q/>.&Q+=8?-JORV[^7SXL 1EX><RO43VG
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M. 1ZCSKY[R[X%$X=-N0K7$X_28BU1SNS"K6E$= 8(=<9&)ER+3=8&BVBLQM
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M<=3+A-^I_&Z<6FAH*(]V&<J';^)I_TT9P298-8A[$!S;\%]'T99'F,$4PW)
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MN@:/KR:@*,\N@S81:?-9\24L\DM^;+D"-4!DD^DS*1"BAF)/XF5,"#+*MZ*
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MEU4/GWD1I;\)PSTSL56@_3X?PP,ZL_&<F;*>*X"]DEXI+B!VK(IL!!<2I%@
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M?S.-E43/VTODK$(:<!=4D1=><@Z!Y:CBK(0TY7K=I/K25_-Q]"B]<W\73?5
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MW93QZGK'XOW&[*V*A2EKH224$J]31MZ5KH$&EIE:FWSGNMLTE)@]&=U5IR&
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M1B.X7!/8*>H-.?&?YY.;Y#-^6"P>BA3FEK9#-WL2]1SZ?6\(1!HD6'0^,,8
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MUD"#F%);+]#;+&?[TK?2^]! !Q-?JM0[FCTN?BMGR]OIXTJ^EX+E3XV'OQ&
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M?9DV3GQ=P-#XB*-7&"&LA2<\Y9!;2XL9S+H+7)M7<LVK67&3BOQ\/S=Z=:B
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MIE_FY?CA:KDS$=ON%H'#^+^X/*8$<:&L4(I5IUZ&ZZS=]0$ZATTH[ZWD$=G
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M8A 9*S0T6FD%A345GHZPG"L)0PS>'I1'V*\NNQH;&P&*\=OR;<;W'LK7>T$
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MAD&5+F%!BY\LDW0Y@25'%^;NP0N\N#%SG#[[O_2VNLWZ*_GI3\1"2"%#C1#
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M\$)*9SL,FY&/ \C3A9.3#<)92=L(B0X551]N8FU,X7VI>NIYE26GC)28N$,
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MQGLKL!'QZ/H0MH18:]&I3+0G/ASF#BK]XW_4/_YSM=O\]2__!U!+ 0(4 Q0
M   ( ,*#;TJGV7R;U.4! 'Y_'@ 1              "  0    !G86QE+3(P
M,38Q,C,Q+GAM;%!+ 0(4 Q0    ( ,*#;TH>.Q))3Q\  *]? 0 1
M      "  0/F 0!G86QE+3(P,38Q,C,Q+GAS9%!+ 0(4 Q0    ( ,*#;TH5
M;IJ;ERH  -C) 0 5              "  8$% @!G86QE+3(P,38Q,C,Q7V-A
M;"YX;6Q02P$"% ,4    " #"@V]*S^:_\&-R  #6DP4 %0
M@ %+, ( 9V%L92TR,#$V,3(S,5]D968N>&UL4$L! A0#%     @ PH-O2IG8
MO8S>(0$ +:4/ !4              ( !X:(" &=A;&4M,C Q-C$R,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( ,*#;TH+:;8PHK(  +GS"  5              "
M ?+$ P!G86QE+3(P,38Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  QW<$
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
